reached_phase_3_plus,Patient Population,Inclusion Criteria,Protocol/Trial ID,Patient Age Group,Min Patient Age Unit,Max Patient Age Unit,Trial.ID,Patient Segment,Max Patient Age,Min Patient Age,Exclusion Criteria,Trial Phase,Patient Gender
1,Patients with amyotrophic lateral sclerosis,"1) Patients who have given written informed consent to participate in this clinical study (or patients for whom a signature was obtained by a proxy, in case patients who have the ability to consent but are unable to sign the consent form in their own handwriting due 2) Patients who have entered the investigator-initiated clinical trial (DA350103) and have received EPI-589 for about 24 weeks, and have had no concerns with safety or tolerability. 3) Patients who can go to outpatient clinic",jRCTs051230064 TrialTroveID-488577,Adults; Older Adults,year(s),,488577,Unspecified,,18.0,"1) Patients who have clinically significant complications or medical history other than ALS, and who are judged to be inappropriate for clinical study by the investigator. 2) Patients with psychiatric disorders, cognitive impairment, or Parkinson's disease. 3) Patients undergoing tracheostomy. 4 ) Patients wearing a non-invasive respiratory support device all day (wearing for 22 hours or more). 5) Patients with a history of or complication of drug allergy or severe allergic disease (anaphylactic shock, etc.). 6) Patients who have a malignant tumor or have a medical history within 5 years before obtaining informed consent. 7) Patients whose AST and ALT levels were 3 times or more higher than the upper limit of normal at the time of screening. 8) Patients with CK =>2.5 times the upper limit of normal at screening. 9) Patients with estimated glomerular filtration rate (eGFR) less than 45 mL/min/1.73m2 at screening. 10) Pregnant women, lactating women, or patients who may be pregnant. 11) Patients or their partners wish to become pregnant, or patients who cannot agree to practice contraception during the period from the time of obtaining informed consent to 30 days after the last dose of the study drug. 12) Patients who participated in a clinical trial other than the investigator-initiated trial (DA350103) before consent was obtained, and 30 days had not passed since the administration of the test drug in the same clinical trial at the time of consent (half-life of the test drug in the same clinical trial If the number of days multiplied by 5 is longer than 30 days, the number of days 5 times the half-life must have passed), or patients participating or plan to participate in a clinical trial other than the investigator-initiated trial (DA350103) at the time of obtaining consent. 13) Patients who received cell therapy or gene therapy before obtaining informed consent. 14) Patients who are judged inappropriate participation in this clinical study by the investigator.",Iv,Both
0,Healthy subjects,"1) Healthy male Japanese subject between 20-55 years of age (inclusive) at the time of consent. 2) Subject who is fully informed and understands the objectives, procedures, anticipated drug effects/pharmacological action, and risks of the study and who 3) Subject with a body weight of between 50.0 kg and 80.0 kg, and a body mass index of at least 16 but lower than 25 at screenin. 4) Subject who is able to comply with the study requirements, including all assessments, physical examination, and reporting of symptoms. 5) Subject with partners of childbearing potential must be practicing abstinence consistently in their lifestyle or be willing to use acceptable and effective birth control from the initial study drug administration until at least 30 days after the last study drug administration . Educational level and degree of understanding of Japanese that enables them to communicate with investigators and study staff.",DA350102 jRCT2071220047 TrialTroveID-479138,Adults,year(s),year(s),479138,Healthy subjects,55.0,20.0,"1)Subject with a history of cardiovascular, hepatic, renal, endocrine, gastrointestinal, hematological, respiratory, psychiatric, or neurologic disease, and who was considered ineligible for the study by the investigator. 2)Subject with an abnormal 12-lead ECG that may jeopardize the subject's safety if he/she participates in the study, or a screening 12-lead ECG that demonstrated any one of the following: Heart rate > 100 bpm or < 50 bpm QRS interval > 120 msec QTcF > 450 msec PR interval > 200 msec 3)Subject who has a history of drug allergy. 4)Subject with any allergy or hypersensitivity to Coenzyme Q10 or Vitamin E. 5)Subject who has a positive immunology at screening. 6) Subject who has a clinically significant abnormality in hematology test, blood chemistry (serum) test, urinalysis, coagulation panel, or lipid panel at screening. 7 ) Subject who has a history of excessive alcohol consumption (roughly defined as drinking at least 1.3 L of beer or 360 mL of sake daily). 8)Subject who ordinarily drinks large quantities (approximately 1.8 L daily or more) of caffeinated beverages (coffee, tea, green tea, cola, tonic drink, etc.). 9) Subject with a history of tobacco dependency or subject who smokes, on average, more than 20 cigarettes daily. 10)Subject who previously received EPI-589. 11)Subject who has participated in an investigational drug study and received any investigational drug within 90 days prior to screening visit, or who is currently participating in another clinical trial. 12)Subject with a history of hospitalization within 45 days prior to screening visit (unless due to tests). 14) Subject with a history of alcohol or drug abuse, or a positive urine drug test at screening or on Period 1 Day -1 . 15)Subject who has a CK, myoglobin (serum and urine), AST, or ALT exceeding the ULN in blood chemistry (serum) test or urinalysis at screening, or who has a CK exceeding the ULN in blood chemistry (serum) test on Period 1 Day -1. 17) Subject who has used prescription or over-the-counter medications (including herbal supplements) within 14 days prior to the initial study drug administration . 18)Subject who consumed Coenzyme Q10 or Vitamin E drugs or supplements within 14 days prior to the initial study drug administration. 19 )Subject who consumed St. John's wort-containing foods or beverages within 14 days prior to the initial study drug administration. 20)Subject who consumed any foods or beverages containing grapefruit or Seville orange within 7 days prior to the initial study drug administration. 22) Subject who responds Yes to Item 4 or 5 of Suicidal ideation on the Columbia Suicide Severity Rating Scale on Period 1 Day -1 . 23)Subject with a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid amplification test between Period 1 Day -8 and Day -1, or clinical symptoms suggestive of infection with SARS-CoV-2 . who is in the opinion of the investigator unsuitable in any other way to participate in this study.",I,Male
0,"Patients with amyotrophic lateral sclerosis (ALS) patients with a diagnosis of definite, probable, or laboratory-supported probable sporadic ALS in accordance with the revised El Escorial criteria.","(1) subjects providing written informed consent (Subject and representative providing written informed conset are needed, if the subject is under 20 years old.) (2) aged between 18 and 79 years at the time of informed consent (3) meet the revised El Escorial criteria for clinically definite, clinically probable laboratory-supported or clinically probable (4) within 18 months from symptom onset at screening (5) ALSFRS-R total score progression of <-0.3 (> 0.3 decline) / month between the onset and screening (If ALSFRS-R at the time of symptom onset is not determined, please set as 48 points) * progression rate is calculated as: (ALSFRS-R at the time of screening --ALSFRS-R at the time of onset) / duration from onset to screening (month). (6) scores of> = 2 points on all 12 items of ALSFRS-R (7) scores of 4 points on three items of respiratory subscore of ALSFRS-R (8) scores of> = 3 points in ALSFRS-R swallowing item ( 9) slow vital capacity (SVC)> = 80% (10) on a stable dose of riluzole for at least 30 day prior to registration for pre-observation period (11) ambulant (12) agreement for genetic research Other main inclusion criteria are patients whose initial symptom of ALS occurred within 1.5 years before screening and patients with ALS Functional Rating Scale-Revised (ALSFRS-R) score progression of >0.3/month.",DERR1-10.2196/42032 EPIC-ALS jRCT2061210031 TrialTroveID-415776,Adults; Older Adults,year(s),year(s),415776,Delay Disease Progression,79.0,18.0,"(1) with a complication or history of significant other medical conditions based on the investigator's judgment (2) complications of psychological disease, cognitive impairment, or Parkinson's disease (3) underwent tracheostomy (4) with experience of using invasive or noninvasive positive pressure ventilation (5) complications or history of drug allergy or severe allergic disease such as anaphylactic shock (6) malignancy within past five years at the time of informed consent (7) contraindications for lumbar puncture (8) contraindications for MRI including Magnetic Resonance Spectroscopy and Difusion Tensor Imaging (9) AST and ALT CK greater than 3 times upper limit of normal at screening (10) CK greater than 2.5 times upper limit of normal at screening (11) eGFR lower than 45 ml / min / 1.73m ^ 2 at screening (12) pregnant, nursing, or plan to get pregnant during the course of this clinical trial at screening (13) childbearing potential, or unwilling to use accepted methods of contraception (14) use of edaravone within 30 days from the start of pre-observation period (15) change the dosage or discontinuation of riluzole after informed consent (16) history of administration of EPI-589 (17) participation in a clinical trial before informed consent and within 30 days from investigational drug administration (If 5 times of the investigational drug half life is longer than 30 days, it should takes longer times than 5 times of the investigational drug half life) or willingness to participate for other clinical trial at the time of informed consent (18) history of cell therapy or gene therapy before infromed consent (19) ineligible for the clinical trial based on the investigator's judgment",Ii,Both
0,Healthy Japanese and Caucasian adult males,"1) Healthy male Japanese or Caucasian subjects between 20 and 55 years of age (inclusive) at the time of consent. 2) Subject who was fully informed and understood the objectives, procedures, anticipated drug effects / pharmacological action and risks of the study and who voluntarily provided written consent to participate in the study. 3) Subject's body weight was between 50.0 and 80.0 kg (Japanese) and 50.0 and 100.0 kg (Caucasian), and body mass index (BMI) was at least 16 kg / m2 but no more than 32 kg / m2 at Screening. 4) Subject who was able to comply with the study requirements, including physical examination, assessments, and reporting symptoms. 5) Subject with female partners of childbearing potential practiced abstinence, consistent with lifestyle or acceptable birth control from the time of signing informed consent until at least 30 days after the last study drug administration. 6) Subject possessed an educational level and degree of understanding of English or Japanese that enabled him to communicate appropriately with the Investigators and study coordinator.",DA301006 jRCT2071210022 TrialTroveID-412705,Adults,year(s),year(s),412705,Healthy subjects,55.0,20.0,"1) Subject with a history of cardiovascular, hepatic, renal, endocrine, gastrointestinal, hematological, respiratory, psychiatric, or neurologic disease, and who were considered ineligible for the study by the Investigator. 2) Subject with a clinically significant abnormal 12-lead ECG that may have jeopardized the subject's ability to complete the study or a Screening 12-lead ECG that demonstrated any 1 of the following: heart rate> 100 beats per minute, QT interval corrected for heart rate using Fridericia correction> 450 msec. 3) Subject who had a history of drug allergy. 4) Subject with any allergy or hypersensitivity to Coenzyme Q10 or Vitamin E supplements. 5) Subject with a history of substance abuse including alcohol and drugs, or a positive urine drug test at Screening. 6) Subject who had a positive immunology at Screening [Hepatitis B surface antigen, Hepatitis C virus antibody, syphilis serological testing, human immunodeficiency virus antibody / antibody]. 7) Subject with any clinically significant abnormal physical examination, clinical laboratory values, vital signs , And 12-Lead ECG Findings At Screening. 8) Subject Who Was Abusing Or Suspected To Be Abusing Alcohol. 9) Subject Who Ordinarily Consumed Large Quantities Of Caffeinated Beverages (Coffee, Tea, Green Tea, Cola, Tonic Drink, Etc). 10) Subject with a history of tobacco dependency or subject who smoked a mean of more than 20 cigarettes daily. 11) Subject who previously received EPI-589. 12) Subject who had participated in an investigational drug study and received any investigational drug within 90 days prior to Screening, or who was participating in another clinical study during the conduct of this study. 13) Subject who had experienced significant blood loss or donated blood (> 400 mL) within 90 days or donated 200 mL of blood or more within 30 days prior to the initial study drug administration (Day 1). Subject who had donated blood components within 14 days prior to the initial study drug administration (Day 1). ) Or intended to donate blood components or blood within 30 days after the last study visit. 14) Subject with a history of hospitalization (except for hospitalization for tests) within 45 days prior to Screening. 15) Subject with a disorder or history of a condition (such as malabsorption and gastrointestinal surgery) that may have interfered with drug absorption, distribution, metabolism, or excretion, or a clinically significant abnormality of the hepatic or renal system. 16) Subject who had consumed coenzyme Q10 or Vitamin E supplements within 14 days prior to the initial study drug administration (Day 1). 17) Subject who had consumed St. John's wort-containing foods or beverages within 14 days prior to the initial study drug administration (Day 1). 1). 18) Subject who had consumed grapefruit or grapefruit-containing juices within 7 days prior to the initial study drug administration (Day 1). 19) Subject who had used prescription or over-the-counter medications within 14 days prior to the initial study drug administration (Day 1). 20) Subject who had consumed alcohol on the day before Screening or subsequently and 2 days before the initial study drug administration (Day 1) and thereafter. 21) Subject who was in the opinion of the Investigators unsuitable in any other way to participate in this study.",I,Male
0,Healthy Subjects,"1) Male Japanese or Caucasian subject between 20-55 years of age (inclusive) at the time of consent. 2) Subject who is fully informed and understands the objectives, procedures, anticipated drug effects / pharmacological action, and risks of the study and who voluntarily provides written consent to participate in the study. 3) Subject with a body weight of between 50.0 kg and 80.0 kg (Japanese) and 50.0 kg and 100.0 kg (Caucasian), and a body mass index of at least 16 kg / m2 but no more than 32 kg / m2 at screening (body mass index is defined as the subject's body weight in kilograms divided by the square of the subject's height in meters). 4) Subject who is able to comply with the study requirements, including all assessments, physical examination, and reporting of symptoms. 5) Male subject with female partners of childbearing potential must be practicing abstinence consistently in their lifestyle or be willing to use acceptable and effective birth control from the time of signing informed consent until at least 30 days after the last study drug administration. 6) Subject must possess an educational level and degree of understanding of English or Japanese that enables them to communicate suitably with investigators and study staff.",DA350101 jRCT2071210023 TrialTroveID-324988,Adults,year(s),year(s),324988,Healthy subjects,55.0,20.0,"1) Subject with a history of cardiovascular, hepatic, renal, endocrine, gastrointestinal, hematological, respiratory, psychiatric, or neurologic disease, and who was considered ineligible for the study by the investigator. 2) Subject with a clinically significant abnormal 12-lead ECG that may jeopardize the subject's ability to complete the study, or a screening 12-lead ECG that demonstrated any one of the following: --Heart rate> 100 bpm or <50 bpm --QRS interval> 120 msec --QTcF> 450 msec (QTcF) = QT / RR1 / 3) --PR interval> 200 msec 3) Subject who has a history of drug allergy. 4) Subject with any allergy or hypersensitivity to Coenzyme Q10 or Vitamin E supplements. 5) Subject who has a positive immunology at screening .. 6) Subject who has a clinically significant abnormality in hematology test or blood chemistry (serum) test, or urinalysis at screening. 7) Subject who has a history of excessive alcohol consumption (roughly defined as drinking at least 1.3 L of beer or 360 mL Sake Daily Of). 8) Subject Who Ordinarily Drinks Large Quantities (Approximately 1.8 L Daily Or More) Of Caffeinated Beverages (Coffee, Tea, Green Tea, Cola, Tonic Drink, Etc.). 9) Subject With A History Of Tobacco Dependency or subject who smokes, on average, more than 20 cigarettes daily. 10) Subject who previously received EPI-589. 11) Subject who has participated in an investigational drug study and received any investigational drug within 90 days prior to screening visit, or who is currently participating in another clinical trial. 12) Subject with a history of hospitalization (unless due to tests) within 45 days prior to screening visit. 13) Subject with a disorder or history of a condition (such as malabsorption and gastrointestinal surgery) that may interfere with drug absorption, distribution, growth, or excretion or a clinically significant abnormality of the hepatic or renal system. 14) Subject with a history of substance abuse including alcohol or drug, or a positive urine drug test at screening or on the day before the initial study drug administration (Day -1). 15) Subject who has a CK, myoglobin (serum and urine), AST, or ALT exceeding the upper limit of normal in blood chemistry (serum) test or urinalysis at screening, or who has a CK exceeding the upper limit of normal in blood chemistry (serum) test on the day before the initial study drug administration (Day -1). 16) Subject who has experienced significant blood loss or donated blood (> 400 mL) within 90 days or donated 200 mL of blood or more within 30 subjects who has donated blood components within 14 days prior to the initial study drug administration (Day 1) or intends to donate blood components or blood within 30 days after the last study visit. 17) Subject who consumed Coenzyme Q10 or Vitamin E supplements within 14 days prior to the initial study drug administration (Day 1). 18) Subject who consumed St. John's wort-containing foods or beverages within 14 days prior to the initial study drug administration (Day 1). 19) Subject who consumed grapefruit or grapefruit-containing juices within 7 days prior to the initial study drug administration (Day 1). 20) Subject who has used prescription or over-the-counter medications (including herbal supplements) within 14 days prior to the initial study drug administration (Day 1). 21) Subject who has consumed alcohol between the day before and the time of screening test or 2 days before the initial study drug administration (Day 1) and subsequently. 22) Subject who responds ""Yes"" to Item 4 or 5 of ""Suicidal ideation"" on the Columbia Suicide Severity Rating Scale on Day -1. 23) Subject with a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid acid amplification test between Day -3 and Day -1, or clinical symptoms suggestive of infection with SARS-CoV-2. 24) Subject who is in the opinion of the investigator unsuitable in any other way to participate in this study.",I,Male
0,Subjects With Amyotrophic Lateral Sclerosis.,"Diagnosis of possible, probable, laboratory supported probable, or definite ALS by E1 Escorial Criteria Forced vital capacity (FVC) = 70% of predicted Weakness onset within 3 years Agreement to use contraception if within reproductive years Willingness and ability to comply with study procedures Stable regimen of dietary supplements and /or riluzole for at least 30 days prior to enrollment Abstention from use of other investigative or non-approved drugs Participants must be able to swallow 0.375 * 0.700 inch tablets",EPI589-15-001 NCT02460679 TrialTroveID-258694,Adults; Older Adults,year(s),year(s),258694,Delay Disease Progression,70.0,21.0,"Allergy to EPI-589 Use of ventilation Participation in other intervention studies Diagnosis of any other neurologic disease Malignancy within the past 2 years History of stroke History of brain surgery Hepatic insufficiency with liver function tests (LFTs) greater than 3 times upper limit of normal (ULN) Renal insufficiency requiring dialysis End stage cardiac failure Participation in a trial of a device, drug, or other therapy for ALS within 3 months of screening or during the trial",Ii,Both
0,Healthy volunteers,"Subject's age is no less than 20 years old. Subjects whose body mass index (BMI) at screening is within a range of > or =18.5 kg/m2 and <25.0 kg/m2. BMI = Body Weight (kg) / [Height (m)]2 And body weight is not less than 50 kg and 45 kg for males and females, respectively. Subject's medical history shows no contraindication to the test medications [hypersensitivity to (Z)-BP or any component of test and reference products]. Subjects who are judged to be in good health by the investigator based upon the results of physical examinations (PEs) and chest X-ray (within 60 days prior to the first study dose), and all items of routine laboratory tests, including serum biochemistry, hematology and urinalysis, are within normal range as judged by the site. Assessment items of blood biochemistry include electrolytes (sodium, potassium, chloride, calcium, phosphorus), albumin, total cholesterol, total bilirubin, ALP, SGOT, SGPT, GGT, BUN, PT, APPT, serum creatinine, triglyceride, glucose, amylase, lipase, ACTH, aldosterone, cortisol, T3, free T4, TSH, and uric acid. Assessment items of hematology tests include red blood cell (RBC), white blood cell (WBC) and platelet count; differential WBC count including neutrophils, lymphocytes, monocytes, eosinophils, and basophils; hemoglobin, and hematocrit. Assessment items of urinalysis include appearance, gravity, pH, erythrocyte, leukocyte, epithelial cells, glucose, protein, ketones, and nitrite Female subjects show negative pregnancy test results within 30 days prior to the first study dose. Subjects did not take any of the following medications in the specified durations: Any medication (except contraceptives) within 14 days prior to the first dose of the study Any enzyme inducer or inhibitor within 30 days prior to the first dose of the study Subjects understood and have signed the written informed consent form.",EFBORAZ20141120 NCT03651349 TrialTroveID-331609,Adults; Older Adults,year(s),,331609,Healthy subjects,,20.0,"Subjects with any properly diagnosed disease within 30 days prior to the first dose of the study Subjects with a clinically significant hematological, endocrinal, cardiovascular, hepatic, renal, gastrointestinal, and/or pulmonary disorders; subjects with any predisposing condition that might interfere with the absorption, distribution, metabolism and excretion of drugs; subjects who have had any previous gastrointestinal surgery, except appendectomy if performed >90 days prior to the first dose of the study Subjects who have received any known hepatic or renal clearance-altering agents (e.g., erythromycin, cimetidine, barbiturates, phenothiazine, clarithromycin, trolearndomycin, ketoconazole, miconazolem fluconazole, itraconazole) for a period of up to 30 days prior to the first dose of the study Subjects had participated in investigational drug trials and took any investigational drugs within 60 days prior to the first study dose. Subjects had blood donation for more than 250 mL within 60 days prior to the first dose of the study. Subjects had a history of drug abuse or alcohol abuse according to DSM IV criteria. Subjects who are smokers or have smoking history Subjects who cannot stop caffeine-intakes for 48 hours prior to the first study dose and during the entire study period. Subjects who are pregnant or lactating For enrollment of female subjects with child-bearing potential, the subject must be practicing sexual abstinence or be using and willing to continue to use a medically acceptable form of birth control for at least 1 month prior to screening (that period will extend to 3 months for oral contraceptive use) and for at least 30 days after the last dose of study drug. For a subject to be considered not to be of child-bearing potential, she must have been amenorrheic for at least 2 years, or must have had a hysterectomy, a bilateral tubal ligation, and/or a bilateral oophorectomy (as determined by the medical history). The male partner of a female study subject with childbearing potential must use a condom and ensure that his partner uses a suitable method of contraception as outlined above. Subjects who are inappropriate to participate in this study, as judged by the clinical investigator Subjects who have been tested positive for the following tests: Human immunodeficiency virus (HIV) Hepatitis B virus (HBV) Hepatitis C virus (HCV)",I,Both
0,,"1. Have the ability to understand the requirements of the study, provide written informed consent, understand and provide written authorization for the use and disclosure of Protected Health Information (PHI) [per Health Insurance Portability and Accountability Act (HIPAA) Privacy Ruling] and comply with the study procedures. 2. Men and women at least 18 years old. 3. Women must have a negative serum pregnancy test and practice an acceptable method of contraception or be of non-childbearing potential (post-menopausal for at least 2 years or who have undergone hysterectomy, oophorectomy or surgical sterilization). 4. Geographic accessibility to the study center and the ability to travel to the clinic for study visits. 5. Presence of a willing and able caregiver. 6. Diagnosis of ALS based on examination by the site PI, meeting El Escorial criteria for possible, laboratory-supported probable, probable or definite ALS or be a person without a diagnosis of ALS disorder 7. Vital capacity ≥ 50% of predicted normal for age, height and gender measured in the seated position and the ability to lie supine for a period of 1 hour. 8. Agrees to the visit schedule as outlined in the informed consent. 9. Pre-study labs within normal range, or if abnormal, deemed not clinically significant by the site investigator.",IRB00263068 NCT04749433,Adults; Older Adults,year(s),,396721,,,18.0,"1. Weakness due to causes other than ALS. 2. Receipt of any investigational drug, device or biologic within 30 days of administration of study compound. 3. Use of anti-inflammatory medications, immunosuppressants, or benzodiazepines. 4. Any concomitant medical disease or condition limiting the safety to participate including, but not limited to: 1. Coagulopathy 2. Active infection 5. Any condition that the site PI feels may interfere with participation in the study 6. Inability to provide informed consent as determined by the site PI. 7. Known clinical evidence of frontotemporal dementia 8. Inadequate family or caregiver support as determined by the site PI. 9. Presence of any of the following conditions: 1. Current drug abuse or alcoholism 2. Unstable medical conditions 3. Unstable psychiatric illness including psychosis and untreated major depression within 90 days of screening",I,Both
0,,"Inclusion Criteria (Healthy Volunteers) 1. All volunteers must be 18 years of age or older, able to read, understand and voluntarily sign and informed consent document. 2. Volunteers must have no current medical history of brain disease 3. Negative pregnancy test if female of childbearing potential. 4. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry for the duration of study participation. Inclusion Criteria (Alzheimer's Disease or ALS) 1. All volunteers must be 18 years of age or older, able to read, understand and voluntarily sign and informed consent document. 2. Subjects must have a diagnosis of Alzheimer's Disease or ALS for which they are under a physician's care. 3. Subjects must have a negative pregnancy test if female of childbearing potential 4. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry for the duration of the study participation.",AAAS4926 NCT04575727,Adults; Older Adults,year(s),,386127,,,18.0,"1. Participants with evidence of brain disease other than ALS or Alzheimer's Disease at the time of enrolment up to agent administration are to be excluded from the study. 2. Concomitant medication use that, in the judgement of the investigator, would make the participant inappropriate for enrolment. 3. Severe concurrent disease, infection, or medical co-morbidity that, in the judgement of the investigator, would make the participant inappropriate for enrolment. 4. Participants who are receiving other investigational radiation drugs. 5. Women who are pregnant or breast feeding. 6. Subjects who are unable to tolerate PET/CT imaging",I,Both
0,,"Study subjects meeting all of the following criteria will be allowed to enroll in the study: 1. Male or female, aged 18 to 80 2. Medically safe to undergo MRI scans 3. Able to safely lie supine for at least 90 minutes in the opinion of the Site Investigator 4. Capable of providing informed consent and following trial procedures 5. Geographically accessible to the site ALS subjects must also meet the following criteria: 1. Sporadic or familial ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by modified El Escorial criteria 2. ALS Cognitive Behavioral Screen score >10 on the cognitive scale and/or >32 on the behavioral scale Those ALS subjects participating in the optional lumbar puncture portion of the study must also meet the following criteria: 1. Subjects medically able to undergo lumbar puncture (LP) as determined by the investigator (i.e., no bleeding disorder, allergy to local anesthetics, a skin infection at or near the LP site, or evidence of high intracranial pressure). For those subjects participating in the PET scan portion of the study, subjects must also meet the following criteria: 1. Medically safe to undergo PET scans 2. No prior radiation exposure that exceeds the site's current guidelines 3. No known allergy to any components of the tracer 4. Baseline ECG values are within normal range 5. Subjects must meet main study entry criteria",2015P000140 NCT02559869 TRACK-ALS,Adults; Older Adults,year(s),year(s),265102,,80.0,18.0,"Study subjects meeting any of the following criteria during screening evaluations will be excluded from entry into the study: 1. Any contraindication to undergo MRI studies such as 1. History of a cardiac pacemaker or pacemaker wires 2. Metallic particles in the body 3. Vascular clips in the head 4. Prosthetic heart valves 5. Claustrophobia 2. Diagnosis of Parkinson's disease or Alzheimer's disease 3. Diagnosis of renal failure 4. Have active or chronic autoimmune disease (such as hepatitis or HIV), infection, or taking immunosuppressive medications such as steroids, cyclophosphamide, etc. 5. Presence of diaphragm pacing system (DPS) 6. The presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair ability of the subject to provide informed consent, according to SI judgment 7. Pregnant women or women currently breastfeeding 8. Anything that, in the opinion of the investigator, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study In addition, any subject meeting any of the following criteria during screening evaluations will be excluded from entry into the PET portion of the study: 1. Radiation exposure that exceeds the site's current guidelines 2. Low affinity TSPO binders determined by having a Thr/Thr polymorphism in the TSPO gene (rs6971) at the Screening Visit Women of Childbearing Potential (WOCBP) For the purposes of this study, women of child bearing potential are defined as all women who are capable of becoming pregnant, unless they meet one of the following criteria: - 12-months post-menopausal - Post-hysterectomy - Surgically sterile",(N/A),Both
0,,"Inclusion Criteria _ALS-patients: - Age ≥18 years - Able to provide written informed consent prior to study participation - Body weight of ≥ 50 kg and a body mass index (BMI) between 19-30 kg/m2 - Vital signs measured after three minutes resting in the supine position must be within the following ranges: - oral body temperature: 35.0-37.5 °C - systolic blood pressure: 90-140 mm Hg - diastolic blood pressure: 50-90 mm Hg - pulse rate: 40-90 bpm - Clinically probable, probable laboratory supported, or definite ALS-diagnosis according to the revised version of the El Escorial World Federation of Neurology criteria (EEC) (46) - Disease duration ≤ 18 months since date of diagnosis - Slow vital capacity (sVC) ≥ 80 % of normal (best of three measurements) - Pre-study ALSFRS-R progression between disease onset and screening of -0.4 points/month or worse (calculated by ALSFRS-R score decline from 48 divided by months since symptom onset until screening) - Patient has to be on a stable dose of disease modifying treatments (Edaravone 60 mg i.v. on ten days/month, Riluzole 100 mg/day) nclusion Criteria _Healthy controls - Age ≥ 18 years - Able to provide written informed consent prior to study participation - Body weight of ≥ 50 kg and a body mass index (BMI) between 19-30 kg/m2 - Vital signs measured after 3 minutes resting in the supine position must be within the following ranges: - oral body temperature: 35.0-37.5 °C - systolic blood pressure: 90-140 mm Hg - diastolic blood pressure: 50-90 mm Hg - pulse rate: 40-90 bpm",18F-RoSMALS NCT05880563,Adults; Older Adults,year(s),,471497,,,18.0,"Exclusion Criteria_ALS-patients - Previous participation in another clinical study involving trial medication within the preceding 12 weeks prior to [18F]RoSMA-18-d6 administration - Tracheostomy or continuous assisted ventilation of any type, or any other significant pulmonary disorder not attributed to ALS - Structural brain or spinal cord abnormalities on MRI (e.g. evidence of stroke, infarct, or other space-occupying lesion or structural abnormality in brain and/or spinal cord.) - Significant illness within two weeks prior to dosing - History of clinically significant drug allergy; history of atopic allergy (asthma, urticaria, eczematous dermatitis). A known hypersensitivity to the study drug or drugs similar to the study drug - History of allergic reaction to drugs or anaphylactic shock. - History of myocardial infarction or history of treated cancer[18F]RoSMA-18-d6 in ALS brain and spinal cord_ Version 1.1_29.11.2022 Page 45 of 98 - Current clinically significant systemic illness or symptoms (e.g., respiratory or cardiovascular disease) that may deteriorate or affect the patient's safety or ability to cooperate during the study. - Gastrostomy - Any medical condition known to have an association with motor neuron dysfunction or involving neuromuscular weakness or another neurodegenerative disease, e.g. Parkinson's Disease (PD) or Alzheimer's disease (AD), which might confound or obscure the diagnosis of ALS - Major internal disorders (e.g. arterial hypertension, diabetes, evidence suggestive of liver or renal disease (bilirubin >1.6 mg/dL, creatinine > 150 μM). - Presence of any concomitant life-threatening disease or impairment likely to interfere with functional assessment - Donation or loss of 400 mL or more of blood within eight weeks prior to dosing. - Clinically relevant abnormalities on blood screening (see 4.3.1) - Use of any prescription drug with central action or over-the-counter (OTC) medication within two weeks prior to dosing, except ALS-medication and Paracetamol which are acceptable. - Use of tobacco products in the previous three months - History of drug (e.g. Cannabis) or alcohol abuse within 12 months prior to dosing - Pregnancy or breast feeding Exclusion criteria_healthy volunteers: - Significant neurological or psychiatric disease - Significant illness within two weeks prior to dosing - History of clinically significant drug allergy; history of atopic allergy (asthma, urticaria, eczematous dermatitis). A known hypersensitivity to the study drug or drugs similar to the study drug. - History of myocardial infarction or history of treated cancer - Current clinically significant systemic illness or symptoms (e.g., respiratory or cardiovascular disease) that may deteriorate or affect the patient's safety or ability to cooperate during the study. - Major internal disorders (e.g. arterial hypertension, diabetes, evidence of suggestive liver or renal disease (bilirubin >1.6 mg/dL, creatinine > 150 μM). - Other clinically significant abnormality on physical, neurological, or laboratory examination that, in the opinion of the investigator precludes the patient from the study. - Clinically significant abnormality on electrocardiogram (ECG) that, in the opinion of the investigator, precludes the patient from the study. - A past medical history of clinically significant ECG abnormalities or a family history of a prolonged QT-interval syndrome. - Structural brain or spinal cord abnormalities on MRI (e.g., evidence of stroke, infarct, or other space-occupying lesion or structural abnormality in brain and/or spinal cord). History of allergic disease or anaphylactic shock. - Presence of any concomitant life-threatening disease or impairment likely to interfere with functional assessment - Use of any prescription drug or over-the-counter (OTC) medication within two weeks prior to dosing. Paracetamol is acceptable. - Use of tobacco products in the previous three months. - History of drug (e.g. Cannabis) or alcohol abuse within 12 months prior to dosing. - Participation in any clinical investigation within four weeks prior to dosing or any ever participation in a research study with an amyloid lowering objective. - Donation or loss of 400 mL or more of blood within eight weeks prior to dosing. - Clinically relevant abnormalities on blood screening (see 4.3.1) - Significant radiation exposure, especially in the last quarter (either X-ray or nuclear medicine studies). Any earlier nuclear medicine studies. - Pregnancy or breast feeding",I,Both
0,,- Signed informed consent - Age ??? 18 years old - Patient with probable or definite sporadic Amyotrophic Lateral Sclerosis (ALS) form according to the modified criteria of El Escorial - Treated with riluzole 2 weeks - Evolution less than 18 months - Mini-Mental State Examination (MMS) score ??? 26 and Frontal Assessment Battery (FAB) (normal) - Affiliated to a social security system,MARIA NCT02405403 PHAO-13-PC/MARIA,Adults; Older Adults,year(s),,254890,,,18.0,"- Another unbalanced progressive pathology - Vascular diseases (hypertension, diabetes, smoking, dyslipidemia) unbalanced - Forced vital capacity <75% - Weight loss> 10% of the weight before disease - Status ""low affinity binder"" or ""mixed affinity binder"", the TSPO respect to the [18 F] DPA-714, which can interfere with the process of neuroinflammation: drugs with anti-inflammatory drugs (NSAIDs, corticosteroids, azathioprine, anti-tumor necrosis factor (TNF), antibiotics) - Benzodiazepine in the week before the PET scan [18F] DPA-714 given the potential consequences for TSPO receivers - Contraindications to MRI in patients with: 1. Metallic foreign body eye. 2. Any implanted electronic medical irremovably (pacemaker, neurostimulator, cochlear implants ...) 3. Metal heart valve, 4. Vascular clips formerly located on cranial aneurysm. - Treatment in the month before the PET scan [18F] DPA-714 antagonist N-methyl-D-aspartate (NMDA) (memantine) - Pregnant women, lactating women, and women in age for procreation and without reliable contraception or without history of hysterectomy - ???Person under guardianship",(N/A),Both
0,,"(for all subjects): - Written informed consent must be obtained before any assessment is performed. - Provide signed and dated written informed consent. - Female subjects must be documented by medical records or physician's note to be either surgically sterile (by means of hysterectomy, bilateral oophorectomy, or tubal ligation) or post-menopausal for at least 1 year or, if they are of child-bearing potential, must commit to the use of a barrier method of contraception for the study duration, - Male subjects and their partners of childbearing potential must commit to the use of a barrier method of contraception for the study duration. - Male subjects must not donate sperm for the study duration. - Able to lie supine on camera bed for a reasonable period of time. - Willing and able to cooperate with study procedures. - Women of child bearing potential must have a negative pregnancy test at screening. Inclusion criteria specific to healthy volunteer subjects: - Males and females aged 45-80 years, healthy with no clinically relevant finding on physical examination at screening and upon reporting for the [18F]PBR06 imaging sessions. - No family history of ALS or frontotemporal dementia. - C-reactive protein level ???10 mg/dL Inclusion criteria specific to ALS subjects - Males and females aged 18 to 80 years. - Sporadic or familial ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by the modified El Escorial criteria; - Subjects with a diagnosis of possible ALS must have upper motor neuron (UMN) signs to be eligible - ALS cognitive behavioral screen score >10 on the cognitive scale and/or >32 on the behavioral scale; - Forced vital capacity of ???40%; or if in the opinion of the investigator can lay flat for up to 90 minutes. If an forced vital capacity (FVC) has been performed within the past 6 months; this data may be used at the discretion of the investigator. - Medications for ALS subjects should be stable for 30 days prior to the Screening Visit and remain unchanged during the subject's participation in the study.",[18F]PBR06 NCT03876002,Adults; Older Adults,year(s),year(s),345363,,80.0,18.0,"(for all subjects): - Low affinity translocator protein (TSPO) binders determined by having a Thr/Thr polymorphism in the TSPO gene at screening. - Treatment with immunosuppressive agents (eg. prednisone, solumedrol) within 30 days of baseline and follow-up imaging.Treatment with anti-inflammatory agents including any medications in the following classes of NSAIDS: carboxylic acids, enolic acids, cyclooxygenase (COX) II Inhibitors within 14 days of baseline and follow-up imaging. Treatment with benzodiazepines within 5 half-lives prior to any [18F]PBR06 imaging visit. - For subjects undergoing arterial line placement, treatment with any antihemostasis medication (e.g., warfarin, heparin, thrombin inhibitors, Factor Xa inhibitors, streptokinase, urokinase, tissue plasminogen activators) within 2 weeks of the planned arterial line placement of either the baseline or follow-up imaging. - For subjects undergoing arterial line placement, a Modified Allen's test indicating insufficient ulnar artery blood supply to the hand. - Current or prior history of alcohol or drug abuse. - Current tobacco use including cigarettes, cigars, and chewing tobacco, or nicotine-containing products such as gum, patch, or ""electronic cigarettes"". - Positive urine drug screen or urine cotinine screen, with the exception of tetrahydrocannabinol (THC) in ALS subjects for whom medical marijuana is prescribed. - Laboratory tests with clinically significant abnormalities and/or clinically significant unstable medical illness. - Subject has received an investigational therapeutic within 30 days prior to screening. - Radiation exposure over the past year (including prior participation in other research protocols, clinical care or participation in this study) exceeding the effective dose of 50 millisievert (mSv), which would be above the acceptable annual limit established by the US Federal Guidelines. - Pregnancy, lactating or breastfeeding. - Evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, alternative neurological, immunodeficiency, pulmonary, or other disorder or disease. - Unsuitable veins for repeated venipuncture. - MRI exclusion criteria include: Findings that may interfere with interpretation of the [18F]PBR06 PET imaging, including but not limited to: significant cortical cerebrovascular disease, infectious disease, space-occupying lesions, hydrocephalus or other abnormalities associated with central nervous system (CNS) disease. - Contraindications to MRI imaging, including but not limited to: Implants such as implanted cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, CNS aneurysm clips and other medical implants that have not been certified for MRI, or history of claustrophobia, which in the opinion of the investigator is severe and prohibits imaging.",I,Both
0,,"1. General Subject Inclusion Criteria In order to be eligible for participation in this trial, the subject must: - Be ??? 40 and < 80 years of age at the Screening Visit. - Be able to read at a 6th grade level or equivalent, (as determined by the investigator, and must have a history of academic achievement and/or employment sufficient to exclude mental retardation.) - Be able to speak, read, hear, and understand the language of the trial staff, and the informed consent form, and possess the ability to respond verbally to questions, follow instructions, and complete questionnaires and detailed neuropsychological test. - Have results of clinical laboratory tests/physical examination, vital signs, and ECG within normal limits (at 90 days prior to [18F]PI-2620 positron emission computed tomography) or clinically acceptable to the investigator at screening. - If female, not be of childbearing potential as indicated by one of the following - Each subject (or legal representative) must sign the informed consent form in accordance with local requirements after the scope and nature of the investigation have been explained to them, and before screening assessments. 2. Cognitively Healthy Subjects 3. Subjects with Alzheimer's disease 4. Subjects with frontotemporal dementia 5. Subjects with Parkinson's disease",NCT03510572 PI-18001,Adults; Older Adults,year(s),year(s),323339,,80.0,40.0,"The subject must be excluded from participating in the trial if the subject fulfil any single criteria described below: 1. General Exclusion Criteria - Based on the investigators' judgement, if the patient is not capable of communicating with the site personnel, if the patient is not proficient in the language in which the psychometric tests will be completed, or if the patient is not sufficient for compliance with the study procedures. - The patient has an abnormal physical examination or abnormal laboratory test results at the screening that are clinically significant to affect results of the research, as judged by the investigator. - If the patient has or is suspicious of having a hypersensitivity or allergy to [18F] PI-2620 or its derivatives. - The patient is pregnant, is attempting to become pregnant, or is nursing (breast-feeding) children. - The patient has a history of alcoholism or drug dependency/abuse within the last 2 years before screening. - The patient has contraindications to undergo positron emission computed tomography or MRI, which include but are not restricted to the examples below: claustrophobia, cardiac pacemaker, metal devices around the eye or spinal cord, cochlear implant, etc.) at the screening visit. - The patient has been treated with any investigational medicinal product (IMP) within 30 days prior to the screening visit. 2. Cognitively Healthy Subjects 3. Subjects with Alzheimer's disease 4. Subjects with frontotemporal dementia 5. Subjects with Parkinson's disease",(N/A),Both
0,,"1. Age 40-75 years old 2. BMI age-suitable 3. Ability to provide written informed consent and willing to comply with protocol requirements, or has a legal authorized representative/guardian who provides surrogate informed consent. 4. No apparent physical disorder. 5. Radial, ulnar or brachial artery suitable for catheterization. 6. Non- smoker, and not taking over the counter nicotine cessation- to limit peripheral metabolism events 7. Devoid of central nervous system prescription drugs for three weeks- to limit peripheral metabolism events. For Cohort 2 part B only: 8. Must have a study partner (informant) who spends a minimum average of 5 hours per week with the participant (e.g. family member, significant other, friend, caregiver), is generally aware of the participant's daily activities, can provide information about the participant's cognitive and functional performance 9. Recent (within 6 mo.) mini mental examination clinical scores.",13180640 NCT05374278,Adults; Older Adults,year(s),year(s),432602,,75.0,40.0,"1. Unable to provide written informed consent and unwilling to comply with protocol requirements, or does not have a legal authorized representative/guardian who can provide surrogate informed consent. 2. Inadequate arterial access. 3. Receipt of radioisotope < 5 half-lives within [18F]RP-115 imaging- as to not confound any scans with radiation background for previous scanning, and unsuitable organ dosimetry thresholds from previous (> two weeks) PET scans. 4. The performed [18F]RP-115 scan(s) must not represent > 3 PET studies total within one year. 5. Contra-indication to magnetic resonance, including permanent pacemaker, implantable metallic device, etc.; or severe claustrophobia. 6. Participants who are pregnant (female patients of childbearing age will be tested prior to injection of tracer- positive test excludes from the study) 7. Participants who are breast-feeding. 8. Have a medical condition or other circumstances that in the opinion of the project physicians would significantly decrease chances of obtaining reliable data, achieving the study objective or completing the study.",Iii,Both
0,,"For all subjects: - Written informed consent or assent is obtained. - Willing and able to cooperate with study procedures. - For females, non-child bearing potential or negative urine pregnancy test on day of [18F]MNI-777 injection. Alzheimer Disease subjects: - The participant is 50 years or older. - Participants have a clinical diagnosis of Alzheimer's disease based on National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria (McKann, 1984) - Modified Hachinski Ischemia Scale score of ??? 4. Parkinson's Disease subjects: - The participant is 30 years or older. - Participants have a clinical diagnosis of PD based on the UK Brain Bank Criteria (Hughes, et al., 1982). - The duration of diagnosis of PD is <20 years prior to the imaging visit - PD subjects must be on stable doses of medications for a period of at least 30 days prior to the imaging visit. - Treatment with dopamine replacement therapies or other symptomatic therapies for PD is permitted; however, subjects must be on a stable dose of medications 30 days prior to the imaging visit. Progressive Supranuclear Palsy subjects: - The participant is 30 years or older. - Participants have a clinical diagnosis of PSP based on National Institute of Neurological Disorders and Stroke/ (NINDS) and the Society for PSP (SPSP) criteria (Litvan, et al. 1996). Chronic Traumatic Encephalopathy subjects: - The participant is 18 years or older. - Subjects with a diagnosis of probable CTE based on a prior history of repetitive brain trauma and at least one concussion, and a current mood disorder (depression, apathy, irritability, suicidal ideation), cognitive symptoms (memory loss, impaired executive function) or behavioral symptoms (disinhibition, aggression and increased violence) (Jordan, 2013). Frontal Temporal Dementia/Pick's disease subjects: - The participant is 50 years or older. - Participants have a clinical diagnosis of FTD based on consensus for clinical diagnosis of frontotemporal dementia (Neary, et al., 1998) Healthy Control subjects: - The participant is 18 - 85 years old. - Negative history of neurological or psychiatric illness based on evaluation by a research physician. - MMSE score must be 29 or above.",MNI-777 NCT02103894,Adults; Older Adults,year(s),year(s),232400,,85.0,18.0,"All subjects will be excluded from participation for the following reasons: - The subject has a clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness. - The subject has any disorder that may interfere with drug absorption distribution, metabolism, or excretion (including gastrointestinal surgery). - The subject has evidence of a structural lesion on MRI that may interfere with interpretation of PET imaging. - The subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease. - The subject has participated in another clinical study within the previous 30 days. - Pregnancy or women who are nursing or breastfeeding",I,Both
0,,,94-N-0205 940205 NCT00001972,,,,223534,,,,,(N/A),Both
0,,"- Over the age of 18 - Has an informant/study partner who will be able to provide independent evaluation of functioning - Speaks English as their primary language (including bilingual patients whose primary language is English) - Fulfills diagnostic criteria for PPA (Primary Progressive Aphasia) or Progressive Apraxia of Speech - Agrees to and is eligible to undergo MRI and PET scanning - If woman of child bearing age, pt must agree to pregnancy test no more than 48 hours before the PET scans",09-008772 NCT01623284,Adults; Older Adults,year(s),,228826,,,18.0,"- Any concurrent illnesses that could account for speech and language deficits, such as: - traumatic brain injury, strokes and developmental syndromes - patients meeting criteria for another neurodegenerative disease (Alzheimer's Disease, Dementia with Lewy Bodies, behavioral variant frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration) - Women who is pregnant or post-partum and breast-feeding - Patients for which MRI is contraindicated (metal in head, cardiac pace maker, etc.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism,(e.g. chemotherapy) - Patient is mute (secondary to dysarthria only)",I,Both
0,,AD: - Male or female >= 50 years of age - Meet National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) criteria for probable AD and have a Mini Mental State Examination (MMSE) score at screening between 10 and 24 inclusive - Have a caregiver who can report on their mental status and activities of daily living (ADL) - Give informed consent or have a caregiver give consent with subject assent. FTD: - Male or female >= 45 years of age - Meet consensus criteria for FTD and have mild to moderate disease severity. Have a caregiver who can report on their mental status and ADL - Give informed consent or have a caregiver give consent with subject assent. CN: - Male or female >= 45 years of age - Have and MMSE >= 29 - Give informed consent,18F-AV-45-010 NCT01890343,Adults; Older Adults,year(s),,230737,,,45.0,"- Have a history or a current clinically significant neurologic disease (other than AD or FTD, as applicable), a diagnosis of other dementing/neurodegenerative disease, or a diagnosis of mixed dementia - Evidence from MRI or other biomarkers that suggests an etiology of dementia other than AD or FTD, as applicable or in the case of CN subjects evidence indicating the presence of AD, FTD or other types of neurologic pathology - Have current clinically significant cardiovascular disease, screening ECG abnormalities, psychiatric disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, cancer or infectious disease - Have a recent history of alcohol or substance abuse or dependence - Women of childbearing potential who are not permanently surgically sterile, or are not refraining from sexual activity while not using adequate contraception. - Require medications with a narrow therapeutic window, are receiving any investigational medications, or have participated in a trial with investigational medications within the last 30 days - Have ever participated in a study with an amyloid targeting agent - Have had a radiopharmaceutical imaging or treatment procedure within 7 days of the imaging, other than as defined in the protocol",Ii,Both
1,,"- Age 30-100 - Subjects who have completed or are scheduled to undergo the neurological evaluation procedures in the Mayo Clinic Study of Aging, Mayo ADRC, or Mayo neurodegenerative disease clinics.",08-005553 NCT00950430 R01AG011378 U01AG006786,Adults; Older Adults,year(s),year(s),241625,,100.0,30.0,"- Subjects unable to lie down without moving for 10 minutes - Women who are pregnant or cannot stop breast feeding for 24 hours - Claustrophobic patients unable to tolerate the scans - Standard safety exclusionary criteria for MRI such as metallic foreign bodies, pacemaker, etc.",Iv,Both
0,,"1. Has the ability to understand and sign the written ICF and local medical privacy authorization forms, which must be obtained prior to the conduct of any study related procedures. 2. Female subjects of non-childbearing potential must be either surgically sterile (hysterectomy, bilateral tubal ligation, salpingectomy, and/or bilateral oophorectomy at least 26 weeks before the Screening Visit) or postmenopausal, defined as spontaneous amenorrhea for at least 2 years, with follicle-stimulating hormone (FSH) in the postmenopausal range at screening, based on the local laboratory's defined ranges. 3. Female subjects of childbearing potential (i.e., ovulating, premenopausal, and not surgically sterile) and all male subjects must agree to practice abstinence from sexual intercourse or use a medically accepted contraceptive regimen (including hormonal contraceptives) during their participation in the study and for 90 days (males) or 6 months (females) after Day 1. Medically accepted contraceptive methods are defined as those with 90% or greater efficacy and are as follows: 1. Male subjects: condoms or surgical sterilization of subject at least 26 weeks before the Screening Visit (i.e., vasectomy). 2. Female subjects: 1. Surgical sterilization at least 26 weeks before the Screening Visit (includes hysterectomy or bilateral tubal ligation, bilateral oophorectomy, or salpingectomy); 2. Intrauterine device or diaphragm with spermicide for at least 12 weeks before the Screening Visit; or 3. Hormonal contraception (oral, implant, injection, ring, or patch) for at least 12 weeks before the Screening Visit. 4. If male, subjects must agree to abstain from sperm donation through 90 days after the Day 1 Visit. 5. Female subjects may not be pregnant, lactating, or breastfeeding. 6. Female subjects of childbearing potential must have negative result for pregnancy test at Screening and Check-in. 7. Subjects must have an estimated glomerular filtration rate (eGFR) of >45 mL/min/1.73m2 at Screening. 8. C-reactive protein level ≤10 mg/dL. 9. Subjects must be willing and able to abide by all study requirements and restrictions. Inclusion Criteria Specific to ALS Subjects: 10. Adult (Age 18 to 80, inclusive) at the Screening Visit 11. Sporadic or familial ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by the modified El Escorial criteria. 12. Forced vital capacity (FVC) of ≥50%; or if in the opinion of the investigator can lay flat for up to 90 minutes. If FVC has been performed within the past 6 months, this data may be used at the discretion of the investigator. 13. For ALS subjects, medication changes within 30 days prior to the Screening Visit should be discussed with the Medical Monitor. Inclusion Criteria Specific to AD Subjects 14. Adult (Age 40 to 80, inclusive) at the Screening Visit 15. Clinical diagnosis of early stage dementia, Alzheimer type, plus positive Aβ and tau PET imaging, cerebrospinal fluid (CSF) and/or plasma biomarkers consistent with 2018 NIA-AA criteria 16. MMSE score >20 at Screening 17. AD medication changes within 30 days prior to the Screening Visit should be discussed with the Medical Monitor. Inclusion Criteria Specific to MS Subjects: 18. Adult (Age 18 to 70, inclusive) at the Screening Visit 19. MS medication changes within 30 days prior to the Screening Visit should be discussed with the Medical Monitor. Inclusion criteria specific to subjects with RRMS: 20. Diagnosis of RRMS based on 2017 McDonald criteria 21. If not newly diagnosed, subjects should have at least 1 documented relapse in the last 24 months. 22. ""Active disease"" subjects should have at least 1 Gadolinium-enhancing (Gd+) T1-weighted brain or spinal cord lesion at Screening MRI. 23. ""Disease in remission"" subjects should have no Gd+ T1-weighted brain or spinal cord lesions at Screening MRI and stable clinical symptoms for at least 3 months prior to Day 1. 24. EDSS score between 2.0 and 5.5 inclusive at Screening Inclusion criteria specific to subjects with progressive MS: 25. Diagnosis of PPMS or SPMS based on 2017 McDonald criteria 26. EDSS score between 3.0 and 6.5 inclusive at Screening 27. No evidence of relapse in the prior 6 months 28. Neurological exam and symptom stability for ≥30 days prior to Day 1 29. Documented evidence of disability progression in the past 24 months not temporally related to a relapse Inclusion Criteria Specific to PD Subjects: 30. Adult (Age 55 to 80, inclusive) at the Screening Visit 31. Diagnosis of definite, idiopathic Parkinson's disease according to UK Parkinson's Society Brain Bank diagnostic criteria 32. PD medication changes within 30 days prior to the Screening Visit should be discussed with the Medical Monitor. Overall",NCT05395624 OP-801-001,Adults; Older Adults,year(s),year(s),433210,,80.0,18.0,"Exclusion Criteria - For All Subjects: Subjects meeting any of the following criteria will be excluded from this study: 1. Body weight >120 kg 2. Evidence of clinically significant or past medical history of hematologic, renal, endocrine, pulmonary, cardiac, gastrointestinal, hepatic, psychiatric, neurologic, immunologic, allergic disease (including multiple or clinically significant drug allergies) or any other condition that, in the opinion of the Investigator, might significantly interfere with the absorption, distribution, metabolism or excretion of study drug or place the subject at an unacceptable risk as a participant in this study 3. History of recurrent kidney or liver malignancy 4. Pacemaker or defibrillator or any non-removable metallic foreign objects in the body not compatible with MRI 5. Inability to lie in a PET/CT or PET/MRI scanner for up to 90 minutes at a time 6. Laboratory results (serum chemistry, hematology, coagulation and urinalysis) outside the normal range at Screening and Check-In and considered clinically significant in the opinion of the Investigator. Any elevation of aspartate transaminase (AST) and alanine transaminase (ALT) more than 3 times above the upper limit of normal at screening and/or check-in is exclusionary. One retest of an exclusionary laboratory result is allowed at the discretion of the Investigator and with approval from the Medical Monitor. 7. Resolved acute illness considered clinically significant by the Investigator within 10 days prior to Screening 8. History of alcoholism or drug abuse within 2 years prior to Screening. No cannabinoid drug use for at least 10 days prior to Day 1. 9. Positive urine drug test, marijuana test or cotinine test at Screening or Check-In 10. Any immunizations within the 28 days prior to screening 11. Received any other investigational medicinal product within 30 days or 5 half-lives (whichever is longer) prior to Day 1 12. Corticosteroid treatment (e.g., prednisone, solumedrol) within 30 days of Baseline 13. Treatment with any of the following classes of nonsteroidal anti-inflammatory drugs (NSAIDS): carboxylic acids, enolic acids, cyclooxygenase (COX) II inhibitors within 14 days of Day 1 14. Lost or donated >450 mL of whole blood or blood products within 30 days prior to Screening 15. MRI exclusion criteria: findings that may interfere with interpretation of the PET imaging, including but not limited to significant cortical/subcortical cerebrovascular disease, infectious disease, space-occupying lesions, hydrocephalus or other abnormalities associated with CNS disease not related to ALS, AD, MS or PD 16. CT exclusion criteria include any medical device or metallic implant that may interfere with image acquisition or affect image reconstruction (e.g., CT attenuation correction). 17. Investigator has reason to believe that the subject may be unable to fulfill the protocol visit schedule or requirements 18. Has any finding that, in the view of the Investigator and Medical Monitor, would compromise the subject's safety in the trial Exclusion Criteria Specific to MS Subjects: 19. Clinical signs or laboratory findings suggestive of neuromyelitis optica (NMO) spectrum disorders or myelin oligodendrocyte glycoprotein (MOG)-associated encephalomyelitis (i.e., presence of anti-NMO [aquaporin-4] antibodies or anti-MOG antibodies) 20. Diagnosis of progressive multifocal leukoencephalopathy (PML) Exclusion Criteria Specific to PD Subjects: 21. Secondary, atypical, or genetic parkinsonism Exclusion Criteria Specific to HV Subjects: 22. Clinically relevant finding on physical examination at Screening 23. Family history of neurological disease that may confound interpretation of imaging results 24. History of any central nervous system disorder or brain trauma that could cause imaging abnormalities in the opinion of the Principal Investigator and Medical Monitor",Iii,Both
0,Patients with Amyotrophic Lateral Sclerosis,Patients must have clinically definite ALS (Awaji Criteria) Male or female age 18 years and less than 75 years at time of ALS study Symptom onset less than 36 months before screening Diagnosis of ALS less than 24 months before screening Clinically definite Upper Motor Neuron signs,ACTRN12621000864820 NCT05039268 TrialTroveID-387398 ZZ-3K3A-202,Adults; Older Adults,year(s),year(s),387398,Delay Disease Progression,75.0,18.0,"Current treatment with anticoagulants (e.g., warfarin, novel oral anticoagulants, heparin) that might preclude safe completion of the lumbar puncture Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia Use of investigational drugs or devices within 60 days prior to Baseline (dietary supplements taken outside of a clinical trial are not exclusionary, e.g., coenzyme Q10) Prolonged prothrombin time or activated partial thromboplastin time >2xULN Severe hypertension or hypotension Glomerular filtration rate (GFR) <35 mL/min Forced vital capacity (FVC) at screening of <50% of predicted Prior exposure to any exogenous form of APC Inability to lie flat for procedures (MRI, PET, LP) Pregnant or lactating during the study period",Ii,Both
0,,"1. Aged of: 1. For healthy participants: Male or female subjects aged 50 years or older 2. For ALS patients: Male or female subjects aged 18 years and older 2. Able to remain in a lying position for up to 45 minutes without respiratory support. 3. A) For ALS patients, confirmed diagnostic of definitive ALS according to El-Escorial criteria14 B) for healthy participants: no neurologic condition (confirmed by physical exam) 4. Have venous access sufficient to allow for blood sampling 5. Are reliable and willing to make themselves available for the duration of the study and are willing to follow CRCHUS-specific study procedures.",2024-5148 NCT05974579,Adults; Older Adults,year(s),,480013,,,18.0,"1. Are currently enrolled or were enrolled in the last 12 weeks in any other clinical trial involving a study drug or off label use of a drug or device, or any other type of medical research judged not to be scientifically or medically compatible with this study. 2. Female participants who are pregnant or breast feeding; or women of childbearing potential (<50 years old) and men who are sexually active who are not willing to use an accepted effective contraceptive method. 3. Plan to have surgery or other invasive procedure during the course of the study (up to 14 days post-injection) 4. Have a progressive medical illness including, but not limited to, any cardiovascular, hepatic, respiratory, hematological, endocrine, psychiatric or neurological disease, convulsions, or any clinically significant laboratory abnormality at screening and at first visit (D0) that, in the judgment of the medical doctor, indicate a medical problem that would preclude study participation. 5. Have one of these conditions (for both patient groups): 1. hepatic disorder such as hepatic encephalopathy, hepatic laboratory abnormalities (ALT or AST ≥3 × ULN or total bilirubin ≥2 × ULN) and hematology abnormalities at screening. 2. severe chronic kidney disease (eg, an estimated glomerular filtration rate [eGFR] <30 mL/min/1.73m or requires chronic dialysis) at screening. 3. Have severe active psychiatric illness. 4. Have a diagnosis of another neurodegenerative disease (e.g. Parkinson disease, Alzheimer's disease, etc). 5. Have a significant infection or known inflammatory process on screening or at Day 0. 6. Alcohol or drug abuse based on patient auto-report 7. Have a history of relevant atopy or drug hypersensitivity or allergy to antibodies; 8. Have an abnormal blood pressure (supine) defined as a diastolic blood pressure >90 or <45 mmHg and/or a systolic blood pressure >160 or <90 mmHg. Re-testing may occur once during the screening visit within 2 hours of the initial abnormal blood pressure measurement at the discretion of the investigator. 6. For ALS patients: 1. Have undergone a tracheostomy for ALS symptoms. 2. Are on nasal intermittent positive pressure ventilation (NIPPV) >4h during the day, while awake for the treatment of ALS related symptoms. 3. Have other causes of neuromuscular weakness. 7. Have received treatment with biologic agents (such as monoclonal antibodies, including marketed drugs and AP-101) within 3 months or 5 half-lives (whichever is longer) prior to study drug injection. 8. Have received any blood or blood products within the 3 months prior to screening. 9. Cannot communicate reliably with the investigator. 10. Are unwilling or unable to give written informed consent. 11. In the opinion of the medical doctor or his/her delegate, are unsuitable for inclusion in the study.",I,Both
0,Patients With Non Fluent Primary Progressive Aphasia,"Patient has a clinical diagnosis of non-fluent/agrammatic variant PPA according to the criteria by Gorno-Tempini et al. (2011) with evidence of left frontal brain hypometabolism. Patients with right-sided hypometabolism are eligible for the study only if they are left-handed. Patient has a FTLD-CDR language domain score of < or = 2, and other individual FTLD-CDR domain scores < or = 1. Patient's age is 18 - 85 years inclusive at the time of having provided informed consent. Patient has adequate visual and auditory abilities and premorbid local language skills to allow neuropsychological testing. Sexually active female patients must be using highly effective contraception methods, or be surgically sterile, or be at least 2 years post-menopausal. Sexually active male patients must be using highly effective contraception methods, or be surgically sterile. Patient and caregiver have signed and dated written informed consent. Availability of a partner/caregiver knowing the patient and being able to accompany the patient to the visits. Patient is legally competent.",AC-TP-001 AIDA EudraCT Number: 2017-000643-41 NCT03174886 TrialTroveID-302891,Adults; Older Adults,year(s),year(s),302891,Frontotemporal Dementia,85.0,18.0,"The patient's brain MRI is incompatible with a diagnosis of nfvPPA. Patient has a history or evidence of a central nervous system (CNS) disorder other than nfvPPA which may cause symptoms of aphasia or dementia (Alzheimer's disease, Dementia with Lewy Bodies, inflammatory/demyelinating CNS conditions, Creutzfeldt-Jakob disease, Huntington's disease, etc.) Patient has a history or currently suffers from a significant psychiatric illness such as schizophrenia, any type of psychotic disorder or bipolar affective disorder. Patient has a history or evidence of cerebrovascular disease (ischemic or haemorrhagic stroke), or diagnosis of possible, probable or definite vascular dementia. Patient has Wernicke's encephalopathy. Patient has metabolic or toxic encephalopathy or dementia due to a general medical condition. Patient suffers from hypothyroidism, defined as thyroid-stimulating hormone elevation > 5.000 mcIU/mL, and/or fT4 levels < 0.7 ng/dL. Patients with corrected hypothyroidism are eligible for the study provided that treatment has been stable for 12 weeks before study entry. Patient has a known pathogenic mutation in GRN or C9orf72. Presence or history of allergy to components of the vaccine. Presence and/or history of immunodeficiency (e.g., HIV). Patient is currently being treated with immunosuppressive drugs. Patient has a history and/or currently suffers from a clinically significant autoimmune disease, or is expected to receive immunosuppressive or immunomodulatory treatment at the present or in the future. Patient has a recent (< or = 5 years since last specific treatment) history of cancer (Exceptions: basal cell carcinoma, intraepithelial cervical neoplasia). Patient has an active infectious disease (e.g., Hepatitis B, C). Patient had a myocardial infarction within the last 2 years. Patient has a current clinically important systemic illness that is likely to result in deterioration of the patient's condition or affect the subject's safety during the study: poorly controlled congestive heart failure (New York Heart Association [NYHA] score > or = 3), poorly controlled diabetes, severe renal insufficiency (Estimated glomerular filtration rate < 30 mL/min), chronic liver disease - ALT (alanine aminotransferase) > 2x upper limit of normal range (ULN), AST (aspartate aminotransferase) > 2x ULN other clinically significant systemic illness, if considered relevant by the investigator. Patient had alcohol or drug dependence within the past year. Patient has a current diagnosis of epilepsy. Pregnant or breastfeeding women. Patient has participated in another interventional clinical trial within 12 weeks before Visit 01. Patient has contraindication for MRI imaging such as metallic endoprosthesis or MRI-incompatible stent implantation. Patient has contraindications for other study procedures, such as CSF sampling. Patient had surgery (under general anaesthesia) within 12 weeks prior to Visit 01 and/or scheduled surgery (under general anaesthesia) during the whole study period. Patient is currently being treated or was treated in the past with any active vaccines for a neurodegenerative disorder. Patients not expected to complete the clinical trial. Patient, in the opinion of the investigator, is unlikely to comply with the clinical study protocol, or is unsuitable for other reasons. Patient is dependent from Sponsor or investigator (e.g. as an employee or as a relative).",I,Both
0,Patients with advanced Parkinson's Disease,"Patients with idiopathic Parkinson's disease meet diagnostic criteria for Specified Disease designated by the Ministry of Health, Labour and Welfare (1995) : the Research. Committee of CNS Degenerative Disease, L-Dopa is effective in the early disease stage and no findings suggestive of CNS Degenerative Disease are found. Age < or = 75 years at the time of medical treatment. Age at onset > or = 35 years. Duration of L-dopa therapy > or = 5 years. Hoehn and Yahr Stage IV in OFF state at the onset of medical treatment. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Scale Part III (MDS-UPDRS-III), minimum motor score of 30 to a maximum motor score of 100 in OFF state. Positive response to dopaminergic therapy as evidenced by remarkable improvement in MDS-UPDRS-III motor score between the defined ""OFF"" and ""ON"" state: a minimum 16 points improvement in the MDS-UPDRS-III after dopaminergic therapy. Patients who can undergo the stereotaxic surgery for Parkinson's disease due to the intolerable motor complication minimum score of 4 to a maximum score of 9 in the MDS-UPDRS-IV part B (diurnal fluctuation of symptom) , not responsive to optimal medical therapy. To be able to comply with the requirements, including the frequent clinical examination after medical treatment, in this study. To keep the therapeutic medicine for Parkinson's disease for at least 2 months prior to participation in this study. Written informed consent.",JMU-AAV-AADC-PD NCT02418598 TrialTroveID-219951 UMIN000017377,Adults; Older Adults,year(s),year(s),219951,Advanced-stage,75.0,35.0,"Patients who is suspected secondary / atypical parkinsonism based on the medical history of cerebral vascular disease, exposure to antipsychotic or toxic agents, and encephalitis or based on the symptom of Progressive supranuclear palsy, Pyramidal tract sign, autonomic sign, Dementia, Hallucination, Delusion and so on or based on the finding by magnetic resonance imaging (MRI) such as Lacunar infarct or atrophy of the midbrain tectum and atrophy of the pons and the cerebellum. Patients with history of 3 hours or more of intensive or violent dyskinesias in the past 6 months. Patients with previous the stereotaxy for Parkinson's disease (pallidotomy, thalamotomy, deep brain stimulation) . Mini-Mental State Examination (MMSE) < or = 20 or patient with a diagnosis of dementia in the neuropsychological evaluation. Patients with medical history of Hallucination, Delusion, schizophrenia or affective disorder within 6 months of informed consent. Patients with history of significant cardiovascular disease including cerebrovascular accident. Malignant neoplasm in the brain, clinically significant neurological disease (for example significant brain atrophy not consistent with age). History of other malignancy, with the exception of treated carcinoma cutaneum, within 5 years. Uncontrolled hypertension: systolic blood pressure > or = 160 mmHg. Coagulopathy or need for anticoagulant therapy. Clinically significant immune dysfunction (for example, the case who require the use of immunosuppressive drugs). Geriatric Depression Scale (GDS) short scale > or = 10 points, or if on antidepressant, the score > 5 points. On monoamine oxidase (MAO)-A inhibitors, or antipsychotic medications. Unable to scan MRI. Cases without abnormal finding in FMT-PET. Premenopausal female or male who desire impregnating a female (excluded: in case when sperm is cryopreserved prior to gene therapy and child is born by using the sperm). Past medical history of convulsive seizure within 3 years or receiving antiepileptic drug or patients with epileptic aberrance in the electroencephalography. Past medical history of serious drug allergy. Patients who have participated in other clinical trial within 6 months. Patients who meet any of the following criteria: Serious renal disorder ( Cr > or = 2.0 mg/dl and BUN > or = 25mg/dl). Serious hepatic disorder ( AST (GOT) / ALT (GPT) < or =2.5xupper limit of normal (ULN). Serious diabetes (casual blood glucose or fasting blood glucose > or = 200 mg/dl and HbA1c > or = 9 %). Any other patients judged by investigators to be inappropriate for the subject of this study.",Iii,Both
1,Patients with Amyotrophic Lateral Sclerosis (ALS).,"1. Age > or = 18 years at the time of screening 2. Diagnosis of ALS according to the Gold Coast Criteria 3. Capable of providing informed consent and complying with trial procedures 4. TRICALS risk profile > -6.0 and < -2.0 (See Section 4.3.4) 5. Those taking Riluzole must be on a stable dose for at least 30 days prior to the baseline visit or must have stopped taking Riluzole at least 30 days prior to the baseline visit 6. Women must not become pregnant (e.g., post-menopausal, surgically sterile, using highly effective birth control methods or not having potentially reproductive sex) for the duration of the study. Highly effective methods of birth control are those with a failure rate of < 1% per year when employed consistently and correctly, e.g. Combined (oestrogen and progestogen containing) hormonal contraception or progestogen-only hormonal contraception 7. Women of childbearing potential must have a negative serum pregnancy test at screening and baseline and be non-lactating. Women of childbearing potential are defined as females who have experienced menarche and are not surgically sterilised (e.g. hysterectomy or bilateral salpingectomy) or post-menopausal (defined as at least 1 year since last regular menstrual period). 8. For participants taking antacids (regularly or as required), participant is willing and able to avoid taking antacids for at least 2 hours before and 6 hours after Triumeq",EudraCT Number: 2020-005069-15 ISRCTN88446415 Lighthouse 2 LIGHTHOUSE 2 Lighthouse II LIGHTHOUSE II LIGHTHOUSEII NCT05193994 NL77109.041.21 TrialTroveID-364543,Adults,year(s),year(s),364543,Delay Disease Progression,65.0,18.0,"1. People who are HLA-B*5701 positive 2. Known hypersensitivity to Dolutegravir, Abacavir or Lamivudine, or to any of the excipients 3. Safety Laboratory Criteria at screening: ALT > or = 5 times upper limit of normal (ULN) AST > or= 3 times ULN Bilirubin > or = 1.5 times ULN Creatinine clearance < 30 mL / min Platelet concentration of < 100 x109 per L Absolute neutrophil count of < 1x109 per L Haemoglobin < 100 g/L Amylase & lipase > or = 2 times ULN Lactate > or = 2 times ULN 4. Moderate to severe hepatic impairment, as defined by local clinical guidelines 5. Presence of HIV antibodies at screening 6. Presence of Hepatitis C antibodies at screening unless participants have had effective treatment for Hepatitis C 7. Presence of Hepatitis B core or surface antigen at screening 8. Participation in any other investigational drug trial or using investigational drug within 30 days prior to screening 9. Use of NIV > or =22 h per day or having a tracheostomy 10. Edaravone dose within 30 days prior to screening. Edaravone is approved by the FDA and in Japan, but remains an investigational product in Europe and Australia 11. Clinically significant history of unstable or severe cardiac, oncological, psychiatric, hepatic, or renal disease or other medically significant illness 12. Taking medication contraindicated with Triumeq: Dofetilideor Fampridine (dalfampridine)",Iii,Both
0,Patients with motor neuron disease (MND)/amyotrophic lateral sclerosis (ALS).,"Subjects must meet all of the following inclusion criteria to be eligible to participate in this study: Age 18-75 years at the time of the screening visit Able to provide informed consent and comply with study procedures Sporadic ALS diagnosed as probable, laboratory-supported probable or definite according to the World Federation of Neurology El Escorial revised criteria as determined by a neurologist with neuromuscular sub-specialty training Diagnosis <24 months from date of enrolment (Forced) Vital capacity at least 60% of predicted value for gender, height and age at the screening visit Must be on a stable dose of riluzole for at least 30 days prior to the screening visit. Subject has established care with a neurologist at one of the four specialized ALS clinics involved in the study and will maintain this clinical care throughout the study. Subjects can participate in clinical registries, but will be excluded to this protocol if they are participating in a clinical trial involving additional or investigative treatment exposure. Negative for HLA B*5701, which is an indicator of potential sensitivity to Abacavir",CUR-101 Lighthouse NCT02868580 TrialTroveID-284540,Adults; Older Adults,year(s),year(s),284540,Delay Disease Progression,75.0,18.0,"A participant will be excluded if he or she has any of the following: Dependence on mechanical ventilation at the time of screening Gastrostomy at the time of screening Absence of Upper Motor Neuron Signs Participation in any other investigational drug trial or using investigational drug (within 12 weeks prior to screening) Known hypersensitivity to dolutegravir, abacavir or lamivudine, or to any of the excipients Presence of the HLA-B*5701 allele at screening Presence of a monogenic cause of ALS (e.g. known mutation in SOD1, expansion in c9orf72 etc.) History of positive test or positive result at screening for HIV Subjects positive for Hepatitis B at screening (+HBsAg), or anticipated need for Hepatitis C virus (HCV) therapy during the study*; Women must not be able to become pregnant (post menopausal for >1 year, surgically sterile, adequate contraception) or breastfeed for the duration of the study. Women of childbearing potential must have a negative pregnancy test at screening and be non-lactating Other interventional clinical trial Subject is taking medication contraindicated with Triumeq. Dofetilide (or pilsicainide [available in Japan]) is prohibited as DTG may inhibit its renal tubular secretion resulting in increased dofetilide concentrations and potential for toxicity. Presence of any of the following clinical conditions at the time of screening: Drug or alcohol abuse Unstable medical disease (such as unstable angina or chronic obstructive pulmonary disease), or active infectious disease (such as Hepatitis B or C or tuberculosis), or current malignancy Unstable psychiatric illness defined as psychosis or untreated major depression within 90 days of the screening visit. This exclusion criteria is based on a prior psychiatric diagnosis that is unstable as determined by the subject's treating Psychiatrist Dementia as previously diagnosed by a medical practitioner Safety Laboratory Criteria at the screening visit: Alanine aminotransferase (ALT) >5 times the upper limit of normal (ULN), OR ALT >3xULN Total bilirubin, lactate, triglycerides, amylase, or lipase greater than 2.0 times the upper limit of normal Subject has creatinine clearance of <50 mL/min via Cockroft-Gault method Subjects with moderate to severe hepatic impairment (Class B or greater) as determined by Child-Pugh classification; Absolute neutrophil count of < 1 x 109/L Platelet concentration of < 100 x 109/L Haemoglobin < 100g/L",Ii,Both
0,"Healthy Western, Japanese and Han Chinese subjects.",,TrialTroveID-513380,,,,513380,Healthy subjects,,,,I,
0,Healthy subjects,"- Adult volunteers in general good health. - Must voluntarily sign and date an informed consent, approved by an independent ethics committee (IEC)/institutional review board (IRB), prior to the initiation of any screening or study-specific procedures. - Individuals between 18 and 55 years of age inclusive at the time of screening. - Body Mass Index (BMI) is ≥ 18.0 to ≤ 29.9 kg/m2 - All male subjects who are sexually active and not surgically sterilized must agree to use an acceptable contraceptive method. Additionally, male subjects must agree to not donate sperm during the study until 30 days after the final dose of study drug. - All female subjects who are sexually active and of childbearing potential must agree to use a highly effective contraceptive method. Additionally, female subjects must agree to not donate eggs during the study and for 30 days after the final dose of study drug.",M24-852 NCT06310876 TrialTroveID-508060,Adults,year(s),year(s),508060,Healthy subjects,55.0,18.0,"- Subject who, in the opinion of the investigator, is incapable of completing study-required visits and procedures - Pregnant or breastfeeding. - Treatment with any other investigational treatment within 30 days",I,Both
0,Healthy subjects,"- Adult volunteers in general good health. - Must voluntarily sign and date an informed consent, approved by an independent ethics committee (IEC)/institutional review board (IRB), prior to the initiation of any screening or study-specific procedures. - Individuals between 18 and 55 years of age inclusive at the time of screening. - Body Mass Index (BMI) is ≥ 18.0 to ≤ 32.0 kg/m2. - All male subjects who are sexually active and not surgically sterilized must agree to use an acceptable contraceptive method. Additionally, male subjects must agree to not donate sperm during the study until 30 days after the final dose of study drug. - All female subjects who are sexually active and of childbearing potential must agree to use a highly effective contraceptive method. Additionally, female subjects must agree to not donate eggs during the study and for 30 days after the final dose of study drug.",M24-851 NCT06145607 TrialTroveID-493451,Adults,year(s),year(s),493451,Healthy subjects,55.0,18.0,"- Subject who, in the opinion of the investigator, is incapable of completing study-required visits and procedures - Pregnant or breastfeeding. - Treatment with any other investigational treatment within 30 days",I,Both
0,Healthy Subjects,"- Adult volunteers in general good health - Must voluntarily sign and date an informed consent, approved by an independent ethics committee (IEC)/institutional review board (IRB), prior to the initiation of any screening or study-specific procedures - Individuals between 18 and 65 years of age inclusive at the time of screening - BMI is > or = 18.0 to < or = 32.0 kg/m2 - All male subjects who are sexually active and not surgically sterilized must agree to use an acceptable contraceptive method. Additionally, male subjects must agree to not donate sperm during the study until 30 days after the final dose of study drug - All female subjects who are sexually active and of childbearing potential must agree to use a highly effective contraceptive method. Additionally, female subjects must agree to not donate eggs during the study and for 30 days after the final dose of study drug.",M24-192 NCT05763459 TrialTroveID-461774,Adults,year(s),year(s),461774,(N/A); Healthy subjects,65.0,18.0,"- Subject who, in the opinion of the investigator, is incapable of completing study-required visits and procedures - Pregnant or breastfeeding. - Treatment with any other investigational treatment within 30 days",I,Both
1,Subjects with amyotrophic lateral sclerosis (ALS),- No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT NCT04297683).,2019P003518F HEALEY ALS Platform – Regimen F NCT05740813 TrialTroveID-459902,Adults; Older Adults,year(s),year(s),459902,Delay Disease Progression,100.0,18.0,"- The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683). 1. Based on the metabolism of the compound, the concomitant use of certain inhibitors and inducers of cytochrome P450 enzymes. 2. Any clinically significant ECG abnormalities. 3. Clinically significant clinical laboratory abnormalities.",Ii/Iii,Both
0,Healthy subjects,,TrialTroveID-396430,Adults,year(s),year(s),396430,(N/A); Healthy subjects,65.0,18.0,,I,Both
0,Patients with Amyotrophic Lateral Sclerosis,"Must have an identified, reliable caregiver Confirmed diagnosis of Familial ALS or Sporadic ALS First ALS symptoms occurred ≤36 months before screening Able to swallow solids No known active COVID-19 infection at screening Vital capacity ≥50% predicted value (for sex, age, ethnic origin, and height) at screening If taking concomitant standard-of-care medications approved for the treatment of ALS (or their components), subjects must be on a stable dose of the medication(s) for >30 days prior to Baseline in order to enter the study. For edaravone, a stable dose is defined by having completed 2 treatment cycles prior to Baseline.",CCR-21-30 M20-405 NCT04948645 TrialTroveID-396402,Adults; Older Adults,year(s),year(s),396402,Delay Disease Progression,80.0,18.0,"History of dementia/severe cognitive problems at screening History of clinically significant medical conditions (other than ALS) or any other reason, including any physical, psychological, or psychiatric condition that, in the opinion of the Investigator, would compromise the safety or interfere with the subject's participation in the study, or would make the subject an unsuitable candidate to receive study drug, or would put the subject at risk by participating in the study. History of abnormal screening laboratory or imaging results that, in the opinion of the Investigator, are indicative of any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, infectious, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal, neurologic, and/or other major disease that would preclude administration of ABBV-CLS-7262. Documented active or suspected malignancy or history of any malignancy within the last 5 years except for successfully treated non-melanoma skin cancer or localized carcinoma in situ of the cervix If female, is known to be pregnant, breastfeeding, considering becoming pregnant, or donating/banking eggs during the study or within 30 days or >5 half-lives (whichever is longer) after the last dose of study drug If male, plans to donate sperm or father a child during the study or within 30 days after the last dose of study drug Known to have received any investigational product within 30 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug or is currently enrolled in another clinical study History of ABBV-CLS-7262 use prior to participation in this study Recent (within 6 months prior to Screening) history of drug or alcohol abuse Previous participation in a stem cell clinical study for treatment of ALS Current or anticipated use of diaphragmatic pacing during the study period Tracheostomy or use of non-invasive ventilatory support ≥22 hours a day",I,Both
1,"Patients (7 amyotrophic lateral sclerosis, 5 Parkinson’s disease, 8 multiple sclerosis, 8 stroke, Alzheimer’s disease) with severe sialorrhea were enrolled",,TrialTroveID-255054,,,,255054,(N/A); Comorbidity in MS; Healthy subjects; Non-motor symptoms/comorbidities; Unspecified; Unspecified MS,,,,Iv,
0,Subjects with amyotrophic lateral sclerosis.,,TrialTroveID-345889,,,,345889,Unspecified,,,,Ii,
0,,,TrialTroveID-252392,,,,252392,Unspecified,,,,Ii,
0,,,TrialTroveID-188598,,,,188598,Unspecified,,,,I,
1,Patients with amyotrophic lateral sclerosis (ALS),"1. Age 18+; 2. ALS diagnosis according to the Gold Coast Criteria; 3. Disease duration < 24 months from symptom onset, as indicated by limb weakness or bulbar symptoms, at the randomization/baseline visit*; 4. Self-sufficiency [Satisfactory bulbar and spinal function (score 3+ on the ALSFRS-R for swallowing, cutting food and handling utensils, and walking)]; 5. Satisfactory respiratory function (FVC ≥80% of predicted); 6. Documented progression of symptoms as measured by the ALSFRS-R scale. Disease progression rate (DFS) must be>= 0.33. DFS =(48- ALSFRS-R at screening)/months from onset to screening. 7. Ability to understand and comply with the study requirements; 8. Ability to give written informed consent personally or, as an alternative, via a legally authorized representative; 9. Treatment with riluzole 50 mg twice/day for at least 4 weeks prior to randomization visit; 10. Intact cognitive function, again determined by the Principal Investigator. - The qualifying first symptoms of ALS are limited to manifestations of weakness in extremity, bulbar, or respiratory muscles. Cramps, fasciculations, or fatigue should not be taken in isolation as a first symptom of ALS.",ALCALS NCT06126315 TrialTroveID-492004,Adults; Older Adults,year(s),,492004,Delay Disease Progression; Symptom relief,,18.0,"1. Antecedent polio infection or other active infection; 2. Motor neuron disease (MND) other than ALS; 3. Involvement of other systems possibly determining a functional impairment (as measured by the endpoints) for the entire duration of the study; 4. Other severe clinical conditions (e.g., cardiovascular disorders, neoplasms) with an impact on survival or functional disability in the next 12 months; 5. Previous use of ALCAR for any reason; 6. Poor compliance with previous treatments; 7. Other experimental treatments in the three months prior to the screening visit (if a subject is receiving another experimental drug, a 3-month wash-out period before participating in the present clinical trial will be required); 8. Women who are lactating or able to become pregnant (e.g. who are not post-menopausal, surgically sterile, or using inadequate birth control) and men unable to practice contraception for the duration of the treatment and three months after its completion; 9. Inability to understand and comply with the study requirements; 10. Unwillingness or inability to take riluzole.",Ii/Iii,Both
0,Patients with definite or probable ALS according to the El Escorial Criteria.,,TrialTroveID-423254,,,,423254,Unspecified,,,,Ii,Both
0,"Patients 40-70 years with definite or probable amyotrophic lateral sclerosis (ALS), disease duration 6-24 months, self-supporting (ie, able to swallow, cut foods/handling utensils, and walk), and with forced vital capacity (FVC)>80% were enrolled.","Bulbar-onset or spinal-onset ALS with 6 – 24 months disease duration, satisfactory bulbar and spinal function (score 3 on the ALS Functional Rating Scale- Revised (ALSFRS-R) Documented progression of symptoms in the last three months; ability to understand, comply with the study requirements, and give written informed consent.",TrialTroveID-166423,Adults; Older Adults,year(s),year(s),166423,Delay Disease Progression,70.0,40.0,"familial ALS, antecedent polio infection, other motor neuron diseases (MND), involvement of other neurological systems, exposure to metals, other severe clinical conditions, poor compliance with previous treatments, experimental treatments, pregnancy or breast feeding, unwillingness or inability to take riluzole.",Ii,Both
0,,,TrialTroveID-147362,,,,147362,Unspecified,,,,I,
0,Patients with Amyotrophic Lateral Sclerosis (ALS).,"Inclusion Criteria a. Definitive or probable diagnosis of ALS b. Age between 40 and 70 years. c. Disease duration between 6 and 24 months; d. Disable 'mild or moderate, documented by a spinal or bulbar function is still satisfactory (minimum score of 3 to ALS-FRS-R scale for swallowing, the ability' to cut food and handling utensils, and walking) and a satisfactory respiratory function (FVC> 80%) e. Documented progression of symptoms in the last 3 months. f. Patients are able to understand, to meet the demands of the Sudio and give written informed consent.",3303 EudraCT Number: 2004-004158-23 FARM5LRKR9 TrialTroveID-109501,Adults; Older Adults,year(s),year(s),109501,Unspecified,70.0,40.0,"Familiarity 'for ALS; b. Previous polio c. Other motor neuron diseases (progressive bulbar palsy, progressive muscular atrophy, primary lateral sclerosis) d. Involvement of other districts nerve (sensory, extrapyramidal, oculomotor, cerebral, self-vegetative) e. Exposure to metals; f. Presence of other serious chronic illnesses and / or life-threatening; g. Presence of dementia; h. Other experimental treatments in the previous three months; i. Poor compliance. Familial ALS Patient and/or caring physician unwilling to take and/or prescribe riluzole.",Ii,Both
0,Patients with amyotrophic lateral sclerosis.,,TrialTroveID-415000,,,,415000,Unspecified,,,,Iii,
0,Healthy volunteers.,"Body Mass Index (BMI) between 18 and 32 kg/m2. Is in general good health, based upon the results of a medical history assessment, physical examination, vital signs, laboratory profile, and 12-lead electrocardiogram (ECG), as judged by the investigator. Female subjects may not be pregnant, lactating, or breastfeeding. Subjects must have a negative urine test for drugs of abuse, cotinine, and breath alcohol test at screening and Check-in",NCT03500627 OP-101-002 TrialTroveID-322747,Adults,year(s),year(s),322747,(N/A); Healthy subjects,65.0,18.0,"Evidence of clinically significant hematologic, renal, endocrine, pulmonary, cardiac, gastrointestinal, hepatic, psychiatric, neurologic, immunologic, allergic disease, or any other condition that, in the opinion of the Investigator, might significantly interfere with the absorption, distribution, metabolism, or excretion of study drug, or place the subject at an unacceptable risk as a participant in this study. History of malignancy (other than successfully treated basal cell or squamous cell skin cancer). History or presence of an abnormal ECG that, in the opinion of the Investigator, is clinically significant. Has used any product containing nicotine within 90 days prior to screening or intends to use any product containing nicotine during the course of the study. Has used medications that affect gastrointestinal motility or gastric emptying; such as metoclopramide, proton pump inhibitors, and H2 blockers; within 30 days prior to Day 1. Has used prescription or over-the-counter medication, vitamins/herbal supplements (with the exception of hormonal contraceptives) within 14 days prior to Day 1",I,Both
1,Patients with Niemann-Pick Disease Type C.,"1. Written informed consent signed by the patient and/or their legal representative/ parent/ impartial witness 2. Male or female aged ≥4 years with a confirmed genetic diagnosis of NPC at the time of signing informed consent. 3. Females of childbearing potential, defined as a premenopausal female capable of becoming pregnant, will be included if they are either sexually inactive (sexually abstinent for 14 days prior to the first dose and confirm to continue through 28 days after the last dose) or using one of the following highly effective contraceptives (i.e. results in <1% failure rate when used consistently and correctly) 14 days prior to the first dose continuing through 28 days after the last dose: 1. intrauterine device (IUD); 2. surgical sterilization of the partner (vasectomy for 6 months minimum); 3. combined (estrogen or progestogen containing) hormonal contraception associated with the inhibition of ovulation (either oral, intravaginal, or transdermal); 4. progestogen only hormonal contraception associated with the inhibition of ovulation (either oral, injectable, or implantable); 5. intrauterine hormone releasing system (IUS); 6. bilateral tubal occlusion. 4. Females of non-childbearing potential who have undergone one of the following sterilization procedures at least 6 months prior to the first dose: 1. hysteroscopic sterilization; 2. bilateral tubal ligation or bilateral salpingectomy; 3. hysterectomy; 4. bilateral oophorectomy; OR be postmenopausal with amenorrhea for at least 1 year prior to the first dose and follicle stimulating hormone (FSH) serum levels consistent with postmenopausal status. FSH analysis for postmenopausal women will be done at screening. FSH levels should be in the postmenopausal range as determined by the central laboratory. 5. Non-vasectomized male patient agrees to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond the last dose of study medication and the female partner agrees to comply with inclusion criteria 3 or 4. For a vasectomized male who has had his vasectomy 6 months or more prior to study start, it is required that they use a condom during sexual intercourse. A male who has been vasectomized less than 6 months prior to study start must follow the same restrictions as a non-vasectomized male. 6. If male, patient agrees not to donate sperm from the first dose until 90 days after their last dose. 7. Patients must fall within: a) A SARA score of 7 ≤ X ≤ 34 points (out of 40) AND b) Either: i. Within the 2-7 range (0-8 range) of the Gait subtest of the SARA scale OR ii. Be able to perform the 9-Hole Peg Test with Dominant Hand (9HPT-D) (SCAFI subtest) in 20 ≤ X ≤150 seconds. 8. Weight ≥15 kg at screening. 9. Patients are willing to disclose their existing medications/therapies for (the symptoms) of NPC including those on the prohibited medication list. Non-prohibited medications/therapies (authorized medicines for NPC [e.g. miglustat], speech therapy, and physiotherapy) are permitted provided: 1. The Investigator does not believe the medication/therapy will interfere with the study protocol/results 2. Patients have been on a stable dose/duration and type of therapy for at least 42 days before Visit 1 (Baseline 1) 3. Patients are willing to maintain a stable dose/do not change their therapy throughout the duration of the study. 10. An understanding of the implications of study participation, provided in the written patient information and informed consent by patients or their legal representative/parent, and demonstrates a willingness to comply with instructions and attend required study visits (for children this criterion will also be assessed in parents or appointed guardians).",BASEC2022-00638 EudraCT Number: 2021-005356-10 IB1001-301 NCT05163288 NL79787.018.21 SNCTP000005101 TrialTroveID-421082,Children; Adults; Older Adults,year(s),,421082,Niemann-Pick Type C,,4.0,"1. Patients who are unable to consistently Patients who have any known hypersensitivity or history of hypersensitivity to: 1. Acetyl-Leucine (DL-, L-, D-) or derivatives. 2. Excipients the IB1001 sachet (namely isomalt, hypromellose, and strawberry flavour). 3. Excipients the placebo sachet (namely isomalt, hypromellose, strawberry flavour, citric acid, microcrystalline cellulose, lactose, denatonium benzoate). 2. Simultaneous participation in another clinical study or participation in any clinical study involving administration of an investigational medicinal product (IMP; 'study drug') for at least 42 days prior to Visit 1. At the discretion of the investigator, Medical Monitor, and Sponsor, the washout period for specific IMPs may be longer based on the pharmacological activity and pharmacokinetics of the drug. 3. Patients with a physical, cognitive, or psychiatric condition which, at the investigator's discretion and in consultation with the Medical Monitor and Sponsor (as applicable), may put the patient at risk, may confound the study results, or may interfere with the patient's participation in the clinical study, i.e. reliably perform study assessments. 4. Known or persistent use, misuse, or dependency of medication, drugs, or alcohol. 5. Current or planned pregnancy or women who are breastfeeding. 6. Patients with severe vision or hearing impairment (that is not corrected by glasses or hearing aids) that, at the investigator's discretion, interferes with their ability to perform study assessments. 7. Patients who have been diagnosed with arthritis or other musculoskeletal disorders affecting joints, muscles, ligaments, and/or nerves that by themselves affects patient's mobility and, at the investigator's discretion, interferes with their ability to perform study assessments. 8. Patients unwilling and/or not able to undergo a 42 day period from any of the following prohibited medication prior to Visit 1 (Baseline 1) and remain without prohibited medication through Visit 6. 1. N-Acetyl-DL-Leucine (e.g. Tanganil®); 2. N-Acetyl-L-Leucine (prohibited if not provided as IMP in the IB1001-301 trial); 3. Sulfasalazine; 4. Rosuvastatin. -",Iii,Both
0,Patients with Niemann-Pick type C disease,"Individuals who meet all of the following criteria are eligible to participate in the study: 1. Written informed consent signed by the patient and/or their legal representative/ parent 2. Male or female aged ≥6 years in Europe OR ≥18 years in the United States with a confirmed diagnosis of NPC at the time of signing informed consent. Patients must have clinical features of NPC and a positive genetic test for mutations in both copies of NPC1 or in both copies of NPC2. 3. Females of childbearing potential, defined as a premenopausal female capable of becoming pregnant, will be included if they are either sexually inactive (sexually abstinent for 14 days prior to the first dose continuing through 28 days after the last dose) or using one of the following highly effective contraceptives (i.e. results in <1% failure rate when used consistently and correctly) 14 days prior to the first dose continuing through 28 days after the last dose: 1. intrauterine device (IUD); 2. surgical sterilization of the partner (vasectomy for 6 months minimum); 3. combined (estrogen or progestogen containing) hormonal contraception associated with the inhibition of ovulation (either oral, intravaginal, or transdermal); 4. progestogen only hormonal contraception associated with the inhibition of ovulation (either oral, injectable, or implantable); 5. intrauterine hormone releasing system (IUS); 6. bilateral tubal occlusion. 4. Females of non-childbearing potential must have undergone one of the following sterilization procedures at least 6 months prior to the first dose: 1. hysteroscopic sterilization; 2. bilateral tubal ligation or bilateral salpingectomy; 3. hysterectomy; 4. bilateral oophorectomy; OR be postmenopausal with amenorrhea for at least 1 year prior to the first dose and follicle stimulating hormone (FSH) serum levels consistent with postmenopausal status. FSH analysis for postmenopausal women will be done at screening. FSH levels should be in the postmenopausal range as determined by the central laboratory. 5. Non-vasectomized male patient agrees to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond the last dose of study medication and the female partner agrees to comply with inclusion criteria 3 or 4. For a vasectomized male who has had his vasectomy 6 months or more prior to study start, it is required that they use a condom during sexual intercourse. A male who has been vasectomized less than 6 months prior to study start must follow the same restrictions as a non-vasectomized male. 6. If male, patient agrees not to donate sperm from the first dose until 90 days after dosing. 7. Patients must fall within: a) A SARA score of 5 ≤ X ≤ 33 points (out of 40) AND i. Within the 2-7 range (out of 0-8 range) of the Gait subtest of the SARA scale OR ii. Be able to perform the 9 Hole Peg Test with Dominant Hand (9HPT-D) (SCAFI subtest) in 20 ≤ X ≤150 seconds. 8. Weight ≥15 kg at screening. 9. Patients are willing to disclose their existing medications/therapies for (the symptoms) of NPC, including those on the prohibited medication list. Non-prohibited medications/therapies (e.g. miglustat, concomitant speech therapy, and physiotherapy) are permitted provided: 1. The Investigator does not believe the medication/therapy will interfere with the study protocol/results 2. Patients have been on a stable dose/duration and type of therapy for at least 6 weeks before Visit 1 (Baseline 1) 3. Patients are willing to maintain a stable dose/do not change their therapy throughout the duration of the study. 10. An understanding of the implications of study participation, provided in the written patient information and informed consent by patients or their legal representative/parent, and demonstrates a willingness to comply with instructions and attend required study visits (for children this criterion will also be assessed in parents or appointed guardians).",EudraCT Number: 2018-004331-71 IB1001-201 NCT03759639 TrialTroveID-337946,Children; Adults; Older Adults,year(s),,337946,Niemann-Pick Type C,,6.0,"Exclusion Criteria Individuals who meet any of the following criteria are not eligible to participate in the study: 1. Asymptomatic patients 2. Patient has clinical features of NPC and a positive biomarker screen and/or filipin test, but a negative result on a previous genetic test for NPC 3. Patients who have any of the following: 1. Chronic diarrhea; 2. Unexplained visual loss; 3. Malignancies; 4. Insulin-dependent diabetes mellitus. 5. Known history of hypersensitivity to the N-Acetyl-Leucine (DL-, L-, D-) or derivatives. 6. History of known hypersensitivity to excipients of Ora-Blend® (namely sucrose, sorbitol, cellulose, carboxymethylcellulose, xanthan gum, carrageenan, dimethicone, methylparaben, and potassium sorbate). 4. Simultaneous participation in another clinical study or participation in any clinical study involving administration of an investigational medicinal product (IMP; 'study drug') within 6 weeks prior to Visit 1. 5. Patients with a physical or psychiatric condition which, at the investigator's discretion, may put the patient at risk, may confound the study results, or may interfere with the patient's participation in the clinical study. 6. Known clinically-significant (at the discretion of the investigator) laboratories in hematology, coagulation, clinical chemistry, or urinalysis, including, but not limited to: 1. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >5x upper limit of normal (ULN); 2. Total bilirubin >1.5x ULN, unless Gilbert's syndrome is present in which case total bilirubin >2x ULN. 7. Known or persistent use, misuse, or dependency of medication, drugs, or alcohol. 8. Current or planned pregnancy or women who are breastfeeding. 9. Patients with severe vision or hearing impairment (that is not corrected by glasses or hearing aids) that, at the investigator's discretion, interferes with their ability to perform study assessments. 10. Patients who have been diagnosed with arthritis or other musculoskeletal disorders affecting joints, muscles, ligaments, and/or nerves that by themselves affects patient's mobility and, at the investigator's discretion, interferes with their ability to perform study assessments. 11. Patients unwilling and/or not able to undergo a 6-week washout period from any of the following prohibited medication prior to Visit 1 (Baseline 1) and remain without prohibited medication through Visit 6. 1. Aminopyridines (including sustained-release form); 2. N-Acetyl-DL-Leucine (e.g. Tanganil®); 3. N-Acetyl-L-Leucine (prohibited if not provided as IMP); 4. Riluzole; 5. Gabapentin; 6. Varenicline; 7. Chlorzoxazone; 8. Sulfasalazine; 9. Rosuvastatin. Extension Phase Inclusion Criteria 1. Completed Visit 6 of the IB1001-201 Parent Study 2. The Principal Investigator determines further treatment with IB1001 to be in patient's best interest 3. Written informed consent signed by the patient and/or their legal representative/parent/ impartial witness for participation in the Extension Phase 4. Patients are willing to continue to remain without the following prohibited medication from Visit 6 throughout the duration the Extension Phase: 1. Aminopyridines (including sustained-release form); 2. N-Acetyl-DL-Leucine (e.g. Tanganil®); 3. N-Acetyl-L-Leucine (prohibited if not provided as IMP); 4. Riluzole; 5. Gabapentin; 6. Varenicline; 7. Chlorzoxazone; 8. Sulfasalazine; 9. Rosuvastatin.",Ii,Both
0,Healthy adults and patients with ALS,"A healthy adult Clinical diagnosis of ALS Baseline FVC >60% predicted for age, sex and height.",AIH in ALS NCT03645031 OCR18018 TrialTroveID-363683,Adults; Older Adults,year(s),year(s),363683,Delay Disease Progression; Healthy subjects,75.0,21.0,Pregnant Diagnosed cardiovascular disease A BMI >35 kg/m2 Currently take selective serotonin reuptake inhibitors (SSRI) History of seizures History of hospitalization for sepsis Respiratory infection or took antibiotic medications within the past 4 weeks Use external respiratory support during any waking hours Participate in a pharmaceutical trial to treat ALS Have any other medical condition the PI or medical director identify would make it unsuitable to participate.,Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis,,02-(AdeVask)-2014 TrialTroveID-255731,,,,255731,Unspecified,,,,Ii,
0,Patients with Amyotrophic Lateral Sclerosis.,Clinically definite or probable ALS according to El Escorial criteria. Life expectancy of more than 1 year. INR < =2 before liposuction. Lack of treatment with immune-suppressants and/or corticosteroids within min. 20 days prior to recruitment. Constant riluzole treatment (50 mg/bid) throughout the study period. Compliance with treatment regimen e.g. will and possibility to attend check-up visits. Polish citizens,ADIPOSTEM DPO/014/33/09/2015 NCT03296501 TrialTroveID-310121,Adults,year(s),year(s),310121,Delay Disease Progression,65.0,18.0,"Primary haematological disease, including hypercoagulable states. Presence of comorbidity that would stand in the way of neurosurgical treatment- Previous history of a spinal-cord surgery at the clinically affected level. Previous/current history of neoplasm or comorbidity that could impact upon patient's survival. PEG Pregnancy /lactation Noninvasive/invasive mechanical ventilation at time of recruitment. Alcohol abuse, cocaine amphetamine, etc.",I,Both
0,"Patients with progressive and debilitating amyotrophic lateral sclerosis, also referred to as ALS or Lou Gehrig's disease.",,TrialTroveID-098220,,,,98220,Delay Disease Progression,,,,I,
0,"Patients with Amyotrophic Lateral Sclerosis. Male and female ALS patients, 18 to 70 years of age, who were ambulatory (with the use of a walker or cane, if needed) and capable of orthostatic blood pressure assessments were enrolled in the study.","Patients who meet the El Escorial criteria for Clinically Definite ALS, Clinically Probable ALS, Clinically Probable-Laboratory Supported ALS, or Definite Familial-Laboratory Supported ALS (i.e., Clinically Possible ALS with an identified SOD gene mutation).",Study 102 TrialTroveID-078903,Adults; Older Adults,year(s),year(s),78903,Unspecified,70.0,18.0,,I,Both
0,Patients with Amyotrophic Lateral Sclerosis.,,Study 101 TrialTroveID-078887,,,,78887,Unspecified,,,,I,
1,Patients with Amyotrophic lateral sclerosis,,TrialTroveID-403861,Children,,,403861,Unspecified,,,,Iii,Both
0,Later stage Amyotrophic Lateral Sclerosis (ALS) patients with poor respiratory function.,,TrialTroveID-109688,,,,109688,Delay Disease Progression,,,,Ii,Both
0,Healthy subjects,,TrialTroveID-483042,,,,483042,Healthy subjects,,,,I,
0,Patients with Amyotrophic Lateral Sclerosis (ALS).,"Ages Eligible for Study: 18 Years to 75 Years; Genders Eligible for Study: Both The patient has been correctly informed The patient must have given his/her informed and signed consent. The patient must be insured or beneficiary of a health insurance plan. The patient is at least 18 years old and less than 75 years old Probable, or laboratory-supported probable or definite ALS as defined by El Escorial Revised ALS diagnostic criteria Stable on riluzole treatment for more than 3 months Disease duration< or = 5 years Vital capacity >or = 70% of normal The patient is available and willing to participate in three study visits occurring at the Nîmes University Hospital within the next six months Ability to swallow without the requirement for nasogastric or PEG feeding Agreement for patient to use an adequate method of contraception throughout the study and for 2 weeks after post study visit The patient is available and willing to participate in seven study visits occurring at the CHU within the next six months",EudraCT number: 2014-001327-71 IMODALS LOCAL/2014/WC-01 NCT02059759 TrialTroveID-202570,Adults; Older Adults,year(s),year(s),202570,Delay Disease Progression,75.0,18.0,"Exclusion Criteria: The patient is participating in another interventional study that may interfere with the results or conclusions of this study Within the past three months, the patient has participated in another interventional study that may interfere with the results or conclusions of this study The patient is in an exclusion period determined by a previous study The patient is under judicial protection The patient is an adult under guardianship The patient refuses to sign the consent It is impossible to correctly inform the patient Other life threatening disease Presence of contra-indicated concomitant treatments Presence of infection (treated or untreated) Vaccination within 8 weeks prior to first experimental dosing Other disease precluding functional assessments Cancer within the past 5 years (except stable non-metastatic basal cell skin carcinoma or in situ carcinoma of the cervix) Severe cardiac or pulmonary disease Documented auto-immune disorders except asymptomatic Hashimoto thyroiditis Women of child bearing age without contraception or pregnant or breast feeding Any clinically significant laboratory abnormality (excepting cholesterol, triglyceride and glucose)",Ii,Both
0,Patients With Frontotemporal Disorders,"1. Diagnosis of probable frontotemporal dementia 2. Male or female age 18 to 86 years 3. If on medications affecting cognition or behaviors (Such as Atypical Antipsychotics, Acetyl Choline Esterase inhibitors), participants must be on stable dosage for at least 4 weeks prior to screening and should remain at a stable dosage during the course of the study. There are no prohibited medications preventing patients from participating in the study. 4. English language speaking 5. Formal education of eight or more years 6. Stable pharmacological treatment of any other chronic conditions for at least 30 days prior to screening 7. A family member or caretaker (study partner) who is expected to be consistently available, administer study drugs of IL-2/abatacept and attend study visits throughout the study. The study partner is also supposed to provide feedback on patient's cognitive and functional status. In the event that the designated study partner is unable to continue participating in the study, the study subject should provide another suitable study partner to ensure the uninterrupted progress of the study. 8. For FTD patients with limited decision-making capacity, the legally authorized representative (LAR) should be present in the decision-making process and trial participation, ensuring they understand the potential risks and benefits, and consent based on the patient's best interest. Extended time for consent will also be considered to ensure comprehension.",NCT06395038 PRO00037661 TrialTroveID-515031,Adults; Older Adults,year(s),year(s),515031,Frontotemporal Dementia,86.0,18.0,"1. Serious, active bacterial, fungal or viral infection, active or latent tuberculosis 2. History of severe pulmonary dysfunction 3. History of severe cardiac dysfunction defined as left ventricular ejection fraction <40%; a history of non-controlled cardiac arrhythmias; history of cardiac tamponade; Unstable angina or MI in the last 3 months 4. Hypersensitivity or allergy to IL-2 or abatacept 5. History of bowel ischemia/perforation, or GI bleeding requiring surgery 6. Hospitalization or change of chronic concomitant medication within one month prior to screening. 7. History of hemorrhage or infarct or > 3 lacunar infarcts, encephalomalacia, aneurysm, vascular malformation, subdural hematoma, space-occupying lesion (e.g. abscess or brain tumor with the exception of small incidental meningiomas) in prior CT or MRI. 8. Clinical or laboratory findings consistent with: 1. Other primary degenerative dementia, (dementia with Lewy bodies, Alzheimer's disease, Huntington's disease, Jacob-Creutzfeld Disease, Down's syndrome, Parkinson's disease, etc.) 2. Seizure disorder 3. History of infectious, metabolic or systemic diseases affecting the central nervous system (syphilis, Lyme disease, other laboratory values, etc.) 9. Clinically significant, advanced, or unstable disease that may interfere with outcome evaluations, such as: 1. Respiratory insufficiency 2. Bradycardia (<45/min.) or tachycardia (>100/min.) 3. Poorly managed hypertension (systolic >180 mm Hg and/or diastolic >100 mm Hg) or hypotension (systolic <90 mm Hg and/or diastolic <60 mm Hg) 4. Uncontrolled diabetes defined by HbA1c >8% 5. Alanine aminotransferase level (ALT) and aspartate aminotransferase (AST) higher than two times normal 6. Serum creatinine higher than 2 mg/dL 7. Neutrophil count <1,500/mm3; platelets <100,000/mm3; hematocrit (HCT) <30%. 8. INR>1.4 10. History of cancer within 3 years of screening with the exception of fully excised non-melanoma skin cancers or non-metastatic prostate cancer that has been stable for at least 6 months. 11. History of acute/chronic hepatitis B or C and/or carriers of hepatitis B 12. Disability that may prevent the patient from completing all study requirements (e.g. blindness, deafness, etc.). 13. Suspected or known allergy to any components of the study treatments. 14. Intake of investigational drug within the previous 30 days or five half-lives of the investigational drug, whichever is longer. 15. Any condition, which in the opinion of the investigator makes the patient unsuitable for inclusion. 16. Contraindication to undergoing an LP including, but not limited to: inability to tolerate an appropriately flexed position for the time necessary to perform an LP; INR >1.4 or other coagulopathy; platelet count of <100,000/μL; infection at the desired lumbar puncture site; taking anti-coagulant medication within 90 days of screening (Note: low dose aspirin is permitted); suspected non-communicating hydrocephalus or intracranial mass; prior history of spinal mass or trauma. 17. Known to be pregnant or lactating, or positive pregnancy test at screening ; This study allows enrolling women of childbearing potential and the treatments may involve unknown risks to the fetus if pregnancy were to occur during the study. This risk is mitigated by requiring proof the participant is not pregnant prior to start of treatment and requiring highly effective contraception during and, for an appropriate interval, after treatment. 18. Lack of reliable study partner.",I,Both
0,Patients With Amyotrophic Lateral Sclerosis,"Patients will be eligible for initial enrollment on this study if they meet the following criteria at the time of screening: 1. Provided informed consent and authorized use of protected health information (PHI) in accordance with national and local patient privacy regulations. 2. ALS meeting El Escorial criteria for possible, probable, lab-supported probable, or definite ALS. 3. At least 18 years old. 4. Total bilirubin less than or equal to 1.5 mg/dL 5. Alanine aminotransferase level (ALT) less than or equal to five times normal, albumin greater than or equal to 3.0 gm/dL 6. Serum creatinine less than 1.5 mg/dL 7. Capable of complying with all study procedures, including the study drug delivery procedure, in the Investigator's opinion. 8. A family member or caretaker who is expected to be consistently available to administer both study drugs of abatacept and IL-2 if the participant is unable to do so. 9. On a stable regimen of riluzole for at least 30 days at the time of screening. If not on riluzole at the time of study entry, willing to refrain from initiation of the agent for the duration of the trial. 10. Patients on edaravone willing to refrain from taking edaravone on the same day as they will receive the abatacept injection for the duration of the trial. If not on edaravone at the time of study entry, willing to refrain from initiation of the agent for the duration of the trial. 11. Forced vital capacity (FVC) ≥50% of predicted capacity for age, height, and sex at screening, or receiving treatment with noninvasive ventilation if FVC < 50% of predicted for age, height, and sex at screening.",NCT06307301 PRO00031998 TrialTroveID-507665,Adults; Older Adults,year(s),,507665,Unspecified,,18.0,"Patients will be ineligible to participate if any of the following are true at the time of screening: 1. Serious, active bacterial, fungal, or viral infection, active or latent tuberculosis. 2. Tracheostomy. 3. Severe cardiac dysfunction defined as left ventricular ejection fraction <40% if an echocardiogram is medically indicated to clarify ongoing symptoms or EKG findings.; a history of non-controlled cardiac arrhythmias; history of cardiac tamponade; Unstable angina or MI in the last 3 months. 4. Hypersensitivity or allergy to IL-2 or abatacept. 5. History of bowel ischemia/perforation, or GI bleeding requiring surgery. 6. History of resistant seizures, history of coma or toxic psychosis lasting >48 hours. 7. Platelets <100,000/mm3; hematocrit <30%. 8. History of cancer in the past 5 years (except cutaneous Basal cell carcinoma or squamous cell carcinoma). 9. Hx of immunomodulation therapy including IL-2 or abatacept administration in the past 90 days. 10. Treatment with another investigational drug, biological agent, or device within 30 days or 5 half-lives of screening, whichever is longer. 11. If female, breastfeeding, known to be pregnant, planning to become pregnant during the study, or unwilling to use effective contraception for the duration of the trial and for 90 days after treatment. 12. If male of reproductive capacity, unwilling to use effective contraception for the duration of the trial and for 90 days after treatment",I,Both
0,Subjects with ALS underwent leukapheresis with subsequent isolation and expansion of Tregs. Amyotrophic lateral sclerosis (ALS) patients exhibited diverse disease symptoms at onset and subsequent progression rates.,,TrialTroveID-297957,,,,297957,Delay Disease Progression,,,,I,
0,Patients with Amyotrophic Lateral Sclerosis,"ALS meeting El Escorial criteria for possible, probable, lab-supported probable, or definite ALS. At least 18 years old. Provided informed consent and authorized use of protected health information (PHI) in accordance with national and local patient privacy regulations. Capable of complying with all study procedures, including the study drug delivery procedure, in the Investigator's opinion. On a stable regimen of riluzole for at least 30 days at the time of screening. If not on riluzole at the time of study entry, willing to refrain from initiation of the agent for the duration of the trial. Patients on edaravone willing to refrain from taking edaravone on the same day as they will receive the Tregs infusion for the duration of the trial. If not on edaravone at the time of study entry, willing to refrain from initiation of the agent for the duration of the trial. Medical record documentation of a decline in ALSFRS-R total score of at least two points in the 90 days prior to screening or at least four points over the 180 days prior to screening. Forced vital capacity (FVC) > or = 65% of predicted capacity for age, height, and gender at screening. Patient able and willing to undergo leukapheresis.",NCT04055623 Pro00022167 Tregs in ALS TrialTroveID-355351,Adults; Older Adults,year(s),,355351,Delay Disease Progression,,18.0,"Presence of any of the following clinical conditions that would interfere with the safe conduct of the study, as determined by the Investigator: Unstable neurological, cardiovascular, cerebrovascular, pulmonary, renal, hepatic, endocrine, or hematologic disease; active malignancy or infectious disease; or other medical illness. Unstable psychiatric illness defined as psychosis (hallucinations or delusions), unstable major depression or substance abuse within 180 days prior to screening. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3 times the upper limit of normal (ULN) at screening. Serum creatinine greater than 1.8 mg/dL or creatinine clearance less than 40 mL/min at screening. History of or positive test result for human immunodeficiency virus (HIV), hepatitis C virus, or hepatitis B virus (i.e., positive for both hepatitis B surface antigen and hepatitis B core antibody) at screening. Tracheostomy. If female, breastfeeding, known to be pregnant, planning to become pregnant during the study, or unwilling to use effective contraception for the duration of the trial and for 90 days after treatment. If male of reproductive capacity, unwilling to use effective contraception for the duration of the trial and for 90 days after treatment. Enrollment in any other interventional study. Treatment with another investigational drug, biological agent, or device within 30 days or 5 half-lives of screening, whichever is longer. Patient participation in an observational/non-interventional clinical study is to be discussed with the Medical Monitor. Prior gene or cell therapy treatments for ALS.",Ii,Both
0,Subjects with Amyotrophic Lateral Sclerosis (ALS),"Age 18 years or older. Sporadic or familial ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria (Appendix 1). Subjects must not have taken riluzole for at least 30 days, or be on a stable dose of riluzole for at least 30 days (riluzole-naïve subjects are permitted in the study). Capable of providing informed consent and following trial procedures. Geographically accessible to the site. Women must not be able to become pregnant (e.g. post-menopausal, surgically sterile, or using adequate birth control methods) for the duration of the study and three months after study completion. Adequate contraception includes: abstinence, hormonal contraception (oral contraception, implanted contraception, injected contraception or other hormonal (patch or contraceptive ring, for example) contraception), intrauterine device (IUD) in place for = 3 months, barrier method in conjunction with spermicide, or another adequate method. Subjects must agree not to take live attenuated vaccines (including seasonal flu vaccine) 30 days before blood collection. Available autologous Tregs product with greater than or equal to 50% expression of CD4, CD25 and FoxP3 determined by flow-cytometry. Subjects must have been previously evaluated and followed clinically by a neuromuscular specialist at Houston Methodist Neurological Institute Normal Alanine aminotransferase level (ALT) Normal Serum creatinine level",NCT03241784 TrialTroveID-306643,Adults; Older Adults,year(s),,306643,Delay Disease Progression,,18.0,"Prior use of cells therapies Concurrent use of other experimental ALS therapies Pregnant or breastfeeding or planning to become pregnant or planning a partner's pregnancy. Other unstable medical or psychiatric illness Known immune deficiency or history of lymphoma or leukemia History of lymphopenia. History of acquired or inherited immune deficiency syndrome, including leukopenia. History of severe untreated chronic obstructive sleep apnea. FVC less than 50% predicted at screening. Exposure to any other agent currently under investigation for the treatment of subjects with ALS (off-label use or investigational) within 30 days of the Baseline Visit. The presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair ability of the subject to provide informed consent, according to the PI's judgment, or a history of active substance abuse within the prior year. Clinically significant history of cardiac, oncologic, hepatic, or renal dysfunction, or other medically significant illness. The presence of any immunologic or autoimmune disease Severe cardiac dysfunction defined clinically, or as a left ventricular ejection fraction less than 40% of predicted or abnormal EKG findings.",I,Both
0,Newly-diagnosed patients with amyotrophic lateral sclerosis (ALS),"Patient is 18 years old and less than 76 years old Possible, Probable, Probable laboratory-supported or Definite ALS as defined by El Escorial Revised ALS diagnostic criteria Disease duration < or = 24 months Slow Vital capacity > or = 70% of normal No prior or present riluzole treatment Lumbar punctures accepted by patient and done Inclusion criteria for the persons taking part in the trial 1 / Run-in period - The patient has been correctly informed - The patient must have given his/her informed and signed consent. - The patient must be 18 years old and less than 76 years old - Possible, Probable, Probable laboratory-supported or Definite ALS as defined by El Escorial Revised ALS diagnostic criteria - Disease duration < or = 24 months - Slow vital capacity > or = 70% of normal - No prior or present riluzole treatment - Lumbar punctures accepted by patient and feasible 2/ Randomised controlled trial period - Run-in period completed, including lumbar puncture and sampling for blood biomarkers at inclusion and at 3 months - The patient is willing to continue participation - Disease duration = 28 months - Stable dose of riluzole treatment for at least 3 months",EudraCT Number: 2015-005347-14 H2020/PHRC-N/2014/GB-01 MIROCALS NCT03039673 TrialTroveID-294523,Adults; Older Adults,year(s),year(s),294523,Delay Disease Progression,75.0,18.0,"Other neurodegenerative disease that could explain signs or symptoms Contra indication for lumbar puncture (history of allergy to xylocaine, presence of contra-indicated treatment, or coagulation test abnormality, clinically significant coagulopathy or thrombocytopenia) Non authorized treatment Other disease or disorders that could preclude functional assessment, or life-threatening disorders Any documented, active, past or present, auto-immune disorders except asymptomatic Hashimoto thyroiditis Using assisted ventilation Feeding through gastrostomy or nasogastric tube Women of child-bearing potential or sexually active man without contraception Pregnant or breast feeding woman Any clinically significant laboratory abnormality (excepting cholesterol, triglyceride, glucose, CK, ferritin) Exclusion criteria for persons taking part in the trial (run-in and Randomised Control Trial periods) - The patient is participating in another research study that may interfere with the results or conclusions of this study - Within the past three months, the patient has participated in another study that may interfere with the results or conclusions of this study - The patient is in an exclusion period determined by a previous study - The patient does not have capacity to give fully informed consent and/or to comply with study requirements and procedures - Significant cognitive impairment as judged by investigator on the basis of his/her assessment of the patient, taking into account information from caregivers - Other neurodegenerative disease that could explain signs or symptoms - Contra indication for lumbar puncture (presence of contra-indicated treatment, –see section 11.3.2, or coagulation test abnormality, clinically significant coagulopathy or thrombocytopenia) - Non authorised treatment (see section 11.3 of the protocol) - Other disease or disorders that could preclude functional assessments or life-threatening disorders - Any Cancer within the past 5 years (except stable non-metastatic basal cell skin carcinoma or in situ carcinoma of the cervix) - Severe cardiac or pulmonary disease - Any documented, active, past or present ,auto-immune disorders except asymptomatic Hashimoto thyroiditis - Using assisted ventilation - Gastrostomy - Women of child-bearing age and sexually active men without effective contraception or woman who are pregnant or breast feeding - Any clinically significant laboratory abnormality (excepting cholesterol, triglyceride and glucose). - Clinically significant evidence of active viral infection at randomisation: CMV, EBV, HIV-1, HBV or HCV History of documented symptomatic and treated asthma within the past 5 years",Ii,Both
1,,,TrialTroveID-415777,,,,415777,Unspecified,,,,Ii/Iii,
0,Patients With Amyotrophic Lateral Sclerosis,"1. Subjects who are qualified for the clinical trial program cycle judged by well-trained physicians; 2. 18 years old≤ age≤ 75 years old, males or females; 3. Forced vital capacity ≥ 80% of predicted vital capacity during the screening period; 4. The total score of the ALSFRS-R scale ≥ 30 points and ≤40 points during enrollment, and the respiratory function item ≥ 3 points; 5. Diagnosis of confirmed or probable ALS in accordance with the revised EI Escorial diagnostic criteria for amyotrophic lateral sclerosis of the World Federation of Neurology; 6. Subjects or their legal representatives clearly understand and voluntarily participate in the study and sign the informed consent form; 7. Subjects (including male subjects) are willing to have no birth plan and voluntarily take effective contraceptive measures during the entire study period and within 3 months after the end of the study, and have no plan to donate sperm or eggs.",KY2023-252-01 NCT06181526 SPECIALS TrialTroveID-497466,Adults; Older Adults,year(s),year(s),497466,Delay Disease Progression,75.0,18.0,"1. Diagnosed with familial ALS (based on family history); 2. With obvious cognitive impairment (MMSE scale: ≤19 points in the illiteracy group，≤ 22 points in the primary school group, and ≤26 points in the junior high school group (more than 8 years of education); 3. Obvious dysphagia; 4. Positive HIV test or history of positive test; 5. Positive hepatitis C virus antibody or positive test history; 6. Hepatitis B active infection (hepatitis B surface antigen positive and/or serum HBV DNA positive or serum HBV DNA > 2 × 108 IU/ml; 7. Have used other investigational drugs within 1 month or within 5 drug half-lives; 8. Diseases and deformities of the lumbar spine; 9. Have other conditions known to be associated with motor neuron dysfunction that may confuse or obscure an ALS diagnosis; 10. Other psychiatric disorders diagnosed according to DSM-V diagnostic criteria, or significant suicide intent; 11. With severe hepatic insufficiency, renal insufficiency or severe cardiac insufficiency (severe hepatic insufficiency refers to ALT value≥2.0 times the upper limit of normal value or AST value≥2.0 times the upper limit of normal value; severe renal insufficiency refers to CRE≥1.5 times the upper limit of normal value or eGFR<40mL/min/1.73m2; severe cardiac insufficiency refers to NYHA class 3-4); 12. Permanently dependent on ventilator-assisted ventilation; 13. History of alcohol and drug abuse; Edaravone users; 14. Patients who are pregnant, breast-feeding, or who are likely to become pregnant and plan to become pregnant; 15. Patients participating in other clinical trials or using other biological agents, drugs, or devices under investigation; 16. Patients who have received any vaccinations within 28 days; 17. Contraindications to MRI (eg, claustrophobia); 18. Unable to be cooperative and complete the follow-up due to other reasons.",I,Both
1,Patients with amyotrophic lateral sclerosis.,,TrialTroveID-294333,,,,294333,Unspecified,,,,Iii,
0,46 year-old male patient with late-stage Amyotrophic Lateral Sclerosis.,,GALS-C TrialTroveID-250098,,,,250098,Symptom relief,,,,I,Male
0,Patients with Amyotrophic Lateral Disease (ALS),"Patients with ALS: Familial and Sporadic ALS, with symptom onset < or equal to 24 months. At least 18 years of age Subjects meet the El Escorial criteria of definite criteria for a diagnosis of ALS. Subjects can be on a stable dose of riluzole for at least a month or not taking or initiating riluzole for the duration of the trial. Not on any experimental medication for the last 1 month or five times the half-life of experimental medication. At screening, must have a Forced Vital Capacity (FVC) = 65% of predicted capacity for age, height and gender. Have fully completed informed consent form Ability to comply with study procedures Women of child-bearing age must be on birth control. Pregnancy test should be done in women in child bearing age. Medically safe to have lumbar puncture to collect CSF",GALS GALS 001 NCT01854294 TrialTroveID-186232,Adults; Older Adults,year(s),,186232,Delay Disease Progression,,18.0,"History of liver disease, severe renal failure, diabetes, coronary heart disease, cancer Clinically significant EKG abnormality at screening Any comorbid condition which would make completion of the trial unlikely FVC < 65% Presence of a bleeding disorder Allergy to local anesthetics Problem with CSF pressure Topical or other skin infection at the lumbar puncture site BMI > 32 kg/m2 Medical or surgical conditions in which a lumbar puncture is contraindicated Use of any anti-platelet or anticoagulant drugs, such as plavix, aggrenox, ticlid, warfarin or coumadin",Ii,Both
0,Patients with sporadic form of Amyotrophic lateral sclerosis (ALS),Both gender Age: 18-55 Sporadic form of disease ALS-FRS more than or equal to 24 FVC more than or equal to 40%,IRCT20080728001031N26 NCT02492516 Royan-Nerve-008 TrialTroveID-261007,Adults,year(s),year(s),261007,Delay Disease Progression,55.0,18.0,Familial form of ALS Malignancy Autoimmune disease Diagnosis of other motor neuron diseases,I,Both
0,Subjects with Amyotrophic Lateral Sclerosis,Diagnosis of Amyotrophic Lateral Sclerosis. Understanding and willingness to sign a written informed consent document,NCT05003921 SC-7-ATG-7-01 TrialTroveID-411366,Adults,,,411366,Delay Disease Progression,,,Active infection Active cancer Chronic multisystem organ failure Pregnancy Anticoagulation medicine use Clinically significant Abnormalities on pre-treatment laboratory evaluation Medical condition that would (based on the opinion of the investigator) compromise patient's safety. Previous organ transplant Hypersensitivity to sulfur Continued drug abuse Pre-menopausal women not using contraception,I,Both
0,"Patients with amyotrophic lateral sclerosis (16 females and 27 males, mean age of 57.3 years)","Diagnosis of the ALS disease before the cell transplantation (diagnose established following the El Escorial criteria for definite ALS) Good understanding of the protocol and willingness to consent Signed informed consent Disease duration: up to 2 years FVC > 50% / pulmonologist certificate about respiratory function of the patient ventilator independent clinical diagnosis of definite ALS based on the El Escorial World Federation of Neurology criteria (i.e., electromyography testing was used to support the clinical diagnosis) age between 20 and 75 years ability to visit the clinic with support or alone. Every patient had a blood test for the levels C-reactive protein (CRP), sodium, potassium, glucose, morphology, coagulation system, urea, creatinine and examination of the bottom of the eye.",NCT02881476 TrialTroveID-285498 UWM/ALS-MSC.2015/001 UwmWjmscAls,Adults; Older Adults,year(s),year(s),285498,Delay Disease Progression,75.0,18.0,"Cancer, Autoimmune diseases Renal failure, Subject is a respiratory dependent. Subject unwilling or unable to comply with the requirements of the protocol Pregnancy, breastfeeding medical or inflammatory disorders markedly interfering with the results of the therapy active infections severe cardiac insufficiency evere renal or liver insufficiency.",I,Both
0,Patients with Amyotrophic Lateral Sclerosis.,Ages Eligible for Study: 20 Years to 65 Years; Genders Eligible for Study: Both Inclusion Criteria: Diagnose established following the World Federation of Neurology criteria. More than 6 and less than 36 months of evolution of the disease. Medullar onset of the disease. More than 20 and less than 65 years old. Forced Vital Capacity equal or superior to 50%. Total time of oxygen saturation <90% inferior to 2% of the sleeping time. Signed informed consent.,20111207ALS NCT01494480 TrialTroveID-158813,Adults,year(s),year(s),158813,Delay Disease Progression,65.0,20.0,"Exclusion Criteria: Neurological or psychiatric concomitant disease. Need of parenteral or enteral nutrition through percutaneous endoscopic gastrostomy or nasogastric tube. Concomitant systemic disease. Treatment with corticosteroids, immunoglobulins or immunosuppressors during the last 12 months. Inclusion in other clinical trials. Unability to understand the informed consent.",Ii,Both
0,Patients with brain injury or neurodegenerative disorders.,"should be included one of the 4 disorders Brain injury: onset duration over 12 months, Age: 19 years or over Cerebral palsy: spastic, dyskinetic or ataxic, Age: 19 years or over Parkinson's disease: modified Hoehn and Yahr stage 2.5, 3, 4, Age: 30 to 75 years ALS: definite of possible ALS, progression during the past 6 months, Age: 19 to 65",NCT02236065 TrialTroveID-216528 UCBnG-CSF,Adults; Older Adults,year(s),year(s),216528,Delay Disease Progression; Mild to Moderate; Motor symptoms; Non-motor symptoms/comorbidities; Spastic CP,75.0,19.0,"Uncontrolled pulmonary, renal dysfunction at enrollment Uncontrolled seizure Malignant cancer Possibility of hypersensitivity to drugs used in this study Contraindication to the study intervention or assessment Pregnant or breast feeding women Non-compliance with the study visits specified in the protocol",Ii,Both
0,Participants With Amyotrophic Lateral Sclerosis,"Key 1. Weakness attributable to ALS and a SOD1 mutation that has been previously described as associated with ALS or is considered likely to cause ALS, as defined in the protocol 2. Slow vital capacity (SVC) ≥50% predicted value based on age, gender and height, measured in upright position 3. Body Mass Index (BMI) ≤35 kg/m2 at time of screening 4. If participants are taking riluzole, edaravone, or AMX0035, they must be on a stable dose for at least 4 weeks prior to initial dosing visit and are expected to remain at that dose until the end of the study 5. Platelet count >50,000/microliter 6. Has normal blood pressure readings, as defined in the protocol Key",2023-510344-20-00 ALN-SOD-ALS-2351 NCT06351592 TrialTroveID-511787,Adults; Older Adults,year(s),,511787,Unspecified,,18.0,"1. Concurrent participation in another interventional clinical trial 2. Has had a tracheostomy 3. Has dementia, as assessed by the investigator 4. Has uncontrolled psychiatric disease, including psychosis, active or recent suicidal ideation, untreated major depression, in the past 30 days 5. Has a medical history of brain or spinal disease/injury that would interfere with the lumbar puncture (LP) process, CSF circulation or safety assessment, as defined in the protocol 6. Presence of an implanted shunt for the drainage of CSF or an implanted central nervous system (CNS) catheter 7. Presents any concern to the study investigator that might confound the results of the study or poses an additional risk to the participant by their participation in the study 8. Was hospitalized (ie, >24 hours) for any reason other than ALS within 30 days of the screening visit NOTE: Other protocol defined inclusion / exclusion criteria apply",I,Both
0,,- All patients with Amyotrophic Lateral Sclerosis sent to a medical consultation,2 ALSParadigm NCT03073239,Adults; Older Adults,year(s),,454913,,,18.0,- Amyotrophic Lateral Sclerosis not confirmed - Ages less than 18 years old,Other,Both
1,Patients with ALS.,,TrialTroveID-078982,,,,78982,Delay Disease Progression,,,,Iii,
0,Subjects with amyotrophic lateral sclerosis.,,TrialTroveID-078979,,,,78979,Unspecified,,,,I,
1,Adult patients with ALS.,,NEALS TrialTroveID-078978,Adults,,,78978,Delay Disease Progression,,,,Iii,
0,ALS patients.,,TrialTroveID-078975,,,,78975,Delay Disease Progression,,,,Ii,
1,"Patients with the diagnosis of probable or definite ALS, of less than five years duration from symptom onset.","Ages Eligible for Study: 21 Years to 80 Years Inclusion criteria A clinical diagnosis of probable or definite lab-supported ALS, either SALS or FALS, according to modified El Escorial criteria. Males or females, 21 to 80 years of age. Patients receiving treatment with Rilutek (riluzole) must be on a stable dose for at least 30 days immediately prior to enrollment. Women of childbearing potential must be non-lactating and surgically sterile or using an effective method of birth control (double barrier or oral contraception) and have a negative pregnancy test. Women will be considered menopausal if they have not had a menstrual cycle (period) for two years. Disease duration less than five years since symptom onset. At least 5 of 10 testable upper extremity muscle groups of MRC grade 4 or better. The patient must have given informed consent that has been approved by the appropriate Institutional Review Board (IRB).",AGI-ALS-III-01 NCT00069186 Orphan Drug:01-1527 TrialTroveID-078693,Adults; Older Adults,year(s),year(s),78693,Delay Disease Progression,80.0,21.0,"Subjects were not eligible if they required tracheostomy ventilation, had a diagnosis of other neurodegenerative diseases, renal disease, or clinically significant history of unstable medical illness over the previous 30 days. Subjects with a history of recent alcohol or drug abuse or non-compliance were excluded as well as subjects with limited mental capacity that prevented them from giving informed consent. Subjects that used creatine within 30 days prior to study initiation were also excluded.",Iii,Both
0,,,TrialTroveID-122392,,,,122392,Unspecified,,,,Ii,
1,Patients with Amyotrophic Lateral Sclerosis.,,TrialTroveID-080471,,,,80471,Delay Disease Progression,,,,Iii,
0,Patients with ALS.,,TrialTroveID-078980,,,,78980,Unspecified,,,,Ii,
0,Subjects with Amyotrophic Lateral Sclerosis.,"Ages Eligible for Study: 21 Years to 85 Years. Genders Eligible for Study: Both Inclusion Criteria: A clinical diagnosis of possible, laboratory-supported probable, probable or definite ALS, according to modified EL Escorial criteria. FVC greater or equal to 60% at the screening visit. Symptom onset within 5 years. 21 to 85 years of age. If patients are taking riluzole, they must be on a stable dose for at least the past thirty days. A woman of childbearing age, must be nonlactating and surgically sterile or using an effective method of birth control (barrier method) and have a negative pregnancy test. Able to maintain adequate hydration levels defined as 6-8 cups (8ounces/cup) of water or a non-caffeinated beverage per day. Willing and able to give signed informed consent that has been approved by an Institutional Review Board (IRB).",6302 AAAB6334 ALSA ID#920 IRB00002357 NCT00355576 TrialTroveID-078743,Adults; Older Adults,year(s),year(s),78743,Delay Disease Progression,85.0,21.0,"Exclusion Criteria: Tracheotomy and mechanical ventilation. Diagnosis of other neurodegenerative diseases (Parkinson’s disease, Alzheimer’s disease, etc). Unstable medical illness (coronary artery disease, advanced cancer, active esophageal or gastroduodenal ulcers, etc) in the last one year. Systemic Lupus Erythematosis. FVC < 60% Pregnancy or lactation. Allergy to minocycline, tetracyclines, celecoxib, sulfonamides, NSAIDS, or creatine. History of congestive heart failure. Renal disease [baseline Cr > 1.5 (men) or 1.2 (women)]. History of significant hepatic disease (baseline AST/ALT or bilirubin > 1.5x normal). Use of an investigational agent within thirty days of enrollment. First degree relative with ALS or gene identified familial ALS. Inability or unwillingness to maintain adequate daily hydration (defined above). Limited mental capacity such that the patient cannot provide written informed consent or comply with evaluation procedures. History of recent alcohol or drug abuse or noncompliance with treatment or other experimental protocols.",Ii,Both
0,Healthy male subjects,"1. Male volunteers 18-55 years of age. 2. Able and willing to provide written informed consent prior to the performance of any study-specific procedures. 3. BMI between 18 and 32 kg/m^2, inclusive. 4. Healthy as determined by medical history, physical examination, vital signs and 12-lead ECG at screening and day -1. 5. All clinical laboratory tests of blood and urine must be within the normal range or show no clinically relevant deviations as judged by the Investigator. 6. Non-smokers, ex-smokers (who have ceased smoking > 6 months prior to the screening visit and have no more than one pack-year history of smoking), or social smokers (no more than 5 cigarettes or equivalent per week and willing to refrain from smoking and using tobacco or nicotine products during the confinement periods).",ACTRN12619001639112 PMX-205-001 TrialTroveID-405701 U1111-1243-2230,Adults,year(s),year(s),405701,(N/A); Healthy subjects,55.0,18.0,"1. Any history or presence of clinically relevant respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, metabolic, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine or other disease that, in the opinion of the Investigator, would impact on the study or the safety of the subjects.. 2. Plasma creatinine, Plasma bilirubin, and ALT or AST > upper limit of normal (ULN), which is determined by the Investigator to be clinically significant. An exception is subjects with Gilbert’s syndrome, who are excluded if plasma bilirubin is > 1.5 × ULN. 3. Positive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody or human immunodeficiency virus (HIV)-1 or HIV-2 antibody at screening. 4. Normal ECG findings or normal variants as determined by the Investigator, with QTc range less than or equal to 450 ms (Fridericia’s correction) at Screening and Day 1. 5. A family history of congenital long QT syndrome or unexplained sudden cardiac death. 6. History of malignancy, except for curatively treated basal cell carcinoma, squamous cell skin cancer or in-situ cervical carcinoma. 7. Use of prescription medications within 14 days prior to study drug administration. 8. Use of over-the-counter medication, vitamins or other food supplements, or herbal medications within 7 days prior to study drug administration. Exceptions are analgesics for minor ailments (e.g., paracetamol and/or ibuprofen up to 2 gm/day and 1.2 gm/day, respectively) and vitamins at standard replacement doses. 9. Intake of grapefruit (including its juice) from 48 hours prior to admission to the clinical research unit. 10. Previous treatment with PMX205 or other complement system inhibitor, including drugs such as Eculizumab. 11. Presence of an elevated body temperature or other possible sign of an active/acute infection at screening or admission to the clinical trial unit, which is determined by the Investigator to be clinically significant. 12. Clinically significant history of chronic or recurrent infections, including opportunistic infections. 13. History of splenectomy. 14. Use of systemic immunosuppressive medications in the past 2 years. 15. Received an investigational therapy within 30 days (or 5 half-lives, whichever is longer) prior to PMX205 administration. 16. History of clinically-significantclinically significant allergic reactions or anaphylaxis, including or any hypersensitivity to penicillins, cephalosporins and related antibiotics. 17. History of alcohol or drug abuse. 18. Positive screen for drugs of abuse (including amphetamines, methamphetamines, methadone, barbiturates, benzodiazepines, cocaine, opiates, methylenedioxymethamphetamine, phencyclidine, tetrahydrocannabinolopiates, cocaine, amphetamines, MDMA, cannabinoids, barbiturates and benzodiazepines) or alcohol at screening and day -1. At the Investigator’s discretion, the drug screen test may be repeated in the possible instance of a false positive due to e.g., poppy seed consumption. 19. Average intake of more than 14 units of alcohol per week (1 unit of alcohol equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits). 20. Donation or loss of more than 400 mL of blood within 60 days prior to study drug administration. 21. Undergone major surgery in the 6 months prior to screening. 22. Any condition which could confound the results of the study, interfere with participation in the study or increase the risks of study participation, in the opinion of the Investigator.",I,Male
1,,"- Frontotemporal dementia meeting diagnostic criteria of the Report of the Work Group on Frontotemporal Dementia and Pick's Disease (McKhann et al, 2001). Diagnosis will be established by clinical interview by a geriatric psychiatrist or neuropsychiatrist, experienced with the diagnosis of FTD. Patients with the language presentation of FTD will be enrolled if their behavioral disturbance meets the inclusion criteria. Use of these diagnostic criteria would allow for enrollment of patients who in a clinical setting carry the diagnosis of: semantic dementia, primary progressive aphasia, cortical-basal degeneration, progressive supranuclear palsy, (amyotrophic lateral sclerosis (ALS) with dementia, and Pick's disease, as all of these diagnoses are now classified under the rubric of FTD. - Frontal Behavioral Inventory (FBI) disinhibition subscale score of >16 (Kertesz et al,1997; Kertesz et al 2000). Explanation of this subscale is found under outcome measures. - Men, women and minority groups will be included, ages 40-90 years old. - Judged by the attending psychiatrist to be in sufficiently good health so as to be treated using the study protocol in usual outpatient care circumstances. - Patient, caregivers and or legal representatives provide informed consent for participation in the study, using standard Johns Hopkins Division of Geriatric Psychiatry and Neuropsychiatry procedures. - Caregiver is available who spends at least 10 hours per week with the patient and is able and willing to accompany the patient in the course of the study and to provide collateral information.",04033101 NCT00127114,Adults; Older Adults,year(s),year(s),234390,,90.0,40.0,"- Presence of a brain disease that might otherwise fully explain the presence of dementia or behavior disturbance, such as stroke, Parkinson's disease, traumatic brain injury, multiple sclerosis, and the like. - Treatment with amantadine is contraindicated in the opinion of the study attending psychiatrist. Examples of this would be patients with advanced heart, liver or kidney disease or a seizure disorder. Creatinine clearance >50mL/min will be required, calculated using the Cockcroft-Gault equation. - Failure of treatment with amantadine for behavior disturbance of FTD in the past. - Treatment with a medication that would prohibit the safe concurrent use of amantadine. - Ongoing regular alcohol use and an unwillingness to stop drinking alcohol during the study period. - Pregnancy or lactation.",Iv,Both
0,Patients with Amyotrophic Lateral Sclerosis,"1. Must have given written informed consent before any study related assessments are performed and must be able to understand purpose of the study, including any possible risks and adverse events. 2. ALS as diagnosed according to the recently proposed Gold Coast diagnostic criteria. 3. First symptom of ALS less than or equal to 18 months prior to screening. The qualifying first symptoms of ALS are limited to manifestations of weakness in extremity, bulbar, or respiratory muscles. Cramps, fasciculations, or fatigue should not be taken in isolation as a first symptom of ALS. 4. Forced vital capacity (FVC) greater than or equal to 60% of predicted value as adjusted for gender, height and age at the Screening Visit. 5. Male or female patients aged 18 years or greater (inclusive) and less than 85 years at the time of ALS diagnosis. 6. Able to swallow liquid. 7. Able to perform reproducible pulmonary function tests 8. Female patients must be post-menopausal or sterilized or must not be breastfeeding, have no intention to become pregnant during the study, and use acceptable methods of contraception or abstain from intercourse. 9. Male patients who have not had a vasectomy and confirmed zero sperm count must agree after receiving the first dose of study drug either to use acceptable methods of contraception or abstain from intercourse. 10. If on riluzole, stable dosing for 30-days prior to screening. 11. Pre-study ALSFRS-R progression between disease onset and screening of greater than or equal to 0.5 points/month (calculated by ALSFRS-R total score decline from 48 divided by the months since onset of ALS symptoms).",AMBALS FLO-AMB-01 NCT05959850 TrialTroveID-478911,Adults; Older Adults,year(s),year(s),478911,Delay Disease Progression; Symptom relief,85.0,18.0,"1. Use of non-invasive ventilation (NIV) support for ALS only or gastrostomy tube at time of screening. 2. Exposure to investigational drug within 12-weeks prior to screening. 3. At screening of any medically significant cardiac, pulmonary, GI, musculoskeletal, or psychiatric illness that might interfere with the patient's ability to comply with study procedures or that might confound the interpretation of clinical safety or data. 4. Patient with a history of significant other major medical conditions based on the Investigator's judgment. 5. Based on the investigator's judgment, patients who may have difficulty complying with the protocol and/or any study procedures. 6. Any person who is an employee or an Investigator or Sponsor, or an immediate relative of an Investigator.",Ii,Both
0,,"For Subjects with Parkinson's Disease 1. Clinically established Parkinson's disease based on Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson's disease (Table 8) and a modified Hoehn & Yahr scale of 1-3 (Table 9). 2. No suspected atypical parkinsonian syndromes due to drugs, metabolic disorders, encephalitis, or degenerative diseases. For Subjects with ALS 3. Confirmed diagnosis of ALS with both upper and lower motor neuron involvement. For All Subjects 4. Ability to undergo retinal imaging. 5. Subject or legally authorized representative must provide signed informed consent (or signed assent form) prior to study entry and have the ability and willingness to attend and comply with the necessary study procedures and visits at the study site. For subjects unable to physically sign the informed consent, a guardian or trusted care giver can sign on their behalf in presence of an independent witness. 6. Contraception use by study subjects of childbearing potential (male and female) and female partners of childrearing potential male subjects should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.",AMDX-2011P NCT05542576 PROBE,Adults; Older Adults,year(s),,442442,(N/A),,18.0,"1. Presence of any underlying physical or psychological medical condition that would make it unlikely that the subject will complete the study per protocol. 2. Clinically significant laboratory abnormalities assessed by the investigator. 3. Active malignancy and/or history of malignancy in the past 5 years, with the exception of completely excised non-melanoma skin cancer or low-grade cervical intraepithelial neoplasia. 4. Prolonged QTcF (>450 ms for males and >470 ms for females), cardiac arrhythmia, or any clinically significant abnormality in the resting ECG, as judged by the investigator. 5. Presence of any ocular condition that would significantly hinder the ability to detect and quantify hyper-fluorescent puncta (e.g., eyes with significant hyper-autofluorescence that would mask the ability to detect, quantify, and discern post-injection hyper-fluorescent signal from pre-injection hyper-autofluorescence signal). 6. Use of any new prescription therapies or vaccines within 7 days prior to the study drug administration. 7. Drugs with potential phototoxicity per Package Insert are prohibited within 48 hours or 5 half-lives, whichever is longer, prior to first study drug until End-of-study (EOS) visit, except for those required for treatment of underlying disease. 8. Administration of investigational product in another study within 30 days prior to the first study drug administration, or five half-lives, whichever is longer. 9. Females who are pregnant or breastfeeding.",Iii,Both
0,Patients (48.5 +or- 14.1 years) with amyotrophic lateral sclerosis (ALS).,,TrialTroveID-078769,Adults,year(s),year(s),78769,Delay Disease Progression,63.0,34.0,,Ii,
0,Subjects with frontotemporal dementia associated to progranulin deficit,Age > 18 years old Mild-moderate Frontotemporal Dementia associated to Progranulin deficit (Clinical Dementia Rating= 0.5-1),AOBS-NEU-RPF-2011 EudraCT Number: 2011-004571-37 ReProIn-FTD TrialTroveID-313628,Adults; Older Adults,year(s),,313628,Frontotemporal Dementia,,18.0,Any medical contidion which may intefere with the possibility to partecipate to this study Severe Frontotemporal Dementia (Clinical Dementia Rating >1),Ii,Both
1,Motor neuron disease (MND) patients with sialorrhoea.,"Patients with motor neuron disease (MND) with bulbar involvement (eight females and two males, age range 46-69 years) diagnosed by El Escorial criteria (1998), electromyography and MRI.",TrialTroveID-080217,,,,80217,Symptom relief,,,,Iii,Both
0,Patients with Amyotrophic Lateral Sclerosis.,Patients must be men or women between the ages of 18 and 70 years Patient is clinical definite or probable ALS by the hospitals listed in the protocol Women who are of child bearing potential must have a negative pregnancy test Willing to comply with the study visits Will not take riluzole during the study period Be able to sign informed consent document,NCT03103815 TrialTroveID-298816 WJ2017001,Adults; Older Adults,year(s),year(s),298816,Delay Disease Progression,70.0,18.0,"Myotonic dystrophy Myasthenia gravis Post-poliomyelitis syndrome Multifocal motor neuropathy with or without conduction block Hirayama disease Kennedy disease Hereditary spastic paraplegia Syringomyelia Spinal cord and brain stem tumors Paraneoplastic syndromes Severe liver or kidney disease disease Infection, severe diarrhea or vomiting Serious heart or lung diseases or malignant tumor history HIV infection Pregnancy or breastfeeding Have no ability to communicate Have participated in other clinical trials within 4 weeks Any form of substance abuse, psychiatric disorder, or other condition that, in opinion of the investigator, may interfere with the study",Ii,Both
0,Patients Patients With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS).,"1. Subjects diagnosed with mutant SOD1-mediated ALS experiencing signs and/or symptoms of lower motor neuron dysfunction, with or without upper motor neuron symptoms. 2. Subjects with rapidly progressing disease (""fast"" progressors), defined as average ALS Functional Rating Scale - Revised decline ≥1.0 per month calculated from score at onset of symptoms compared to score at Screening ALSFRS-R. 3. ALSFRS-R score ≥ 25 at Screening. 4. Slow vital capacity (SVC) ≥65% of predicted normal value. 5. King's stage ≤3 at Screening 6. Capable of providing informed consent and complying with trial procedures, in the documented opinion of the Investigator. 7. Titer for neutralizing antibodies (NAb) to AAV rh10 >[1:50] at Screening 8. Normal renal clearance at Screening. 9. Normal coagulation function. 10. Platelet count >150 10^3/mm^3. 11. For subjects on anticoagulant or antiplatelet therapy: able to temporarily stop or bridge therapy for the AMT-162/placebo administration procedures.",AMT-162-001 NCT06100276 TrialTroveID-489925,Adults; Older Adults,year(s),,489925,Delay Disease Progression,,18.0,"1. SOD1 mutation in positions 2-12 of the MiR targeting sequence, also defined as complementary deoxyribonucleic acid (cDNA) position 128-139, which also corresponds to amino acid regions 43-47. (Position 1 is defined as the start codon ATG.). 2. Homozygosity for the D91A (formerly D90A) SOD1 gene mutation. 3. History of significant chronic pain or sensory syndrome. 4. Presence of unstable psychiatric illness. 5. Active suicidal ideation within 6 months prior to screening. 6. Reproductive status that includes any of the following: - Women who are pregnant or have positive pregnancy test at Screening or during Lead-in period - Women who are breastfeeding - Women of childbearing potential (WOCBP) who are unwilling or unable to use birth control to avoid pregnancy for the entire study period - Men who are unwilling to use birth control for the entire study period 7. History of structural Central Nervous System (CNS) disease, may impact intrathecal infusion or cause difficulty placing the catheter. 8. Known allergy or sensitivity to immunosuppression regimens in this protocol 9. Unstable cardiac function. 10. Uncontrolled blood pressure, defined as systolic ≥ 180 millimeters of mercury (mmHg) or diastolic ≥ 120 mmHG 11. Malignancy within 5 years prior to first dose of immunosuppression unless treated definitively without evidence of recurrence 12. Known immunocompromised status including individuals who have undergone organ transplantation; who test positive at Screening for the human immunodeficiency virus (HIV), HCV antibody (anti-HCV) or hepatitis B surface antigen (HBsAg); or who have history of active tuberculosis (TB) or a positive tuberculosis blood test during Screening 13. Anticipated survival, per Investigator judgment, that is shorter than the duration of Screening plus Lead-in plus 6 months after treatment in Part 1 or Part 2 14. Presence of tracheostomy and/or dependent on mechanically assisted ventilation, defined as being unable to lay supine without it, unable to sleep without it, or continuous daytime use- with exception of continuous positive airway pressure (CPAP) and bilevel positive airway pressure (BiPAP) for obstructive sleep apnea. 15. Presence of an implanted shunt for the drainage of CSF or an implanted CNS catheter 16. Laboratory test values during Screening or during the Lead-in period that are clinically significant in the opinion of the Investigator. 17. Any of the following prior or concomitant treatments: - Change in dose of riluzole (RILUTEK®, TIGLUTIK®) or edaravone (RADICAVA®) within 30 days prior to immunosuppression (i.e., riluzole and/or edaravone are allowed if dose is stable). - Concomitant medications contraindicated for use with rituximab or sirolimus, including strong inducers and strong inhibitors of CYP3A4 and P-glycoprotein. - Chronic systemic corticosteroid use, defined as >10 mg of prednisone or equivalent systemic corticosteroid taken for more than 2 consecutive weeks within 2 months prior to first dose of immunosuppression. - Treatment with stem cells for any indication within 6 months prior to first dose of immunosuppression. - Any prior treatment with SOD suppression therapy (viral microRNA or antisense oligonucleotide (ASO) mediators). - Any prior administration of an AAV gene therapy. - Treatment with any other investigational study medication within 90 days prior to signing Informed Consent - Planned treatment with live vaccines during Lead-in period or at any time after receipt of AMT-162/placebo. - Warfarin within 30 days prior to Screening labs. If a subject switches to a different anticoagulant for the sole purpose of meeting criteria for participation in the study, ICF should be signed before the switch. 18. Presence of any other condition or clinically significant laboratory values which, in the opinion of the Investigator (by its nature or by being inadequately controlled), might put the subject at significantly higher risk due to participation in the study or might influence the results of the study or the subject's ability to complete the study",Iii,Both
0,,,TrialTroveID-493738,,,,493738,Unspecified,,,,I,
0,"Amyotrophic Lateral Sclerosis(ALS) patients (18 male, 2 female; ALS- FRSr 40.7/48) with either a predominant (N 9) or pure lower motor neuron degeneration (progressive muscular atro- phy; PMA; n 11).",Ages Eligible for Study: 18 Years to 80 Years; Genders Eligible for Study: Both Inclusion Criteria: Patients between 18 and 80 years of age. Clinical diagnosis of amyotrophic lateral sclerosis with predominant affection of the lower motor neuron or the clinical ALS variant of progressive muscular atrophy (PMA) Clinical signs of lower motor neuron degeneration in at least one anatomic region beyond the brain stem. Sporadic and familial ALS. Onset of paresis six months to four years before study inclusion. Treatment with riluzol 100mg/d at least 1 month before study inclusion.,ANA-ALS01 EudraCT Number: 2010-019218-26 NCT01277315 TrialTroveID-140927,Adults; Older Adults,year(s),year(s),140927,Delay Disease Progression,80.0,18.0,"Exclusion Criteria: Diagnosis of amyotrophic lateral sclerosis with predominant affection or the upper motor neuron without clinical signs of a concurrent affection of the lower motor neuron in at least one anatomic region beyond the brain stem (spastic ALS) - Diagnosis of primary lateral sclerosis (PLS) Patients with known intolerance to anakinra, riluzol or one of the additives Clinically severe hypoventilation syndrome with vital capacity < 50% Pregnancy or breastfeeding Continuous non-invasive ventilation with ventilator-free time < 2 hours - Tracheotomy and mechanical ventilation Laboratory parameters outside the normal range that correspond to a clinically severe cardiovascular, pulmological, hematological, hepatological, metabolic or renal disease Malignancies Severe renal insufficiency (creatinine clearance < 30 ml/min) History of recurrent infections or a disease that may predispose to infections Severe neutropenia (absolute neutrophil count < 1.5 x 109/l) Monoclonal gammopathy of unknown significance Infections including infections with HIV and hepatitis B and C Dementia and unable to give informed consent History of epilepsy and epileptic seizures Contraindication to E coli-derived proteins, anakinra or any components of the product Concurrent therapy of anakinra and etanercept or other TNF blocking agents",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis.,"A clinical diagnosis by a study investigator of laboratory-supported probable, probable, or definite ALS, according to the modified El Escorial criteria[1] Vital capacity (VC) greater or equal to 50% of predicted Diagnosis with ALS within 3 years prior to enrollment If patients are taking riluzole for ALS, they must be on a stable dose for at least thirty days prior to the baseline visit Women of childbearing age must use protection against pregnancy.",NCT04204889 TOALS TrialTroveID-363866,Adults; Older Adults,year(s),year(s),363866,Unspecified,80.0,21.0,"Requirement for tracheotomy ventilation or non-invasive ventilation for > 23 hours per day Diagnosis of other neurodegenerative diseases (e.g., Parkinson disease, Alzheimer disease) Clinically significant history of unstable medical illness (e.g., unstable angina, advanced cancer) over the last 30 days Current pregnancy or lactation Limited mental capacity such that the patient cannot provide written informed consent or comply with evaluation procedures Receipt of any investigational drug within the past 30 days from enrollment",I,Both
0,"Patients (mean age 71+or-8 years, 89 male) with cognitive disorders of variable severity (25 patients with MCI, 192 with Alzheimer’s disease and 35 with other forms of dementia).",,TrialTroveID-014876,Adults; Older Adults,year(s),year(s),14876,Cognitive Function; Frontotemporal Dementia; Mild; Mild Cognitive Impairment/Prodromal; Moderate; Vascular Dementia,79.0,63.0,,Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis.,Patients who had already been diagnosed with ALS at other hospitals and who were willing to participate in the study and who could come to the study hospital for intravenous infusion treatment.,TrialTroveID-418152,,,,418152,Delay Disease Progression,,,,Ii,
0,Patients with Amyotrophic lateral sclerosis,"For the subject of this study, the Takeda Hospital neurologist and this medical treatment medical attendant performs confirmation, the medical examination of the anamnesis. Among patients meeting amyotrophy-related lateral sclerosis medical treatment guidelines diagnostic criteria, the purpose of this study is understood and intends for a patient of the amyotrophic lateral sclerosis to have a poor intractable disease in the effectiveness by the existing cure that obtained consent in a document. Age, the sex do not matter. 1 The target disease patient who was admitted to the Takeda Hospital in an operation and treatment, an inspection purpose 2 The target disease patient who visits a hospital for treatment in the outpatient department of the Takeda Hospital 3 The patient who acquired an agreement of this study entry by the free will of the person in a document",jRCTb050190128 PB5160011 TrialTroveID-312311 UMIN000024132,,,,312311,Delay Disease Progression,,,"The patient corresponding to the following standards excludes it from a patient targeted for the final examination. 1 The person that quantity of fat necessary for this study is not provided 2 The patient whom I am dialyzing 3 Pregnant patient 4 This study medical attendant is the patient who ethical, it is scientific, and made a decision from the viewpoint of safety if the participation in this study is inappropriate of the subject 5 The patient who needs Agent approval I confirm an anamnesis to advocate next and, from having experience or not that underwent a blood transfusion or transplant, do a competent thing judging. But I decide to reconfirm when I become able to confirm it about the anamnesis which I was not able to confirm at the time of a competent judgment later. 1 Infection with bacteria such as Treponema pallidum, a gonococcus, the tubercle bacillus 2 Sepsis and the doubt 3 Malignant tumor 4 Serious metabolism internal secretion disease 5 Serious blood disorder 6 Liver disease 7 Communicable spongy brain fever and the doubt 8 Family career to be concerned with a specific hereditary disease and the disease concerned 9 Pulmonary embolism",I,Both
0,Patients with El Escorial clinically-definite ALS (Amyotrophic Lateral Sclerosis). The median age was 57 (range 36-75) and 15were male.,,TrialTroveID-294141,Adults; Older Adults,year(s),year(s),294141,Unspecified,75.0,36.0,,I,Both
0,Subjects with Amyotrophic Lateral Sclerosis.,"Ages Eligible for Study: 18 Years and older, Genders Eligible for Study: Both Women and males over 18-year-old. Good understanding of the protocol and aptitude to grant the informed assent. Diagnosis of sporadic ALS, with diagnosis of certainty, that is to say, definite or probable, in agreement with the criteria of ""El Escorial"", of the World Federation of Neurology. Forced vital capacity of at least 50 % of the one that would correspond to them for sex, height and age. More than 6 and less than 36 months of evolution of the disease (from the beginning of the symptoms). Possibility of obtaining, at least, 50gr of adipose tissue. Treatment with riluzole, for at least, a month before the inclusion.",CeTMad/ELA/2011 EudraCT Number: 2011-006254-85 NCT02290886 REec-2013-0095 TrialTroveID-191427,Adults; Older Adults,year(s),,191427,Delay Disease Progression,,18.0,"Any concurrent illness that could affect the measure of the clinical trial variables (hepatic, renal, cardiac insufficiency, diabetes mellitus, others) Previous stem cell therapy. Any lymphoproliferative disease. Riluzole with 4 weeks of study entry and at any time during the study. Hemophiliacs or subjects with bleeding disorders. Known hypersensitivity to fetal bovine serum HIV infection. Serum creatinine > 3.0 in subjects not on hemodialysis. Skin infection at the infusion site or systemic infection Active drug or alcohol addiction Pregnant, planning to become pregnant or not on accepted birth control method if subject is of child bearing potential. Subjects that are breast feeding Any condition that the Principal Investigator considers would render the subject unfit for the study. Exclusion Criteria: Any concomitant disease that under investigator's criteria could concern the measures of the clinical variables of the trial (hepatic, renal or cardiac insufficiency, diabetes mellitus, etc). Previous therapy with stem cells. Participation in another clinical trial during 3 months previous to the entry in this trial. Any disease lymphoproliferative Tracheostomy and /or gastrostomy. Haemophilia, diathesis hemorrhagic or anticoagulative current therapy. Hypersensitivity known to the bovine foetal whey or the gentamicin. Medical precedents of infection of the HIV or any serious condition of immunocompromised. Positive HBV or HCV serology Levels of creatinine in whey > 3.0 in subjects not submitted to haemodialysis.",Iii,Both
0,Subjects with Amyotrophic Lateral Sclerosis (ALS).,"Diagnosis of ALS according to the World Federation of Neurology revised EI Escorial criteria. Onset of weakness within 3 years prior to Day 1 visit. Slow Vital Capacity ≥ 50% of predicted normal adjusted for sex, age, and height (from the sitting position). ALS Functional Rating Scale-Revised (ALSFRS-R) ≥ 30 at the Screening visit (Week -2). If female, must be postmenopausal, surgically sterilized, or agree to use highly effective methods of contraception from Screening through Week 36. Males with a woman partner of childbearing potential must agree to use highly effective methods of contraception from Screening through Week 36. Documented history of vaccinations within 5 years prior to Screening visit against encapsulated bacterial pathogens or willing to undergo vaccinations.",ANX005-ALS-01 ANX005-IF-01 CCR-20-127 EudraCT Number: 2021-000325-26 NCT04569435 TrialTroveID-385677,Adults; Older Adults,year(s),,385677,Delay Disease Progression,,18.0,"Clinically significant, ongoing or intercurrent illness, medical condition, or medical history that would jeopardize the safety of the participant, limit participation, or compromise the interpretation of the safety data derived from the participant. Participants with body weight > 150 kilograms. Antinuclear antibodies (ANA) titer ≥ 1:160 (for either of the 2 ANA results a minimum of 2 weeks apart) during the Screening Period.",Ii,Both
0,Healthy Volunteers,"Male and females 18 years and older Females must be postmenopausal, surgically sterilized, or willing and able to use 2 methods of contraception throughout the study and for 1 month after the final study visit Willing and able to undergo vaccination if not vaccinated recently",ANX005-CP01 NCT02937753 NCT03010046 TrialTroveID-293551,Adults; Older Adults,year(s),year(s),293551,(N/A); Frontotemporal Dementia; Healthy subjects,80.0,18.0,"History of any autoimmune disease, meningitis, septicemia or pneumonia History of hypercoagulable diseases, hyperviscosity, thrombosis, renal dysfunction or acute renal failure Known genetic deficiencies of the complement cascade system History of conditions whose symptoms and effects could alter protein catabolism or IgG utilization, e.g. protein-losing enteropathies or nephrotic syndrome Body weight less than 50 kg or greater than 100 kg Hypersensitivity or allergic reactions to any excipients in the ANX005 drug product (Cohorts 4b and 5b) Known selective IgA deficiency or presence of antibodies to IgA at screening (Cohorts 4b and 5b) Prior reaction or hypersensitivity to blood products, including IVIg or any of the excipients in IVIg.",I,Both
0,Patients With Amyotrophic Lateral Sclerosis,"All participants must adhere to contraception restrictions Female participants of childbearing potential must adhere to contraception restrictions Have possible, clinically probable, clinically probable-laboratory supported or definite familial or sporadic ALS in accordance with the El-Escorial criteria or who have a diagnosis of ALS as defined by the Gold Coast Criteria; progressive motor impairment documented by history or repeated clinical examination, preceded by normal motor development, and presence of upper and lower motor neuron dysfunction in at least 1 body region or lower motor neuron dysfunction in at least 2 body regions and investigations excluding other conditions In familial ALS participants, a confirmed pathogenic superoxide dismutase 1 (SOD1) mutation Onset of symptoms (i.e, weakness) within past 24 months prior to screening, at the time of obtaining informed consent Have slow vital capacity (SVC) of greater than or equal to (> or =) 50 percentage (%) of predicted values. Participants with SVC of <50% of predicted values may be permitted to enter the open-label extension, based on the opinion of the investigator Absence of bilevel positive airway pressure (BiPAP)/proportional assist ventilation (PAV) > 4 hours for symptoms attributable to ALS. Use of a CPAP for pre-existing conditions will be allowed If on riluzole, must be on a stable dose. If on edaravone, must have completed 2 cycles and are expected to remain on the same dose throughout the study Able to provide informed consent which includes compliance with the requirements and restrictions Have venous access sufficient to allow for blood sampling Have clinical laboratory test results within the normal reference range for the population or study site, or results with acceptable deviations that are judged to be not clinically significant by the investigator",250403 AP-101-02 AP101-02 EudraCT Number: 2020-005971-11 NCT05039099 TrialTroveID-413450,Adults; Older Adults,year(s),,413450,Unspecified,,18.0,"Have participated or currently participating in another clinical trial within 12 weeks of baseline (Day 1) Have undergone a tracheostomy for ALS symptoms Are on nasal intermittent positive pressure ventilation (NIPPV) >4 hours per day for the treatment of ALS related symptoms Have other causes of neuromuscular weakness Have cognitive impairment, severe disease in the cardiovascular, hematological, renal system, neurodegenerative disease, pulmonary disorder, or psychiatric illness Pregnant or nursing women Have been exposed to any antisense treatment targeting SOD1 within 6 months of the baseline visit Have undergone stem cell therapy",Ii,Both
0,Patients with familial and sporadic amyotrophic lateral sclerosis (ALS).,"All participants must adhere to contraception restrictions Female patients of non-childbearing potential due to: Menopause: spontaneous amenorrhea for at least 12 months not induced by a medical conditions such as anorexia nervosa and not taking medications that induced the amenorrhea (e.g., oral contraceptives, hormones, gonadotropin releasing hormones, anti-estrogens, selective estrogen receptor modulators, or chemotherapy) Surgical sterilization Have possible, probable, probable laboratory supported or definite and definite familial laboratory-supported ALS in accordance with the El-Escorial criteria Have familial or sporadic ALS. With onset of ALS symptoms, specifically onset of muscle weakness within past 48 months Have slow vital capacity (SVC) of (greater than or equal to) =60% If on riluzole, must be on a stable dose If on edaravone, must have completed 2 cycles and are expected to remain on the same dose throughout the study Able to provide informed consent. If the patient is not able to provide written consent due to aggravation of disease condition, written informed consent may be provided by a legally authorized representative Have venous access sufficient to allow for blood sampling Have clinical laboratory test results within normal reference range for the population or study site, or results with acceptable deviations that are judged to be not clinically significant",AP101-01 NCT03981536 TrialTroveID-351306,Adults; Older Adults,year(s),,351306,Unspecified,,18.0,"Are currently enrolled in, or discontinued from, within the last 30 days, a clinical trial involving an investigational drug or device or off-label use of a drug or device, or any other type of medical research judged not to be scientifically or medically compatible with this study Have previously completed or withdrawn from this study Have a history or presence of medical illness including, but not limited to, any cognitive, cardiovascular, hepatic, hematological, renal, endocrine, or psychiatric, or any clinically significant laboratory abnormality that indicates a medical problem that would preclude study participation Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies Show evidence of hepatitis C and/or positive hepatitis C antibody Show evidence of hepatitis B and/or positive hepatitis B surface antigen Are women who are lactating. Have undergone a tracheostomy unless it was removed at least 6 months prior Are on feeding tube, unless the insertion of a feeding tube is considered prophylactic Are on nasal intermittent positive pressure ventilation (NIPPV) >4 hours per day or at the discretion of the medical monitor Have undergone stem cell therapy",I,Both
1,Single Subject With C9ORF72-Associated Frontotemporal Dementia (FTD),"1. Diagnosis of C9ORF72-associated FTD with documentation of a clinical genetic test demonstrating the presence of a pathogenic repeat expansion in C9ORF72 2. Age 18 or older 3. Capable of providing informed consent at the Screening Visit and complying with study procedures throughout the study, in the Principal Investigator's opinion. 4. In the case that the subject lacks the ability to provide informed consent. Informed consent will be sought from the subject's surrogate representative. 5. Able to safely swallow study drug capsule at screening and throughout study. May use thickened substances to assist in swallowing drug.",LAM-002A-FTD-EAP NCT05483322 TrialTroveID-438542,Adults; Older Adults,year(s),,438542,Frontotemporal Dementia,,18.0,"1. Clinically significant unstable medical condition (other than FTD) that would pose a risk to the subject, according to the Principal Investigator's judgment (e.g., cardiovascular instability, systemic infection, or clinically significant laboratory abnormality or ECG changes). 1. Gastrointestinal disease (e.g., gastric or intestinal bypass surgery, jejunostomy tube, pancreatic enzyme insufficiency, malabsorption syndrome, symptomatic inflammatory bowel disease, chronic diarrheal illness, bowel obstruction) that might interfere with drug absorption or with interpretation of gastrointestinal AEs. Gastrostomy tube placement is allowed prophylactically or to supplement nutrition/hydration but may not be used for study drug administration. 2. Hepatic profile showing any of the following: i. Serum alanine aminotransferase (ALT) >5 × upper limit of normal (ULN). ii. Serum aspartate aminotransferase (AST) >5 × ULN. iii. Serum bilirubin >1.5 × ULN. c. Renal profile showing an estimated creatinine clearance (eClCR) <30 mL/minute (with eClCR to be calculated by the method at the laboratory performing the serum creatinine test). 2. Presence of a neurodegenerative cognitive or motor syndrome (e.g., Alzheimer's disease, Parkinson's disease) not related to the C9ORF72 repeat expansion. 3. Presence of unstable psychiatric disease or substance abuse that would impair ability of the participant to provide informed consent, in the Principal Investigator's opinion. 4. Active cancer or history of cancer, except for the following: basal cell carcinoma or successfully treated squamous cell carcinoma of the skin, cervical carcinoma in situ, prostatic carcinoma in situ, or other malignancies curatively treated and with no evidence of disease recurrence for at least 3 years. Active cancer includes cancers with current disease manifestations or therapy that could adversely affect subject safety and longevity, create the potential for drug-drug interactions, or compromise the interpretation of study results. 5. Prior solid organ transplantation. 6. Ongoing immunosuppressive therapy including systemic or enteric corticosteroids at screening or for the duration of the trial, at the discretion of the site investigator and medical monitor. 7. Use within 14 days prior to randomization or for the duration of the trial of a strong inhibitor or inducer of cytochrome P450 (CYP) 3A4 or expected requirement for chronic use of a strong inhibitor or inducer of CYP3A4 during study therapy (see Table 2 for a l list of drugs known to be strong inhibitors or inducers of CYP3A4), at the discretion of the Principal Investigator or Sponsor. 8. Use within 14 days prior to randomization or for the duration of the trial of drug that is a moderate-to-strong substrate of CYP2C9 (including warfarin, tolbutamide, phenytoin, glimepiride) or expected requirement for chronic use of such drugs during study therapy, at the discretion of the Principal Investigator or Sponsor. 9. Use of investigational treatments for FTD (off-label use or active participation in a clinical trial) within 5 half-lives (if known) or 30 days (whichever is longer) prior to the Screening Visit. 10. Exposure at any time to any gene therapies under investigation for the treatment of FTD (off-label use or investigational). 11. If female, breastfeeding, known to be pregnant, planning to become pregnant during the study, or of child-bearing potential and unwilling to use effective contraception for the duration of the trial and for ≥30 days after discontinuing treatment. 12. Anything that would place the subject at increased risk or preclude the subject's full compliance with or completion of the study, in the Principal Investigator's opinion. 13. If the subject is being re-screened, the disqualifying condition has not been resolved, or the mandatory wash-out duration has not occurred.",Iv,Female
0,Patients with Amyotrophic Lateral Sclerosis.,"Diagnosis of C9ORF72-associated ALS with BOTH of the following: Documentation of a clinical genetic test demonstrating the presence of a pathogenic repeat expansion in C9ORF72. If there is a strong clinical suspicion for C9ALS based on C9-positive family history and El Escorial Criteria consistent with a diagnosis of ALS, clinical testing for the C9ORF72 repeat expansion may be performed with study screening labs at the discretion of the Site Investigator (SI), medical monitor, and study sponsor. AND Must meet possible, laboratory-supported probable, probable, or definite criteria for diagnosing ALS by revised El Escorial criteria (Brooks 2000). Age 18 or older Capable of providing informed consent at the Screening Visit and complying with study procedures throughout the study, in the SI's opinion, and at the discretion of the medical monitor and study sponsor. In the case that a participant lacks the ability to provide informed consent. Informed consent will be sought from the participant's surrogate representative. Able to safely swallow study drug capsule at screening and throughout study. May use thickened substances to assist in swallowing drug. Vital Capacity greater than and equal to 50% of predicted at the time of the Screening Visit measured by Slow Vital Capacity (SVC), or, if required due to COVID-19 pandemic-related restrictions and with Sponsor approval, Forced Vital Capacity (FVC) measured in-person or via telemedicine. Participants must either not take or be on a stable dose of riluzole (as either a tablet or oral suspension) for greater than 30 days prior to the Screening Visit. Riluzole-naïve participants are permitted in the study. Participants must either not take edaravone or have completed at least one 14-day cycle with plan for continuation of edaravone prior to the Screening Visit. Participants must be off cycle and at least 2 days after the last dose administration of edaravone at the time of study visit. Edaravone-naïve participants are permitted in the study. Participants must be able to complete all study procedures, including the lumbar punctures (LP) at the time of the Screening Visit, in the SI's opinion. Geographically accessible to the site.",LAM-002A-ALS-CLN01 NCT05163886 TrialTroveID-421066,Adults; Older Adults,year(s),,421066,Delay Disease Progression,,18.0,"Clinically significant unstable medical condition (other than ALS) that would pose a risk to the participant, according to the SI's judgment [e.g., cardiovascular instability, systemic infection, or clinically significant laboratory abnormality or electrocardiogram (ECG) changes]. Gastrointestinal disease (e.g., gastric, or intestinal bypass surgery, jejunostomy tube, pancreatic enzyme insufficiency, malabsorption syndrome, symptomatic inflammatory bowel disease, chronic diarrheal illness, bowel obstruction) that might interfere with drug absorption or with interpretation of gastrointestinal AEs. Gastrostomy tube placement is allowed prophylactically or to supplement nutrition/hydration but may not be used for study drug administration. Hepatic profile showing any of the following: i. Serum alanine aminotransferase (ALT) greater than 5 × upper limit of normal (ULN). ii. Serum aspartate aminotransferase (AST) greater than 5 × ULN. iii. Serum bilirubin greater than 1.5 × ULN. c. Renal profile showing an estimated creatinine clearance (eClCR) less than 30 mL/minute (with eClCR to be calculated by the method at the laboratory performing the serum creatinine test). Presence of a neurodegenerative cognitive or motor syndrome (e.g., Alzheimer's disease, Parkinson's disease) not related to the C9ORF72 repeat expansion. Presence of unstable psychiatric disease or substance abuse that would impair ability of the participant to provide informed consent, in the SI's opinion. Active cancer or history of cancer, except for the following: basal cell carcinoma or successfully treated squamous cell carcinoma of the skin, cervical carcinoma in situ, prostatic carcinoma in situ, or other malignancies curatively treated and with no evidence of disease recurrence for at least 3 years. Active cancer includes cancers with current disease manifestations or therapy that could adversely affect subject safety and longevity, create the potential for drug-drug interactions, or compromise the interpretation of study results. Prior solid organ transplantation. Ongoing immunosuppressive therapy including systemic or enteric corticosteroids at screening or for the duration of the trial, at the discretion of the site investigator and medical monitor. Use within 5 days prior to randomization or for the duration of the trial of a strong inhibitor or inducer of cytochrome P450 (CYP) 3A4 or expected requirement for chronic use of a strong inhibitor or inducer of CYP3A4 during study therapy. Use within 5 days prior to randomization or for the duration of the trial of drug that is a moderate-to-strong substrate of CYP2C9 (including warfarin, tolbutamide, phenytoin, glimepiride) or expected requirement for chronic use of such drugs during study therapy, at the discretion of the site investigator and medical monitor. Use of investigational treatments for ALS (off-label use or active participation in a clinical trial) within 5 half-lives (if known) or 30 days (whichever is longer) prior to the Screening Visit. Exposure at any time to any gene therapies under investigation for the treatment of ALS (off-label use or investigational). If female, breastfeeding, known to be pregnant, planning to become pregnant during the study, or of child-bearing potential and unwilling to use effective contraception for the duration of the trial and for 3 months after discontinuing treatment. If male of reproductive capacity, unwilling to use effective contraception for the duration of the trial and for 3 months after discontinuing study treatment. Anything that would place the participant at increased risk or preclude the participant's full compliance with or completion of the study, in the SI's opinion. If a participant is being re-screened, the disqualifying condition has not been resolved, or the mandatory wash-out duration has not occurred. Contraindication to undergoing a lumbar puncture (LP) in the SI's opinion. Participants undergoing the LP must not be currently taking anticoagulation and antiplatelet medications such as warfarin and clopidogrel bisulfate (Plavix™), that would be a contraindication to LP; aspirin and non-steroidal anti-inflammatories are allowed.",Ii,Both
0,,,TrialTroveID-400873,,,,400873,Unspecified,,,,I,
0,Patients with Niemann-Pick Disease Type C.,"The patient has a confirmed diagnosis of NPC (NPC1 or NPC2)* and at least one neurological symptom. The patient is two years of age or above. The patient is a permanent resident of US. If taking miglustat (Zavesca®), the patient must have been on the target dose for the past six weeks. If the patient is a sexually active female of child-bearing potential (post-menarche), it is agreed to use highly effective contraception during the EAP and until three weeks after the last dose of arimoclomol. Confirmed negative urine pregnancy test for sexually active female of child-bearing potential (post-menarche). All sexually active male patients with female partners of child-bearing potential (postmenarche) agree to use a condom in addition to the birth control used by their partners during treatment and until three weeks after the last dose of arimoclomol. If the patient has a history of seizures, the condition must be adequately controlled, i.e., the pattern of seizure activity must be stable, and the patient must be on a stable dose and regimen of antiepileptic medication during one month prior to screening. Patient or parent/guardian must provide written informed consent to participate in EAP. In line with Patterson et al. 2017",NCT04316637 OR-ARI-EAP-NPC TrialTroveID-370535,Children; Adults; Older Adults,year(s),,370535,Niemann-Pick Type C,,2.0,"Severe liver insufficiency. Renal insufficiency. The patient has a known or suspected allergy or intolerance to arimoclomol or its constituents. The patient is pregnant, planning to become pregnant (while on the EAP program) or is currently breastfeeding. The patient will undergo treatment with another investigational drug*, whilst participating in the program or in the 4 weeks prior to commencing treatment with arimoclomol. The patient is either eligible and able to participate in or is currently participating in an active interventional clinical trial within the indication. The patient, in the opinion of the clinician, is unable to comply with the treatment or has a medical condition that would potentially increase the risk to the patient by participation. The patient has a medical condition which hinders the clinician's assessment of arimoclomol safety and efficacy (e.g. certain epileptic conditions or severe cataplexy). Including unlicensed product provided under an Early Access Program or equivalent compassionate use programs",Other,Both
1,"Patients with amyotrophic lateral sclerosis. Eligible participants are patients aged > or = 18?years who meet the revised El Escorial criteria for clinically possible, clinically probable, clinically probable laboratory-supported or clinically definite ALS, or have familial ALS caused by a known pathogenic mutation. The patients will be < or = 18 months since first appearance of weakness, have a baseline ALSFRS-R > or = 35, and a relatively preserved lung function with SVC > or = 70% of predicted normal.","Subject meets revised El Escorial criteria for clinically possible, clinically probable / clinically probable ALS laboratory-supported, clinically definite ALS or clinically definite familial ALS laboratory-supported 18 months or less since first appearance of weakness (e.g. limb weakness, dysarthria, dysphagia, shortness of breath) ALS Functional Rating Scale-Revised (ALSFRS-R) equal to or above 35 and erect (seated) Slow Vital Capacity (SVC) % predicted equal to or above 70% at Screening",20180389 EudraCT Number: 2018-000137-13 NCT03491462 NL65582.041.18 ORARIALS-01 SNCTP000003805 TrialTroveID-317692,Adults; Older Adults,year(s),,317692,Delay Disease Progression,,18.0,Tracheostomy or use of non-invasive ventilation for more than 2 hours during waking hours at the time of Screening and Baseline Pregnant or breast-feeding Current or anticipated use of diaphragmatic pacing Any other relevant medically significant condition which could present risk to the subject or interfere with the assessment of safety or has an increased risk of causing death during the trial,Iii,Both
0,Patients with ALS.,,TrialTroveID-080120,,,,80120,Unspecified,,,,Ii,
0,Subjects who completed 12 weeks of treatment and the week 16 follow up visit of the double blind study had the option to enroll in a 6-month open label study.,"Ages Eligible for Study: 18 Years and above Inclusion Criteria: Familial or sporadic ALS. Vital capacity equal to or more than 60% predicted value for gender, height and age at the screening visit. First ALS symptoms occurred no more than five years prior to screening. Must be able to take oral medication.",AALS-001-Extension AALS-001-OL TrialTroveID-078851,Adults; Older Adults,year(s),,78851,Delay Disease Progression,,18.0,Exclusion Criteria Dependence on mechanical ventilation.,Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis (ALS).,"Ages Eligible for Study: 18 Years and above, Inclusion Criteria Familial or sporadic ALS. Vital capacity equal to or more than 60% predicted value for gender, height and age at the screening visit. First ALS symptoms occurred no more than five years prior to screening. Must be able to take oral medication.",AALS-001 NCT00244244 TrialTroveID-078846,Adults; Older Adults,year(s),,78846,Delay Disease Progression,,18.0,Exclusion Criteria Dependence on mechanical ventilation.,Ii,Both
1,Subjects with Amyotropic Lateral Sclerosis who completed the ORARIALS-01 trial,"Subject is able to comprehend and is willing to provide written informed consent and is capable and willing to comply with trial procedures, or in the circumstance that the subject is incompetent, informed consent/assent is provided in accordance with local regulation and/or procedures Subject has completed the ORARIALS-01 trial (i.e., met one of the surrogate survival endpoints of tracheostomy or PAV or has completed the 76 weeks randomized treatment period) Subject completed ORARIALS-01 while on treatment, where on treatment is defined as having taken the last dose of IMP within 2 weeks of the End of Trial visit (whether at week 76 or prior)",EudraCT Number: 2019-000374-39 NCT03836716 NL69675.041.19 ORARIALS-02 SNCTP000003764 TrialTroveID-342818,Adults; Older Adults,year(s),,342818,Delay Disease Progression,,18.0,"Known or suspected allergy or intolerance to the IMP (Arimoclomol or constituents) Exposure to any other investigational treatment, advanced therapy medicinal product or use of any other prohibited concomitant medications Women who are lactating or pregnant, or men or women unwilling to use a highly effective method of birth control if not surgically sterile (defined as bilateral tubal ligation, bilateral oophorectomy, or hysterectomy for women; vasectomy for men) for female participants until 4 weeks after last dose and for male participants until 3 months after last dose. Pre-menopausal women must have a negative pregnancy test prior to dosing with trial medication. Any of the following medically significant conditions: Clinically significant renal or hepatic disease OR clinical laboratory assessment (results > or = 3 times the upper limit of normal [ULN] for aspartate aminotransferase and/or alanine aminotransferase, bilirubin > or = 2 times the ULN, or creatinine > or = 1.5 times the ULN). Any new condition or worsening of existing condition which, in the opinion of the investigator, would put the subject at undue risk. Any serious adverse event or moderate/severe adverse event from the ORARIALS-01 trial which is ongoing at the time of transitioning to ORARIALS-02 and assessed as probably related to IMP",Iii,Both
1,Patients with rapidly progressive SOD1 positive familial ALS.,"Ages Eligible for Study: 18 Years and older; Genders Eligible for Study: Both Inclusion Criteria: Type of ALS that is hereditary (runs in families)only El Escorial criteria for familial ALS and a family history of a pathogenic mutation in a gene known to be associated with ALS, such as the SOD1 gene. Willingness to undergo genetic testing and to learn the results. Demonstrable mutation in the SOD1 gene that is reported to be associated with a rapid rate of disease progression (i.e. A4V, A4T, C6F, C6G, V7E, L8Q, G10V, G41S, H43R, H48Q, D90V, G93A, D101H, D101Y, L106V, I112M, I112T, R115G, L126X, G127X, A145T, V148G, V148I). Age 18 years or older; male or female. Capable of providing informed consent and complying with trial procedures. Diagnosis within less than 6 months of the anticipated date of the baseline visit AND study participants' subjective evaluation that they expect their physical condition to permit travel to the study site for both the baseline and 2-month study visits. Women must not be able to become pregnant (e.g. post menopausal for at least one year, surgically sterile, or practicing adequate birth control methods) for the duration of the study. Adequate contraception includes: oral contraception, implanted contraception, intrauterine device in place for at least 3 months, or barrier method in conjunction with spermicide. Women of childbearing potential must have a negative pregnancy test at screening visit and be non-lactating. Identifiable local medical doctor to assist with urgent care of any medical complications that may arise. Absence of any of the exclusion criteria.",20100758 20101021 Arimoclomol in SOD1 fALS NCT00706147 TrialTroveID-093162,Adults; Older Adults,year(s),,93162,Delay Disease Progression,,18.0,"Exclusion Criteria: Taking riluzole, or on a stable dose for at least thirty days prior to the baseline visit. History of known sensitivity or intolerability to Arimoclomol or to any other related compound. Exposure to any investigational drug within 30 days of the screening visit. Presence of any of the following clinical conditions: -Substance abuse within the past year. -Unstable cardiac, pulmonary, renal, hepatic, endocrine, hematologic, or active infectious disease. -AIDS or AIDS-related complex. -Unstable psychiatric illness defined as psychosis (hallucinations or delusions), untreated major depression within 90 days of the screening visit. -Positive pregnancy test at screening visit. Screening laboratory values: -Creatinine greater than 1.5. -Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) greater than 3.0 times the upper limit of normal. -Total bilirubin greater than 2.0 times the upper limit of normal. -White blood cell (WBC) count less than 3,500/mm3. -Platelet concentration less than 100,000/ul. -Hematocrit level less than 33 for female or less than 35 for male. -Coagulation tests greater than 1.5 times upper limit of normal. Female patients who are breast-feeding.",Ii/Iii,Both
0,Healthy volunteers.,,TrialTroveID-080193,,,,80193,Healthy subjects,,,,I,
0,Healthy volunteers.,,TrialTroveID-080092,,,,80092,Healthy subjects,,,,I,
0,Volunteers With Amyotrophic Lateral Sclerosis.,"Ages Eligible for Study: 18 Years and older Inclusion Criteria Familial or sporadic ALS. Diagnosed with laboratory-supported probable, probable or definite ALS according to the World Federation of Neurology El Escorial criteria for less than or equal to 36 months' duration prior to the Screening Visit. Vital capacity (VC) equal to or greater than 70% predicted value for gender, height and age at the Screening Visit. Geographic accessibility to the study site. Ability to take oral medication at the Screening Visit, based on verbal report. Fluency in English, Spanish or Canadian French. Women must not be able to become pregnant (e.g. post menopausal for at least 1 year, surgically sterile, or practicing adequate birth control methods) for the duration of the study.",AALS-003 NCT00561366 TrialTroveID-079897,Adults; Older Adults,year(s),,79897,Delay Disease Progression,,18.0,"Exclusion Criteria Taking riluzole, or on a stable dose not exceeding 50 mg twice per day for at least 30 days prior to the Screening Visit. History of known sensitivity or intolerability to arimoclomol or to any other related compound. Prior exposure to arimoclomol through a clinical trial or physician-sponsored IND. Exposure to any investigational agent within 30 days of the Screening Visit. Presence of any of the following clinical conditions: -Substance abuse within the past year. -Unstable cardiac, pulmonary, renal, hepatic, endocrine, hematologic, or active malignancy or infectious disease. -AIDS or AIDS-related complex. -Unstable psychiatric illness defined as psychosis (hallucinations or delusions), untreated major depression within 90 days of the Screening Visit. Laboratory values: Screening serum creatinine greater than or equal to 1.5 mg/dL, creatinine clearance less than 70 cc/min, alanine aminotransferase (ALT) greater than 3.0 times the upper limit of normal, total bilirubin greater than 1.5 times the upper limit of normal, white blood cell (WBC) count less than 3,500/mm3, platelet concentration of <100,000/ul, hematocrit level of less than 33 % for female or less than 35 % for male, or coagulation tests (PT, PTT) greater than or equal to 1.5 times upper limit of normal. Female volunteers who are breast-feeding. Dependence on mechanical ventilation (invasive or non-invasive) including Continuous Positive Airway Pressure [CPAP] or Bi-level Positive Airway Pressure [BiPAP]) prior to the Screening Visit. Dependence is defined as: subject unable to lie supine without it, or unable to sleep without it, or has a requirement for daily daytime use. Occasional use during some days is acceptable.",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis,"Diagnosis of ALS based on source-verifiable medical record and meets the Gold Coast Criteria Pathogenic or likely pathogenic SOD1 mutation based on source-verifiable medical records or genetic testing during Screening Slow Vital Capacity (SVC) ≥ 50% of predicted value adjusted for sex, age, and height (from a sitting position) at Screening Body Mass Index (BMI) ≥ 18.0 kg/m2 at Screening Able to complete at least 6 months of follow-up If taking any medication or supplement to treat ALS or ALS symptoms, must be on stable dose for ≥ 4 weeks prior to Day 1 and expected to remain at that dose until final study visit and not expected to start these medications after the first dose of ARO-SOD1 Able and willing to provide written informed consent and to comply with all study assessments Participants of childbearing potential must agree to use highly effective contraception in addition to a condom during the study and for at least 90 days following the end of study or last dose of study drug, whichever is later. Males must not donate sperm and females must not donate eggs during the study and for at least 90 days following the end of the study or last dose of study drug, whichever is later.",AROSOD1-1001 EudraCT Number: 2023-509032-26 NCT05949294 TrialTroveID-478079,Adults; Older Adults,year(s),,478079,Delay Disease Progression,,18.0,"Current or anticipated need of a diaphragm pacing system (DPS) during the study Participants using tofersen can be enrolled only after a washout period of approximately 20 weeks from the last tofersen dose to the first planned dose of ARO-SOD1 History of having received stem cell therapy for ALS treatment Any current or anticipated contraindications to lumbar puncture (LP) The presence of an implanted shunt for drainage of CSF or an implanted central nervous system (CNS) catheter Human immunodeficiency virus (HIV), seropositive for hepatitis B virus (HBV), seropositive for hepatitis C virus (HCV) Uncontrolled hypertension Severe cardiovascular disease History of drug abuse or alcoholism within 6 months of study enrollment Inability to comply with study requirements",I,Both
0,,,TrialTroveID-499424,,,,499424,Healthy subjects,,,,Iii,
0,Patients with ALS,,TrialTroveID-459727,,,,459727,Unspecified,,,,Ii,
0,Patients with amyotrophic lateral sclerosis,"El Escorial criteria for probable or definite ALS. Males and and non pregnant females between 18 and 70 years of age. Patients with an ALS-FRS-R score of at least 30 with an ALS diagnosis of two years or less. No history of active psychiatric disorder. Patients receiving antidepressants as a preventive treatment, with no history of active psychiatric disorder may be included. Patient has a good understanding of the study and nature of the procedure. Patient provides written informed consent prior to any study procedure. Patients should either be on a stable dose of Riluzole and/or Radicava (if applicable) for at least 30 days, or not be treated with Riluzole and/or Radicava Patient is medically able to tolerate immunosuppression regimen. Presence of a willing and able caregiver who understands the need to attend all follow-up visits, even if mobility declines.",ASTRO-001-IL NCT03482050 TrialTroveID-263255,Adults; Older Adults,year(s),year(s),263255,Delay Disease Progression,70.0,18.0,"Patient has a past infection or a positive test for HBV,HCV or HIV. Patient is in need of respiratory support. Patient has a lower than 10/12 in ALS-FRS-R respiratory parameters or below 70% of predicted slow vital capacity (SVC). Patient has renal failure. Patient has impaired hepatic function. Patient has a Body Mass Index (BMI) of <18.5 or > 30. Patient suffers from significant cardiac disease, diabetes, autoimmune diseases, chronic severe infection, malignant disease or any other disease or condition that may risk the patient or interfere with the ability to interpret the study results. Patient has systemic inflammation or active infections. Patient has been treated previously with any stem cell therapy. Current use of immunosuppressant medication or use of such medication within 6 weeks of Screening visit (Visit 0). Patient has participated in another clinical treatment trial or received other experimental medications outside of a clinical trial within 1 month prior to start of this study. Any known immunodeficiency syndrome. Any concomitant disease or condition limiting patient safety to participate.",Iii,Both
0,Subjects with Amyotrophic lateral sclerosis,,TrialTroveID-490059,,,,490059,Unspecified,,,,I,
0,Patients with Amyotrophic Lateral Sclerosis (ALS).,"Sporadic or familial ALS diagnosed as clinically possible, probable, lab-supported probable, or definite ALS defined by revised El Escorial criteria. Age 18 years or older. Capable of providing informed consent and complying with study procedures, in the SI's opinion. Time since onset of weakness due to ALS < or = 36 months at the time of the Master Protocol Screening Visit. SVC > or = 50% of predicted capacity for age, height, and sex at the time of the Master Protocol Screening Visit. Participants must either not take riluzole or be on a stable dose of riluzole for > or = 30 days prior to the Master Protocol Screening Visit. Riluzole-naïve participants are permitted in the study. Participants must either not take edaravone or have completed at least one cycle of edaravone prior to the Master Protocol Screening Visit. Edaravone-naïve participants are permitted in the study. Participants must have the ability to swallow pills and liquids at the time of the Master Protocol Screening Visit and, in the SI's opinion, have the ability to swallow for the duration of the study. Geographically accessible to the site.",ALS04 NCT04390386 TrialTroveID-374610,Adults; Older Adults,year(s),year(s),374610,Delay Disease Progression,70.0,18.0,"Clinically significant unstable medical condition (other than ALS) that would pose a risk to the participant, according to SI's judgment (e.g., cardiovascular instability, systemic infection, untreated thyroid dysfunction, or clinically significant laboratory abnormality or EKG changes). Lab abnormalities include, but are not limited to: Hemoglobin < 10 g/dL, White Blood Cells < 3.0 x 103/mm3, Neutrophils, Absolute < or = 1000/mm3, Eosinophilia (absolute eosinophil count of > or = 500 eosinophils per microliter), low platelet counts (< 150 x 109 per liter), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3 times the upper limit of normal (ULN), eGFR < 30 mL/min/1.73m2, thyroid-stimulating hormone (TSH) levels >10 mIU/L or <0.01 mIU/L. Presence of unstable psychiatric disease, cognitive impairment, dementia or substance abuse that would impair ability of the participant to provide informed consent, in the SI's opinion. Active cancer or history of cancer, except for the following: basal cell carcinoma or successfully treated squamous cell carcinoma of the skin, cervical carcinoma in situ, prostatic carcinoma in situ, or other malignancies curatively treated and with no evidence of disease recurrence for at least 3 years. Use of investigational treatments for ALS (off-label use or active participation in a clinical trial) within 5 half-lives (if known) or 30 days (whichever is longer) prior to the Master Protocol Screening Visit. Exposure at any time to any gene therapies under investigation for the treatment of ALS (off-label use or investigational). If female, breastfeeding, known to be pregnant, planning to become pregnant during the study, or of child-bearing potential and unwilling to use effective contraception for the duration of the trial and for 3 months, or longer as specified in each RSA, after discontinuing study treatment. If male of reproductive capacity, unwilling to use effective contraception for the duration of the trial and for 3 months, or longer as specified in each RSA, after discontinuing study treatment. Anything that would place the participant at increased risk or preclude the participant's full compliance with or completion of the study, in the SI's opinion. If a participant is being re-screened, the disqualifying condition has not been resolved, or the mandatory wash-out duration has not occurred. For those participating in the optional CSF collection, contraindication to undergoing a lumbar puncture (LP) in the SI's opinion. Participants undergoing the LP must not be currently taking anticoagulation medications such as warfarin that would be a contraindication to LP; aspirin and non-steroidal anti-inflammatories are allowed.",Ii,Both
0,Patients with amyotrophic lateral sclerosis,"Signed informed consent prior to initiation of any program-specific procedures. Familial or sporadic ALS defined as clinically possible, probable, or definite by Awaji-Shima Consensus Recommendations or other standard guidance. Adequate hematologic, renal, and liver function as defined by the patient's physician. Females of childbearing potential should be using and committed to continue using one of the following acceptable birth control methods: Sexual abstinence (inactivity) for 1 month prior to screening through study completion; or Intrauterine device (IUD) in place for at least 3 months prior to study through study completion; or Stable hormonal contraception for at least 3 months prior to study through study completion; or Surgical sterilization (vasectomy) of male partner at least 6 months prior to study. To be considered of non-childbearing potential, females should be surgically sterilized (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least 2 months prior to study) or be post-menopausal and at least 3 years since last menses. Males with female partners of childbearing potential must use contraception through study completion.",ALS-03 NCT04309604 TrialTroveID-369817,Adults; Older Adults,year(s),,369817,Unspecified,,18.0,"Dependence on invasive mechanical ventilation, defined as being unable to lay supine without it, unable to sleep without it, or continuous daytime use; presence of tracheostomy at screening; Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other opportunistic infections; or major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of baseline. Immunized with live-attenuated vaccines within 30 days before dosing. Participants must agree to forego live-attenuated vaccines throughout the program, including 12 weeks after the last dose of IC14. History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies. Pregnancy or breastfeeding. Presence of any of the following clinical conditions: History of one or more of the following: cardiac insufficiency (New York Heart Association III/IV), uncontrolled cardiac arrhythmias, unstable ischemic heart disease, or uncontrolled hypertension (systolic blood pressure > 170 mmHg or diastolic blood pressure > 110 mmHg). History of venous thromboembolic disease within 6 months, myocardial infarction, or cerebrovascular accident. Unstable pulmonary, renal, hepatic, endocrine or hematologic disease. Autoimmune disease, mixed connective tissue disease, scleroderma, polymyositis, or significant systemic involvement secondary to rheumatoid arthritis. Evidence of active malignant disease, malignancies diagnosed within the previous 5 years, or breast cancer diagnosed within the previous 5 years (except skin cancers other than melanoma). History of human immunodeficiency virus infection or other immunodeficiency illness.",I,Both
0,Patients with Amyotrophic Lateral Sclerosis,"Signed informed consent prior to initiation of any study-specific procedures. Familial or sporadic MND defined as clinically possible, probable, or definite by Awaji-Shima Consensus Recommendations. Rapidly progressive MND as defined by a decline of 3 or more points in the ALSFRS-R score during the prior 3 months. First symptoms of MND within 3 years of informed consent. Age between 18 and 75 years at time of informed consent. Seated Forced Vital Capacity (FVC) > or = 65% of predicted value. Not taking riluzole or edaravone or on a stable dose of riluzole or edaravone for at least 3 months prior to screening visit. Adequate bone marrow reserve, renal and liver function: absolute neutrophil count > or = 1.5 x 109/L lymphocyte count < 6.0 x 109/L platelet count > or = 150 x 109/L hemoglobin > or = 110 g/L eGFR > or = 40 mL/min/1.73 m2 ALT and/or AST < or = 2x ULN total bilirubin < or = 1.5x ULN serum albumin > or = 28 g/L Females of childbearing potential should be using and committed to continue using one of the following acceptable birth control methods: Sexual abstinence (inactivity) for 1 month prior to screening through study completion; or Intrauterine device (IUD) in place for at least 3 months prior to study through study completion; or Stable hormonal contraception for at least 3 months prior to study through study completion; or Surgical sterilization (vasectomy) of male partner at least 6 months prior to study. To be considered of non-childbearing potential, females should be surgically sterilized (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least 2 months prior to study) or be post-menopausal and at least 3 years since last menses. Males with female partners of childbearing potential must use contraception through study completion. Able to give informed consent and able to comply with all study visits and all study procedures",ALS03 NCT03508453 TrialTroveID-323146,Adults; Older Adults,year(s),year(s),323146,Delay Disease Progression,75.0,18.0,"Dependence on mechanical ventilation, defined as being unable to lay supine without it, unable to sleep without it, or continuous daytime use; presence of tracheostomy at screening; or presence of diaphragm pacing system at screening. Treatment with a drug or device within the last 30 days that has not received regulatory approval. Treatment within 12 months with immunomodulator or immunosuppressant agent (including but not limited to cyclophosphamide, cyclosporine, interferon-alpha, interferon-beta-1a, rituximab, alemtuzumab, azathioprine, etanercept, infliximab, adalimumab, certolizumab, golimumab, anakinra, rilonacept, secukinumab, tocilizumab, mycophenolate mofetil, methotrexate, haematopoietic stem cell transplantation, anti-sense drugs, gene therapy, cell-depleting agents, total lymphoid irradiation). Treatment with intravenous immunoglobulin within 2 months or dimethyl fumarate within 3 months. Non-steroidal anti-inflammatory drugs are acceptable. Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other opportunistic infections; or major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks. Live-attenuated vaccines within 30 days before dosing. Subjects must agree to forego live-attenuated vaccines throughout the study, including 12 weeks after the last dose of study drug. History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies. Presence of any of the following clinical conditions: History of one or more of the following: cardiac insufficiency (New York Heart Association [NYHA] III/IV), uncontrolled cardiac arrhythmias, unstable ischemic heart disease, or uncontrolled hypertension (systolic blood pressure > 170 mmHg or diastolic blood pressure > 110 mmHg). History of venous thromboembolic disease within 12 months, myocardial infarction, or cerebrovascular accident. Unstable pulmonary, renal, hepatic, endocrine or hematologic disease. Autoimmune disease, mixed connective tissue disease, scleroderma, polymyositis, or significant systemic involvement secondary to rheumatoid arthritis. Evidence of active malignant disease, malignancies diagnosed within the previous 5 years, or breast cancer diagnosed within the previous 5 years (except skin cancers other than melanoma) History of human immunodeficiency virus infection or other immunodeficiency illness. Unstable psychiatric illness defined as psychosis or untreated major depression within 90 days. History of drug abuse (not including marijuana use) or alcoholism within the past 12 months. Significant neuromuscular disease other than MND. Other ongoing disease that may cause neuropathy, such as toxin exposure, dietary deficiency, uncontrolled diabetes, hyperthyroidism, cancer, systemic lupus erythematosus or other connective diseases, infection with HIV, hepatitis B virus (HBV), or hepatitis C (HCV), Lyme disease, multiple myeloma, Waldenström's macroglobulinemia, amyloid, and hereditary neuropathy. Pregnancy or breastfeeding. Deprivation of freedom by administrative or court order",Ii,Both
0,Patients with amyotrophic lateral sclerosis,"A patient must fulfill all of the following criteria to be eligible for enrollment: Signed informed consent prior to initiation of any study-specific procedures. Familial or sporadic motor neurone disease (MND) defined as clinically possible, probable, or definite by Awaji-Shima Consensus Recommendations. First symptoms of MND within 3 years of informed consent. Age between 18 and 75 years at time of informed consent. Seated Forced Vital Capacity (FVC) > or = 65% of predicted value. Not taking riluzole or on a stable dose of riluzole for at least 4 weeks prior to screening visit. Adequate bone marrow reserve, renal and liver function: absolute neutrophil count > or = 1500/µL lymphocyte count < 48% platelet count > or = 150,000/µL hemoglobin > or = 11 g/dL Estimated glomerular filtration rate (eGFR) > or = 40 mL/min/1.73 m2 Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) < or = 2x upper imit of normal (ULN), total bilirubin < or = 1.5x ULN serum albumin > or = 2.8 g/dL Females of childbearing potential should be using and committed to continue using one of the following acceptable birth control methods: Sexual abstinence (inactivity) for 1 month prior to screening through study completion; or Intrauterine device (IUD) in place for at least 3 months prior to study through study completion; or Stable hormonal contraception for at least 3 months prior to study through study completion; or Surgical sterilization (vasectomy) of male partner at least 6 months prior to study. To be considered of non-childbearing potential, females should be surgically sterilized (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least 2 months prior to study) or be post-menopausal and at least 3 years since last menses. Males with female partners of childbearing potential must use contraception through study completion. Medically safe to have lumbar puncture to collect cerebrospinal fluid. Able to give informed consent and able to comply with all study visits and all study procedures.",ALS01 NCT03487263 TrialTroveID-321826,Adults; Older Adults,year(s),year(s),321826,Delay Disease Progression,75.0,18.0,"A patient fulfilling any of the following criteria at screening is to be excluded from enrollment in the study: Dependence on mechanical ventilation, defined as being unable to lay supine without it, unable to sleep without it, or continuous daytime use; presence of tracheostomy at screening; or presence of diaphragm pacing system at screening. Treatment with a drug or device within the last 30 days that has not received regulatory approval. Treatment within 12 months with immunomodulator or immunosuppressant agent (including but not limited to cyclophosphamide, cyclosporine, interferon-a, interferon-ß-1a, rituximab, alemtuzumab, azathioprine, etanercept, infliximab, adalimumab, certolizumab, golimumab, anakinra, rilonacept, secukinumab, tocilizumab, mycophenolate mofetil, methotrexate, haematopoietic stem cell transplantation). Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other opportunistic infections or major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks. History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies. Presence of any of the following clinical conditions: Bleeding diathesis or receipt of anticoagulants within 7 days (or any other clinical condition that would, in the opinion of the investigator, place the patient at increased risk during lumbar puncture). History of one or more of the following: cardiac insufficiency (New York Heart Association [NYHA] III/IV), uncontrolled cardiac arrhythmias, unstable ischemic heart disease, or uncontrolled hypertension (systolic blood pressure > 170 mmHg or diastolic blood pressure > 110 mmHg). History of venous thromboembolic disease within 12 months, myocardial infarction, or cerebrovascular accident. Unstable pulmonary, renal, hepatic, endocrine or hematologic disease. Autoimmune disease, mixed connective tissue disease, scleroderma, polymyositis, or significant systemic involvement secondary to rheumatoid arthritis. Evidence of active malignant disease, malignancies diagnosed within the previous 5 years, or breast cancer diagnosed within the previous 5 years (except skin cancers other than melanoma). Human immunodeficiency virus infection or other immunodeficiency illness. Unstable psychiatric illness defined as psychosis or untreated major depression within 90 days. Drug abuse or alcoholism within the past 12 months. Significant neuromuscular disease other than MND. Other ongoing disease that may cause neuropathy, such as toxin exposure, dietary deficiency, uncontrolled diabetes, hyperthyroidism, cancer, systemic lupus erythematosus or other connective diseases, infection with HIV, hepatitis B virus (HBV), or hepatitis C (HCV), Lyme disease, multiple myeloma, Waldenström's macroglobulinemia, amyloid, and hereditary neuropathy. Pregnancy or breastfeeding. Deprivation of freedom by administrative or court order.",I,Both
0,Patients With Amyotrophic Lateral Sclerosis.,"Capable of providing informed consent and informed consent form signed prior to initiation of any study-specific procedures. Familial or sporadic ALS defined as clinically possible, probable, or definite by El Escorial Criteria. Rapidly progressive ALS defined by the Revised ALS Functional Rating Scale (ALSFRS-R) slope > or = 1 (48 minus ALSFRS-R score at screening / disease duration in months = 1). Upper Motor Neuron Burden Score of > or = 25 (out of 45) at screening First symptoms of ALS within 3 years of the screening visit Age between 18 and 80 years at the time of the screening visit. Not taking riluzole or edaravone or on a stable dose of riluzole or edaravone for at least 3 months prior to screening visit. Adequate bone marrow reserve, renal and liver function: absolute neutrophil count > or = 1500/µL lymphocyte count < 6000/µL platelet count > or = 150,000/µL hemoglobin > or = 11 g/dL creatinine clearance > or = 60 mL/min alanine transaminase (ALT) and/or aspartate transaminase (AST) < or = 3x upper limits of normal (ULN) total bilirubin < or = 1.5x ULN serum albumin > or = 2.8 g/dL Females of childbearing potential should be using and committed to continue using one of the following acceptable birth control methods: Sexual abstinence (inactivity) for 1 month prior to screening through study completion; or Intrauterine device (IUD) in place for at least 3 months prior to study through study completion; or Stable hormonal contraception for at least 3 months prior to study through study completion; or Surgical sterilization (vasectomy) of male partner at least 6 months prior to study. To be considered of non-childbearing potential, females should be surgically sterilized (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least 2 months prior to study) or be post-menopausal and at least 3 years since last menses. Males with female partners of childbearing potential must use contraception through study completion. Ability to safely lie flat for 90 min for magnetic resonance-positron emission tomography (MR-PET) procedures in the opinion of the Investigator. Patients must also have a genotype associated with a high or mixed affinity translocator protein (TSPO) (Ala/Ala or Ala/Thr) and ability to safely undergo MR-PET scans based on the opinion of the Investigator.",ALS02 NCT03474263 TrialTroveID-320908,Adults; Older Adults,year(s),year(s),320908,Unspecified,80.0,18.0,"Dependence on invasive or non-invasive ventilation, defined as being unable to lay supine without it, unable to sleep without it, or continuous daytime use; presence of tracheostomy at screening; or presence of diaphragm pacing system at screening. Exposure to any experimental treatment for ALS within the last 30 days or five half-lives, whichever is longer. Treatment within 12 months with immunomodulator or immunosuppressant agent (including but not limited to cyclophosphamide, cyclosporine, interferon-a, interferon-ß-1a, rituximab, alemtuzumab, azathioprine, etanercept, infliximab, adalimumab, certolizumab, golimumab, anakinra, rilonacept, secukinumab, tocilizumab, mycophenolate mofetil, methotrexate, cell-depleting agents, total lymphoid irradiation, dimethyl fumarate). Treatment with intravenous immunoglobulin (IVIG) within 2 months. Non-steroidal anti-inflammatory drugs (NSAIDs) are acceptable. Exposure at any time to any cell or gene therapies under investigation for the treatment of ALS. Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other opportunistic infections; or major episode of infection requiring hospitalization or treatment with intravenous (IV) antibiotics within 4 weeks. Live-attenuated vaccines within 30 days before dosing. Subjects must agree to forego live-attenuated vaccines throughout the study, including 60 days after the last dose of study drug. History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies. History of one or more of the following: cardiac insufficiency (New York Heart Association [NYHA] III/IV), uncontrolled cardiac arrhythmias, unstable ischemic heart disease, or uncontrolled hypertension (systolic blood pressure > 170 mmHg or diastolic blood pressure > 110 mmHg). History of myocardial infarction, or cerebrovascular accident. Unstable pulmonary, renal, hepatic, endocrine or hematologic disease. Autoimmune disease, mixed connective tissue disease, scleroderma, polymyositis, or significant systemic involvement secondary to rheumatoid arthritis. Evidence of active malignant disease, malignancies diagnosed within the previous 5 years, or breast cancer diagnosed within the previous 5 years (except skin cancers other than melanoma). History of human immunodeficiency virus infection or other immunodeficiency illness. Unstable psychiatric illness defined as psychosis or untreated major depression within 90 days. History of drug abuse (not including marijuana use) or alcoholism within the past 12 months. Significant neuromuscular disease other than ALS. Other ongoing disease that may cause neuropathy, such as toxin exposure, dietary deficiency, uncontrolled diabetes, hyperthyroidism, cancer, systemic lupus erythematosus or other connective diseases, infection with HIV, hepatitis B virus (HBV), or hepatitis C (HCV), Lyme disease, multiple myeloma, Waldenström's macroglobulinemia, amyloid, and hereditary neuropathy. Pregnancy or breastfeeding. Deprivation of freedom by administrative or court order. Any contraindication to undergo magnetic resonance imaging (MRI) studies such as history of a cardiac pacemaker or pacemaker wires; metallic particles in the body; vascular clips in the head; prosthetic heart valves; or severe claustrophobia. Unwilling or unable to discontinue benzodiazepine usage [other than lorazepam (Ativan), clonazepam (Klonopin), or zolpidem (Ambien)] for one day prior to and during scanning. Research imaging-related radiation exposure exceeds current institutional Radiology Department guidelines",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis.,"Inclusion Criteria: Participants must. Have a diagnosis of ALS. Have had ALS for three or fewer years. Have a forced vital capacity (FVC, a respiratory measurement) of at least 50 percent of normal. Have an Appel ALS score (objective grading scale that assesses disease severity) of less than 100.",TrialTroveID-079879,,,,79879,Delay Disease Progression,,,Exclusion Criteria: Elevated cholesterol levels or active treatment for elevated cholesterol. Participants must not: Have a history of high cholesterol. Be currently taking a cholesterol-lowering medication.,Ii,
0,Patients with Amyotrophic Lateral Sclerosis (ALS).,"Patients should voluntarily participate in the experiment by signing an informed consent form. Patients should comply with the research process and cooperate with the interventions applied throughout the experiment. Patients should be between 30 and 65 years of age, and both sexes are acceptable. Patients should comply with the diagnostic criteria and exclusion criteria for amyotrophic lateral sclerosis in the Chinese Guidelines for the Diagnosis and Treatment of Amyotrophic Lateral Sclerosis developed by the Chinese Society of Neurology of the Chinese Medical Association in 2012. Patient's amyotrophic lateral sclerosis history must not exceed 5 years. ALS functional scale score (ALSFRS-R) should be > or = 2 points for each patients.",lj11128 NCT04391361 TrialTroveID-374769,Adults,year(s),year(s),374769,Delay Disease Progression,65.0,30.0,"Patients with cardiac conduction block, severe ventricular insufficiency, severe hepatorenal insufficiency and severe, progressive or uncontrolled major organ and systemic disease. High or low blood pressure: systolic blood pressure >150 or <110 mmHg; bradycardia (<60 beats per minute). Patients with ventilator-assisted ventilation. Patients who are allergic to research intervention drugs. Patients with obvious signs of dementia. Female patients who are pregnant or breastfeeding or who have a plan to become pregnant in the near future. Persons with other psychiatric disorders that may affect the assessment of their condition. Severely obese patients (BMI >35kg/m2).",Ii,Both
0,Patient with Amyotrophic Lateral Sclerosis (ALS).,"Documented diagnosis of Amyotrophic Lateral Sclerosis. Capable of giving informed consent (signed, verbal or assent as applicable and as listed in the protocol)",HBALS01 NCT04514952 TrialTroveID-382158,,,,382158,Delay Disease Progression,,,"Other acute or chronic medical conditions that, in the opinion of the investigator, may increase the risks associated with study participation or HB-adMSCs administration. Any abnormal, inexplicable laboratory result that, in the opinion of the investigator, may increase the risks associated with study participation or HB-adMSCs administration. Participation in other interventional research studies within the past 30 days. Unwillingness to return for follow-up visits.",I,Both
0,Patients with amyotrophic lateral sclerosis,Diagnosis of ALS defined or probable according to the criteria established by the World Federation of Neurology Age between 18 and 70 years. Patient that offers sufficient guarantees of adherence to the protocol. Neurophysiological data that confirm lower motor neuron involvement at lumbar and cervical level. Assessment of the motor deficit in the dorsiflexion of both feet (between 3 and 5 points on the MRC scale).,EudraCT Number: 2019-002302-46 IMIB-TCIM/ELAII-2019-01 NCT04849065 TCIM-ELAII TrialTroveID-361959,Adults; Older Adults,year(s),year(s),361959,Delay Disease Progression,70.0,18.0,"Mellitus diabetes. Other diseases that may occur with polyneuropathies. Previous history of cerebral stroke. Previous pathology of the peripheral nervous system that affects one or both lower or upper limbs, with or without clinically evident neurological sequelae. Pregnant or breast-feeding patients Patients who are physiologically capable of becoming pregnant, unless they are using a reliable method of contraception (Annex III) Patients with cardiac, renal, hepatic, systemic, immune disease that may influence the patient's survival during the trial. Positive serology for hepatitis B, hepatitis C or HIV. Clinical and anesthesiological criteria that contraindicate either sedation or the extraction of MO itself (alteration of the coagulation system or anticoagulated patient with inability to withdraw anticoagulation, hemodynamic instability, skin alteration in the puncture site, etc.) Inclusion in other clinical trials in the last 6 months. Inability to understand informed consent.",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis.,"To participate in this trial, patients will have to meet following criteria: Established diagnosis of definite ALS according to El Escorial Criteria and data available from detailed neurologic observation (including ALSFRS, Norris scale, spirometry, brain and spinal cord MRI) for at least 6 months prior to the study entrance. Riluzole naive or at stable dose for at least 2 months. Patients between 18–65 years, both sexes, life expectancy more than 2 years. Patients able to provide written informed consent.",AMSC in ALS AMSC-ALS-001 EudraCT number: 2011-000362-35 NCT03828123 TrialTroveID-165435,Adults,year(s),year(s),165435,Delay Disease Progression,65.0,18.0,"Patients meeting any of the following criteria will be excluded from the participation in this study: FVC less than 70%. In case of primary bulbar paralysis less than 15 points on Norris bulbar scale. Less than 15 points on Norris spinal scale. Pregnancy, breastfeeding. Coagulopathy. Skin infection at the site of bone marrow aspiration or application of the cell product. Gastrostomy. Any significant medical condition that would compromise the safety of the patient (e.g. recent myocardial infarction, congestive heart failure, renal failure, liver failure, cancer, systemic infection, reccurent thromboembolic disease .....). Alcohol or drug abuse. Cancer. Women of childbearing potential not using effective contraception (established oral contraception, intrauterine device, ligation of the uterine tube) including proven contraceptive measures taken by their sexual partners. Fertile men not using proven contraceptive measures including effective contraception of their partner (established oral contraception, intrauterine device, ligation of the uterine tube).",Iii,Both
0,Patients with Amyotrophic Lateral Sclerosis.,"All patients will have ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by the World Federation of Neurology criteria for the diagnosis of ALS. Examination and neurophysiological testing confirm a pure motor syndrome compatible with the diagnosis of ALS. All other possible causes of weakness have been excluded by extensive investigations. Age greater than 18 years, if female, must be post-menopausal, had a hysterectomy, or agree to two forms of birth control. Permanent resident or citizen of the United States. Geographic accessibility to the study site and willingness and ability to comply with follow-up. History of a chronic onset of a progressive motor weakness of less than two years duration. Subjects must be taking a stable dose of riluzole for at least 30 days prior to enrolment or not be on riluzole, and not have been on it for at least 30 days prior to enrolment (riluzole-naïve subjects are permitted in the study). Able to comply with protocol requirements, including MRI testing. Can provide written informed consent.",15-008008 NCT03268603 TrialTroveID-308228,Adults; Older Adults,year(s),,308228,Unspecified,,18.0,"Use of Radicava (edaravone) within 30 days of screening or intent to use Radicava® at any time during the course of the study including the follow up period. Any clinically significant medical condition (e.g., within six months of baseline, had myocardial infarction, angina pectoris, and/or congestive heart failure) that, in the opinion of the investigator, would compromise the safety of patient. Pulmonary Slow Vital Capacity (SVC) less than 65% of predicted for age, gender, and body type. Autoimmunity, including Crohn's disease or rheumatoid arthritis Current use of immunosuppressant medication or use of such medication within 4 weeks of Screening visit (Visit 1). Malignancy 5 years prior to enrollment, including melanoma,with the exception of localized skin cancers (with no evidence of metastasis, significant invasion, or re-occurrence within three years of baseline). Active systemic or local infection near the lumbar puncture site. Inability to lie flat for the duration of intrathecal cell transplantation, or inability to tolerate study procedures for any other reason. Other active systemic disease as defined by laboratory abnormalities delineated in Appendix IV. Use of herbal medications, nutritional supplements or other unapproved drugs or investigational medicinal products being used or studied for the treatment of ALS. Unwilling to forgo initiating the use of any new supplements during participation in the study. Enrolled in an investigational drug trial within 30 days of baseline visit Prior stem cell therapy for a neurological disease Kokmen Short Test of Mental Status score <32 Presence of a tracheostomy Ventilator dependent Pregnancy Men or women of childbearing potential who are unwilling to employ adequate contraception Chronic low back pain requiring invasive procedures (i.e. epidural injections or lumbar spine surgery)",Ii,Both
1,"Patients with amyotrophic lateral sclerosis (ALS) Per March 28, 2018 protocol amendment, Canada-based ALS patients will be enrolled.","ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria. Having onset of ALS disease symptoms, including limb weakness within 24 months at the Screening Visit. ALSFRS-R > or = 25 at the screening Visit. Upright slow vital capacity (SVC) measure > or = 65% of predicted for gender, height, and age at the screening Visit. Rapid progressors Participants taking a stable dose of Riluzole are permitted in the study. Citizen or permanent resident of the United States or Canadian citizen able to travel to a US site for all follow-up study visits.",BCT-002-US CIRM CLIN2-0989 NCT03280056 TrialTroveID-293113,Adults,year(s),year(s),293113,Delay Disease Progression,60.0,18.0,"Prior stem cell therapy of any kind. History of autoimmune or other serious disease (including malignancy and immune deficiency) that may confound study results. Current use of immunosuppressant medication or anticoagulants (per Investigator discretion). Exposure to any other experimental agent or participation in an ALS clinical trial within 30 days prior to Screening Visit. Use of RADICAVA (edaravone injection) within 30 days of screening or intent to use edaravone at any time during the course of the study including the follow up period. Use of non-invasive ventilation (BIPAP), diaphragm pacing system or invasive ventilation (tracheostomy). Feeding tube Pregnant women or women currently breastfeeding.",Iii,Both
0,Patients with amyotrophic lateral sclerosis.,,TrialTroveID-271339,,,,271339,Unspecified,,,,Ii,
0,Patients with Amyotrophic Lateral Sclerosis (ALS) at the early disease stages.,"Ages Eligible for Study: 20 Years to 75 Years, Genders Eligible for Study: Both Inclusion Criteria: Patient must fulfill El Escorial criteria (APPENDIX 2) for definite or probable ALS (sporadic and not familial) Participants, either men or non pregnant women are between 20 and 75 years of age. The patient is mentally intact and psychologically stable Patients will be with an ALS-FRS-R scale (APPENDIX 3) of at least 30 and disease duration of less than 2 years. Patient has sufficiently bulky muscles. Participant understands the nature of the procedure and provides written informed consent prior to any study procedure.",MSC-NTF-002-HMO-CTIL NCT01777646 TrialTroveID-181174,Adults; Older Adults,year(s),year(s),181174,Delay Disease Progression,75.0,20.0,"Exclusion Criteria: Patient has a positive test for HBV, HCV or HIV. Patient has high protein in the CSF (Protein > 70 mg/ml). Patient has lymphocytosis in the CSF (lymphocytes > 5/ml). Patient is positive for anti-GM1 antibodies. Patient has significant conduction blocks or slow nerve conduction velocities (a reduction of more than 30%) confirmed by nerve conduction velocity - EMG studies. The patient is a respiratory dependent patient. Patients with renal failure (Cr > 2 mg/dl). Patients with impaired hepatic function (ALT, AST or GGT 2-fold higher than normal upper limit). Patients suffering from significant cardiac disease, malignant disease or any other disease that may risk the patient or interfere with the ability to interpret the results Patient with active infections. Participation in another clinical trial within 1 month prior to start of this study. Patient has not been treated previously with any cellular therapy. Subject unwilling or unable to comply with the requirements of the protocol.",Ii,Both
0,Patients with amyotrophic lateral sclerosis (ALS).,"Males and females ages 18 to 75 years old, inclusive. ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria. Disease onset, as defined by first reported occurrence of symptomatic weakness, spasticity, or bulbar symptoms, of more than 12 months and less than or equal to 24 months. Current disease symptoms must include limb weakness. ALSFRS-R =30 at the Screening Visit. Upright slow vital capacity (SVC) measure =65% of predicted for gender, height, and age at the Screening Visit. Subjects must be taking a stable dose of riluzole for at least 30 days prior to enrolment or not be on riluzole, and not have been on it for at least 30 days prior to enrolment (riluzole-naïve subjects are permitted in the study). Capable of providing informed consent and willing and able to follow study procedures, including willingness to undergo lumbar puncture. Geographic accessibility to the study site and willingness and ability to comply with follow-up. Women of child-bearing potential must agree not to become pregnant for the duration of the study. Women must be willing to consistently use two forms of contraceptive therapy throughout the course of the trial, and undergo a pregnancy test one week before bone marrow aspiration. Men must be willing to consistently use two forms of contraceptive if their partners are of child-bearing age. Citizen or permanent resident of the United States.",BCT-001-US NCT02017912 TrialTroveID-122551,Adults; Older Adults,year(s),year(s),122551,Unspecified,75.0,18.0,"Prior stem cell therapy of any kind. Inability to lie flat for the duration of intrathecal cell transplantation and/or bone marrow biopsy, or inability to tolerate study procedures for any other reason. History of autoimmune disease (excluding thyroid disease) myelodysplastic or myeloproliferative disorder, leukemia or lymphoma, whole body irradiation, hip fracture, or severe scoliosis. Any unstable clinically significant medical condition other than ALS (e.g., within six months of baseline, had myocardial infarction, angina pectoris, and/or congestive heart failure), treatment with anticoagulants that, in the opinion of the investigator, would compromise the safety of patients. Any history of malignancy including any malignancy affecting the central nervous system and melanoma, within the previous 5 years, with the exception of localized skin cancers (with no evidence of metastasis, significant invasion, or re-occurrence within three years of baseline). Serum AST or ALT value >3.0 times the upper normal limit. Serum creatinine value >2.0 times the upper normal limit. Positive test for Hepatitis B, Hepatitis C, HIV. Current use of immunosuppressant medication or use of such medication within 4 weeks of Screening visit (Visit 1). Any history of acquired or inherited immune deficiency syndrome. Exposure to any other experimental agent (off-label use or investigational) or participation in a clinical trial within 30 days prior to Screening Visit (Visit 1). Use of non-invasive ventilation (NIV), diaphragm pacing system or invasive ventilation (tracheostomy). Any history of either substance abuse within the past year, or unstable psychiatric disease according to PI judgment. Placement or usage of feeding tube. Pregnant women or women currently breastfeeding.",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis (ALS). Patients diagnosed as early stage ALS disease with duration of less than 6 months and patients diagnosed with progressive stage ALS disease with duration of 6-12 months.,"Ages Eligible for Study: 20 Years to 75 Years, Genders Eligible for Study: Both Inclusion Criteria: For early stage ALS- Patients will be with ALS-FRS-R scale of at least 30 and disease duration of less than 2 years.Or, for progressive stage ALS- Patients will be with an ALS-FRS-R scale of 15-30 and disease duration of less than 2 years. For early stage ALS- Patient has sufficiently bulky muscles. Or, for progressive stage ALS- Patient with at least 60% FVC. Participant understands the nature of the procedure and provides written informed consent prior to any study procedure. For group 1(intramuscular injections): Consenting patients fulfilling the El Escorial criteria for definite ALS (sporadic and not familial). Age: 20-75, males and (non-pregnant) females. The patients will be mentally intact and psychologically stable. Patients will be at an early stage of the disease with an ALS-FRS scale of at least 30 and disease duration of less than 6 months. Only patients with sufficiently bulky muscles will be included. All patients will sign an informed consent form. For Group 2 (Intrathecal injection): Consenting patients fulfilling the El Escorial criteria for definite ALS (sporadic and not familial). Age: 20-75, males and (non-pregnant) females. The patients will be mentally intact and psychologically stable. Patients will be at a not very progressed stage of the disease with an ALS-FRS scale of at least 25 and disease duration of less than 12 months. All patients will sign an informed consent form.",MSC-NTF 28/12/09 MSC-NTF-001-HMO-CTIL NCT01051882 TrialTroveID-121611,Adults; Older Adults,year(s),year(s),121611,Delay Disease Progression,75.0,20.0,"Exclusion Criteria: Positive test for HBV, HCV, HIV and Mycoplasma. High protein in the CSF. Lymphocytosis in the CSF. Positive for anti-GM1 antibodies. Patient has significant conduction blocks or slow nerve conduction velocities (a reduction of more than 30%) confirmed by nerve conduction velocity - EMG studies. The patient is a respiratory dependent. Renal failure, impaired hepatic function Patients suffering from significant cardiac disease, malignant diseases or any other disease that may risk the patient or interfere with the ability to interpret the results Active infections. Participation in another clinical trial within 1 month prior to start of this study. Subject unwilling or unable to comply with the requirements of the protocol. Patient has not been treated previously with any cellular therapy.",Iii,Both
0,Patients with Amyotrophic Lateral Sclerosis,Diagnosis of definite or possible ALS according to revised EL Escorial criteria Age: 20-75 years documented progression of disease during the last 6 months. Absence of concomitant diseases Adequate assurances of adherence to protocol The patient must be able to communicate verbally or with the use of non-verbal communication system Group 1 Maximum score of 1 on walking item of ALS functional rating scale. Forced vital capacity > or equal to 60. Group 2 Forced vital capacity > or equal to 60. Ambulation difficulties (maximum score of 2 on walking item of ALS functional rating scale). Group 3 Independent ambulation (score 4 on a scale ALS-FRS). Forced vital capacity > or equal to 70.,EudraCT Number: 2009-014484-39 hNSCALS NCT01640067 TrialTroveID-171191,Adults; Older Adults,year(s),year(s),171191,Delay Disease Progression,75.0,20.0,"The presence of at least one of the following will lead to patient exclusion. Psychiatric diseases or other neurological diseases different from ALS. Other systemic diseases. Neoplasms or other diseases reducing life expectancy. Antecedent polio infection. Corticosteroids, immunoglobulin or immunosuppressive treatment. Involvement in other clinical trials. 2 or more critical items in MMPI. Neuropsychological evaluation suggestive of mental deterioration or cognitive sphere disturbance. Impediments to MRI. Patients unable to understand informed consent form and study aims. Women who are pregnant or childbearing potential for the duration of the study. Non-pregnant status will be documented by beta-HCG negative test 7 days before treatment start.",I,Both
0,Patients with amyotrophic lateral sclerosis (ALS),"Minimum age : 25 Maximum age : 70 Gender : both Inclusive criteria: Definite, probable or laboratory supported probable ALS (El Escorial criteria) Age 25-70 yrs Disease progression for duration of more than 6 months and less than 36 months EMG-NCV confirms the diagnosis FVC more than 50% INR less than 1.5 Platelet count more than 100000",IRCT201107221696N3 TrialTroveID-151759,Adults; Older Adults,year(s),year(s),151759,Delay Disease Progression,70.0,25.0,Exclusion Criteria: Any major systemic or psychiatric illness Any coexisting neurodegenerative disease No other major pathology in brain or spinal cord History of hematologic or lymphoproliferative disease History of stem cell treatment of any kind,Ii,Both
0,Patients with amyotrophic lateral sclerosis (ALS),Patients diagnosed as definite or probable ALS disease according to EL Escorial criteria ALSFRS-R more than 26 FVC more than 40% Age 25-70 years Time passed since onset of the symptoms till inclusion be 3 years or less,IRCT20200828048551N1 TrialTroveID-404742,Adults; Older Adults,year(s),year(s),404742,Delay Disease Progression,70.0,25.0,Any major systemic disease Any coexisting neurodegenerative disease No other major pathology in brain or spinal cord pregnancy or lactation,Ii,Both
0,Patients With Amyotrophic Lateral Sclerosis (ALS),"Males and females ages 18 to 70 years old, at the Screening Visit. Sporadic or familial ALS diagnosed patients fulfilling the El Escorial clinical criteria for definite. Capable of providing informed consent and willing and able to follow study procedures, including willingness to undergo multiple/repeated lumbar punctures. ALSFRS-R > or = 15 at the Screening Visit.",0208-16-HMO NCT04821479 TrialTroveID-400308,Adults,year(s),year(s),400308,Delay Disease Progression,65.0,18.0,"Patients with severe cognitive decline or inability to understand and sign the informed consent. Participation in another clinical trial within 1 year prior to start of the study Patients with active infections. Positive test for Hepatitis B, Hepatitis C, and/or HIV per laboratory evaluations at the screening visit. Any history of solid malignancy including any malignancy affecting the central nervous system within 5 years of the Screening Visit",Iii,Both
0,Patients With Amyotrophic Lateral Sclerosis ALS patients who treated at least 2 times of BM-MSC treatments were enrolled,,TrialTroveID-393178,,,,393178,Delay Disease Progression,,,,Ii,
0,Patients with Amyotrophic Lateral Sclerosis,"(Inclusion criteria at the time of first registration) ALS that meets the diagnostic criteria (Updete Awaji) as definite or probable ALS Severity is class1 to 3 ALS onset within 3 years %FVC greater than or equal to 70% Completion of this trial is expected Age between 20 to 80 The written informed consent obtained as much as possible from subjects.If the subject does not have ability to write etc, the Informed Consent Obtained Written From Legal Representative. [Inclusion Criteria At The Time Of Second Registration] ALS Severity Is Class1 To 3 Pasento FVC Greater Than Or Equal To 70 Pasento Completion Of This Trial Is Expected Ready to infuse of investigational product which satisfies specification of acceptance criteria Standard treatment (Riluzole, Edaravone, etc.) is not scheduled to change",jRCT2013190010 TrialTroveID-376371,Adults; Older Adults,year(s),year(s),376371,Delay Disease Progression,80.0,20.0,"[Exclusion criteria at the time of first registration] Bulbar paralysis related ALS or uncontrollable mental symptoms Diagnosed as dementia Diagnosed as HBV, HCV, HIV, HTLV-1, syphilis or Human parvovirus B19 by initial screening Pancytopenia (WBC <2000/uL, Hb <10.0g/dl, Plt <100000/uL) Past history of neoplasms (except CR), severe diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, severe mental and behavioral disorders, severe diseases of the nervous system, severe congenital malformations, deformations and chromosomal abnormalities Past history of penicillin and streptomycin allergy or other severe allergy (shock, anaphylactoid symptoms etc.) Poor general condition due to (Endocrine, nutritional and metabolic diseases, Mental disorders, diseases of nervous system, diseases of circulatory system (Uncontrollable and refractory heart failure, moderate or severe valvular heart disorder, uncontrollable and refractory atrial fibrillation, refractory atrial and ventricular thrombus, history of ischemic heart disease and PCI within the past 12 months, serious arrhythmia), diseases of the respiratory system, diseases of the digestive system, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system (dialysis etc) ), injury, poisoning and certain other consequences of external causes etc] Intracranial lesion (severe asymptomatic lesion, severe old infarction, severe white matter lesion, severe multiple lesions, severe microbleeding or multiple hemosiderosis, Cerebrovascular diseases such as Moyamoya disease or high risk AN etc, severe intracerebral hemorrhage etc) including past history of these issues. 70% or more stenosis or dissecting in the artery causing cerebral infarction even though after revascularization (except complete thrombotic occlusion) Severe arteriosclerotic change and calcification in the blood vessels of head and neck. Preoperative possible uncontrollable HT under depressor therapy (systolic pressure more than 140mmHg, diastolic pressure more than 90mmHg) Participation in other clinical trials or past history of cellular therapy Pregnant or possibly pregnant, nursing women or those who plan to be pregnant during the study period or male patients who wish partner to get pregnant Other patients judged by investigators as inappropriate for this study [Exclusion criteria at the time of second registration] Past history of neoplasms (except CR), severe diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, severe mental and behavioral disorders, severe diseases of the nervous system, severe congenital malformations, deformations and chromosomal abnormalities Past history of penicillin and streptomycin allergy or other severe allergy (shock, anaphylactoid symptoms etc.) Poor general condition due to (Endocrine, nutritional and metabolic diseases, Mental disorders, diseases of nervous system, diseases of circulatory system (Uncontrollable and refractory heart failure, moderate or severe valvular heart disorder, uncontrollable and refractory atrial fibrillation, refractory atrial and ventricular thrombus, history of ischemic heart disease and PCI within the past 12 months, serious arrhythmia), diseases of the respiratory system, diseases of the digestive system, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system (dialysis etc), injury, poisoning and certain other consequences of external causes etc] Intracranial lesion (moderate asymptomatic lesion, old infarction, white matter lesion, multiple lesions, microbleeding or multiple hemosiderosis, Cerebrovascular diseases such as Moyamoya disease or AN etc, severe intracerebral hemorrhage etc) 70% or more of stenosis or dissecting in the artery causing cerebral infarction even though after revascularization (except complete thrombotic occlusion) Severe arteriosclerotic change and calcification Preoperative possible uncontrollable hypertension under depressor therapy Pregnant, nursing women or those who plan to be pregnant during the study period or male patients who wish partner to get pregnant Other patients judged by investigators as inappropriate for this study",Ii,Both
0,"Motor neuron disease subjects with Motor Neuron Disease, Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, Progressive Muscular Atrophy, Progressive Bulbar Palsies",- Patients age 24-20 years old - Patients with the diagnosis of definite Motor Neuron Disease,NCT03067857 SCA-MND1 TrialTroveID-296758,Adults; Older Adults,year(s),year(s),296758,Delay Disease Progression; Unspecified,70.0,24.0,HIV/HBV/HCV Malignancies Bleeding Pneumonia Renal failure liver dysfunction Severe anemia (hb < 8) Bone Marrow diseases Pregnancy and lactation Acute medical conditions/infections such as respiratory infections ventilatory support,Iii,Both
0,Patients with Amyotrophic Lateral Sclerosis,"Women and males over 18-year-old. Diagnosis of ALS in agreement with the criteria of ""EL SCORE"" Less than 24 months of evolution of the disease (from the beginning of the symptoms). Good understanding of the protocol and aptitude to grant the informed consent Infertile women (post-menopause or hysterectomized) Brazilian citizen and permanent resident.",NCT02987413 TrialTroveID-292145,Adults; Older Adults,year(s),,292145,Unspecified,,18.0,"Any significant medical condition (congestive heart failure, angina, respiratory failure, and others) Any auto-immune disease Any malignant diseases Systemic infection Mental illness Depressive state",I,Both
0,Patients With Amyotrophic Lateral Sclerosis.,"Age between 18 and 70 Possible, probable or definite ALS following El Escorial Revised Criteria (Brooks, 2000) ALSFRS-r >or=30 at enrollment Forced Vital Capacity >or=65% of the height and weight standard No-pregnancy agreement Regional accessibility to the study site Capability to give away agreed consensus Patients will be followed at Academic Institutions at their hometown",401922/2014-6 NCT02917681 TrialTroveID-287450,Adults; Older Adults,year(s),year(s),287450,Delay Disease Progression,70.0,18.0,"Previous cellular therapy Incapacity to lay still during bone marrow aspirate or intrathecal MSC injections Personal history of auto-Immune, myeloproliferative or myelodysplastic diseases, leukemia, lymphoma, whole-body irradiation, hip fracture, severe scoliosis or incapacity to undergo any of the study's proposed procedures Any other disease that may interfere with the study Any other neurological diseases Aspartate or alanine aminotransferases elevated >3x normality upper limit Serum creatinine >2x normality upper limit Hepatitis B and C, HIV, HTLV I and II and syphilis Immunosuppressant drug use within 6 weeks from the study's screening Pregnancy or breast-feeding Acquired or inherited Immunodeficiency Participation in other clinical trials Non-invasive ventilation, tracheostomy or diaphragm pacing Substance abuse within one year and other unstable mental health diseases according to researcher's judgement Gastrostomy or any alternative feeding means Inappropriate in-vitro MSC expansion.",Iii,Both
0,Patients With Amyotrophic Lateral Sclerosis,diagnosis of the ALS disease before the cell transplantation (diagnose established following the El Escorial criteria for definite ALS) good understanding of the protocol and willingness to consent signed informed consent disease duration: up to 2 years FVC > 50% / pulmonologist certificate about respiratory function of the patient,NCT02881489 TrialTroveID-285529 UWM/ALS-MSC.2015/002 UwmBmmscALS,Adults,year(s),year(s),285529,Delay Disease Progression,65.0,18.0,"cancer, autoimmune diseases renal failure, subject is a respiratory dependent. subject unwilling or unable to comply with the requirements of the protocol pregnancy, breastfeeding",I,Both
0,Patients with Amyotrophic Lateral Sclerosis (ALS),"Age greater than 18 years, if female, must be menopausal or had hysterectomy Resident and citizen of the United States History of a chronic onset of a progressive motor weakness Able to comply with protocol requirements Can provide written consent",09-001995 NCT01142856 TrialTroveID-225119,Adults; Older Adults,year(s),,225119,Delay Disease Progression,,18.0,"Does not have renal disease (Creatine > 2.0) Does not have active systemic disease Does not have any clinically significant abnormalities on prestudy laboratory evaluation Does not have any clinically significant medical condition (e.g.,within 6 months of baseline, had a myocardial infarct, angina pectoris, and/or congestive heart failure), that in the opinion of the investigator, would compromise the safety of the patient Does not have a history of cancer including melanoma with the exception of localized skin cancers (with no evidence of metastasis, significant invasion,or re-occurrence within 3 years of baseline). Has not used an investigational drug within 30 days of baseline visit Does not have a tracheostomy Does not have a Beck's Depression Inventory score >16",I,Both
0,Subjects with Amyotrophic Lateral Sclerosis.,Patients with the diagnosis of definite Motor Neuron Disease/amyotrophic lateral sclerosis. Age 18-80 years.,NCT02242071 NGBSI-10 TrialTroveID-217041,Adults; Older Adults,year(s),year(s),217041,Delay Disease Progression,80.0,18.0,HIV/HBV/HCV. Malignancies. Bleeding tendencies. Pneumonia. Renal failure. Severe liver dysfunction. Severe anemia [hb less than 8]. Any bone marrow disorder. Space occupying lesion in brain. Pregnancy and lactation. Other acute medical conditions/infections such as respiratory infection and pyrexia. left ventricular ejection fraction less than 25%. Patient on artificial ventilatory support.,I,Both
0,Patients with Amyotrophic Lateral Sclerosis,"Ages Eligible for Study: 18 Years to 70 Years, Genders Eligible for Study: Both Principal inclusion criteria: Aged between 18 and 70 years. Diagnosis of definite or probable ALS according to the criteria established by the World Federation of Neurology (World Federation of Neurology Research Group on Neuromuscular Diseases 1994). Patient providing sufficient guarantees of adherence to protocol. Neurophysiological data confirming lower motor neuron involvement of lumbar level. No motor deficit in dorsiflexion of both feet (4 + or 5 points on the MRC). The patient must fulfill all inclusion criteria.",EudraCT Number: 2011-004801-25 NCT02286011 TCIM ELA TCIM-ELA TCIM/ELA TrialTroveID-213436,Adults; Older Adults,year(s),year(s),213436,Delay Disease Progression,70.0,18.0,"Principal exclusion criteria: Diabetes Mellitus. Other diseases that may occur with polyneuropathy. A previous history of stroke. A previous pathology of peripheral nervous system that affects one or both lower limbs with or without clinically evident neurologic sequelae. Patients who are pregnant or breastfeeding active Patients physiologically capable of becoming pregnant, unless they are using reliable contraception (Annex III) Patients with heart, kidney, liver, systemic immune that may influence patient survival during the test. Positive serology for hepatitis B, hepatitis C or HIV. Clinical criteria and anesthesia sedation contraindicating either itself or extraction MO (Altered coagulation system or anticoagulated patient inability to withdraw anticoagulation, hemodynamic instability, altered skin puncture area, etc.) Included in other clinical trials in the last 6 months. Inability to understand informed consent.",I,Both
0,Patients diagnosed as early stage of ALS with the duration of disease less than 6 months and patients diagnosed with advanced stage of ALS disease with duration of 6-12 months will be recruited and allocated based on their disease severity to two treatment groups:,"Ages Eligible for Study: 18 Years to 65 Years, Genders Eligible for Study: Both Inclusion Criteria: Diagnosis of the ALS disease before the cell transplantation (diagnose established following the El Escorial criteria for definite ALS). Good understanding of the protocol and willingness to consent. Patient is mentally intact and psychologically stable. Signed informed consent",ALS-BMSC #01 NCT02193893 NeuStem-ALS TrialTroveID-213322 ZPO 02,Adults,year(s),year(s),213322,Delay Disease Progression,65.0,18.0,"Exclusion Criteria: Concomitant of other systemic disease or diseases: Inflammation (high protein or lymphocytosis in the CSF), active infections. Diabetes. Cardio-vascular disorders. Cancer. Autoimmune diseases. Renal failure. Impaired hepatic function. Subject is a respiratory dependent. Subject unwilling or unable to comply with the requirements of the protocol. Patient has been treated previously with any cellular therapy.",I,Both
0,Patients with Amyotrophic Lateral Sclerosis,"Ages Eligible for Study: 18 Years to 60 Years; Genders Eligible for Study: Both Sporadic ALS according to escorial criteria Onset of disease with spinal cord involvement, Less than 3 years of disease onset with Disease progression at 6 past months Mild to moderate spinal and bulbar disability,at least having score3 in swallowing, 2 in chewing and waking in ALS-FRS and FVC(functional vital capacity) equal or more than 50% of prediction amount Normal polysomnography Signed consent form",NCT02116634 TrialTroveID-207245,Adults,year(s),year(s),207245,Delay Disease Progression,60.0,18.0,"Pregnancy or lactation, Vascular disease,diabetes, systemic disease as cancer, autoimmune , liver or hematologic disease Hospitalization due to serious illness in the last two months Survival time less than two years Hypersensitivity to any component used in the cell culture",Iii,Both
1,Patients With Amyotrophic Lateral Sclerosis (ALS),"Ages Eligible for Study:18 Years and older,Genders Eligible for Study:Both,Accepts Healthy Volunteers:No Inclusion Criteria: Patients with a confirmed diagnosis of ALS according to El Escorial criteria. Diagnosis-time less than four years. Over 18 years old. Forced vital capacity > or = 40%. One year of evolution. Adequate nutritional state",NCT01933321 TrialTroveID-193196,Adults; Older Adults,year(s),,193196,Delay Disease Progression,,18.0,"Exclusion Criteria: Severe bulbar ALS involucre. Inadequate nutritional status. Spondylotic myelopathy, or abnormalities in imaging study. Having concomitant neurological or psychiatric disease. Systemic disease with poor-control. History of treatment with steroids or immunoglobulins in the last year. Participate in the past three months in a Clinical Trial. History of malignancy or cancer today. Intracranial hypertension. Clinical suggestive data of infection in the site of lumbar puncture. Tracheostomy. Use of mechanical ventilation. Forced vital capacity less than 40%. HIV-seropositive or presence of antibodies against hepatitis B or C in the serological studies.",Ii/Iii,Both
0,Patients with Amyotrophic Lateral Sclerosis.,Ages Eligible for Study: 18 Years to 65 Years; Genders Eligible for Study: Both Inclusion Criteria: Age:18-65. Both gender. Duration of disease<2 years. FVC>40% ALS-FRS>26.,NCT01771640 Royan-Nerve-006 TrialTroveID-180658,Adults,year(s),year(s),180658,Delay Disease Progression,65.0,18.0,"Exclusion Criteria: Neurological and psychiatric concomitant disease. Concomitant systemic disease. Treatment with corticosteroid,Ig,immunosuppressive during 12 months.",I,Both
0,Patients with Amyotrophic Lateral Sclerosis,Ages Eligible for Study: 18 Years to 65 Years; Genders Eligible for Study: Both Inclusion Criteria: Age:18-65 Both gender Duration of disease<2 years FVC>40% ALS-FRS>26,NCT01759797 Royan-Nerve-005 TrialTroveID-180040,Adults,year(s),year(s),180040,Unspecified,65.0,18.0,"Exclusion Criteria: Neurological and psychiatric concomitant disease Concomitant systemic disease Treatment with corticosteroid,Ig,immunosuppressive during 12 months.",I,Both
0,Patients with Amyotrophic Lateral Sclerosis.,Ages Eligible for Study: 18 Years to 70 Years; Genders Eligible for Study: Both Age:18-65 Both gender Duration of disease<2 years. FVC>40% ALS-FRS>26.,NCT01759784 Royan-Nerve-004 TrialTroveID-179958,Adults; Older Adults,year(s),year(s),179958,Unspecified,70.0,18.0,"Neurological and psychiatric concomitant disease. Concomitant systemic disease. Treatment with corticosteroid, Ig, immunosuppressive during 12 months.",I,Both
0,Patients with ALS with mean revised ALS Functional Rating Scale (ALSFRS-R) score of 30.2 (+or- 10.58) at baseline Patients with ALS attending the Neurology Clinic of a tertiary care referral centre.,"Patients above the age of 18 years with a diagnosis of clinically definite, probable or probable lab-supported ALS were included in the study.",TrialTroveID-177338,Adults,year(s),year(s),177338,Delay Disease Progression,64.0,18.0,"Patients with comorbidities like hyperthyroidism, diabetes mellitus, chronic liver or renal disease, human immunodeficiency virus (HIV) infection, respiratory insufficiency requiring ventilator support at baseline, pregnant or lactating women and those with local lesions or pressure sores precluding lumbar puncture were excluded.",Ii,Both
0,"Thirty seven patients with definite ALS who had undergone intrathecal delivery of aMSC were compared to nine ALS patients matched for age, type, and severity of ALS.",,TrialTroveID-175665,,,,175665,Delay Disease Progression,,,,Ii,
0,"Adult, non-ventilator-dependent patients with clinically definite amyotrophic lateral sclerosis.","All patients must have clinically-defined ALS as defined by the World Federation of Neurology criteria Age greater than 18 years If female, must be post-menopausal or had a hysterectomy Permanent resident or citizen of the United States History of a chronic onset of a progressive motor weakness of greater than one year, but less than two years duration Must have vital capacity greater than 65% of predicated for age, gender, and body type Able to comply with protocol requirements, including MRI testing Can provide written informed consent",11-008415 NCT01609283 TrialTroveID-168986,Adults; Older Adults,year(s),,168986,Unspecified,,18.0,"Any clinically significant medical condition (e.g., within six months of baseline, had myocardial infarction, angina pectoris, and/or congestive heart failure) that, in the opinion of the investigator, would compromise the safety of patient. Autoimmunity, including Crohn's disease, rheumatoid arthritis, psoriasis Malignancy including melanoma with the exception of localized skin cancers (with no evidence of metastasis, significant invasion, or re-occurrence within three years of baseline). Any other malignancy will not be allowed. Active systemic or local infection near the lumbar puncture site Other active systemic disease as defined by laboratory abnormalities Use of herbal medications or other unapproved drugs Enrolled in an investigational drug trial within 30 days of baseline visit Kokmen Short Test of Mental Status score <32 Beck's Depression Inventory score >18 Presence of a tracheostomy Ventilator dependent",I,Both
0,Patients with Amyotrophic Lateral Sclerosis (ALS).,Ages Eligible for Study: 18 Years to 70 Years; Genders Eligible for Study: Both Inclusion Criteria: Diagnose established following the World Federation of Neurology criteria. More than 6 and less than 36 months of evolution of the disease. Medullar onset of the disease. More than 18 and less than 70 years old. Forced Vital Capacity > or = 50%. Total time of oxygen saturation <90% inferior to 5% of the sleeping time. Signed informed consent.,EC07/90762 EudraCT Number: 2006-003096-12 Extension CMN/ELA NCT01254539 TrialTroveID-139000,Adults; Older Adults,year(s),year(s),139000,Delay Disease Progression,70.0,18.0,"Exclusion Criteria: Neurological or psychiatric concomitant disease. Need of parenteral or enteral nutrition through percutaneous endoscopic gastrostomy or nasogastric tube. Concomitant systemic disease. Treatment with corticosteroids, immunoglobulins or immunosuppressors during the last 12 months. Inclusion in other clinical trials. Unability to understand the informed consent.",Iii,Both
0,Patients with Amyotrophic lateral sclerosis (ALS).,,TrialTroveID-137610,,,,137610,Delay Disease Progression,,,,Ii,
0,Amyotrophic Lateral Sclerosis (ALS) patients.,,TrialTroveID-128341,,,,128341,Delay Disease Progression,,,,I,
0,Patients with bulbar involvement and severe loss of movement.,"Patients with sporadic amyotrophic lateral sclerosis (SALS) were included in this study. Inclusion criteria for the selected patients were: Disease duration had been longer than 6 months. ALS had been confirmed by ENMG on two separate occasions. The patient had been receiving maximal medical therapy as directed by a qualified hospital neurology department. The patient’s neurologic condition was in rapid decline and vital capacities were in a terminal period, as suggested by mechanical ventilator dependence or the inability to swallow or speak.",TrialTroveID-128299,Adults; Older Adults,year(s),year(s),128299,Unspecified,71.0,34.0,"Exclusion criteria were: The presence of a neurologic deficit not related to ALS (e.g. cervical spinal cord injury). An anatomical myelomalasia of the cervical cord, as visualized by magnetic resonance imaging (MRI). Any serious pre-existing medical conditions that would make treatment of the patient inappropriate.",Ii,Both
0,"Nine patients with definite ALS were included (group A, 5 men, 4 women, mean age 54 + or - 12.6 years, mean disease duration 29 + or - 13.8 months, mean ALSFRS score 27.1 + or - 9.9) Nine patients with ALS, matched for age and severity of the disease (4 men, 5 women, mean age 57 + or - 13.5, mean disease duration 33 + or - 26 months, mean ALSFRS score 27.5 + or - 5.8) comprised the control group (group B).",,TrialTroveID-125440,Adults; Older Adults,year(s),year(s),125440,Delay Disease Progression,71.0,41.0,,Ii,Both
0,"Patients with Amyotrophic Lateral Sclerosis. Eleven (five males, six females) were included in the trial with a median age of 46 years (range 32–61).",Ages Eligible for Study: 20 Years to 65 Years Inclusion Criteria Diagnosis established following the World Federation of Neurology criteria. More than 6 and less than 36 months of evolution of the disease. Medullar onset of the disease. More than 20 and less than 65 years old. Forced Vital Capacity equal or superior to 50%. Total time of oxygen saturation < 90% inferior to 2% of the sleeping time. Signed informed consent.,CMN/ELA EudraCT number: 2006-003096-12 ISCIII: EC07/90762 NCT00855400 TrialTroveID-105299,Adults,year(s),year(s),105299,Delay Disease Progression,65.0,20.0,"Exclusion Criteria Neurological or psychiatric concomitant disease. Need of parenteral or enteral nutrition through percutaneous endoscopic gastrostomy or nasogastric tube. Concomitant systemic disease. Treatment with corticosteroids, immunoglobulins or immunosuppressors during the last 12 months. Inclusion in other clinical trials. Unability to understand the informed consent.",Iii,Both
0,Thirteen multiple sclerosis patients with a mean EDSS score of 6.8 and 14 amyotrophic lateral sclerosis patients with a mean ALSFRS score of 22.0 were included in this trial. 15 MS patients (mean EDSS=6.71.05) and 19 ALS patients (mean ALSFRS=20.268.56),,TrialTroveID-099163,,,,99163,Unspecified; Unspecified MS,,,,Iii,
0,Amyotrophic lateral sclerosis (ALS) patients.,,TrialTroveID-079164,,,,79164,Delay Disease Progression,,,,I,
0,Patients with Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease).,"Ages Eligible for Study: 18 Years to 80 Years; Genders Eligible for Study: Both Inclusion Criteria: Adult male and female subjects > 18 years of age. Good understanding of the protocol and willingness to consent. Moderate to severe Diagnosis of ALS according to the World Federation of Neurology El Escorial criteria. Vital capacity at least 50% predicted value for gender, height and age. More than 6 and less than 36 months of evolution of the disease. Hematocrit greater than 30 % prior to bone marrow aspiration. Platelet count greater than 100 Thousand/uL at screening. INR less than or equal to 1.5.",2008-ALS-I NCT01082653 TrialTroveID-121274,Adults; Older Adults,year(s),year(s),121274,Delay Disease Progression,80.0,18.0,"Exclusion Criteria: Any concurrent illness, which affects the bone marrow. Any concomitant medication that affects the bone marrow. Previous stem cell therapy. Any lymphoproliferative disease. Riluzole with 4 weeks of study entry and at any time during the study. Hemophiliacs or subjects with bleeding disorders. Known hypersensitivity to fetal bovine serum HIV infection. Serum creatinine > 3.0 in subjects not on hemodialysis. Skin infection at the infusion site or systemic infection. Current smoker. Active drug or alcohol addiction Pregnant, planning to become pregnant or not on accepted birth control method if subject is of child bearing potential. Subjects that are breast feeding. Any condition that the Principal Investigator considers would render the subject unfit for the study.",I,Both
0,,"1. Inclusion criteria for VCI (Group A, n=80) - Males or females with age >= 20 years old. - Patients fulfill the AHA/ASA criteria for vascular cognitive impairment. - Provision of signed informed consent from the subject and the subject's legally authorized representative or caregiver (if applicable). - The subject has an appropriate caregiver capable of accompanying the subject, if necessary. 2. Inclusion criteria for AD / MCI (Group B, n=120) - Males or females with age >= 20 years old. - Patients fulfill the National Institute on Aging (NIA) - Alzheimer's Association Diagnostic Guidelines. - Provision of signed informed consent from the subject and the subject's legally authorized representative or caregiver (if applicable). - The subject has an appropriate caregiver capable of accompanying the subject, if necessary. 3. Inclusion criteria for FTD (Group C, n=30) - Males or females with age >= 20 years old. - Patients fulfill the criteria of probable FTD. - Provision of signed informed consent from the subject and the subject's legally authorized representative or caregiver (if applicable). - The subject has an appropriate caregiver capable of accompanying the subject, if necessary. 4. Inclusion criteria for normal control (Group D, n=30) - Males or females with age >= 20 years old. - Provision of signed informed consent. 5. Inclusion criteria for PSP (Group E, n=80) - Males or females with age >= 20 years old - Patients fulfill the 2017 Movement Disorder Society criteria of PSP. - Provision of signed informed consent from the subject and the subject's legally authorized representative or caregiver (if applicable) - The subject has an appropriate caregiver capable of accompanying the subject, if necessary.",201800984A0 NCT04309253,Adults; Older Adults,year(s),,369824,,,20.0,- Life expectancy less than 1 year. - Clinically significant abnormal laboratory values (such as AST/ALT >= 3X of upper normal limits). - Clinically significant or unstable medical or psychiatric illness. - Epilepsy history. - Cognitive impairment resulting from trauma or brain damage. - Substance abuse or alcoholism in the past 3 months. - Stroke history within the recent 3 months.,Ii,Both
0,Subjects With Frontotemporal Dementia People with Frontotemporal Dementia with GRN Mutations,"- Male or female, 30 to 75 years of age - Carriers of a pathogenic GRN mutation - FTD as evidenced by CDR + NACC FTLD global score of 0.5, 1.0, or 2.0 - Presence of 1 or more of the criteria for diagnosis of possible bvFTD or PPA - A protocol defined minimum thalamic volume on each side on Screening MRI - Able and willing to comply with all procedures and the study visit schedule - Able and willing to give written informed consent prior to study participation, and agree to designate a legal representative to act on their wishes to continue participation should they lose capacity to consent at some point during the study - An identified, informed study partner who is able and willing to support the participant in the study and to provide assessments of the participant during the study",ASPIRE-FTD AVB-PGRN-001 EudraCT Number:2022-002568-62 FTD-GRN NCT06064890 NL82614.000.22 TrialTroveID-487580,Adults; Older Adults,year(s),year(s),487580,Frontotemporal Dementia,75.0,30.0,"- Severe dementia, defined as CDR + NACC FTLD global score of 3.0, or other symptoms that preclude the ability to comply with study procedures and/or pose unacceptable safety risk to the subject - Any concurrent disease that may cause cognitive impairment unrelated to mutations in the GRN gene, such as other causes of dementia, neurosyphilis, hydrocephalus, stroke, small vessel ischemic disease, uncontrolled hypothyroidism, or vitamin B12 deficiency - Clinically significant abnormality on MRI at Screening considered to be a contraindication to Intrathalamic infusion - Surgically significant pattern of brain atrophy on MRI at Screening that interferes with planned neurosurgical trajectory - Previous treatment with any gene or cell therapy - Previous treatment with any investigational medicinal product (IMP) within 60 days or 5 half-lives (whichever is longer) prior to study drug treatment - Concomitant disease, any clinically significant laboratory abnormality, or treatment which, in the opinion of the Investigator, may pose an unacceptable safety risk to the participant or interfere with study conduct or the participant's ability to comply with study procedures including neurosurgical administration under anesthesia",Iii,Both
0,,,TrialTroveID-319862,,,,319862,Unspecified,,,,I,
0,"Six consecutive patients (4 men, 2 women), mean age 48.5 years. Patients with spasticity in motor neuron disease. Three were diagnosed with PLS, 3 with upper motor neuron predominant ALS. Mean disease duration preoperatively was 55 months, mean ALSFRS-R at baseline 29.2.",,TrialTroveID-121202,,,,121202,Symptom relief,,,,Ii,Both
0,Healthy subjects,"1 Both male and female healthy subjects; 2 18 years old and above (including 18 years old); 3 Weight: Male subjects should not be less than 50.0kg, female subjects should not be less than 45.0kg, body mass index [BMI = weight (kg) / height 2 (m2)] in the range of 19.0 ~ 26.0kg/m2 (including boundary values); 4 Subjects must give informed consent to this study before the experiment and voluntarily sign a written informed consent form; 5 The subjects can communicate well with the researchers and complete the research in accordance with the research regulations.",BT-BLF-O-BE-01 CTR20233503 TrialTroveID-495473,Adults; Older Adults,year(s),,495473,(N/A); Healthy subjects,,18.0,"1 Those who are prone to allergies, those who are allergic to any ingredient in baclofen and its related compounds and excipients, or those who are allergic to two or more drugs (or foods) 2 Those who cannot adhere to a uniform diet (such as intolerance to standard meals, etc.) or those who have difficulty swallowing 3 Those who cannot tolerate venipuncture and those who have a history of fainting from needles and bleeding 4 Have had or are currently suffering from important diseases such as the circulatory system, respiratory system, digestive system, blood system, nervous system, immune system, urinary system, endocrine system, and mental system, and have any disease that may significantly affect drug absorption, distribution, metabolism, and excretion. Those with a history of surgery or bleeding diseases (such as gastrointestinal ulcers, hemorrhagic stroke, etc.) 5 Those who have undergone major surgery within 6 months before screening, or those who plan to have surgery during the study period, and those who have undergone surgery that will affect drug absorption, distribution, metabolism, and excretion (except appendicitis surgery) 6 Physical examination, vital sign monitoring, electrocardiogram examination, chest low-dose CT, laboratory examination (blood routine, urinalysis, blood biochemistry, coagulation function, blood pregnancy (only for female subjects), etc.) during the screening period, as determined by the researcher Abnormalities with clinical significance 7 Those with clinically significant abnormal test results for hepatitis B surface antigen, hepatitis C antibody, Treponema pallidum antibody or HIV antibody 8 Those who drank excessive amounts (more than 8 cups a day, 1 cup = 200mL) of tea, coffee or caffeinated beverages within 3 months before screening; or consumed any caffeinated food or beverage within 48 hours before the first dose of the study ( Such as coffee, strong tea, chocolate, etc.) 9 Within 48 hours before the first dose of the study, those who have ingested any drinks or foods rich in xanthine or grapefruit ingredients or other substances that affect drug absorption, distribution, metabolism, excretion, etc. 10 Have used any drugs that interact with baclofen within 28 days before screening (such as: levodopa/dopa decarboxylase (DDC) inhibitors, central nervous system (CNS) depressants, antidepressants, lithium, antibiotics High blood pressure drugs, drugs that damage kidney function, etc.) 11 Those who have used long-acting estrogen or progesterone injections or implants within 6 months before screening; those who have used short-acting contraceptive pills within 30 days before the test 12 Those who have used any prescription drugs, over-the-counter drugs, Chinese herbal medicines, or health care products within 14 days before the first dose of the study 13 Those who smoked more than 5 cigarettes a day in the 3 months before signing the informed consent form, and those who cannot accept the ban on smoking after enrollment and throughout the trial period 14 The alcohol breath test result is positive before the first dose of the study, or the alcohol consumption exceeds 14 standard units per week within 6 months before screening (1 standard unit contains 14g of alcohol, such as 360mL of beer or 45mL of spirits with an alcohol breath volume of 40% or 150mL wine) 15 Those who have a positive urine drug screen before taking the drug for the first time in the study or have a history of drug abuse (such as morphine, marijuana, methamphetamine, methylenedioxyamphetamine, ketamine, etc.) within 1 year before the test 16 Pregnant or lactating women, as well as male subjects (or their partners) or female subjects who plan to have children during the entire trial and within 3 months after the end of the study 17 Female subjects who had unprotected sex within 14 days before screening 18 Those who participated in other clinical trials and took the study drug within 3 months before the first use of the study drug 19 Those who have donated blood or lost ≥400mL of blood or received blood components within 3 months before the first medication in the study, or plan to donate blood or receive blood components during the study or within 3 months after the end of the study 20 Those who have been vaccinated within 14 days before the first dose of the study, or plan to be vaccinated during the study or within 14 days after the last dose of the study drug 21 The researcher believes that there are any circumstances that may affect the subject's provision of informed consent or compliance with the trial protocol, or that the subject's participation in the trial may affect the trial results or their own safety.",I,Both
0,Healthy Volunteers.,"1. The subjects understand the purpose and requirements of the trial, agree to abide by the trial management regulations, and voluntarily sign the informed consent; 2. Healthy subjects over the age of 18 (inclusive), both male and female; 3. Body mass index (BMI) within [19.0 to 26.0] (subject to the rounded value), including the critical value (BMI=weight/height 2 kg/m2), male weight > or = 50.0Kg, female weight > or = 45.0Kg; 4. The subjects had no reproductive plans (including sperm donation and egg donation) and voluntarily took effective contraceptive measures from 1 month before signing the informed consent form to 3 months after the last administration of the experimental drug.",CTR20222440 FH-BE-BLF TrialTroveID-447098,Adults; Older Adults,year(s),,447098,(N/A); Healthy subjects,,18.0,"1 History of important diseases such as nervous system, mental system, cardiovascular and cerebrovascular system, endocrine system, digestive system, urinary system, reproductive system, immune system, respiratory system, or existing diseases of the above systems or any clinically significant persistent chronic diseases (including But not limited to epilepsy, Parkinson's disease, nystagmus, ataxia, schizophrenia, depression, mania, peptic ulcer, urinary retention, etc.); 2 Those who have undergone major surgery within 1 year before signing the informed consent form, or plan to undergo surgery during the study period; 3 Allergic constitution, clinical history of allergy to food, drugs, etc., or known allergy to baclofen and its excipients; 4 Those who have used prescription drugs (including vaccination), non-prescription drugs, Chinese herbal medicines or health products within 14 days before signing the informed consent; 5 Use of any drug that interacts with baclofen within 28 days before signing the informed consent form (eg: levodopa/dopa decarboxylase (DDC) inhibitors, central nervous system (CNS) depressants, antidepressants, Lithium, antihypertensive drugs, drugs that reduce renal function, etc.); 6 Those who have participated in any drug or medical device clinical trials within 3 months before signing the informed consent; 7 The total blood loss due to blood donation or other reasons within 3 months before signing the informed consent form is > or = 400mL, or those who plan to donate blood components within 3 months after the end of the study; 8 There is no guarantee that fruits that affect metabolic enzymes (such as grapefruit, dragon fruit) should be fasted from 7 days before the signing of the informed consent form to the end of the test. Alcoholic or alcoholic beverages or food (such as animal offal, coffee, strong tea, chocolate, cola, etc.); 9 Those who drink excessive tea, coffee and/or caffeinated beverages (more than 8 cups, 1 cup = 250 mL) every day within 3 months before signing the informed consent; 10 Those who have a history of fainting of needles or blood, or those who cannot tolerate venipuncture for blood collection, or those who have difficulty in blood collection; 11 Those who have special requirements for diet and cannot comply with the unified dietary arrangement; 12 Those who smoked more than 5 cigarettes per day within 3 months before signing the informed consent form or those who could not give up the use of tobacco products throughout the study period; 13 The average weekly alcohol intake in the 6 months before signing the informed consent form exceeded 14 units of alcohol (1 unit ≈ 360mL of beer/45mL of high liquor/150mL of wine), or those who could not give up drinking during the trial, or alcohol breath test > 0mg /100mL; 14 Female subjects who were breastfeeding at the time of screening, or those with positive pregnancy test results; 15 Those with a history of drug use or drug abuse, or a positive urine drug screen; 16 Hepatitis B surface antigen or Treponema pallidum, human immunodeficiency virus, hepatitis C antibody test results are positive; 17 Physical examination, vital signs examination, 12-lead electrocardiogram examination, laboratory examination, imaging examination results judged by the investigator to be unsuitable to participate in the trial; 18 Patients with acute illness during the pre-study screening period or before the study drug; 19 For other reasons, the investigators considered unsuitable candidates.",I,Both
0,Patients at risk for or with AD and at risk for or with ALS,"Study participants meeting all of the following criteria will be allowed to enroll in the study: Must be 55-90 years old, inclusive and have one of the following: Subjective cognitive decline(SCD) Minor neurocognitive disorder(mild cognitive impairment(MCI)) Major neurocognitive disorder(possible or probable AD) OR Must be 18-80 years old, inclusive and have one of the following: Sporadic or familial ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by the revised El Escorial criteria Asymptomatic carrier of an ALS-causative mutation per CLIA-certified genetic testing results (MGH site only) Screening CSF level of CCL2 level > or= 250 pg/mL Up-to-date immunization records per CDC guidelines Routine vaccinations should be administered at a minimum of 14 days prior to any study visit with an LP Must have received the Recombinant Zoster Vaccine (RZV, also known as Shingrix) within 4 years prior to enrollment. Note: Only one dose of RZV is needed prior to the Baseline Visit. Must be fully vaccinated for COVID-19 per CDC guidelines If a participant is planning to receive a COVID-19 booster shot, should be administered a minimum of 14 days prior to the Screening LP. For participants with ALS: Must either not be taking or be on a stable dose of any FDA approved treatment for ALS for at least 30 days or at least 1 cycle prior to screening ALSFRS-R score > or= 27 Must be ambulatory, defined as able to walk at least within the home every day. Use of gait assistive devices is allowed. Some use of a wheelchair is also allowed. Greater than 12-month life expectancy in the opinion of the investigator For participants with AD: MoCA score > or = 8 The participant must have a study partner that can accompany them to every visit and co-sign any informed consent document. Must either not be taking or be on a stable dose of any FDA approved treatment for AD for at least 30 days prior to screening. Participants cannot be taking Aducanumab(see exclusion criterion #15). Ability to medically undergo LP in the opinion of the investigator (e.g., no bleeding disorder, allergy to local anesthetics, prior lumbar surgery which might make LP difficult, a skin infection at or near the LP site, evidence of high intracranial pressure, or anticipated difficulty getting into position for LP). Capable of providing informed consent and following study procedures. In the case that a participant lacks the ability to provide informed consent, informed consent will be obtained from the participant's surrogate representative and assent obtained from the participant.",NADALS NCT05189106 TrialTroveID-422687,Adults; Older Adults,year(s),year(s),422687,Cognitive Function; Delay Disease Progression; Mild Cognitive Impairment/Prodromal; Preclinical/At-Risk,90.0,18.0,"Study participants meeting any of the following criteria during screening evaluations will be excluded from entry into the study: Women who are pregnant, breastfeeding, or planning to become pregnant during the trial Any unstable clinically significant medical condition other than ALS or AD (e.g., within six months of baseline, including but not limited to myocardial infarction, angina pectoris, congestive heart failure, or neoplasm undergoing active treatment). Active cancer or history of cancer, except for the following: basal cell carcinoma, cervical carcinoma in situ, prostatic carcinoma in situ, or other malignancies curatively treated and with no evidence of disease recurrence for at least 5 years. Active cancer includes cancers with current disease manifestations or therapy that could adversely affect participant safety and longevity, create the potential for drug-drug interactions, or compromise the interpretation of study results. History of diverticulitis or bowel perforation. Active ulcerative colitis, Crohn's disease, and history of peptic ulcer disease within the past 5 years or after the age of 65. Active, serious infection, including localized infection in the opinion of the investigator. Positive for latent or active tuberculosis (TB). Note: Patients with a history of latent or active TB must have had an adequate course of treatment documented prior to study participation. Evidence of active hepatitis B or C infection. History of severe hepatic or renal impairment. eGFR < 60 mL/min/1.73 m2 Have any of the following specific abnormalities on screening laboratory tests: ALT or AST >2.5x upper limits of normal (ULN) Alkaline phosphatase (ALP) > or= 2x ULN Total bilirubin > or= 1.5x ULN, Note: patients with elevated bilirubin secondary to Gilbert's disease are eligible to participate in the study. Hemoglobin <10 g/dL (100.0 g/L) Total white blood cell count <3000 cells/μL (<3.00 x 103/μL or <3.00 billion/L) Neutropenia (absolute neutrophil count [ANC] <1500 cells/μL) (<1.50 x 103/μL or <1.50 billion/L) Lymphopenia (lymphocyte count <1000 cells/μL) (<1.00 x 103/μL or <1.00 billion/L) Thrombocytopenia (platelets <100,000 cells/μL) (<100 x 103/μL or <100 billion/L) Laboratory abnormalities in vitamin B12, thyroid stimulating hormone (TSH), or other common laboratory parameters that might contribute to cognitive dysfunction Personal history of pulmonary embolus (provoked or unprovoked) or deep vein thrombosis, or a history of unprovoked pulmonary embolus in a first-degree family member. Treatment with anticoagulants that, in the opinion of the investigator, would compromise the safety of the participant. Previous therapy with baricitinib. Current use of strong Organic Anion Transporter 3(OAT3) inhibitors (e.g., probenecid) or other prohibited medication (refer to Section 6.7.1) within 5.5 half-lives or 30 days of screening, whichever is longer. For participants with AD: Current use of Aducanumab or within 30 days of screening. Receiving other experimental interventions for AD or ALS within 5.5 half-lives or 30 days of screening, whichever is longer. Use of permanent assisted ventilation (invasive ventilation via tracheostomy, or >22 hours of non-invasive ventilation per day, e.g., via BiPAP). Have had any major surgery within 8 weeks prior to screening or will require major surgery during the study that, in the opinion of the investigator, would pose an unacceptable risk to the patient. Note: Placement of a gastrostomy tube and an intravenous port are not considered major surgery.",Iii,Both
0,Patients with Amyotrophic Lateral Sclerosis,"Patients conforming to Definite and Probable of Awaji standard (revised El Escorial diagnostic criteria incorporating Awaji recommendations) Patients with severity 1 or 2 degrees in ALS severity classification Patients with 2 or more of all items constituting ALSFRS-R Patients with normal respiratory function (% FVC> 80%) Patients within 2 years after onset of ALS at document acquisition Patients participating in this study, patients who got consent in writing",JapicCTI-173709 jRCTs031180058 TrialTroveID-328541,Adults; Older Adults,year(s),year(s),328541,Delay Disease Progression,75.0,20.0,"(1) Patients with reduced respiratory function and complaints of dyspnea.Patients scoring = <3 points on each single ALSFRS-R item (10.Dyspnea11.Orthopnea12.Respiratory insufficiency) (2) Patients with complications that may substantially influence evaluation of drug efficacy (3) Patients who underwent a spine surgery after ALS onset or who are scheduled for a spine surgery during this study (cervical spondylosis, slipped disk etc.) (4) Patients with the syndromes which may be ALS mimic syndromes such as cervical spondylosis, multifocal motor neuropathy (5) Patients with hemorrhage (those with thrombocytopenic purpura, bleeding tendency due to angiopathy, hemophilia and other coagulopathy, operation, digestive tract ulcer, Hemorrhage of urinary tract, etc.) (6) Patients with hemorrhagic tendency (those with visceral tumor, gastrointestinal diverticulitis, colitis, subacute bacterial endocarditis, etc.) (7) Patients who had just undergone an operation (8) Patients with serious liver dysfunction (9) Patients with plateletcount <100,000 / microliter (10) Patients who are taking drugs which are fibrinolytic agents (t-PA and UK) or anticoagulant agents or anti-platelet agents (11) Patients with severe hypertension whose systolic blood pressure> = 180 mmHg cannot be lowered>= 150 mmHg by lowering blood pressure agents (12) Patients undergoing cancer treatment (13) Patients with a history of hypersensitivity to Edaravone if they are going to use Edaravone (14) Patients with a history of hypersensitivity to Batroxobin (15) Patients with severe illness (16) Male patients who do not consent to using reliable contraception methods during the studied period (17) Premenopausal women (18) Patients who has participated in another clinical trial twelve weeks prior to inclusion in this study (19) Patients with renal dysfunction with creatinine clearance of 50mL per min or below (20) Patients who are not eligible due to physician's judgments judgments judgment",Ii,Both
0,Patients with amyotrophic lateral sclerosis.,"Patients conforming to Definite and Probable of Awaji standard (revised El Escorial diagnostic criteria incorporating Awaji recommendations) Patients with severity of 3 degrees in ALS severity classification Patients with 1 or more points in all items constituting ALSFRS-R Patients with normal respiratory function (% FVC> 60%) Patients within 3 years after onset of ALS at document acquisition Patients participating in this study, patients who got consent in writing",JapicCTI-173708 jRCTs031180059 TrialTroveID-328535,Adults; Older Adults,year(s),year(s),328535,Delay Disease Progression,75.0,20.0,"(1) Patients with reduced respiratory function and complaints of dyspnea.Patients scoring = <3 points on each single ALSFRS-R item (10.Dyspnea11.Orthopnea12.Respiratory insufficiency) (2) Patients with complications that may substantially influence evaluation of drug efficacy (3) Patients who underwent a spine surgery after ALS onset or who are scheduled for a spine surgery during this study (cervical spondylosis, slipped disk etc.) (4) Patients with the syndromes which may be ALS mimic syndromes such as cervical spondylosis, multifocal motor neuropathy (5) Patients with hemorrhage (those with thrombocytopenic purpura, bleeding tendency due to angiopathy, hemophilia and other coagulopathy, operation, digestive tract ulcer, hemorrhage of urinary tract, hemorrhage of urinary tract etc.) (6) Patients with hemorrhagic tendency (those with visceral tumor, gastrointestinal diverticulitis, colitis, subacute bacterial endocarditis, etc.) (7) Patients who had just undergone an operation (8) Patients with serious liver dysfunction (9) Patients with plateletcount <100,000 / microliter (10) Patients who are taking drugs which are fibrinolytic agents (t-PA and UK) or anticoagulant agents or anti-platelet agents (11) Patients with severe hypertension whose systolic blood pressure> = 180 mmHg cannot be lowered>= 150 mmHg by lowering blood pressure agents (12) Patients undergoing cancer treatment (13) Patients with a history of hypersensitivity to Edaravone if they are going to use Edaravone (14) Patients with a history of hypersensitivity to Batroxobin (15) Patients with severe illness (16) Male patients who do not consent to using reliable contraception methods during the studied period (17) Premenopausal women (18) Patients who has participated in another clinical trial twelve weeks prior to inclusion in this study (19) Patients with renal dysfunction with creatinine clearance of 50mL per min or below (20) Patients who are not eligible due to physician's judgments judgments judgment",Ii,Both
0,Patients with amyotrophic lateral sclerosis.,"Patients conforming to Definite and Probable of Awaji standard (revised El Escorial diagnostic criteria incorporating Awaji recommendations) Patients with severity 1 or 2 degrees in ALS severity classification Patients with 2 or more of all items constituting ALSFRS-R Patients with normal respiratory function (% FVC > 80%) Patients within 2 years after onset of ALS at document acquisition About patients participating in this study, patients who got consent in writing",JapicCTI-153050 TrialTroveID-328269,Adults; Older Adults,year(s),year(s),328269,Delay Disease Progression,75.0,20.0,,Ii,Both
0,Adult subjects with amyotrophic lateral sclerosis (ALS).,"Must meet the laboratory-supported probable, probable, or definite criteria for diagnosing ALS according to the World Federation of Neurology El Escorial criteria. Participants taking concomitant riluzole at study entry must be on a stable dose for greater than or equals to (>=) 30 days prior to the first dose of study treatment (Day 1). Participants taking concomitant riluzole must be willing to continue with the same dose regimen throughout the study, unless the Investigator determines that riluzole should be discontinued for medical reasons, in which case it may not be restarted during the study. Participants taking concomitant edaravone at study entry must be on a stable dose for >= 60 days prior to the first dose of study treatment (Day 1). Adequate respiratory function as indicated by slow vital capacity (SVC) >= 65% of predicted value as adjusted for sex, age, and height (from the sitting position).",261AS101 NCT03945279 TrialTroveID-342190,Adults; Older Adults,year(s),,342190,Unspecified,,18.0,"Ongoing medical condition (e.g., wasting or cachexia, severe anemia) that would, in the opinion of the Investigator, interfere with the conduct or assessments of the study. Significant cognitive impairment or unstable psychiatric illness, including psychosis, suicidal ideation, suicide attempt, or untreated major depression less than or equals to (<=) 90 days of Screening, which in the opinion of the Investigator would interfere with the study procedures. Treatment with drugs that are transported by Breast Cancer Resistance Protein (BCRP) and P-glycoprotein (P-gp) including, but not limited to, rosuvastatin, sulfasalazine, dabigatran, digoxin and fexofenadine. Current enrollment or plan to enroll in any interventional clinical study in which an investigational treatment or approved therapy for investigational use is administered within 30 days or 5 half-lives of the agent, whichever is longer, prior to the Baseline Visit (pre-dose on Day 1). Participation in a noninterventional study focused on ALS natural history may be allowed at the discretion of the Investigator and after consultation with the Sponsor.",I,Both
0,Healthy Volunteers,,TrialTroveID-294783,,,,294783,Healthy subjects,,,,I,
0,,- Hallucinations visual - Confusion - Catatonia - Significant fluctuation of symptoms - Unusual or paradoxical reaction to the treatment - Progressive cognitive deterioration,38RC13.200 NCT02841358 NPCPsy,Adults; Older Adults,year(s),,283026,,,18.0,- Patients under 18 years - Patients unable to give their free consent and without a legal representative - Breastfeeding or pregnant women,(N/A),
0,Patients with Amyotrophic Lateral Sclerosis,"Amyotrophic Lateral Sclerosis (ALS) volunteers must be diagnosed within 3 years prior to participation as having possible, probable, or definite ALS, either sporadic or familial according to modified El Escorial criteria Age 18-80, able to provide informed consent, and comply with study procedures Participants must not have started Riluzole and/or Nuedexta for at least 30 days, or be on a stable dose of Riluzole and/or Nuedexta for at least 30 days, prior to screening (Riluzole and/or Nuedexta -naïve participants are permitted in the study)",BIO-2017-0270 NCT03427086 TrialTroveID-318345,Adults; Older Adults,year(s),year(s),318345,Delay Disease Progression,80.0,18.0,"The presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair ability of the participant to provide informed consent, according to PI judgment. Exposure to any experimental agent within 30 days of entry or at any time during the trial or enrollment in another research study within 30 days of or during this trial. Slow Vital Capacity test less than 50% of the predicted value Patients who had already undergone tracheostomy",Ii,Both
0,Healthy volunteers,"Informed consent: signed written informed consent before inclusion in the study Sex and Age: men/women, 18-55 years old inclusive Body Mass Index (BMI): 18.5-30 kg/m2 inclusive Vital signs: systolic blood pressure 100-139 mmHg, diastolic blood pressure 50-89 mmHg, heart rate 50-90 bpm, measured after 5 min at rest in the sitting position Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the investigator and to comply with the requirements of the entire study Contraception and fertility (women only): women of child-bearing potential must be using at least one of the protocol defined and reliable methods of contraception",BASEC2022-02098 BL-001-1001 NCT05818306 SNCTP000005554 TrialTroveID-455406,Adults,year(s),year(s),455406,(N/A); Healthy subjects,55.0,18.0,"Electrocardiogram 12-leads (supine position): clinically significant abnormalities Physical findings: clinically significant abnormal physical findings which could interfere with the objectives of the study Bowel movements: on average ≥3 stools per day or <3 stools per week Laboratory analyses: clinically significant abnormal laboratory values indicative of physical illness Allergy: ascertained or presumptive hypersensitivity to the formulation's ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers may affect the outcome of the study Diseases: significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, hematological, endocrine, psychiatric or neurological diseases that may interfere with the aim of the study Gastrointestinal: evidence of acute or chronic gastrointestinal disorders Medications and probiotics: probiotics, nutraceuticals, and medications, including over the counter medications and herbal remedies for 2 weeks and antibiotics for 3 months before the start of the study. Hormonal contraceptives for women will be allowed",I,Both
0,,"- Adult aged ≥ 18 years old - ALS defined, probable or likely based on neurophysiological data according to Airlie House criteria (Brooks, 2000) - Sporadic ALS or familial ALS defined by the existence of a case of ALS or FTD among first or second degree relatives of the patient included (Byrne et al, 2011). - Participant affiliated to a social security scheme - Free, informed and signed consent for the examination of the genetic characteristics of the participant",GENIALS NCT04819555 RIPH3-RNI20-GENIALS,Adults; Older Adults,year(s),,435206,,,18.0,- All conditions mimicking ALS including motor neuropathies with multiple conduction blocks and all cases of ALS that do not meet the criteria of the Airlie House classification. - Patients who are cognitively incapable of signing the consent to participate in this study.,Other,Both
0,,"Patients group : - Men and women ≥ 18 years old - Person affiliated to a French social security scheme or equivalent - ALS diagnosed according to El Escorial criteria - Diagnosis of ALS < 6 months - Onset of symptoms < 2 years - Signed informed consent Non-inclusion criteria : - Pregnant or breast-feeding - Treatment with oral or injectable anticoagulants, antiplatelet agents (EXCEPT aspirin at the maximum authorized dosage of 160 mg per day) - Unbalanced diabetes - Long-term corticosteroid therapy - Persons deprived of their liberty by judicial or administrative decision; Persons under legal protection: guardianship or curators - Genetic mutations associated with ALS Control group : Inclusion criteria: - Male or female volunteer aged 18 or over - Person affiliated to a French social security scheme or equivalent - Signed informed consent Non-inclusion criteria : - Pregnant or breast-feeding women - Treatment with oral or injectable anticoagulants, antiplatelet agents (except aspirin at the maximum authorized dosage of 160 mg per day) - Unbalanced diabetes - Long-term corticosteroid therapy - Neurological diseases - Patient under legal protection (safeguard of justice, curators and guardianship), or in a situation of deprivation of liberty - Genetic mutations associated with ALS",DIAGALS DR230136 NCT06230562,Adults; Older Adults,year(s),year(s),502002,,100.0,18.0,,Other,Both
0,,"- Subjects able to undergo a lumbar puncture - Subjects registered with the French Social Security, in agreement with the French law on biomedical experimentation To be assigned in the study subgroups, subjects will have to fulfill the specific following criteria: Group 1: Controls - absence of cognitive complaint (completion of the memory complaint questionnaire) - absence of significant cognitive impairment: normal MMSE according to age and education levels - Subjects capable of and willing to comply with the protocol and to give their written informed consents after having received and understood the subject information Group 2: Alzheimer's Disease - Diagnosis of probable Alzheimer's disease dementia according to the NIA 2011 criteria1 - MMSE ≥ 16 - Subjects who have a study partner. The study partner is required to complete several scales and to drive back the subject after the lumbar puncture for safety reasons. If the subjects or their study partners are not able to drive, their transport fees will be reimbursed by the promotor - Subjects and his/her study partners capable of and willing to comply with the protocol and to give their written informed consents after having received and understood the subject information. According to the legal protection or the mental capacities of the subject, he/she will be accompanied by him/her legally acceptable representative during this procedure Group 3: Frontotemporal Dementia - Diagnosis of probable frontotemporal dementia according to the FTDC 2011 criteria2 - MMSE ≥ 16 - Subjects who have a study partner. The study partner is required to complete several scales and to drive back the subject after the lumbar puncture for safety reasons. If the subjects or their study partners are not able to drive, their transport fees will be reimbursed by the promotor - Subjects and his/her study partners capable of and willing to comply with the protocol and to give their written informed consents after having received and understood the subject information. According to the legal protection or the mental capacities of the subject, he/she will be accompanied by him/her legally acceptable representative during this procedure",2020_26 2021-A00879-32 BIOWATCH NCT05288842,Adults; Older Adults,year(s),year(s),427868,,85.0,40.0,"- General exclusion criteria: - Subjects with dementia caused by a non-neurodegenerative disease, including patients with severe cerebrovascular risk factor load - Subjects who have contraindications to perform a lumbar puncture - Subjects who have contraindications to perform a MRI scan Associated illnesses or conditions: - Subjects with other neurodegenerative disease such as Lewy body dementia and Parkinson's disease - Subjects with other serious neurological disorder such as brain tumor, stroke, epilepsy, hydrocephalus and any condition which contraindicates, in the investigator's judgment, entry to the study; - Subjects with severe metabolic or endocrine disorder (excluding hypothyroidism under stable hormone replacement therapy, controlled type 2 diabetes or common dyslipidaemia), previously known or identified at screening - Subjects under metformin treatment. Biological exclusion criteria: - Subjects with known active HCV, HBV or HIV - Subjects with clinical or significant laboratory abnormalities, previously known or identified at screening, in the judgment of the investigator Others: - Pregnancy or breastfeeding or Women of childbearing age without effective contraception (a pregnancy test will be done) - Subjects with excessive alcohol intake or drug abuse, in the judgment of the investigator - Subjects who, in the opinion of the investigator, have a risk of non-compliance to the study procedures or who are otherwise not appropriate to include in this clinical trial (for example, being impossible to contact in case of emergency)",Other,Both
0,,,TrialTroveID-197280,,,,197280,(N/A); Unspecified,,,,I,
0,Patients with ALS,Patients with ALS approved by neurologist with 31-46 ALSFRS-R score Patients should be treated with a fixed dose of Rilozule 3 months ago. Patients should not be detrimental to any other chronic disease and do not use ventilator.,IRCT20160809029275N2 TrialTroveID-402477,Adults; Older Adults,year(s),year(s),402477,Delay Disease Progression,75.0,18.0,Patients with malignancy Patients with other chronic disruptive diseases Pregnancy Others Neurodegenerative disease,Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis.,"1. ALS patients who are categorized as either Definite ALS or Probable ALS in the El Escorial and revised Airlie House criteria for the diagnosis of ALS 2. Patients at Grade 1 or 2 in the Japan ALS Severity Scale of the grant-in-aid program for chronic diseases from the Japanese Ministry of Health, Labor and Welfare 3. Patients with ALS within 2 years of symptom onset at the time of the first registration 4. Patients with change in total ALSFRS-R score during the observation period from -1 to -4 points 5. Patients with score of at least 2 on all items of ALSFRS-R; 4.Writing, 5.Feeding behavior 1 must have at least 2 points on each side.",jRCT2051220002 TrialTroveID-432754,Adults; Older Adults,year(s),year(s),432754,Delay Disease Progression,75.0,20.0,"1. Patients with tracheostomy 2. Patients who had decreased respiratory function and complained of dyspnea at the time of enrollment. One of the three items on the ALSFRS-R related to respiratory dyspnea, orthopnea, or respiratory failure is less than 3 points. 3 . Patients whose percent FVCs are at least 80 percent at the time of first and second registrations 4. Patients who have nerve conduction study findings of demyelination such as conduction block",Iii,Both
0,Patients with amyotrophic lateral sclerosis,"Those who agree to attend the current clinical study among ALS patients joining an accompanying clinical trial ""Phase 1/2 Dose Escalation Study of Bostinib in Patients with Amyotrophic Lateral Sclerosis (ALS)""",jRCTs051180229 TrialTroveID-406623,Adults; Older Adults,year(s),year(s),406623,Unspecified,75.0,20.0,,Iii,Both
0,Patients with Amyotrophic Lateral Sclerosis (ALS).,"[Phase 1 part] Inclusion criteria: Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study. To be additionaly signed by a delegate signer if the subject is unable to handwrite. Patients aged ≥20 years and <80 years at the time of informed consent Patients with positive already-reported SOD1 gene mutation and progressive muscle weakness; sporadic ALS patients who are categorized as either ""Definite ALS"" or ""Probable ALS"" or ""Probable-laboratory supported ALS"" in the Updated Awaji Criteria for the diagnosis of ALS Patients at Grade 1 or 2 in the Japan ALS Severity Scale of the grant-in-aid program for chronic diseases from the Japanese Ministry of Health, Labour and Welfare; patients with positive SOD1 mutation of Grade 1, 2 or 3 Patients with ALS that occurred within 2 years at the time of the first registration; patients with positive SOD1 mutation within 5 years after disease onset Patients who can visit hospital regularly as outpatients Patients with change in total ALSFRS-R score during the observation period are -1 to -3 points Urine pregnancy test (for females of childbearing potential) negative at screening Female patients of nonchildbearing potential must meet at least 1 of the following criteria: Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; status may be confirmed with a serum follicle stimulating hormone (FSH) level confirming the postmenopausal state; Have undergone a documented hysterectomy and/or bilateral oophorectomy; Have medically confirmed ovarian failure. All other female patients (including female patients with tubal ligations) are considered to be of childbearing potential. Male and female patients of childbearing potential must agree to use one highly effective method of contraception as outlined in this protocol, throughout the study and for at least 28 days after the last dose of investigational product. Patients with appropriate renal function as defined as follows at the time of the first and second registrations a. Serum creatinine ≤1.5 × upper limit of normal (ULN) or estimated creatinine clearance ≥60 mL/min as calculated using the method standard for the institution. Patients with appropriate hepatic function as defined as follows at the time of the first and second registrations b. Total serum bilirubin ≤1.5 × ULN unless the patient has documented Gilbert syndrome; c. AST and ALT ≤2.5 × ULN Able to take oral tablets Patients whose acute effect of previous treatment has recovered to the baseline or CTCAE v.4.03 ≤ Grade 1 at the time of the first and second registrations Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures [Phase 2 part] Inclusion criteria: Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study. To be additionally signed by a delegate signer if the subject is unable to handwrite. Patients aged ≥20 years and ≤75 years at the time of informed consent ALS patients who are categorized as either ""Definite ALS"" or ""Probable ALS in the El Escorial and revised Airlie House criteria for the diagnosis of ALS Patients at Grade 1 or 2 in the Japan ALS Severity Scale of the grant-in- aid program for chronic diseases from the Japanese Ministry of Health, Labour and Welfare Patients with ALS within 2 years of symptom onset at the time of the first registration Patients with change in total ALSFRS-R score during the observation period from -1 to -4 points Patients with score of at least 2 on all items of ALSFRS-R; 4.Writing, 5.Feeding behavior (1) must have at least 2 points on each side. Urine pregnancy test (for females of childbearing potential) negative at screening Female patients of nonchildbearing potential must meet at least 1 of the following criteria: Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; status may be confirmed with a serum follicle stimulating hormone (FSH) level confirming the postmenopausal state; Have undergone a documented hysterectomy and/or bilateral oophorectomy; Have medically confirmed ovarian failure. All other female patients (including female patients with tubal ligations) are considered to be of childbearing potential. Patients with appropriate renal function as defined as follows at the time of the first and second registrations a. Estimated creatinine clearance or eGFR ≥60 mL/min (mild renal impairment) as calculated using the method standard for the institution (the CKD-EPI equation is recommended, other methods such as Cockcroft-Gault or MDRD may be used. The same method should be applied throughout the study period.). Patients with appropriate hepatic function as defined as follows at the time of the first and second registrations Total serum bilirubin 1.5 × ULN unless the patient has documented Gilbert syndrome; AST and ALT 2.5 × ULN Patients who can consistently take the investigational drug and other oral tablets with water throughout the study period. Patients whose adverse event during previous treatment has recovered to the baseline (Visit 5: before the start of study drug administration) or CTCAE v.4.03 ≤ Grade 1 at the time of the first and second registrations. Excluding the case where the investigator (sub-investigator) judges that the event is not a safety risk. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures",iDReAM JMA-IIA00419 jRCT1090220419 jRCT2051190001 NCT04744532 TrialTroveID-348435 UMIN000036295 WI240618,Adults; Older Adults,year(s),year(s),348435,Delay Disease Progression,75.0,20.0,"Exclusion criteria: Patients with tracheostomy Patients who have used non-invasive ventilation due to ALS symptoms Patients whose %FVCs are less than 70% at the time of first and second registrations Patients who have nerve conduction study findings of demyelination such as conduction block Patients who are taking edaravone; patients who started riluzole or edaravone after start of the observation period; patients who changed the dosage of riluzole after start of the observation period Patients with bulbar type ALS with dysphagia and dysarthria Patients with cognitive impairment Pregnant female patients; breastfeeding female patients; fertile male and female patients of childbearing potential who are unwilling or unable to use 1 highly effective methods of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product History of clinically significant or uncontrolled cardiac disease including: History of, or active, congestive heart failure; Uncontrolled angina or hypertension within 3 months prior to registration; Myocardial infarction within 12 months prior to registration; Clinically significant ventricular arrhythmia (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes); Diagnosed or suspected congenital or acquired prolonged QT interval history or prolonged QTc (QTcF should not exceed 500 msec); Unexplained syncope Uncontrolled hypomagnesemia or uncorrected hypokalemia due to potential effects on the QT interval Patient who is taking the following medicines during study drugs administration. a Combination of warfarin or other anticoagulation. Combination of therapeutic anticoagulant therapy with low molecular weight heparin is acceptable b Src or c-Abl inhibitors c Other treatments for cancer d Drugs known to prolong the QT interval or predispose to Torsades de Pointe e Current or anticipated use of a strong or moderate CYP3A inhibitor and inducer f Drugs affecting gastric pH such as Proton pump inhibitors (e.g., lansoprazole) History of malignancy within 5 years prior to registration with the exception of basal cell carcinoma or cervical carcinoma in situ or Stage 1 or 2 cancer that is considered adequately treated and currently in complete remission for at least 12 months Patients who were enrolled in other clinical study within 12 weeks before the first registration, or are expected to be enrolled in other clinical study using a study drug during this study Known prior or suspected severe hypersensitivity to study drugs or any component in their formulations Patients with active, uncontrolled bacterial, fungal, or viral infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness Recent or ongoing clinically significant GI disorder (eg, Crohn's disease, ulcerative colitis, or prior total or partial gastrectomy). Patients with chronic obstructive pulmonary disease Major surgery or radiotherapy within 14 days prior to registration at the time of the first registration Patient who fulfills the conditions: Neutrophil count (ANC) <1,500/mm3 or white blood cell <3,000/mm3 at the time of the first and second registration Hemoglobin <9.0 g/dL at the time of the first and second registrations Platelet count <100,000/L at the time of the first and second registrations Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or Pfizer employees, including their family members, directly involved in the conduct of the study Exclusion criteria: Patients with tracheostomy Patients who had decreased respiratory function and complained of dyspnea at the time of enrollment (One of the three items on the ALSFRS-R related to respiratory (10) dyspnea, (11) orthopnea, or (12) respiratory failure is less than 3 points). Patients whose %FVCs are at least 80 % at the time of first and second registrations Patients who have nerve conduction study findings of demyelination such as conduction block Patients using edaravone within 4 weeks prior to enrollment in the observation period; patients using edaravone at the time of enrollment in the observation period; patients who started edaravone after start of the observation period Patients who started riluzole after start of the observation period; patients who changed the dosage of riluzole after start of the observation period Patients with bulbar-onset type ALS with dysphagia and dysarthria Patients with Parkinson's disease and syndromes, schizophrenia, cognitive impairment, and other comorbidities that may have a significant impact on the evaluation of drug efficacy Patients with a history of spinal surgery such as cervical spondylosis or disc herniation after the onset of ALS, or patients who were scheduled to undergo surgery during the study period Patients whose symptoms could not be ruled out as symptoms of a disease that requires differential diagnosis, such as cervical spondylosis or multifocal motor neuropathy. Pregnant female patients; breastfeeding female patients History of clinically significant or uncontrolled cardiac disease including: History of, or active, congestive heart failure; Uncontrolled angina or hypertension within 3 months prior to registration; Myocardial infarction within 12 months prior to registration; Clinically significant ventricular arrhythmia (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes); Diagnosed or suspected congenital or acquired prolonged QT interval history or prolonged QTc (QTcF should not exceed 500 msec); Unexplained syncope Uncontrolled hypomagnesemia or uncorrected hypokalemia due to potential effects on the QT interval Patient who is taking the following medicines during study drugs administration. Refer to Prohibited Medications. a Combination of warfarin or other anticoagulation. Combination of low molecular weight heparin is acceptable b Src or c-Abl inhibitors c Drugs known to prolong the QT interval or predispose to Torsades de Pointe d Current or anticipated use of a strong or moderate CYP3A inhibitor and inducer e Drugs affecting gastric pH such as Proton pump inhibitors (e.g., lansoprazole) History of malignancy within 5 years prior to the first registration with the exception of basal cell carcinoma or cervical carcinoma in situ or Stage 1 or 2 cancer that is considered adequately treated and currently in complete remission for at least 12 months Patients who were enrolled in other clinical study within 12 weeks before the first registration, or are expected to be enrolled in other clinical study using a study drug during this study Known prior or suspected severe hypersensitivity to study drugs or any component in their formulations Patients with active, uncontrolled bacterial, fungal, or viral infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness Recent or ongoing clinically significant GI disorder (eg, Crohn's disease, ulcerative colitis, or prior total or partial gastrectomy). Patients with chronic obstructive pulmonary disease Major surgery within 14 days prior to registration at the time of the first registration Patient who fulfills the conditions: Neutrophil count (ANC) <1,500/mm3 or white blood cell <3,000/ mm3 at the time of the first and second registration Hemoglobin <9.0 g/dL at the time of the first and second registrations Platelet count <100,000/μL at the time of the first and second registrations Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or Pfizer employees, including their family members, directly involved in the conduct of the study",Iii,Both
0,Patients with Mild Cognitive Impairment or Dementia,Cognitive decline with mild cognitive impairment (Clinical Dementia Rating Stage 0.5) through moderate dementia (CDR Stages 1 and 2),062016 NCT02921477 TrialTroveID-287785,Adults; Older Adults,year(s),year(s),287785,Frontotemporal Dementia; Lewy Body Dementia; Mild; Mild Cognitive Impairment/Dementia Risk; Mild Cognitive Impairment/Prodromal; Moderate; Parkinson's Disease Dementia; Vascular Dementia,89.0,45.0,"Subjects with a history of hypersensitivity to bosutinib Subjects with contraindications for lumbar puncture, such as bleeding abnormalities, use of anticoagulant medications, and local skin or spine abnormalities Reversible causes of cognitive impairment that explains the clinical status entirely, such as hypothyroidism, depression Advanced stages of any terminal illness or any active cancer that requires chemotherapy Pre-existing renal impairment Pre-existing hepatic impairment QT prolongation Significant cytopenia Cardiovascular, cerebrovascular, and peripheral vascular arterial thrombosis Women who are pregnant, may become pregnant, or are breastfeeding Women of child-bearing potential and male participants with female partners who are of child-bearing potential Subjects unable to give informed consent or in vulnerable categories, such as prisoners",I,Both
1,patients with Amyotrophic lateral sclerosis (ALS),"(1) diagnosis of possible or definite ALS according to the revised ElEscorial criteria. (2) using the Medical Research Council (MRC) scale to assess the target muscle strength MRC > or = 4, and the gait impaired but still standing (with the highest lower limb score of 8 in the total ALSFRS-R score). (3) using the modified Ashworth score (mAs) to evaluate moderate to severe lower limb spasm (LL) mAs > or = 2, and gait interference with ankle clonus or Achilles tendon contracture. (4) the mild disease progression rate (delta FS), measured as delta FS1= (48-ALSFRS-R at recruitment)\ duration from onset to injection (month) < 0.5.",ChiCTR2200061794 TrialTroveID-437586,Adults; Older Adults,year(s),year(s),437586,Delay Disease Progression; Symptom relief,70.0,18.0,"(1) other diseases with spasm (such as stroke, Parkinson's, etc.). (2) according to the ultrasonic evaluation, there was no fibrous degeneration in the spastic muscle, so it was not suitable for botulinum toxin A injection. (3) stop taking oral antispasmodic drugs for less than one month, or are using other drugs that act on neuromuscular junctions (such as quinine, aminoglycoside antibiotics, azithromycin, morphine, etc.). (4) FVC < 80% of patients tested by lung function. (5) ALS course > 4 years, age less than 18 years or more than 70 years old. (6) bulbar involvement such as dyspnea or dysphagia. (7) those who are allergic to botulinum toxin An or refuse to sign an informed consent form for botulinum toxin A injection treatment.",Iv,Both
1,Patients with Amyotrophic Lateral Sclerosis.,,TrialTroveID-079389,,,,79389,Unspecified,,,,Ii/Iii,
0,Healthy adults,"Healthy male and non-childbearing potential female participants, 18 to 60 years of age inclusive, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening and baseline 1 (laboratory parameters are listed in Table 8-4. Participants must weigh at least 50 kg at screening to participate in the study, and must have a body mass index within the range of 18.0 to 30.0 kg/m2 as measured at screening. Body mass index = Body weight (kg) / [Height (m)]2. At screening and baseline vital signs (systolic blood pressure, diastolic blood pressure and pulse rate) will be assessed in the supine position and again in the standing position (after at least 3 minutes in each position). Oral body temperature will also be taken with the other supine vital sign assessments. Supine vital signs must be within the following ranges at screening and baseline 1: oral body temperature 35.0-37.5 °C (inclusive) systolic blood pressure, 90-139 mmHg (inclusive) diastolic blood pressure, 50-89 mmHg (inclusive) pulse rate, 40-90 bpm (inclusive) Participants should be excluded if their standing vital signs (relative to supine) show findings which, in the opinion of the Investigator, are associated with clinical manifestation of postural hypotension (i.e. absence of any other cause). An Investigator should carefully consider enrolling participants with either a > 20 mmHg decrease in systolic blood pressure or a > 10 mmHg decrease in diastolic blood pressure accompanied by a > 20 bpm increase in pulse rate.",CLMI070A02104 EudraCT Number: 2021-000298-10 ISRCTN77772103 NCT05330286 QSC205070 TrialTroveID-429802,Adults,year(s),year(s),429802,Healthy subjects,60.0,18.0,"Participants who have received any investigational medicinal product in a clinical research study within the 90 days or 5 half-lives, whichever is longer, prior to Period 1 Day 1. Participants who have previously been administered investigational medicinal product in this study. Participants who have taken part in Part 1 are not permitted to take part in Part 2. Significant illness, which has not resolved within two (2) weeks prior to initial dosing. Men planning to father children in the near future (next 6 months). Male participant who reports to have a pregnant or nursing (lactating) partner. Sexually active males unwilling to adhere to the contraception requirements of the study as detailed below: A condom is required for all sexually active male participants to prevent them from fathering a child AND to prevent delivery of the investigational drug via seminal fluid to their partner. Males with partners of childbearing potential must use a condom during intercourse while taking investigational drug and for 118 days after stopping investigational drug (duration to cover one spermatogenesis cycle plus 5 half-lives). Additionally, male participants with female partners of childbearing potential should also use another highly effective method of contraception. Highly effective contraception methods include: Partner's bilateral tubal occlusion Male participant sterilization (vasectomy; at least 6 months prior to screening). Partner's use of oral (estrogen and progesterone; or progesterone only that inhibits ovulation), injected, or implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine system, or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), for example hormone vaginal ring or transdermal hormone contraception. In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months. Total abstinence (when this is in line with the preferred and usual lifestyle of the participant). Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. Males with partners of non-childbearing potential must use a condom during intercourse while taking investigational drug and for 28 days after stopping investigational drug (duration to cover 5 half lives). In addition, male participants should not donate sperm for 118 days after stopping investigational drug. Women of childbearing potential who report to be pregnant or nursing (lactating). Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant. Women are considered not of child-bearing potential if they are post-menopausal or have had surgical bilateral salpingectomy or bilateral oophorectomy (with or without hysterectomy) or total hysterectomy at least six weeks before screening. Women are considered post menopausal if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) and serum follicle stimulating hormone concentration of =40 IU/L. Follicle stimulating hormone and luteinizing hormone testing is required of any female participant, regardless of reported reproductive/menopausal status at screening. Refer to Section 8.4.3 Pregnancy and Assessments of Fertility.",I,Both
0,Amyotrophic Lateral Sclerosis Patients,,TrialTroveID-198310,,,,198310,Unspecified,,,,Other,
0,ALS patients.,"Age-lower limit 20 years-old < or = , Age-upper limit: 75 years-old > or =, Gender: Male and Female Inclusion criteria: Patients diagnosed as having ALS and satisfying all of the following. Eligible patients Patients diagnosed as having ALS and satisfying all of the following requirements are eligible for this study. (l) Patients in whom ALS is ""definite,"" ""probable"" or ""probable-laboratory-supported"" according to the EL Escorial Modified Airlie House Diagnostic Criteria; (2) Patients having received no treatnent with NDDPX08 before; (3) Patients whose ALS is rated as grade 1, 2 or 3 according to the ALS Severity Criteria; (4) Patients with %FVC of 70% or higher; (5) Patients who developed ALS within 3 years before giving informed consent to participate in this study; (6) Patients between 20 and 75 years of age at the time of giving informed consent in writing; (7) Patients having given informed consent to participate in the study in writing (as a rule, the patient's own signature is needed, but the signature may be attached by the proxy consenter if the patient is unable to do so due to hand dysfunction); (8) Patients with a magnitude of change in ALSFRS-R score (Attachment 3) between -1 and -4 during the pretreatment 12-weeek observation period.",08R-103 JPRN-UMIN000008527 TrialTroveID-171734 UMIN000008527,Adults; Older Adults,year(s),year(s),171734,Unspecified,75.0,20.0,"Exclusion criteria Patients falling under any of the following criteria (1) through (10) are excluded from the study. (1) Patients to whom the diagnosis has not been disclosed; (2) Patients with a history of allergy to any component ofthe test drug; (3) Patients with severe psychiatric symptoms (hallucination, delusion) or dementia; (4) Patients with severe orthostatic hypotension or other Wpes of hypotension; (5) Patients with a severe complication(s) such as heart, kidney and/or liver disease; (6) Patients found by echocardiography to have valvular heart disease (e.g., valve hypertrophy, restricted range of valve motion, stenosis associated with such abnormalities, etc.) or having a history of such disease (patients with moderate disease of only one valve are eligible for the study); (7) Pregnant, possibly pregnant or lactating women; (8) Patients using any other clinical trial drug or having participated in any other clinical trials within 3 months before; (9) Patients incompetent to give consent to participate in the study; (10) Other patients judged by the attending physician as inappropriate for the study.",Ii,Both
1,Patients with ALS,No history of other neurological diseases such as stroke and dementia No orthopedic problems Not having diabetes. addiction. hepatitis The patient's education level at least up to the fifth grade,IRCT20201020049089N1 TrialTroveID-404984,Adults; Older Adults,year(s),year(s),404984,Symptom relief,80.0,18.0,Lack of cooperation of the patient during testing and exercises Failure to refer the patient for the second stage tests after the interventions Patients whose diet is changed.,Ii/Iii,Both
0,,,TrialTroveID-429124,,,,429124,Frontotemporal Dementia,,,,I,
0,,"- over the age of 21 - will have an informant/study partner who will be able to provide independent evaluation of functioning - must fulfill clinical diagnostic criteria for atypical AD, and hence should either have a chief complaint of difficulty with language and fulfill criteria for logopenic variant of primary progressive aphasia, or present with visuospatial/perceptual deficits and fulfill criteria for posterior cortical atrophy - speaks English as their primary language (including bilingual patients whose primary language is English) - agrees to and is eligible to undergo MRI and PET scanning - if woman of child bearing age, must agree to pregnancy test no more than 48 hours before the PET scans",12-007139 NCT01723553,Adults; Older Adults,year(s),,229561,,,18.0,"- subjects with concurrent illnesses that could account for the presenting syndrome, such as traumatic brain injury, strokes or developmental syndromes - subjects meeting criteria for another neurodegenerative disease, particularly typical Alzheimer's dementia - women that are pregnant or post-partum and breast-feeding - subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, and if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm) - subjects will also be excluded if they do not have an informant, do not consent to research or do not complete all components of the study (neurological exam, neuropsychometric tests, MRI, PiB PET)",I,Both
0,,- All participants will be over the age of 21 - Have symptoms suggestive of a neurodegenerative and/or related disorder,19-009999 AND1 NCT04680130,Adults; Older Adults,year(s),,392523,,,21.0,"- Participants will be excluded if they have any concurrent illnesses that could account for all of their symptoms, such as traumatic brain injury, encephalitis, strokes or developmental syndromes - Women that are pregnant or post-partum and breast-feeding will be excluded - Participants will be excluded if they have any of the following genetic conditions which can increase the chance of cancer: Cowden disease, Lynch syndrome, Hypogammaglobulinemia, Wiskott-Aldrich syndrome and Down's syndrome - Participants will be excluded if MRI is contraindicated (metal in head, cardiac pace maker, etc), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma, intracranial neoplasm or large cortical infarcts) - Participants will be excluded if they are medically unstable or are on medications that might affect brain structure or metabolism (e.g. chemotherapy)",Other,Both
1,Patients with Amyotrophic Lateral Sclerosis,"1. > or = 18 years at the time of screening. 2. Diagnosis of ALS according to the revised El Escorial criteria (possible, probable-laboratory supported, probable or definite). 3. Capable of providing informed consent and complying with trial procedures, including randomization to sub-studies. 4. TRICALS risk profile > -6.0 and < -2.0 ** 5. The use of riluzole will be permitted during the study. Subjects taking riluzole must be on a stable dose for at least 30 days prior to the baseline visit, or stopped taking riluzole at least 30 days prior to the baseline visit. 6. Women of childbearing potential* must have a negative pregnancy test at baseline and be non-lactating. 7. Men must agree to practice contraception for the duration of the trial and for at least 3 months after last dose of study drug. 8. Men must not plan to father a child or to provide sperm for donation for the duration of the trial and 3 months after the last dose of study drug. 9. Women must not be able to become pregnant (e.g. post-menopausal***, surgically sterile or using effective birth control methods) for the duration of the study. Effective contraceptives are defined as having a failure rate of less than 1% per year when used consistently and correctly and, when applicable, in accordance with the product label, including: abstinence, hormonal contraception, intrauterine device in place for > or = 3 months Appendix 1). Women of childbearing potential must have a negative pregnancy test at baseline, and be non-lactating. Women who are pregnant or are actively seeking to become pregnant, and women of reproductive potential who are not using effective contraceptives are excluded.",CPMS 53777 EudraCT Number: 2020-000579-19 ISRCTN15671139 MAGNET NCT06008249 NL76763.041.21 TrialTroveID-482552,Adults; Older Adults,year(s),,482552,Delay Disease Progression,,18.0,"1. Laboratory Criteria at baseline: - ALT (alanine transaminase) ≥ 5 times upper limit of normal (ULN) - AST (aspartate aminotransferase) ≥ 3 times ULN - Bilirubin ≥ 1.5 times ULN - Estimated glomerular filtration rate (eGFR) < 50 mL / min / 1.73 m2 based on Cystatin C, if not available eGFR can also be calculated based on creatinine clearance. - Platelet concentration of < 100 x109 per L - Absolute neutrophil count of < 1x109 per L - Haemoglobin < 100 g/L (<6.2 mmol/L) - Amylase & lipase ≥ 2 times ULN (suspected pancreatitis) - Lactate ≥ 2 times ULN (suspected lactate acidosis) 2. Moderate to severe hepatic impairment according to Child-Pugh classification (Class B or higher; score ≥ 7). Child-Pugh classification is based on bilirubin, albumin, International Normalized Ratio (INR) and presence of encephalopathy or ascites. 3. Participation in any other investigational drug trial or using investigational drug (within 30 days prior to screening). 4. Hypothyroidism unresponsive to thyroid hormone supplementation. 5. Subjects using non-invasive ventilation (NIV, ≥22 h per day) or having a tracheostomy. 6. Subjects taking edaravone within 30 days prior to screening. Edaravone is approved by the FDA, but remains an investigational product in Europe and Australia. 7. Clinically significant history of unstable or severe cardiac (e.g. congestive heart failure, coronary insufficiency and arrhythmias), oncological, hepatic or renal disease, neuromuscular diseases, significant pulmonary disorder or other medically significant illness. 8. Drug or alcohol abuse. 9. Unstable psychiatric illness defined as psychosis or untreated major depression within 90 days of the screening visit. This exclusion criterion is based on a prior psychiatric diagnosis that is unstable as determined by the subject's treating Psychiatrist. 10. Presence of frontotemporal dementia which prevents informed consent. Lithium carbonate study-specific exclusion criteria: 1. Patients heterozygous or homozygous for the A-allele of rs12608932 (UNC13A) 2. Known allergy or hypersensitivity to lithium, or its excipients, or to the components of the placebo. 3. Brain injury with posttraumatic epilepsy or neurologic deficit, excluding a concussion in the medical history. Brain infarction is an exclusion criterion, a transient ischemic attack is not. 4. Addison disease. 5. Patients with the following co-medication: antipsychotics, digoxin and calcium antagonists, carbamazepine, methyldopa, verapamil and diltiazem. 6. Brugada Syndrome or family history of Brugada Syndrome. 7. Plasma sodium <120 mmol/L",Iii,Both
0,Subjects with behavioral variant Frontotemporal Dementia (bv-FTD) or semantic variant Primary Progressive Aphasia,"Age 40-85 A diagnosis of behavioral variant FTD (bv-FTD) or semantic variant Primary Progressive Aphasia (sv-PPA, which is generally accompanied by a behavioral syndrome), or agrammatic/non-fluent Primary Progressive Aphasia (nfv-PPA) with behavioral symptoms Neuropsychiatric Inventory (NPI) agitation/aggression subscale score > or = 4 or disinhibition subscale score > or = 4 or repetitive behavior subscale > or = 4 or total score = 6. On each subscale, a score higher than 4 represents moderate to severe symptoms Folstein Mini-Mental State Examination (MMSE) score 5-26/30 An study partner (usually a family member) is required to provide information during interviews about the patient Capacity to consent. Subjects without capacity to consent must have capacity to appoint a surrogate Structural MRI or CT scan after symptom onset",NCT02862210 NYSPI 7310 TrialTroveID-284202,Adults; Older Adults,year(s),year(s),284202,Frontotemporal Dementia,85.0,40.0,"Medical contraindication or history of intolerability to lithium, falls in the last month, current abnormal thyroid functions (T3, T4 or thyroid stimulating hormone (TSH); treated hypothyroidism with normal thyroid function tests will not lead to exclusion), creatinine level > 1.5 mg/100 ml or glomerular filtration rate < 44 ml/min/1.73m^2 will also lead to exclusion The diagnosis of bipolar disorder or schizophrenia or schizoaffective disorder Alcohol or substance use disorder in the prior 6 months Current diagnosis of other major neurological disorder, e.g., Alzheimer's Disease (AD), stroke with residual clinical deficits, multiple sclerosis, Parkinson's disease. Subjects with MRI or CT evidence of cerebrovascular disease but without clinical signs of stroke will be included Sitting blood pressure > 150/90 mm Hg, unstable cardiac disease, severe or unstable medical illness Use of medications, including diuretics, known to have adverse effects when combined with lithium. Use of antipsychotic medications will be permitted Current major depression or suicidality or dangerous behavior with risk of harm to self and others Corrected QT interval (QTc) interval > 460 ms at the time of baseline electrocardiogram (EKG) Woman of child-bearing potential",Ii,Both
0,Patients with amyotrophic lateral sclerosis.,"To be included, participants were required to meet the Escorial criteria of ALS.",TrialTroveID-172823,,,,172823,Unspecified,,,,Other,
1,Patients with Amyotrophic Lateral Sclerosis or Motor Neuron Disease (MND),"Diagnosed with ALS/MND, either definite or probable according to the El Escorial revised criteria Can provide written informed consent Able and willing to comply with all study requirement Male or female, 25-80 years old Randomised into the EMERALD trial",EMERALD-OLE GCMR0001-OLE NCT04997954 TrialTroveID-410990,Adults; Older Adults,year(s),year(s),410990,Delay Disease Progression,80.0,25.0,"Participants who are bedridden History of any psychiatric disorder other than depression associated with their underlying condition including immediate family history of schizophrenia Heavy consumption of alcohol or use of illicit drug Hypersensitivity to cannabinoids or any of the excipients Any of the following: eGFR <30 mL/min/1.73m2, ejection fraction <35%, or AST and ALT >5 X ULN Unwillingness of a female participant of child-bearing potential, or their partner, to use effective contraception during the study and 30 days thereafter Pregnant, lactating mother or female participant planning pregnancy during the course of the study and for 30 days thereafter Received any investigational drug or medical device within 30 days prior randomisation except MediCabilis CBD Oil Any other significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study Inability to cooperate with the study procedures Unwilling to stop driving vehicle or operating dangerous machinery whilst on study drug. Close affiliation with the study team, e.g. close relative of the investigator",Iv,Both
1,Patients with Amyotrophic Lateral Sclerosis (ALS) or Motor Neuron Disease (MND),"Affected by ALS/MND, either of definite or probable according to the El Escorial revised criteria Can provide written informed consent Able and willing to comply with all study requirement Male or female, ages 25-80 years old Onset of first symptom within the last 2 years Forced Vital Capacity (FVC) of at least 60% on baseline",GCMR0001 NCT03690791 TrialTroveID-327987,Adults; Older Adults,year(s),year(s),327987,Delay Disease Progression; Spasticity; Symptom relief,80.0,25.0,"Participants who are bedridden Have used or taken cannabis or cannabinoid-based medications within 30 days of study entry History of any psychiatric disorder other than depression associated with their underlying condition including immediate family history of schizophrenia Heavy consumption of alcohol or use of illicit drug Hypersensitivity to cannabinoids or any of the excipients Any of the following: eGFR <30 mL/min/1.73m2, ejection fraction <35%, or ASL and ALT >5 X ULN Unwillingness of a female participant of child bearing potential, or their partner, to use effective contraception during the study and 30 days thereafter Pregnant, lactating mother or female participant planning pregnancy during the course of the study and for 30 days thereafter Received any investigational drug or medical device within 30 days prior randomisation Any other significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study Inability to cooperate with the study procedures Unwilling to stop driving vehicle or operating dangerous machinery whilst on study drug. Close affiliation with the study team, e.g. close relative of the investigator",Iii,Both
0,Patients with amyotrophic lateral sclerosis.,,TrialTroveID-294518,,,,294518,Symptom relief,,,,Ii,
1,Subjects with diagnosis of a Qualifying Condition for Medical Marijuana Have pain from cancer or SCD,Clinical diagnosis of a Qualifying Condition for Medical Marijuana Must be 18 years or older unless they have consent from their parent or legal guardian as defined under state law parameters Must be willing to complete online surveys at baseline and the follow up points in this study Have pain from cancer or SCD. Some examples are: Acute biphenotypic leukemia Acute lymphocytic leukemia (ALL) Acute myeloid leukemia (AML) Chronic lymphocytic leukemia (CLL) Chronic myeloid leukemia (CML) Multiple myeloma Myelodysplastic syndromes (MDS) Myelofibrosis Non-Hodgkin lymphoma (NHL) SCD T-cell leukemia T-cell lymphoma Other cancer types Agree to have other standard tests done to see if you can be in the clinical trial,NCT03944447 OMNI-Can Pro00033337 TrialTroveID-349174,Children; Adults; Older Adults,year(s),,349174,AIDS-related; Burn-related; Cancer-related; Cancers-related; Chronic pain; COVID-19 Complication Support; Exposure prophylaxis (PEP/PrEP); Fibromyalgia; HIV-related; Other; Pain associated with MS; Post-operative; Spinal cord injury; Treatment,,7.0,"Pregnancy Breastfeeding Inability to provide informed consent Inability to complete study visits or questionnaires Active suicidality or psychosis, that could be exacerbated by the administration of cannabis",Iv,Both
0,,- diagnosis of probable or definite ALS,IRB201602098-N NCT02962050 R01NS100859,Adults; Older Adults,year(s),year(s),290564,,90.0,18.0,- allergies to barium or capsaicin - History of stroke - Head and Neck Cancer - Other disorder that might contribute to swallowing impairment - Not enrolled in other research investigations that might impact swallowing - Not pregnant,Other,Both
0,Patients with Amyotrophic Lateral Sclerosis (ALS),"diagnosis of probable or definite Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis Rating Scale Revised score greater than 34, forced vital capacity greater than 70%, cognition within normal limits as determined by Montreal assessment of cognition score >25",NCT02710110 TrialTroveID-274911,Adults; Older Adults,year(s),year(s),274911,Delay Disease Progression,85.0,21.0,"allergies to barium, tracheotomy or mechanical ventilation, diaphragmatic pacer, concurrent respiratory disease (e.g. COPD), pregnant at the time of the study due to radiation exposure",I,Both
0,,- diagnosis of probable or definite ALS,IRB201600163 NCT02710162,Adults; Older Adults,year(s),year(s),274908,,85.0,21.0,- allergies to barium or capsaicin - tracheotomy or mechanical ventilation - absence of diaphragmatic pacer - respiratory disease (COPD).,(N/A),Both
0,Subjects with Amyotrophic Lateral Sclerosis and Primary lateral Sclerosis,Diagnosis of ALS or PLS Age greater than 18 years Clinically significant spasticity.,NCT03929068 Sinemet-001 TrialTroveID-348375,Adults; Older Adults,year(s),,348375,Spasticity; Symptom relief,,18.0,"Individuals currently taking carbidopa-levodopa or with known hypersensitivity of any component of carbidopa-levodopa Narrow-angle glaucoma Current use of a non-selective monoamine oxidase inhibitor (MAOI) History of malignant melanoma or suspicious skin lesions History of depression, suicidal ideation, or psychosis History of myocardial infarction, ventricular arrhythmia, or severe cardiopulmonary disease Uncontrolled hypertension Asthma Renal disease Hepatic disease Endocrine disease History of peptic ulcer Pregnant and/or breastfeeding Current participation in another interventional study",I,Both
1,Patients with amyotrophic lateral sclerosis (ALS).,"A- ALS clinically defined, ALS clinically likely,or likely with instrumental support. B- Age, over 18 years. C- Disease duration less than 36 months. D- The patients must be already treated with riluzole, in association with vitamine E (400 mg/Kg) as an antioxidant (for 30 days every three months). E- Slight or moderate neurological impairment, as documented by efficient bulbar or spinal function. This means for instance a score defined by ALS-FRS-R of at least 3 for bulbar(i.e. swallowing)/spinal functions; moreover thre breathing function must be acceptable. F- Patients must be able to understand and agree to the present research protocol and they must provide a signed informed consent. G- For fertile women, a potential pregnancy need to be ruled out by appropriate lab test.",EudraCT Number: 2007-002379-16 TrialTroveID-109547,Adults; Older Adults,year(s),,109547,Delay Disease Progression,,18.0,"A- Patients with severe psychiatric disorders (as defined by DSM IV axis I or II). B- Patients with mental retardation severe or very severe. C- Patients affectd by clinically evident hypothiroidism. D- Patients under medical therapies which cannot be administered in association with lithum. E- Previously reported allergic reactions against lithium salts. F- Patients affected by cardiovascular disorders and/or renal faliure. G- Patients under diuretic therapy. H- Epileptic patients. I- Patients affected by motro neuron disorder s others then ALS. J- Presence of other neurological symptoms (sensitive, extrapyramidal, oculomotore, cerebellar, autonomic disorders). K- Previously reported loww compliance to drug therapies. L- Patients carrying PEG or tracheostomy.",Iv,Both
0,Subjects with Amyotrophic Lateral Sclerosis (ALS),"Have definite or probable ALS with a forced vital capacity of >60% predicted. Men must practice a reliable method of birth control during study and for 2 weeks following study. Women must be non-fertile or post-menopausal. Riluzole is allowed if dose has been stable for at least 30 days. Other allowed medications: lipid-lowering drugs, anti-hypertensives, anti-depressants, oral medications for type II diabetes, estrogen replacement therapy, thyroid replacement therapy, antihistamines, antacids, nonsteroidal anti-inflammatory drugs (except indomethacin), histamine H2-receptor antagonists, proton-pump inhibitors, calcium supplements, topical eye medications, and topical antibiotics.",CC100B NCT03049046 TrialTroveID-295588,Adults,year(s),year(s),295588,Unspecified,64.0,18.0,Greater than 250 pounds Have serious or unstable illnesses as determine by the investigator. Have current or a history of asthma or severe drug allergies or pollen allergy. Have had serious infectious disease affecting the brain within the preceding 5 years; or have existing evidence of serious infection. Have laboratory test values that are considered clinically significant as determined by the investigators. Have ECG abnormalities that are clinically significant. Have donated blood (a pint or more) or received an experimental drug within 30 days prior to dosing. Have a history of chronic alcohol or drug abuse within the past 2 years.,I,Both
0,Healthy subjects.,Ages Eligible for Study: 18 Years to 64 Years; Genders Eligible for Study: Both Inclusion Criteria: Men must practice a reliable method of birth control during study and for 2 weeks following study. Women must be non-fertile or post-menopausal.,CC100A NCT02050334 TrialTroveID-201835,Adults,year(s),year(s),201835,Healthy subjects,64.0,18.0,"Exclusion Criteria: Have serious or unstable illnesses as determined by the investigator. Have current or a history of asthma, or severe drug allergies or pollen allergy. Have used medications (except for calcium supplements or externally applied eye drops or antibiotics) within 30 days prior to dosing or are expected to use other medications during the study. Have had serious infectious disease affecting the brain within the preceding 5 years; or have known or existing evidence of serious infection. Have laboratory test values that are considered clinically significant as determined by the investigator. Have ECG abnormalities that are clinically significant. Have donated blood (a pint or more) or received an experimental drug within 30 days prior to dosing. Have a history of chronic alcohol or drug abuse within the past 2 years.",I,Both
0,Subjects with ALS.,,TrialTroveID-078192,,,,78192,Unspecified,,,,Ii,
0,"Patients suffering from Amyotrophic Lateral Sclerosis (ALS). The study included 38 patients, 28 males and 10 females (mean age 62.2 +/- SD 12.1-years).","Study Population: 1. patients 2. adults (18 to 64 years), elderly (65 years) 3. females and males Specific vulnerable populations: women of childbearing age Inclusion criteria: a. SLA defined, probable, or likely to support laboratory b. age '> 18 years; c. disease duration less than 36 months; d. the patient should be treated with riluzole, the standard dose, in combination or not in cycles of thirty days every three months of vitamin E (400 mg / day) as an antioxidant e. negativity 'of the pregnancy test in women age' fertile.",2289/2007 EudraCT Number: 2007-004165-17 TrialTroveID-109374,Adults; Older Adults,year(s),year(s),109374,Delay Disease Progression,75.0,50.0,"Exclusion criteria: a. motor neuron diseases other than ALS, b. poor compliance with previous treatments; c. Patients participating in other clinical trials; d. patients who have a history of sensitivity 'or intolerance to cephalosporins.",Ii,Both
0,Patients with ALS.,"Ages Eligible for Study: 20 Years to 85 Years Inclusion Criteria Diagnosis of definite or probable ALS by the El Escorial Criteria. Participants must be medically able to undergo the study procedures. Subjects must have a registered nurse who can administer the drug daily and also inspect the IV site. Willing to pay for the cost of drug, administration, and safety testing. Able to give informed consent.",Internal-16964 NCT00718393 TrialTroveID-094243,Adults; Older Adults,year(s),year(s),94243,Unspecified,85.0,20.0,"Exclusion Criteria Pregnant. Patients who are not diagnosed with ALS by a physician. Patients unable to give informed consent. Patients who have a history of sensitivity to cephalosporin or penicillin antibiotics (such as Ancef, Keflex, Ceclor, Ceftin, Lorabid, Suprax, or Fortaz).",I,Both
1,,"Patient Selection Criteria Eligible subjects, 18 years or older. Had a clinical diagnosis of familial or sporadic ALS, a VC greater than or equal to 60% predicted, and disease duration of no more than 5 years. Upper extremity strength had to be sufficient so that at least four of eight muscle groups could be evaluated using MVIC.",TrialTroveID-078869,Adults; Older Adults,year(s),,78869,Delay Disease Progression,,18.0,Patient Selection Criteria Other serious medical illnesses. Subjects were excluded if they had taken other investigational drugs in the preceding 4 weeks.,Iii,
0,Subjects with familial Amyotrophic Lateral Sclerosis,Diagnosis of familial ALS (fALS) Relative of a fALS person and carry the FUS gene,17-0159-F6A NCT03707795 TRANSLATE TrialTroveID-334799,Adults; Older Adults,year(s),year(s),334799,Unspecified,80.0,20.0,"Under 20 years or over 80 years of age Cannot tolerate steroids, including betamethasone Are unwilling or unable to attend all scheduled research visits Currently participating in another clinical drug trial Major neurological disease, other than ALS Pregnant",I,Both
0,Healthy adult subjects.,"- Male or female and age is between 18 and 55 years, inclusive. - Women must be of non-childbearing potential and may not be pregnant, lactating, or breast-feeding. Non-childbearing potential is defined by at least one of the following criteria: - At least 2 years spontaneous amenorrhea (not attributable to environmental or pathological causes, e.g., anorexia or excessive exercise) with follicle-stimulating hormone (FSH) in post-menopausal range at screening; - At least 3 months post-surgical bilateral oophorectomy or tubal ligation; or - Hysterectomy (must be greater than 5 years post-hysterectomy if due to cancer); - Females must have negative results for pregnancy tests performed: - At screening based on a urine specimen obtained within 28 days prior to initial study drug administration, and - Prior to dosing based on a serum sample obtained on Day -1. - If male, subject must be surgically sterile or practicing at least 1 of the following methods of contraception, from initial study drug administration through 90 days after administration of the last dose of study drug: - Partner(s) using an IUD; - Partner(s) using hormonal contraceptives (oral, vaginal, parenteral, or transdermal). - Subject and/or partner(s) using double-barrier method (condoms, contraceptive sponge, diaphragm, or vaginal ring with spermicidal jellies or creams); - Total abstinence from sexual intercourse as the preferred life style of the subject; periodic abstinence is not acceptable. - If male, subject agrees to abstain from sperm donation through 90 days after administration of the last dose of study drug. - Body Mass Index (BMI) is >or= 18 to < 32 kg/m2, inclusive. - A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG), as judged by the investigator. - Must voluntarily sign and date each informed consent, approved by an Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.",NCT02666963 RTA 901-C-1503 TrialTroveID-272113,Adults,year(s),year(s),272113,(N/A); Diabetic Neuropathy; Healthy subjects,55.0,18.0,"- History of clinically significant drug allergies, including allergies to any of the components of the investigational product and/or clinically significant food allergies as determined by the investigator; History of clinically significant drug allergies, including allergies to any of the components of the investigational product and/or clinically significant food allergies as determined by the investigator; - Presence or history of any significant cardiovascular, gastrointestinal, hepatic, renal, pulmonary, hematologic, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease, as determined by the investigator; - Presence of any other condition (including surgery) known to interfere with the absorption, distribution, metabolism, or excretion of medicines. - Requirement for any over-the-counter and/or prescription medication, vitamins, and/or herbal supplements on a regular basis. - Use of any medications (over-the-counter and/or prescription medication), vitamins, and/or herbal supplements, within the 30-day period prior to study drug administration or within 5 half-lives (if known), whichever is longer. - Recent (6-month) history of drug or alcohol abuse. - Positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), or HIV antibodies (HIV Ab) at screening. - Donation or loss of 550 mL or more blood volume (including plasmapheresis) or receipt of a transfusion of any blood product within 8 weeks prior to study drug administration. - Receipt of any investigational product within a time period equal to 10 half-lives of the product, if known, or a minimum of 30 days prior to study drug administration. - Positive screen results for drugs of abuse, alcohol, or cotinine at screening or Day -1. - Consumption of alcohol within 72 hours prior to study drug administration. - Consumption of grapefruit, grapefruit products, star fruit, star fruit products, or Seville oranges within the 72-hour period prior to study drug administration. - Use of tobacco or nicotine-containing products within the 6-month period preceding study drug administration. - Current enrollment in another clinical study. - Previous enrollment in this study. - Screening laboratory analyses that show any of the following abnormal laboratory results: - Alanine transaminase (ALT) level above 1.2× the upper limit of normal (ULN). - Aspartate transaminase (AST) level above 1.2× the ULN. - Any other laboratory results that are outside of the laboratory normal reference range and considered clinically significant by the investigator. - Clinically-significant abnormal ECG; ECG with QTc using Fridericia's correction formula (QTcF) > 450 msec is exclusionary. - Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive RTA 901.",I,Both
0,Patients with Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) Patients with Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Degeneration (FTD) who have the C9ORF72 repeat expansion mutation.,"Documentation of a clinical genetic test demonstrating a hexanucleotide repeat expansion (HRE) in the C9orf72 gene Has a reliable caregiver/informant to accompany the patient to all study visits For patients with ALS (with or without FTD): Diagnosis of ALS (probable, possible, laboratory-supported probable or definite) according to the World Federation of Neurology revised E1 Escorial criteria Onset of weakness within 3 years prior to Screening Slow vital capacity (SVC) > or = 60% of predicted normal adjusted for sex, age, and height (from the sitting position) Able to perform reproducible pulmonary function tests. ALS Functional Rating Scale-Revised (ALSFRS-R) > or = 30 and score of 3 or 4 on Item #3 (swallowing) at Screening For patients with FTD: A gradual, progressive decline in behavior, language, or motor function consistent with mild cognitive impairment, mild behavioral impairment, mild cognitive/behavioral impairment, behavioral variant FTD, primary progressive aphasia, or amnestic syndrome CDR Dementia Staging Instrument plus National Alzheimer's Coordinating Center Behavior and Language Domains (CDR plus NACC FTLD) global score of 0.5-2.0 at Screening",153073 CCR-21-69 EudraCT Number: 2021-002251-11 NCT04993755 TPN-101-C9-201 TrialTroveID-410706,Adults; Older Adults,year(s),,410706,Comorbidity in ALS; Delay Disease Progression; Frontotemporal Dementia,,18.0,"Presence of other significant neurological or psychiatric disorders History of clinically significant brain abnormality Clinically significant medical illness Tracheostomy or diaphragmatic pacing Autoimmune disease requiring treatment or management (quiescent rheumatoid arthritis, psoriasis, or controlled Type 1 diabetes are acceptable) History of human immunodeficiency virus (HIV) or hepatitis B infection, or any active infection during Screening, unless the patient will have been symptom-free for at least 30 days prior to randomization 3. Active alcohol, drug abuse or substance abuse, or any other reason that makes it unlikely that the patient will comply with study procedures in the opinion of the investigator 4. Clinically significant findings on Screening laboratory testing, physical examination or vital signs that are not specific to ALS/FTD that could interfere with the conduct of the study, the interpretation of the data, or increase patient risk 5. Clinically significant intercurrent illness or medical condition (e.g., hematological, endocrine, cardiovascular, renal, hepatic, or gastrointestinal disease) that would jeopardize the safety of the patient, limit participation, or compromise the interpretation of the data derived from the patient 6. History of HIV infection, hepatitis B or hepatitis C, or any active infection 7. History of cancer within 5 years of Screening, with the exception of fully excised non-melanoma skin cancers 8. Receipt of an investigational agent within 30 days or 5 half-lives prior to Screening, whichever is longer 9. Prior treatment with any monoclonal antibody within 6 months of Screening 10. Receipt of systemic corticosteroids within 30 days prior to Screening 11. Any vaccination within 30 days prior to study drug administration 12. Has smoked or used tobacco products within 6 months prior to study drug administration 13. Hypertension, defined as confirmed systolic blood pressure (SBP) > 170 mmHg and/or diastolic blood pressure (DBP) > 100 mmHg at Screening 14. Hypotension, defined as confirmed SBP < 90 mmHg and/or DBP < 60 mmHg at Screening 15. Any major surgery within 4 weeks of Screening 16. Females who are pregnant (positive pregnancy test at Screening or prior to administration of study drug), breastfeeding, or unable or unwilling to use highly effective methods of contraception throughout the study 17. Contraindication to undergoing a lumbar puncture (LP) including, but not limited to: inability to tolerate an appropriately flexed position for the time necessary to perform an LP; international normalized ratio (INR) > 1.4 or other coagulopathy; platelet count of < 120,000/µL; infection at the desired LP site; taking anti-platelet or anti-coagulant medication within 30 days of Screening (Note: aspirin is permitted); severe degenerative arthritis of the lumbar spine; suspected non-communicating hydrocephalus or intracranial mass; prior history of spinal mass or trauma 18. Allergy to any of the components of the study drug 19. History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) 20. Physical and laboratory test findings, including the following: a. Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG, or clinical laboratory determinations beyond what is consistent with the target population b. Clinically significant abnormality on 12-lead ECG prior to study drug administration, confirmed by repeat testing c. Total bilirubin, alanine aminotransferase (ALT), or aspartate aminotransferase (AST) > 2 × upper limit of normal (ULN), confirmed by repeat testing d. Serum creatinine > 168µmol/L (1.9mg/dL), confirmed by repeat testing e. Hematocrit < 35% for males and < 32% for females, absolute neutrophil cell count of < 1500/µL f. Clinically significant abnormal thyroid stimulating hormone (TSH) test g. Abnormally increased number of white blood cells (> 7 cells/mm3) in the CSF obtained at the Screening Visit; if there is evidence that the spinal tap was traumatic, patients with > 7 cells/mm3 must be discussed with the medical monitor to determine if they may be eligible h. Hemoglobin A1C >7%, confirmed by repeat testing i. Positive blood screen for HIV, hepatitis C antibody, or hepatitis B surface antigen",Ii,Both
0,Patients aged 49-68 with Amyotrophic Lateral Sclerosis. Duration of the disease was from six month to three years.,,TrialTroveID-105840,Adults; Older Adults,year(s),year(s),105840,Delay Disease Progression,68.0,49.0,,Ii,
0,All participants that completed the 18-month trial treatment duration requested to continue in the Investigator Initiated Trial.,,TrialTroveID-496749,,,,496749,Delay Disease Progression; Symptom relief,,,,Ii,
1,,,TrialTroveID-458257,,,,458257,Unspecified,,,,Iii,
0,Healthy Subjects,"Males and females, 18-55 years of age, inclusive, with a Body Mass Index (BMI) of 18.5-29.9 kg/m², inclusive. Female subjects must meet at least one of the following criterion: Agree to abstain from sexual intercourse from screening and throughout the duration of the study, with a documented secondary contraceptive method. Have used and agree to continue to use a reliable method of contraception (e.g., hormonal contraceptives, condom with spermicide, IUD) for at least 30 days before initial dosing and throughout the duration of the study. Surgically sterile (bilateral oophorectomy or hysterectomy, bilateral tubal ligation at least 3 months before initial dosing or Essure® device placement before the year 2018). At least 1 year Good health as determined by lack of clinically significant abnormalities in health assessments performed at screening. Signed and dated informed consent form, which meets all criteria of current FDA regulations. Subject understands the requirements of the study and is willing to comply with all study requirements.",NCT05436678 NST-PK-003 TrialTroveID-435753,Adults,year(s),year(s),435753,Healthy subjects,55.0,18.0,"Females who are pregnant, lactating or likely to become pregnant during the study. History of allergy or hypersensitivity to ciprofloxacin or other fluoroquinolones, celecoxib or other NSAIDs, any component of the study products, or history of any drug hypersensitivity or intolerance which, in the opinion of the Investigator, would compromise the safety of the subject or the study. Significant history or current evidence of chronic infectious disease, system disorders, organ dysfunction especially cardiovascular disorders (e.g., heart failure, edema), respiratory disorders (e.g., asthma), hypertension, renal or hepatic disorders, diabetes or obesity. QTc interval > 450 msec for males or > 470 msec for females or any clinically significant ECG abnormalities that, in the Investigator's opinion, would compromise the subject's safety for inclusion in the study. Significant history or current evidence of risk factors for Torsade de Pointes (TdP) (e.g., cardiac disease, heart failure, clinically significant hypokalemia or other electrolyte disorders, family history of Long QT Syndrome), as determined by the Investigator. History or current evidence of myasthenia gravis or myasthenic syndrome. History or current evidence of epilepsy, other seizures disorders, or other risk factors that may predispose to seizures or lower the seizure threshold; tendinitis or tendon rupture; peripheral neuropathy or aortic aneurysms. Significant acute illness (e.g. acute infection) within 14 days before initial dosing, as determined by the Investigator. Clinically significant history or presence of gastrointestinal disease (e.g., peptic ulcer, gastrointestinal bleeding) or history of malabsorption within the last year, as determined by the Investigator. History of psychiatric disorders (e.g., anxiety, depression, insomnia, confusion) occurring within the last two years, which required the subject to be hospitalized or treated with medication. Presence of a medical condition requiring regular treatment with prescription drugs (except hormonal contraceptives). Use of pharmacologic agents (prescription or over-the-counter) or herbal products known or suspected to induce or inhibit drug-metabolizing enzymes (especially inducers and inhibitors of CYP1A2 and CYP2C9) within 30 days before initial dosing. Use of dietary products (e.g., grapefruit products of all types) known or suspected to induce or inhibit drug-metabolizing enzymes (especially inducers and inhibitors of CYP1A2 and CYP2C9) within 14 days before initial dosing. Use of any prescription medications (other than hormonal contraceptives and those noted above), especially prescription medications implicated in TdP or cardiac arrhythmia, terfenadine, pimozide, ergotamine; dihydroergotamine or over-the-counter medications implicated in TdP or cardiac arrhythmia; medications that interfere with hemostasis (e.g., warfarin, selective serotonin reuptake inhibitors, selective serotonin norepinephrine reuptake inhibitors), other quinolones, digoxin, and NSAIDs or antibiotics (all dosage forms and routes of administration; other than the study drugs) within 14 days before initial dosing. Known or suspected to be a poor CYP2C9 metabolizer. Receipt of any drug as part of a research study within 30 days before initial dosing or 5 half-lives, whichever is longer. Drug or alcohol addiction, as determined by the Investigator, in the 12 months before initial dosing. History of excessive alcohol consumption (on average more than 14 units of alcohol/week) during the past 12 months. Donation or significant loss of whole blood (480 mL or more) within 30 days or plasma within 14 days before initial dosing. Positive test results for HIV, Hepatitis B surface antigen, or Hepatitis C antibody. Positive test results for drugs of abuse or cotinine at screening. If female, has a positive pregnancy test at screening. Use of tobacco- or nicotine-containing products within 90 days before initial dosing. Difficulty swallowing capsules or tablets whole. Unable or unwilling to comply with protocol restrictions and required study procedures.",I,Both
0,Healthy adult subjects,"Males and females, 18-55 years of age, inclusive, with a Body Mass Index (BMI) of 18.5 29.9 kg/m², inclusive. Female subjects must meet at least one of the following criterion: Agree to abstain from sexual intercourse from screening and throughout the duration of the study. Have used and agree to continue to use a reliable method of contraception (e.g., hormonal contraceptives, condom with spermicide, IUD) for at least 30 days before initial dosing and throughout the duration of the study. Surgically sterile (bilateral oophorectomy or hysterectomy, bilateral tubal ligation at least 3 months before initial dosing or Essure device placement before the year 2018). At least 1 year postmenopausal and have a documented FSH level > or = 40 mIU/mL at screening. Good health as determined by lack of clinically significant abnormalities in health assessments performed at screening. Signed and dated informed consent form, which meets all criteria of current FDA regulations. Subject understands the requirements of the study and is willing to comply with all study requirements.",NCT05232461 NST-PK-001 TrialTroveID-424645,Adults,year(s),year(s),424645,Healthy subjects,55.0,18.0,"Females who are pregnant, lactating or likely to become pregnant during the study. History of allergy or hypersensitivity to ciprofloxacin or other fluoroquinolones, celecoxib or other NSAIDs, any component of the study products, or history of any drug hypersensitivity or intolerance which, in the opinion of the Investigator, would compromise the safety of the subject or the study. Significant history or current evidence of chronic infectious disease, system disorders, organ dysfunction especially cardiovascular disorders (e.g., hearth failure, edema), respiratory disorders (e.g., asthma), hypertension, renal or hepatic disorders, diabetes or obesity. QTc interval > 450 msec for males or > 470 msec for females or any clinically significant ECG abnormalities that, in the Investigator's opinion, would compromise the subject's safety for inclusion in the study. Significant history or current evidence of risk factors for Torsade de Pointes (TdP) (e.g., cardiac disease, heart failure, clinically significant hypokalemia or other electrolyte disorders, family history of Long QT Syndrome), as determined by the Investigator. History or current evidence of myasthenia gravis or myasthenic syndrome. History or current evidence of epilepsy, other seizures disorders, or other risk factors that may predispose to seizures or lower the seizure threshold; tendinitis or tendon rupture; peripheral neuropathy or aortic aneurysms. Significant acute illness (e.g. acute infection) within 14 days before initial dosing, as determined by the Investigator. Clinically significant history or presence of gastrointestinal disease (e.g., peptic ulcer, gastrointestinal bleeding) or history of malabsorption within the last year, as determined by the Investigator. History of psychiatric disorders (e.g., anxiety, depression, insomnia, confusion) occurring within the last two years, which required the subject to be hospitalized or treated with medication. Presence of a medical condition requiring regular treatment with prescription drugs (except hormonal contraceptives). Use of pharmacologic agents (prescription or over-the-counter) or herbal products known or suspected to induce or inhibit drug-metabolizing enzymes (especially inducers and inhibitors of CYP1A2 and CYP2C9) within 30 days before initial dosing. Use of dietary products (e.g., grapefruit products of all types) known or suspected to induce or inhibit drug-metabolizing enzymes (especially inducers and inhibitors of CYP1A2 and CYP2C9) within 14 days before initial dosing. Use of any prescription medications (other than hormonal contraceptives and those noted above), especially prescription medications implicated in TdP or cardiac arrhythmia, terfenadine, pimozide, ergotamine; dihydroergotamine or over-the-counter medications implicated in TdP or cardiac arrhythmia; medications that interfere with hemostasis (e.g., warfarin, selective serotonin reuptake inhibitors, selective serotonin norepinephrine reuptake inhibitors), other quinolones, digoxin, and NSAIDs or antibiotics (all dosage forms and routes of administration; other than the study drugs) within 14 days before initial dosing. Known or suspected to be a poor CYP2C9 metabolizer. Receipt of any drug as part of a research study within 30 days before initial dosing or 5 half-lives, whichever is longer. Drug or alcohol addiction, as determined by the Investigator, in the 12 months before initial dosing. History of excessive alcohol consumption (on average more than 14 units of alcohol/week) during the past 12 months. Donation or significant loss of whole blood (480 mL or more) within 30 days or plasma within 14 days before initial dosing. Positive test results for HIV, Hepatitis B surface antigen, or Hepatitis C antibody. Positive test results for drugs of abuse at screening. If female, has a positive pregnancy test at screening. Use of tobacco- or nicotine-containing products within 90 days before initial dosing. Difficulty swallowing capsules or tablets whole. Unable or unwilling to comply with protocol restrictions and required study procedures (including consuming the entire high-fat, high-calorie breakfast).",I,Both
0,Patients with amyotrophic Lateral Sclerosis,"Able to comprehend and willing to sign an informed consent form (ICF) Males or females between the ages of 18 and 75 years of age, inclusive Diagnosis of familial or sporadic ALS (defined as meeting the laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS according to the Gold Coast criteria) Disease duration after first symptom (muscle weakness) less than 30 months prior to screening Pre-enrollment ALSFRS-R slope from disease onset = 0.3 points per month ALSFRS-R at screening > or = 25 Item 3 (swallowing) in ALSFRS-R > or = 3 Subjects may be treated in parallel with riluzole and/or edaravone and/or sodium phenylbutyrate and/or taurursodiol; 60 days of stable use prior to enrollment is required Upright slow vital capacity (SVC) > or = 60% of predicted for age, height, weight and sex at screening according to the GLI-2012 18 < BMI < 30 A caregiver (if one is needed) Female subjects must be post-menopausal (> or = 1 year) OR sterilized, OR if of childbearing potential (i.e., females who have had their first period unless they are anatomically or physiologically incapable to become pregnant), must have a negative pregnancy test, and agree to use contraceptive drugs or devices (e.g., diaphragm plus spermicide, or oral contraceptives) for the duration of the study and 10 weeks after the last treatment dose AND require male partners to use a condom during sexual intercourse",EudraCT Number: 2022-002185-32 MOH_2022-04-27_010760 NCT05357950 NST003 PARADIGM TrialTroveID-384235,Adults; Older Adults,year(s),year(s),384235,Delay Disease Progression; Symptom relief,75.0,18.0,"A past history of adverse reaction/hypersensitivity to either NSAIDs, celecoxib or fluoroquinolones, ciprofloxacin Any known clinically significant abnormal gastric mucosal erosion, ulcer or tumor or/and GI disorder and/or bariatric surgery Known history of clinically significant impairment of renal function (creatinine = 1.5) Known or suspected symptomatic congestive heart and/or coronary heart disease, previous history of myocardial infarction, uncontrolled arterial hypertension, or rhythm abnormalities requiring permanent treatment Known history of QT/QTc prolongation, Torsade de pointes (TdP) (e.g. heart failure, hypokalemia, family history of Long QT syndrome) and the use of concomitant medications that prolong the QT/QTc interval Known or suspected diagnosis or family history of epilepsy in first degree relatives Known predisposition to tendinitis Known or suspected to be a poor CYP2C9 metabolizers who also uses pharmacologic agents (prescription or over-the-counter) or herbal products known or suspected to induce or inhibit CYP2C9 within 30 days before enrollment Tracheostomy or percutaneous gastrostomy use Presence at screening of any medically significant cardiac, pulmonary, musculoskeletal, or psychiatric illness that might interfere with the subject's ability to comply with study procedures or that might confound the interpretation of clinical safety data, including, but not limited to: Mean systolic blood pressure >160 mm Hg and/or mean diastolic blood pressure >100 mm Hg (measurements taken after a few minutes rest) that persist on 3 successive measurements taken at least 2 minutes apart NYHA Class II or greater congestive heart failure Chronic obstructive pulmonary disease or asthma requiring daily use of bronchodilator medications Poorly controlled or brittle diabetes mellitus Cognitive impairment, related to ALS or otherwise, sufficient to impair subject's ability to understand and/or comply with study procedures and provide informed consent Subject who is treated with chronic aspirin or NSAIDs and is at risk if stopped. Clopidogrel is allowed and can replace Aspirin. Any contraindication for ciprofloxacin and celecoxib according to the current prescribing information. Female who is pregnant or breastfeeding or with intention of becoming pregnant during the course of the study. Any impairment or social circumstance that, in the opinion of the Investigator, would render the subject not suitable to participate in the study. Subject, or subject's legal guardian(s) is/are unable to understand the nature, scope, and possible consequences of the study. Subject is participating in (or plans to participate in) any other investigational drug trial, or plans to be exposed to any other investigational agent, device and/or procedure, from 30 days prior to Screening through study completion.",Ii,Both
0,Patients with Amyotrophic lateral sclerosis,"Able to comprehend and willing to sign an Informed Consent Form (ICF) Males or females between the ages of 18 and 75 years of age, inclusive Diagnosis of familial or sporadic ALS (defined as meeting the laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS according to the World Federation of Neurology El Escorial criteria) Disease duration after first symptom less than 3 years prior to baseline Patients may be treated in parallel with Riluzole and/or Edaravone; 30 days of stable use prior to enrollment is required Upright forced vital capacity (FVC) > or = 50% of predicted for age, height, weight and sex at screening Patient is able to swallow tablets/ capsules A caregiver (if one is needed) Female patients must be post-menopausal (> or = 1 year) OR sterilized, OR if of childbearing potential (i.e., females who have had their first period unless they are anatomically or physiologically incapable to become pregnant), must have a negative pregnancy test, and agree to use contraceptive drugs or devices (e.g., diaphragm plus spermicide, or oral contraceptives) for the duration of the study and 10 weeks after the last treatment dose AND require male partners to use a condom during sexual intercourse",NCT04165850 NST002 TrialTroveID-361518,Adults; Older Adults,year(s),year(s),361518,Delay Disease Progression,75.0,18.0,"A past history of adverse reaction/hypersensitivity to either NSAIDs, celecoxib or fluoroquinolones, ciprofloxacin Any known clinically significant abnormal gastric mucosal erosion, ulcer or tumor or/and GI disorder Known history of clinically significant impairment of renal function (creatinine = 1.5) Known or suspected congestive heart and/or coronary heart disease, previous history of myocardial infarction, uncontrolled arterial hypertension, or rhythm abnormalities requiring permanent treatment Known history of QT/QTc prolongation, Torsade de pointes (TdP) (e.g. heart failure, hypokalemia, family history of Long QT syndrome) and the use of concomitant medications that prolong the QT/QTc interval Known or suspected diagnosis or family history of epilepsy Presence at screening of any medically significant cardiac, pulmonary, musculoskeletal, or psychiatric illness that might interfere with the patient's ability to comply with study procedures or that might confound the interpretation of clinical safety data, including, but not limited to: Mean systolic blood pressure >180 mm Hg; mean diastolic blood pressure >100 mm Hg (measurements taken after few min rest) that persist on 3 successive measurements taken at least 2 minutes apart NYHA Class II or greater congestive heart failure Chronic obstructive pulmonary disease or asthma requiring daily use of bronchodilator medications Poorly controlled or brittle diabetes mellitus Cognitive impairment, related to ALS or otherwise, sufficient to impair patient's ability to understand and/or comply with study procedures and provide informed consent Patient who is treated with chronic aspirin or NSAIDs, and is at risk if stopped. Clopidogrel is allowed and can replace Aspirin. Female who is pregnant or breastfeeding or with intention of becoming pregnant during the course of the study Any impairment or social circumstance that, in the opinion of the Investigator, would render the patient not suitable to participate in the study Patient, patient's parent(s), or patient's legal guardian(s) is/are unable to understand the nature, scope, and possible consequences of the study Patient is participating in (or plans to participate in) any other investigational drug trial, or plans to be exposed to any other investigational agent, device and/or procedure, from 30 days prior to Screening through study completion",Ii,Both
0,Patients With familial or sporadic ALS (Amyotrophic Lateral Sclerosis).,"Able to comprehend and willing to sign an Informed Consent Form (ICF) Males or females between the ages of 18 and 75 years of age, inclusive Diagnosis of familial or sporadic ALS (defined as meeting the possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS according to the World Federation of Neurology El Escorial criteria) less than 5 years prior to baseline Patients may be on Riluzole and/or Edaravone; 30 days of stable use is required to make safety assessments more reliable Upright Forced Vital Capacity (FVC) = 50% of predicted for age, height and sex at screening Patient is able to swallow tablets/ capsules A caregiver (if one is needed) Female patients must be post-menopausal (= 1 year) OR sterilized, OR if of childbearing potential (i.e., females who have had their first period unless they are anatomically and physiologically incapable to become pregnant), must have a negative pregnancy test, and agree to use contraceptive drugs or devices (e.g., diaphragm plus spermicide, or oral contraceptives) for the duration of the study and 10 weeks after the last treatment dose AND require male partners to use a condom during sexual intercourse",NCT04090684 NST001 TrialTroveID-357284,Adults; Older Adults,year(s),year(s),357284,Delay Disease Progression,75.0,18.0,"A past history of adverse reaction/hypersensitivity to either NSAIDs, celecoxib or fluoroquinolones, ciprofloxacin Any known clinically significant abnormal gastric mucosal initial gastroscopic of an erosion, ulcer or tumor or/and GI disorder Known history of impaired renal function. Known or suspected congestive heart and/or coronary heart disease, previous history of myocardial infarction, uncontrolled arterial hypertension, or rhythm abnormalities requiring permanent treatment Known history of QT/QTc prolongation, Torsade de pointes (TdP) (e.g. heart failure, hypokalemia, family history of Long QT syndrome) and the use of concomitant medications that prolong the QT/QTc interval. Known or suspected diagnosis or family history of epilepsy Presence at screening of any medically significant cardiac, pulmonary, musculoskeletal, or psychiatric illness that might interfere with the patient's ability to comply with study procedures or that might confound the interpretation of clinical safety data, including, but not limited to: Mean systolic blood pressure >180 mm Hg; mean diastolic blood pressure >100 mm Hg (measurements taken after few min rest) that persist on 3 successive measurements taken at least 2 minutes apart NYHA Class II or greater congestive heart failure Chronic obstructive pulmonary disease or asthma requiring daily use of bronchodilator medications Poorly controlled or brittle diabetes mellitus Cognitive impairment, related to ALS or otherwise, sufficient to impair the patient's ability to understand and/or comply with study procedures and provide informed consent Female who is pregnant or breastfeeding or with intention of becoming pregnant during the course of the study Any impairment or social circumstance that, in the opinion of the Investigator, would render the patient not suitable to participate in the study Patient, patient's parent(s), or patient's legal guardian(s) is/are unable to understand the nature, scope, and possible consequences of the study Patient is participating in (or plans to participate in) any other investigational drug trial, or plans to be exposed to any other investigational agent, device and/or procedure, from 30 days prior to Screening through study completion",Iii,Both
1,,"- Meet the DSM-IV criteria for primary degenerative dementia - Meet standard clinical criteria for frontotemporal dementia (ie., frontotemporal degeneration including both the frontal/behavioural variant and primary progressive aphasia) - Have significant behavioural problems as demonstrated by a score of at least eight on the Neuropsychiatric Inventory (NPI) an - An independent clinical decision to receive psychotropic medication for behavioural disorders",07-48 218-2006 NCT00376051,Adults; Older Adults,year(s),,236790,,,18.0,"- An abnormal biochemical screening (blood cell count, vitamin B12 or thyroid function tests) - Significant medical illness or other medical/neurological conditions which diminish cognitive function (including: drug overdose, severely disturbed liver, kidney, lung or heart function, anemia, hypothyroidism, vitamin B12 or folic acid deficiency, syphilis, uncontrolled diabetes, Parkinson's disease, Huntington's chorea, progressive supranuclear paralysis, brain tumour, subdural hematoma, multiple sclerosis, or brain trauma); - An Hachinski ischemic score ???444; - Electrocardiographic, laboratory or physical evidence of significant cardiovascular disease; - Hypertension >160 mmHg systolic or >100 mmHg diastolic; - A brain computed tomographic scan that could not be interpreted as consistent with FTLD; - Presence of premorbid or current psychiatric diagnosis (including: major depression, schizophrenia, psychotic symptoms of a severity likely to provoke violent or dangerous behaviour such as command hallucinations to harm people or persecutory delusions that provoke violent reactions, psychoactive substance abuse or dependence); - Contraindications to receiving citalopram (such as concomitant MAOI or within 2 weeks, or hypersensitivity to citalopram); or - Ongoing need for psychotropic medications (i.e., unsuitable for washout) or administration of a depot antipsychotic injection within one treatment cycle of visit 1",Iv,Both
0,Patients with motor neurone disease.,Patients with sporadic MND.,TrialTroveID-121291,,,,121291,Delay Disease Progression,,,Patients with the necessity of tube feeding will not be included because of missing data about bioavailability of tube feeded CDP-choline.,Ii,
0,Patients with sporadic Motor Neurone Disease (MND).,After giving their informed consent 10 consecutive patients with sporadic Motor Neurone Disease (MND) were included in this study. Three patients were primarily bulbar.,TrialTroveID-120980,,,,120980,Unspecified,,,Patients with the necessity of tube feeding were excluded because of missing data about bioavailability of tube fed CDP-choline.,Ii,
0,Subjects with Amyotrophic lateral sclerosis,"Ability of the subject or his/her legally authorized representative to provide informed consent. Adult ALS subjects (> or = 18 years of age) Diagnosis of ALS, according to the Revised El Escorial Criteria for ALS Subjects with disease onset < or = 5 years Upright (sitting position) Slow Vital Capacity (SVC) as adjusted for sex, age and height > or = 50% predicted Subjects must have documented ALSFRSR score of 36-45 at baseline. Subjects taking concomitant Riluzole or Edaravone or Albrioza at study entry must be on a stable dose for > or = 30 days prior to the first dose of study treatment (Day 1). Screening values of coagulation parameters including platelet count, international normalized ratio (INR), prothrombin time (PT), and activated partial thromboplastin time (APTT) should be within normal ranges. Agree to practice highly effective contraception during the study and continue contraception for 90 days after their last dose of study treatment.",CK0803-101-1 NCT05695521 REGALS TrialTroveID-443188,Adults; Older Adults,year(s),year(s),443188,Delay Disease Progression,95.0,18.0,"Uncontrolled infection, not responding to appropriate antimicrobial agents after seven days of therapy. The Protocol medical monitor is the final arbiter of eligibility. Antiplatelet or anticoagulant therapy within the 14 days prior to Day 1 or anticipated use during the study, including but not limited to daily aspirin including low dose aspirin (defined as < or = 150 mg/day), clopidogrel, dipyridamole, warfarin, dabigatran, rivaroxaban and apixaban Clinically significant low platelet count (defined as < 100,000/mm3), coagulation tests, or laboratory abnormalities that would render a subject unsuitable for inclusion Unwillingness to comply with study procedures, including follow-up, as specified by this protocol, or unwillingness to cooperate fully with the Investigator Have any other conditions, which, in the opinion of the Investigator would make the subject unsuitable for inclusion, or could interfere with the subject participating in or completing the study Concurrent participation in any other interventional clinical study Treatment with another investigational drug, biological agent, or device, including, but not limited to sodium phenylbutyrate, within 1 month of Screening, or 5 half-lives of investigational agent, whichever is longer Treatment of cancer in the last 5 years (except in situ carcinoma of the cervix or basal cell carcinoma) Female subjects who are pregnant or currently breastfeeding Other unspecified reasons that, in the opinion of the Investigator or Sponsor, make the subject unsuitable for enrollment.",I,Both
0,Patients with amyotrophic lateral sclerosis.,,TrialTroveID-407238,,,,407238,Unspecified,,,,I,
0,Patients with amyotrophic lateral sclerosis,(1) Patients with new onset or within 2 years after onset at the start of screening (2) Patients with 1 or 2 severity according to ALS severity criteria (3) Subjects who can receive treatment on an outpatient basis,jRCT2063200047 TrialTroveID-398906,Adults; Older Adults,year(s),year(s),398906,Unspecified,80.0,20.0,"(1) Patients undergoing tracheostomy (2) Patients who have worn non-invasive respiratory assist device (3) Patients with% FVC of 80% or less (4) Patients with chronic obstructive pulmonary disease (COPD) (5) Patients with impaired respiratory function who complained of dyspnea at the end of screening (ALS FRS-R: 10. Dyspnea, 11. Orthopnea, 12. Respiratory failure, any of those 3 items is 3 points or less) (6) Patients using Edaravone injection within 4 weeks before the start of screening (7) Patients who started taking Riluzole, or patients who changed or discontinued the dose after obtaining informed consent (8) Patients with cognitive dysfunction (Alzheimer's disease and other dementia, Parkinson's disease, or other neurological disorders, etc.) that principal investigator / sub investigator has determined to affect their ability to participate in this trial or the evaluation of the clinical trial ( 9) Patients with a history of surgery on the spine such as cervical spondylosis and herniated disc after the onset of ALS, or patients scheduled for surgery during the clinical trial period (10) Patients who could not rule out the possibility of diseases symptoms that require differential diagnosis such as cervical spondylosis and multifocal motor neuropathy (11) Patients with serious respiratory, cardiovascular or hepato-renal disorders (12) Patients with complication of malignant tumor or history of it (however, patients who in remission for 5 years could be included) (13) Patients with collagen disease and related diseases (14) Patients with severe diabetes mellitus (HbA1C> 10%) ) (15) Patients with active infectious disease requiring medical treatment (including HB antigen, HCV antibody, HIV antibody, HTLV-1 antibody, Syphilis) (16) Patients who received high-dose intravenous immunoglobulin therapy within 8 weeks before the start of screening (17) Patients who are taking systemic steroid hormone or immunosuppressant drugs (18) Patients who have been treated with bone marrow transplantation or stem cell therapy (19) Patients who are pregnant / possibly pregnant or breastfeeding (20) Male or female patients who could not agree to birth control explained by principal investigator / sub investigator from completion of informed consent until completion of observation period (21) Patients with history of allergy to aminoglycoside antibiotics including kanamycin (22) Patients with history of allergy to human serum albumin formula or xenogeneic-derived protein (cow and swine) (23) Patients who participated in other clinical trials within 12 weeks before completion of informed consent for the clinical trial (24) Patients with or with a history of drug allergies or severe allergic diseases (anaphylactic shock, etc.) (25) Patients with severe complications that principal investigator / sub investigator judged as inappropriate (26) Patients who the principal investigator / sub investigator judged as inappropriate to participate",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis (ALS),"Diagnosis of possible or more definite ALS according to the El Escorial criteria FVC >50% of predicted for age, height and gender. At least four of 12 ALSFRS-R questions scored as 2 or 3 at screening. Diminished but measurable grip strength (1) in at least one hand (females:10-50 pounds; males, 10-70 pounds). Taking riluzole at a stable dose or not taking riluzole at screening. On Radicava at a stable dose for at least 30d or not taking this Life expectancy at least 6 months Able to swallow tablets without crushing. Age: 18+ years at enrollment. Subjects are capable of giving written consent. If sexually active, must agree to use contraceptive or abstinence for duration of treatment Females of child bearing age must have negative pregnancy test at screening",NCT04245709 TrialTroveID-366483,Adults; Older Adults,year(s),,366483,Delay Disease Progression,,18.0,"Concurrent illness or laboratory abnormalities that could confound the measurement of ALS progression or interfere with the ability to complete the study. Taking any investigational study drug within 30 days of screening or five half-lives of the prior agent. No previous exposure to clenbuterol. Pregnancy Clinically relevant EKG abnormality (arrhythmia, cardiomyopathy) Tachycardia (resting heart rate greater than 100 beats per minute) History of seizure disorder Hyperthyroidism Pheochromocytoma Pregnancy Have any other co-morbid conditions that in the opinion of the study investigator, places the participant at increased risk of complications, interferes with study participation or compliance, or confounds study objectives History of hypersensitivity to 2-agonist drugs such as albuterol, levalbuterol (Xopenex), bitolterol (Tornalate), pirbuterol (Maxair), terbutaline, salmeterol (Serevent). The use of the following concomitant meds is prohibited during the study: diuretics (furosemide, Lasix), digoxin (digitalis, Lanoxin);blockers such as atenolol (Tenormin), metoprolol (Lopressor), and propranolol (Inderal); tricyclic antidepressants such as amitriptyline (Elavil, Etrafon), doxepin (Sinequan), imipramine (Janimine, Tofranil), and nortriptyline (Pamelor); monoamine oxidase inhibitors such as isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine (Parnate); or other bronchodilators such as albuterol (Ventolin), levalbuterol (Xopenex), bitolterol (Tornalate), pirbuterol (Maxair), terbutaline (Brethine, Bricanyl), salmeterol (Serevent), isoetherine (Bronkometer), metaproterenol (Alupent, Metaprel), or isoproterenol (Isuprel Mistometer).",Ii,Both
0,Amyotrophic Lateral Sclerosis patients with sialorrhea refractory to medical therapy were enrolled in this study.,,TrialTroveID-121197,,,,121197,Symptom relief,,,,Ii,
0,Patients with Amyotrophic Lateral Sclerosis (ALS) ALS patients who don’t meet the criteria to enroll in a clinical trial an opportunity to try CNM-Au8 as a novel investigational therapy through this EAP program,,TrialTroveID-505607,,,,505607,Delay Disease Progression,,,,Ii,
1,Patients with Early-onset Amyotrophic Lateral Sclerosis (ALS),,RESTORE-ALS TrialTroveID-475642,,,,475642,Unspecified,,,,Iii,
0,Patients diagnosed with Amyotrophic Lateral Sclerosis,"Participants must have completed the randomized placebo-controlled Treatment Period without compliance issues. Able to understand and give written informed consent to participate in the open-label extension. If referred from a third party (neurologist or a State based ALS organisation), participant agrees to maintain transfer of care to a neurologist participating in the study.",CNMAu8.205 OLE NCT05299658 TrialTroveID-428461,Adults; Older Adults,year(s),year(s),428461,Delay Disease Progression,80.0,30.0,"Lack of treatment compliance during the randomized placebo controlled Treatment Period. Positive pregnancy test at the Week 36 visit, or, females who plan to get pregnant during the course of this extension or within 6 months of the end of this extension. Based on the investigator's judgment, patients who may have difficulty complying with the protocol and/or any study procedures. Patient with clinically significant abnormalities in haematology, blood chemistry, ECG, or physical examination identified during the W36 visit which according to Investigator may interfere with continued participation. Patients with clinically significant hepatic or renal dysfunction or clinical laboratory findings that would limit the interpretability of change in liver or kidney function, or those with low platelet counts (< 150 x 10^9 per liter) or eosinophilia (absolute eosinophil count of ≥ 500 eosinophils per microliter) at the Week 36 visit. Patient is considered a suicide risk in the opinion of the Investigator, has previously made a suicide attempt, or is currently demonstrating active suicidal ideation. Subjects with intermittent passive suicidal ideation are not necessarily excluded based on the assessment of the Investigator.",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis (ALS),"Able to understand and give written informed consent. Male or female participants aged 18 years or greater (inclusive) at the time of ALS diagnosis. Participants with a confirmed diagnosis of ALS per Gold Coast criteria as determined by a neurologist specializing in ALS (e.g., the site principal investigator or sub-investigator for this study). Participant is able to daily consume up to 240 mL of the investigational drug suspension without substantial dysphagia, OR can intake the investigational product through a gastrostomy tube. Participant must have completed standard clinical safety labs within the prior 90 days from the Baseline visit including a chemistry panel (e.g., CMP) and a hematology panel (e.g., CBC). In the judgement of the Investigator the participant's expected survival is greater than six-months. Participants who have established care with a neurologist at the specialized ALS center involved in the study and will maintain this clinical care throughout the duration of the EAP within the United States. OR Prior participation in the HEALEY Platform ALS trial (Regimen C) Open Label Extension (NCT04414345) will be considered an automatic inclusion.",CNMAu8.EAP02 EAP02 NCT05281484 TrialTroveID-414605,Adults; Older Adults,year(s),,414605,Delay Disease Progression,,18.0,"Participant is eligible for participation in: (i) the HEALEY ALS Platform trial (NCT04297683), or (ii) any active study investigating CNM-Au8 for the treatment of ALS. Participant has a history of any clinically significant or unstable medical condition (other than ALS) that may interfere with assessment of safety or compromise the study objectives. Based on the investigator's judgment, participants who may have difficulty complying with the protocol and/or any study procedures. Within the prior 90-days the participant has had clinically significant findings on standard hepatic, hematologic, or renal safety assays. Participant is currently involved in another placebo-controlled clinical trial (note: concomitant therapy with other investigational products is permitted with certain restrictions. Females who are pregnant or nursing or who plan to get pregnant during the EAP or within 6 months of the end of this trial. Females of child-bearing potential, or men, who are unwilling or unable to use accepted methods of birth control. History of gold allergy. OR These exclusion criteria will not be applied if the participant was previously enrolled in the HEALEY Platform ALS trial (Regimen C) Open Label Extension (NCT04414345).",Ii,Both
1,Patients with Amyotrophic Lateral Sclerosis (ALS).,"Sporadic or familial ALS diagnosed as clinically possible, probable, lab-supported probable, or definite ALS defined by revised El Escorial criteria. Age 18 years or older. Capable of providing informed consent and complying with study procedures, in the SI's opinion. Time since onset of weakness due to ALS < or = 36 months at the time of the Master Protocol Screening Visit. Vital Capacity > or = 50% of predicted capacity for age, height, and sex at the time of the Master Protocol Screening Visit measured by Slow Vital Capacity (SVC), or, if required due to pandemic-related restrictions, Forced Vital Capacity (FVC). Participants must either not take riluzole or be on a stable dose of riluzole for > or = 30 days prior to the Master Protocol Screening Visit. Riluzole-naïve participants are permitted in the study. Participants must either not take edaravone or have completed at least one cycle of edaravone prior to the Master Protocol Screening Visit. Edaravone-naïve participants are permitted in the study. Participants must have the ability to swallow pills and liquids at the time of the Master Protocol Screening Visit and, in the SI's opinion, have the ability to swallow for the duration of the study. Geographically accessible to the site.",2019P003518C HEALEY ALS Platform Trial - Regimen C NCT04414345 SFD20018-C TrialTroveID-376187,Adults; Older Adults,year(s),,376187,Delay Disease Progression,,18.0,"Clinically significant unstable medical condition (other than ALS) that would pose a risk to the participant, according to SI's judgment (e.g., cardiovascular instability, systemic infection, untreated thyroid dysfunction, or clinically significant laboratory abnormality or EKG changes). Lab abnormalities include, but are not limited to: Hemoglobin < 10 g/dL, White Blood Cells < 3.0 x 103/mm3, Neutrophils, Absolute = 1000/mm3, Eosinophilia (absolute eosinophil count of > or = 500 eosinophils per microliter), low platelet counts (< 150 x 109 per liter), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3 times the upper limit of normal (ULN), eGFR < 30 mL/min/1.73m2, thyroid-stimulating hormone (TSH) levels >10 mIU/L or <0.01 mIU/L. Presence of unstable psychiatric disease, cognitive impairment, dementia or substance abuse that would impair ability of the participant to provide informed consent, in the SI's opinion. Active cancer or history of cancer, except for the following: basal cell carcinoma or successfully treated squamous cell carcinoma of the skin, cervical carcinoma in situ, prostatic carcinoma in situ, or other malignancies curatively treated and with no evidence of disease recurrence for at least 3 years. Use of investigational treatments for ALS (off-label use or active participation in a clinical trial) within 5 half-lives (if known) or 30 days (whichever is longer) prior to the Master Protocol Screening Visit. Exposure at any time to any gene therapies under investigation for the treatment of ALS (off-label use or investigational). If female, breastfeeding, known to be pregnant, planning to become pregnant during the study, or of child-bearing potential and unwilling to use effective contraception for the duration of the trial and for 3 months, or longer as specified in each RSA, after discontinuing study treatment. If male of reproductive capacity, unwilling to use effective contraception for the duration of the trial and for 3 months, or longer as specified in each RSA, after discontinuing study treatment. Anything that would place the participant at increased risk or preclude the participant's full compliance with or completion of the study, in the SI's opinion. If a participant is being re-screened, the disqualifying condition has not been resolved, or the mandatory wash-out duration has not occurred. For those participating in the optional CSF collection, contraindication to undergoing a lumbar puncture (LP) in the SI's opinion. Participants undergoing the LP must not be currently taking anticoagulation medications such as warfarin that would be a contraindication to LP; aspirin and non-steroidal anti-inflammatories are allowed. History of allergy to gold, gold salts, or colloidal gold preparations.",Ii/Iii,Both
0,"Patients with amyotrophic lateral sclerosis People living with ALS, who were an average of 16 months from symptom onset.","Able to understand and give written informed consent. Male or female patients aged 30 years or greater (inclusive) and less than 80 years of age at the time of Screening. Patients whose conditions are defined as possible or probable or definite ALS per the diagnostic criteria by Awaji-Shima criteria as determined by a neurologist sub- specialising in ALS (e.g., the Principal Investigator by study site). For patients taking riluzole, stable dosing of riluzole over the prior 30-days from Screening. At the time of Screening either disease duration less than or equal to 24-months from symptom onset, or disease duration less than or equal to 12-months from diagnosis. Forced vital capacity (FVC) 60% of predicted value as adjusted for gender, height, and age at the Screening Visit. Patient who has established care with a neurologist at one of the specialized ALS clinics involved in the study and will maintain this clinical care throughout the study. If a patient is referred from a third party (neurologist or a State based ALS organization) they must be willing to transfer care to the neurologist participating in the study. Following completion of the 36-week randomized placebo controlled treatment period, interested participants must meet the following inclusion criteria to enroll in the open-label extension: Participants must have completed the randomized placebo controlled Treatment Period without compliance issues Able to understand and give written informed consent to participant in the open-label extension. If referred from a third party (neurologist or a State based ALS organization), participant agrees to maintain transfer of care to a neurologist participating in the study.",CNMAu8.205 NCT04098406 RESCUE-ALS TrialTroveID-357443,Adults; Older Adults,year(s),year(s),357443,Delay Disease Progression,80.0,30.0,"Patients will be excluded from the study if they meet any of the following criteria: At Screening patients who utilize, or in the Investigator's judgment will be imminently dependent upon: Non-invasive ventilation > 22 hours per day, or Tracheostomy Note: If the patient requires non-invasive ventilation postrandomisation, they will be allowed to continue in the study. Patients with Familial ALS (e.g., 2 or more family members with ALS or motor neuron disease) Patients with a history of carpal tunnel syndrome, polyneuropathy, or in the investigators judgement diseases that could induce polyneuropathy and interfere with electromyography (EMG) recordings. Patients with too severe atrophy of the Abductor Digiti Minimi (ADM), Abductor Pollicis Brevis (APB), Biceps Brachii (BB), or Tibialis Anterior (TA) muscles in the least clinically affected hand and leg, respectively, to allow for reliable EMG recordings. Patient with a history of significant other major medical conditions based on the Investigator's judgment. Based on the investigator's judgment, patients who may have difficulty complying with the protocol and/or any study procedures. Patient with clinically significant abnormalities in haematology, blood chemistry, ECG, or physical examination not resolved by the Baseline visit which according to Investigator can interfere with study participation. Patients with clinically significant hepatic or renal dysfunction or clinical laboratory findings that would limit the interpretability of change in liver or kidney function, or those with low platelet counts (< 150 x 109 per liter) or eosinophilia (absolute eosinophil count of = 500 eosinophils per microliter) at Screening. Patient participating in any other investigational drug trial or using investigational drug (within 12 weeks prior to screening and thereafter). Females who are pregnant or nursing or who plan to get pregnant during the course of this clinical trial or within 6 months of the end of this trial. Females of child-bearing potential, or men, who are unwilling or unable to use accepted methods of birth control. Active inflammatory condition or autoimmune disorder. Positive screen for drugs of abuse. History of gold allergy. Patient is considered a suicide risk in the opinion of the Investigator, has previously made a suicide attempt, or is currently demonstrating active suicidal ideation. Subjects with intermittent passive suicidal ideation are not necessarily excluded based on the assessment of the Investigator. Following completion of the 36-week randomized placebo controlled treatment period, interested participants will be excluded from participating in the open-label extension phase if they meet any of the following criteria: Lack of treatment compliance during the randomized placebo controlled Treatment Period. Positive pregnancy test at the Week 36 visit, or, females who plan to get pregnant during the course of this extension or within 6 months of the end of this extension. Based on the investigator's judgment, patients who may have difficulty complying with the protocol and/or any study procedures. Patient with clinically significant abnormalities in hematology, blood chemistry, ECG, or physical examination identified during the W36 visit which according to Investigator may interfere with continued participation. Patients with clinically significant hepatic or renal dysfunction or clinical laboratory. findings that would limit the interpretability of change in liver or kidney function, or those with low platelet counts (< 150 x 109 per liter) or eosinophilia (absolute eosinophil count of = 500 eosinophils per microliter) at the Week 36 visit. Patient is considered a suicide risk in the opinion of the Investigator, has previously made a suicide attempt, or is currently demonstrating active suicidal ideation. Subjects with intermittent passive suicidal ideation are not necessarily excluded based on the assessment of the Investigator.",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis,"Able to understand and give written informed consent. Male or female participants aged 18 years or greater (inclusive) at the time of ALS diagnosis. Participants whose conditions are defined as ""definite ALS"" or ""probable ALS"" or ""possible ALS"" diagnostic criteria by the revised El Escorial Criteria as determined by a neurologist specializing in ALS (e.g., the Principal Investigator or subinvestigator at the site). Participant is able to daily consume 60 mL of the investigational drug suspension without substantial dysphagia, OR can intake the drug through a gastrostomy tube. In the judgement of the Investigator, the participant's expected survival is greater than six- months. Participants who have established care with a neurologist at the specialized ALS center involved in the study and will maintain this clinical care throughout the duration of the EAP.",CNMAu8.EAP01 EAP01 NCT04081714 TrialTroveID-356802,Adults; Older Adults,year(s),,356802,Delay Disease Progression,,18.0,"Participant is eligible for a clinical study with CNM-Au8 for the treatment of ALS. Participant with a history of any clinically significant or unstable medical condition based on the Investigator's judgment that may interfere with assessment of the study objectives. Based on the investigator's judgment, participants who may have difficulty complying with the protocol and/or any study procedures. Participant with clinically significant abnormalities in hematology, blood chemistry, ECG, or physical examination not resolved by the Baseline visit which according to Investigator can interfere with EAP participation1. Participants with clinically significant hepatic or renal dysfunction or clinical laboratory findings that would limit the interpretability of change in liver or kidney function, or those with low platelet counts (< 150 x 109 per liter) or eosinophilia (absolute eosinophil count of ≥ 500 eosinophils per microliter) at Screening. Participants with a prior history of, or positive serological assay for the presence of HIV infection, or laboratory evidence of active or chronic infection with hepatitis C (HCV) or hepatitis B (HBV). Note, participants who have been vaccinated for HBV and have detectable HB antibodies are not excluded unless positive for surface antigen (HBsAg). Participant has participated in any other investigational drug trial (within 4-weeks prior to screening or at least five-half lives of the investigational product), unless waived at the discretion of the Sponsor (e.g., for other investigational drug trials with no known interaction with CNM-Au8). Females who are pregnant or nursing or who plan to get pregnant during the course of this clinical trial or within 6 months of the end of this trial. Females of child-bearing potential, or men, who are unwilling or unable to use accepted methods of birth control. History of gold allergy.",Ii,Both
0,Patients diagnosed with Amyotrophic Lateral Sclerosis.,"Able to understand and give written informed consent. Male or female patients aged 35 years or greater (inclusive) and less than 75 years of age at the time of ALS diagnosis. Patients with a confirmed ALS diagnosis: ""definite ALS"" or ""probable ALS"" or ""possible"" diagnostic criteria per the revised El Escorial Criteria as determined by a neurologist subspecializing in ALS (e.g., the Principal Investigator by study site). Stable background therapy (e.g., stable dosing of riluzole within the prior 6-weeks) per Investigator discretion. At the time of Screening disease duration less than or equal to 24-months from symptom onset OR within 12-moths of a confirmed ALS diagnosis. Forced vital capacity (FVC) >/= 60% of predicted value as adjusted for gender, height, and age at the Screening Visit. Patients who are ambulatory (e.g., normal ambulation, early ambulation difficulties, or walks with assistance) on the ALSFRS-R scale.",CNMAu8.203 NCT03843710 REPAIR-ALS TrialTroveID-343595,Adults; Older Adults,year(s),year(s),343595,Delay Disease Progression,75.0,35.0,"At Screening patients who utilize, or in the Investigator's judgment will be imminently dependent upon during the course of this study: Non-invasive ventilation Gastrostomy (e.g., use of percutaneous endoscopic gastrostomy tube) Use of wheel chair Patient who have previously undergone tracheostomy. Patient with a history of significant other major medical condition based on the Investigator's judgment. Based on the investigator's judgment, patients who may have difficulty complying with the protocol and/or study procedures. Patient with clinically significant abnormalities in hematology, blood chemistry, ECG, or physical examination not resolved by the Baseline visit which according to Investigator can interfere with study participation. Patient participating in any other investigational drug trial or using investigational drug (within 12 weeks prior to screening and thereafter) Females who are pregnant or nursing or who plan to get pregnant during the course of this clinical trial or within 6 months of the end of this trial. Positive screen for drugs of abuse or known alcohol abuse. Women of child-bearing potential, or men, who are unwilling or unable to use accepted methods of birth control during the study or for 6 months following completion of study participation. Women with a positive pregnancy test, are lactating, or are planning to become pregnant during the study. Patients with implanted metal objects in their body that may be affected by an MRI procedure. Patients who are claustrophobic or otherwise unlikely to be able to complete the MRI scanning procedures. Patients with a history of gold allergy.",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis (ALS),"Confirmed diagnosis of ALS (Possible, Lab-supported Probable, Probable or Definite El Escorial Criteria) Duration of ALS symptoms < or = 36 months Progressive weakness in upper extremities, with EMG supported evidence of denervation in both upper extremities Forced Vital Capacity > or = 50% of predicted normal in supine Age: 18 years or older Able to provide Informed Consent Be geographically accessible to the study site and able to travel to study site for required visits Have caregiver to assist in the transportation and care required by participation in the study Not taking riluzole and/or edaravone or on a stable dose for > or = 30 day For women of child bearing capacity, negative pregnancy test prior to surgery and willingness to use birth control for the duration of the trial. Medically able to undergo craniotomy as determined by the site PI and/or investigators Medically able to tolerate the immunosuppression regimen as determined by the site PI",NCT05306457 STUDY00000278 TrialTroveID-428784,Adults; Older Adults,year(s),,428784,Unspecified,,18.0,Using invasive ventilatory assistance Diagnosis of another active or unstable medical illness that may interfere with study participation at discretion of PI Presence of any of the following conditions: Current drug or alcohol abuse Any known immunodeficiency syndrome Unstable medical condition Unstable psychiatric illness including psychosis and untreated major depression within 90 days of screening Persons of child bearing capacity not willing to practice birth control Receiving any investigational device/biologic/drug in the past 30 days or any previous exposure to stem cell therapy Any condition in the upper extremities that precludes serial strength or coordination testing Any condition that the investigators feel may pose complications for the surgery Any condition or ALS disease phenotype that the site PI feels may interfere with participation in the study or in the interpretation of study endpoints Allergy to Beta-Lactam antibiotics Donor Specific Antibodies (DSA) > or = 2500MFI or CPRA > or = 20% Contraindications to MRI,I,Both
0,ALS subjects with moderate leg involvement.,"Confirmed diagnosis of ALS (Lab-supported Probable, Probable or Definite EI Escorial Criteria) Duration of symptoms < or = 36 months Progressive weakness in lower extremities, with EMG supported evidence of denervation in both lower extremities. Forced Vital Capacity > 60% of predicted normal in supine. Male/Female; Age: 18 and older Able to provide Informed Consent Be geographically accessible to the study site and able to travel to study site for required visits Have caregiver to assist in the transportation and care required by participation in the study Not taking riluzole or on a stable dose for > or = 30 days For women of child bearing capacity, negative pregnancy test prior to surgery Medically able to undergo thoracolumbar laminectomy or laminoplasty as determined by the site PI and Neurosurgeon Medically able to tolerate the immunosuppression regimen as determined by the site PI",NCT02943850 Pro00042350 TrialTroveID-289249,Adults; Older Adults,year(s),,289249,Delay Disease Progression,,18.0,Using invasive ventilatory assistance Diagnosis of another active or unstable medical illness that may interfere with study participation at discretion of PI Presence of any of the following conditions: Current drug or alcohol abuse Any known immunodeficiency syndrome Unstable medical condition Unstable psychiatric illness including psychosis and untreated major depression within 90 days of screening Persons of child bearing capacity not willing to practice birth control Receiving any investigational device/biologic/drug in past 30 days or any previous exposure to stem cell therapy Any condition in the lower extremities which precludes serial strength testing Any condition that the Neurosurgeon feels may pose complications for the surgery Any condition or ALS disease phenotype that the site PI feels may interfere with participation in the study or in the interpretation of study endpoints,Iii,Both
1,"Patients with Dementia, Alzheimer disease, Vascular dementia, Dementia of Lewy Body, frontotemporal dementia and Mild Cognitive Impairment","Mild and moderate dementia Diagnosis is one of five types of dementia.Alzheimer disease, Vascular dementia, Dementia of Lewy Body, frontotemporal dementia, Mild Cognitive Impairment: (MCI) Clinical Dementia Rating (CDR) is 0.5,1 or 2 (mild-moderate dementia). Mini-Mental State Examination (MMSE) score is between 15 and 28. Treatment has been kept with four drugs, donepezil, galantamine, rivastigmine, memantine and some other drug.5 Agreement with clinical trial is between 50 and 89 years old.6 A declaration of consent shall be valid if drawn up as a document providing sufficient evidence.",jRCTs061180062 TrialTroveID-313732 UMIN000019587,Adults; Older Adults,year(s),year(s),313732,Frontotemporal Dementia; Lewy Body Dementia; Mild; Mild Cognitive Impairment/Dementia Risk; Moderate; Vascular Dementia,89.0,50.0,"Metabolic encephalopathy (hypothyroidism, Vitamin B12 deficiency) Post head trauma Delirium due to any drugs Alcohol abuse Depression under medication Mental disorder treated by antipsychotic drugs Schizophrenia, mania, severe heart failure, and severe liver injury. Chronic renal failure with creatinine clearance less than 20 ml / min. Treated with malignancy Investigator decides inappropriate for enrollment",Iii,Both
0,Patients with Amyotrophic Lateral Sclerosis.,"Eligible subjects had a clinical diagnosis of ALS, a vital capacity (VC) greater than 50% predicted, and symptom onset less than 5 years.",TrialTroveID-079174,,,,79174,Delay Disease Progression,,,,Ii,Both
0,"Patients with definite, probable, or laboratory-supported probable ALS.","Ages Eligible for Study: 21 Years - 85 Years, Genders Eligible for Study: Both Inclusion Criteria: Clinical diagnosis of definite, probable, or laboratory-supported probable ALS. Negative pregnancy test for women of childbearing age and adequate birth control measures. Subjects must be able and willing to give informed consent and must be capable of complying with the trial procedures. FVC > or = 60% of predicted. Age 21 to 85 years, inclusive. Disease duration of less than 5 years. Subjects may take riluzole (without change in dose for more than 30 days before enrollment). Patients who have taken CoQ10 in the past will be eligible if they stop at least 30 days before enrollment. Patients who have taken vitamin E in the past will be eligible if they stop at least 14 days before enrollment.",AAAA1536 NCT00243932 QALS study TrialTroveID-078993,Adults; Older Adults,year(s),year(s),78993,Delay Disease Progression,85.0,21.0,"Exclusion Criteria: Dependency on mechanical ventilation (non-invasive ventilation > 23 hours). Severe and unstable concomitant medical or psychiatric illness. Have insufficiently controlled diabetes mellitus as determined by as a hemoglobin A1c of greater than 10 (Patients on medication for diabetes mellitus that, in the investigator’s opinion, is sufficiently controlled, may participate in the study if they agree to enhanced glucose monitoring and diabetes control through their primary care physician or endocrinologist while taking the study medication.) Be taking warfarin, which interferes with blood clotting (is an ""anticoagulant"") (If patients must begin warfarin therapy during the trial, they may remain on the study medication if the treating physician closely monitors anticoagulation status to assure that adequate and consistent anticoagulation is achieved. Should this not be the case, i.e., should there be concern that the study medication interferes with appropriate anticoagulation, the study medication will be discontinued.) Women who are breast feeding or have a high likelihood of pregnancy. Have significant hepatic (liver) dysfunction (by history, or with serum transaminase levels greater than or equal to three times the upper limit of normal). FVC less than 60%. Exposure to CoQ10 within 30 days of enrollment. Have been exposed to other experimental medications (including minocycline, celecoxib and others at the principal investigator’s discretion) within 30 days of enrollment. (Therapeutic doses of these medications given for indications other than ALS, e.g., celecoxib for osteoarthritis, may be permitted after review by the principal investigator.) Exposure to vitamin E within 14 days of enrollment. Sensitivity to color additive FD&C Yellow No. 5 Sensitivity to aspirin. Exclusion criteria were forced vital capacity (FVC) of less than 60%, severe medical illness, or disease onset more than 5 years before study entry.",Ii,Both
0,,"- patient with consent - patient with following disease: Parkinson's disease, Amyotrophic lateral sclerosis, Glioblastoma, cancer without neurological disease (pulmonary cancer, breast cancer, ovarian cancer, melanoma, thymoma), rheumatoid arthritis.",69HCL22_0275 CTRL COH NCT05370079,Adults; Older Adults,year(s),,431922,,,18.0,- refusal consent - patient with neurological disorder compatible with paraneoplastic neurological syndrome or auto-immune encephalitis - patient under guardianship,Other,Both
0,Patients with Amyotrophic Lateral Sclerosis.,"Ages Eligible for Study: 18 Years to 85 Years, Genders Eligible for Study: Both Inclusion Criteria: Age 18-85 Male or Female Clinically definite or probable ALS by El Escorial criteria ALS-FRS > 25 If on Riluzole they must be on a stable dose for at least 30 days prior to screening Capable of providing informed consent and complying with trial procedures",NCT01259050 TrialTroveID-139279 Zinc-ALS,Adults; Older Adults,year(s),year(s),139279,Delay Disease Progression,85.0,18.0,"Exclusion Criteria: Patients with FVC below 50% History of liver disease Severe renal failure Creatinine greater than or equal to 1.5 mg/dL History of intolerance to zinc or copper Evidence of motor neuron disease for greater than 5 years Any other co-morbid condition which would make completion of the trial unlikely If female, pregnant or breast-feeding; or, if of childbearing age, an unwillingness to use birth control. Any other trial medications. Non-trial medications are not cause for exclusion Patient with history of significant anemia Elevated levels of zinc at baseline Patients with copper levels below normal at baseline",Iii,Both
0,Patients with amyotrophic lateral sclerosis (ALS).,"Ages Eligible for Study: 18 Years to 80 Years; Genders Eligible for Study: Both Inclusion Criteria: Able to provide informed consent. Diagnosis of clinically definite ALS, clinically probable-laboratory supported ALS, clinically probable ALS, or clinically possible ALS based on the revised El Escorial criteria. Patients with ALS < or = 3 years since symptom onset. Symptom onset is defined as date of first muscle weakness or dysarthria. Upright slow vital capacity (SVC)> or = 60% of predicted. If taking riluzole and/or Nuedexta, stable regimen is required for > or = 30 days prior to screening. Medically (either independently or with caregiver assistance) able to comply with study procedures, including subcutaneous (SC) injections of study medication and adherence to concomitant medication restrictions. Patients with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease who have had symptoms for less than 3 years.",NCT01906658 QSC01-ALS-01 TrialTroveID-185472,Adults; Older Adults,year(s),year(s),185472,Unspecified,80.0,18.0,"Exclusion Criteria: Any medical condition known to have an association with motor neuron dysfunction which might confound or obscure the diagnosis of ALS. Tracheostomy, diaphragm pacing, or ongoing need for assisted ventilation of any type (e.g., bilevel positive airway pressure) for treatment of ALS-related respiratory dysfunction (vital capacity of < 60% predicted, nocturnal desaturation, and/or nocturnal hypoventilation). Patients on assisted ventilation for other reasons require approval from the Medical Monitor. (Supplemental oxygen is acceptable). Recorded diagnosis or evidence of major psychiatric disorder. Clinically evident cognitive and/or behavioral impairment that in the opinion of the Investigator would impair the ability of the patient to comply with the study procedures. Therapies and/or Medications: - History of prior sensitivity to Acthar or other porcine protein products. - Chronic systemic corticosteroid use, defined as > 20 mg of prednisone or equivalent systemic corticosteroid taken for more than 4 consecutive weeks within 6 months prior to randomization. Topical, inhaled, or intra-articular corticosteroids are allowed. - Planned treatment with live or live attenuated vaccines once enrolled in the study. Participation in another therapeutic (drug or device) investigational study within 30 days prior to screening. Type 1 or type 2 diabetes mellitus, or patients currently taking hypoglycemic medication. Contraindication per Acthar Prescribing Information, Appendix D Section 4: scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, or adrenal cortical hyperfunction. - For the purposes of this study, osteoporosis is defined as a history of a lumbar spine and/or femoral neck T-score < or = -2.5 on bone densitometry (DXA), OR osteoporosis requiring pharmacologic therapy, OR a history of non-traumatic low impact hip or vertebral fracture, OR patient reported history of osteoporosis. - For the purposes of this study, history of peptic ulcer is defined as < or = 6 months prior to screening. - For the purposes of this study, uncontrolled hypertension is defined as mean systolic blood pressure > or = 140 mmHg and diastolic blood pressure > or = 90 mmHg on > or = 3 seated readings taken at least 5 minutes apart during the screening period. - For the purposes of this study, congestive heart failure is defined as New York Heart Association Functional Class III-IV.",Ii,Both
1,Patients with amyotropic lateral sclerosis (ALS) and symptom onset (defined as first muscle weakness or dysarthria) < or = to two years prior to the screening visit.,"Is 18-75 years of age at Screening Has ALS symptom onset within 2 years prior to Screening Has forced vital capacity (FVC) no higher than 60% at screening If taking riluzole, is on a stable dose for 4 weeks before Screening",MNK14042068 NCT03068754 PENNANT PER-007-18 TrialTroveID-291420,Adults; Older Adults,year(s),year(s),291420,Delay Disease Progression,75.0,18.0,"Has tracheostomy, diaphragm pacing, or an ongoing need for assisted ventilation of any type Has used any medication within a time period not allowed per protocol Has history of Type 1 or Type 2 diabetes mellitus, or any clinically significant infection Used edaravone less than 1 week before Screening Received any stem cell replacement therapy Used steroids within a time period not allowed per protocol",Ii/Iii,Both
0,Patients with Amyotrophic Lateral Sclerosis (ALS).,,TrialTroveID-414519,,,,414519,Delay Disease Progression,,,,Ii,
0,Frontotemporal dementia (FTD) patients,,TrialTroveID-506618,,,,506618,Frontotemporal Dementia,,,,Ii,
0,Patients with amyotrophic lateral sclerosis.,,TrialTroveID-463414,,,,463414,Unspecified,,,,I,
0,Patients with amyotrophic lateral sclerosis (ALS),,TrialTroveID-463412,,,,463412,Unspecified,,,,Iii,
0,Patients (age = 57.7 + or - 11.1 y) with the neurodegenerative disease amyotrophic lateral sclerosis.,,TrialTroveID-079570,Adults; Older Adults,year(s),year(s),79570,Unspecified,69.0,47.0,,Ii,
0,Subjects with amyotrophic lateral sclerosis (ALS).,"Ages Eligible for Study: 18 Years to 80 Years Inclusion Criteria A clinical diagnosis of definite, probably or laboratory supported probably ALS, either sporadic or familial ALS according to a modified El Escorial criteria. Willing and able to give informed consent. FVC greater than or equal to 50% predicted. Evidence of abnormality in upper and/or lower extremity motor function (clinical evidence of muscle atrophy and weakness in an upper and/or lower extremity). The patient should have at least 4 or 8 testable upper extremity muscle groups. Subjects may take riluzole. Riluzole must have been at stable doses for at least thirty days prior to baseline visit. If woman of childbearing age, must be non-lactating and surgically sterile or using an effective method of birth control (double barrier or oral contraceptive) and have a negative pregnancy test. Disease duration less than five years.",M01RR00036 NCRR-M01RR00036-0745 NCT00005674 TrialTroveID-079012,Adults; Older Adults,year(s),year(s),79012,Delay Disease Progression,80.0,18.0,,Ii,Both
0,,Ages Eligible for Study 21 Years to 80 Years Inclusion Criteria Diagnosis of probable or definite ALS. At least 5 of 10 testable upper extremity muscle groups (shoulder and elbow extensors/flexors and grip) of Medical Research Council (MRC) grade 4 or better. At least 5 years from onset of symptoms.,NCT00070993 R01 AT000967-01 R01 AT000967-03 R01-AT000967 R01-AT000967-02 TrialTroveID-078732,Adults; Older Adults,year(s),year(s),78732,Delay Disease Progression,80.0,21.0,Exclusion Criteria Requires tracheostomy ventilation. History of renal disease.,Ii,Both
0,,- ALS - FVC >=50% - Abnormality in upper and/or lower extremity motor function - Not pregnant - Disease duration <5 years,M01RR00109 NCRR-M01RR00109-0750 NCT00005766,Adults; Older Adults,year(s),year(s),224420,,80.0,18.0,,Ii,Both
0,Elderly and patients with Alzheimer's Disease (AD),,TrialTroveID-177421,Older Adults,,,177421,(N/A),,,,I,
0,Young and elderly healthy volunteers.,,TrialTroveID-133804,Older Adults,,,133804,Healthy subjects,,,,I,
0,,,TrialTroveID-359391,,,,359391,Unspecified,,,,Iii,
0,Subjects with Amyotrophic Lateral Sclerosis,"Male or female subjects aged 18-75 years, both inclusive; Must provide written informed consent before any study related procedures; Should be capable to complete all trial related procedures, assessments and visits in the judgement of Investigator; Familial or sporadic ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria; Disease duration from ALS diagnosis < or =24 months; ALSFRS-R total score > or = 36 at screening visit; ALSFRS-R Breathing sub-score should be > or =9 at the time of screening; ALSFRS-R Bulbar sub-score should be > or =9 at the time of screening; Peak inspiratory flow rate (PIFR) > or = 100 L/minute; Forced vital capacity (FVC) >70% of predicted value; Participant must be receiving treatment with stable dose of standard of care treatment for > or =30 days prior to signing informed consent.",AZT-006 NCT04428775 TrialTroveID-376925,Adults; Older Adults,year(s),year(s),376925,Delay Disease Progression,75.0,18.0,"Subjects with bulbar-onset ALS; Any use of non-invasive ventilation (e.g., continuous positive airway pressure, non-invasive bi-level positive airway pressure or non-invasive volume ventilation) for any portion of the day, or mechanical ventilation via tracheostomy, or on any form of oxygen supplementation; Any other significant neurological disorder which can interfere with study assessments, e.g., significant cognitive impairment and/or clinical dementia; Significant psychiatric illness like schizophrenia, bipolar disorder etc. Subjects with depression can be included, only if the depression has been stable and no episode of major depression has occurred in past one year; Severe cardiac disease (e.g.,corrected QT interval > 500ms), Torsade de Pointes, evidence of significant heart failure (New York Heart Association [NYHA] Class 3 or greater, myocardial infarction or unstable angina in the 6 months prior to screening); Any moderate-to-severe pulmonary disease or difficulty taking inhaled drugs; Inability to tolerate the administration of an oral inhaled powder via dry powder inhaler (DPI); Has taken any investigational study drug within 30 days or five half-lives of the drug, whichever is longer, prior to dosing; Currently taking cromolyn, or has taken cromolyn, within the past 12 months; Allergy to cromolyn or cromolyn products, such as Intal®, Nasalcrom®, Opticrom®, Gastrocrom®, etc.; Taking inhaled protein products on a chronic basis (such as insulin, parathyroid hormone [PTH], etc.); Subjects who weigh 88 lb (40 kg) or less, or, body mass index (BMI) of <17.5 or >35.0 at screening; Moderate-to-severe liver disease: aspartate aminotransferase (AST), alanine aminotransferase (ALT), or bilirubin concentrations >3 times the upper limit of normal; patients with hepatic diseases such as hepatic cirrhosis, hepatic cancer and active hepatitis Moderate-to-severe renal disease: creatinine clearance <45 mL/min/1.73 m2 (by Cockcroft-Gault calculation); Any clinically significant disorder or laboratory abnormality that, in the investigator's opinion, could interfere with the subject's participation in the study, place the subject at increased risk, or confound interpretation of the study results; Pregnant or breast-feeding females or sexually active females with childbearing potential, if no adequate contraceptive measures are used.",Ii,Both
0,Subjects With Amyotrophic Lateral Sclerosis/Motor Neuron Disease who Complete Study CMD-2019-001,signed informed consent prior to initiation of any study-specific procedures and treatment documented completion of protocol-specified assessments following completion of 24 weeks treatment on study CMD-2019-001 Investigator considers patient has been tolerating treatment on study CMD-2019-001 and may benefit from continued treatment with CuAT,CMD-2020-001 NCT04313166 TrialTroveID-370043,Adults; Older Adults,year(s),year(s),370043,Delay Disease Progression,75.0,18.0,not dependent on mechanical ventilation,Ii,Both
1,Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease,"signed informed consent familial or sporadic ALS/MNS by Awaji-shima Consensus Recommendations not taking riluzole or on stable dose of riluzole for 4 weeks prior to screening visit no prior exposure to agents other than riluzole for treatment of ALS adequate bone marrow reserve, renal and liver function women of childbearing potential must have a negative pregnancy test and be non-lactating women and men with partners of childbearing potential must take effective contraception while on treatment",CMD-2019-001 NCT04082832 TrialTroveID-356775,Adults; Older Adults,year(s),year(s),356775,Delay Disease Progression,75.0,18.0,"presence of a gastrointestinal disorder (eg, malabsorption) that might jeopardize intestinal absorption of study drug inability to perform seated SVC known immune compromising illness or treatment drug abuse or alcoholism clinically significant or active cardiovascular disease acute or chronic infection diagnosis of malignancy within 2 years prior to screening dementia that may affect patient understanding and/or compliance with study requirements and procedures current use of strong inducers or inhibitors of CYPs 2C19 and 2D6 current us of medications (other than riluzole) that are metabolized predominantly by CYP 1A2",Ii/Iii,Both
0,Patients with amyotrophic lateral sclerosis/motor neuron disease who have successfully completed study CMD-2016-001,"Signed informed consent prior to initiation of any study-specific procedures and treatment Documented completion of protocol-specific assessments following completion of six 28-day treatment cycles in study CMD-2016-001 Principal Investigator considers the patient would benefit from continued treatment with Cu(II)ATSM Not taking riluzole or on the same (or lower) dose used during the CMD-2016-001 study Adequate bone marrow reserve, renal and liver function Women and men with partners of childbearing potential must take effective contraception while on study treatment",CMD-2017-001 NCT03136809 TrialTroveID-300572,Adults; Older Adults,year(s),year(s),300572,Delay Disease Progression,75.0,18.0,"Inability to swallow oral medications or presence of a gastrointestinal disorder (e.g.,malabsorption) deemed to jeopardize intestinal absorption of study drug Dependence on mechanical ventilation (invasive or non-invasive) for any part of day or night, where dependence is defined as being unable to lie flat (supine) without it, unable to sleep without it, or daytime use Dementia that may affect either outcome measures or patient understanding and/or compliance with study requirements and procedures Current use of strong inducers or inhibitors of CYPs 2C19 and 2D6",Iii,Both
0,Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease,"Signed informed consent prior to initiation of any study-specific procedures; Familial or sporadic ALS/MND defined as clinically possible, probable, or definite by Awaji-shima Consensus Recommendations; First ALS/MND symptoms occurred no more than 2 years prior to screening visit; Seated FVC > or = 70% and SNP > or = 50% of predicted value; Not taking riluzole or on a stable dose of riluzole for at least 4 weeks prior to screening visit (participants are not allowed to start taking riluzole during the study); Age between 18 and 75 years at time of informed consent; Patient has a competent caregiver who can and will be responsible for administration of study drug; Adequate bone marrow reserve, renal and liver function: absolute neutrophil count > or =1500/µL lymphocyte count < 48% platelet count > or = 150,000/µL hemoglobin > or = 11 g/dL creatinine clearance > or = 60 mL/min (Cockroft & Gault formula) ALT and/or AST < or = 2 x ULN total bilirubin < or = 1.5 x ULN serum albumin > or = 2.8 g/dL Women and men with partners of childbearing potential must take effective contraception while on study and women of childbearing potential must have a negative pregnancy test and be non-lactating at screening",CMD-2016-001 NCT02870634 TrialTroveID-284623,Adults; Older Adults,year(s),year(s),284623,Delay Disease Progression,75.0,18.0,"Inability to swallow oral medications or presence of GI disorder deemed to jeopardize intestinal absorption of Cu(II)ATSM Dependence of mechanical ventilation (non-invasive or invasive) for any part of day or night Exposure to any other investigational agent within 3 months or two investigational agents within 6 months prior to screening visit Active GI disease (except gastrointestingal reflux disease) within 30 days of screening visit Known immune compromising illness or treatment Presence of any of the following clinical conditions drug abuse or alcoholism unstable cardiac, pulmonary, renal, hepatic, endocrine or hematologic disorder active infectious disease AIDS or AIDS-related complex current malignancy unstable psychiatric illness, defined as psychosis or untreated major depression within 90 days of screening visit neuromuscular disease other than ALS/MND Dementia that may affect either outcome measures or patient understanding and/or compliance with study requirements and procedures Use of anticoagulants at therapeutic doses within 7 days prior to screening visit Current use of strong inducers or inhibitors of CYPs 2C19 and 2D6",I,Both
1,Amyotrophic lateral sclerosis (ALS) patients.,,TrialTroveID-294514,,,,294514,Unspecified,,,,Iv,
0,Patients with Sporadic or familial ALS and healthy volunteers.,"Male or female, aged at least 18 years. Sporadic or familial ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria. Patient is able to understand and express informed consent (in the opinion of the site investigator). Patient has access to the Internet on a desktop computer, laptop, or tablet and has a working email address. Patient or caregiver is willing and able to use a computer and enter data on a secure website. Patient is able to read and write English. Patient is expected to survive for the duration of the trial. Women must not be pregnant (will have evidence of a negative pregnancy test obtained by local physician within past 7 days or be post-menopausal) Women must not be able to become pregnant (e.g., post-menopausal, surgically sterile, or using adequate birth control methods) for the duration of the study and three months after study completion. Adequate contraception includes: abstinence, hormonal contraception (oral contraception, implanted contraception, injected contraception or other hormonal contraception, for example patch or contraceptive ring), intrauterine device (IUD) in place for > or = 3 months, barrier method in conjunction with spermicide, or another adequate method.",NCT04499963 pro00103700 TrialTroveID-381128,Adults; Older Adults,year(s),,381128,Delay Disease Progression; Healthy subjects,,18.0,Patient is taking other experimental treatments for ALS (those that are part of an active research study). Prior side effects from curcumin or turmeric containing products Patient has a medical or psychiatric illness that could in the investigator's opinion interfere with the patient's ability to participate in this study. Pregnant women or women currently breastfeeding. Life expectancy shorter than the duration of the trial. Taking an antiplatelet agent or anticoagulant (due to the theoretically increased risk of bleeding from curcumin products).,Ii,Both
0,,,TrialTroveID-182580,,,,182580,Unspecified,,,,I,
0,Healthy male and female subjects aged 18 to 55 years,,TrialTroveID-486783,Adults,year(s),year(s),486783,(N/A); Healthy subjects,55.0,18.0,,I,Both
0,Patients with lysosomal and peroxisomal inborn errors of metabolism undergoing hematopoietic stem cell transplantation (HCT).,"Inclusion Criteria: - Mucopolysaccharidosis (MPS) Disorders: - MPS IH (Hurler syndrome) - MPS-VI (Maroteaux-Lamy syndrome) - MPS VII (Sly syndrome). - Glycoprotein metabolic disorders: - Alpha mannosidosis - Fucosidosis - Aspartylglucosaminuria - Sphingolipidoses and Recessive Leukodystrophies: Presymptomatic patients with globoid cell leukodystrophy (GLD, also known as Krabbe disease) and metachromatic leukodystrophy (MLD) will be eligible for treatment on this protocol. White matter disease by magnetic resonance imaging (MRI) alone is not an exclusion if the patient is asymptomatic. - Peroxisomal Disorders: Presymptomatic patients with inherited peroxisomal disorders associated with of very long chain fatty acids (VLCFA) elevation, identified by family history or laboratory testing (including neonatal screening), are eligible for this protocol. White matter disease by MRI alone is not an exclusion if the patient is asymptomatic. - Other Inherited Diseases of Metabolism: - Wolman syndrome (acid lipase deficiency) - Niemann-Pick B patients (sphingomyelin deficiency) - Niemann-Pick C subtype 2 - Donor Availability: Patients considered for transplantation must have a sufficient graft as based on current criteria of the University of Minnesota Blood and Marrow Transplantation Program: Priority will be as follows, although in circumstances in which timing is of the essence, cord blood grafts may be chosen over an unrelated graft, despite the priority listed above. - Multidisciplinary Evaluation: Patients will be eligible for transplantation only after they are seen and evaluated by members of the Inherited Metabolic and Storage Disease Program (IMSD) team, and the team has offered transplantation to the patient/family.",0801M25201 0801M25202 MT2008-02 NCT00668564 TrialTroveID-207950,Children; Adults,,year(s),207950,Acid sphingomyelinase deficiency; Adults; Hurler syndrome (MPS 1H); Niemann-Pick Type C; Pediatric; Treatment; Unspecified MLD,21.0,,"Exclusion Criteria: - Symptomatic patients with peroxisomal or lysosomal disorders are excluded but may be considered for other treatment protocols. - Major organ dysfunction. Evidence of major organ impairment, including: - Cardiac: left ventricular ejection fraction <40% - Renal: serum creatinine >2.5 x normal for age - Hepatic: total bilirubin >3 x normal, or Alanine transaminase (ALT) > 3 x normal - Pulmonary: requirement for continuous oxygen supplementation - Pregnancy - Evidence of human immunodeficiency virus (HIV) infection or known HIV positive serology - Patients >21 years of age.",Ii,Both
1,Children and Adults who are undergoing a hematopoietic cell transplant for an inherited metabolic storage disease.,"Inclusion Criteria: - Patients with adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy, Gaucher's disease, Fucosidosis, Wolman disease, Niemann-Pick disease and Batten disease (CLN3) who have a human leukocyte antigen (HLA)-identical or haplotype mismatched (at 1-3 antigens) related marrow, or umbilical cord blood donor. One or two umbilical cord blood (UCB) units may be used. - Patients with GM1 gangliosidosis, Tay Sachs disease or Sandhoff disease who have a HLA-identical or 1 antigen mismatched related or unrelated donor, or suitably matched umbilical cord blood unit(s). One or two UCB units may be used. - Patients with adrenoleukodystrophy must have magnetic resonance imaging (MRI) findings, neurological and neuropsychometric function consistent with the diagnosis, and for boys with parietal-occipital dysmyelination a performance intelligence quotient (IQ) > or = 80. In cases, when the performance IQ is not > or = 80, the protocol committee may recommend transplant if the patient's clinical condition and neuropsychometric status are deemed to be acceptable based upon consideration of such factors as age at onset of cerebral disease, magnitude of change in performance IQ and neurologic deficits. - Patients with arylsulfatase A deficiency (Metachromatic Leukodystrophy) must have either the presymptomatic late infantile, juvenile or adult form of the disease and must have acceptable neurological and neuropsychometric function. - Patients with galactocerebrosidase deficiency (Globoid Cell Leukodystrophy) must have acceptable neurological and neuropsychometric function. - Patients with acid lipase deficiency (Wolman disease) must have a liver biopsy that documents no evidence of hepatic cirrhosis, and acceptable neurological and neuropsychometric function. - Patients with fucosidase deficiency (Fucosidosis) must have acceptable neurological and neuropsychometric function. - Patients with glucocerebrosidase deficiency (Gaucher's Disease) must have acceptable neurologic and neuropsychometric function. - Patients with Batten's disease (CLN3) must have acceptable Neurological and neuropsychometric function. - Absence of major organ dysfunction. Organ evaluation results as follows: - Cardiac: ejection fraction > 30% - Renal: serum creatinine < 2x normal or creatinine clearance 60 mL/min. - Hepatic: total bilirubin < 2x normal and Aspartate aminotransferase (AST) < 2x normal. - Signed consent.",MT1995-01 NCT00176904 TrialTroveID-207956,Children; Adults,,,207956,Adult MLD; GM1 Type Unspecified; Juvenile MLD; Late-infantile MLD (LI-MLD); Late-onset; Pediatric; Sandhoff Disease (HEXB deficiency); Tay-Sachs Disease (HEXA deficiency); Unspecified; Unspecified Niemann-Pick Disease,,,"Exclusion Criteria: - Patients with symptomatic late infantile form of metachromatic leukodystrophy. - Patients with symptomatic infantile globoid leukodystrophy. - Note: Patients with Hurler syndrome, mucopolysaccharidosis (MPS) VI, or Mannosidosis disease are no longer eligible for this protocol, but can be transplanted under protocol MT 9907 (NCT00176917 - Hematopoietic Cell Transplantation for Hurler Syndrome, Maroteaux Lamy Syndrome (MPS VI), and Alpha Mannosidase Deficiency (Mannosidosis)). - Pregnancy. - Evidence of human immunodeficiency virus (HIV) infection or known HIV positive serology. - Patients or parents are psychologically incapable of undergoing bone marrow transplant (BMT) with associated strict isolation or documented history of medical non-compliance. - Patients > or = 50 kg may be at risk for having cell doses below the goal of > or = 10 x 10 ^ 6 CD34 cells/kg and therefore will not be eligible to receive unrelated peripheral blood stem cells (PBSCs).",Ii/Iii,Both
0,Patients With Amyotrophic Lateral Sclerosis,"1. Able to comprehend and willing to sign an Informed Consent Form (ICF). 2. Male or female, ≥ 18 years old and ≤85 years old, at the time of signing the ICF. 3. Confirmed diagnosis of familial or sporadic ALS, defined as meeting the probable, laboratory-supported probable, or definite criteria for a diagnosis of ALS according to the World Federation of Neurology Modified El Escorial criteria (1). 4. ALS duration of less than 36 months from the symptom onset. 5. FVC of ≥ 50 %. 6. Able to swallow tablets without crushing. 7. A female patient is eligible to participate if she is not breastfeeding, has negative pregnancy test at screening, has no intention of becoming pregnant during the course of the study, and agrees to use appropriate contraceptive drugs or devices (as defined in section 3.4 of the study protocol) for the duration of the study. 8. If male and has a partner who may become pregnant, agrees to ensure that he and/or his partner use a reliable form of birth control (as defined in section 3.4 of the study protocol) for the duration of the study and refrain from donating sperm during this period. 9. Participants receiving standard care for ALS prior to entering the trial (i.e. Riluzole, Edaravone, and Albrioza), must be on a stable dosing regimen prior to the randomization and agree to remain on this dosage during the study period: - In the case of taking Riluzole, the patient must have been on a stable dose at least 30 days prior to start date. - In the case of taking Edaravone, the patient must have been on a stable dose at least 30 days prior to start date. - In the case of receiving Albrioza, the patient must have been on a stable dose at least 30 days prior to start date. 10. For participants who consent to the optional biopsy: - Participants with normal platelet or coagulation test values. - Participants who are receiving anticoagulant medications will need to abstain from using anticoagulants for a specific number of days before and after the biopsy, as decided by the study doctor on a case-by-case basis.",ALS-DARI-1 NCT06249867 TrialTroveID-503396,Adults; Older Adults,year(s),year(s),503396,Unspecified,85.0,18.0,"1. Patients with, or at risk for, the following conditions: - Untreated or uncontrolled narrow-angle glaucoma; - Gastric retention - Urinary retention - Liver disease 2. Patients with a known history of severe allergic or anaphylactic reactions to antimuscarinic medications 3. If diagnosed with another neurodegenerative disease (e.g. Multiple Sclerosis, Parkinson, Myasthenia Gravis, and Alzheimer's disease). 4. Subjects with severe hepatic impairment or abnormal liver enzymes, as defined as Child-Pugh B and C scores. 5. Subject has a history of, or positive test result at Screening, for hepatitis C virus antibody. 6. Subjects with acute or prolonged hepatitis B & C. 7. Any medical condition that might interfere with the patient's participation in the trial, poses any added risk for the patient, or confounds the assessment of the patient according to the Investigator's judgement. 8. Subjects with any uncontrolled (unresolved) medical condition other than ALS, as determined by the Investigator. 9. Subjects who are currently enrolled in another clinical trial and receiving an Investigational Product (IP) (including but not limited to stem cell therapy or gene therapy). 10. Treatment with an investigational drug within 1 month or within a time period equal to 5 half-lives (if known) whichever is longer, of starting study treatment. 11. Patients with prior darifenacin treatment. 12. History of drug and/or alcohol abuse (according to Diagnostic and Statistical Manual of Mental Disorders) prior to the screening as determined by the Investigator. 13. If female, subjects who are pregnant, breastfeeding, or intending to conceive during the course of the study. 14. Subjects with an abnormal electrocardiogram (ECG) at screening (any abnormality that the PI believes that entering the study place the participant at risk). 15. Subjects who are receiving strong CYP3A4 inducers such as carbamazepine (anticonvulsant), phenytoin (anticonvulsant), rifampin (antibiotic), and modafinil (wakefulness-promoting agent). 16. Subjects who are receiving potent CYP3A4 inhibitors such as clarithromycin (macrolide antibiotic), ketoconazole and itraconazole (antifungal medications), nefazadone (antidepressant), nelfinavir and ritonavir (protease inhibitors). 17. Subjects who are receiving or received within 30 days prior to the starting of the trial CYP2D6 substrates with a narrow therapeutic window such as include flecainide (Class IC anti-arrhythmic), thioridazine (antipsychotic) and tricyclic antidepressants. 18. Subjects who are receiving or received botulinum injections in the past 6 months. 19. Subjects who are receiving or received within 30 days prior to the starting of the trial antimuscarinic medications for the treatment of overactive bladder such as fesoterodine, oxybutynin, solifenacin, tolterodine, and trospium. 20. Only for patients that consented to the Optional Needle Muscle Biopsy procedures. 21. Subject is taking an anticoagulant (with the exception of aspirin at the investigator's discretion) or is at risk of increased or uncontrolled muscle biopsy-related bleeding. 22. Subjects with bleeding risk factors which include, but are not limited to, anatomical factors at or near the muscle biopsy site (e.g., vascular abnormalities, neoplasms, or other abnormalities) or abnormal platelet or coagulation test values at visit 1.",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis,"Subjects must meet all of the following inclusion criteria to be eligible to participate in this study: Age 18 years or older at the time of the screening visit. Able to provide informed consent and comply with study procedures. ALS diagnosed as probable, laboratory-supported probable or definite according to the World Federation of Neurology El Escorial revised criteria as determined by a neurologist with neuromuscular subspecialty training. A ratio of HERV-K:RPP greater than or equal to 13 measured by quantitative PCR at the screening visit. Duration of disease less than 2 years, or if greater than 2 years, disease progression at a rate that in the judgement of the investigator would allow for completion of the study. If taking riluzole or edaravone, must be on a stable dose for at least 30 days prior to the screening visit, or stopped taking riluzole or edaravone at least 30 days prior to the screening visit. Subject has a competent caregiver who can and will be responsible for administering study drug. If there is no caregiver, another qualified individual must be available to do this. Subject has established care with a neurologist and will maintain this clinical care throughout the study. Subject has had neuroimaging within the last 24 months for participants enrolling at the NIH Clinical Center.",15-N-0126 150126 NCT02437110 TrialTroveID-257041,Adults; Older Adults,year(s),,257041,Symptom relief,,18.0,"A participant will be excluded if he or she has any of the following: Dependence on daytime mechanical ventilation (invasive or non-invasive, including Continuous Positive Airway Pressure (CPAP) or Bilevel Positive Airway Pressure (BiPap) at the time of the screening visit. Participation in any other investigational drug trial or using investigational drug (within 4 weeks prior to the Day 0 visit and thereafter). History of severe sulfonamide allergy (i.e. anaphylaxis). History of positive test or positive result at screening for HIV or HTLV-1. Participants must not be able to become pregnant (e.g., post-menopausal for at least one year, surgically sterile, or using adequate methods of contraception) or breastfeed for the duration of the study. Adequate methods of contraception include: implanted contraception, intrauterine device in place for at least 3 months, or barrier method in conjunction with spermicide. Participants of childbearing potential must have a negative pregnancy test at screening and be non-lactating. Presence of any of the following clinical conditions at the time of screening: Drug abuse or alcoholism Unstable medical disease (such as unstable angina or chronic obstructive pulmonary disease), or active infectious disease (such as Hepatitis C or tuberculosis), or current malignancy Unstable psychiatric illness defined as psychosis or untreated major depression within 90 days of the screening visit Dementia Diabetes mellitus Hemophilia Use of contraindicated medications: amiodarone, dronedarone, lovastatin, simvastatin, rifampin, rifapentine, rifabutin, cisapride, pimozide, midazolam, triazolam, dihydroergotamine, ergonovine, ergotamine, methylergonovine, St. John s wort, alfuzosin, salmeterol, sildenafil for pulmonary arterial hypertension, oxcarbazepine, phenobarbital, phenytoin or dofetilide. Safety Laboratory Criteria at the screening visit: Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3.0 times the upper limit of normal Serum creatinine, serum phosphorous, total bilirubin, triglycerides, amylase, or lipase greater than 2.0 times the upper limit of normal Estimated glomerular filtration rate <60mg/dl. Platelet concentration of <100,000/ (micro)l. PT and PTT >1.2 times the upper limit of normal for participants enrolling at the NIH Clinical Center. Hemoglobin <10mg/dL. Positive Hepatitis B Surface Antigen and Hepatitis C Virus Antigen",I,Both
0,Subjects with amyotrophic lateral sclerosis,"1. Patients diagnosed with amyotrophic lateral sclerosis (ALS) after medication; 2. The modified amyotrophic Lateral Sclerosis Function Scale score (ALSFRS-R) was > or =2 points for each item (including dyspnea and upright breathing) Aspiration and respiratory dysfunction must all be 4 points); 3. The percentage of forced vital capacity to the estimated value (FVC%) > or = 60%; 4. The course of the disease is 2 years or less (from the first appearance of any symptoms of ALS); 5. Age 45-70 years old (including 45 and 70 years old), gender is not limited; 6. Voluntarily participate in this clinical trial, give informed consent and sign informed consent",ChiCTR2300074923 TrialTroveID-482403,Adults; Older Adults,year(s),year(s),482403,Unspecified,70.0,45.0,"1. Those diagnosed with familial ALS (based on family history); 2. Those with obvious cognitive impairment (MMSE scale: illiterate group < or = 19 points, primary school group, < or = 22 points, junior high school and above group (greater than 8 years of education) < or = 26 points); 3. Significant dysphagia; 4. Severe renal insufficiency: creatinine clearance < 30 mL/min (Cockcroft-Gault formula), or other known Severe renal insufficiency; 5. Severe liver function damage: ALT, AST > 3 times the upper limit of normal value, or other known liver diseases such as acute and chronic activity Hepatitis, cirrhosis, etc.; 6. During the screening period, patients with acute myocardial infarction or interventional therapy within the last 6 months and heart failure (according to the NYHA classification as Grade III-IV patients); 7. Complicated with malignant tumors, serious diseases of blood, digestion or other systems; 8. Allergies; 9. Pregnancy and lactation; 10. Within 30 days prior to screening 11. Other situations deemed unsuitable for inclusion by researchers.",Ii,Both
0,"Patients with a tauopathy (frontotemporal lobar degeneration [FTLD] with predicted tau pathology, corticobasal degeneration syndrome [CBS] or progressive supranuclear palsy [PSP])","A probable tauopathy defined as: Probable or possible progressive supranuclear palsy (PSP) defined as: at least a 12-month history of: postural instability or falls during the first 3 years that symptoms are present and prominent decreased saccade velocity or supranuclear ophthalmoplegia; age at symptom onset > or = 40 years by history; and an akinetic-rigid syndrome with prominent axial rigidity. OR, Progressive nonfluent aphasia (PNFA)defined as: at least a 6-month history of difficulty with expressive speech characterized by at least 3 of the following: apraxia of speech, speech hesitancy, labored speech, word finding difficulty, or agrammatism; and the symptoms above are the subject's principal neurological deficit and the symptoms constituted the initial clinical presentation. OR, Corticobasal Degeneration syndrome (CBS) defined as: at least a 6-month history of progressive cortical dysfunction evidenced by at least one of the following: ideomotor apraxia, alien limb phenomenon, cortical sensory loss, focal or asymmetric myoclonus, or apraxia of speech /nonfluent aphasia; and at least a 6-month history of progressive extrapyramidal dysfunction evidenced by at least one of the following: focal or asymmetrical rigidity (limb or axial) or asymmetrical dystonia (limb or axial); and lacking prominent and sustained L-dopa response. OR Frontotemporal Dementia with Parkinsonism linked to Chromosome 17 (FTDP-17): Motor, cognitive or behavioral dysfunction, as defined below associated with a previously demonstrated mutation of the MAPT gene, and meets criteria for PNFA, CBS or PSP as defined above, or CDR-FTLD = 1.0. Documented age 40-85 years at the time of the onset of symptoms associated with the neurological deficits described in inclusion criterion 1. Judged by investigator to be able to comply with neuropsychological evaluation at baseline. Must have reliable caregiver accompany subject to all study visits. Caregiver must read, understand and speak local language fluently in order to ensure comprehension of informed consent form and informant-based assessments of subject. Caregiver must also have frequent contact with subject (at least 3 times per week for one hour) and be willing to monitor study medication compliance and the subject's health and concomitant medications throughout the study. FTLD Modified Hachinski score < or = 3.(Knopman et al., 2008) This modified Hachinski will not include the focal neurological signs, symptoms or pseudobulbar affect questions, given the prominence of all three in CBS/PSP. MMSE > or = 15 at Visit 1. Written informed consent provided by both subject and caregiver who are both fluent English speakers. Subject resides outside a skilled nursing facility or dementia care facility. Residence in an assisted living facility is allowed. If the subject is receiving levodopa/carbidopa, a dopamine agonist, COMT inhibitor or other Parkinson's medication the dose must have been stable for at least 120 days prior to Visit 1 and must remain stable for the duration of the study. Able to tolerate MRI scan during screening without use of sedation. Able to ambulate with or without assistance.",AL-108 NAP Pilot NCT01056965 TrialTroveID-242433,Adults; Older Adults,year(s),year(s),242433,Frontotemporal Dementia; Unspecified PSP,85.0,40.0,"Insufficient fluency in local language to complete neuropsychological and functional assessments. A diagnosis of Amyotrophic Lateral Sclerosis or other motor neuron disease. Any of the following: Abrupt onset of symptoms defined in inclusion criteria 1 associated with ictal events, Head trauma related to onset of symptoms defined in inclusion criteria 1, Severe amnesia within 6 months of the symptoms defined in inclusion criteria 1, Cerebellar ataxia, Choreoathetosis, Early, symptomatic autonomic dysfunction, or Tremor at rest. History of other significant neurological or psychiatric disorders including, but not limited to, Alzheimer's disease, dementia with Lewy bodies, Prion disease, stroke, Parkinson's disease, any psychotic disorder, severe bipolar or unipolar depression, seizure disorder, tumor or other space-occupying lesion, or head injury with loss of consciousness within past 20 years temporally related to onset of symptoms. Within 4 weeks of screening or during the course of the study, concurrent treatment with memantine (stable dose memantine, greater than 6 months is allowed), acetylcholinesterase inhibitors, antipsychotic agents or mood stabilizers (valproate, lithium, etc.) or benzodiazepines (other than temazepam or zolpidem). Treatment with lithium, methylene blue, tramiprosate, ketone bodies, Dimebon or any putative disease-modifying agent directed at tau within 90 days of screening. A history of alcohol or substance abuse within 1 year prior to screening and deemed to be clinically significant by the site investigator. Any malignancy (other than non-metastatic basal cell carcinoma of the skin) within 5 years of Visit 1 or current clinically significant hematological, endocrine, cardiovascular, renal, hepatic, gastrointestinal, or neurological disease. For the non-cancer conditions, if the condition has been stable for at least the past year and is judged by the site investigator not to interfere with the patient's participation in the study, the patient may be included. Clinically significant lab abnormalities at screening, including creatinine > or = 2.5 mg/dL, vitamin B12 below laboratory normal reference range, or TSH above laboratory normal reference range. Systolic blood pressure greater than 180 or less than 90 mm Hg. Diastolic blood pressure greater than 105 or less than 50 mm Hg. ECG abnormal at screening and judged to be clinically significant by the site investigator. Treatment with any investigational drugs or device or participation in an investigational drug study within 60 days of screening. Known history of serum or plasma progranulin level < 110.9 ng/mL. Known presence of known disease-associated mutation in TDP-43, PGRN, CHMPB2 or VCP genes or any other FTLD causative genes not associated with underlying tau pathology (eg. Chr. 9 associated FTD). History of deep brain stimulator surgery other than sham surgery for DBS clinical trial. History of early, prominent REM behavior disorder. Women of childbearing potential who are not using at least two forms of medically recognized contraception. An employee or relative of an employee of Allon Therapeutics Significant anatomical nasal abnormality (e.g., septal deviation obstructing airflow to at least one nostril or septal perforation) or history of nasal turbinate surgery. History of a clinically significant medical condition that that would interfere with the subject's ability to comply with study instructions, would place the subject at increased risk, or might confound the interpretation of the study results. Contraindication to MRI examination for any reason (eg., severe claustrophobia, ferromagnetic metal in body, etc.). Structural abnormality on MRI within 2 years of baseline that precludes diagnosis of PSP, CBS or PNFA, such as cortical infarct in brain region that might account for subject's symptoms. In subjects receiving anti-Parkinson's Disease medication at the time of screening, in the opinion of the investigator substantial worsening of motor signs or symptoms compared to normal functioning following overnight withdrawal of the anti-Parkinson medication. Subject not willing to attempt LP.",I,Both
0,Patients with Amyotrophic Lateral Sclerosis,"Male and female patients ≥18 years of age with Sporadic or familial ALS If taking riluzole, edaravone, and/or sodium phenylbutyrate and taurursodiol, must be on a stable dose prior to Screening.",CORT113176-652 DAZALS EudraCT Number: 2021-005611-31 NCT05407324 NL80995.041.22 TrialTroveID-434057,Adults; Older Adults,year(s),,434057,Delay Disease Progression; Symptom relief,,18.0,"History of a clinically significant non-ALS neurologic disorder Inability to swallow capsules. Human immunodeficiency virus (HIV) or current chronic/active infection with hepatitis C virus or hepatitis B virus Women who are pregnant, planning to become pregnant, or are breastfeeding. Use of non-invasive ventilation (NIV) or mechanical ventilation via tracheostomy, or on any form of oxygen supplementation. Current or anticipated need of a diaphragm pacing system (DPS). Currently using glucocorticoids or have a history of regular systemic glucocorticoid use within the last 12 months. Previous exposure or treatment with glucocorticoid receptor modulators or antagonists.",Ii,Both
0,Healthy subjects,"Participant inclusion criteria 1. Healthy male subjects or non-pregnant, non-lactating healthy female subjects of non-childbearing potential (women of non-childbearing potential, as defined in the clinical protocol) 2. Age 18 to 60 years at the time of signing informed consent 3. Body mass index of 18.0 to 30.0 kg/m² as measured at screening 4. Weight of =102 kg at screening 5. Must be willing and able to communicate and participate in the whole study 6. Must provide written informed consent 7. Must agree to adhere to the contraception requirements defined in the clinical protocol",CORT113176-654 EudraCT Number: 2022-000181-18 IRAS 1005009 ISRCTN52169163 QSC207407 TrialTroveID-431662,Adults,year(s),year(s),431662,Healthy subjects,60.0,18.0,"Participant exclusion criteria 1. Subjects who have received any investigational medicinal product (IMP) in a clinical research study within the 90 days before the first dose in this study, or less than 5 elimination half-lives prior to the first dose, whichever is longer 2. Subjects who are, or are immediate family members of, a study site or Sponsor employee 3. Subjects who have previously been administered IMP in this study. 4. Evidence of current SARS-CoV-2 infection or required to self-isolate in accordance with current government guidelines 5. History of any drug or alcohol abuse in the past 2 years 6. Regular alcohol consumption in male subjects >21 units per week and female subjects >14 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 ml glass of wine, depending on type) 7. A confirmed positive alcohol breath test at screening or admission 8. Current smokers and those who have smoked within the last 6 months before the first dose in this study. A confirmed breath carbon monoxide (CO) reading of greater than 10 ppm at screening or admission 9. Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 6 months before the first dose in this study 10. Female subjects of childbearing potential including those who are pregnant or lactating (all female subjects must have a negative pregnancy test at screening and admission). A woman is considered of childbearing potential unless she is permanently sterile (hysterectomy, bilateral salpingectomy and/or bilateral oophorectomy) or is postmenopausal (had no menses for 12 months without an alternative medical cause and a serum follicle-stimulating hormone concentration =40 IU/L). 11. Male subjects with pregnant or lactating partners 12. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the Investigator or delegate at screening 13. Clinically significant abnormal clinical chemistry, haematology or urinalysis as judged by the Investigator. Subjects with Gilbert’s syndrome are allowed 14. Confirmed positive drugs of abuse test result 15. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results 16. Subject has active renal and/or hepatic disease, as evidenced by: 16.1. An estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m² using Modification of Diet in Renal Disease (MDRD) equation at screening 16.2. ALT and/or AST >1.5 times the upper limit of normal at screening or on admission 16.3. Subjects with borderline results can have these tests repeated once 17. History of clinically significant cardiovascular, renal, hepatic, endocrine, metabolic, respiratory, gastrointestinal (GI), neurological or psychiatric disorder, as judged by the Investigator 18. Subject had any form of cancer within the 5 years before the first dose in this study, with the exception of basal cell and/or squamous cell cancer of the skin that has been treated completely and is without evidence of local recurrence or metastasis 19. Subject has a history and/or symptoms of adrenal insufficiency 20. Subject has a history of clinically significant GI disease including gastroesophageal reflux disease, malabsorption syndrome, colon cancer, chronic colitis, Crohn’s disease, inflammatory bowel disease, gastroparesis, cholecystectomy, constipation, chronic diarrhoea, obstruction, GI bleeding, and/or peptic ulcers 21. Subject has a condition that could be aggravated by glucocorticoid antagonism (e.g., asthma, any chronic inflammatory condition). Subjects with inactive seasonal hay fever may be included. Subjects with childhood (aged less than 18 years) asthma may be included provided they have had no symptoms and required no treatment for at least 5 years 22. Subjects with a QTcF interval of >450 msec at screening or baseline (before the first dose of study medication), based on the mean of three ECGs 23. History of additional risk factors for torsades de pointes (e.g., heart failure, hypokalaemia, family history of long QT syndrome) 24. Supine heart rate (HR) at rest of <40 bpm or >100 bpm. Blood pressure (BP) outside the following ranges: diastolic BP 40-90 mmHg; systolic BP 90-140 mmHg (subjects aged 18-45 years) and 90-160 mmHg (subjects aged >45 years). Heart rate and BP can be retested twice in the supine position at intervals of 5 min on a given day at screening and admission. 25. Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients 26. Donation or loss of greater than 400 ml of blood or plasma within the previous 3 months",I,Both
0,Healthy male participants,"Body mass index (BMI) of 18.0 to 30.0 kg/m^2, inclusive Body weight < or = 100 kg. Must agree to adhere to the requirements on contraception, exposure to sexual partners, and sperm donation as defined in the protocol Additional criteria apply.",CORT113176-653 EudraCT Number: 2021-002456-36 NCT04994743 TrialTroveID-410677,Adults,year(s),year(s),410677,Healthy subjects,65.0,18.0,"Received any investigational drug in a clinical research study within the last 90 days History of alcohol abuse or drug addiction (including soft drugs like cannabis products) within past 5 years. Regular alcohol consumption Positive drug, nicotine (cotinine), or alcohol screen Current smokers, user of e-cigarettes and nicotine replacement products and those who have used these products within the last 3 months Have a pregnant partner Clinically significant abnormal clinical chemistry, hematology (including coagulation), or urinalysis Positive hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody or human immunodeficiency virus (HIV) results Positive nasopharyngeal polymerase chain reaction (PCR) test for severe acute respiratory syndrome Covid Virus-2 (SARS-CoV-2) on Day -1 or within 8 weeks prior to screening. Contact with COVID-19 positive (or suspected) persons within 14 days prior to first dose Active renal and/or hepatic disease History of clinically significant cardiovascular, renal, hepatic, endocrine, metabolic, respiratory, gastrointestinal (GI), neurological, or psychiatric disorder Abnormalities in brain and lumbar spine, or other medical or surgical conditions or clinically significant abnormal findings, for which lumbar puncture is contraindicated History of clinically significant back pain, back pathology and/or back injury History of significant active bleeding or coagulation disorder or have taken non-steroidal anti-inflammatory drugs or other drugs that affect coagulation or platelet function within 14 days prior to lumbar puncture Allergy to lidocaine (Xylocaine®) or its derivatives Any form of cancer within the 5 years (exceptions apply) History and/or symptoms of adrenal insufficiency Have a condition that could be aggravated by glucocorticoid antagonism Donation or loss of greater than 400 mL of blood within the previous 3 months Currently using glucocorticoids or have a history of systemic glucocorticoid use at any dose within the last 12 months or 3 months for inhaled products Additional criteria apply.",I,Male
0,Healthy Subjects,"Body mass index 18.0 to 30.0 kg/m^2, inclusive Willing and able to participate in the whole study Have regular bowel movements (i.e., average stool production of > or =1 and < or =3 stools per day) Provide written informed consent Adhere to the contraception requirements",CORT113176-651 EudraCT Number: 2021-002544-78 NCT04990310 TrialTroveID-410425,Adults,year(s),year(s),410425,Healthy subjects,65.0,30.0,"Have received any investigational medicine in a clinical research study within 90 days Are, or are immediate family members of, a study site or sponsor employee Evidence of current severe acute respiratory syndrome (SARS-CoV-2) infection History of any drug or alcohol abuse, or regularly consume >21 units alcohol per week Current smoker or user of e-cigarettes and nicotine replacement products within the last 6 months Have pregnant or lactating partners Radiation exposure, exceeding 5 milliSieverts (mSv) in the last 12 months or 10 mSv in the last 5 years Clinically significant abnormal results of clinical chemistry, hematology or urinalysis as judged by the investigator Confirmed positive drugs of abuse test result Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) antibody results Active renal and/or hepatic disease History of clinically significant cardiovascular, renal, hepatic, dermatological, chronic respiratory or gastrointestinal (GI) disease, neurological or psychiatric disorder Any form of cancer within the last 5 years (exceptions apply) History and/or symptoms of adrenal insufficiency Condition that could be aggravated by glucocorticoid antagonism or activation Donation of blood or plasma or loss of greater than 400 mL of blood within the previous 3 months Are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies (other than up to 4 g of paracetamol per day) within 14 days. COVID-19 vaccines are accepted concomitant medications. Exceptions may apply on a case by case basis. Currently using glucocorticoids or have a history of systemic glucocorticoid use at any dose within the last 12 months or 3 months for inhaled products Additional criteria apply.",I,Male
0,Healthy Volunteers,"Body mass index (BMI) 18.0 to 30.0 kg/m^2, inclusive Body weight < or =102 kg Willing to consume a high-fat breakfast, including pork Agrees to adhere to the contraception requirements of the protocol Additional criteria apply.",271965 CORT113176-650 EudraCT Number: 2019-004258-27 NCT04249323 TrialTroveID-366565,Adults,year(s),year(s),366565,Healthy subjects,60.0,18.0,"Received any investigational drug or device in a clinical research study within the last 90 days History of any drug or alcohol abuse in the last 2 years; a confirmed positive drugs of abuse test result Regular alcohol consumption; a confirmed positive alcohol breath test at screening Current smoker; a confirmed positive breath carbon monoxide reading; current user of e-cigarettes or nicotine replacement products in the last 6 months Female of childbearing potential, pregnant or breastfeeding Have a pregnant partner Clinically significant abnormal clinical chemistry, hematology, or urinalysis result Positive for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), or human immunodeficiency virus (HIV) Active renal or hepatic disease History of clinically significant cardiovascular, renal, hepatic, endocrine, metabolic, respiratory, gastrointestinal, neurological, or psychiatric disorder Any form of cancer in the last 5 years (exceptions apply) History of adrenal insufficiency Have a condition that could be aggravated by glucocorticoid and/or mineralocorticoid blockade Currently using glucocorticoids or a history of systemic glucocorticoid use in the last 12 months or 3 months for inhaled products Additional criteria apply.",I,Both
1,Patients with ALS.,"Participants earlier in the course of their disease, having the onset of ALS symptoms, including limb weakness, within the prior 24 months, all ALSFRS-R items 2 at Screening, and upright slow vital capacity >=65% of predicted for gender, height and age.",Study BCT-006-US TrialTroveID-493193,,,,493193,Unspecified,,,,Iii,
1,Patients with amyotrophic lateral sclerosis (ALS) who completed the Company's recently concluded pivotal Phase 3 clinical trial and meet specific eligibility requirements.,"1. Participation in the BCT-002-US study, successful completion of all scheduled treatments and follow-up assessments. 2 Able to provide to the Investigator written informed consent regarding the investigational drug, or, as applicable, on whose behalf a legally authorized representative of the participant has provided such consent. 3. Able to safely undergo a bone marrow aspiration.",BCT-003-US NCT04681118 TrialTroveID-391780,Adults,year(s),year(s),391780,Delay Disease Progression,63.0,18.0,"Inability to lie flat for the duration of intrathecal cell transplantation and/or bone marrow biopsy, or inability to tolerate treatment procedures for any other reason (lying flat with BiPAP or NIV are not exclusionary). History of clinically significant autoimmune disease (excluding thyroid disease) myelodysplastic or myeloproliferative disorder, leukemia or lymphoma, whole body irradiation, hip fracture, or severe scoliosis. Any unstable clinically significant medical condition other than ALS (e.g., within six months of baseline, had myocardial infarction, angina pectoris, and/or congestive heart failure), treatment with anticoagulants that, in the opinion of the Investigator, would compromise the safety of the participant. Any history of malignancy within the previous 5 years, with the exception of non- melanoma localized skin cancers (with no evidence of metastasis, significant invasion, or re-occurrence within three years of baseline). Current use of immunosuppressant medication or use of such medication within 4 weeks of the pre-treatment visit. Any history of acquired or inherited immune deficiency syndrome. Tracheostomy and/or mechanical ventilation. Feeding tube use, BiPAP or NIV are not exclusionary. Pregnant women or women currently breastfeeding or unwilling to use effective birth control methods during the treatment (if of childbearing age). Positive test result for Hepatitis B virus (HBV; surface antigen (HBsAg) and IgM antibodies to core antigen (IgM anti-HBc)), Hepatitis C virus (HCV), Human Immune deficiency virus (HIV) 1 and 2.",Iii,Both
0,Patients with Early Amyotrophic Lateral Sclerosis.,"Amyotrophic lateral sclerosis defined in accordance to the El Escorial criteria (possible, probable or defined) 18 to 85 years old patient, male or female Patient with social security cover",2012_69 EudraCT Number: 2013-001228-21 FAIR-ALS NCT02164253 SAFE-FAIR-ALS SAFEFAIRALS TrialTroveID-211006,Adults; Older Adults,year(s),year(s),211006,Delay Disease Progression,85.0,18.0,Achieved respiratory defined by a FVC <70% Evolution of more than 24 months Demented subject Severe malnutrition Patients with treatment potentially at risk of agranulocytosis and neutropenia Patients with a history of agranulocytosis or iatrogenic under haematological disease Incapable of giving consent Indication against MRI Indication against lumbar puncture Patient refused lumbar puncture Hypersensitivity to iron chelators Concomitant treatment with antacids containing aluminum Presence of another serious illness to life-threatening or disabling cons to the use of the treatment mixture of oxygen and nitrous oxide equally,Ii,Both
1,Patients with amyotrophic lateral sclerosis.,"Categorized as; possible, laboratory supported probable, probable, or definite ALS (revised El Escorial criteria) Spinal and bulbar forms of ALS Duration of the disease of less than 18 months since the first symptoms of motor deficit or amyotrophy (isolated cramps or fasciculation will not be considered). Duration of the disease of less than 6 months since the diagnosis An upright slow vital capacity > or = 75% of the predicted value for age, height, and sex or at least one test on inspiratory pressure > or = 60% of the predicted value for age, height, and sex which could be either maximal inspiratory pressure or a SNIFF test. (The best predictive test is sniff test but sometime patients are not able to do it.) (In case of a limit abnormal value for one of them, it will be recommended that patient re-assessment occurs three months later). A mild functional handicap score for ALSFRS-R > or = 36 An upright slow vital capacity > 70% of the predicted value for age, height, and sex Able to swallow (required for oral treatment) Patients weight included between 40 kg and 130 kg If the patient is under riluzole, it has to be for at least 1 month before inclusion with stable dose (to rule out the principal risk of hepatitis)",2016_76 EudraCT Number: 2017-003763-35 FAIR-ALS II NCT03293069 TrialTroveID-309968,Adults; Older Adults,year(s),year(s),309968,Delay Disease Progression,75.0,18.0,"Patients with high frequency of comorbidity or vital risks that may reasonably impair life expectancy Progressing axis I psychiatric disorders (psychosis, hallucinations, substance addiction, bipolar disorder, severe depression, suicidal ideation), in accordance with the Diagnostic and Statistical Manual of Mental Disorders. Before entry into the study, exclusion or stabilization of conditions must occur for patients suffering from mild or moderate depressive episodes (not in remission) or severe and uncontrolled anxiety. Dementia according to the Diagnostic and Statistical Manual of Mental Disorders Exposure to any other experimental drug up to 30 days before day 1 Due to the risk of agranulocytosis (estimated at 2%) caused by the Investigational Medicinal Products (IMPs) and the unknown mechanism by which this agranulocytosis is induced, combining Deferiprone with other medicinal products known to cause agranulocytosis (as described in the IB) will not be allowed. Such medicinal products include clozapine as well as some NSAIDs (e.g. Phenylbutazone or Metamizole), antithyroid agents, sulfonamide antibiotics or methotrexate. A history of relapsing neutropenia Patients with agranulocytosis or with a history of agranulocytosis. Hypersensitivity to Deferiprone Patients with anaemia (regardless of latter aetiology) or a history of another haematological disease. Haemochromatosis is not an exclusion criterion if controlled. Pregnant or breastfeeding women or women of childbearing potential not taking highly effective contraception. Kidney or liver failure. Inability to provide informed consent. Participation in another clinical trial within 1 month prior to inclusion in the study Patients under trusteeship",Ii/Iii,Both
0,,- Parkinson's disease according to Movement Disorders Society criteria - Amyotrophic Lateral Sclerosis according to El escorial criteria - Age and sex matched healthy controls,2010_29 2010-A01216-33 LymphoEnergy NCT02880033,Adults; Older Adults,year(s),year(s),285271,,80.0,18.0,"- Severe comorbidities (cancer, other degenerative diseases, hemopathy, inflammatory diseases)",(N/A),Both
0,Subjects with Amyotrophic lateral sclerosis,"1. Male or female subject with age 20 years to 75 years at the time of signed consent 2. Patients who are defined as ""definite ALS,"" ""probable ALS"" or ""probable-laboratory-supported ALS,"" met diagnostic criteria revised EL Escorial for Airlie House. 3. ALS-FRS > 20 4. Patients who can eat a meal, excrete, or move with oneself alone, and do not need assistance in everyday life. 5. Patients of less than 3 years after the onset of ALS. 6. Subject has an identified, reliable, study partner (e.g., caregiver, family member, social worker, or friend) 7. If patients are duly capable of study consent but are unable to sign by themselves due to aggravation of disease condition, written informed consent can be obtained from a legally authorized representative who can sign on behalf of the patients after confirming the patients' agreement to study participation",EudraCT Number: 2020-003962-38 NCT04762589 NL75564.041.20 RT001-014 TrialTroveID-396647,Adults; Older Adults,year(s),year(s),396647,Delay Disease Progression,75.0,20.0,"1. Received treatment with other experimental therapies within the last 30 days prior to the first dose 2. Previously received treatment with RT001 3. Refusal to discontinue fish oils or other oil-based supplements for the duration of the study (Screening till last study procedure completed) 4. SVC < 70 at screening 5. Subject has a feeding tube or the need for a feeding tube is anticipated within the first 6 months after enrollment. 6. Subject resides at a skilled nursing or dementia care facility, or admission to such a facility is planned during the study period 7. Evidence of any clinically significant neurological disorder other than ALS 8. The subject has a history of or currently has schizophrenia, schizoaffective disorder or bipolar disorder according to DSM-V or ICD-10 criteria 9. Subject has had a significant illness or infection requiring medical intervention in the past 30 days 10. Female who is breastfeeding or has a positive pregnancy test 11. Male participant or female participant of childbearing potential, who is sexually active and unwilling/unable to use a medically acceptable and effective double barrier birth control method throughout the study 12. Unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject’s ability to return for visits as scheduled 13. History, within the last 2 years, of alcohol abuse or physical opioid dependence",Ii,Both
0,Patients with amyotrophic lateral sclerosis.,,TrialTroveID-333164,,,,333164,Unspecified,,,,I,
0,"Participants with frontotemporal dementia, Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), dementia with Lewy bodies (DBL), vascular cognitive disorders, or Huntington's disease who also exhibit disinhibited behavior.","Documented diagnosis of a Neurodegenerative Disorder including frontotemporal dementia, Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), dementia with Lewy bodies (DBL), vascular cognitive disorders, or Huntington's disease, at least 3 months prior to Baseline The participant has behavior from 2 of the 3 categories of disinhibited behavior from the definition of the behavioral variant of frontotemporal dementia The behavioral changes are not due to a pre-existing major psychiatric disorder (e.g., schizophrenia, bipolar disease, etc.) and are not due to the direct effect of systemic illness, drug action, or substance use Disinhibition scale score of > or =4 on the 3 core disinhibition items of the Frontal Behavioral Inventory (FBI) at Screening and Baseline",15-AVP-786-203 NCT02534038 TrialTroveID-263745,Adults; Older Adults,year(s),year(s),263745,(N/A); Behavioral Symptoms - Other; Frontotemporal Dementia; Lewy Body Dementia; Unspecified PSP; Vascular Dementia,90.0,50.0,"Participants with symptoms of disinhibition that is not secondary to Neurodegenerative Disorders Participants with myasthenia gravis Participants with co-existent clinically significant or unstable systemic diseases that could confound the interpretation of the safety results of the study (e.g., malignancy [except skin basal-cell carcinoma or untreated prostate cancer], poorly controlled diabetes, poorly controlled hypertension, unstable pulmonary, renal or hepatic disease, unstable ischemic cardiac disease, dilated cardiomyopathy, or unstable valvular heart disease)",Ii,Both
0,Healthy adult males or females.,"Ages Eligible for Study: 18 Years to 60 Years, Genders Eligible for Study: Both. Inclusion Criteria: Healthy adult males or females. 18 - 60 years of age. BMI 18 - 32 kg/m2.",14-AVP-786-102 NCT02336347 TrialTroveID-250379,Adults,year(s),year(s),250379,(N/A); Healthy subjects,60.0,18.0,Exclusion Criteria: History or presence of significant disease. History of substance abuse and/or alcohol abuse with the past 2 years. Use of tobacco-containing or nicotine-containing products within 6 months. Use of any prescription or the over-the-counter medications within 14 days.,I,Both
0,Healthy adult males and females,Ages Eligible for Study: 18 Years to 50 Years; Genders Eligible for Study: Both Inclusion Criteria: Healthy adult males and females 18 - 50 years of age BMI 18 - 30 kg/m2,14-AVP-786-101 NCT02174822 TrialTroveID-211881,Adults,year(s),year(s),211881,(N/A); Healthy subjects,50.0,18.0,Exclusion Criteria: History or presence of significant disease History of substance abuse and/or alcohol abuse with the past 3 years Use of tobacco-containing or nicotine-containing products within 6 months Use of any prescription or the over-the-counter medications within 14 days,I,Both
0,Healthy Volunteers.,Ages Eligible for Study: 18 Years to 45 Years; Genders Eligible for Study: Male Inclusion Criteria: Healthy adult males 18 - 45 years of age BMI 18 - 30 kg/m2,13-AVR-134 NCT02174835 TrialTroveID-211878,Adults,year(s),year(s),211878,(N/A); Healthy subjects,45.0,18.0,Exclusion Criteria: History or presence of significant disease History of substance abuse and/or alcohol abuse with the past 3 years Use of tobacco-containing or nicotine-containing products within 6 months Use of any prescription or the over-the-counter medications within 14 days,I,Male
0,Healthy subjects.,Ages Eligible for Study: 18 Years to 45 Years; Genders Eligible for Study: Male Inclusion Criteria: Healthy adult males. 18 - 45 years of age. BMI 18 - 30 kg/m2.,12-AVR-132 NCT01787747 TrialTroveID-178131,Adults,year(s),year(s),178131,(N/A); Healthy subjects,45.0,18.0,Exclusion Criteria: History or presence of significant disease History of substance and/or alcohol abuse within the past 3 years Use of tobacco-containing or nicotine-contining products within 6 months Use of any prescription of over-the-counter (OTC) medication within 14 days,I,Male
1,Amyotrophic lateral sclerosis patient receiving palliative care,Diagnosed ALS Age > or = 18 years Written informed consent from the patient or adjacent Finnish spoken as mother language,EudraCT Number: 2018-000142-18 TrialTroveID-324339,Adults; Older Adults,year(s),,324339,Unspecified,,18.0,"Previous history of intolerance to the study drug or related compounds and additives. Significant cognitive dysfunction or lack of ability to communicate Psychological or other emotional problems that are likely to invalidate informed consent, or limit the ability of the subject to comply with the protocol requirements.",Iv,Both
0,Subjects with Treatment of Agitation Associated With Dementia,"Individuals diagnosed with any form of dementia (i.e., probable Alzheimer's Disease; vascular dementia; mixed; frontotemporal dementia) Subjects who have met DSM-5 criteria for dementia (major neurocognitive disorder) who have instances of acute psychomotor agitation. History of psychomotor agitation (e.g., kick, bite, flailing) to the point that it impairs social activities, requires staffing, or medical intervention, or impairs ability for functional activities of daily living. Subjects are expected to exhibit behaviors that are congruent with the International Psychogeriatric Association criterion for agitation representing a change from the subject's usual behavior. Subjects who have a score of < or =16 on the Mini-Mental State Exam (MMSE). Subjects with a remote (>5 years) history of stroke may be included, regardless of size/location. Subjects who read, understand, and provide written informed consent, or who have a legally authorized representative (LAR). Subjects who are deemed to be medically appropriate for study participation by the principal investigator. Subjects who are at their current location for at least 14 days before screening and plan to remain at the same location for the duration of the study. Subjects who have the capability to participate in the study and self-administer the investigational product. Subjects who are on a stable concomitant medications regimen for the treatment of any concurrent conditions for at least one month prior to the screening visit.",BXCL501-203 NCT05276830 TrialTroveID-427128,Older Adults,year(s),,427128,Behavioral Symptoms - Agitation; Frontotemporal Dementia; Moderate; Severe; Vascular Dementia,,65.0,"Subjects who have dementia associated with Parkinson's disease and/or Lewy Body Disease are excluded. Subjects suffering from alcohol and/or substance abuse. Subjects with agitation caused by acute intoxication must be excluded. Subjects with significant risk of suicide or homicide per the investigator's assessment. Subjects who have hydrocephalus, seizure disorder, or history of significant head trauma, subarachnoid bleeding, brain tumor, encephalopathy, meningitis, or focal neurological findings, with a recent (1 year) large (non-microvascular) stroke who may be considered medically unstable or in recovery must be excluded. History of clinically significant syncope or syncopal attacks, orthostatic hypotension within the past 2 years. Subjects with laboratory or ECG abnormalities. Subjects with serious, unstable, or uncontrolled medical illnesses must be excluded. Subjects who have received an investigational drug within 30 days prior to Screening must be excluded. Subjects who are considered by the investigator, for any reason, to be an unsuitable candidate for receiving dexmedetomidine must be excluded. Subjects whose agitation is attributed to pain or infection, delirium, concomitant medications, environmental conditions, or another psychiatric condition or medical condition as determined by the investigator.",Ii,Both
0,Healthy adult subjects.,,TrialTroveID-179548,Adults,,,179548,Healthy subjects,,,,I,
1,Subjects with amyotrophic lateral sclerosis.,Ages Eligible for Study: 18 Years and older ; Genders Eligible for Study: Both Inclusion Criteria: Subject has the ability to understand the purpose and risks of the study and provide signed and dated informed consent (or have the consent confirmed by a witness if unable to write) and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations. Subject was enrolled in either CL211 or Study 223AS302. Subject has completed their last visit in Study CL211 or Study 223AS302. Subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 1 month (females) or 3 months (males) after their last dose of study treatment.,223AS304 DeNDRoN 058ext ENVISION EudraCT Number: 2011-006119-70 MREC N° 12/NW/0413 NA_00071274 NCT01622088 NL40561.041.12 TrialTroveID-169730 UKCRN ID: 12687,Adults; Older Adults,year(s),,169730,Delay Disease Progression,,18.0,"Exclusion Criteria: Subject withdrew prematurely from Study CL211 or Study 223AS302. Subject permanently discontinued study treatment in Study CL211 or Study 223AS302 for any reason other than enrollment into this study. Subject from Study CL211 or Study 223AS302 has a significant change in medical history (including laboratory tests or a clinically significant condition) that in the opinion of the Investigator would impair the subject's medical fitness for participation and preclude treatment. Female subject who is pregnant or breastfeeding. Subject is currently enrolled in any investigational drug study other than Study CL211 or Study 223AS302. Subject is taking pramipexole, other dopamine agonists, any other agent with dopaminergic activity, or any other disallowed concomitant medication. Subject is unwilling or unable to comply with the requirments of the protocol including the presence of any condition (physical, mental, or social) that is likely to affect the subject's ability to comply with the protocol. At a minimum, subjects who are not able to travel to the study site must be willing to agree to remote blood draws for clinical laboratory evaluations and telephone visits to report AEs, concomitant medications, and ALSFRS-R scores.",Iii,Both
0,Healthy volunteers.,"Ages Eligible for Study: 18 Years to 55 Years; Genders Eligible for Study: Both Inclusion Criteria: Subjects who, in the opinion of the Investigator, are healthy as determined by pre-study medical history, physical examination and 12-lead ECG. Adult males/females aged 18 to 55 years inclusive. Male subjects and female subjects of childbearing potential must practice effective contraception during the study and 90 days after their last dose of study drug.",223HV106 NCT01607034 TrialTroveID-168549,Adults,year(s),year(s),168549,Healthy subjects,55.0,18.0,"Exclusion Criteria: History of malignant disease, including solid tumors and hematologic malignancies. History of any clinically significant endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major diseases, as determined by the Investigator. Surgery within 90 days prior to check in.",I,Both
0,Healthy Volunteers.,"Ages Eligible for Study: 18 Years to 55 Years; Genders Eligible for Study: Both Inclusion Criteria: Subjects who, in the opinion of the investigator, are healthy as determined by medical history, physical examination, and 12 Lead ECG. Adult males/females aged 18 to 55 years inclusive. Male and female subjects of childbearing age must practice effective contraception during the study and up to 90 days after their last dose of study drug.",223HV105 NCT01597310 TrialTroveID-167533,Adults,year(s),year(s),167533,Healthy subjects,55.0,18.0,"Exclusion Criteria: History of malignant disease, including solid tumors and hematologic malignancies. Clinically significant current active infection or serious infection. History of gastrointestinal bleeding, peptic ulcer disease, hemorrhoids or epistaxis. Personal or family history of any bleeding disorder, and/or coagulation profile results outside of normal limits. Known allergy or hypersensitivity to warfarin.",I,Both
0,Healthy Volunteers,"Ages Eligible for Study: 18 Years to 55 Years; Genders Eligible for Study: Both Inclusion Criteria: Subjects who, in the opinion of the Investigator, are healthy as determined by medical history, physical examination, and 12 lead ECG Adult males/females aged 18 to 55 years inclusive Male and female subjects of childbearing potential must practice effective contraception during the study and up to 90 days after their last dose.",223HV104 NCT01536249 TrialTroveID-162708,Adults,year(s),year(s),162708,Healthy subjects,55.0,18.0,"Exclusion Criteria: History of malignant disease, including solid tumors and hematologic malignancies. History of clinically significant endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, and renal, or other major diseases, as determined by the Investigator. Treatment with prescription medication and/or over-the-counter products and herbal-containing and/or alternative health preparations and procedures. Surgery within 90 days prior to check-in.",I,Both
0,Healthy Volunteers,"Ages Eligible for Study: 18 Years to 60 Years; Genders Eligible for Study: Both Inclusion Criteria: Aged 18 to 60 years old inclusive on Day 1. Subjects who, in the opinion of the Investigator, are healthy as determined by pre study medical history, physical examination, and 12 lead ECG. Male subjects and female subjects of childbearing potential must practice effective contraception (per protocol specifications). Normal systemic blood pressure defined as a systolic blood pressure of 90 to 140 mmHg and a diastolic blood pressure of 50 to 90 mmHg.",223HV102 NCT01511029 TrialTroveID-160501,Adults,year(s),year(s),160501,Healthy subjects,60.0,18.0,"Exclusion Criteria: History of cardiovascular disease (e.g., hypertension, arrhythmia, heart failure, Long QT Syndrome, or other conditions/diseases causing prolongation of the QT/QTc interval), in the opinion of the Investigator. A prolongation of QT/QTc interval (e.g., repeated demonstration of a QT/QTc interval >450 ms before study treatment administration. Clinically important abnormalities in resting ECG that may interfere with the interpretation of QTc interval changes at screening, check-in, or pre-dose on Day -1 of the first treatment period. Other medically significant illness. Clinically significant abnormal laboratory values. Pregnant women or women breastfeeding.",I,Both
0,Healthy volunteers.,"Ages Eligible for Study: 18 Years to 55 Years; Genders Eligible for Study: Both Inclusion Criteria: Must give written informed consent. Adult males/females aged 18 to 55 years inclusive and between 19 and 30 kg/m2 body mass index (BMI), inclusive at screening. Subjects who are healthy as determined by prestudy medical history, physical examination and 12-lead ECG. Subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 1 month (females) or 3 months (males) after their last dose of study treatment. Normal systemic blood pressure defined as a systolic blood pressure of 90 to 140 mmHg and a diastolic blood pressure of 50 to 90 mmHg.",223HV103 NCT01449578 TrialTroveID-154751,Adults,year(s),year(s),154751,Healthy subjects,55.0,18.0,"Exclusion Criteria: History of cardiovascular disease (e.g., hypertension, arrhythmia, heart failure, Long QT Syndrome, or other conditions/diseases causing prolongation of the QT/QTc interval). A prolongation of QT/QTc interval (e.g., repeated demonstration of a QT/QTc interval >450 ms before study treatment administration) at screening, admission or pre-dose on Day 1. Any clinically important abnormalities in resting ECG that may interfere with the interpretation of QTc interval changes at screening, admission or pre-dose on Day 1. Prior exposure to dexpramipexole. Treatment with pramipexole or any dopamine agonist within 1 year. Treatment with another investigational drug or approved therapy for investigational use within 30 days, or 5 half-lives (whichever is longer), or in follow up for any other drug, biologic, or device study. Currently active infection or serious infection (e.g., pneumonia, septicemia) within the 2 months prior to Day -2 as determined by the Investigator. Female subjects who are pregnant, currently breastfeeding, or attempting to conceive during the study.",I,Both
0,Healthy Subjects and subjects with renal impairment.,"Ages Eligible for Study: 18 Years to 75 Years, Genders Eligible for Study: Both Inclusion Criteria: Adult males/females aged 18 to 75 years inclusive and between 19 and 36 kg/m2 inclusive BMI. Subjects with renal impairment must have stable renal disease (i.e., no change in disease status within the 28 days prior to dosing) as determined by the Investigator with laboratory and clinical findings that support the diagnosis of renal impairment. Subjects with renal impairment (excluding ESRD subjects), must have 2 separate estimates of creatinine clearance that are within 25% of each other, obtained >5 days apart, but not >6 months apart Subjects must have a GFR (estimated GFR; as defined by estimation of creatinine clearance using the MDRD formula) of > or = 80 (healthy volunteers), between 50 and 79 (mild renal impairment), between 30 and 49 (moderate renal impairment), or <30 (severe renal impairment), or must require dialysis < or = 3 times a week (ESRD). Healthy volunteers must be matched to renally impaired subjects for age (+ or = 10 years), gender, and if possible BMI (+ or = 20%).",223RI101 NCT01424176 TrialTroveID-151922,Adults; Older Adults,year(s),year(s),151922,Comorbidity in ALS; Healthy subjects,75.0,18.0,"Exclusion Criteria: Healthy volunteers who have received prescription medication within the 14 days prior to dosing (except for birth control). Renally impaired subjects who have received prescription medication within the 14 days prior to dosing (except for birth control and medications taken at a stable dose for underlying conditions, as determined by the Investigator).",I,Both
0,Healthy Japanese and Caucasian subjects.,"Ages Eligible for Study: 18 Years to 60 Years Genders Eligible for Study: Both Inclusion Criteria: Subjects who are able and willing to give written informed consent. Adult Japanese and Caucasian males/females aged 18 to 60 years inclusive and between 18 and 30 kg/m2 body mass index (BMI), inclusive. Male and female subjects will be enrolled on the study. Male subjects and female subjects of childbearing potential, must practice effective contraception during the study and be willing and able to continue contraception for 1 month (females) or 3 months (males) after their last dose of study treatment Japanese subjects must be born in Japan and have both parents and four grandparents of Japanese descent. Japanese subjects must have lived outside of Japan for no more than 5 years. Japanese subjects must not have significant changes with regard to diet; i.e., their diet must not have significantly changed since leaving Japan. Caucasian subjects will be matched individually (on a 1:1 basis) to Japanese subjects with respect to gender and age, and if possible BMI.",223HV101 NCT01424163 TrialTroveID-151907,Adults,year(s),year(s),151907,Healthy subjects,60.0,18.0,"Exclusion Criteria: Subjects who do not conform to the above inclusion criteria. Female subjects who are pregnant, trying to become pregnant or lactating. Subjects who have a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases or disorders. Subjects who have a clinically relevant surgical history. Subjects who have previously received dexpramipexole or pramipexole.",I,Both
0,Patients with amyotrophic lateral sclerosis.,"Patient has provided signed informed consent for this trial before the commencement of any study-related procedure. Patient is actively participating in Knopp Protocol KNS-760704-CL201 and has completed the Part 2 Week 28 visit in that study or patient is actively receiving RTPB under Research IND #60,948.",CL211 KNOPP CL211 KNS-760704-CL211 NCT00931944 TrialTroveID-111411,Adults; Older Adults,year(s),year(s),111411,Delay Disease Progression,80.0,21.0,"Patient did not participate in Knopp Protocol KNS-760704-CL201 or patient did not receive RTPB under Research IND #60,948. Patient discontinued from KNS-760704-CL201 for any reason other than enrollment into this study (applies to patients enrolled in KNS-760704-CL201 only). Patient was not taking RTPB under Research IND #60,948 prior to April 30, 2009 (applies to patients enrolled under Research IND #60,948 only).",Ii,Both
1,Patients with amyotrophic lateral sclerosis.,"Ages Eligible for Study: 18 Years to 80 Years, Genders Eligible for Study: Both Inclusion Criteria: Aged 18 to 80 years old, inclusive, on Day 1. Diagnosis of sporadic or familial ALS. Onset of first ALS symptoms within 24 months prior to Day 1(symptom onset is defined as the date of onset of weakness). World Federation of Neurology El Escorial criteria are met for a possible, laboratory-supported probable, probable, or definite ALS diagnosis. Upright slow vital capacity (SVC) of > or = 65% of predicted value for age, height, and gender at screening. Patients taking or not taking Riluzole are eligible for this study: if a patient has never taken Riluzole, he or she is eligible; if a patient is currently taking Riluzole, he or she must have been on a stable dose for at least 60 days; if a patient has discontinued Riluzole, he or she must have stopped taking it for at least 30 days. Must be able to swallow tablets at the time of study entry. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations. Subject meets the possible, laboratory-supported probable, probable, or definite criteria for diagnosing ALS according to the World Federation of Neurology El Escorial criteria (revised according to the Airlie House Conference 1998 (see Appendix A) [Brooks 2000]). Subjects meeting the definition of “possible ALS” must have upper motor neuron (UMN) and lower motor neuron (LMN) signs/symptoms in at least 1 region). Subject is able to take oral treatment without crushing or breaking the tablets at the time of study entry by the assessment of the site Investigator. Subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 1 month (females) or 3 months (males) after their last dose of study treatment. Patients with symptom onset 24 months or lesser before randomization, slow vital capacity 65% or more of predicted, and no history of or current neutropenia were included.",223AS302 DeNDRoN 058 EMPOWER EudraCT Number: 2010-022818-19 KNS-760704-CL301 NCT01281189 NL35564.041.11 TrialTroveID-105607 UKCRN ID: 9001,Adults; Older Adults,year(s),year(s),105607,Delay Disease Progression,80.0,18.0,"Exclusion Criteria: Subject with a clinically significant history of unstable or severe cardiac, oncologic, hepatic, or renal disease, or other medically significant illness Subject with clinically significant abnormal clinical laboratory values, as determined by the Investigator at the Screening visit. Pregnant women or women breastfeeding. Prior exposure to dexpramipexole. Currently taking pramipexole or other dopamine agonists. Subject in whom causes of neuromuscular weakness other than ALS have not been excluded. Subject with significant cognitive impairment, clinical dementia, or psychiatric illness. Subject with a diagnosis of other neurodegenerative diseases (e.g., Parkinson’s disease, Alzheimer’s disease, etc.). Subject with a clinically significant pre-existing pulmonary disorder not attributed to ALS. Subject with a history of severe drug allergy or severe allergic disease (anaphylactic shock) Subject with clinically significant ECG abnormalities at the Screening visit (e.g. QTc >500 msec (where QTc is the interval between the start of the QRS complex and the end of the T wave corrected for heart rate), or acute ST segment elevations). Subject with neutrophil count <1.96 x 10 3/µL at the Screening visit or any documented history of neutropenia. Subject with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) value >3.0 times the upper limit of normal at the Screening visit. Subject with creatinine clearance (CrCl, calculated according to the Modification of Diet in Renal Disease equation) < or = 50 mL/minute at the Screening visit. Subject with a history of alcohol or drug abuse within 1 year of Day 1, as determined by Investigator. Subject unlikely to comply with study requirements. Subject who has been exposed to any other experimental agent (off-label use or investigational) within 30 days of Day 1 (see Section 10.6.1.2). Subject with prior exposure to dexpramipexole [KNS 760704 or the (R)-(+)-enantiomer of pramipexole]. Subject taking l-pramipexole or other dopamine agonists.",Iii,Both
0,Patients with amyotrophic lateral sclerosis.,"Ages Eligible for Study: 21 Years to 80 Years Inclusion Criteria Patients with diagnosis of familial or sporadic ALS, defined as meeting the possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS according to the World Federation of Neurology El Escorial criteria. Patients with ALS symptom onset < 24 months from randomization. Patients with upright VC > 70% of predicted for age, height, and gender.",CL201 KNS 760704-CL201 KNS-760704-CL201 NCT00647296 TrialTroveID-078900,Adults; Older Adults,year(s),year(s),78900,Delay Disease Progression,80.0,21.0,"Exclusion Criteria Patients in whom causes of neuromuscular weakness other than ALS have not been excluded. Patients without clinical evidence of upper motor neuron dysfunction. Patients with clinically suspected ALS according to the World Federation of Neurology El Escorial criteria. Patients with prior exposure to KNS-760704 or the R(+) enantiomer of pramipexole (i.e., R(+)-pramipexole). Patients taking other investigational agents (including lithium) within 30 days of randomization or during the study.",Ii,Both
0,Healthy volunteers.,,KNS 760704-CL002 TrialTroveID-078890,,,,78890,Healthy subjects,,,,I,Both
0,Healthy adult female and male volunteers,"Ages ranged from 30 to 58 years, with a mean age of 44.2 years.",KNS 760704-CL001 TrialTroveID-078888,Adults,year(s),year(s),78888,Healthy subjects,58.0,30.0,,I,Both
0,Patients with Amyotrophic Lateral Sclerosis.,Diagnosis of probable-definite ALS (El-Escorial Criterion); ALSFRS-R Bulbar subscale score <10 Bamboo oral reading speaking rate <140 words per minute No allergies to barium sulfate.,NCT03883581 OCR20392 TrialTroveID-345808,Adults; Older Adults,year(s),year(s),345808,Delay Disease Progression,90.0,18.0,"Treatment for sialorrhea within the past 3 months that includes either Botox or radiation treatment Participation in another disease modifying study targeting bulbar or cough function Use of invasive mechanical ventilation/presence of tracheostomy Advanced frontotemporal dementia or significant cognitive dysfunction Nil per oral status for feeding (i.e., NPO, nothing by mouth) Previously prescribed Nuedexta. Additionally, if participants are taking Riluzole or other medications to control sialorrhea, they must be on a stable dose for at least 30 days prior to enrollment in the current study.",Iii,Both
0,Healthy adults.,"Healthy adults, 18 to 65 years of age, inclusive Willing to sign informed consent form Cytochrome P450 2D6 genotype that confers extensive metabolizer profile (as per documented phenotype interpretation from local laboratory and approval from Avanir)",17-AVR-135 NCT03381664 TrialTroveID-315238,Adults,year(s),year(s),315238,(N/A); Healthy subjects,65.0,18.0,"History or presence of significant pulmonary, hepatic, renal, hematologic, allergic, endocrine (including diabetes), immunologic, dermatologic, neurologic (including history or presence of seizures or convulsive disorders), psychiatric disease (including history of suicidal ideation or behavior) or any eating disorder deemed clinically significant by the investigator History or presence of significant cardiovascular disease, including complete heart block, QT interval corrected for heart rate (QTc) prolongation, and/or torsades de pointes History or presence of any gastrointestinal (GI) disease or condition that could compromise participant safety or affect the absorption of study drug, including GI ulcers, GI bleeding, esophageal or gastric varices, and dyspepsia requiring regular (i.e., more frequently than once a month) use of acid-reducing drugs Known hypersensitivity/intolerance to dextromethorphan or quinidine Participants whom the principal investigator or his delegate deems to be ineligible",I,Both
1,Nursing Home Patients With Pseudobulbar Affect (PBA),"Diagnosis of a neurological disorder affecting the brain (e.g. Alzheimer's and other dementias, stroke, Trauma Brain Injury, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Huntington's disease, Parkinson's disease) of at least 3 months duration prior to baseline and which is not rapidly progressing Diagnosis of Pseudo bulbar Affect (PBA) A Center for Neurologic Study-Liability Scale (CNS-LS) score of 13 or greater at Baseline Minimum Data Set (MDS) information for patient available within 60 days prior to Baseline Informant who is willing to comply with study procedures",15-AVR-404 NCT02496039 TrialTroveID-261362,Adults; Older Adults,year(s),year(s),261362,(N/A); Behavioral Symptoms - Other; Non-motor symptoms/comorbidities; Symptom relief,90.0,18.0,"Patients who have received NUEDEXTA in the past 1 year Patients with the diagnosis of Severe Depressive Disorder that would interfere with the conduct of the study Patients who have a history of schizophrenia spectrum and other psychotic disorders Patients with co-existent clinically significant or unstable systemic diseased that could confound the interpretation of the safety results of the study (e.g. Malignancy, poorly controlled diabetes, poorly controlled hypertension, unstable pulmonary, renal or hepatic disease, unstable ischemic cardiac disease, dilated cardiomyopathy, or unstable valvular heart disease) Patients with myasthenia gravis",Iv,Both
1,,"- 18 to 80 years of age, inclusive - Confirmed diagnosis of ALS or probable ALS - Clinical history of pseudobulbar affect - If female, must not be pregnant, breast-feeding, or planning a pregnancy during the course of the study, and must have a negative urine pregnancy test prior to start of study - If female, must have been practicing an established method of birth control for at least the prior month (oral contraceptive tablets, hormonal implant device, intrauterine device, diaphragm and contraceptive cream or foam, condom with spermicide, tubal ligation, or abstinence) or be surgically sterile or post-menopausal - Must be willing to not take any prohibited medications during participation in the study",99-AVR-102 AVP-923 NCT00021697,Adults; Older Adults,year(s),year(s),224640,,80.0,18.0,"- Known sensitivity to quinidine or opiate drugs (codeine, etc.) - On any anti-depressive medication - Recently (within two months) diagnosed with ALS - Currently participating in, or who within the past 30 days have participated in, the study of another investigational new drug - Previously received treatment with co-administration of dextromethorphan and quinidine - History of substance abuse within the past two years - Women who are pregnant or likely to become pregnant during the course of the study",Iii,Both
0,Patients with Amyotrophic Lateral Sclerosis (ALS).,"ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria. Age 18 years or older. Exhibits bulbar dysfunction manifested by dysarthria and/or dysphagia, according to PI judgment, exhibits a score of 55 or above on the CNS-Bulbar Function Scale. Capable of providing informed consent and following trial procedures. Geographic accessibility to the site. Women must not be able to become pregnant for the duration of the study and must be willing to be on two contraceptive therapies. Slow vital capacity (SVC) measure > or =50% of predicted for gender, height, and age at the screening visit Must be able to swallow capsules throughout the course of the study, according to PI judgment Subjects must not have taken riluzole for at least 30 days or be on a 50mg BID dose of riluzole for at least 30 days prior to randomization (subjects how have never taken riluzole are permitted in the study) Subjects taking anti-sialorrhea medication(s) must be on a stable dose for at least 30 days prior to randomization (anti-sialorrhea naïve subjects are permitted in the study) Must be able to safely swallow at least 30 milliliters (mLs) of water for the water swallowing test.",2012P001274 NCT01806857 NUE-2012 TrialTroveID-182930,Adults; Older Adults,year(s),,182930,Delay Disease Progression,,18.0,"Prior use of Nuedexta. Current use of dextromethorphan, quinidine, quinine, mefloquine or opioids. History of quinidine, quinine, or mefloquine-induced thrombocytopenia, hepatitis, or other hypersensitivity reactions. History of known sensitivity or intolerability to dextromethorphan. Use of an mono amine oxidase inhibitor (MAOI) or within 14 days of stopping an MAOI. Prolonged QT interval, congenital long QT syndrome, history suggestive of torsades de pointes, or heart failure. Complete atrioventricular (AV) block without implanted pacemaker, or subjects at high risk of complete AV block. Concomitant use with drugs that both prolong QT interval and are metabolized by cytochrome P 2D6 (CYP2D6) (i.e., thioridazine or pimozide). Exposure to any other experimental agent (off-label use or investigational) within 30 days prior to Baseline Visit. Invasive ventilator dependence, such as tracheostomy. Any history of either substance abuse within the past year, unstable psychiatric disease, cognitive impairment, or dementia, according to PI judgment. Placement and/or usage of feeding tube. Pregnant women or women currently breastfeeding. Unable to turn diaphragm pacing device off during swallowing tests. Salivatory Botox within 90 days (3 months) of screening. Salivatory radiation within 180 days (6 months) of screening.",Ii,Both
1,Patients with Amyotrophic Lateral Sclerosis with Pseudobulbar Affect.,,TrialTroveID-175656,,,,175656,Unspecified,,,,Iv,
1,Patients diagnosed with pseudobulbar affect (PBA) resulting from an underlying neurological disorder.,"282 patients (86.5% of total # of patients in parent study (#77401)) completed the 12-week double-blind phase of the parent study, so were eligible to enroll in the open label extension phase.",STAR-Ext TrialTroveID-114507,Adults; Older Adults,year(s),year(s),114507,Symptom relief,80.0,18.0,,Iii,Both
0,Healthy volunteers.,,ACSS TrialTroveID-106736,,,,106736,Diabetic Neuropathy; Healthy subjects,,,,I,
1,Amyotrophic Lateral Sclerosis patients with pseudobulbar affect.,,TrialTroveID-080397,,,,80397,Symptom relief,,,,Iii,
1,Patients with Amyotrophic Lateral Sclerosis or Multiple Sclerosis. Patients with pseudobulbar affect (PBA).,"Ages Eligible for Study 18 Years to 80 Years;Genders Eligible for Study: Both Main Inclusion Criteria: The patient has a diagnosis of Amyotrophic Lateral Sclerosis (according to El Escorial Criteria, WFN, 1998) and the time from diagnosis of ALS is not be longer than 30 months, or the patient has a diagnosis of multiple sclerosis or probable multiple sclerosis (according to McDonald criteria, 2001) The patient has a clinical history and clinical relevant symptoms of Pseudobulbar Affect (PBA) CNS-LS score at baseline is 13 or greater",07-AVR-123 HUM00016766 NA_00014202 NCT00573443 STAR TrialTroveID-077401,Adults; Older Adults,year(s),year(s),77401,Symptom relief,80.0,18.0,"Exclusion Criteria: Patients with myasthenia gravis Any personal history of complete heart block, QTc prolongation, or torsades de pointes Any family history of congenital QT interval prolongation syndrome Patients with known sensitivity to quinidine, dextromethorphan or opiate drugs (codeine, etc.",Iii,Both
1,Common underlying conditions in the 553 treated pseudobulbar affect patients were: MS (40.3%);ALS (31.8%); stroke (8.3%); traumatic brain injury (3.8%); primary lateral sclerosis (2.9%); Parkinson’s disease (2.7%); and Alzheimer’s disease (2.5%).,"Ages Eligible for Study: 18 Years to 80 Years Inclusion Criteria Eligible patients were 18 to 75 years of age with a clinical diagnosis of PBA. Clinical diagnosis of pseudobulbar affect. If female, must not be pregnant or breast feeding. The patient has a confirmed diagnosis of a neurological disorder, such as ALS, Alzheimer's disease, multiple sclerosis, Parkinson's disease, stroke, traumatic brain injury or other. Possible side effects include nausea, sleepiness, fatigue, dizziness, euphoria, confusion, rash or diarrhea. They must meet a number of inclusion criteria that ultimately determines eligibility. For the purposes of this study, PBA was defined as ‘a syndrome characterized by outbursts of crying defined as ‘a syndrome characterized by outbursts of crying ately given the context in which they occur’. No specific threshold for severity of PBA symptoms was required for threshold for severity of PBA symptoms was required for diogram (ECG) with no evidence of rate-corrected QT interval (QTc) prolongation (450 msec in men; 470 msec in women), heart block (isolated right bundle branch block without clinical history of heart disease was allowable), sinus bradycardia (550 bpm), ventricular allowable), sinus bradycardia (550 bpm), ventricular quency), or unifocal ventricular ectopic beats (45/min). Patients with ALS were required to have a vital capacity 50% at baseline. Patients completing prior controlled studies of twice daily DM/Q 30/30 mg to treat PBA in MS23 or ALS22 were also eligible to participate, provided MS23 or ALS22 were also eligible to participate, provided they met all eligibility requirements at the time of enrollment in this study.",02-AVR-107 NCT00056524 TrialTroveID-005588,Adults; Older Adults,year(s),year(s),5588,Behavioral Symptoms - Other; Non-motor symptoms/comorbidities; Symptom relief,80.0,18.0,"Exclusion Criteria: Sensitivity to quinidine or any opiate drugs. Current or prior history of major psychiatric disturbance. Currently participated in a trial within the past 30 days. Exclusion criteria were myasthenia gravis; a history of ventricular tachycardia or torsades de pointes; sensitivity to quinidine or opiate drugs; major psychiatric disturbance;a history of substance abuse in the past 2 years; any major systemic disease that would interfere with interpretation of study results (e.g., malignancy, uncontrolled diabetes, dilated cardiac myopathy, ischemic or valvular heart disease); hypotension (systolic blood pressure [BP] 5100 mmHg); a history of postural or any unexplained syncope; renal, hepatic, or pulmonary disease; or clinically significant deviations in standard laboratory tests. Female patients could not be pregnant or breastfeeding; those with child-bearing potential were required to use an established method of birth control.",Iii,Both
0,Healthy Adult Subjects.,"Healthy adult males and females, 18 to 55 years of age. Body Mass Index (BMI) > or =19 and < or = 30 kg/m2 (for both males and females)",15-AVP-786-103 NCT02402595 TrialTroveID-254771,Adults,year(s),year(s),254771,(N/A); Healthy subjects,55.0,19.0,"History or presence of significant disease. History of substance abuse or dependence (except caffeine), or treatment for substance use disorder(s) within the year prior to screening or within 6 months for nicotine including e-cigarettes. Use of any tobacco-containing or nicotine-containing products within 6 months prior to the first dose. Use of any prescription or the over-the-counter medications within 14 days.",I,Both
0,Healthy volunteers.,,06-AVR-121 TrialTroveID-129210,,,,129210,Healthy subjects,,,,I,Both
0,Patients with Amyotrophic Lateral Sclerosis,"Male and female patients aged 18 to 85 years at the time of the Screening Visit. Able to provide informed consent and comply with study procedures. Sporadic ALS diagnosed as definite, probable, or possible according to the Awaji criteria as determined by a neurologist subspecializing in ALS. Disease duration at recruitment less than 24 months from diagnosis. Patient must have the results of magnetic resonance imaging scan of brain and spinal cord undergone within 2 years (24 months) prior to the Screening Visit. Forced vital capacity >60% of predicted value as adjusted for gender, height, and age at the Screening Visit. Must be on a stable dose of riluzole for at least 30 days prior to the Screening Visit. Patient who has established care with a neurologist at 1 of the 5 specialised ALS clinics involved in the study and will maintain this clinical care throughout the study. If a patient is referred from a third party (neurologist or a State based ALS organisation) they should be willing to transfer care to the neurologist participating in the study. Patients may participate in clinical registries, but will be excluded if they are participating in a clinical study involving an alternative investigational treatment. Women of childbearing potential must have a negative urine pregnancy test at screening and Baseline, and be surgically sterile or postmenopausal, or using highly effective methods of contraception throughout the study and for 30 days after the last dose of IP.",ACTRN12618000534280 SPIRIT Compliant TEALS Study TrialTroveID-323292 U1111-1211-7805,Adults; Older Adults,year(s),year(s),323292,Delay Disease Progression,85.0,18.0,"Dependence on mechanical ventilation at the time of screening. Gastrostomy at the time of Screening/Baseline Visit. If the patient has a gastrostomy tube inserted post randomisation they will be allowed to continue in the study. Participation in any other IP study or using an IP (within 12 weeks prior to screening). Known hypersensitivity to Tecfidera or any excipients in this product. Presence of a monogenic cause of ALS (e.g. known mutation in superoxide dismutase-1 (SOD1), expansion in c9orf72 etc.). Taking immunosuppressive medications. Positive test for human immunodeficiency virus (HIV), hepatitis B (+HbsAg), or hepatitis C. Presence of any of the following clinical conditions at the time of screening: -Unstable medical disease (such as unstable angina, heart failure, chronic obstructive pulmonary disease, liver disease or renal disease), or active infectious diseases (such as hepatitis B or C or tuberculosis), or current malignancy. -Unstable psychiatric illness defined as psychosis or untreated major depression within 90 days of the Screening Visit. This exclusion criteria is based on a prior psychiatric diagnosis that is unstable as determined by the patient’s treating Psychiatrist. -Dementia as previously diagnosed by a medical practitioner. Safety Laboratory Criteria at the Screening Visit: -Alanine aminotransferase >3 × the upper limit of normal (ULN). -Total bilirubin, lactate, triglycerides, amylase, or lipase >2 × the ULN. -Patient has impaired renal function defined as creatinine clearance of <40 mL/min via Cockroft Gault method. -Absolute neutrophil count of <2 × 109/L. -Absolute lymphocyte count of <0.5 × 109/L. -Platelet concentration of <100 × 109/L. -Haemoglobin <100 g/L. Female patients who are pregnant or lactating, or intend to become pregnant during the study period.",Ii,Both
0,Healthy Volunteers,"1.Healthy men or women between 18 and 55 years of age at screening (inclusive); 2.Subjects must be willing and able to give written informed consent, and must sign an ethics-committee-approved Informed Consent Form prior to any study-related procedures being performed; 3.Body mass index between 19 to 32 kg/m2 (inclusive) and a weight of at least 50 kg; 4.For males: When engaging in sexual activity with a woman of childbearing potential, both the subject and his female partner must use highly effective contraception, consisting of 2 forms of birth control (1 of which must be a male barrier method such as latex or polyurethane condoms) from screening, throughout the clinical study period, and for 90 days after the final study drug administration; 5.For males: The subject must not donate sperm from screening, throughout the clinical study period, and for 90 days after the final study drug administration; 6.For females: The subject must have been surgically sterilized (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation; proper documentation required) at least 6 months before screening, or be postmenopausal (defined as 24 months without menses before screening, with an estradiol level of < 200 pmol/L and a follicle-stimulating hormone level of > 40 IU/L at screening); 7.Able to communicate with the investigator and study staff; 8.Willing and able to comply with the requirements of the study, scheduled visits, laboratory tests, and other study procedures; 9.Agrees to abide by study restrictions and agrees to remain in the study unit for the confinement period.",EudraCT Number: 2016-003859-30 NL59310.056.16 TrialTroveID-285693,Adults,year(s),year(s),285693,Healthy subjects,55.0,18.0,"1.History of clinically significant neurologic, psychiatric, endocrine, pulmonary, cardiovascular, gastrointestinal, hepatic, pancreatic, renal, metabolic, hematologic, immunologic, or allergic disease, or other major disorders; 2.Current significant medical or psychiatric condition, including suicidal ideation in the last 6 months (as assessed by the C-SSRS) or a lifetime suicide attempt; 3.Clinical laboratory test values outside the normal range at screening or baseline unless assessed by the investigator as clinically non-significant values; 4.Supine systolic blood pressure <90 or >140 mmHg, supine diastolic blood pressure <50 or >90 mmHg, pulse rate <40 or >110 bpm, or elevated body temperature at screening or baseline; 5.History of serious adverse reaction or serious hypersensitivity to any drug; 6.Evidence of clinically significant hepatic or renal impairment including alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >1.5 x the upper limit of normal (ULN), or bilirubin >1.2 x ULN, or GGT > 2.5 x ULN, or creatinine clearance (determined by MDRD) of <70 mL/min1,73m^2; 7.History of seizures; 8.History or presence of an abnormal ECG, including, but not limited to, complete left bundle branch block, second- or third-degree heart block, evidence of prior myocardial infarction, or any other abnormality that is clinically significant in the investigator’s opinion or precludes accurate interpretation and calculations of cardiac intervals (e.g., QT, QRS); 9.A QTcF value>450 msec or QRS >120 msec demonstrated in at least two ECGs recorded more than 30 min apart; 10.Hemoglobin level <7.5 mmol/L; 11.Any blood donation or other loss of blood greater than 500 mL within 3 months of screening or plasma donation within 2 weeks of screening; 12.Participation in any other investigational drug study within 90 days of first study drug administration, or previous participation in a study with DNL104. 13.Use of any prescription drug within 7 days or 5 half-lives (whichever is longer) of the first dose administration and anticipated use through the follow-up 1 visit; 14.Use of any over-the-counter medication (including vitamin/mineral supplements, and herbal medicines such as St. John's Wort) within 7 days of the first dose administration and anticipated use through the follow-up 1 visit; 15.Any surgical or medical condition possibly affecting drug absorption (e.g., gastrectomy); 16.Poor peripheral venous access; 17.Alcohol, caffeine, or grapefruit consumption within 48 h before dosing; 18.Average daily caffeine intake greater than 450 mg/ day (equivalent to 4 cups per day); 19.History of alcoholism, drug abuse, or drug addiction in the last 2 years; 20.Positive drug or alcohol test at screening; 21.Use of tobacco or nicotine products within the previous month before the first dose administration; 22.Positive serology for HIV, HBV, or HCV, by HIV1 and HIV2 antibodies, Hepatitis B antigen or Hepatitis C antibodies, respectively; 23.Subjects who are part of the clinical staff personnel or family members of the clinical site staff; 24.Any other issue which, in the opinion of the Investigator, will make the subject ineligible for study participation; 25.Subjects who are unwilling to agree to any food restrictions that may be required.",I,Both
0,Healthy Male Participants,"- Males, aged between 18 to 65 years, inclusive - Body mass index between 18.0 and 32.0 kg/m2 - In good health - When engaging in sex with a woman of child bearing potential, both the male participant and his female partner must use highly effective contraception - History of a minimum of 1 bowel movement per day",DNLI-F-0009 NCT06281158 TrialTroveID-505876,Adults,year(s),year(s),505876,Healthy subjects,65.0,18.0,"- History or clinical manifestation of any clinically significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder - Have a history of malignancy, except fully resected basal cell carcinoma - History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance - History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs - Have previously completed or withdrawn from this study or any other study investigating DNL343 and have previously received DNL343",I,Male
1,Patients with Amyotrophic Lateral Sclerosis.,No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT NCT04297683).,2019P003518G HEALEY ALS Platform – Regimen G NCT05842941 TrialTroveID-449641,Adults; Older Adults,year(s),year(s),449641,Delay Disease Progression,100.0,18.0,"The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683). Diagnosis of epilepsy or seizure within 6 months of randomization Hypersensitivity to DNL343 or any of the excipients contained within the DNL343 drug product The concomitant use of prescription or over-the-counter (OTC) medications that are inducers of certain cytochrome P450 enzymes, substrates of certain cytochrome P450 enzymes, or substrates of certain drug transporters.",Ii/Iii,Both
0,Patients with sporadic or familial ALS,"Diagnosis of sporadic or familial ALS < or = 4 years since ALS symptom onset Stable doses of approved ALS treatments (riluzole and/or edaravone) for at least 2 months prior to screening Participants must be able to swallow the study intervention Vital capacity >50% predicted at screening Women must have been surgically sterilized, be postmenopausal, or for participants of childbearing potential, must not be pregnant, and both the participant and the male partner must use highly effective contraception Men, and sex partner if a woman of childbearing potential, must use highly effective contraception",DNLI-F-0003 EudraCT Number: 2021-001766-37 NCT05006352 NL77969.056.21 TrialTroveID-393846,Adults; Older Adults,year(s),year(s),393846,Delay Disease Progression,80.0,18.0,"Any history of unstable or poorly controlled psychiatric, endocrine, pulmonary, cardiovascular, gastrointestinal, hepatic, pancreatic, renal, metabolic, hematologic, immunologic, or allergic disease, or other major disorders Positive serum pregnancy test or currently lactating or breastfeeding History of malignancy within 5 years History of clinically significant neurologic disorders other than ALS",I,Both
0,Healthy subjects,Body mass index (BMI) > or =18.5 to < 30 kg/m^2 and body weight of at least 50 kg For women: Must have been surgically sterilized or be postmenopausal.,DNLI-F-0002 NCT04581772 TrialTroveID-386637,Adults,year(s),year(s),386637,Healthy subjects,55.0,18.0,"History of clinically significant endocrine, pulmonary, cardiovascular, gastrointestinal, hepatic, pancreatic, renal, metabolic, hematologic, immunologic, or allergic disease, or other major disorders History of malignancy, except fully resected basal cell carcinoma History of clinically significant neurologic or psychiatric diseases; head trauma with loss of consciousness; or clinically significant depression or suicidal ideation",I,Both
0,Healthy subjects.,"Women of non-childbearing potential and men; aged 18-50 years, inclusive BMI 18-32 kg/m², inclusive, and body weight of at least 50 kg",DNLI-F-0001 EudraCT Number: 2019-004027-21 NCT04268784 NL72239.056.19 TrialTroveID-355585,Adults,year(s),year(s),355585,Healthy subjects,50.0,18.0,"History of clinically significant neurologic, psychiatric, endocrine, pulmonary, cardiovascular, gastrointestinal, hepatic, pancreatic, renal, metabolic, hematologic, immunologic, or allergic disease, or other major disorders",I,Both
0,Patients with frontotemporal dementia and Healthy Participants,"Part A: Women of non-childbearing potential (surgically sterilized or post menopausal) or men, aged =18 to = 55 years BMI of = 18 to = 32 kg/m² When engaging in sex with a woman of child bearing potential, both the male participant and his female partner must use highly effective contraception Part B: Women of non-childbearing potential (surgically sterilized or post menopausal) or men, aged > or =18 to < or = 80 years. Women who are of childbearing potential but on highly effective, low user dependent contraceptive methods will be allowed. BMI of > or = 18 to < or = 32 kg/m² Part C:Have a Clinical Dementia Rating® plus National Alzheimer's Coordinating Center frontotemporal lobar degeneration global score > or = 0.5 Have confirmed granulin (GRN) mutation via genetic testing or historical records available for review by investigator When engaging in sex with a woman of child bearing potential, both the male participant and his female partner must use highly effective contraception All participants who completed Part B of this trial are eligible for an 18-month OLE if the participant has no unresolved clinically significant TEAEs, where continued dosing may represent a risk to participant safety.",DNLI-H-0001 EudraCT Number: 2021-005733-16 FTD-GRN NCT05262023 NL81299.056.22 TrialTroveID-422947,Adults; Older Adults,year(s),year(s),422947,Frontotemporal Dementia; Healthy subjects; Unspecified PSP,80.0,18.0,"Have any history of clinically significant neurologic, psychiatric, endocrine, pulmonary, cardiovascular, gastrointestinal, hepatic, pancreatic, renal, metabolic, hematologic, immunologic, or allergic disease, or other major disorders Have a history of malignancy, except fully resected basal cell carcinoma or other malignancies at low risk of recurrence Have a clinically significant history of stroke, cognitive impairment due to causes other than FTD, seizure within 5 years of screening, or head trauma with loss of consciousness within 2 years of screening Have a positive serum pregnancy test or are currently lactating or breastfeeding",Iii,Both
0,Subjects With Amyotrophic Lateral Sclerosis,"Key Inclusion Criteria (Double-Blind Part): Women of non-childbearing potential and men, aged 21-80 years Willingness and ability to complete all aspects of the study; participant should be capable of completing assessments either alone or with help of a caregiver Diagnosis of laboratory-supported probable, probable, or definite (sporadic or familial) ALS according to the El Escorial World Federation of Neurology revised research diagnostic criteria Less than 3 years since symptom onset Forced vital capacity (FVC) >50% predicted measured within 30 days of screening If subject is taking approved ALS treatments (riluzole and/or edaravone), doses must be stable for > or =2 months prior to screening and subject is expected to stay on a stable regimen throughout the study 11) Subjects must be able to swallow the study capsules. Open Label Extension: 1) Successful completion of both periods of the double-blind, crossover part of this study within 6 months of anticipated first dose of OLE 2) Body weight of at least 45 kg 6) Stable prescription medications including riluzole and/or edaravone for > or = 1 month. New prescription medications or changes to existing medications during this trial period are allowed with investigator discretion. 7) Subjects must be able to swallow the study capsules; thickening agents to assist in swallowing are permitted. Key Inclusion Criteria (Open-Label Extension): Successful completion of both periods of the the double-blind, crossover part of the study Continued diagnosis of laboratory-supported probable, probable, or definite (sporadic or familial) ALS according to the El Escorial World Federation of Neurology revised research diagnostic criteria",DNLI-D-0003 EudraCT Number: 2018-003623-11 NCT03757351 NL67676.056.18 TDR16536 TrialTroveID-337679,Adults; Older Adults,year(s),year(s),337679,Delay Disease Progression,80.0,21.0,"Key Exclusion Criteria (Double-Blind Part): History of a clinically significant non-ALS neurologic disorder (other than frontal temporal lobe dementia), including, but not limited to, muscular dystrophy, spinal stenosis, peripheral neuropathy, inherited neuropathies, AD, Parkinson's disease, Lewy body dementia, vascular dementia, Huntington's disease, epilepsy, stroke, multiple sclerosis, brain tumor, or brain infection or abscess Unstable or poorly controlled comorbid disease process of any organ system currently requiring active treatment or likely to require treatment adjustment during the study Key Exclusion Criteria (Open-Label Extension): Presence of laboratory abnormalities, physical examination findings, or AEs determined to be clinically significant by the investigator from the double-blind part of the study that have not resolved by the final follow-up visit as part of the double-blind study period New diagnosis of clinically significant neurological disorder (other than frontal temporal lobe dementia) 3) History of head trauma resulting in loss of consciousness or clinically significant concussion within 1 year prior to screening, or any head trauma that resulted in permanent neurological impairment. 4) Clinical laboratory test values ??outside the normal range for screening, unless assessed by the investigator and the CRO medical monitor as clinically acceptable or as specified in other exclusion criteria below. 21) Use or intention of using prohibited prescription or freely available medicines (including vitamin / mineral supplements and herbal medicines such as St. John's wort) that are moderate to strong CYP3A inducer or inhibitor, within 7 days or 5 half-lives (which is longer) after the first dose administration until the last follow-up visit. Other medicines are allowed if the patient has a stable regimen at least 30 days before the first administration. Non-systemic medications (eg topical medications that are unlikely to achieve meaningful plasma exposure), subcutaneous lidocaine, paracetamol and caffeine for the treatment of post-LP headaches, and medications necessary to treat AEs and medical emergencies are permitted. Others medication can also be allowed if this has been agreed jointly by both the researcher and the sponsor. 22) The use of anticoagulation, daily aspirin> 100 mg, or anti-platelet medication within 5 half-times of times for the first administration of study medication or anticipated necessity of using this medication up to and including the follow-up visit. Cave: daily use of OTC NSAIDs at doses as described in the OTC label for less than 3 consecutive days is permitted. 23) History of bleeding diseases such as thrombocytopenia (defined as thrombocytes <140,000 / uL), von Willebrand disease, hemophilia, and other factor deficiencies. Open Label Extension: 1) Presence of laboratory abnormalities, physical examination findings or side effects that were found to be clinically significant by the investigator from the double-blind part of the study that were not resolved by the FFU visit 2) For test subjects who received the double-blind part of the examination> completed 14 days prior to initiation of OLE, presence of clinical laboratory test values outside the normal range in OLE screening, significant abnormalities in physical examination or persistent side effects of the double-blind part of the examination, unless assessed by the investigator as clinically acceptable 3) New diagnosis of a clinically significant non-ALS neurological disorder (other than frontal temporal lobe dementia), including, but not limited to: muscular dystrophy, spinal stenosis, peripheral neuropathy, hereditary neuropathies, AD, Parkinson's disease, Lewy body dementia, vascular dementia, Huntington's disease, epilepsy, stroke, multiple sclerosis, brain tumor or brain infection or abscess 4) Any diagnosis of new disease that was excluded in the randomized, double-blind part of the study. Newly developed spinal cord disease or other abnormalities in the lumbar region that may disrupt the lumbar puncture (e.g. skin infection, structural abnormalities) are permitted to Investigator's discretion 10) Participation in any other drug research or use of research drugs within 7 days or 5 half-lives (which is longer) prior to OLE initiation, or planned use of research drugs during the OLE 12) Use of or intention to do so to use unauthorized prescription or self-care medications (including vitamin / mineral supplements and herbal medicines such as St. John's wort) that are moderate to strong CYP3A4 / 5 inducer or inhibitor within 7 days or 5 half-lives (whichever is longer) of the first dose. Note: other medications are allowed if the patient is at least 30 days before the first dose has followed a stable regimen. Non-systemic drugs (eg, local drugs that are unlikely to achieve significant plasma exposure ), subcutaneous lidocaine, paracetamol and caffeine for the treatment of post-LP headaches, and drugs necessary for the treatment of AEs and medical emergencies are permitted. Other medication may also be permitted if jointly agreed by both the researcher and the sponsor. 13) Use of anticoagulation, daily aspirin> 100 mg, or platelet inhibitors within 5 half-lives before the first administration of the study drug or the expected need for these drugs during the last follow-up visit. Note: the use of OTC NSAIDs in doses specified on the OTC drug label for less than 3 consecutive days is permitted. 14) History of bleeding disorders, including but not limited to thrombocytopenia (defined as platelets <140,000 / µL), von Willebrand 's disease , hemophilia and other deficiencies of factors.",I,Both
0,Healthy Subjects,,TrialTroveID-327301,,,,327301,(N/A); Healthy subjects,,,,I,
0,MS and ALS patients,,TrialTroveID-322502,,,,322502,Unspecified; Unspecified MS,,,,I,
0,Healthy subjects,"- Male or female participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent - Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring - Body weight between 50.0 and 100.0 kg, inclusive, if male, and between 40.0 and 90.0 kg, inclusive, if female, body mass index between 18.0 and 30.0 kg/m^2, inclusive - All contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies - Having given written informed consent prior to undertaking any study-related procedure",BDR16957 NCT05797701 TrialTroveID-464738 U1111-1256-9220,Adults,year(s),year(s),464738,(N/A),55.0,18.0,"- Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, or infectious disease, or signs of acute illness - Any medication (including St John's Wort) within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of the medication, with the exception of hormonal contraception or menopausal hormone replacement therapy; any non-live Covid-19 vaccine within the last 2 weeks before randomization, any live attenuated vaccine within the last 28 days before randomization and any other non-vaccine biological drugs given within 4 months before randomization - Positive result for hepatitis B, C or human immunodeficiency virus (HIV) - Positive result on urine drug screen - Positive urine alcohol test - Positive severe acute respiratory syndrom coronavirus 2 (SARS-CoV-2) test - Any consumption of citrus fruits (grapefruit, orange, etc) or their juices within 5 days before inclusion The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.",I,Both
0,Healthy volunteers,"Male and/or female participant, between 18 and 55 years of age, inclusive. Body weight between 50.0 and 100.0 kg, inclusive, if male, and between 40.0 and 90.0 kg, inclusive, if female, body mass index between 18.0 and 30.0 kg/m2, inclusive. Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination). Having given written informed consent prior to undertaking any study-related procedure. Not under any administrative or legal supervision or under institutionalization due to regulatory or juridical order.",NCT05795907 TDU16519-TDR16520 TrialTroveID-458128 U1111-1254-0034,Adults,year(s),year(s),458128,(N/A); Healthy subjects,55.0,18.0,"Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteo-muscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness. Personal medical history of seizure. Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for vomiting only: more than twice a month). Any medication (including St John's Wort) within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of the medication, with the exception of hormonal contraception or menopausal hormone replacement therapy; any vaccination within the last 28 days and any biologics (antibody or its derivatives) given within 4 months before inclusion. Positive result for hepatitis B, C or HIV Positive result on urine drug screen Positive alcohol test. Any consumption of citrus fruits or their juices within 5 days before inclusion. Current psychiatric disorder, suicidal ideation in the previous 6 months (as assessed by the C-SSRS), or a lifetime suicide attempt. Additional exclusion criteria applied, and specially for Part 1b, criteria related to the study procedure of lumbar puncture. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.",I,
0,Adult participants with ALS.,"Adults with diagnosis of possible, clinically probable, clinically probable laboratory-supported, or definite ALS, with disease duration 2 years and respiratory function SVC > or = 60% at screening Type of participant and disease characteristics Diagnosis of possible, clinically probable ALS, clinically probable laboratory supported ALS, or clinically definite ALS according to the revised version of the El Escorial World Federation of Neurology criteria Time since onset of first symptom of ALS ≤2 years. Slow Vital Capacity (SVC) ≥60% of the predicted value. Be able to swallow the study tablets at the screening visit. Either not currently receiving riluzole or on a stable dose of riluzole for at least 4 weeks before the screening visit. Participants receiving riluzole are expected to remain on the same dose throughout the duration of the study. Either not currently receiving edaravone or on the approved standard schedule of edaravone treatment. Participants receiving edaravone must have completed at least 1 cycle of treatment before the screening visit and are expected to continue edaravone treatment throughout the duration of the study. Either not currently receiving the combination of sodium phenylbutyrate and taurursodiol or on the approved standard schedule of the combination of sodium phenylbutyrate and taurursodiol treatment for at least 4 weeks before the screening visit. Participants receiving the combination of sodium phenylbutyrate and taurursodiol are expected to remain on the approved standard schedule throughout the duration of the study. Participants with a body weight no less than 45 kg and body mass index no less than 18 kg/m2 at the screening visit Female participants with childbearing potential are eligible to participate if they are not pregnant or breastfeeding and agree to use adequate contraceptive method during study intervention period and for at least 32 days after the last dose of study drug. Male participants must agree to use highly effective contraceptive method during the study period and for at least 92 days following their last dose of the study drug. Male participants must not donate sperms for the duration of study and 92 days after last dose of study drug. Eligibility criteria include participants aged18–80 years with diagnosis of possible, clinically probable, clin-ically probable laboratory-supported, or definite ALS, with dis-ease duration2 years and slow vital capacity60% atscreening",ACT16970 CCR-21-72 CTR20221567 EUCT number: 2023-509442-36-00 EudraCT Number: 2021-004156-42 HIMALAYA jRCT2031220078 NCT05237284 NL79644.041.21 TrialtroveID-415581 U1111-1263-5766,Adults; Older Adults,year(s),year(s),415581,Delay Disease Progression,80.0,18.0,"A history of seizure (History of febrile seizure during childhood is allowed). Having central IV lines, such as a peripherally inserted central catheter (PICC XE ' PICC ' \f Abbreviation \t 'peripherally inserted central catheter' ) or midline or portacath lines. With significant cognitive impairment, psychiatric disease, other neurodegenerative disorder (eg, Parkinson disease or AD), substance abuse other causes of neuromuscular weakness, or any other condition that would make the participants unsuitable for participating in the study or could interfere with assessment or completing the study in the opinion of the Investigator. History of recent serious infection (eg, pneumonia, septicemia) within 4 weeks of the screening visit; infection requiring hospitalization or treatment with IV antibiotics, antivirals, or antifungals within 4 weeks of screening; or chronic bacterial infection (such as tuberculosis) deemed unacceptable as per the Investigator's judgment. With active herpes zoster infection within 2 months prior to the screening visit. A documented history of attempted suicide within 6 months prior to the screening visit, present with suicidal ideation of category 4 or 5 on the Columbia Suicide Severity Rating Scale (CSSRS) , or in the Investigator's judgment are at risk for a suicide attempt. History of unstable or severe cardiac, pulmonary, oncological, hepatic, or renal disease or another medically significant illness other than ALS precluding their safe participation in this study. Participants who are pregnant or are currently breastfeeding. A known history of allergy to any ingredients of SAR443820. Currently or previously treated with any strong or moderate CYP3A4 inhibitors or strong CYP3A4 inducers within the specified washout period before the screening visit. Received a live vaccine within 14 days before the screening visit. Participants with concurrent participation in any other interventional clinical study or who have received treatment with another investigational drug (eg sodium phenylbutyrate or taurursodiol ) within 4 weeks or 5 halflives of the investigational agent before the screening visit, whichever is longer. Participants who have received stem cell or gene therapy for ALS at any time in the past. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3.0 × upper limit of normal (ULN) Bilirubin >1.5 × ULN unless the participant has documented Gilbert syndrome (isolated bilirubin >1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin is <35%) Serum albumin <3.5 g/dL Estimated glomerular filtration rate <60 mL/min/1.73 m2 (Modification of Diet in Renal Disease [MDRD]) The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.",Ii,Both
0,Healthy volunteers,"East Asian (Chinese and Japanese) male and/or female participant must be 20 to 55 years of age inclusive, at the time of signing the informed consent. Chinese or Japanese ethnicity, according to the following criteria: Chinese; born in China or ethnic Chinese born outside of China, and a descendent of 4 ethnic Chinese grandparents who were all born in China. Japanese; born in Japan or ethnic Japanese born outside of Japan, and a descendent of 4 ethnic Japanese grandparents who were all born in Japan. Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and ECG. Body weight within 50.0 and 100.0 kg, inclusive, if male, and between 40.0 and 90.0 kg, inclusive, if female, and body mass index (BMI) within the range 18.0 and 30.0 kg/m2, inclusive",EudraCT Number: 2021-001076-42 NCT04982991 PKM17247 TrialTroveID-377375 U1111-1264-3008,Adults,year(s),year(s),377375,Healthy subjects,55.0,20.0,"Medical history of any seizure. Any medication (including St John's Wort) within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of the medication, any live attenuated vaccine given within 3 months or any non-live vaccine given within 2 weeks before inclusion, and any biologics (antibody or its derivatives) given within 4 months before inclusion. Positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test. Current psychiatric disorder, suicidal ideation in the previous 6 months (as assessed by the Columbia-Suicide Severity Rating Scale [C-SSRS]), or a lifetime suicide attempt. A ""yes"" response to questions 4 or 5 on the Suicidal Ideation section, or a score of 4 or 5 on the Intensity of Ideation section of the baseline/screening version of the C-SSRS at screening, or on the Since Last Visit version of the C-SSRS at baseline. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial",I,Both
0,Patients with Amyotrophic Lateral Sclerosis,"Participants who complete the Day 180 Visit in VMALS-002-2 are eligible to enroll in this extension study, VMALS-002-2b.",NCT05176093 REViVALS-1B TrialTroveID-422050 VMALS-002-2b,Adults; Older Adults,year(s),year(s),422050,Delay Disease Progression,80.0,18.0,,Ii,Both
0,Subjects with amyotrophic lateral sclerosis.,"Clinically definite or probable Amyotrophic Lateral Sclerosis (ALS) or laboratory-supported probable ALS as defined in the revised El Escorial/Airlie House diagnostic criteria The site of onset of ALS symptoms is a limb and experiencing symptoms of lower motor dysfunction (e.g., weakness, atrophy, cramps, poor circulation, etc.) with upper motor neuron symptoms (e.g., weakness, brisk reflexes, spasticity) Onset of ALS symptoms < or = 4 years Slow Vital Capacity (SVC) > or = 50% of predicted value at Screening Not taking riluzole, or on a stable dose (defined as no noted toxicities) for at least 30 days prior to Screening and throughout the study Not taking edaravone or on a maintenance cycle for at least 30 days prior to Screening and throughout the study For females of childbearing potential, a negative urine pregnancy test at Screening and on Day 0 Male Participants and their female partners must agree to use double-barrier contraception during the study or provide proof of postmenopausal state (minimum 1 year) or surgical sterility Male Participants must not donate sperm during the study Female Participants must be nonpregnant, nonlactating, and either postmenopausal for at least 1 year, or surgically sterile for at least 3 months, or agree to use double-barrier contraception from 28 days prior to randomization (Day 0) and/or their last confirmed menstrual period prior to study randomization (whichever is longer) until the end of the study Capable of complying and willing to comply with the requirements and restrictions in the informed consent form and this protocol Willing to forgo new experimental ALS treatments for at least 6 months following randomization",NCT04632225 REViVALS-1A TrialTroveID-279969 VMALS-002-2,Adults; Older Adults,year(s),year(s),279969,Delay Disease Progression,80.0,18.0,"Progressive or degenerative neurological disorder such as Alzheimer's disease, Parkinson's disease, vascular dementia, multiple sclerosis, and other neurological or vascular disorders felt by the Investigator to preclude participation Requires tracheotomy ventilation or noninvasive ventilation related to bulbar function Evidence by physical examination, history, or laboratory evaluation of significant concomitant disease with a life expectancy of < 6 months at Screening INR values > 2.0 Platelet count < 100,000/mcL Inflammatory disorder of the blood vessels (inflammatory angiopathy or vasculitis, such as Buerger's disease) Active infection (chronic infection or severe active infection that may compromise the Participant's wellbeing or participation in the study in the Investigator's judgment) Chronic inflammatory disease (e.g., Crohn's disease, rheumatoid arthritis) Positive human immunodeficiency virus (HIV) or human T-cell lymphotrophic virus (HTLV) I/II test at Screening Active acute or chronic hepatitis B Active hepatitis C Immunosuppression due to underlying disease (e.g., rheumatoid arthritis, systemic lupus erythematosus) or to currently receiving immunosuppressive drugs, (e.g., chemotherapy, corticosteroids) or to radiation therapy Stroke or myocardial infarction within 3 months prior to Screening Active deep vein thrombosis Recent history ( < 3 years) or presence of cancer except basal cell carcinoma or squamous cell carcinoma of the skin that was excised and has shown no evidence of recurrence for at least 1 year Major psychiatric disorder diagnosed in the past 6 months that has not been stabilized or in the Investigator's opinion would not allow the patient to participate in the scheduled procedures Use of an investigational drug for the treatment of ALS in the past 30 days or 5 half-lives (if available), whichever is longer, or previous participation in a clinical study with Engensis Stem cell administration for investigational treatment of ALS or other conditions in the 6 months prior to Screening",Ii,Both
0,Subjects With Amyotrophic Lateral Sclerosis.,"Ages Eligible for Study: 21 Years to 75 Years; Genders Eligible for Study: Both Inclusion Criteria: Age >or= 21 years, but < or = 75 years Subjects diagnosed with: -Clinically definite ALS, -Clinically probable ALS, or -Clinically probable-laboratory supported ALS as specified in the revised El Escorial / Airlie House diagnostic criteria Onset of ALS < 2 years at Screening Forced Vital Capacity (FVC) > or = 60% of predicted Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) > or = 30 Not taking riluzole, or on a stable dose for at least thirty days prior to Screening (defined as no noted toxicities) Able and willing to give informed consent If female of childbearing potential, negative urine pregnancy test at Screening and using acceptable method of birth control during the study.",NCT02039401 TrialTroveID-200898 VMALS-001 / B,Adults; Older Adults,year(s),year(s),200898,Delay Disease Progression,75.0,21.0,"Exclusion Criteria: Neurological symptom(s) due to vitamin B12 deficiency Requires tracheotomy ventilation or noninvasive ventilation > 16 hours / day Comorbidities such as Parkinson's disease, schizophrenia, renal failure, or any other severe complication that, in the Investigator's opinion, will compromise the safety of the patient or confound interpretation of the data collected in this study Other neuromuscular disease Inflammatory disorder of the blood vessels (inflammatory angiopathy, such as Buerger's disease) Active infection Chronic inflammatory disease (e.g., Crohn's disease, rheumatoid arthritis) Positive HIV or HTLV at Screening Active Hepatitis B or C as determined by Hepatitis B core antibody (HBcAb), antibody to Hepatitis B surface antigen (IgG and IgM; HBsAb), Hepatitis B surface antigen (HBsAg) and Hepatitis C antibodies (Anti-HCV) at Screening Subjects with known immunosuppression or currently receiving immunosuppressive drugs, chemotherapy or radiation therapy Stroke or myocardial infarction within last 3 months Patients with a recent history (< 5 years) of malignant neoplasm except basal cell carcinoma or squamous cell carcinoma of the skin (if excised and no evidence of recurrence); Subjects requiring > 81 mg daily of acetylsalicylic acid; subjects may be enrolled if willing/able to switch to <or= 81 mg daily of acetylsalicylic acid or to another medication Subjects requiring regular COX-2 inhibitor drug(s) or non-specific COX-1/COX-2 inhibiting drugs, or high dose steroids (excepting inhaled steroids); subjects may be enrolled if willing/able to undergo medication wash-out prior to the first dosing and to refrain from taking these drugs for the duration of the study Have used an investigational drug within 30 days of Screening Pregnant or currently lactating Major psychiatric disorder in past 6 months Known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or who in the opinion of the Investigator are not suitable to participate.",Iii,Both
1,"Patients Diagnosed as Mild Neurocognitive Disorder criteria with sub types of Alzheimer’s disease, Frontotemporal lobar degeneration, Lewy body disease, Vascular disease as per DSM V criteria","Age above 60 years of either sex. Diagnosed as Mild Neurocognitive Disorder criteria with sub types of Alzheimer’s disease, Frontotemporal lobar degeneration, Lewy body disease, Vascular disease as per DSM V criteria Mini Mental State Examination (MMSE) < 2",CTRI/2019/08/020596 TrialTroveID-356001,Adults; Older Adults,year(s),year(s),356001,(N/A); Frontotemporal Dementia; Lewy Body Dementia; Mild; Vascular Dementia,80.0,60.0,"Other Neuro cognitive disorders due to Parkinson’s disease, trauma, medical conditions etc. Substantial neuropsychiatric or behavioral symptoms. Patients with severe or uncontrolled somatic disorders will be excluded. Patients with clinically relevant depression (CSDD>10). Patient on any other medications like psychotropic, neurotropic etc since 4 weeks. Patient with substance abuse like alcohol, tobacco etc",Iv,Both
1,Subjects with Motor Neuron Disease.,"Gender: Both, Min age: 18 years, Max age: 85 years Inclusion criteria: At the age of 18 years old and above, not limited to men and women. Meet the diagnostic criteria for ALS diagnosis / probable. The patients' informed consent to accept the trial. Women must not be able to become pregnant for the duration of the study. Women of childbearing potential must have a negative pregnancy test at screening and be non-lactating.",ChiCTR-TRC-14004981 TrialTroveID-213653,Adults; Older Adults,year(s),year(s),213653,Unspecified,85.0,18.0,"Exclusion criteria: Have allergy history of donepezil hydrochloride, piperidine derivatives or formulation excipients patients. Have Semi lactose intolerance, Lapp lactase deficiency or glucose galactose malabsorption and other rare genetic problems patients. Associated with other serious diseases including liver, kidney, cardiovascular disease. Combined with mental illness or severe neurosis patients. Unable to express subjective symptoms. Clinical evidence of unstable medical or psychiatric illness in the investigator’s judgment.",Iv,Both
1,Subjects diagnosed with Amyotrophic Lateral Sclerosis who have mild to moderate cognitive impairment and speak English.,,TrialTroveID-105587,,,,105587,Symptom relief,,,,Iv,
1,Patients with Alzheimer's disease and other dementias,"Inclusion criteria for clinical cohort construction of Alzheimer's disease and other dementias: ①Age ≥ 50 and ≤ 85 years. ②Meet the diagnostic criteria for dementia or MCI. ③Neurocognitive assessment scores: 11 ≤ MMSE ≤ 28, CDR ≤ 2. ④Patients and their family members are informed and sign an informed consent form. Inclusion criteria for drug interventions: ①Age ≥ 50 and ≤ 85 years old; ② Complies with the 2011 NIA-AA AD diagnostic criteria; ③ Patients with mild to moderate illness have a neuropsychological score of 11 points ≤ MMSE ≤ 24 points, 0.5 ≤ CDR ≤ 1 point; ④ The total score of the improved HACHINSKI ischemic score (m-HIS) is less than 4 points; ⑤ Hamilton Depression Scale (24 item version) with a total score of ≤ 20 points; ⑥ Head MRI plain scan during screening period: showing the highest possibility of AD (with hippocampal atrophy); If the patient can provide a head MRI film that meets the requirements of the protocol within 3 months before screening, it can be used as a screening basis and does not need to be repeated; If the inclusion criteria for drug intervention are met, the skull MRI that meets the protocol requirements still needs to be rescanned during the baseline period; ⑦ There were no obvious positive signs in the nervous system examination; ⑧ The subjects should have stable and reliable caregivers, or at least have frequent contact with caregivers (at least 3 days per week and at least 2 hours per day), who will assist the patients in participating in the entire study process. Caregivers must accompany the subjects during research visits and assist them in completing scales such as NPI and ADCS-ADL23. ⑨ Patients and their families are informed and sign informed consent forms.",ChiCTR2300078043 TrialTroveID-493918,Adults; Older Adults,year(s),year(s),493918,Cognitive Function; Frontotemporal Dementia; Lewy Body Dementia; Mild; Mild Cognitive Impairment/Prodromal; Moderate; Severe; Vascular Dementia,85.0,50.0,"Exclusion criteria for clinical cohort construction of Alzheimer's disease and other dementia: ①Presence of other neurological diseases that can cause brain dysfunction (such as depression, brain tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, traumatic brain injury, normal pressure hydrocephalus, etc.). ②Presence of other systemic diseases that can cause cognitive impairment (such as liver failure, renal failure, abnormal thyroid function, severe anemia, folate or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.). ③Suffering from diseases that prevent cooperation in completing cognitive assessments. ④Presence of contraindications for magnetic resonance imaging (MRI). ⑤Presence of mental and neurological developmental delays. ⑥Refusal to undergo blood tests. ⑦Refusal to sign an informed consent form. Exclusion criteria for drug interventions: ① Other neurological diseases that can cause brain dysfunction (such as depression, brain tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, traumatic brain injury, normal intracranial pressure hydrocephalus, etc.); ② Other systemic diseases that can cause cognitive impairment (such as liver dysfunction, kidney dysfunction, thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.); If blood test data from patients within the first half month of screening can be obtained, it can be used as a screening basis and does not need to be collected repeatedly; If the researcher is unable to determine whether the subject's condition has changed, additional pre enrollment blood tests can be added; ③ Suffering from diseases that cannot cooperate in completing cognitive tests; ④ There are contraindications to magnetic resonance imaging; ⑤ Existence of mental and neurological developmental delays; ⑥ Refuse to draw blood; ⑦ MRI examination showed significant focal lesions, with one of the following: a>2 infarcted lesions with a diameter greater than 2cm, or mHIS total score ≥ 4; b. Key areas such as the thalamus, hippocampus, entorhinal cortex, paraolfactory cortex, angular gyrus, cortex, and other subcortical gray matter nuclei in infarcted areas; c. Fazekas Scale grading of white matter damage ≥ 3; ⑧ There are abnormal laboratory indicators: liver function (ALT, AST), renal function (Cr), creatine kinase exceeding the upper limit of the normal range by 2 times; ⑨ Participants in clinical research on other drugs; ⑩ Within one month prior to the start of this study, other medications that affect cognitive function were used, such as memantine, cholinergic drugs, antipsychotic drugs, anxiolytics, and cognitive enhancers; ⑪ Individuals who are allergic to donepezil or citicoline capsules or have a history of adverse reactions; ⑫ Researchers believe that participants are not suitable for the experiment; ⑬ Refusing to sign informed consent form.",Iv,Both
1,Patients with Amyotrophic Lateral Sclerosis.,,TrialTroveID-338865,Adults; Older Adults,year(s),year(s),338865,Symptom relief,69.0,35.0,,Iv,Both
1,Patients with Amyotrophic Lateral Sclerosis.,,TrialTroveID-167932,,,,167932,Symptom relief,,,,Iv,
1,Patients had cramps and diagnosed with Amyotrophic Lateral Sclerosis.,"Ages Eligible for Study: 18 Years and older Inclusion Criteria: Patients must be at least 18 years of age and have full legal capacity. Patients must voluntarily give written informed consent. Patients diagnosed with possible, probable laboratory supported, probable or definite ALS according to the revised El Escorial criteria (Brooks 2000). Patients must score severity of cramps on the VAS 5 or more. Patients must be able to communicate and report adverse events by phone. Patients must have laboratory parameters within the following limits: Creatinine, Bilirubin,Transaminases less than 3x upper limit of normal. Patients may take any medication for the treatment of ALS (ALS -specific and -symptomatic) but may not change this medication during the study period. Patients must not have cannabis or cannabinoids for at least one month prior to the study and agree not to use it at all during the study. They have to have a negative urinary test for cannabinoids at baseline. Pre-menopausal females must provide negative pregnancy test within fourteen days before beginning of study participation and have to apply adequate (barrier) birth-control methods. Patients must agree not to drive a vehicle or use dangerous machines during the entire study period.",NCT00812851 THC SG TrialTroveID-103048,Adults; Older Adults,year(s),,103048,Symptom relief,,18.0,"Exclusion Criteria: Patients who are not willing or able to sign the consent form. Doubt of investigator concerning compliance of the patient. Patients who have a history of failure to respond to, or had significant adverse effects from or hypersensitivity to THC or any cannabinoid. Patients who have significant concomitant illness(-es), or acute, uncontrolled infections, which might make evaluation of treatment and side effects difficult. Patients with a history of significant psychiatric disorder, explicitly of schizophrenia. Patients who are current drug abusers, including alcohol abusers. Patients with severe coronary artery disease or hemodynamically relevant ECG-documented arrhythmia. Pregnancy or breast feeding.",Iv,Both
0,,"1. Male or female participants, at least 18 years of age. 2. Clinically diagnosed with amyotrophic lateral sclerosis (ALS), fronto-temporal dementia (FTD), or both; or a carrier of a mutation known to cause ALS or FTD (with or without symptoms); or a normal control. 3. Participant is able and willing to undergo testing (psychometric testing, MRI or CT, PET, radioactive tracer injection; for those unable to undergo an MRI, CT will be used to generate regions-of-interest). 4. Pre-menopausal women will undergo a urine pregnancy test within 24 hours of drug administration.",IND 123119 Protocol B NCT02414230 T807ALS,Adults; Older Adults,year(s),,255308,,,18.0,"1. Has any condition that, in the Investigator's opinion, could increase risk to the participant, limit the participant's ability to tolerate the experimental procedures, or interfere with the collection/analysis of the data (for example, participants with significant respiratory involvement may not be able to lie flat during the scanning procedures). 2. Is deemed likely unable to perform the imaging procedures for any reason. 3. Has a high risk for Torsades de Pointes or is taking medications known to prolong QT interval. 4. Has hypersensitivity to F 18 T807 or any of its excipients. 5. Contraindications to PET, PET-CT or MR (e.g. electronic medical devices, inability to lie still for long periods) that make it unsafe for the individual to participate. 6. Severe claustrophobia. 7. Currently pregnant or breast-feeding.",Ii,Both
1,Canadian Patients with Amyotrophic Lateral Sclerosis,,TrialTroveID-511751,,,,511751,Unspecified,,,,Iii,Both
1,Patients with Amyotrophic Lateral Sclerosis,Subjects must provide a signed and dated informed consent form (ICF) to participate in the study. Subjects must be able (in the judgment of the Investigator) to understand the nature of the study and all risks involved with participation in the study Subjects must be willing to cooperate and comply with all protocol restrictions and requirements. Subjects who successfully complete Week 96 of Study MT-1186-A03 or Week 48 of Study MT-1186-A04 and have been compliant with study drug (80-120%).,jRCT2041220069 MT-1186-A-301 NCT05568615 TrialTroveID-444366,Adults; Older Adults,year(s),,444366,Delay Disease Progression,,18.0,"Subjects of childbearing potential unwilling to use a highly effective method of contraception from the Visit #1 until 3 months after the last dose of study medication. Subjects who have a significant risk of suicide. Subjects with any suicidal behavior or suicidal ideation of type 4 (active suicidal ideation with some intent to act, without a specific plan) or type 5 (active suicidal ideation with specific plan and intent) based on the C-SSRS at Week 96 of the A03 study or at Week 48 of the A04 study. Subjects who are not eligible to continue in the study, as judged by the Investigator.",Iii,Both
0,Healthy subjects,Subjects who meet all of the following criteria and who have the capability of giving informed consent will be included in the study. Healthy adult male or female volunteers Japanese Subjects aged between 20 and 45 years at the time of informed consent Subjects who have thoroughly understood the contents of the study and voluntarily provided written informed consent to participate in the study,Food Effect Study MT-1186-J06 NCT05342597 TrialTroveID-430360,Adults,year(s),year(s),430360,Healthy subjects,45.0,20.0,"Subjects who met any of the following exclusion criteria between screening and investigational product administration were excluded from the study: Subjects with a current or previous history of cardiac, hepatic, renal, gastrointestinal, respiratory, psychiatric/nervous, hematopoietic, or endocrine diseases, and those whom the investigator (or subinvestigator) deems unsuitable for the study History of drug or food allergies History of alcohol or drug abuse or dependence Body mass index (BMI) of < 18.0 or > 30.0, or a body weight of < 50 kg [BMI formula: body weight (kg)/height (m)2, rounded to one decimal place] Positive test for any of the following at screening: hepatitis B surface (HBs) antigen, serological test for syphilis, hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antigen/antibody Any clinically significant 12-lead ECG abnormality or corrected QT interval (QTc) using Fridericia's formula (QTcF) interval > or = 450 msec Blood donation or sampling with a total volume of > or = 400 mL within 12 weeks, > or = 200 mL within 4 weeks, or > or = 800 mL within one year before providing informed consent Blood component donation or blood sampling within 2 weeks before providing informed consent Subjects who have undergone any surgery known to affect the gastrointestinal absorption of drugs (except for appendectomy and herniotomy) Female subjects who do not agree to use an effective method of contraception from screening or 2 weeks before the start of investigational product administration, whichever comes earlier, to 14 days after the completion (or discontinuation) of investigational product administration. Male subjects who do not agree to use an effective method of contraception from the start of investigational product administration to 14 days after the completion (or discontinuation) of investigational product administration Subjects who have previously received edaravone Subjects who have participated in another clinical study and received an investigational product within 12 weeks before providing informed consent Subjects who have used any drugs other than the single use of acetylsalicylic acid within 7 days before the initiation of investigational product administration Use of any nutritional supplement(s) within 7 days before the initiation of investigational product administration Use of alcohol or any products containing xanthin or caffeine within 24 hours before screening and visit on Day -1 Use of grapefruit, grapefruit juice, or any processed food(s) containing these substances within 24 hours before screening and visit on Day -1 Use of any tobacco or nicotine-containing product(s) within 24 hours before screening and visit on Day -1 Female subjects who have a positive pregnancy test at screening and on Day -1, are pregnant or breast feeding, or plan to get pregnant during the study Subjects judged by the investigator (or subinvestigator) to be unsuitable for the study for any other reason",I,Both
0,Patients with amyotrophic lateral sclerosis who had PEG tubes,,PMC 3208-6 Study J05 TrialTroveID-423335,,,,423335,Unspecified,,,,I,
1,"Subjects With Amyotrophic Lateral Sclerosis adult patients diagnosed with definite or probable ALS, baseline forced vital capacity ≥70%, and baseline disease duration ≤2 years","Subjects must provide a signed and dated informed consent form (ICF) to participate in the study. Subjects must be able (in the judgment of the Investigator) to understand the nature of the study and all risks involved with participation in the study. Subjects must be willing to cooperate and comply with all protocol restrictions and requirements. Subjects will be male or female, ≥ 18 to 75 years of age at the time the ICF is signed. Subjects will be diagnosed with Definite ALS or Probable ALS according to the El Escorial revised criteria for the diagnosis of ALS. Subjects with a baseline score ≥ 2 points on each individual item of the ALSFRS- R at screening and baseline visits. Subjects have a screening and baseline %forced vital capacity (FVC) ≥ 70%. Subjects with 1- to 4-point decline for 8 weeks (±7 days) in ALSFRS-R total score between screening and baseline visits. Subjects whose first symptom of ALS has occurred within 2 years of providing written informed consent.",20-2340 BASEC2020-02985 CCR-20-158 EudraCT Number: 2019-004256-11 jRCT2031200301 MT-1186-A02 NCT04569084 SNCTP000004361 TrialTroveID-385686,Adults; Older Adults,year(s),year(s),385686,Delay Disease Progression,75.0,18.0,"Exclusions Related to Primary Diagnosis Subjects with a history of spinal surgery after the onset of ALS, such as surgery for cervical spondylosis or a herniated disc, or plans for such surgery during the study period. Exclusions Related to Other Neurological Disorders (including, but not limited to the following) Subjects with the possibility that the current symptoms may be symptoms of a disease requiring differential diagnosis, such as cervical spondylosis and multifocal motor neuropathy, cannot be ruled out. Exclusions Related to General Health or Concomitant Conditions Subjects undergoing treatment for a malignancy. Subjects with a complication that could have a significant effect on efficacy evaluations, such as Parkinson's disease or syndrome, schizophrenia, bipolar disorder, and dementia. Subjects who have the presence or history of any clinically significant (CS) disease (except ALS) that could interfere with the objectives of the study (the assessment of safety and efficacy) or the safety of the subject, as judged by the Investigator. Subjects who are female, of childbearing potential, and pregnant (a positive pregnancy test) or lactating at the screening visit (Visit 1). Subjects of childbearing potential unwilling to use acceptable method of contraception from the screening visit until 3 months after the last dose of study medication. Subjects who are sexually active who do not agree to use contraception during the study period. Subjects who have a significant risk of suicidality. Subjects with any suicidal behavior or suicidal ideation of type 4 (active suicidal ideation with some intent to act, without a specific plan) or type 5 (active suicidal ideation with specific plan and intent) based on the Columbia-Suicide Severity Rating Scale (C-SSRS) within the 3 months before the screening visit. Subjects who have alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevations greater than 2 times the upper limit of normal (ULN) at screening. Subjects with a Glomerular Filtration Rate (GFR) < 30 mL/Min Per 1.73 m2 at screening, using the Larsson Equation. Exclusions Related to Medications Subjects with history of hypersensitivity to edaravone, any of the additives or inactive ingredients of edaravone, or sulfites. Subjects with hereditary problems of fructose intolerance (eg, fructose, sucrose, invert sugar, and sorbitol). Subjects who participated in another study and were administered an investigational product within 1 month or 5 half-lives of the investigational agent, whichever is longer, before providing informed consent for the present study. Subjects who have received any previous treatment with edaravone. Subjects who have received stem cell therapy. Subjects who are unable to take their medications orally at baseline (Visit 2).",Iii,Both
0,Healthy volunteers.,"Healthy adult male volunteers Cohort 1: Japanese, Cohort 2: Japanese or Caucasian Subjects aged between 20 and 45 years at the time of informed consent Subjects who have thoroughly understood the contents of the study and voluntarily provided written informed consent to participate in the study",MT-1186-J02 NCT04481789 TrialTroveID-380057,Adults,year(s),year(s),380057,Healthy subjects,45.0,20.0,"Additional screening criteria check may apply for qualification: Subjects with a current or previous history of cardiac, hepatic, renal, gastrointestinal, respiratory, psychiatric/nervous, hematopoietic, or endocrine diseases, and those whom the investigator (or subinvestigator) deems unsuitable for the study Body mass index (BMI) of <18.0 or >30.0, or body weight of <50 kg (BMI formula: body weight [kg]/height [m]2, rounded to one decimal place) Subjects who have undergone any surgery known to affect the gastrointestinal absorption of drugs Subjects who do not agree to use an effective method of contraception from initiation of study drug administration to 14 days after completion (discontinuation) of study drug administration Subjects who have previously received edaravone Subjects who have participated in another clinical study and received a study drug within 12 weeks before providing informed consent Use of any drug(s) other than the study drug or as-needed use of acetylsalicylic acid within 7 days before the initiation of study drug or victim drug administration Use of any alcohol, xanthine, or caffeine-containing product(s) within 24 hours before screening and Day -1 visiting Use of any supplement(s) within 7 days before the initiation of study drug or victim drug administration Use of grapefruit, grapefruit juice, or any processed food(s) containing these substances during the following periods (Cohort 1: within 7 days before the initiation of victim drug administration, Cohort 2: within 24 hours before each Day -1 visiting) Use of any tobacco or nicotine-containing product(s) (Cohort 1: within 12 weeks before the initiation of victim drug administration during the following periods, Cohort 2: within 24 hours before each Day -1 visiting) Use of any health food(s) containing St John's Wort (Hypericum perforatum) within 2 weeks before the initiation of victim drug administration (only in Cohort 1)",I,Male
1,Amyotrophic Lateral Sclerosis (ALS) patients in Argentina.,,TrialTroveID-373066,,,,373066,Unspecified,,,,Iv,Both
1,Adult subjects with Amyotrophic Lateral Sclerosis,"Patients, who are more than 18 years of age and are diagnosed to have possible, probable or definite ALS as per the El Escorial Criteria 2014, will be included.",CTRI/2019/11/021838 ESEALS TrialTroveID-360982,Adults; Older Adults,year(s),year(s),360982,Unspecified,80.0,18.0,"Patients will be excluded if they have liver or kidney disorder (eGFR< 50ml/min), malignancy, uncontrolled hypertension, or any structural brain or spinal cord lesion",Iv,Both
1,Patients with amyotrophic lateral sclerosis (ALS) Adults with ALS who initiate edaravone (IV or oral formulation) treatment as part of their clinical care,"Male and female aged 18 years or older at enrollment Sporadic or familial ALS diagnosed as possible, probable, probable-laboratory supported or definite as defined by the World Federation of Neurology revised El Escorial criteria Decision made to prescribe Edaravone prior to screening Participant will likely be able to obtain commercial Edaravone and likely to complete 6 cycles of treatment, per site investigator estimation Participant either naïve to Edaravone or who did not receive any Edaravone dose within 1 month prior to screening Signed informed consent by the subject, or a witness if a subject cannot read or write or is physically unable to talk or write, obtained before any study-related activities are undertaken",NCT04259255 REFINE-ALS TrialTroveID-360137,Adults; Older Adults,year(s),,360137,Delay Disease Progression,,18.0,Study participants meeting any of the following criteria during screening evaluations will be excluded from entry into the study: Participant with a contraindication to Edaravone Participant is participating in an interventional clinical trial,Iv,Both
1,Patients with Amyotrophic Lateral Sclerosis (ALS),"Either possible, probable, or definite ALS, predominantly lower motor neuron disease, predominantly upper motor neuron disease, or bulbar With or without cognitive involvement Willing to participate On no experimental treatment Ages 18 - 85 No prior exposure to Edaravone (Radicava) On a stable dose of Riluzole for 30 days or off Riluzole Male or female Females of childbearing age must use contraception",NCT04097158 TrialTroveID-357767,Adults; Older Adults,year(s),year(s),357767,Unspecified,85.0,18.0,Unstable medical illness Abnormal liver function (>2x ULN) Unlikely to survive for 26 weeks,Iv,Both
1,Italian patients with Amyotrophic Lateral Sclerosis.,,TrialTroveID-378613,,,,378613,Delay Disease Progression,,,,Iv,
1,Patients with Amyotrophic Lateral Sclerosis (ALS).,,TrialTroveID-364529,,,,364529,Unspecified,,,,Iv,
0,Healthy Volunteers,"Healthy males aged 20 to 55 years (both inclusive) at signature of the Informed Consent Form (ICF). Able to provide written informed consent to participate in this study after reading the ICF, and after having the opportunity to discuss the study with the Investigator or designee, before any screening or study related procedures take place. In the Investigator's opinion, subject is able to understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the protocol restrictions and requirements. A body weight of > or = 45 kg and a body mass index (BMI) ranging from 18 to 30 kg/m2 (both inclusive) at screening and Day -1. Good health and free from clinically significant illness or disease in the opinion of the investigator on the basis of a physical examination, medical history, ECG, vital sign, and clinical laboratory test (biochemistry, hematology, coagulation and urinalysis) at screening and Day -1. Male subjects must practice effective contraception during the study, from the time of the first dose of Investigational Medicinal Product (IMP) until 14 days after the last dose of IMP.",3208-4 MCI-186-J25 NCT04029090 TrialTroveID-353853,Adults,year(s),year(s),353853,(N/A); Healthy subjects,55.0,20.0,"Subjects with PR > 240 msec, QRS > or = 120 msec, or QTcF > 450 msec on the screening or Day -1 ECG, or any clinically significant electrocardiographic abnormality in the opinion of the Investigator. Subject who has a history of cardiac disease or arrhythmias that can cause QTc prolongation. Subject who has a family history of Torsade de Pointes, long-QT syndrome, hypokalemia or sudden death. Subjects with potassium levels outside of the laboratory reference ranges at screening or Day -1. Subjects with clinically significant deviations from normal in physical examination, vital signs, ECG or clinical laboratory test at screening or Day -1 in the opinion of the Investigator. Presence or history of any clinically significant disease or organ dysfunction in the opinion of the Investigator. Presence or history of allergy to food, any medical product or relevant excipient that is of clinical significant. Subjects were previously administered MCI-186. Presence or history of alcohol abuse or a positive alcohol test. Presence or history of drug abuse or a positive drug screen test. Positive test for hepatitis C virus antibody, hepatitis B surface antigen, human immunodeficiency virus (HIV) antigen/antibody or syphilis test at screening. Participation in another trial within 12 weeks or 5 times the half-life of the drug whichever is longer before providing a signed ICF. For biologics, the minimum period is at least 24 weeks or the period of the pharmacodynamic effect, or 10 times the half-life of the drug, whichever is longer before providing a signed ICF. Donate blood more than 200 mL within 4 weeks, 400 mL within 12 weeks or 1000 mL within 52 weeks, respectively before providing a signed ICF. Donate plasma or platelet component within 2 weeks before providing a signed ICF. Use of any prescription or non-prescription medications including herbal remedies and vitamin/mineral/protein supplements, except for acetylsalicylic acid, within 7 days prior to IMPs dosing. Use of tobacco or nicotine containing products for 24 hours before each visit of screening or Day -1. Consumption of alcohol, xanthines, or grapefruit containing products for 24 hours before each visit of screening or Day -1.",I,Male
0,Subjects With Severe Hepatic Impairment.,"All subjects -Able to provide written informed consent to participate in this study after reading the participant information sheet and Informed Consent Form (ICF), and after having the opportunity to discuss the study with the Investigator or designee. -Male or female subjects age 18 to 75 years (inclusive) at signature of the ICF. -In the Investigator's opinion, subject is able to understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the Protocol restrictions and requirements. -A body weight of > or = 50 kg and a body mass index (Quetelet index) ranging from 18 to 37 kg/m2 (inclusive) at Screening and Day -1. -Female subjects who are: postmenopausal for at least 1 year, confirmed by follicle-stimulating hormone assessment (>40 mIU/mL), or surgically sterilised (hysterectomy, bilateral oophorectomy or salpingectomy), or congenital sterility. Female subjects of child-bearing potential must practice effective contraception (see Protocol body) from the Screening Visit or at least 2 weeks before IMP administration, until 30 days after IMP dosing. Male subject must practice effective contraception from the time of IMP dosing until 90 days after IMP dosing. Adhering to strict abstinence is considered an accepted contraceptive method. Hepatic impaired subjects (in addition) -Diagnosis of cirrhosis due to parenchymal liver disease, which is documented in the medical history and physical examination and confirmed by at least one of the following: hepatic ultrasound, computed axial tomography scan, magnetic resonance imaging and/or liver biopsy. A Child-Pugh classification score of 10 to 14 obtained during the Screening period (i.e., within 21 days of IMP administration). -Chronic (>6 months) and stable hepatic impairment defined as no clinically significant change in disease status at least 14 days before Screening. -Acceptable clinical conditions in the opinion of the Investigator on the basis of a physical examination, medical history, 12-lead electrocardiogram (ECG), vital signs and clinical laboratory tests (biochemistry, haematology, coagulation and urinalysis) at Screening, Day -1 and pre-dose on Day 1. Subjects with stable mild chronic concurrent diseases, such as degenerative joint disease, controlled diabetes, hypertension or hyperlipidaemia, etc. may be included. -Healthy subjects (in addition) -Subjects with normal hepatic function confirmed with tests within the normal reference range or results with minor deviations which are not considered by the Investigator to be clinically significant. -Good health and free from clinically significant illness or disease in the opinion of the Investigator on the basis of a physical examination, medical history, ECG, vital signs and clinical laboratory tests (biochemistry, haematology, coagulation and urinalysis) at Screening, Day -1 and pre-dose on Day 1.",3208-3 EudraCT Number: 2018-001163-23 MCI-186-E05 MCI-186-E05 HP NCT03664544 TrialTroveID-332552,Adults; Older Adults,year(s),year(s),332552,(N/A); Healthy subjects,75.0,18.0,"All subjects -Presence or history of severe allergy to food, or any medical product or relevant excipient that is of clinical significance. -Subjects who have previously been administered MCI-186. -As a result of the medical screening process, the Investigator considers the subject not suitable for the study. -Clinically significant 12-lead ECG abnormalities, including but not limited to, corrected QT interval using Fridericia's formula (QTcF) of >450 ms (male subjects) or >470 ms (female subjects) at Screening, Day -1 or before dosing. -Any other history or condition (surgical or medical) of disease which will increase the risk to the subject, will affect the PK of the study drug, or will otherwise influence the assessments to be made in this study, in the opinion of the Investigator. Subjects who have undergone cholecystectomy may be included. -History of drug abuse or tested positive for alcohol or drugs of abuse at Screening and Day -1, excluding drugs which may cause a positive drug or abuse test if medically indicated or prescribed. -Subjects who regularly, or on average, drink more than 35 units of alcohol per week (one unit is equivalent to 300 mL of beer, 25 mL of spirits or 150 mL of wine). -Presence of active infection requiring antibiotics. -Positive test for human immunodeficiency virus antigen/antibody at Screening. -Donation of one or more units of blood (450 mL) within 3 months prior to Screening, or plasma in the 7 days prior to Screening, or platelets in the 6 weeks prior to Screening, or the intention to donate blood within 3 months after the last Follow-up assessment. -Participation in another study within the last month (if single dose), or at least 4 months (if multiple dose), or within 10 times the half-life of the respective drug (whichever is longer) before Screening. For biologics, the minimum period is at least 6 months before Screening, the period of the pharmacodynamic effect, or 10 times the half life of the respective drug, whichever is longer. -Subject is currently taking non-permitted concomitant medication. The subjects with normal hepatic function are restricted from use of any concomitant medications (including paracetamol) unless discussed and agreed with the Sponsor. In subjects with hepatic impairment, the use of prescribed medications is permitted for hepatic or concomitant disease as described in the Protocol body. -Not willing to abstain from consumption of coffee, tea, cola, energy drinks or chocolates from admission to the unit (Day -1) to discharge from the unit (Day 3). -Uncontrolled, or untreated hypertension defined as a mean of three repeated measurements of systolic blood pressure >180 mmHg and/or diastolic blood pressure >100 mmHg. -Subjects have estimated glomerular filtration rate <60 mL/min/1.73 m2 as determined by Modification of Diet in Renal Disease formula. -Any condition associated with dehydration. -Female subjects: who have a positive pregnancy test at Screening or on Day -1. who are pregnant, lactating or planning to become pregnant during the study. Hepatic impaired subjects (in addition) -Subjects with severe ascites or pleural effusion which will, in the opinion of the Investigator, adversely affect the subject's ability to participate in the study. -Subjects with severe encephalopathy (Grade III or IV). -Subjects with sclerosing cholangitis. -Serum albumin <2.0 g/dL. -Haemoglobin <10 g/dL. -Start of any new medication or any changes to a current dosage within 14 days before IMP administration. Healthy subjects (in addition) -History or presence of any parenchymal hepatic disease. -Positive test for hepatitis B surface antigen or hepatitis C virus antibody. -History of or active suicidal ideation, or suicide attempt as evidenced by positive response to either Question 4 (active suicidal ideation with some intent to act) or Question 5 (active suicidal ideation with specific plan and intent) on the Columbia-Suicide Severity Rating Scale (C-SSRS; Screening Version).",I,Both
1,Patients with Amyotrophic Lateral Sclerosis,,3208-5 TrialTroveID-330298,,,,330298,Delay Disease Progression,,,,Iv,
1,Patients with amyotrophic lateral sclerosis.,,TrialTroveID-325114,,,,325114,Unspecified,,,,Iii,
1,"Patients with amyotrophic lateral sclerosis, who are naive pertaining to edaravone treatment. ALS patients who were edaravone treatment-naïve have been enrolled in the surveillance program and will be followed up for 5 years.","ALS patients who receive an edaravone product for the first time (in case of transferred patients, ALS patients who have started the surveillance in the previous institution)",SUNRISE Japan TrialTroveID-317338 UMIN000023978,,,,317338,Delay Disease Progression,,,ALS patients who meet contraindications to the use of edaravone,Iv,Both
0,Patients with amyotrophic lateral sclerosis (ALS).,,TrialTroveID-315808,,,,315808,Delay Disease Progression,,,,Ii,
0,Healthy subjects with and without Mild or Moderate Renal Impairment,Able to provide written informed consent to participate in this study after reading the ICF Subjects is able to understand and willing to cooperate and comply with the Protocol restrictions and requirements A body weight of >or=45 kg in males or >or=40 kg in females and a body mass index ranging from 18 to 30 kg/m2 Renal impaired subjects (in addition) Subjects with mild renal impairment defined as eGFR 60-89 mL/min/1.73m2 and subjects with moderate renal impairment defined as eGFR 30-59 mL/min/1.73m2 Chronic and stable renal impairment Healthy subjects (in addition) Subject with normal renal function defined as eGFR>or=90 mL/min/1.73m2 Good health and free from clinically significant illness or disease,MCI-186-J22 NCT03289208 TrialTroveID-309684,Adults; Older Adults,year(s),year(s),309684,(N/A); Healthy subjects,75.0,20.0,"Presence or history of severe allergy to food, or any medicinal product or relevant excipient that is of clinical significance Subjects were previously administered MCI-186 Positive urine drug screen (if not due to concomitant medication) or alcohol test History of alcohol abuse or drug abuse Presence of active infection requiring antibiotics Positive test for human immunodeficiency virus (HIV) antigen/antibody, hepatitis B surface antigen (HBsAg), or hepatitis C virus antibody (HCVAb) Renal impairment subject (in addition) Acute renal failure History of renal transplantation Aspartate aminotransferase (AST) activity, or an alanine aminotransferase (ALT) activity of at least 3 times the upper limit of normal (ULN) range Uncontrolled, or untreated hypertension defined as systolic blood pressure (SBP)>180 mmHg and/or diastolic blood pressure (DBP)>110 mmHg Start of any new medication or new any changes to a current dosage Healthy subject (in addition) History or presence of any renal disease Uncontrolled, or untreated hypertension defined as systolic blood pressure (SBP)>160 mmHg and/or diastolic blood pressure (DBP)>100 mmHg",I,Both
0,Healthy subjects and subjects with mild or moderate hepatic impairment.,"All subjects Able to provide written informed consent to participate in this study after reading the ICF Subjects is able to understand and willing to cooperate and comply with the Protocol restrictions and requirements. A body weight of > or = 45 kg in males or > or = 40 kg in females and a body mass index ranging from 18 to 30 kg/m2 Hepatic impaired subjects (in addition) A Child-Pugh score of 5 or 6 for subjects with mild hepatic impairment, and between 7 and 9, inclusive, for subjects with moderate hepatic impairment Chronic and stable hepatic impairment Healthy subjects (in addition) Subject with normal hepatic function Good health and free from clinically significant illness or disease",MCI-186-J23 NCT03289234 TrialTroveID-309683,Adults; Older Adults,year(s),year(s),309683,(N/A); Healthy subjects,75.0,20.0,"All subjects Presence or history of severe allergy to food, or any medicinal product or relevant excipient that is of clinical significance Subjects were previously administered MCI-186. Positive urine drug screen (if not due to concomitant medication) or alcohol test History of drug abuse Presence of alcohol abuse Presence of active infection requiring antibiotics Positive test for human immunodeficiency virus (HIV) antigen/antibody Uncontrolled, or untreated hypertension defined as systolic blood pressure (SBP)>160 mmHg and/or diastolic blood pressure (DBP)>100 mmHg eGFR <60 mL/min/1.73m2 Hepatic impairment subject (in addition) Subjects with severe ascites Healthy subject (in addition) History or presence of any parenchymal hepatic disease Positive test for hepatitis B surface antigen (HBsAg) and hepatitis C virus antibody (HCVAb)",I,Both
1,Patients with Amyotrophic Llateral Sclerosis (ALS),"ALS patients diagnosed as ALS definite, ALS probable, or probable ALS laboratory supported in EI Escorial arranged Airie House diagnosis criteria, with disease duration within 3 years",TrialTroveID-306199 UMIN000024854,Adults; Older Adults,year(s),year(s),306199,Unspecified,75.0,20.0,Severe renal dysfunction (Cr > 3.0 mg/dl) and impossible evaluations for motor functions,Iii,Both
0,Patients with Amyotrophic Lateral Sclerosis (ALS),,TrialTroveID-294466,Adults; Older Adults,year(s),year(s),294466,Delay Disease Progression,77.0,35.0,,Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis.,"Age: 20 years and older; Gender: Male and Female. Inclusion criteria: Patients diagnosed ALS, aged equal/over 20 years old.",TrialTroveID-252252 UMIN000016352,Adults; Older Adults,year(s),,252252,Delay Disease Progression,,20.0,Exclusion criteria: Severe kidney failure. Past history with hyper-reaction against Edaravone. Physician's opinion against participation.,Iii,Both
1,Amyotrophic lateral sclerosis patients with retained broad functionality (all ALSFRS-R individual item scores > or = 2points) and normal respiratory function (%FVC > or = 80%).,"Ages Eligible for Study: 20 Years to 75 Years ; Genders Eligible for Study: Both Inclusion Criteria: Patients whose conditions are defined as ""definite ALS""or ""probable ALS""diagnostic criteria revised EL Escorial for Airlie House. Patients who can eat a meal, excrete, or move with oneself alone, and do not need assistance in everyday life. Patients of less than 2 years after the onset of ALS. Patients whose progress of the condition during 12 weeks before administration meet other requirements.",J19 MCI186-19 NCT01492686 Study 19 TrialTroveID-157748,Adults; Older Adults,year(s),year(s),157748,Delay Disease Progression,75.0,20.0,"Exclusion Criteria: Patients with such complications as Parkinson's disease, schizophrenia, dementia, renal failure, or other severe complication, and patients who have the anamnesis of hypersensitivity to edaravone. Pregnant, lactating, and probably pregnant patients, and patients who want to become pregnant, and patients who can not agree to contraception. Patients who have participated in other trials within 12 weeks before consent, or who are participating in other clinical trials at present. In addition to the above exclusion criteria, patients judged to be inadequate to participate in this study by their physician.",Iii,Both
0,"Patients with Muro disease. Patients with Kii ALS/PDC (ratio of men to women, 4:1; average age, 68.4 years; average duration of the illness, 9.4 years)",Age-lower limit 20 years-old <= Age-upper limit 80 years-old >= Gender: Male and Female Inclusion criteria: Patients who live or have lived in ALS/PDC focus of Mie prefecture. ALS: probable ALS diagnosed by El Escorial criteria. PDC: patients with dementia and parkinsonism. Range of Age: 20-80 years Requirement a caregiver of patient. Patients who can take a medical examination at Minami Ise Hospital regularly. Informed consent.,TrialTroveID-152786 UMIN000006103,Adults; Older Adults,year(s),year(s),152786,Comorbidity in ALS; Other Dementia,80.0,20.0,"Exclusion criteria: A patient with other neuronal or muscular disorders A patients with systemic disorders those present dementia, parkinsonism or amyotrophy Encephalitis A patients with abnormal neuroradiological findings those suggest other disorders present dementia, parkinsonism or amyotrophy A patients with severe psychiatric disorders A patient with malignancy A patient with severe renal dysfunction A patient wit sever heart dysfunction A patient with severe liver dysfunction A patient with sever drug allergy A patients with drug or alcoholic abuse A patient with pregnancy or in the lactation period A patient who was inappropriate for this study",Ii,Both
1,"Patients with ALS. 22 subjects with Upper extremity palsy (UEP) , 14 subjects with lower extremity palsy (LEP) and 13 subjects with bulbar palsy (BP)",,TrialTroveID-121739,Adults; Older Adults,year(s),year(s),121739,Unspecified,72.0,50.0,,Iii,Both
1,Amyotrophic lateral sclerosis patients.,Ages Eligible for Study: 20 Years and above Inclusion Criteria Patients who ware completed drug administration without discontinuation in the preceding confirmatory study NCT00330681.,MCI186-17 NCT00424463 TrialTroveID-79058,Adults; Older Adults,year(s),,79058,Delay Disease Progression,,20.0,"Exclusion Criteria Patients with such complications as Parkinson's disease, schizophrenia, dementia, renal failure, or other severe complication, and patients who have the anamnesis of hypersensitivity to edaravone. Patients whose creatinine clearance is 50mL/min or less at the time of completion of drug administration in the study NCT00330681. Pregnant, lactating, and probably pregnant patients, and patients who want to become pregnant, and patients who can not agree to contraception. Patients who are participating in other clinical trials except the study NCT00330681. In addition to the above exclusion criteria, patients judged to be inadequate to participate in this study by their physician.",Iii,Both
1,"Patients with ALS whose severity is classified as grade III, based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores after 24 weeks MCI-186 administration via intravenous drip.","Ages Eligible for Study: 20 Years - 75 Years, Genders Eligible for Study: Both. Inclusion Criteria: Patients who are defined as ""definite ALS"", ""probable ALS"" or ""probable-laboratory-supported ALS"", met diagnostic criteria revised EL Escorial for Airlie House. Patients who cannot take at least one action of eating a meal, excreting, or moving with oneself alone, and need assistance in everyday life. Patients whose progress of the condition during 12 weeks before administration meet other requirements.",MCI186-18 NCT00415519 TrialTroveID-078952,Adults; Older Adults,year(s),year(s),78952,Delay Disease Progression,75.0,20.0,"Exclusion Criteria: Patients judged to be inadequate to participate in this study by their physician, because those patients' general condition deteriorated to the point that they need to be hospitalized for severe hepatic disease, sever heart disease, sever renal disease and so on, or they need to be administered antibiotics to infection. Patients who complain the difficulty in breathing caused by deteriorating the respiratory function. Patients with such complications as Parkinson's disease, schizophrenia, dementia, renal failure, or other severe complication, and patients who have the anamnesis of hypersensitivity to edaravone. Pregnant, lactating, and probably pregnant patients, and patients who want to become pregnant, and patients who can not agree to contraception. Patients who have administered other investigational products within 12 weeks before consent, or who are participating in other clinical trials at present. In addition to the above exclusion criteria, patients judged to be inadequate to participate in this study by their physician.",Iii,Both
1,Patients with Amyotrophic Lateral Sclerosis,"Ages Eligible for Study: 20 Years to 75 Years.; Gender: Both Inclusion Criteria: Patients who are defined as ""definite ALS,"" ""probable ALS"" or ""probable-laboratory-supported ALS,"" met diagnostic criteria revised EL Escorial for Airlie House. Patients who can eat a meal, excrete, or move with oneself alone, and do not need assistance in everyday life. Patients of less than 3 years after the onset of ALS. Patients whose progress of the condition during 12 weeks before administration meet other requirements. Patients also had a Japanese ALS severity classification (25) of 1 or 2. (The Japanese ALS severity classification score ranges from 1 to 5 according to the severity classification of the Specifi ed Disease Treatment Research Program for ALS of the Ministry of Health, Labor and Welfare of Japan. Severity Classification: 1) able to work or perform housework; 2) independent living but unable to work; 3) requiring assistance for eating, excretion or ambulation; 4) presence of respiratory insuffi ciency, difficulty in coughing out sputum or dysphagia; and 5) using a tracheostomy tube, tube feeding or tracheostomy positive pressure ventilation.)",JapicCTI-060256 MCI186-16 NCT00330681 Study 16 TrialTroveID-078836,Adults; Older Adults,year(s),year(s),78836,Delay Disease Progression,75.0,20.0,"Exclusion Criteria: Patients judged to be inadequate to participate in this study by their physician, because those patients' general condition deteriorated to the point that they need to be hospitalized for severe hepatic disease, severe heart disease, severe renal disease and so on, or they need to be administered antibiotics to infection. Patients who complain the difficulty in breathing caused by deteriorating the respiratory function. Patients with such complications as Parkinson's disease, schizophrenia, dementia, renal failure, or other severe complication, and patients who have the anamnesis of hypersensitivity to edaravone. Pregnant, lactating, and probably pregnant patients, and patients who want to become pregnant, and patients who can not agree to contraception. Patients who have participated in other trials within 12 weeks before consent, or who are participating in other clinical trials at present. In addition to the above exclusion criteria, patients judged to be inadequate to participate in this study by their physician. reduced respiratory function and complaints of dyspnea; infections that require antibiotic therapy; deteriorated general condition as judged by investigators; renal dysfunction with creatinine clearance of 50 ml/min or below within 28 days before treatment; and undergoing cancer treatment.",Iii,Both
0,Subjects with Amyotrophic Lateral Sclerosis.,,TrialTroveID-078784,,,,78784,Delay Disease Progression,,,,Ii,
0,Healthy subjects.,,MT-1186-G01 TrialTroveID-350974,,,,350974,Healthy subjects,,,,I,
0,Patients with Amyotrophic Lateral Sclerosis.,,Study J04 TrialTroveID-423334,,,,423334,Unspecified,,,,I,
0,Healthy subjects.,Healthy adult male or female volunteers Japanese Subjects aged between 20 and 45 years at the time of informed consent Subjects who have thoroughly understood the contents of the study and voluntarily provided written informed consent to participate in the study,MT-1186-J03 NCT04493281 Study J03 TrialTroveID-423333,Adults,year(s),year(s),423333,Healthy subjects,45.0,20.0,"Additional screening criteria check may apply for qualification: Subjects with a current or previous history of cardiac, hepatic, renal, gastrointestinal, respiratory, psychiatric/nervous, hematopoietic, or endocrine diseases, and those whom the investigator (or subinvestigator) deems unsuitable for the study Body mass index (BMI) of <18.0 or >30.0, or body weight of <50 kg (BMI formula: body weight [kg]/height [m]2, rounded to one decimal place) Subjects who have undergone any surgery known to affect the gastrointestinal absorption of drugs Female subjects who do not agree to use an effective method of contraception from screening or 2 weeks before the start of investigational product administration, whichever comes earlier, to 14 days after the completion (or discontinuation) of investigational product administration. Male subjects who do not agree to use an effective method of contraception from the start of investigational product administration to 14 days after the completion (or discontinuation) of investigational product administration Subjects who have previously received edaravone Subjects who have participated in another clinical study and received an investigational product within 12 weeks before providing informed consent",I,Both
1,Subjects with Amyotrophic Lateral Sclerosis who have successfully completed Study MT-1186-A02,Subjects or their legally authorized representative must provide a signed and dated informed consent form to participate in the study. Subjects must be able (in the judgment of the Investigator) to understand the nature of the study and all risks involved with participation in the study. Subjects must be willing to cooperate and comply with all protocol restrictions and requirements. Subjects must have successfully completed all Study MT-1186-A02 visits and have been compliant with study drug.,BASEC2022-00492 EudraCT Number: 2021-003900-42 jRCT2071210117 MT-1186-A04 NCT05151471 SNCTP000005181 TrialTroveID-420326,Adults; Older Adults,year(s),,420326,Delay Disease Progression,,18.0,"Subjects of childbearing potential unwilling to use an acceptable method of contraception from the screening visit until 3 months after the last dose of study medication. Subjects who are sexually active who do not agree to use contraception during the study period. Subjects who are female, of childbearing potential, and pregnant (a positive pregnancy test) or lactating at the screening visit. Subjects who have a significant risk of suicide. Subjects with any suicidal behavior or suicidal ideation of type 4 (active suicidal ideation with some intent to act, without a specific plan) or type 5 (active suicidal ideation with specific plan and intent) based on the Columbia-Suicide Severity Rating Scale (C-SSRS) at Week 48 of Study MT-1186-A02. Subjects who are not eligible to continue in the study, as judged by the Investigator in conjunction with the MTDA medical monitor. Subjects who are unable to take their medications orally or through a PEG/RIG tube.",Iii,Both
0,Healthy Japanese Adult Subjects,Subjects who meet all of the following criteria and who have the capability of giving informed consent will be included in the study. Healthy adult male or female volunteers Japanese Subjects aged between 20 and 45 years at the time of informed consent Subjects who have thoroughly understood the contents of the study and voluntarily provided written informed consent to participate in the study,jRCT2031200361 MT-1186-Z-101 NCT04776135 TrialTroveID-397963,Adults,year(s),year(s),397963,(N/A); Healthy subjects,45.0,20.0,"Subjects who meet any of the following criteria between screening and investigational product administration will be excluded from the study. Subjects with a current or previous history of cardiac, hepatic, renal, gastrointestinal, respiratory, psychiatric/nervous, hematopoietic, or endocrine diseases, and those whom the investigator (or subinvestigator) deems unsuitable for the study History of drug or food allergies History of alcohol or drug abuse or dependence Body mass index (BMI) of <18.0 or >30.0, or a body weight of <50 kg (BMI formula: body weight [kg]/height [m]2, rounded to one decimal place) Positive test for any of the following at screening: Hepatitis B surface antigen, serological test for syphilis, hepatitis C virus antibody, or human immunodeficiency virus antigen/antibody, subject has a positive COVID-19 virus test on Day -1 Any clinically significant 12-lead ECG abnormality or QTcF interval =450 msec Blood donation or sampling with a total volume of =400 mL within 12 weeks, =200 mL within 4 weeks, or =800 mL within one year before providing informed consent Blood component donation or blood sampling within 2 weeks before providing informed consent, or blood donation and transfusion from informed consent to the start of investigational product administration Subjects who have undergone any surgery known to affect the gastrointestinal absorption of drugs (except for appendectomy and herniotomy) Female subjects of childbearing potential who do not agree to use an effective method of contraception from screening or 2 weeks before the start of investigational product administration, whichever comes earlier, to 14 days after the completion (or discontinuation) of investigational product administration. Male subjects who do not agree to use an effective method of contraception from the start of investigational product administration to 14 days after the completion (or discontinuation) of investigational product administration Subjects who have previously received edaravone Subjects who have participated in another clinical study and received an investigational product within 12 weeks before providing informed consent Subjects who have used any drugs other than the single use of acetylsalicylic acid within 7 days before the initiation of investigational product administration Use of alcohol or any products containing xanthin or caffeine within 24 hours before screening and visit on Day -1 Use of any nutritional supplement(s) within 7 days before the initiation of investigational product administration Use of grapefruit, grapefruit juice, or any processed food(s) containing these substances within 24 hours before screening and visit on Day -1 Use of any tobacco or nicotine-containing product(s) within 24 hours before screening and visit on Day -1 Female subjects who have a positive pregnancy test at screening and on Day -1, are pregnant or breast feeding, or plan to get pregnant during the study Subjects with a history of reconstructive nasal surgery, or any evidence of deformities or asymmetry of the nose, non-patent nares/obstructed nasal airway, or the presence of nasal ulcers or polyps that would prevent an adequate NGT insertion. Subjects judged by the investigator (or subinvestigator) to be unsuitable for the study for any other reason",I,Both
1,Subjects With Amyotrophic Lateral Sclerosis,Subjects must provide signed and dated informed consent form (ICF) to participate in the study. Subjects must be able (in the judgment of the Investigator) to understand the nature of the study and all risks involved with participation in the study. Subjects must be willing to cooperate and comply with all protocol restrictions and requirements. Subjects who successfully completed Study MT-1186-A01,19-2377 EudraCT Number: 2020-000376-38 jRCT2041200084 MT-1186-A03 NCT04577404 TrialTroveID-386225,Adults; Older Adults,year(s),,386225,Delay Disease Progression,,18.0,"Subjects of childbearing potential unwilling to use a highly effective method of contraception from Visit 1 until 3 months after the last dose of study medication. Subjects who have a significant risk of suicide. Subjects with any suicidal behavior or suicidal ideation of type 4 (active suicidal ideation with some intent to act, without a specific plan) or type 5 (active suicidal ideation with specific plan and intent) based on the C-SSRS at Visit Subjects who are not eligible to continue in the study, as judged by the Investigator. Subjects who are unable to take their medications orally or through a PEG/RIG tube.",Iii,Both
1,Patients with amyotrophic lateral sclerosis.,,MT-1186-G03 TrialTroveID-373996,,,,373996,Unspecified,,,,Iii,
0,Patients with amyotrophic lateral sclerosis who had a gastrostomy.,"Patients aged between 20 and 80 years at the time of informed consent Japanese patients Among patients with ALS, those ""Clinically definite ALS,"" ""Clinically probable ALS"" or ""Clinically probable-laboratory-supported ALS"" according to El Escorial Revised Airlie House criteria ALS Patients with gastrostomy Patients who can consent to contraception Patients who have thoroughly understood the contents of the study and voluntarily provided written informed consent to participate in the study",JapicCTI-205129 jRCT2080225036 MT-1186-J05 NCT04254913 TrialTroveID-366825,Adults; Older Adults,year(s),year(s),366825,Unspecified,80.0,20.0,"Patients in whom the possibility could not be ruled out that the current symptoms were symptoms of a disease requiring differential diagnosis, such as cervical spondylosis and multifocal motor neuropathy Patients undergoing treatment for malignancy. Patients who have presence of clinically significant liver, heart, or renal disease requiring hospitalization (except ALS) and infections requiring antibiotics. Patients who have a problem in general condition and are judged ineligible by the Investigator Body mass index (BMI) of <15.0 or >30.0, or a body weight of <40 kg Patients judged by the investigator (or subinvestigator) to be unsuitable for the study for any other reason",I,Both
0,Japanese patients with Amyotrophic Lateral Sclerosis,"Patients aged between 20 and 75 years at the time of informed consent Japanese patients Among patients with ALS, those ""Clinically definite ALS,"" ""Clinically probable ALS"" or ""Clinically probable-laboratory-supported ALS"" according to El Escorial Revised Airlie House criteria Patients who can consent to contraception Patients who have thoroughly understood the contents of the study and voluntarily provided written informed consent to participate in the study",JapicCTI-195050 jRCT2080224962 MT-1186-J04 NCT04176224 TrialTroveID-361981,Adults; Older Adults,year(s),year(s),361981,Unspecified,75.0,20.0,"Patients in whom the possibility could not be ruled out that the current symptoms were symptoms of a disease requiring differential diagnosis, such as cervical spondylosis and multifocal motor neuropathy Patients undergoing treatment for malignancy Patients who have presence of clinically significant liver, heart, or renal disease requiring hospitalization (except ALS) and infections requiring antibiotics. Patients who have a problem in general condition and are judged ineligible by the Investigator Body mass index (BMI) of <18.0 or >30.0, or a body weight of <50 kg Patients judged by the investigator (or subinvestigator) to be unsuitable for the study for any other reason",I,Both
0,,,TrialTroveID-350976,,,,350976,Unspecified,,,,Ii,
1,Subjects with Amyotrophic Lateral Sclerosis (ALS),"Subjects will be male or female, > or = 18 to 75 years of age at the time the ICF is signed Subjects will be diagnosed with Definite ALS, Probable ALS, Probable laboratory-supported ALS, or Possible ALS according to the El Escorial revised criteria for the diagnosis of ALS. Subjects will be living and functioning independently (eg, able to eat, excrete, ambulate independently without assistance of others). The use of supportive tools and adaptive utensil is allowed Subjects will have a baseline forced vital capacity percentage (%FVC) > or = 70%. Subjects whose first symptom of ALS occurred within 3 years of the time of providing written informed consent. disease duration < or =3 years; and who are functioning independently.",EudraCT Number: 2019-002108-41 JapicCTI-195070 jRCT2080224982 MT-1186-A01 NCT04165824 TrialTroveID-350975,Adults; Older Adults,year(s),year(s),350975,Delay Disease Progression,75.0,18.0,"Subjects who have the presence or history of any clinically significant disease (except ALS) that could interfere with the objectives of the study (the assessment of safety and efficacy) or the safety of the subject, as judged by the Investigator. Subjects of childbearing potential unwilling to use acceptable method of contraception from the screening visit until 3 months after the last dose of study medication. Subjects who are sexually active who do not agree to use contraception during the study period. Subjects who are female and pregnant (a positive pregnancy test) or lactating at the screening visit (Visit 1). Subjects who have a significant risk of suicidality. Subjects with any suicidal behavior or suicidal ideation of type 4 (active suicidal ideation with some intent to act, without a specific plan) or type 5 (active suicidal ideation with specific plan and intent) based on the Columbia-Suicide Severity Rating Scale (C-SSRS) within the 3 months before the screening visit. Subjects who have ALT or AST elevations greater than 2 times the ULN at screening. Subjects with a Glomerular Filtration Rate (GFR) <30 mL/Min Per 1.73 m2. Exclusions Related to Medications: Subjects with history of hypersensitivity to edaravone, any of the additives or inactive ingredients of edaravone, or sulfites. Subjects with hereditary fructose intolerance. Subjects who participated in another study and were administered an investigational product within 1 month or 5 half-lives of the investigational agent, whichever is longer before providing informed consent for the present study. Subjects who are unable to take their medications orally.",Iii,Both
0,Healthy volunteers,Additional screening criteria check may apply for qualification: Healthy adult male volunteers Japanese or Caucasian Subjects aged between 20 and 45 years at the time of informed consent Subjects who have thoroughly understood the contents of the study and voluntarily provided written informed consent to participate in the study,MT-1186-J01 NCT04481750 TrialTroveID-350519,Adults,year(s),year(s),350519,Healthy subjects,45.0,20.0,"Additional screening criteria check may apply for qualification: Subjects with a current or previous history of cardiac, hepatic, renal, gastrointestinal, respiratory, psychiatric/nervous, hematopoietic, or endocrine diseases, and those whom the investigator (or subinvestigator) deems unsuitable for the study Body mass index (BMI) of <18.0 or >30.0, or body weight of <50 kg (BMI formula: body weight [kg]/height [m]2, rounded to one decimal place) Subjects who have undergone any surgery known to affect the gastrointestinal absorption of drugs Subjects who do not agree to use an effective method of contraception from initiation of study drug administration to 14 days after completion (discontinuation) of study drug administration Subjects who have previously received edaravone Subjects who have participated in another clinical study and received a study drug within 12 weeks before providing informed consent",I,Male
0,Chinese Healthy Volunteers,"Age: 18-65 years old (including upper and lower limits); Weight > or = 50 kg, body mass index (BMI) between 18-28 kg / m^2 (including upper and lower limits); Understand and sign the informed consent voluntarily, and volunteer to participate in this research.",NCT04219865 NJYK-CPEDRV-I TrialTroveID-364988,Adults,year(s),year(s),364988,Healthy subjects,65.0,18.0,"A history of diseases of the heart, liver, lung, kidney, digestive tract, blood, or neuropsychiatric system judged by the investigator as clinically significant; A comprehensive physical examination, neurological examination, laboratory examination, ECG examination, or cognitive assessment indicates that the subject has an abnormality that the researcher has determined to be clinically significant; Have taken any drug within two weeks before the study administration, and the researcher believes that this situation may affect the evaluation results of this study; There is a history of food or drug allergy or allergies that the researcher judges to be clinically significant; Those with positive results of serological examination (HBsAg, anti-HCV, anti-HIV, TP-Ab); A history of alcohol or drug abuse that the investigator believes may affect the evaluation results of this study within one year before the study administration; Cannot quit smoking or drinking during the study period or the carbon monoxide breath test > 7 ppm during the screening period CO breath test, so if the subject's CO breath is> 7ppm, but the urine cotinine test is negative, it means that the CO breath test result may be false positive, the subject can be enrolled; As a subject who has participated in any drug clinical trial within 3 months before the first administration of the study; Those who donated blood or blood products > or = 400 mL or 2 units within three months of the study; Do not agree to avoid the use of tobacco, alcohol or caffeinated beverages, or vigorous exercise, or other factors that affect drug absorption, distribution, metabolism, excretion, etc. during the 24 hours before and during the test; Pregnant or lactating women, or those who tested positive for serum HCG before the test administration, or those who were unable or unwilling to take researcher-approved contraception during the study according to the researcher's instructions; Subjects with poor compliance or unable to comply with the relevant provisions of the research protocol due to personal reasons, the investigator judges that the subjects are not suitable to participate in this clinical study.",I,Both
1,Patients with amyotrophic lateral sclerosis,"(1) Clinically confirmed, probable, and probable ALS according to the EI Escorial criteria revised in 1998; (2) The subject must be between 18 and 80 years of age (inclusive) at the time of signing the informed consent; (3) Signed the informed consent form.",ChiCTR2400082879 TrialTroveID-513626,Adults; Older Adults,year(s),year(s),513626,Unspecified,80.0,18.0,"(1) Participated in other clinical studies within 3 months; (2) Pregnant and lactating women; (3) Endotracheal intubation or invasive ventilation; (4) Allergic to any component of edaravone; (5) Alt or AST greater than 2 times normal, (6) Creatinine clearance of & Lt. 50 ml per minute, (7) Disease or injury that interferes with functional assessment or is life-threatening, (8) Any known non-ALS-related amyotrophic lateral sclerosis; (9) Major mental illness, cognitive impairment; (10) A history of irregular drug use in the past; (11) Coagulopathy; (12)The presence of proteinuria at a moderate to high level; (13) Patients with impaired liver and kidney function; (14) Systolic blood pressure below 90mmHg, or diastolic blood pressure below 50 mmHg, with a heart rate of less than 50 beats per minute; (15) Had a history of localized inflammation in the last month; (16) Had a history of chronic systemic inflammation; (17) Was unwilling or unable to participate in and complete the study.",Iv,Both
0,Healthy subjects,"Subjects must meet all inclusion criteria at screening (or as noted) to be eligible for study participation, as follows: 1. Informed consent signed and dated by the subject 2. Healthy male and female subjects of any ethnic and racial origin, aged 20 to 45 years, inclusive 3. Female subjects who: - Are postmenopausal (defined as a minimum of 12 consecutive months of spontaneous amenorrhea confirmed by a serum follicle-stimulating hormone level > 40 IU/L), or - Are surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation), confirmed by medical documentations, or - Are of child-bearing potential must agree to use at least 1 highly effective method of contraception from at least 1 month prior to the initiation of the study through 3 months after the final dose, where highly effective methods of contraception include: - Intrauterine device - Intrauterine system - Contraceptive implant - Combined injectable contraceptives - Hormonal oral contraceptives when used in combination with male condoms with spermicide - If a female subject confirms that her male partner(s) has been verified to be clinically sterile (ie, documented infertility or surgical sterilization), this method is acceptable as the only means of contraception Note: The following are not acceptable methods of contraception: - Periodic sexual abstinence (eg, calendar, ovulation, symptothermal, and post-ovulation methods), declaration of sexual abstinence for the duration of the study, withdrawal, and lactational amenorrhea method - Spermicides alone - Hormonal oral contraceptives alone - Male condoms used in combination with female condoms or - Agrees to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. 4. Male subjects who are sexually active and whose partners are females of child-bearing potential, even if surgically sterilized (ie, status post vasectomy), who: - Avoid sperm donation during the entire study period and through 90 days after the last dose of study drugs, and - Agree to practice effective barrier contraception, or - Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject 5. Body mass index (BMI) of 19 to 30 kg/m2 (inclusive) (BMI = weight (kg)/(height [m])2) 6. Non-smokers (defined as having abstained from tobacco- or nicotine-containing products [eg, cigarettes, chewing tobacco, snuff, nicotine patches, and electronic cigarettes] in the 6 months prior to screening), stable light smokers, and ex-smokers will be included. Stable light and ex-smokers are defined as follows: ""A light smoker is defined as someone smoking ≤5 cigarettes per day; an ex-smoker is someone who has completely stopped smoking for at least 3 months."" 7. In good health, as determined by the investigator at screening and confirmed at check-in, with no clinically significant findings from medical history, physical examination, 12-lead ECG, vital signs measurements, and clinical laboratory evaluations 8. Subjects must be willing to understand and able to comply with all research procedures and restrictions, and are able to communicate effectively with researchers.",NCT06107205 TrialTroveID-490509 TTYP01-02-2022,Adults,year(s),year(s),490509,Healthy subjects,45.0,20.0,"Subjects will not be eligible for study participation if they meet any of the exclusion criteria at screening (or as noted), or will be discontinued at the discretion of the investigator in consultation with the medical monitor if they develop any of the exclusion criteria during the study. 1. History of any hypersensitivity or allergic reaction to active ingredients or excipients of the study drugs (eg, known allergy to bisulfite containing foods such as bottled lemon juice, grape juice, canned fruits, wine, jam, jelly, etc.) 2. Positive test result for infectious diseases at screening or baseline, including human immunodeficiency virus antibody, hepatitis B surface antigen, hepatitis C virus antibody, and syphilis antibody 3. Positive alcohol test at screening or baseline, or has a history of alcohol abuse (alcohol consumption in excess of 1 standard drink per day for women and 2 standard drinks per day for men; whereby 1 standard drink is equivalent to 12 oz beer [5% alcohol], 5 ounces of wine [12% alcohol], and 1.5 ounces of 80 proof [40% alcohol]) 4. Females who are pregnant, planning to become pregnant, or breastfeeding during the study or within 3 months after the study; or have a positive pregnancy test result at screening or check-in 5. Any abnormal physical examination, vital sign, ECG, or laboratory values at screening or check-in that are considered clinically significant by the investigator 6. Special dietary requirements or restrictions and cannot follow a uniform diet 7. History of febrile illness or evidence of active infection within 14 days prior to the first dose 8. Any subject with SARS-CoV-2 infection, based on a rapid test or positive polymerase chain reaction for SARS-CoV-2, or subjects who received the SARS-CoV-2 vaccine within 1 month prior to the first dosing, or plans to have the vaccine within 1 month after the last dose 9. Positive drug screen at screening or check-in, or has a history of drug abuse within the past 5 years 10. Clinically significant interventional therapies (surgery, paracentesis, etc.) within 3 months prior to the study, or plan to have any surgeries during the study 11. Blood loss of non-physiological reasons ≥ 400 mL (ie, trauma, blood collection, blood donation) within 3 months prior to the first dose of study drugs, or plan to donate blood during this study and within 1 month after the last dosing 12. Currently uses more than 5 tobacco products (refer to inclusion criterion 6) per day 13. Received an experimental agent (eg, vaccine, drug, biologic, device, blood product, or medication) within 3 months prior to the first dose of study drugs, or plans to receive another experimental agent during the duration of this study 14. Is unwilling to abstain from alcohol-containing products and xanthine/caffeine-containing products, including any foods and beverages, within 48 hours prior to the first dose 15. Used any over-the-counter medications or prescription drugs (other than hormone replacement therapy, oral contraceptives, or 650 mg acetaminophen/day), nutritional supplements, or herbal medicines within 1 month from screening, unless, in the opinion of the investigator and sponsor, the drug will not interfere with study assessments 16. Abnormal renal function estimated glomerular filtration rate calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation < 90 mL/min/1.73 m2 17. Abnormal QT prolongation of QTcF ≥ 450 msec for males or QTcF ≥ 470 msec for females (confirmed by repeated examination) 18. History of hypokalemia or family history of long QT syndrome 19. Any current or historical conditions that may interfere with the absorption/distribution/metabolism/excretion of the study drugs, in the opinion of the investigator (eg, dysphagia, gastrointestinal diseases) 20. Any clinically relevant acute or chronic medical conditions or diseases of the cardiovascular, gastrointestinal, hepatic, renal, endocrine, pulmonary, neurologic, psychiatric, immune, or dermatologic systems that would pose a risk to subject's safety or interfere with the study assessments, as determined by the investigator 21. Poor venous access (eg, history of difficult blood draws) for blood sample collection or intravenous dosing 22. Any other conditions that would, in the opinion of the investigator, put the subjects at increased risk for participation in this study",I,Both
0,Healthy volunteers,"Age between 18 and 40, inclusive; Non-smokers, ex-smokers and moderate smokers will be included. ""A moderate smoker is defined as someone smoking 5 cigarettes or less per day, an ex-smoker is someone who completely stopped smoking for at least 3 months.""; If female, must be of non-childbearing potential (defined as either surgically sterilized or at least 1 year postmenopausal) or must agree to use a clinically acceptable method of contraception (e.g., oral, intrauterine device [IUD; diaphragm], injectable, transdermal or implantable contraception) or abstinence, for at least 1 month prior to randomization, during the study and 3 month following completion of the study. Females of childbearing potential must have a negative serum human chorionic gonadotropin (hCG) pregnancy test at screening; Body Mass Index (BMI) of 18 to 30 kg/m2, inclusive; and a total body weight >50 kg at screening for male subjects, total body weight > 45 kg for female subjects; Female subjects of child bearing potential and all male participants who have not had a vasectomy must use effective contraception during the study Ability to understand and willingness to sign a written informed consent form (the consent form must be signed by the subject prior to any study-specific procedures), and evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study; Willingness and ability to comply with study procedures and follow-up examination. Adequate organ function as evidenced by the following peripheral blood counts or serum chemistry values within 28 days before randomization: Hemoglobin greater than or equal to 9 g/dL Neutrophil count (ANC) greater than or equal to 1,500/microL Platelet count greater than or equal to 100,000/microL Serum creatinine less than or equal to 1.5 mg/dL (less than or equal to 132.6 micromol/L) and creatinine clearance greater than or equal to 60 ml/min Creatine phosphokinase (CPK) less than or equal to 2x upper limit of normal (ULN) Hepatic function variables: Total bilirubin </= 1.5x ULN Total alkaline phosphatase (ALP) >/= 1.5x ULN, or if > 1.5x ULN, then ALP liver fraction or 5' nucleotidase must be </=1x ULN Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be </= 2.5x ULN",Auzone-01 NCT04370431 TrialTroveID-373533,Adults,year(s),year(s),373533,(N/A); Healthy subjects,40.0,18.0,"Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease. Subjects with a history of hypersensitivity to edaravone or any of the inactive ingredients of the formulation (such as sulfite and sodium bisulfite). Subjects with PR >240 msec, QRS =120 msec, or QTcF >450 msec for male & QTcF >470 msec for female on the screening or Day -1 ECG, or any clinically significant electrocardiographic abnormality in the opinion of the investigator. Male subjects with partners currently pregnant; male subjects able to father children who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 3 months after the last dose of investigational product. Female subjects currently pregnant or lactating; female subjects able to bear children or of child bearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 3 months after the last dose of investigational product. Subjects whose urine drug/alcohol screening was positive at the time of screening and/or on Day-1. Subjects having difficulty in swallowing pills/tablets. Subjects smoking > 5 cigarettes per day within 3 months prior to the screening visit. Subjects unwilling or unable to comply with the Lifestyle Guidelines described in the protocol. Subjects who are investigational site staff members directly involved in the conduct of the studies and their family members, site staff members otherwise supervised by the Investigator, or subjects who are the sponsors' employees directly involved in the conduct of the studies. Evidence of any severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial. Subjects who have participated in another clinical trial less than 3 months before or donated his/her blood in a quantity greater than 200 milliliters (mL) within 1 month of the screening period of this clinical trial.",I,Both
0,Healthy subjects,"Healthy adult male and female subjects, aged between 18 and 45 years inclusive; Male weight > or = 50 kg, female weight > or = 45 kg, body mass index (BMI) between 19~26 kg/m2 including both ends; No clinically significant abnormal vital signs, physical examination, laboratory examination, electrocardiogram examination and other results; Subjects who can understand and sign informed consent before any trial-related procedures.",CTR20202055 TrialTroveID-389173 XWY-3-LC-04,Adults,year(s),year(s),389173,Healthy subjects,45.0,18.0,"Those who are clearly allergic to this product or any of its excipients (mannitol, hypromellose, crospovidone, silicon dioxide, magnesium stearate), allergic or allergic to drugs or food; Those who have a history of any serious clinical disease, severely impaired liver function, or have circulatory, endocrine, neurological, or hematological, immunological, psychiatric, and metabolic abnormalities, and have been determined by the investigator to be unsuitable for inclusion. People with a history of epilepsy and convulsions; Those who have a history of repeated oral ulcers or who have had oral ulcers in the 14 days before screening, severely damaged oral cavity and have not healed, or those who have an abnormal oral mucosa confirmed by the researcher; Abnormal ECG (with clinical significance) or abnormal vital signs (systolic blood pressure <90 mmHg or > or = 140 mmHg, diastolic blood pressure <55 mmHg or > or = 90 mmHg; heart rate <50 bpm or >100 bpm); Those who test positive for hepatitis B surface antigen, hepatitis C antibody, human immunodeficiency virus antibody or Treponema pallidum specific antibody; Alcoholics or frequent drinkers within 6 months before screening, that is, drinking more than 14 units of alcohol per week (1 unit = 360 mL beer or 45 mL 40% alcoholic spirits or 150 mL wine); screening period and check-in day Alcohol breath test result is greater than 0.0mg/100ml; Those who smoked more than 3 cigarettes per day in the past three months or who could not give up smokers during the entire trial period; or those who were positive for nicotine screening before the first dose during the screening period Those with positive drug screening; Excessive consumption of tea, coffee or caffeine-containing beverages within 3 months before screening (average more than 8 cups a day, 1 cup = 250 mL) tea, coffee or caffeinated beverages; or within 48 hours before the first administration, taking tea or any caffeinated food Or beverages (such as coffee, chocolate, etc.); those who have consumed a large amount of beverages or foods (such as grapefruit, grapefruit juice, grapefruit jam, etc.) containing special foods (such as dragon fruit, mango, grapefruit, etc.) within 14 days before screening ); or within 48 hours before the first administration, ingested any beverage or food rich in grapefruit (grapefruit); Any drugs that inhibit or induce liver metabolism of drugs have been used in the first 3 months of screening or during the trial (such as inducers-barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole; inhibitors- -SSRI antidepressants, cimetidine, diltiazem macrolides, nitroimidazoles, sedative hypnotics, verapamil, fluoroquinolones, antihistamines); Those who have taken any prescription drugs or over-the-counter drugs, Chinese medicines, health care products in the 14 days before screening, or have received vaccinations in the 14 days before screening; Participants in any other drug clinical trials as subjects within 3 months before screening; Those who donated blood or lost more than 200 mL of blood 3 months before screening; Reproductive subjects (male and female) do not agree to use reliable contraceptive methods for contraception during the study period and within 1 month after administration, such as IUD, ovarian cap, oral contraceptives, injectable progesterone, subcutaneous hormone implants Entry or barrier method or abstinence. Female subjects had a positive blood pregnancy test from the screening period to before the first dose. Women who are pregnant or breastfeeding; Those who are known to be unable to tolerate intravenous indwelling needles or venous blood collection and/or blood collection difficulties; The researcher thinks that should not be included.",I,Both
1,Subjects with Amyotrophic lateral sclerosis ADORE participants that complete the full study period. Patients who stopped treatment (for other than safety reasons) but completed the study period will be also invited to participate in ADOREXT,"All patients: 1. who completed the full study period in the main ADORE study (FAB122-CT-2001; (EudraCT number 2020-003376-40); 2. whom the investigator has no concern and judges tolerable for the continued treatment with FAB122 from a risk and benefit point of view; 3. a female subject should not be able to become pregnant and needs to meet at least one of the following criteria: - female subject who is not of reproductive potential is eligible without requiring the use of contraception. A woman is considered not having childbearing potential when becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. - female who is of reproductive potential and has a negative pregnancy test at screening and at baseline and is non-lactating. A female subject who is of reproductive potential agrees to use (or have their partner use) adequate birth control methods starting from the time of consent through 30 days after the last dose of study therapy. Longer periods of birth control may be required per local requirements. Acceptable methods of birth control include combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device in place for ≥3 months, intrauterine hormone-releasing system, bilateral tubal occlusion or vasectomised partner. 4. a male patient must: - agree he will not donate sperm during the study and until 104 days after the last dose, AND use a condom during sexual intercourse with pregnant or non-pregnant women of childbearing potential (WOCBP) partner even if he is vasectomized. - in addition WOCBP partner of the male patient must use the following acceptable methods of birth control during the study and until 104 days after the last dose: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device in place for ≥3 months, intrauterine hormone-releasing system, bilateral tubal occlusion or vasectomised partner; 5. providing informed consent.",ADOREXT EudraCT Number:2022-003050-32 FAB122-CT-2201 NCT05866926 NL83050.100.22 TrialTroveID-457360,Adults; Older Adults,year(s),year(s),457360,Delay Disease Progression; Symptom relief,80.0,18.0,"Not applicable, as study is an open-label extension of an already existing study",Iii,Both
1,Patients with Amyotrophic Lateral Sclerosis,"1. Age 18 – 80 years (both inclusive), male or female; 2. Diagnosis of definite, probable, probable laboratory supported or possible ALS as based on the El Escorial and the revised Airlie House diagnostic criteria for ALS; 3. Onset of first symptoms* no longer than 24 months prior to randomization; *Date of onset is the date the patient reported one or more of the following symptoms: Muscle weakness in limbs; speech/swallowing difficulties; respiratory symptoms: dyspnea was noticed 4. SVC equal to or more than 70% of the predicted normal value for gender, height and age at screening visit; 5. Change in ALSFRS-R score between 0.35 points and 1.5 points per month (both inclusive) in the period from onset of first symptoms to the Screening visit; 6. Patients on riluzole should be on stable doses > or =30 days prior to the baseline visit and this dose should be maintained during the entire trial. 7. A female subject should not be able to become pregnant and needs to meet at least one of the following criteria: • female subject who is not of reproductive potential is eligible without requiring the use of contraception. A woman is considered not having childbearing potential when becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause • female who is of reproductive potential and has a negative pregnancy test at screening and at baseline and is non-lactating. A female subject who is of reproductive potential agrees to use (or have their partner use) or practicing adequate birth control methods starting from the time of consent through 30 days after the last dose of study therapy. Longer periods of birth control may be required per local requirements. Acceptable methods of birth control include combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), , intrauterine device in place for =3 months, intrauterine hormone-releasing system, bilateral tubal occlusion or vasectomised partner. 8. A male patient must: • agree he will not donate sperm during the study and until 104 days after the last dose, AND • use a condom during sexual intercourse with pregnant or non-pregnant women of childbearing potential (WOCBP) partner even if he is vasectomized • in addition WOCBP partner of the male patient must use the following acceptable methods of birth control during the study and until 104 days after the last dose: hormonal contraception (oral, implanted, injected or other hormonal (e.g., patch or contraceptive ring) contraception), intrauterine device in place for > or = 3 months, barrier method in conjunction with spermicide OR use of appropriate double barrier contraception as per local regulations or guidelines; 9. Capable of providing informed consent and complying with trial procedures. Muscle weakness in limbs Speech/swallowing difficulties Respiratory symptoms: dyspnea was noticed SVC equal to or more than 70% of the predicted normal value for gender, height and age at screening visit; Change in ALSFRS-R score between 0.35 points and 1.5 points per month (both inclusive) in the period from onset of first symptoms to the Screening visit; Capable of providing informed consent and complying with trial procedures. The main inclusion criteria are: definite, probable, probably laboratory supported or possible ALS (based on the El Escorial and the revised Airlie House diagnostic criteria, Slow Vital Capacity (SVC) 70%, onset of first symptoms 24 months prior to randomization, and change in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) score between 0.35 and 1.5 points per month (both inclusive) in the period between first symptoms and the screening visit",21/YH/0144 ADORE EudraCT Number: 2020-003376-40 FAB122-CT-2001 NCT05178810 NL74715.041.21 NL79225.041.21 TrialTroveID-411401,Adults; Older Adults,year(s),year(s),411401,Delay Disease Progression,80.0,18.0,"1. Diagnosis of Primary Lateral Sclerosis; 2. Diagnosis of Frontotemporal Dementia; 3. Diagnosis of other neurodegenerative diseases (e.g. Parkinson disease, Alzheimer disease); 4. Diagnosis of polyneuropathy; 5. Other causes of neuromuscular weakness; 6. Have a significant pulmonary disorder not attributed to ALS and/or require treatment interfering with the evaluation of ALS on respiratory function; 7. Use of intravenous (IV) edaravone within 6 months of the screening visit; 8. Depend on mechanical ventilation (invasive or non-invasive) or require tracheostomy at Screening; 9. Renal impairment as indicated by a creatinine clearance of less than 50 mL/min as calculated by the Cockcroft Gault equation; 10. Subject has a history of clinically significant hepatic disease, hepatitis or biliary tract disease, or subject has a positive screening test for HIV, hepatitis B or C; 11. Presence of any of the following clinical conditions: a. Unstable cardiac, pulmonary, endocrine, hematologic or active infectious disease b. Unstable psychiatric illness defined as psychosis, untreated major depression within 90 days of the screening visit c. Significant cognitive impairment, clinical dementia or psychiatric illness d. Cancer that is currently under active treatment or is likely to require treatment during the trial that may alter the subject´s function and interfere with assessment of ALS disease progression. 12. Any comorbidity that may interfere with the functions as scored with the ALSFRS-R; 13. History of known sensitivity or intolerability to edaravone, to any related compound, or to any of the excipients; 14. Exposure to any investigational drug within 30 days of the screening visit; 15. Current substance or alcohol dependence.",Iii,Both
0,Healthy subjects.,,TrialTroveID-325435,,,,325435,Healthy subjects,,,,I,
0,Healthy volunteers and patients with amyotrophic lateral sclerosis.,,TrialTroveID-269589,,,,269589,Healthy subjects,,,,I,
0,Patients diagnosed with amyotrophic lateral sclerosis,"1. Provision of written informed consent and compliance with study procedures 2. Diagnoses of definite, probable or possible ALS according to the El Escorial criteria, supported by laboratory values and confirmed by a trained and qualified expert physician 3. Aged between 18 and 70 years of age (both inclusive) 4. Women must not be able to become pregnant (post-menopausal for at least a year, surgically sterile or practicing adequate birth control methods) for the duration of the study 5. Women of childbearing potential must have a negative serum pregnancy test at screening and be non-lactating 6. Vital capacity equal to or more than 70% predicted normal value for gender, height and age at screening 7. No clinically significant abnormality on 12-lead ECG performed at screening",EudraCT number: 2015-000685-64 NL52559.041.15 TrialTroveID-269586,Adults; Older Adults,year(s),year(s),269586,Unspecified,70.0,18.0,"1. Other causes of neuromuscular weakness have not been excluded 2. Significant cognitive impairment, clinical dementia or psychiatric illness 3. Diagnosis of other neurodegenerative disease 4. Significant pulmonary disorder not attributed to ALS, requirement of treatment complicating evaluation of ALS on respiratory function 5. History of known sensitivity or intolerability of edaravone or to any related compound 6. Severe disturbance of consciousness 7. Hepatic impairment as indicated by Child-Pugh Class B or C (moderate to severe hepatic insufficiency) 8. Renal impairment as indicated by a creatinine clearance of less than 50 mL/min as calculated by the Cockcroft Gault equation using serum creatinine. 9. Serious difficulty swallowing and/or inability to eat high-fat high-calorie meal 10. Tracheostomy or non-invasive ventilation 11. Administration of antibiotics, CYP3A4 and or PgP inhibitors 12. Smoking 13. Advanced cancer 14. Exposure to any investigational drug within 30 days of the screening visit 15. Malnourishment based on laboratory data, dehydration or on a sodium free diet 16. Presence of any of the following clinical conditions: a. Substance abuse within the past year b. Uncontrolled cardiac, pulmonary, renal, hepatic, endocrine, hematologic or active infectious disease c. AIDS or AIDS related disease, hepatitis B virus (HBV) or hepatitis C virus (HCV) d. Unstable psychiatric illness defined as psychosis, untreated major depression within 90 days of the screening visit",I,Both
1,Patients with amyotrophic lateral sclerosis,,ADORE TrialTroveID-212552,,,,212552,Delay Disease Progression,,,,Ii/Iii,
1,Patients with Amyotrophic Lateral Sclerosis.,Patients who fulfilled the criteria for the NO-ALS study and have completed the study will be proposed inclusion in the NO-ALS extension study protocol. Patients from both arm 1 and arm 2 in the NO-ALS study will be allowed inclusion in the prolongation study,266376 NCT05095571 TrialTroveID-417379,Adults; Older Adults,year(s),,417379,Delay Disease Progression,,35.0,"Individuals will be excluded if any of the following exclusion criteria apply: Dementia, fronto temporal dementia (FTD) or other neurodegenerative disorder interfering with compliance. Metabolic, neoplastic, or other physically or mentally debilitating disorder. Patients who become tracheostomized as part of the treatment of ALS. Patients with short expected survival at the discretion of the investigator. Such cases cannot be expected to follow protocol procedures. Use of Vit B3 or blue berry extracts outside the study",Iv,Both
1,Patients with Amyotrophic Lateral Sclerosis.,Arm 1 (newly diagnosed ALS patients) Have a clinical diagnosis of probable ALS according to the revised El Escorial criteria. MR of the brain and cervical spine cannot explain symptoms. Diagnosed with likely ALS within 6 months from enrolment and treated with Riluzole 50mg x 2 Symptom onset no longer than 2 year prior to inclusion. ALS-FRC-R of 36 or more (not any item below 2). Age equal to or greater than 35 years at time of enrollment Arm 2 (earlier diagnosed ALS patients) Have a clinical diagnosis of probable ALS according to the revised El Escorial criteria. MR of the brain and cervical spine cannot explain symptoms. Treated with Riluzole 50mg x 2.,98955 NCT04562831 NO-ALS TrialTroveID-385546,Adults; Older Adults,year(s),,385546,Delay Disease Progression,,35.0,"Dementia, FTD or other neurodegenerative disorder at baseline visit Any psychiatric disorder that would interfere with compliance in the study. Use of high dose vitamin B3 supplementation within 30 days of enrollment Metabolic, neoplastic, or other physically or mentally debilitating disorder at baseline visit. Genetically confirmed mitochondrial disease Patients who become tracheostomized as part of the treatment of ALS Patients with short expected survival at the discretion of the investigator. Such cases cannot be expected to follow protocol procedures.",Iv,Both
0,Patients with amyotrophic lateral sclerosis (ALS).,,TrialTroveID-321723,,,,321723,Unspecified,,,,Ii,
0,Patients with amyotrophic lateral sclerosis (ALS).,18 years or older Diagnosis of probable or definite (sporadic or familial) ALS by El Escorial criteria Onset of symptomatology for more than 6 months If female: not lactating; negative pregnancy test; agree to use an effective method of birth control throughout study,H1479983999044 NCT03489200 TrialTroveID-321722,Adults; Older Adults,year(s),,321722,Delay Disease Progression,,18.0,"Tracheostomy, invasive ventilation, or non-invasive positive pressure ventilation Gastrostomy Evidence of major psychiatric disorder or clinically evident dementia Diagnosis of a neurodegenerative disease in addition to ALS Current medication apart from riluzole that in the opinion of the investigator would make the patient unsuitable for study participation Recent history (within the previous 6 months) or current evidence of alcohol or drug abuse Concurrent unstable disease involving any system (e.g. carcinoma other than basal cell carcinoma), any cardiac dysrhythmia, myocardial infarction, clinical or ECG signs of myocardial ischemia, cardiac insufficiency, angina symptoms, current symptoms of coronary artery disease, or any other condition that in the opinion of the investigator would make the patient unsuitable for study participation Baseline QTc (Bazett) > 450 msec for males and > 470 msec for females Known hepatitis B/C or HIV positive serology Renal impairment defined as blood creatinine > 2x ULN Hepatic impairment and/or liver enzymes (ALT or AST) > 3x ULN Hemostasis disorders or current treatment with oral anticoagulants Participated in any other investigational drug or therapy study with a non-approved medication, within the previous 3 months No medical insurance",Ii,Both
0,Healthy subjects,"1) Healthy volunteers aged 18-60 (including the boundary value), male or female (not less than 4 cases of a single sex); 2) Male weight ≥ 50kg, female weight ≥ 45kg, and body mass index (BMI) 18.0 -30.0kg/m2 (including the upper and lower limits); 3) The medical history, physical examination, vital signs, 12-lead electrocardiogram, laboratory examination, and imaging examination (abdominal B-ultrasound, chest X-ray) are normal at the time of screening, or the researcher Judging that the abnormality has no clinical significance; 4) The subject should take effective contraceptive measures from the period of taking the study drug to within 3 months after the last dose to avoid pregnancy or make the partner pregnant;",CTR20230343 FB-1071-01-102 TrialTroveID-459434,Adults,year(s),year(s),459434,Healthy subjects,60.0,18.0,"1) Have a history of chronic diseases or serious diseases such as cardiovascular, respiratory, liver, kidney, gastrointestinal tract, endocrine, immune, mental, nervous, or blood and lymphatic system diseases, and are not suitable to participate in this study as judged by the investigator; 2) Have epilepsy , cerebrovascular disease and other nervous system diseases; 3) Acute infection or acute disease within 2 weeks before screening; 4) Laboratory test results at the time of screening exceed the reference value range and have clinical significance; 5) Blood biochemical tests suggest ALT, AST , ALP, and total bilirubin are greater than the upper limit of the reference value range; 6) Subjects with abnormal heart function judged by the investigator: a. 12-lead electrocardiogram showed clinically significant abnormalities during screening, or corrected QT interval: QTcF ≤ 350 milliseconds or ≥ 450 milliseconds; b. History of long QT syndrome or confirmed family history of long QT syndrome (grandparents, parents and siblings); 7) history of clinically significant drug or food allergy, or history of atopic allergic disease, or known Allergy to the test drug or its excipients or similar drugs; 8) Those with factors that significantly affect drug absorption, distribution, metabolism, excretion, etc., such as inability to take the test drug orally, obvious nausea and vomiting, and malabsorption; 9) Human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody or Treponema pallidum-specific antibody test results are positive; 10) Eat food and drugs that induce photoallergies within 48 hours before screening , such as grapefruit or drinks containing grapefruit (see Appendix 4); 11) Those who are known to have a history of drug abuse or who have a positive drug abuse screening; 12) Those who smoked 5 or more cigarettes a day within 6 months before screening, Or those with positive urine cotinine test during the screening period; 13) The average weekly alcohol intake in the 3 months before screening exceeds 21 units of alcohol (male) / 14 units of alcohol (female) (1 unit ≈ 360mL beer, or 45mL spirits with 40% alcohol content, or 150mL wine) or alcohol screening positive; 14) Drinking excessive tea, coffee and/or caffeinated beverages (more than 8 cups, 1 Cup = 250 mL); 15) Blood donation or blood loss ≥ 400 within 3 months before the first administration",I,Both
0,Healthy Volunteers,"1. Healthy subjects aged 18-60 (inclusive), male or female (no less than 1/3 of a single gender); 2. Male weight > or = 50 kg, female weight > or = 45 kg and body mass index (BMI) 18.0-30.0 kg/m2 (including upper and lower limits); 3. The medical history, physical examination, vital signs, 12-lead electrocardiogram, laboratory examination, and imaging examination (abdominal B-ultrasound, chest X-ray) are normal at the time of screening, or the abnormality judged by the investigator has no clinical significance; 4. Subjects should take effective contraceptive measures from the period of taking the study drug to 3 months after the last dose to avoid pregnancy or make their partner pregnant; 5. The subjects understood and followed the research process, participated voluntarily, and signed the informed consent form.",CTR20230290 FB-1071-01-101 TrialTroveID-451496,Adults,year(s),year(s),451496,Healthy subjects,60.0,18.0,"1. Clinically significant history of chronic diseases or serious diseases such as cardiovascular, liver, kidney, respiratory, blood and lymph, endocrine, immune, mental, nervous, gastrointestinal system; 2. Have neurological diseases such as epilepsy and cerebrovascular disease; 3. Those with acute infection or acute disease within 2 weeks before screening; 4. A history of clinically significant ECG abnormalities, or a family history of long QT syndrome (grandparents, parents, and siblings); 5. Have a history of drug or food allergy, or atopic allergic disease history, or known allergy to the test drug or its excipients or similar drugs; 6. Those who smoked 5 or more cigarettes a day within 6 months before screening, or those who had a positive urine test for cotinine during the screening period; 7. A history of alcohol abuse with an average alcohol intake of more than 21 units (men)/14 units (women) per week (1 unit ≈ 360 mL of beer, or 45 mL of 40% spirits, or 150 mL of wine ); 8. Have a history of drug abuse, or screen multiple drugs combined detection kit (colloidal gold method) during the screening period (including benzodiazepine, methamphetamine, cocaine, morphine, ketamine, THC, Methylenedioxyamphetamine) positive; 9. Those who have special requirements for diet and cannot accept a unified diet; 10. Those who cannot tolerate venipuncture, those who have a history of fainting from needles and blood; 11. Those who have difficulty swallowing; 12. Irregular menstruation or irregular bleeding; 13. Donate blood or lose blood > or = 400 mL, accept blood transfusion or use blood products within 3 months before administration; 14. Participated in any drug or device clinical trial within 3 months before screening; 15. Those who drank excessive tea, coffee and/or caffeinated beverages (more than 8 cups, 1 cup = 250 mL) within 3 months before screening; 16. Taking strong CYP3A4 inhibitors or strong inducers within 4 weeks prior to screening 17. Have taken any prescription drugs within 4 weeks before screening, and used any over-the-counter drugs (including Chinese herbal decoction pieces, traditional Chinese medicine granules, etc.) within 2 weeks before screening; 18. Have eaten foods that induce photoallergies, such as grapefruit or drinks containing grapefruit, within 48 hours before screening 19. The laboratory test results at the time of screening exceed the reference value range and have clinical significance, but ALT, AST and ALP need to be within the reference value range; 20. Human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody or Treponema pallidum specific antibody (TPPA) test results are positive; 21. 12-lead electrocardiogram at the time of screening showed abnormal clinical significance, or corrected QT interval: QTcF < or = 350 milliseconds or > or = 450 milliseconds; 22. Ear temperature > 37.5°C, pulse rate > 100 beats/min or < 50 beats/min, systolic blood pressure > or = 140 mmHg or < 90 mmHg, diastolic blood pressure > or = 90 mmHg or < 50 mmHg; 23. Positive blood pregnancy test; 24. Subjects considered by the investigator to be unsuitable to participate in the study",I,Both
0,Adults With Amyotrophic Lateral Sclerosis,"Diagnosis of familial or sporadic ALS FVC of > or = 50 percent predicted If female, is not breastfeeding and is not pregnant Has been on a stable dose of riluzole, or has not taken riluzole, for at least 30 days prior to screening If taking concomitant edaravone at study entry, must have completed at least one cycle of edaravone therapy prior to screening Not currently taking and has not taken for at least 30 days prior to screening any Theophylline containing medications, clozapine, or duloxetine No active infection in the 30 days prior to randomization Has not taken any fluoroquinolone antibiotics for at least 30 days prior to screening",NCT04840823 REALS-1 TrialTroveID-393104,Adults; Older Adults,year(s),year(s),393104,Unspecified,85.0,18.0,"Hypersensitivity/allergy to fluoroquinolones Diagnosed with another neurodegenerative disease Significant pulmonary disorder not attributed to ALS, central nervous system disorder associated with seizures, myasthenia gravis, active rheumatologic disease, tendinopathy, or any severe uncontrolled medical condition (other than ALS) Severe renal impairment or impaired liver function Baseline prolongation of QT interval/corrected QT interval (QTc) at screening, treatment with any agent that may prolong Qt/QTc interval, or history of any other at-risk other cardiac condition Currently enrolled in another clinical trial involving an experimental drug or device",Iii,Both
0,"Patients (5M and 6F) (median age=53 Range:35-70) referring to our tertiary ALS centre (8 patients had probable or defined ALS, 1 primary lateral sclerosis, 2 UMN prevalent ALS).",,TrialTroveID-159636,Adults; Older Adults,year(s),year(s),159636,Symptom relief,70.0,35.0,,Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis,Inclusion criteria: To be arruoalti patients must meet the following criteria: 1. be able to grant informed consent 2. being male or female age 'between 18 and 75 years 3. have a diagnosis of ALS according to revised criteria of EI Escorial Criteria 4. estimated to have a life expectancy greater than 6 months .,21404132 EudraCT Number: 2010-020257-13 EudraCT Number: 2010-020257-14 TrialTroveID-133532,Adults; Older Adults,year(s),year(s),133532,Symptom relief,75.0,18.0,Exclusion criteria: 1. inability 'or refugee to understand the study design or participate in the procedures provided for study 2. any contraindication to the use of eperisone 3. presence of other diseases as well as neurological SLA 4. Pregnant or breast-feeding or plan to start a grravidanza during the study period.,Ii,Both
0,Healthy Volunteers,"1 Healthy volunteer subjects, male and female (both male and female), aged 18 years and above (including 18 years old) 2 The weight of male subjects is not less than 50.0kg, the weight of female subjects is not less than 45.0kg, and the body mass index (BMI) is in the range of 19.0~26.0kg/m2 [BMI=weight (kg)/height 2 (m2)] (including critical values) 3 Female subjects are willing to have no childbearing plans from 2 weeks before screening to 6 months after the last administration of the study drug and voluntarily take effective non-drug contraceptive measures (see appendix) and have no plan to donate eggs; male subjects are willing to voluntarily Screening until 6 months after the last dose of the study drug has no childbearing plans and voluntarily take effective non-drug contraceptive measures (see Appendix) and no sperm donation plans 4 Sign an informed consent form before screening, fully understand the trial content, process and possible adverse reactions, and be able to complete the study in accordance with the trial protocol requirements",CTR20240554 TrialTroveID-510355 WBYY23117,Adults; Older Adults,year(s),,510355,(N/A); Healthy subjects,,18.0,"1 Diseases with abnormal clinical manifestations that have occurred or are occurring before screening and need to be excluded, including but not limited to the nervous/psychiatric system, respiratory system, cardiovascular and cerebrovascular systems, digestive tract system (any history of gastrointestinal diseases that affect drug absorption), blood And those with a history of chronic or serious diseases such as lymphatic system, liver and kidney function, endocrine system, immune system diseases, etc. 2 Vital sign examination, physical examination, clinical laboratory examination (blood routine, urine routine, blood biochemistry), pregnancy examination (for women), immune examination, 12-lead electrocardiogram and other examinations, if the results show abnormalities with clinical significance 3 Those who have undergone surgery within 3 months before screening or plan to have surgery during the study period, or those who have undergone surgery that will affect drug absorption, distribution, metabolism, and excretion 4 Those who have a clinical history of allergies to food, drugs, etc., especially those who are known to be allergic to eperisone hydrochloride and any ingredients in the excipients of this product 5 Those who have used any prescription drugs, over-the-counter drugs, Chinese herbal medicines (or Chinese patent medicines) and vitamins within 2 weeks before screening 6 The average weekly drinking volume in the 3 months before screening is greater than 14 units of alcohol (1 unit of alcohol ≈ 360mL beer or 45mL spirits with an alcohol content of 40% or 150mL wine), or those who cannot abstain from alcohol during the trial 7 Those who smoked more than 5 cigarettes per day on average within 3 months before screening, or who were unable to stop using any tobacco products during the trial 8 Those who donated blood including blood components or lost a large amount of blood (≥400mL) within 3 months before screening 9 Those with a history of drug abuse within 6 months before screening 10 Those with a history of drug abuse within 6 months before screening 11 Have used any drugs that inhibit or induce hepatic drug metabolism within 28 days before screening (such as: inducers - barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole; inhibitors - SSRI antibiotics Depressants, cimetidine, diltiazem, macrolides, nitroimidazole, sedative-hypnotics, verapamil, fluoroquinolones, antihistamines) 12 Those who have participated in other drug clinical trials within 3 months before screening or who are not participating in clinical trials themselves 13 Those who have received vaccination within 1 month before screening (special: 1 month for new coronavirus adenovirus vector vaccine, 2 weeks for inactivated and recombinant vaccines), or those who plan to be vaccinated during the study period 14 Those who drank excessive amounts of tea, coffee and/or caffeinated beverages (average more than 8 cups, 1 cup ≈ 250mL) per day in the 3 months before screening 15 Those who have special dietary requirements and cannot accept a uniform diet 16 People with difficulty swallowing 17 People who are lactose intolerant (people who have had diarrhea after drinking milk) 18 Those engaged in related occupations such as driving, operating machinery or instruments, etc. 19 Those who cannot tolerate venipuncture or those who have a history of needle or blood fainting 20 Female subjects who are lactating or pregnant twenty one Those who the researcher believes are not suitable to participate in clinical trials",I,Both
0,Healthy subjects,"1 Healthy subjects, both male and female, aged 18 to 65 years old (including 18 and 65 years old); 2 Weight: male weight ≥50.0kg, female weight ≥45.0kg, body mass index (BMI) [BMI = weight (kg)/height 2 (m2)] between 19.0~26.0kg/m2 (including the boundary value); 3 Subjects agree that they have no plans to have children within 3 months from signing the informed consent form to the end of the trial. Men have no plans to donate sperm and women have no plans to donate eggs. During this period, they agree to voluntarily take effective non-drug contraceptive measures; 4 The subject fully understands the purpose, nature, method and possible adverse reactions of the trial, is able to communicate well with the researcher and is able to complete the research in accordance with the research regulations, voluntarily serves as a subject, and signs an informed consent form before the start of any research procedures.",2023-YPLS-BE-062 CTR20234216 TrialTroveID-499248,Adults,year(s),year(s),499248,(N/A); Healthy subjects,65.0,18.0,"1 Those who have had sexual intercourse without effective non-drug contraceptive measures between the end of their last menstrual period and before screening (female subjects only); 2 Participated in other medical or clinical trials within 3 months before screening; 3 Those with a history of specific allergies (asthma, urticaria, eczema, etc.), or allergies (such as those allergic to two or more drugs or food), or those with a history of allergies to eperisone hydrochloride tablets or preparation excipients; 4 Those with a history of chronic or acute diseases of the nervous system, respiratory system, cardiovascular system, digestive system, blood and lymphatic system, endocrine system, immune system, musculoskeletal system, etc., which are judged by the research doctor to be likely to affect the research results; 5 Those with a history of toxic epidermal necrolysis (TEN) and ocular mucocutaneous syndrome (Stevens-Johnson syndrome); 6 People who are lactose intolerant (people who have had diarrhea after drinking milk); 7 Those who have difficulty swallowing tablets; 8 Difficulty in blood collection, dizziness from blood, or dizziness from needles; 9 Those who smoke ≥ 5 cigarettes per day within 3 months before screening, or those who cannot stop using any tobacco products during the trial; 10 The average weekly drinking volume in the 6 months before screening is greater than 14 units of alcohol (1 unit of alcohol = 360 mL beer or 45 mL spirits or 150 mL wine) or has consumed alcoholic products within 2 days before taking the drug, or has an alcohol breath test Those who are positive, or those who cannot stop using any alcohol products during the test; 11 Those with a positive urine drug screen or those with a history of drug abuse within five years before screening or those who have used drugs within 3 months before screening; 12 Those who have used any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health products within 2 weeks before screening; 13 Those who have taken any drugs that interact with the experimental drugs (such as taking methocarbamol, etc.) within 30 days before screening; 14 Taking any drugs that alter liver enzyme activity within 30 days before screening (e.g., inducers—barbiturates, carbamazepine, phenytoin, glucocorticoids; inhibitors—SSRI antidepressants, cimetidine, diltiazem , macrolides, nitroimidazole, sedative-hypnotics, verapamil, fluoroquinolones, antihistamines, omeprazole); 15 Those who have received vaccination within 1 month before screening, or those who plan to receive vaccination during the trial; 16 Those who have undergone surgery within 3 months before screening, or plan to have surgery during the study period; 17 Those who have suffered massive blood loss (≥400 mL) within 3 months before screening, or those who have a history of blood donation (≥400 mL) within 3 months before screening, or those who plan to donate blood during the trial; 18 Those who have consumed dragon fruit, mango, grapefruit, lime, carambola, or food or beverages prepared from them within 48 hours before taking the experimental drug, or who cannot stop eating dragon fruit, mango, grapefruit, lime, and carambola during the test or food or drink prepared therefrom; 19 Eat foods and beverages containing xanthines (caffeine, theophylline, theobromine and madeine) within 48 hours before taking the experimental drug, including coffee, tea, chocolate, etc., or do not stop eating foods and beverages containing xanthines (caffeine, theophylline, theobromine and madeine) during the test. Foods and beverages containing xanthines (caffeine, theophylline, theobromine and madeine), including coffee, tea, chocolate, etc.; 20 Those who have engaged in strenuous exercise (such as rope skipping, swimming, long-distance running, etc.) within 48 hours before taking the investigational drug, or who cannot stop strenuous exercise (such as rope skipping, swimming, long-distance running, etc.) during the trial; 21 Those who plan to operate dangerous machinery such as driving vehicles during the test period; 22 Female subjects are lactating or have a positive pregnancy test result during the screening period or trial; 23 Female subjects who use oral contraceptives within 30 days before screening, or long-acting estrogen or progesterone injections or implants within the past 6 months; 24 People with liver dysfunction; 25 Abnormalities that are clinically significant as judged by the study physician, including physical examination, vital signs examination, electrocardiogram, or clinical laboratory tests; 26 Other reasons that the researcher deems inappropriate for enrollment or subjects withdraw from the trial due to their own reasons.",I,Both
0,Subjects with Amyotrophic Lateral Sclerosis,"Age between 25 to 80 upper motor neuron signs and lower motor neuron signs were identified in neurological examination. Meet the revised El Escorial Criteria for clinically possible, probable-laboratory -supported, probable, definite ALS. Disease duration < 3 years (Within 3 years from symptom onset) ALSFRS-R score between 21 to 46 Patient who can visit an outpatient under the aid of his or her own walking or caregivers. The person who have agreed in writing to participate in this clinical trial by themselves and the legal representative FVC over 50% at screening",HYNR-EPO NCT03835507 TrialTroveID-342634,Adults; Older Adults,year(s),year(s),342634,Unspecified,80.0,25.0,"Person who were not compatible with ALS Patient with PLS or PMA A group of patients who are concerned about the adverse effects of the drug administration (e.g. malignant hypertension,...) ALSFRS-R score below 20 at screening Ventilator user or Tracheostomy state patients at screening Gastrostomy state at screening FVC below 50% at screening or patient who cannot perform FVC test. EKG abnormality, history of coronary stent , CABG at screening Person who was given another clinical trial drug three months prior to screening. History of seizure/ epilepsy Abnormal renal function (serem creatinine > 2.0mg/dl) Abnormal liver function(AST/ALT/bilirubin over 2 times the upper normal limit Pregnant Bleeding tendency at screening Infectious disease at screening Drug sensitivity Person who injected erythropoietin 6 months prior to screening Malignant tumor Other neurological disease (stroke, parkinson's disease, dementia...) Psychological disease Hb more than 16g/dL",Iii,Both
0,Patients with Amyotrophic Lateral Sclerosis (ALS).,"Inclusion criteria: Caucasian male or female outpatients Aged 18 to 75 years inclusive Diagnosis of probable or definite ALS First symptoms of ALS by no more than 2 years In treatment with steady regimen of Riluzole and Vitamin E by at least 3 months, and desiring its continuation FVC 75 of predicted No conditions known to be contraindications to the use of EPO Written informed consent",EPO200501 EudraCT Number: 2005-005873-31 TrialTroveID-109558,Adults; Older Adults,year(s),year(s),109558,Unspecified,75.0,18.0,"Exclusion Criteria Subjects who underwent tracheostomy Subjects with signs of conduction blocks of motor nerves, sensory nerves or both on nerve conduction study Subjects with clinical signs of dementia - history of myocardial infarction or thrombotic vascular events such as stroke, pulmonary emboli, deep vein thrombosis, TIA Clinically evident cardiac disease ischemic heart disease or congestive heart failure Uncontrolled hypertension Active malignancy Polycytemia Myeloproloferative disorders Hypercoagulabily disorders Porphyria Known hypersensitivity to human albumin Pregnant and lactating women Subjects who received an experimental drug or have participated in a clinical trial within 3 months prior to screening Employees of the Investigator or study centre with direct involvement in the study or in other sudies under the direction of the Investgator or study center",Ii,Both
0,"Patients with Amyotrophic lateral sclerosis (ALS). Patients with diagnosis of laboratory-supported probable, probable, or definite ALS according to El Escorial revised criteria.","Principal inclusion criteria: Age 18-75 years Diagnosis of sporadic or familial ALS Onset of weakness < or =36 months prior enrolment Willingness to undergo active contraception (excluding estroprogestinic drugs) for fertile female subjects throughout the entire study period Written informed consent. All patients will be required to take riluzole 100 mg daily and patients will be considered eligible if on stable dose for at least 60 days. Not following riluzole for any reason (e.g.side effects,etc.) will not be considered an exclusion criteria. Patients on riluzole at the randomization will be asked to remain on stable dose for the whole study. Patients not on riluzole will not take it for the entire study period",EPOSS2010 EudraCT Number: 2011-001329-26 TrialTroveID-203402,Adults; Older Adults,year(s),year(s),203402,Unspecified,75.0,18.0,"Principal exclusion criteria: Hematocrit >49% in men and >47% in women, hemoglobin value >15 g/dl in men and >13 g/dl in women Tracheotomy Clinical diagnosis of frontotemporal dementia, Parkinson or Alzheimer disease History and/or instrumental evidence of previous myocardial infarction or thrombotic vascular events (such as stroke, transient ischemic attack, pulmonary emboli, retinal thrombosis, deep vein or arterial thrombosis including asymptomatic carotid and/or vertebral stenosis >30%) Clinically evident cardiac disease (ischemic heart disease, congestive heart failure, arrhythmia) Uncontrolled hypertension (systolic blood pressure >160 mmHg and diastolic blood pressure >95 mmHg irrespective of anti-hypertensive treatments at two consecutive evaluations) Active malignancy, polycythemia, myeloproliferative disorders Hypercoagulable disorders (ref. Deitcher S, in Current Clinical Medicine 2009, Cleveland Clinic ed., Elsevier) Porphyria Known hypersensitivity to human albumin Female subjects pregnant or lactating Use of post-menopausal drugs (estrogen, progestinic, or their combination) Use of hormonal contraception drugs Use of experimental drug or participation in a clinical trial within 3 months prior to screening 16. previous treatment with hematopoietic stem cells",Ii,Both
1,"Patients with comorbid major depression, amyotrophic lateral sclerosis and multiple sclerosis.","Ages Eligible for Study: 18 Years to 70 Years Inclusion Criteria: Patients between 18 and 70 years of age with documented ALS or MS. > or = 14 score on the 17-item HAM-D. Ability to give informed consent. Symptoms of depression including: Sleep difficulty, loss of interest in people and things around you, feelings of guilt, lack of energy, difficulty concentrating, appetite changes, irritability and feelings that life is not worth living. Diagnosis of non-psychotic Major Depression (determined at screening visit). Diagnosis of ALS.",LXP-113 NCT00965497 Pro00003013 TrialTroveID-095453,Adults; Older Adults,year(s),year(s),95453,"Adults, major depression; Comorbidities in depression; Comorbidity in ALS; Comorbidity in MS",70.0,18.0,"Exclusion Criteria: History of psychotic disorders. Previous diagnosis of Psychotic depression, Bipolar depression, Suicide risk. History of substance abuse in the previous 6 months. History of unstable medical disorders. Pregnancy or planning for pregnancy. Severity of ALS or MS that limits participating in the study protocol. Alcohol or illicit drug abuse within the previous 6 months. Currently taking Celexa (citalopram) or escitalopram. History of unstable medical disorder; pregnancy or planning for pregnancy.",Iii,Both
0,,,TrialTroveID-449050,,,,449050,Unspecified,,,,I,
0,Patients with Frontotemporal Dementia,"Korean male or female at 40-85 years of age Diagnosis of one of the 3 subtyes of FTD according to the diagnostic criteria for 3 subtypes of FTD -Probable bvFTD (behavior variant FTD) -svPPA (semantic variant primary progressive aphasia) -nfvPPA (nonfluent/agrammatic variant primary progressive aphasia) K-MMSE > or = 10 Subjects with trusted caregivers who regularly contact the subjects and can accompany the subjects when visiting the hospital. Negative result of amyloid PET imaging A subject who is informed of the clinical trial and signs a consent form (If unable to sign, a consent from a legally acceptable representative is required)",2022-02-089 FTD_ET-STEM KCT0007072 NCT05315661 TrialTroveID-429197,Adults; Older Adults,year(s),year(s),429197,Frontotemporal Dementia,85.0,40.0,"Subjects with dementia cause by other than FTD (i.e. infection of central nervous system, Creutzfeld-Jacob disease, severer head trauma, Huntington's disease, Parkinson's disease, Alzheimer's disease and vascular dementia) Subjects with psychological disorder. (i.e. depression, schizophrenia , bipolar disorder, etc) (except for subjects who were misdiagnosed with psychological disease due to the initial neuropsychiatric symptoms of FTD) Subjects with uncontrolled hypotension, hypertension, diabetes and thyroid disease. Subjects with a cancer (including brain tumor) Subjects with bleeding disorder Woman of childbearing age who refused to practice medically acceptable contraceptive method (post menopausal patient with no menstruation for at least 12 months is considered as infertile) Pregnant or lactating females History of stroke within 3 months prior to study enrollment Substance/alcohol abuse 1 Contraindicated for any of the tests performed during the clinical trial period(for example, MRI, CT,PET) A subject in whom Ommaya reservoir insertion and general anesthesia are considered difficult Abnormal Laboratory findings at Screening Suspected active lung disease based on chest X-ray at Screening Positive hepatitis B nuclear antibody and hpatitis C antibody Subjects who the principal investigator considers inappropriate for participation in the study due to the possible harmful effect on the subjects,difficulty in study completion, or previous or current medical conditions that may disturb evaluation of study results Subjects who the principal investigator considers impossible to comply with clinical research procedures.",I,Both
0,Patients with amyotrophic lateral sclerosis and healthy volunteers.,"ALS Subject Inclusion Criteria: Male or female, aged 18 to 80. Sporadic or familial ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria. Slow vital capacity (SVC) measure > or = 50% of predicted for gender, height and age at the Screening Visit,OR in the opinion of the SI, ability to perform and safely complete all study visit procedures. Subjects must not have taken riluzole for at least 30 days, or be on a stable dose of riluzole for at least 30 days prior to the Screening Visit and continue on the stable dose throughout the course of the study (riluzole-naïve subjects are permitted in the study). Subjects must be able to swallow oral medication at the Screening Visit and expected to be able to swallow tablets throughout the course of the study. Capable of providing informed consent and following trial procedures. Geographically accessible to the site. Women must not be able to become pregnant (e.g., post menopausal, surgically sterile, or using adequate birth control methods) for the duration of the study and three months after study completion. Adequate contraception includes: abstinence, hormonal contraception (oral contraception, implanted contraception, injected contraception or other hormonal contraception, for example patch or contraceptive ring), intrauterine device (IUD) in place for = 3 months, barrier method in conjunction with spermicide, or another adequate method. Use of medications known to affect the neurophysiology measures in the study must be scheduled, not as needed (pro re nata, PRN). A subject must have been on a fixed dose for 30 days prior to the Screening Visit, and there must be no reason to believe that a subsequent change would be necessary during the course of the study. These medications include: benzodiazepines, muscle relaxants, tricyclic antidepressants, selective serotonin reuptake inhibitors, non-selective serotonin reuptake inhibitors, hypnotics (including anti-histamines) and anti-cholinergics. TMS shows sufficient MEP amplitude and/or NCS studies show sufficient CMAP amplitude Healthy Control Subject Inclusion Criteria: Male or female, aged 18 to 80. Absence of a known neurological disorder. Capable of providing informed consent and following trial procedures. Geographically accessible to the site. Age (+/- 10 years and site-matched to a ALS participant within 6 months of their Baseline visit).[Matched controls only] TMS shows sufficient MEP amplitude and/or NCS studies show sufficient CMAP amplitude (amplitudes defined in MOP). Use of medications known to affect the neurophysiology measures in the study must be scheduled, not as needed (pro re nata, PRN). A subject must have been on a fixed dose for 30 days prior to the Screening Visit, and there must be no reason to believe that a subsequent change would be necessary during the course of the study. These medications include: benzodiazepines, muscle relaxants, tricyclic antidepressants, selective serotonin reuptake inhibitors, non-selective serotonin reuptake inhibitors, hypnotics (including anti-histamines) and anti-cholinergics.",2014D002776 NCT02450552 TrialTroveID-255732,Adults; Older Adults,year(s),year(s),255732,Healthy subjects,80.0,18.0,"ALS Subject Exclusion Criteria: ALS Subject Exclusion Criteria: Medical condition, laboratory finding, or physical exam finding that precludes participation. Serum AST and ALT value >2.0 times the upper normal limit Clinically significant conduction abnormalities on electrocardiogram or a known history of cardiac arrhythmia, myocardial infarction within the past 24 months, or congestive heart failure. Estimated glomerular filtration rate < 50 mL/min at Screening Visit. Concomitant digoxin treatment. Known allergic reactions to components of the study product(s). Exposure to any other agent currently under investigation for the treatment of patients with ALS (off-label use or investigational) within 30 days of the Screening Visit including ezogabine, exposure to cell replacement therapy within six months of the Screening Visit or any prior intraparenchymal cell replacement injection within the spinal cord or brain at anytime in the past. Presence of tracheostomy at the Screening Visit. History of clinically significant urinary retention, , or current use of medications to treat urinary retention. History of drug and or alcohol abuse within 12 months of the Screening Visit. The presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair ability of the subject to provide informed consent, according to SI judgment. Clinically significant history of unstable or severe cardiac, oncologic, hepatic, or renal disease, or other uncontrolled medical condition. Presence of feeding tube. Current use of an antipsychotic, antiepileptic (except benzodiazepines, gabapentin, pregabalin) or class 1 (e.g. flecainide) or class 3 (e.g. amiodarone) antiarrhythmic medications (including . Quinidine or a quinidine-containing drug such as Nuedexta is allowed if the quinidine dose is not greater than 20 mg/day (for a full list of medications, please reference the study MOP). Inability to perform either TMS or NCS studies due to insufficient MEP or CMAP amplitude. Pregnant women or women currently breastfeeding. Contraindication to TMS studies including ferromagnetic metal in the head or neck ( such as potentially found in aneurysm clips ) , implanted medication pumps, implanted brain stimulators, pacemakers, cochlear implants), or history of epilepsy. Dental fillings are permitted. Anything else that, in the opinion of the SI, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study. Healthy Control Subject Exclusion Criteria: History of ALS or other neurodegenerative disease. Presence of positive family history of ALS. Current use of an antipsychotic or antiarrhythmic medication Definitely or possibly pregnant. Contraindication to TMS studies including ferromagnetic metal in the head or neck ( potentially found in aneurysm clips, implanted medication pumps, implanted brain stimulators, pacemakers, cochlear implants), or history of epilepsy. Dental fillings are permitted. Anything that, in the opinion of the SI, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study.",Ii,Both
0,,"1. Male or female participants, at least 18 years of age. 2. Clinically diagnosed with frontotemporal dementia (FTD), or a carrier of a mutation known to cause FTD (with or without symptoms); or a normal control. 3. Participant is able and willing to undergo testing (MRI or CT, PET, radioactive tracer injection, LP; for those unable to undergo an MRI, CT will be used to generate regions-of-interest). 4. Pre-menopausal women will have a negative a urine pregnancy test within 24 hours of T807 drug administration.",IND 123119 Protocol C NCT02707978,Adults; Older Adults,year(s),,274750,,,18.0,"1. Has any condition that, in the Investigator's opinion, could increase risk to the participant, limit the participant's ability to tolerate the experimental procedures, or interfere with the collection/analysis of the data (for example, participants with severe chronic back pain might not be able to lie still during the scanning procedures). 2. Is deemed likely unable to perform the imaging procedures for any reason. 3. Has a history of Torsades de Pointes or is taking medications known to prolong QT interval. To determine who will be excluded from this study based on this criterion, we will review participant's medical history and current medications at time of screening. Participants will be excluded from the study if any of the following restricted medications are being taken: - Disopyramide - Dofetilide - Ibutilide - Procainamide - Quinidine - Sotalol - Bepridil 4. Has hypersensitivity to F 18 T807 or any of its excipients. 5. Contraindications to PET, PET-CT or MR (e.g. electronic medical devices, inability to lie still for long periods) that make it unsafe for the individual to participate. 6. Severe claustrophobia. 7. Currently pregnant or breast-feeding. 8. For those electing to undergo the optional lumbar puncture: on anticoagulant of any form prior to lumbar puncture.",Ii,Both
0,,"1. Written informed consent must be obtained before any assessment is performed. 2. Female subjects must be documented by medical records or physician's note to be either surgically sterile (by means of hysterectomy, bilateral oophorectomy, or tubal ligation) or post-menopausal for at least 1 year or, if they are of child-bearing potential, must commit to use a barrier contraception method for the duration of the study. 3. Male subjects and their partners of childbearing potential must commit to the use of two methods of contraception, one of which is a barrier method for male subjects for the study duration. 4. Male subjects must not donate sperm for the study duration. 5. Willing and able to cooperate with study procedures",201700982A0 NCT03625128,Adults; Older Adults,year(s),year(s),330235,,90.0,20.0,"1. Implantation of metal devices including cardiac pacemaker, intravascular metal devices. 2. Major systemic diseases including coronary arterial disease, heart failure, uremia, hepatic failure, prominent strokes (except for patients with VCI), acute myocardial infarction, poorly controlled diabetes, previous head injury, intracranial operation, hypoxia, sepsis or severe infectious diseases. 3. Current or prior history of major psychiatric disorders, epilepsy and major depression. 4. History of severe allergic or anaphylactic reactions particularly to the tested drugs. 5. History of positive test for human immunodeficiency virus (HIV). 6. Life expectancy less than 1 year. 7. Pregnant women, lactating or breast-feeding women. 8. Clinically significant abnormal laboratory values and/or clinically significant or unstable medical or psychiatric illness. 9. Substance abuse or alcoholism for at least 3 months. 10. Cognitive impairment resulting from trauma brain injury. 11. Prior participation in other research protocols or clinical care in the last year in addition to the radiation exposure expected from participation in this clinical study, such that radiation exposure exceeds the effective dose of 50 mSv. 12. Subject has received an investigational drug or device within 30 days of screening 13. Patients in whom MRI was contraindicated and with history of claustrophobia in MRI 14. General MRI, and / or PET exclusion criteria. MRI exclusion criteria include: Findings of cerebrovascular disease (more than two lacunar infarcts, any territorial infarct >1cm3, or deep white matter abnormality corresponding to an overall Fazekas scale of 3 with at least one confluent hyperintense lesion on the FLAIR sequence that is ???20 mm in any dimension, except for patients with VCI), infectious disease, space-occupying lesions, normal pressure hydrocephalus or any other abnormalities associated with CNS disease. 15. Severe language impairment precluding cognitive assessments, defined as a score of 3 points in the language score of the National Institute of Health Stroke Scale. 16. Subjects having high risks for the study according to the PI discretion.",(N/A),Both
0,,- Must be over the age of 18 - Must speak English as your primary language - Must have an informant who can provide independent evaluation of functioning - Must present with a chief complaint of progressive impairment of speech/language or changes in behavior - Must fulfill diagnostic criteria for Primary Progressive Aphasia or Frontotemporal Dementia,16-001703 NCT02736695 SLD3,Adults; Older Adults,year(s),,276655,,,18.0,"- Any subject who is mute or whose speech is unintelligible will be excluded - All subjects with concurrent illnesses that could account for speech and language deficits, such as traumatic brain injury, strokes or developmental syndromes, and subjects meeting criteria for another neurodegenerative disease, such as amnestic Alzheimer's type dementia, dementia with Lewy bodies, progressive supranuclear palsy, and corticobasal syndrome will be excluded - All pregnant, post-partum and breast-feeding women will be excluded - Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, etc.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism,(e.g. chemotherapy).",Other,Both
0,Subjects with primary lateral sclerosis PLS or upper motor neuron predominate ALS,"Male or female, aged 18-99; Diagnosis of upper motor neuron disease, compatible with PLS but may include upper motor neuron (UMN) predominant ALS, defined as only upper motor neuron (UMN) features in at least 2 body regions on examination. EMG within 3 months of enrollment with minimal or no evidence of lower motor neuron disease, Time from symptom onset > 18 months No previous allergy to dalfampridine No current or exposure to any therapeutic agent targeting PLS or ALS within 30 days of enrollment. Must have a forced vital capacity (FVC) > or = 60% of expected Written informed consent prior to screening is present. Subjects on a stable dose of or have not taken Riluzole for at least thirty days Impaired walking as measured by a Hauser Index of greater than 1 and less than 7 (2 to 6, inclusive); Mini Mental Status Score > 22 and deemed by the PI of being capable of providing informed consent and following trial procedures. Geographically accessible to the site. Women must not be able to become pregnant (e.g., post-menopausal, surgically sterile, or using adequate birth control methods) for the duration of the study and three months after study completion. Adequate contraception includes: abstinence, hormonal contraception (oral contraception, implanted contraception, injected contraception or other hormonal contraception, for example patch or contraceptive ring), intrauterine device (IUD) in place for = 3 months, barrier method in conjunction with spermicide, or another adequate method.",2016-247 NCT02868567 OCR16600 TrialTroveID-284541,Adults; Older Adults,year(s),year(s),284541,Unspecified,99.0,18.0,"History of clinically significant liver disease, renal disease, peripheral neuropathy, serious peripheral vascular disease, known HSP or + C9orf72 or SPG4 mutation, or any other medical condition felt to be exclusionary by the investigator; Unwillingness to sign informed consent or any other reasons for which the investigator feels the subject cannot complete the study; Women who are pregnant, breastfeeding, or trying to become pregnant; Active cancer within the previous 2 years, except treated basal cell carcinoma of the skin; Subjects taking any other experimental drugs within 30 days prior to enrollment; Patient has any history of seizures; brain surgery, brain implants, any metallic implants above the neck, cardiac pacemakers, cochlear implants, piercing or body modification above the neck, known history of TMS related complications or side-effects, tinnitus. Patient has moderate or severe renal impairment as defined by a calculated creatinine clearance of =50 mL/minute; Patient has been administered botulinum toxin in the lower extremities within 6 months prior to the screening visit and/or is expected to receive botulinum toxin in the lower extremities during the course of the study; Patient has a known allergy to pyridine-containing substances or any of the inactive ingredients of the dalfampridine tablet (colloidal silicon dioxide, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, and titanium dioxide); Patient has a history of drug or alcohol abuse within the past year; Patient has clinically significant abnormal laboratory values. Anything else that, in the opinion of the SI, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study.",I,Both
0,Subjects with Amyotrophic Lateral Sclerosis (ALS).,"Clinical diagnosis of laboratory-supported probable, probable, or definite ALS Age: 18-70 years Disease duration: 3-36 months Forced vital capacity: at least 60% of predicted ALSFRS-R: at least 30, respiratory items: at least 10 Decline of ALSFRS-R in the last 3 months before enrollment: 1-8 Must take riluzole, on a stable dose for at least 30 days prior to baseline visit with no serious side effects. They must continue the riluzole treatment for at least 6 months after enrollment. Patients of childbearing potential must be using an effective method of birth control Willing and able to give informed consent",NCT01935518 PUTH-2013121 TrialTroveID-193283,Adults; Older Adults,year(s),year(s),193283,Delay Disease Progression,70.0,18.0,"Familial ALS Pregnant or nursing women Patients after tracheotomy or continuous ventilator-dependent (time with non-invasive ventilator more than 22 hours per day for 7 consecutive days.) After percutaneous endoscopic gastrostomy Alanine Transaminase (ALT) or Aspartate Transaminase (AST): at least 3 times the upper limit of normal Abnormal creatinine or urea nitrogen Severe cardiac disease, pulmonary disease, hematic disease, autoimmune disease, mental disease, dementia and substance abuse History of malignancy History of intracranial hemorrhage History of severe bleeding of digestive tract, lungs, nose and skin Allergic to fasudil Participating in other clinical studies or using other investigational drugs at present",Ii,Both
0,"Subjects with possible, probable laboratory-supported, probable, or definite ALS","Between 18 and 75 years of age (inclusive) at Screening 1. Subject has had a diagnosis of probable laboratory-supported, probable, or definite ALS (as defined by El Escorial Revised ALS diagnostic criteria) by Screening 1, and no other cause of the neurological impairment has been identified by Screening 2. Average decrease in ALSFRS-R of 0.5 to 3 (inclusive) points per month, calculated using the most recent historical ALSFRS-R score from at least 3 months prior to Screening 1. If there is no qualifying previous score, an estimated rate will be calculated using the historical date of ALS symptom onset (weakness and/or dysarthria and/or dysphagia). Percent predicted SVC ≥ 50% at Screening 1. ALS symptom onset (weakness and/or dysarthria, and/or dysphagia) within 48 months of Screening 1. Subjects taking riluzole, edaravone, or phenylbutyrate (PB) and/or tauroursodeoxycholic acid (TUDCA) may be included if the following criteria are met at Screening 1, and there is no change in treatment between Screening 1 and Enrollment: Stable dose of riluzole for at least 30 days; Stable dose of edaravone for at least 3 cycles; and/or Stable dose of PB and/or TUDCA for at least 90 days Subjects taking any of these drugs prior to screening who intend to discontinue them before starting the study must have discontinued the drug(s) at least 28 days before Screening 1. Women of childbearing potential (WCBP) must agree to abstain from sex or use an adequate method of contraception for the duration of the screening period, the study drug treatment period, and for 28 days after the last dose of study drug. Males must agree to abstain from sex with WCBP or use an adequate method of contraception for the duration of the study drug treatment period and for 75 days after. Capable of providing informed consent and following trial procedures (where subject consents but is unable to sign the informed consent a legally authorized representative (LAR)/surrogate must sign on their behalf). .",NCT05218668 REAL TrialTroveID-424018 WP-0512-003,Adults; Older Adults,year(s),year(s),424018,Delay Disease Progression,75.0,18.0,"ALSFRS-R < 24 at Screening 1. Expected change in dosing of riluzole, edaravone, or PB and/or TUDCA between Screening 1 and the end of the study. Presence of other causes of neuromuscular weakness or other neurodegenerative diseases that could interfere with the objectives of the study or the safety of the subject, in the opinion of the Investigator. Mechanical ventilation via tracheostomy. (Use of non-invasive ventilation e.g., continuous positive airway pressure, non-invasive bi-level positive airway pressure or non-invasive volume ventilation is not an exclusion). Any medical condition (including cardiovascular, hematologic, renal, hepatic, or psychiatric diseases) that in the opinion of the Investigator would disallow safe participation in the trial or interpretation of the study results. Suicidal ideation per the Columbia-Suicide Severity Rating Scale (C-SSRS) that in the opinion of the Investigator would pose a safety risk. ALT ≥ 3 x upper limit of normal (ULN) or aspartate aminotransferase (AST) ≥ 3 x ULN at Screening 2. Estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73m2 at Screening 2. Participants who, in the opinion of the Investigator, are unable or unlikely to comply with the dosing schedule or study evaluations. Treatment in a clinical trial with another investigational drug within 28 days or 5 half-lives of drug before Screening 1, whichever is longer. Exposure at any time to any gene therapies under investigation for the treatment of ALS. Treatment with clenbuterol within 28 days of Screening 1, or any time between Screening 1 and enrollment. On more than one of the following drug classes: long-acting nitrates, beta-blockers, or calcium channel blockers. (Note: subjects may be on one of the drug classes.) Systolic blood pressure < 90 mmHg and/or diastolic blood pressure < 60 mmHg at Screening 2. (Note: in the case of a systolic blood pressure < 90 and/or diastolic blood pressure < 60, BP measurements should be repeated after 10 minutes, and the higher reading used for Inclusion/Exclusion.) Known hypersensitivity to the active (fasudil) or inactive ingredients in the study drug. Known to be pregnant or lactating; or positive pregnancy test for WCBP. At Screening 2, neutrophil count < 1,500/mm3, platelets < 100,000/mm3, international normalized ratio (INR) > 1.5 or any contraindication to or unable to tolerate lumbar puncture, including use of anticoagulant medications that cannot be withheld. For example, if a subject is taking warfarin and it cannot be withheld for lumbar puncture, this would exclude the subject from study entry. At Screening 2, neutrophil count < 1,500/mm3, platelets < 100,000/mm3, international normalized ratio (INR) > 1.5 or any contraindication to or unable to tolerate lumbar puncture, including use of anticoagulant medications such as warfarin. Daily administration of aspirin up to 81 mg is not a contraindication, as long as the dose is held 3 days before lumbar puncture.",Ii,Both
1,Patients with amyotrophic lateral sclerosis,"1. World Federation of Neurology modified El Ecorial criteria for diagnosis of patients with laboratory support probable, clinically probable, or definite sporadic and familial amyotrophic lateral sclerosis (ALS) 2. Age 18 to 80 years old 3. ALS duration no longer than 18 months(from day of onset) 4. Patient 's ALSFRS-R total scored ≥27，Each single item is scored at least 2（dyspnoea, orthopnea and respiratory insufficiency ≥3） 5. Forced vital capacity (FVC%) no less than 70% of predicted normal for gender, height and age 6. According to brain function AI analysis in accordance with depressive EEG characteristics 7. Women and men of childbearing potential should use medically acceptable contraception 8. Voluntarily participate, and sign an informed consent form",FB1006 M2022300 NCT05923905 TrialTroveID-475526,Adults; Older Adults,year(s),year(s),475526,Unspecified,80.0,18.0,"1. Patients with dementia or severe neurological, psychiatric or systemic disease that is poorly controlled or may interfere with the conduct of the trial or the results of the trial 2. Pregnant women and lactating women 3. Suicide attempt or attempted suicide 4. Combined with other neurological diseases similar to ALS symptoms, or affecting the evaluation of drug efficacy, such as cervical spondylotic myelopathy, lumbar spondylosis, dementia, etc. 5. Patients with history of spinal surgery after ALS onset 6. ALT or AST > 2 times ULN，creatinine clearance < 60 mL/min/1.73m2 (MDRD) 7. Patients who are allergic to the investigational product 8. Having participated in other clinical studies within 3 months before randomization 9. Patients that the investigator considers unsuitable for participation in the study",Iv,Both
0,Healthy subjects,"Key 1. Healthy, adult, male 19 55 years of age, inclusive, at the screening. 2. For elderly subjects(Part A Cohort 5 only), healthy, elderly, male or female (of non childbearing potential only) over 60 years of age, inclusive, at screening. 3. In the case of the elderly(Part A Cohort 5 only), they have a history of mild disease, but can participate if the researcher judges that they can stop taking the drug at least 2 weeks before the expected first dose or before the half-life is 5 times or more) 4. The continuous non smoker who have not used nicotine containing products for at least 3 months prior to (the first) dosing and throughout the study are based on subjective self reporting. 5. Body mass index (BMI) ≥ 18 and ≤ 32 kg/m2 at the screening. 6. Medically healthy with no clinically significant medical history, physical examination, simplified neurological examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or designee. 7. In Cohort 5, A female subject must be of non childbearing potential Key",FB418_P101 NCT05995782 TrialTroveID-481538,Adults,year(s),year(s),481538,(N/A); Healthy subjects,55.0,19.0,"1. Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study. 2. History or presence of a clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee. 3. History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study. 4. Is at suicidal risk in the opinion of the PI as per the following criteria: 1. Any suicide attempts within 12 months prior to screening or any suicidal intent, including a plan, within 3 months prior to screening. 2. C-SSRS answer of",I,Both
0,Healthy adults and patients with Amyotrophic Lateral Sclerosis.,"Participants must meet all of the following inclusion criteria at Screening to be eligible for participation in this study: Part A healthy males or females between the ages of 18 and 65 years of age and Part B males and females aged between 18 and 80 years of age, inclusive at the times of signing the informed consent; Female participants who: Are postmenopausal (over or equal to 1 year), OR Are surgically sterile, confirmed by medical documentations, OR If they are of child bearing potential, agree to use at least 1 highly effective method of contraception and 1 additional effective method at the same time, from at least 1 month prior to the initiation of the study through 3 months after the last administration. OR Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant; Agree to refrain from egg donation and in vitro fertilization during the entire study period and through 90 days after the last dose of study drug; Male participants, even if surgically sterilized (i.e., status postvasectomy), who: Agree to practice effective barrier contraception and avoid sperm donation during the entire study period and through 90 days after the last dose of study drug, OR Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant; Able to give a signed written informed consent form (the informed consent form must be signed by the participant prior to any study-specific procedures); have a full understanding of the study content, procedures, and possible AEs; and be willing and able to comply with study procedures and follow-up examinations; Results of vital signs, physical examination, laboratory examinations, abdominal and Chest X-ray, 12-lead electrocardiogram (ECG), and other examination at Screening or Baseline are normal or abnormal but not clinically significant. Assessment may be repeated once if deemed appropriate by the investigator; Part A: Additional Inclusion Criteria for Healthy Adult Participants: Body mass index (BMI, weight [kg] / height2 [m2]) of 18 to 26 kg/m2, inclusively, with a minimum body weight of 50 kg for males, and 45 kg for females; Part B: Additional Inclusion Criteria for ALS Patients: Diagnosis of familial or sporadic ALS (defined as meeting the possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS ≤ 24 months prior to screening, according to the World Federation of Neurology El Escorial criteria published in 2000 ; Participants on riluzole or sodium phenylbutyrate/taurursodiol must be on a stable dose for at least 30 days prior to study enrollment; or patients on edaravone must have completed at least 2 cycles of dosing with edaravone at the time of screening or have not taken edaravone for at least 30 days prior to screening and not planning to start edaravone during the course of the study. Two cycles of dosing are defined as having completed Cycle 1 infusion, which is 14 consecutive days of intravenous (IV) edaravone followed by 14 days off edaravone, and Cycle 2, which is 10 out of 14 days of IV edaravone; Slow vital capacity (SVC) ≥ 60% of predicted within 1 month prior to Treatment Day 1.",FC-US-001 NCT05978908 TrialTroveID-480369,Adults,year(s),year(s),480369,Healthy subjects; Unspecified,65.0,18.0,"Participants who meet any of the following exclusion criteria at Screening (unless otherwise stated) are not to be enrolled in this study: Females who are pregnant, planning to become pregnant, or breastfeeding during the trial or within 3 months after the trial, or those with abnormal pregnancy test results that are clinically significant at Screening or Baseline (Day -1) as judged by the investigator; Has a positive alcohol test at Screening or the Baseline, or has a history of alcohol abuse; Participants who have been drinking excessive amounts of tea, coffee or caffeinated drinks (more than 8 cups a day, 1 cup =250 mL) per day within 3 months before Screening; Currently uses tobacco, nicotine or tobacco products, e-cigarettes or has stopped using tobacco products within the past 3 months and/or has a positive urine cotinine test at Screening or Baseline; Positive urine screening for drug abuse; Has received an experimental agent (vaccine, drug, biologic, device, blood product or medication) within 1 month prior to the first dose of study drug, or plan to receive another experimental agent during the duration of this trial; Positive test result for active infectious diseases screening at Screening or Baseline, including human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C (HCV) antibody, and syphilis antibody (TP); Serious infection within 1 months before Screening or symptoms of infection during Screening period, including acute and chronic infections and local infections (bacterial, viral, parasitic, fungal, or other opportunistic pathogens), which is inappropriate to participant as deemed by the investigator; Blood loss of non-physiological reasons ≥ 400 mL (i.e., trauma, blood collection, blood donation) within 2 months prior to the first dose of study drug, or plan to donate blood during this trial and within 1 month after the last dosing; Except as noted, has used any over-the-counter medications, prescription drugs (other than hormone replacement therapy), nutritional supplements, or herbal medicines unless, in the opinion of the investigator and sponsor, the drug will not interfere with study assessments; Abnormal renal function estimated glomerular filtration rate calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation < 90 mL/minute/1.73 m2 at screening or on Day -1; Current or chronic history of liver disease or known hepatic or biliary abnormalities, or clinically significant abnormal results of liver function test at screening or on Day -1, including alanine aminotransferase (ALT) or/and aspartate aminotransferase (AST) > 1.5 × upper limit of normal (ULN) or/and total bilirubin > ULN； Abnormal QT wave prolongation QTcF wave ≥ 450 ms for males or QTcF wave ≥ 470 ms for females (confirmed by repeated examinations); A history of hypokalemia or family history of long QT syndrome; Use of concomitant medicines that prolong QT/QTc. Has a clinically significant medical condition (other than ALS in Part B) including the following: neurological, metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urological disorder, or central nervous system infection that would pose a risk to the participant if they were to participate in the study or that might confound the results of the study; Cancer with metastatic potential (other than basal cell carcinoma, carcinoma in situ of the cervix, or squamous cell carcinoma of the skin excised with clean margins) diagnosed and treated within the last five years; Has clinically significant interventional therapies (surgery, paracentesis, etc.) within 6 months prior to the trial, or plan to have any surgeries during the trial; History of any hypersensitivity or allergic reaction to active ingredients or excipients of the study drug; At the time of screening, ALS patients (Part B) use any non-invasive ventilation, e.g. continuous positive airway pressure, noninvasive bi-level positive airway pressure or noninvasive volume ventilation, for any portion of the day, or mechanical ventilation via tracheostomy, or on any form of oxygen supplementation; Participants on any other immunomodulatory therapy; Participants with prior history of solid organ (kidney, liver, heart, lung, pancreas) or bone marrow transplant; Current psychiatric disorder, suicidal ideation in the previous 6 months (as assessed by the C-SSRS), or a lifetime suicide attempt; Other unspecified reasons that, in the opinion of the Investigator or Sponsor, make the participant unsuitable for enrollment.",I,Both
0,Subjects with amyotrophic lateral sclerosis,"1.Signed informed consent form 2.Between 18-65 years of age 3.Patients diagnosed with a laboratory supported, clinically ""probable"" or ""definite"" amyotrophic lateral sclerosis according to the Revised El Escorial criteria",ChiCTR2200064504 TrialTroveID-445398,Adults,year(s),year(s),445398,Delay Disease Progression; Symptom relief,65.0,18.0,"1.First degree relative or more than one relative with PD 2.Diagnosis of major depression or psychosis (DSM-V criteria) 3.Any of the following within the previous 2 months: hospital admission, narcosis or sedation, abdominal trauma 4.Primary disease of gastrointestinal tract (exception: chronic gastritis) 5.Previous abdominal or anorectal surgery (causing structural abnormalities of the intestines) 6.Any of the following within the previous 2 months: gastrointestinal or respiratory tract infection, food intoxication 7.The use of probiotics or antibiotics within three months prior to FMT 8.Contra-indications for colonoscopy 9.Other immune disorder or clinical immunosuppression 10.Drug abuse 11.Malignancy 12.Any severe comorbidity that might interfere with the study course as determined by the treating physician 13.Pregnancy or inadequate anti conception for the duration of the trial",I,Both
1,Patients with Amyotrophic lateral sclerosis.,"(1)Patients were diagnosed as clinically definite ALS, clinically probable ALS, or clinically probable and laboratory supported ALS according to El Escorial criteria from the World Federation of Neurology in 1998. Patients who can't be defined as specific type or have family history were excluded. (2)According to the ALS or HSS, the disease was mild or moderate state; (3)Age ranges from 18 to 65; (4)Can cooperate to complete the inspection; (5)Agree to participate in this study and sign informed consent;",ChiCTR2100046015 TrialTroveID-403111,Adults,year(s),year(s),403111,Delay Disease Progression,65.0,18.0,"1)Age younger than 18 or older than 65; 2)According to the ALS or HSS, the disease was end stage; 3)Patients who had gastrostomy before; 4)Pregnant or lactating women; 5)Patients who had throat diseases like vocal nodules; 6)Patients who had severe diseases in kidney, liver, hematological system or had cancer; 7)Patients who have used anti-biotics, probiotics, high-dose vitamins or other therapy regulating gut microbiota.",Iv,Both
1,Subjects with Amyotrophic Lateral Sclerosis,"Patients diagnosed with a laboratory supported, clinically ""probable"" or ""definite"" amyotrophic lateral sclerosis according to the Revised El Escorial criteria (Brooks, 2000) Sporadic or familial ALS Female or male patients aged between 18 and 70 years old Disease duration from symptoms onset no longer than 18 months at the screening visit Patients treated with a stable dose of Riluzole (100 mg/day) for at least 30 days prior to screening Patients with a weight > 50 kg and a BMI > or = 18 Patients with a FVC (Forced Vital Capacity) equal or more than 70% predicted normal value for gender, height, and age at the screening visit Patients able and willing to comply with study procedures as per protocol Patients able to understand, and capable of providing informed consent at screening visit prior to any protocol-specific procedures Use of effective contraception both for males and females",FeTr-ALS NCT03766321 TrialTroveID-338338,Adults; Older Adults,year(s),year(s),338338,Delay Disease Progression,70.0,18.0,"Known organic gastrointestinal disease History of gastrointestinal malignancy; ongoing malignancies Use of immunosuppressive or chemotherapy within the past 2 years Celiac disease and/or food (e.g.lactose) intolerance Previous gastrointestinal surgery Any condition that would make endoscopic procedures contraindicated Acute infections requiring antibiotics Antimicrobial treatment or probiotics 4 weeks prior to screening Severe comorbidities (heart, renal, liver failure); severe renal (eGFR< 30ml/min/1.73m2), or liver failure or liver aminotransferase (ALT/AST > 2x Upper limit of normal), Autoimmune diseases, inflammatory disorders (SLE, Rheumatoid arthritis, connective tissue disorder) or chronic infections (HIV, hepatitis B or C infection) Abuse of alcohol or drugs HIV, tuberculosis, hepatitis Participation in clinical trials <30 days before screening Existing blood dyscrasia (e.g., myelodysplasia) White blood cells<4,000/mm³, platelets count<100,000/mm³, hematocrit<30% Patients who underwent non-invasive ventilation, tracheotomy and /or gastrostomy Women who are pregnant or breastfeeding",Iv,Both
0,Subjects with Dementia,Due to side effects dementia patients who can not take donepezil.,EFATD TrialTroveID-313650 UMIN000003683,Adults; Older Adults,year(s),year(s),313650,Frontotemporal Dementia; Lewy Body Dementia; Other Dementia; Vascular Dementia,90.0,20.0,"head trauma,malignancy,metabolic encephalopathy,alcohl abuse, Mental disorder,chronic renal failure and patients treated by major tranquilizer.",Ii,Both
0,Subjects with amyotrophic lateral sclerosis.,,TrialTroveID-367862,,,,367862,Unspecified,,,,I,
0,,,TrialTroveID-502974,,,,502974,Unspecified,,,,I,
0,Amyotrophic lateral sclerosis patients. Mean age of the total subject sample at the time of implantation was 49.2 + or - 10.3 years.,"Inclusion criteria: Confirmed ALS according to the El Escorial clinical and neurophysiological criteria. No structural damage to the rain or spinal cord on cervical and cranial magnetic resonance imaging (MRI). Pulmonary function test showing a forced vital capacity (FVC) of at least of 30 %. Appropriate nutritional status, with a body mass index of at least 19 kg/m2.",TrialTroveID-163081,Adults,year(s),year(s),163081,Delay Disease Progression,59.0,39.0,"Exclusion Criteria: Severe bulbar affection (FVC less than 30%). Inadequate nutritional status or a body mass index lower than 18 kg/m2. Tracheostomy. Presence of systemic disorders, such as malignant neoplasm, cardiovascular disease (decompensated hypertension, ischaemic cardiopathy and arrhythmia), previous stroke, or coagulation abnormalities. Evidence of cervical spondylotic myelopathy or structural abnormalities on MRI. Patients with a current or past history of neurological disease other than ALS and those enrolled in other clinical trials were excluded.",Ii,Both
0,"Patients with amyotrophic lateral sclerosis. Subjects who meet the El Escorial criteria of possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of amyotrophic lateral sclerosis.","Ages Eligible for Study: 18 Years and older; Genders Eligible for Study: Both Inclusion Criteria: Age 18 years or older. Sporadic or familial ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria (Appendix 1). Onset of weakness or spasticity due to ALS < or = 2 years (24 months) prior to Baseline Visit. Slow vital capacity (SVC) measure > or =65% of predicted for gender, height, and age at the screening visit. Subjects must not have taken riluzole for at least 30 days, or be on a stable dose of riluzole for at least 30 days, prior to randomization (riluzole-naïve subjects are permitted in the study). Subjects must be able to swallow oral medication at the Screening Visit and expected to be able to swallow the capsule throughout the course of the study. Capable of providing informed consent and following trial procedures. Geographically accessible to the site. Women must not be able to become pregnant (e.g. post menopausal, surgically sterile, or using adequate birth control methods) for the duration of the study and three months after study completion. Adequate contraception includes: abstinence, hormonal contraception (oral contraception, implanted contraception, injected contraception or other hormonal (patch or contraceptive ring, for example) contraception), intrauterine device (IUD) in place for > or = 3 months, barrier method in conjunction with spermicide, or another adequate method. Subjects must agree not to take live attenuated vaccines (including seasonal flu vaccine) 30 days before randomization, throughout the duration of the trial and for 60 days following the trial.",2013P000313 NCT01786174 TDI-132/Gilenya TrialTroveID-162194,Adults; Older Adults,year(s),,162194,Delay Disease Progression,,18.0,"Exclusion Criteria: Prior use of fingolimod (Gileny). History or presence of cardiac conditions including: -Cardiovascular or cerebrovascular disease in the previous 6 months (eg. myocardial infarction, unstable angina, or stroke) -Congestive heart failure -First, second- or third-degree atrioventricular block, sick sinus syndrome, or other serious cardiac rhythm disturbances -Any history of Torsades de Pointes Treatment with a prohibited medication within 30 days of the Baseline Visit: a. Class Ia or III antiarrhythmic medications: i.e., Quinidine, Sotalol Includes Nuedexta b. QT interval prolonging medications c. Ketoconazole d. Beta-blockers e. Calcium channel blockers f. Immunosuppressant medication g. Chemotherapeutic (anti-neoplastic) medications Evidence on examination or ECG of bradycardia (<55 bpm), QTc >450ms for women or >430 msec for men, or 1st degree or higher conduction block. History of unexplained syncope or cardiac syncope. Serum AST and ALT value >2.0 times the upper normal limit. Active infection (acute or chronic). History of diabetes. History of macular edema or uveitis. History of lymphopenia. History of acquired or inherited immune deficiency syndrome, including leukopenia. History of severe untreated chronic obstructive sleep apnea. Exposure to any other agent currently under investigation for the treatment of patients with ALS (off-label use or investigational) within 30 days of the Baseline Visit. Presence of tracheostomy. Use of non-invasive ventilation for hypoventilation due to ALS (such as BiPAP). Presence of feeding tube. Presence of diaphragmatic pacing system. The presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair ability of the subject to provide informed consent, according to PI judgment, or a history of active substance abuse within the prior year. Clinically significant history of unstable or severe cardiac, oncologic, hepatic, or renal disease, or other medically significant illness. Pregnant women or women currently breastfeeding.",Ii,Both
0,Patients with amyotrophic lateral sclerosis.,"Minimum Age :18 Years; Maximum Age: 75 Years Key Inclusion Criteria Diagnosis of ""definite"" or ""probable"" amyotrophic lateral sclerosis according to the revised El Escorial criteria (as defined by the Committee on Neuromuscular Diagnosis of ""possible"" amyotrophic lateral sclerosis according to the revised El Escorial criteria plus abnormally reduced short intracortical inhibition on transcranial magnetic stimulation. Disease duration of less than five years. Sniff nasal inspiratory pressure of greater than 50% predicted. Normal cardiac rhythm (as determined by electrocardiograph) and left ventricular function (assessed by echocardiography). Ability to provide consent.",ACTRN12608000338369 FANS TrialTroveID-095021,Adults; Older Adults,year(s),year(s),95021,Delay Disease Progression,75.0,18.0,Key Exclusion Criteria History of dementia or major psychiatric disorder. Involvement in other clinical trials. Pregnancy or lactation. History of cardiac disease. Significant impairment of hepatic and/or renal function. Any patient considered to be non compliant.,Ii,Both
0,,- Participants must have a diagnosis of PPA or a related dementia syndrome,NCT04720001 STU00206530,Adults; Older Adults,year(s),year(s),394884,,100.0,18.0,- Pregnant - Breastfeeding - Receiving radiation clinically,(N/A),Both
0,,"- Subjects who, in the opinion of the investigator, can tolerate the PET scan procedures",NCT04726527 PPA STU00044931,Adults; Older Adults,year(s),,395277,,,18.0,"- Clinically significant cardiovascular disease - clinically significant hepatic, renal, pulmonary, metabolic, or endocrine disturbances - Pregnant - Breastfeeding - Women of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception. - History of relevant severe drug allergy or hypersensitivity - Patients who have received an investigational medication under an FDA Investigational New Drug (IND) protocol within the last 30 days.",(N/A),Both
0,,"- Subjects diagnosed by a dementia specialist with symptomatic clinical syndromes with expected Frontotemporal Dementia (FTD) pathology will be enrolled. Clinical syndromes associated with FTD pathology include: behavioral-variant FTD, FTD with motor-neuron disease, non-fluent/agrammatic and semantic variants of primary progressive aphasia, progressive supranuclear palsy syndrome and corticobasal syndrome. - Have provided informed consent or have a legally authorized (LAR) provide consent for study procedures - Have had volumetric brain MRI obtained in site's companion protocol within one year of enrollment - Can tolerate PET scan procedures",18F-AV-1451-A19 NCT03040713,Adults; Older Adults,year(s),,295259,,,18.0,"- Have clinically significant cardiac, hepatic, renal, pulmonary, metabolic, or endocrine disturbances that pose potential safety risk - Have history of risk factors for Torsades de Pointes (TdP) or taking medication known to cause QT prolongation - Have history of drug or alcohol dependence within the last year - Are females of childbearing potential who are not surgically sterile, not refraining from sexual activity, or not using reliable contraception - Have history of relevant severe drug allergy or hypersensitivity - Have received an investigational medication under FDA IND protocol within 30 days of planned imaging session - Have received a radiopharmaceutical for imaging/therapy within 24 hours of imaging session - Possess PET scan evidence of amyloid deposition - Determined by the investigator to be unsuitable for this type of study",I,Both
0,,- Must have primary progressive aphasia,NCT03283449 R01AG056258 STU00200893,Adults; Older Adults,year(s),year(s),309207,,100.0,20.0,- Pregnancy - Breastfeeding - Receiving radiation clinically,I,Both
0,,"- Members of families with established MAPT mutations, who either have the capacity to consent to participate in the protocol, or else have designated a surrogate/proxy to consent to participate in this study",AAAP4551 NCT02676843 R01NS076837,Adults; Older Adults,year(s),,272750,,,18.0,- Unwillingness to participate - Usage of medication which significantly prolongs QT interval - Pregnancy or plans for pregnancy within 90 days after participating in study,Ii,Both
1,,- We will study subjects that fulfill clinical inclusion criteria for neurodegenerative AOS that have been seen and diagnosed at Mayo Clinic,"12-008988, 17-010087 NCT01818661 R01DC012519-09",Adults; Older Adults,year(s),,230224,,,18.0,"- Subjects with concurrent illnesses that could account for speech and language deficits, such as traumatic brain injury, strokes or developmental syndromes will be excluded. - Women that are pregnant or post-partum and breast-feeding will be excluded. All women who can become pregnant must have a pregnancy test no more than 48 hours before the PET scan. - Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism,(e.g. chemotherapy). - Subjects will also be excluded if they do not have an informant, or do not consent to research.",Iv,Both
0,Patients with Amyotrophic Lateral Sclerosis,"Documented diagnosis of ALS diagnosis of less than 3 years. Expected survival > 6 months Frequent fasciculations noted during clinical examination of any single muscle (>6 visible fasciculations per minute) observed in Part I Normal oral cavity exam at screening Proficient in English Male subjects will either be surgically sterile or agree to use a medically acceptable method of contraception during sexual contact with females of childbearing potential, and will refrain from sperm donation for 45 days following the study Male subjects will either be surgically sterile or agree to use a medically acceptable method of contraception during sexual contact with females of childbearing potential, and will refrain from sperm donation for 45 days following the study",FLX-787-106 NCT03338114 TrialTroveID-312279,Adults; Older Adults,year(s),,312279,Symptom relief,,18.0,"Presence of clinically significant or unstable condition that would result in an increased risk of study participation or difficulty in interpretation of the study results Tremor or other movement disorder that would interfere with recording Inability to lie flat Presence of major gastrointestinal disorders, such as inflammatory bowel disease, diverticulitis, active peptic ulcer disease, or significant gastroesophageal reflux disease (i.e., not well-controlled on antacids or proton pump inhibitors), or oral or esophageal lesions/ulcers Presence of laryngospasm or significant swallowing problems Presence of percutaneous endoscopic gastrostomy, esophagogastroduodenoscopy, or G-tube Inability to tolerate a spicy sensation in the mouth or stomach Actively using illicit drugs or history of chronic substance abuse within the past year prior to screening, including abuse of alcohol Participated in a clinical study (except natural history studies without administration of an investigational product) within 30 days prior to screening Pregnant, breastfeeding, or planning to become pregnant Blood pressure of > or =160 mmHg systolic and/or > or =100 mmHg diastolic Clinically significant abnormalities in laboratory findings (including screening complete electrolyte panel, complete blood count, liver function tests).",Iii,Both
0,Adult Subjects With Amyotrophic Lateral Sclerosis (ALS),"Documented diagnosis of ALS diagnosis of less than 5 years. Greater than 6 fasciculations per minute noted at least in the tongue by clinical, ultrasound, or EMG evaluation. Normal oral cavity exam at screening.",FLX-787-107 NCT03334786 TrialTroveID-312126,Adults; Older Adults,year(s),,312126,Delay Disease Progression,,18.0,"Presence of clinically significant or unstable condition that would result in an increased risk of study participation or difficulty in interpretation of the study results. Tremor or other movement disorder that would interfere with recording. Presence of major gastrointestinal disorders, such as inflammatory bowel disease, diverticulitis, active peptic ulcer disease, or significant gastroesophageal reflux disease (i.e., not well-controlled on antacids or proton pump inhibitors), or oral or esophageal lesions/ulcers. Presence of laryngospasm or significant swallowing problems. Inability to tolerate a spicy sensation in the mouth or stomach. Actively using illicit drugs or history of chronic substance abuse within the past year prior to screening, including abuse of alcohol. Participated in a clinical study (except natural history studies without administration of an investigational product) within 30 days prior to screening. Pregnant, breastfeeding, or planning to become pregnant. Blood pressure of > or = 160 mmHg systolic and/or > or = 100 mmHg diastolic. Clinically significant abnormalities in laboratory findings (including screening complete electrolyte panel, complete blood count, liver function tests).",Iii,Both
0,"Adult Subjects with Motor Neuron Disease (MND) including Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS) or Progressive Muscular Atrophy (PMA)","Documented diagnosis of Motor Neuron Disease (MND) [including Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS) or Progressive Muscular Atrophy (PMA)] Expected survival > 6 months Weekly muscle cramping (defined as: a sustained muscle contraction that's most often painful and lasts seconds to minutes)",COMMEND FLX-787-203 NCT03196375 TrialTroveID-294782,Adults; Older Adults,year(s),,294782,Symptom relief,,18.0,"Presence of major gastrointestinal disorders, such as inflammatory bowel disease, diverticulitis, active peptic ulcer disease, or significant gastroesophageal reflux disease (i.e., not well-controlled on antacids or proton pump inhibitors), or oral or esophageal lesions/ulcers Presence of laryngospasm or significant swallowing problems Presence of percutaneous endoscopic gastrostomy, esophagogastroduodenoscopy, or G-tube Unable or unwilling to discontinue medications for cramps and/or opiates Inability to tolerate a spicy sensation in the mouth or stomach Actively using illicit drugs or history of chronic substance abuse within the past year prior to screening, including abuse of alcohol Intention to change the current level of tobacco use or use of nicotine-containing products (i.e., new smokers or those actively trying to quit may not enrolled) Participated in a clinical study (except natural history studies without administration of an investigational product) within 30 days prior to screening",Ii,Both
0,Patients with amyotrophic lateral sclerosis spasticity and spasms/cramps.,"Diagnosed with Amyotrophic Lateral Sclerosis (ALS) or Progressive Lateral Sclerosis (PLS) for at least 12 months; Subjects must be able to provide written informed consent; Subjects must be able and willing to comply with all study requirements; Subjects must be able to take the study products; Spasticity of at least 3 months duration that is not completely relieved by current therapy; Subjects with an estimated > 60 cramps per month (or > 15 per week); and, All females of childbearing potential will agree to use a medically acceptable method of contraception throughout the duration of the study and have a negative urine pregnancy test at screening.",ACTRN12616001060437 Flex-202 TrialTroveID-279746,Adults; Older Adults,year(s),,279746,Spasticity; Symptom relief,,18.0,"Subjects with flaccid paralysis; Subjects with significant cognitive impairment, clinical dementia or psychiatric illness; Subjects with a diagnosis of another neurodegenerative disease (e.g. Parkinson disease, Alzheimer disease); Subjects who have a food allergy or intolerance/hypersensitivity to products containing ginger; Subjects with a history of abuse of any street drugs such as marijuana or illicit drugs or alcohol within the past 1 year prior to signing the Informed Consent Form (ICF); Use of any tobacco- or nicotine-containing products within 1 week prior to Screening and throughout the duration of the study; Subjects who participated in an interventional clinical study within 30 days prior to the first administration of study product; Subjects whose other conditions/diseases are unstable and are likely to result in hospitalisation or a change in their medication regimen; Subjects who are pregnant or lactating; and, Subjects who in the opinion of the Investigator are not suitable to participate in this clinical trial.",I,Both
0,Healthy adult subjects.,,TrialTroveID-275419,Adults; Older Adults,year(s),year(s),275419,(N/A); Healthy subjects; Spasticity,77.0,50.0,,I,
0,"Patients who suffer from cramps, spasms and/or spasticity as a consequence of amyotrophic lateral sclerosis. Subjects with ALS or primary lateral sclerosis (PLS) patients with frequent muscle cramps.",Male or female subjects with cramps associated with the amyotrophic lateral sclerosis for at least three months prior to screening that is not completely relieved by current therapy.,TrialTroveID-269677,,,,269677,Symptom relief,,,,Ii,Both
0,Definite or probable amyotrophic lateral sclerosis (ALS) patients according to the El Escorial diagnostic criteria were included.,,TrialTroveID-080425,,,,80425,Delay Disease Progression,,,,Ii,
0,Healthy volunteers.,,TrialTroveID-330861,,,,330861,Healthy subjects,,,,I,
0,Patients with ALS.,,TrialTroveID-080369,,,,80369,Unspecified,,,,Ii,
0,Healthy adults.,,TrialTroveID-080272,Adults,,,80272,Healthy subjects,,,,I,
0,Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation,"Male or female ages aged > or = 21 and < or = 75 years Genotyped positive for a FTD-GRN mutation, and aware of it Prodromal to moderate FTD-GRN Resides in a stable living situation, living at home, senior residential setting, or an institutional setting without the need for continuous (ie, 24-hour) nursing care Proficiency (oral and written) in the language in which study-related documents, including the ICF and standardized tests, will be administered Able to swallow capsules Be in good general health, willing and able to comply with the protocol requirements, and expected to complete the study as designed (in the judgment of the investigator) 1.Informed consent form (ICF) signed by the subject or legally acceptable representative indicating that the subject or legally acceptable representative understands the purpose of and procedures required for the study before any study-specific procedures are performed 2.A support person may be required to participate in the study (in the judgment of the investigator at screening or as required by local regulations). The support person must sign an acknowledgement of responsibilities form at the study center before any study-specific activities required for the support person are performed. The first required activity will be performed at screening. The support person will accompany the subject to the study center at screening and on Days 1 and 28 (or be available by telephone on Days 1 and 28), and if not living in the same household, interacts with the subject approximately 4 times per week, and be able to complete the study 3.Prodromal to moderate FTD-GRN, and for subjects who require a support person (refer to inclusion criterion No. 2), a Clinical Dementia Rating Sum of the Boxes (CDR SB) score <16 at screening 4. Heterosexually active subjects (men and women) of childbearing potential and their partners must practice true abstinence (periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable) or use 2 highly-effective methods of contraception, including at least 1 barrier method, from informed consent until 1 week after last dose. Non-childbearing potential and highly-effective methods of contraception are defined in Section 4.4 5.Women of childbearing potential must have a negative pregnancy test at screening and Day 1 6.Proficiency (oral and written) in the language in which study-related documents, including the ICF and standardized tests, will be administered 7.Able to swallow capsules 8.Be in good general health, willing and able to comply with the protocol requirements, and expected to complete the study as designed (in the judgment of the investigator)",EudraCT Number: 2014-001489-85 FRM-0334-002 NCT02149160 TrialTroveID-232757,Adults; Older Adults,year(s),year(s),232757,Frontotemporal Dementia; Mild Cognitive Impairment/Dementia Risk,75.0,21.0,"1.Employees of Inv.or study center or family members or employees of FORUM Pharma orWCT directly involved in conduct of study 2.Female subj.who are pregnant,breastfeeding or planning to become pregnant during study 3.Unstable medical condition that is C.S.(in Inv.judgment)within 30days before screen 4.Untreated vitamin B12or folate deficiency(must be stably treated for at least 6months before screen) 5.C.S.untreated hypothyroidism(if treated,thyroid-stimulating hormone lev. and thyroid supplementation dose must stable for at least 6months before screen) 6.C.S.abnormal serum electrolytes(sodium,potassium and magnesium)after repeat testing(in Inv.judgment) 7.ALTorAST>2.5times upper limit of normal 8.Renal insufficiency with serum creatinine>2.0mg/dL,unless receiving current treatment with an ACE inh.in which case M.M. should be contacted 9.Insufficiently controlled diabetes mellitus(in Inv.judgment) 10.C.S.hematologic abnormalities including thrombocytopenia and leukocytosis(in Inv.judgment) 11.Malign. tumor within 3years before screen.with exception of squamous and basal cell carcinoma or cervical carcinoma in situ or brachytherapy for localized prostate cancer 12.Systemic infection of any kind or any acute,subacute or chronic inflammatory process(eg, rheumatoid arthritis,chronic obstructive pulmonary dis.or gastrointestinal inflammatory dis.) 13.MRI/CT scan performed within 12mnths before screen.with findings with C.S.comorbid pathology other than FTD.If MRI/CT is unavailable or occurred>12mnts screen, an MRI scan must be be done & findings confirmed before the Day -7 procedures are performed, a copy of the DICOM standard image &report must be available 14.Diagnosis of motor neuron disease,including probable amyotrophic lateral sclerosis 15.History of brain tumor,subdural hematoma or other C.S.(in Inv.judgment)space-occupying lesion on CTorMRI 16.Stroke within 18months before screening or history of stroke concomitant with onset of dementia 17.Head trauma with C.S.(in Inv.judgment)loss of consciousness within 12months before screen.or concurrent with onset of dementia 18.Onset of dementia within 12months before screen.secondary(in Inv. judgment)to cardiac arrest,surgery with general anesthesia or resuscitation 19.Specific degenerative CNSdisease diagnosis other thanFTD(eg.Parkinson’s,Alzheimer’s,Huntington’s,Creutzfeldt Jakob,Down’s) 20.Wernicke’s encephalopathy 21.Epilepsy if present antiseizure therapy is required for seize control 22.Current diagnosis of severe major depressive disorder with psychotic features,if present condition or treatment interferes with subj’s ability to complete study(in Inv. judgment) 23.Significant suicide risk as defined by1)suicidal ideations as endorsed on items 4or5 on Columbia Suicide Severity Rating Scale within past year at screen.or baseline2)suicidal behaviors detected by C-SSRS within 2years before screen3)Inv.assessment 24.History or current diagnosis of psychosis 25.History within 2years before screen or current evidence of substance abuse as defined by Diagnostic and Statistical Manual of Mental Disorders 4th Edition Text Rev 26.C.S.urine drug screen or serum alcohol test result(in Inv. judgment)at screen(may be repeated once) 27.C.S.abnormality on screen.or baseline ECG,including but not necessarily limited to confirmed corrected QTc value > or = 450msec for males or > or =470msec for fem.In subj.with QRS value>120msec those with QTc value>480msec are NOTeligible 28.History of myocardial infarction or unstable angina within 6months before screen.or history of>1myocardial infarction within 5years before screen 29.C.S.(in Inv.judgment)cardiac arrhythmia(including atrial fibrillation),cardiomyopathy or cardiac conduction defect(subj.with pacemaker are acceptable) 30.Cardiovascular disease history including symptomatic hypotension or hypertension(supine diastolic blood pressure>95mmHg)not stabilized by medical therapy(in Inv.judgment) 31.IMP,biologic or m.d. within 30days before screen.or planning to use IMP(other than FRM0334)during study 32.Sensitive and/or narrow therapeutic range cytochrome P450(CYP)1A2 substrates including alosetron,duloxetine,melatonin,ramelteon,theophylline and tizanidine 33.Warfarin-derived anticoagulants,heparin,NSAIDs and anti-platelet drugs(clopidogrel and others)10days before CSF sample collection on D-7andD28 34.Hypersensitivity to histone deacetylase inhibitor medication or currently receiving treatment with an HDACi,including valproic acid and amisulpride 35.Immunosuppressants including systemic corticosteroids and NSAIDs(occasional use of NSAIDs is allowed,with the except. of 10days before CSFsample collection on D-7andD28) 36.Chronic intake of opioid containing analgesics 37.Psychostimulants including amphetamines 38.Clozapine and amisulpride;other antipsychotics are allowed if on stable dose(no change in dose or frequency)for at least 30days before screen.and expected to remain stable during the study",Ii,Both
0,ALS patients,The inclusion criterion was a diagnosis of SALS with duration less than 3.5 years.,TrialTroveID-121983,,,,121983,Delay Disease Progression,,,"The exclusion criteria included tracheotomy, artificial respiration and dyspnea.",Ii,
0,Patients with definite or probable amyotrophic lateral sclerosis.,"Patients with clinically definite or probable ALS of less than six years duration, with a forced vital capacity of at least 50% of predicted and limitation of motor function in at least one limb.",TrialTroveID-106555,,,,106555,Delay Disease Progression,,,,Ii,Both
0,,"Ages Eligible for Study 18 Years to 65 Years, Inclusion Criteria All subjects must have a verifiable diagnosis of ALS of 0.5 to 2 years' duration. The diagnosis must be supported by the Revised Criteria of the World Federation of Neurology. The grades of diagnosis must be clinically definite ALS or clinically probable ALS. All subjects must be over age 18 and below 65. The ALS is mildly to moderate based on ALS Health State Scale. Electrophysiological features show CMAP amplitude of motor nerve normal or mild declining. Serum creatine kinase is normal or mild upper, less than 500U/L.",NCT00397423 R01-123456-1 TrialTroveID-078724,Adults,year(s),year(s),78724,Delay Disease Progression,65.0,18.0,"Exclusion Criteria If anyone of the above eligibility requirements is not met. Use of any other investigational agent within 30 days beginning the treatment phase of this study. Severe cardiac, pulmonary, hepatic or/and hematic disease. HIV positivity or signs and symptoms consistent with HIV infection. Pregnant or nursing women. History of cancer with less than 5 years documentation of a disease-free state. History of anaphylactic reaction or hypersensitivity to G-CSF (Filgrastim) or proteins derived from E.coli. Alcohol or drug abuse in recent 1 year. Can't understand or obey the rules of treatment. Blood donor in recent 30 days.",Ii,Both
0,,"- Outpatients with a clinical diagnosis of Frontotemporal Dementia or Pick Complex (PC/FTD) documented for at least 1 year with either primary progressive aphasia or frontotemporal dementia - recent MRI or CT confirming frontotemporal lobar atrophy consistent with Frontotemporal Dementia or Pick Complex PC/FTD - opportunity to perform certain activities of daily living as described in the Alzheimer's Disease Cooperative Study -- Activities of Daily Living Inventory - living with or having regular visits (least 4 days/week) from a responsible caregiver - Mini Mental State Examination score > 5 and the ability to complete baseline neuropsychometric testing - able to see, hear, and communicate sufficiently, and willing to complete serial neuropsychometric tests - female subjects of childbearing age must be surgically sterile or practicing an effective method of birth control before entry and throughout the study.",CR003106 NCT00416169,Adults; Older Adults,year(s),year(s),237177,,80.0,30.0,"- No neurodegenerative disorders and other causes of dementia or cognitive impairment from acute cerebral injuries, cerebrovascular disease or hypoxic cerebral damage, vitamin deficiency states, infection cerebral neoplasia - no primary memory disturbance or an amnestic syndrome more compatible with Alzheimer's disease or other primary degenerative dementia - no uncontrolled epilepsy or clinically significant psychiatric disease, cardiovascular disease, hepatic, renal, pulmonary, metabolic, or endocrine disturbances, active peptic ulcer and urinary outflow obstruction - no use of any agent used for the treatment of dementia or other cognitive impairment - no history of severe drug allergy or hypersensitivity to cholinesterase inhibitors, choline agonists or similar agents, or bromide",Ii,Both
0,"Patients (median age 58 years; range 45–71 years; 6 men, 4 women) with definite ALS based on revised El Escorial criteria. A group of 32 healthy subjects (17 women, median age 54.1 years, range 46 to 64 years) served as a control group for the cross-sectional image analyses.","Ages Eligible for Study: 18 Years and above Inclusion Criteria Amyotrophic lateral sclerosis or chronic stroke - 18 years or older - Women of childbearing potential only with reliable contraception allowed and safe methods of birth control (ie hormonal Oral contraceptives, as an implant or injection, some forms of Intrauterine spiral, sexual abstinence or a vasektomierter partners) - Written informed consent",EudraCT Number: 2005-001113-18 GCSFEPO_01 NCT00298597 TrialTroveID-078765,Adults; Older Adults,year(s),,78765,Delay Disease Progression; Healthy subjects,,18.0,Exclusion Criteria Leucocytes > 10000/Âµl. Hematocrit > 48%. Thrombocytes < 150000/Âµl. Severe rheumatoid arthritis. Severe infection. Severe liver or renal failure. Severe arterial hypertension. Recurrent thromboembolic events. Severe coronary heart disease. Myocardial infarction. Malignant tumor. Leukemia. Peripheral arterial occlusion disease.,Ii,Both
0,,,TrialTroveID-395961,,,,395961,Unspecified,,,,I,
0,Healthy Female Subjects of Non-Childbearing Potential,"Body mass index (BMI) range 18.5 to 35 kilograms per square meter (kg/m2) In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, and vital signs; Clinical laboratory evaluations within the reference range for the test laboratory, unless deemed not clinically significant by the principal investigators (PIs) Females of non-childbearing potential only",GP40957 NCT03807739 TrialTroveID-341032,Adults,year(s),year(s),341032,Healthy subjects,65.0,18.0,"History or clinical manifestation of any significant medical condition as determined by the PI (or designee) History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the PI (or designee) History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs Use of any prescription medications/products within 14 days prior to Check-in (Day -1) for their first treatment period and during the entire study duration, unless deemed acceptable by the PI Use of oral antibiotics within 4 weeks or intravenous antibiotics within 8 weeks prior to the Screening evaluation and during the entire study duration Use of any over-the-counter, non-prescription preparations within 14 days prior to Check-in (Day -1) for their first treatment period and during the entire study duration, unless deemed acceptable by the PI Use of acid reducing medications (proton pump inhibitors [PPIs], histamine H2-receptor antagonists [H2RAs]) within 14 days prior to Check-in (Day -1) for their first treatment period and during the entire study duration. As an alternative, antacids may be allowed at least 4 hours before or after dose Use of any vaccines (including seasonal flu and H1N1 vaccines) within 14 days prior to Check-in (Day -1) for their first treatment period Use of tobacco- or nicotine-containing products within 6 months prior to Check-in (Day -1) for their first treatment period and during the entire study Any acute or chronic condition or any other reason that, in the opinion of the PI, would limit the subject's ability to complete and/or participate in this clinical study",I,Female
0,Healthy female participants.,"Healthy female participants between 30 and 65 years of age, inclusive; Within body mass index range 18.0 to 35.0 kilograms per square meter (kg/m^2), inclusive; Female participants will be of non-childbearing potential; In good health, determined by no clinically significant findings from medical history, 12-lead echocardiogram (ECG), and vital signs; Clinical laboratory evaluations within the reference range for the test laboratory, unless deemed not clinically significant by the investigator; Normal ophthalmology assessment.",EudraCT number: 2017-000299-27 GP39778 NCT03237741 TrialTroveID-306390,Adults,year(s),year(s),306390,Healthy subjects,65.0,30.0,"Males and females of childbearing potential; Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal (GI), neurological, or psychiatric disorder (as determined by the investigator; History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator; History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs; History of GI bleeding or GI ulcers; Any personal or family history of bleeding disorders, and any personal use of drugs known to affect blood clotting within 30 days of dosing; Any acute or chronic medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the subject's safe participation in and completion of the study.",I,Female
0,Patients with Amyotrophic Lateral Sclerosis (ALS),"Male or female participants with a diagnosis of possible, laboratory-supported probable, probable, or definite ALS according to modified El Escorial criteria Upright forced vital capacity of at least 50 percent (%) Ability to fast from food for 8 hours prior to dosing and 2 hours after dosing (with exception of OSE participants)",EudraCT Number: 2017-002931-41 GN29823 NCT02655614 TrialTroveID-271474,Adults; Older Adults,year(s),,271474,Unspecified,,18.0,"Currently taking riluzole unless on a stable dose for the 3 months prior to Day -1 and without current liver enzyme or liver function abnormalities Currently taking edaravone unless after completion of at least the second 14-day drug-treatment period, as long as Day 1 occurs during a drug-free period at least 24 hours after the last edaravone dose and at least 5 days prior to the first dose of the next cycle Positive for hepatitis C antibody, hepatitis B surface antigen, or human immunodeficiency virus (HIV) antibody Clinically significant thrombocytopenia Currently taking nutritional/herbal supplements, except for over-the-counter vitamins that are within Recommended Dietary Allowance (RDA), unless discontinued at least 7 days prior to Day -1, except upon approval of both the investigator and Sponsor For participants participating in a designated drug-drug interaction (DDI) cohort in the MAD stage of the study, who require midazolam/caffeine administration: known allergy, religious prohibition, or other condition limiting midazolam or caffeine administration",I,Both
0,Healthy subjects.,,TrialTroveID-440237,,,,440237,(N/A); Healthy subjects,,,,I,
0,Healthy subjects,"1. Healthy male and female subjects age 18 to 55 years of age included. 2. Subjects must weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) within the range of 18-32 kg/m2 inclusive. 3. At screening, vital signs (systolic and diastolic blood pressure and pulse rate) will be assessed in the sitting position after the subject has rested for at least three minutes, and again (when required) after three minutes in the standing position. Sitting vital signs should be within the normal ranges. 4. Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant must use highly effective methods of contraception during intercourse while taking drug and for 30 days after stopping study medication; and sexually active males must use a condom, during intercourse while taking drug and for 30 days after stopping study medication.",GFH312X3101 NCT04676711 TrialTroveID-392450,Adults,year(s),year(s),392450,(N/A); Healthy subjects,55.0,18.0,"Healthy subjects fulfilling any of the following criteria are not eligible for inclusion in this study: 1. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the subject in case of participation in the study. 2. A history of clinically significant ECG abnormalities, or any abnormalities defined in protocol. 3. History of immunodeficiency diseases, including a positive test for HIV antibody. 4. Chronic infection with Hepatitis B (HBV) or Hepatitis C (HCV). 5. Infections requiring parenteral antibiotics within the 6 months prior to Screening. 6. History of any venous thromboembolism, TIA, intracranial hemorrhage, neoplasm, arteriovenous malformation, vasculitis, bleeding disorder, coagulation disorders or screening blood tests that indicate altered coagulability (platelet count, APTT, PT, etc.). 7. History of significant cardiovascular, respiratory, renal, neurological disease. 8. Significant illness which has not resolved within two (2) weeks prior to initial dosing. 9. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases. 10. Recent (within the last three years) and/or recurrent history of autonomic dysfunction (e.g., recurrent episodes of fainting, palpitations, etc.). 11. Known family history or known presence of long QT syndrome, or concomitant use of agents known to prolong the QT interval unless they can be permanently discontinued for the duration of study. 12. Donation or loss of 400 ml or more of blood within eight (8) weeks prior to initial dosing, or longer if required by local regulation. 13. Plasma donation (>400 mL) within 14 days prior to first dosing. 14. Use of any prescription drugs, herbal supplements (including Silybum marianum and Valeriana officinalis), within two weeks prior to initial dosing, and/or over-the- counter (OTC) medication, dietary supplements (vitamins included) within one weeks prior to initial dosing. 15. Smokers of more than two per week. Urine cotinine levels will be measured during screening, and urine cotinine ??? 500 ng/ml will exclude a subject. 16. History of drug abuse or unhealthy alcohol use within the 12 months prior to dosing, or evidence of such abuse as indicated by the laboratory assays conducted during screening. 17. History of recreational cannabis use within four weeks prior to dosing, or evidence of such use as indicated by the laboratory assays conducted during screening. 18. Participant is unwilling to refrain from strenuous exercise (including weightlifting) from 7 days prior to admission to the site until completion of the final Follow-up visit. 19. Exposure to any significantly immune suppressing drug (including experimental therapies as part of a clinical trial) within the 4 months prior to screening or 5 half-lives, whichever is longer. 20. Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days, or twice the duration of the biological effect of the investigational product, whichever is longer; or longer if required by local regulations. 21. Exposure to more than four new chemical entities within 12 months prior to the first dosing day.",I,Both
0,Amyotrophic Lateral Sclerosis (ALS) patients who received glatiramer acetate (GA) immunization.,Patients meeting (El) Escorial criteria for Amyotrophic Lateral Sclerosis (ALS). Participants must meet enrollment criteria and be able to travel to the study site in New York at the start of the trial and each month for the next six months.,TrialTroveID-079350,,,,79350,Delay Disease Progression,,,,Ii,
0,Patients with definite or probable amyotrophic lateral sclerosis,Diagnosis of definite or probable ALS in accordance with the El-Escorial criteria. Subject has experienced his/her first ALS symptoms within 3 years prior to the screening visit. Slow VC test equal or greater than 70% of the predicted value. The sum of the 3 respiratory items on the ALSFRS-R must total at least 10 points. Stable dose of riluzole for at least 8 weeks prior to screening. Age - 18-70 (inclusive). Subjects and caregivers (if applicable) were willing and able to provide a written informed consent.,ALS-GA-201 EudraCT Number: 2006-001688-49 GA-201 GoALS NCT00326625 TrialTroveID-079039,Adults; Older Adults,year(s),year(s),79039,Delay Disease Progression,70.0,18.0,"The use of invasive or non-invasive ventilation. Subject having undergone gastrostomy. Subjects had a clinically significant or unstable medical or surgical condition, including cardiovascular, hepatic, pulmonary, renal, autoimmune, endocrine, metabolic or malignancy, or any other condition that, in the investigator’s opinion, placed the subject at undue risk by participating in the study. Subjects participating in any other clinical trial (within 12 weeks prior to screening and thereafter). Women who were pregnant or nursing at the time of screening or who intended to be during the study period. Women of child-bearing potential who did not practice medically acceptable methods of contraception. Alcohol or drug abuse at the time of study. A known sensitivity to mannitol. Subjects without a caregiver or healthcare professional to inject the study medication if unable to do so themselves. Subjects who, at the time of at screening and baseline visits, were unable to comply with the planned schedule of study visits and study procedures.",Ii,Both
0,Patients with possible or probable ALS by El Escorial criteria were recruited from our ALS clinic.,,TrialTroveID-080381,,,,80381,Delay Disease Progression,,,,Ii,
0,"Subjects with 4 different primary tauopathy syndromes: CBS, nfvPPA, sMAPT, and TES","The inclusion criteria are listed below and are the same for each diagnostic cohort, except where noted. Participants must meet all of the specified inclusion criteria to be randomized to study drug (active or placebo) treatment. Between 35 and 80 years of age (inclusive); Able to walk at least 10 steps with minimal assistance (stabilization of one arm or use of cane/walker); MRI at Screening is consistent with the underlying neurodegenerative disease of the respective diagnostic cohort (i.e., CBS, nfvPPA, sMAPT, or TES), with no large strokes or severe white matter disease; Mini Mental State Exam (MMSE) at Screening is between 20 and 30 (inclusive); Amyloid beta (A beta) positron emission tomography (PET) scan (florbetapir or equivalent) at Screening is not consistent with underlying Alzheimer's disease (AD). Previous A beta PET scan negativity (assessed by a certified neuro radiologist) or previous AD CSF biomarker (A beta)/tau level) negativity may be used instead of performing an Aß PET scan at Screening at the PI's discretion; The following medications are allowed, but must be stable for 2 months prior to Screening: FDA-approved AD medications FDA-approved Parkinson's disease medications; Other medications (except those listed under exclusion criteria) are allowed as long as the dose is stable for 30 days prior to Screening; Has a reliable study partner who agrees to accompany the participant to visits, and spends at least 5 hours per week with the participant; Agrees to 3 lumbar punctures; Signed and dated written informed consent obtained from the participant and the participant's study partner in accordance with local IRB regulations; Women of childbearing potential (WCBP) must agree to abstain from sex or use an adequate method of contraception for the duration of the Screening period, the study drug treatment period, and for 155 days after the last dose of study drug; Males must agree to abstain from sex with WCBP or use an adequate method of contraception for the duration of the study drug treatment period and for 215 days after the last dose of study drug. For CBS Only Meets 2013 consensus criteria for possible or probable corticobasal degeneration (CBD), CBS subtype (Armstrong et al. 2013). For nfvPPA Only Meets 2011 consensus criteria for nfvPPA (Gorno-Tempini et al. 2011). Patients meeting 2013 Armstrong criteria for CBS-nfvPPA or 2017 Movement Disorder Society (MDS) criteria for progressive supranuclear palsy and speech/language disorders (PSP-SL) (Höglinger et al. 2017) would be assigned to this cohort since both of these definitions were derived from the 2011 Gorno-Tempini criteria. For sMAPT Only Has known frontotemporal lobar degeneration- (FTLD-) causative MAPT mutation confirmed in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory (Ghetti et al. 2015); CDR-FTLD (Knopman et al. 2008) sum of boxes score = 1.0. Sum of boxes is used instead of the global Clinical Dementia Rating Scale (CDR) because the global CDR does not take into account FTLD specific measures; Has any clinical phenotype of sMAPT. For TES Only Meets 2016 criteria for probable TES (Reams et al. 2016); At least 5 years or greater between symptom onset and 1st known traumatic brain injury/concussive episode.",NCT03658135 TauBasket TrialTroveID-332160 UCSF-001-AET-1,Adults; Older Adults,year(s),year(s),332160,Frontotemporal Dementia; Other Dementia,80.0,35.0,"The exclusion criteria are listed below and are the same for each diagnostic cohort. Participants meeting any of the following exclusion criteria will be excluded from randomization to study drug (active or placebo) treatment. A diagnosis of probable AD (McKhann et al. 2011) or progressive supranuclear palsy- Richardson's syndrome (PSP-RS) (Höglinger et al. 2017). Since variants of progressive supranuclear palsy (PSP) are known to cause nfvPPA and CBS, a diagnosis of PSP-SL or progressive supranuclear palsy-corticobasal syndrome (PSP- CBS) would not be exclusionary; Any other medical condition other than CBS, nfvPPA, sMAPT or TES that could account for cognitive or motor deficits (e.g., active seizure disorder, stroke, vascular dementia, substance abuse or alcoholism); History of a prominent and sustained response to levodopa therapy in the opinion of the PI; History of significant cardiovascular, hematologic, renal, or hepatic disease (or laboratory evidence thereof); History of major psychiatric illness or untreated depression that in the opinion of the PI would pose a safety risk or interfere with the appropriate interpretation of study data; Neutrophil count <1,500/mm3, platelets <100,000/mm3, serum creatinine >1.5 x upper limit of normal (ULN), total bilirubin >1.5 x ULN, alanine aminotransferase (ALT) >3 x ULN, aspartate aminotransferase (AST) >3 x ULN, or International Normalized Ratio (INR) >1.2 at Screening evaluations; Evidence of any clinically significant findings on Screening or baseline evaluations which, in the opinion of the PI would pose a safety risk or interfere with appropriate interpretation of study data; Current or recent history (within four weeks prior to Screening) of a clinically significant bacterial, fungal, or mycobacterial infection; Current clinically significant viral infection; Major surgery within four weeks prior to Screening; Any contraindication for MRI or unable to tolerate MRI scan at Screening; Any contraindication to or unable to tolerate lumbar puncture at Screening, including use of anti-coagulant medications such as warfarin. Daily administration of 81 mg aspirin will be allowed as long as the dose is stable for 30 days prior to Screening; Participants who, in the opinion of the PI, are unable or unlikely to comply with the dosing schedule or study evaluations; Prior treatment with BIIB092; Treatment with another investigational drug within 30 days or 5 half-lives of drug before Screening, whichever is longer. Treatment with investigational drugs other than BIIB092 while on study will not be allowed; Treatment with systemic corticosteroids within 30 days or 5 half-lives of drug before Screening, whichever is longer. Treatment with systemic corticosteroids while on study will not be allowed; Known hypersensitivity to the inactive ingredients in the study drug (BIIB092 or placebo); Known to be pregnant or lactating; or positive pregnancy test at Screening or Baseline (Day 1); Cancer within 5 years of Screening, except for basal cell carcinoma; History of serum or plasma progranulin level less than one standard deviation below the normal participant mean for the laboratory performing the assay; History or evidence at Screening of known disease-associated mutations in GRN, TBK1, C9ORF72, TARBP, CHMPB2, or VCP genes (FTLD causative gene mutations not associated with underlying tau pathology).",I,Both
0,Patients with amyotrophic lateral sclerosis (ALS).,,TrialTroveID-205673,,,,205673,Unspecified,,,,Ii,
1,Patients with Amyotrophic Lateral Sclerosis (ALS).,Genders Eligible for Study: Both Inclusion Criteria: Age between 18 and 85 Definite or probable ALS according to revised El Escorial criteria Maximum 2 years from initiation of symptoms to study entry Mild to moderate disability according to revised ALS functional rating scale (ALSFRS-r) permanent use of rilosole for at least 30 days.,91-01-54-17265 IRCT201207238509N2 NCT01825551 TrialTroveID-180430,Adults; Older Adults,year(s),year(s),180430,Delay Disease Progression,85.0,18.0,Exclusion Criteria: Familial ALS Pregnancy or lactation Myeloproliferative or hematologic disorders Active immunological disease Liver or renal or heart disease HIV positive Significant cognitive disorder Hypersensitivity to GCSF,Ii/Iii,Both
0,Patients with amyotrophic lateral sclerosis,,TrialTroveID-351652,,,,351652,Unspecified,,,,Iii,
0,Patients with sporadic (SALS) or familiar (FALS) ALS,"1) Diagnosis of, probable, probable laboratory supported or definite sporadic (SALS) or familiar (FALS) ALS according to the revised El Escorial criteria; 2) age >18 yrs; 3) onset =18 months before randomization; 4) sVC =70% in spinal onset; 5) riluzole 100 mg/day or no riluzole; 6) written informed consent",EudraCT Number: 2014-005367-32 PROMISE TrialTroveID-298075,Adults; Older Adults,year(s),,298075,Delay Disease Progression,,18.0,"1) PEG, NIV or tracheotomy; 2) known heart, renal or liver failure; 3) known intolerance to alfa2agonists; 4) known conditions at risk for cardiovascular disorders or symptomatic hypotension; 5) participation in a clinical trial within 3 months prior to the screening; 6) cognitive impairment defined by the Edinburg Cognitive and Behavior ALS Screen (ECAS) scale",Ii,Both
0,"Patients with Alzheimer's disease and Dementia,","(1) Those with positive BPSD symptoms due to Alzheimer's disease, frontotemporal dementia, or vascular dementia (2) Those who are 60 years old or older at the time of obtaining consent (3) Gender: any gender (4) After receiving sufficient explanation of the study, and with full understanding of the subject, if the subject's free and voluntary written consent can be obtained, consent will be obtained from the subject, and written consent will also be obtained from a surrogate. If it is difficult to obtain consent (5) Those who are in contact with family members or caregivers for more than 10 hours per week (6) Those who can go to the outpatient clinic according to the research implementation schedule",jRCTs031220715 TrialTroveID-487208,,,,487208,Behavioral Symptoms - Other; Cognitive Function; Frontotemporal Dementia; Vascular Dementia,,,,Ii,
1,Patients with amyotrophic lateral sclerosis.,"(1) Age 18-70 years old, gender is not limited. (2) The diagnosis meets the ALS confirmed and proposed diagnosis in the ALS2020 diagnostic standard (Gold Coast standard); (3) The duration of the disease from the onset of the subject to the time of admission ≤ 3 years; (4) Before admissionALSFRS-R scores were all ≥ 2 points, and the respiratory function items were ≥ 3 points; (5) ALSFRS-R decreased by 1-4 points (≥1 and ≤4) within 3 months of the screening period; (6) Forced Vital Capacity (%FVC) ≥ 70%; (7) Patients need to sign an informed consent form.",ChiCTR2200062823 TrialTroveID-441147,Adults; Older Adults,year(s),year(s),441147,Delay Disease Progression; Symptom relief,70.0,18.0,"(1) Other neurological diseases similar to ALS symptoms or affecting the evaluation of drug effectiveness, such as cervical spondylosis, lumbar spondylosis, dementia, etc.; (2) Severe renal insufficiency: creatinine clearance < 30 mL/min (Cockcroft-Gault formula), or other known serious renal insufficiency diseases; (3) Severe liver function damage: ALT, AST > 3 times the upper limit of normal value, or other known liver diseases such as acute and chronic active hepatitis, cirrhosis, etc.; (4) Screening period, acute myocardial infarction or interventional treatment in the past 6 months, heart failure patients (III-IV according to NYHA classification ); (5) Patients with other serious primary diseases of the nervous system, heart, lungs, hematopoietic system or endocrine system and psychosis; (6) Suspected or indeed have a history of alcohol or drug abuse; (7) Pregnant or lactating women, subjects of childbearing age (including male subjects with heterosexual sex and their female partners with reproductive potential) who have pregnancy plans or are unwilling to take effective contraception within 3 months from the beginning of screening to the cessation of the drug; (8) Have participated in other clinical trials within 30 days before screening, or are participating in other clinical trials; (9) The researchers believe that it is not suitable to participate in this study.",Iv,Both
0,,,TrialTroveID-286282,,,,286282,(N/A); Unspecified; Unspecified MS,,,,I,
0,Patients with amyotrophic lateral sclerosis,"(1) Age 18-70 years old, gender is not limited. (2) The diagnosis meets the ALS confirmed and proposed diagnosis in the ALS2020 diagnostic standard (Gold Coast standard); (3) The duration of the disease from the onset of the subject to the time of screening ≤ 4 years; (4) Before admission,ALSFRS-R scores were all ≤ 2 points; (5) ALSFRS-R decreased by 1-4 points (≥1 and ≤4) within 3 months of the screening period; (6) Patients need to sign an informed consent form.",ChiCTR2400079885 TrialTroveID-500356,Adults; Older Adults,year(s),year(s),500356,Delay Disease Progression,70.0,18.0,"(1) Other neurological diseases similar to ALS symptoms or affecting the evaluation of drug effectiveness, such as cervical spondylosis, lumbar spondylosis, dementia, etc.; (2) Patients with other autoimmune diseases, such as multiple sclerosis, polymyositis, myasthenia gravis, Guillain Barre syndrome, ankylosing spondylitis, rheumatoid arthritis, systemic lupus erythematosus, vitiligo, etc.; (3) Severe renal insufficiency: creatinine clearance < 30 mL/min (Cockcroft-Gault formula), or other known serious renal insufficiency diseases; (4) Severe liver function damage: ALT, AST > 3 times the upper limit of normal value, or other known liver diseases such as acute and chronic active hepatitis, cirrhosis, etc.; (5) Screening period, acute myocardial infarction or interventional treatment in the past 6 months, heart failure patients (III-IV according to NYHA classification ); (6)Patients with severe pulmonary insufficiency such as COPD and pulmonary fibrosis. (7)Patients with other serious primary diseases of the nervous system, heart, lungs, hematopoietic system or endocrine system and psychosis; (8)Suspected or indeed have a history of alcohol or drug abuse; (9)Patients with SOD1 gene mutation; (10) Pregnant or lactating women, subjects of childbearing age (including male subjects with heterosexual sex and their female partners with reproductive potential) who have pregnancy plans or are unwilling to take effective contraception within 3 months from the beginning of screening to the cessation of the drug; (11) Have participated in other clinical trials within 30 days before screening, or are participating in other clinical trials; (12) The researchers believe that it is not suitable to participate in this study.",I,Both
0,Healthy males and females aged 18-55 years.,Inclusion criteria Subject have given your written consent to take part in this study. Subject are between 18 and 55 years of age (inclusive. Subject are in good physical and mental health. Subject's body weight must be appropriate in relation to your height. The use of suitable anti conception in the 3 months before start of the study and subject will remain using this until 3 months after the study and/or you can not invoke an pregnancy (males) or you can not get pregnant (females). No abnormalities are diagnosed during the screening.,DC-001 EudraCT Number: 2009-016817-68 NCT02442557 NL30321.040.09 TrialTroveID-216269,Adults,year(s),year(s),216269,(N/A); Healthy subjects,55.0,18.0,"Subject are pregnant, planning to get pregnant or breastfeeding; If subject have relatives (1st degree) who have MS. If subject smoke 5 or more cigarettes per day or are not able to stop smoking during the admission period. If subject have abused drug (past and present) and or alcohol. The use of prescribed medication in the 14 days before start of the study, except for hormone based anticonceptionals, standard vitamines and paracetamol. If subject recieved a vaccination within the 4 weeks before the start of the study. Subject have taken part in another clinical drug study during the last 3 months prior to the study. Subject have donated blood in the three months before admission. Subject have donated plasma in the 7 days before admission. if Subject have recieved bloodproducts in the 6 month before start of start of the study. Subject are Hepatitis B, C or HIV positive. If no immune response can be achieved by DC-TAB in your blood;. Subject are not suitable to participate in this study according to the investigator.",I,Both
0,Healthy subjects.,"Healthy males or females of any race, between 18 and 55 years of age, inclusive. Body mass index between 18.0 and 30.0 kg/m2, inclusive, with a body weight of at least 50.0 kg. In good physical and mental health, including no clinically significant findings from medical history, physical examination, psychiatric examination, 12 lead ECG, vital signs measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia [eg, suspicion of Gilbert's syndrome based on total and direct bilirubin] is not acceptable) at screening or check in as assessed by the investigator (or designee). Females who are not pregnant or lactating, and females of childbearing potential and males will agree to use contraception. Has clinical laboratory test results within the reference ranges of the testing laboratory, with the exception of results outside the reference ranges that are deemed not clinically significant by the Investigator (or designee) at screening and check-in. Has supine blood pressure and pulse rate within the following ranges after 5 minutes rest: systolic blood pressure 90 to 140 mmHg, diastolic blood pressure 40 to 90 mmHg, and pulse rate 45 to 90 bpm. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.",HTL0014242-101 NCT03785054 TrialTroveID-339103,Adults,year(s),year(s),339103,(N/A); Healthy subjects,55.0,18.0,"Past or current history of any mental, behavioural, or neurodevelopmental disorder as defined by the tenth revision of the International Classification of Diseases (ICD-10)16 including, but not limited to, diagnoses of: organic, including symptomatic, mental disorders (F00-F09); mental and behavioural disorders due to psychoactive substance use (F10-F19); schizophrenia, schizotypal, and delusional disorders (F20-F29); mood [affective] disorders (F30-F39); neurotic, stress-related, and somatoform disorders (F40-F48); disorders of adult personality and behaviour (F60-F69). Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, haematological, pulmonary, gastrointestinal, neurological, respiratory, or endocrine disorder, as determined by the Investigator (or designee). Active or history of cardiovascular or cerebrovascular disease, including hypertension, angina, ischaemic heart disease, transient ischaemic attacks, bundle branch block, evidence of myocardial ischaemia, stroke, and peripheral arterial disease sufficient to cause symptoms and/or require therapy to maintain stable status. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator (or designee). Active neoplastic disease or history of any neoplastic disease within 5 years of screening (except for basal or squamous cell carcinoma of the skin or carcinoma in situ that has been definitely treated with standard of care). Active infection (eg, sepsis, pneumonia, abscess) or a serious infection (eg, resulting in hospitalisation or requiring parenteral antibiotic treatment) within 6 weeks prior to dosing. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair will be allowed). Any of the following at screening and/or predose: QT interval corrected for heart rate using Fridericia's method (QTcF) >450 ms confirmed by repeat measurement QRS duration >110 ms confirmed by repeat measurement PR interval >220 ms confirmed by repeat measurement findings which would make QTc measurements difficult or QTc data uninterpretable history of additional risk factors for torsades de pointe (eg, heart failure, hypokalemia, family history of long QT syndrome). History of alcoholism or drug/chemical abuse. Alcohol consumption of >14 units (females) and >21 units (males) per week. One unit of alcohol equals ½ pint (285 mL) of beer or lager, 1 glass (125 mL) of wine, or 1/6 gill (25 mL) of spirits. Positive alcohol breath test result or positive urine drug screen, including cotinine (confirmed by repeat) at screening or check in. Positive hepatitis panel and/or positive human immunodeficiency virus test. Any of the following haematology values at screening or check-in, as confirmed by 1 repeat if necessary: haemoglobin <11 g/dL for females, and <12 g/dL for males absolute neutrophil count <1.5 × 109/L (<1500/microL). Renal or liver impairment at screening or check-in defined as, confirmed by 1 repeat if necessary: serum creatinine > or =135 micro mol/L ALT and/or AST > or =2 × ULN ALP and/or total bilirubin >1.5 × ULN (an isolated total bilirubin >1.5 × ULN is acceptable if total bilirubin is fractionated and direct bilirubin is <35%). Participation in a clinical study involving administration of an investigational drug (new chemical entity) or medical device within the last 90 days or 5 half-lives of the investigational medication, whichever is longer, prior to dosing. Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to dosing. Use or intend to use any prescription medications/products within 14 days or 5 half lives of the medication/product, whichever is longer, prior to check-in (hormone replacement therapy, oral, implantable, transdermal, injectable, or intrauterine contraceptives are acceptable). Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant derived preparations within 14 days prior to check in. Use or intend to use slow release medications/products considered to still be active within 14 days prior to check in. Received live attenuated vaccination within 6 weeks prior to screening or intends to receive such a vaccination during the study. Use of tobacco or nicotine containing products (including but not limited to; cigarettes, electronic cigarettes, pipes, cigars, chewing tobacco, nicotine patch, or nicotine gum) within 6 months prior to check-in and the inability to abstain from nicotine-containing products until the follow-up visit. Receipt of blood products within 2 months prior to check in. Donation of blood (>400 mL) or comparable blood loss (>350 mL) from 3 months prior to screening, plasma donation from 2 weeks prior to screening, or platelets donation from 6 weeks prior to screening. Poor peripheral venous access. Consumption of caffeine-containing foods and beverages within 72 hours of screening or is unable to abstain from caffeine-containing foods and beverages from 7 days prior to check in until discharge. Consumption of any foods or beverages which alter CYP1A2 activity, eg, barbecued food or cruciferous vegetables, such as broccoli and cauliflower, within 14 days prior to check-in (a list of prohibited foods will be provided to subjects). Consumption of any foods or beverages containing Seville-type oranges, grapefruit, or poppy seeds within 7 days prior to check-in. Have previously completed or withdrawn from this study, and have previously received the IMP. Subjects who, in the opinion of the investigator (or designee; including input from subjects' general practitioner, as applicable), should not participate in this study.",I,Both
0,Patients with sporadic ALS.,,TrialTroveID-372757,,,,372757,Unspecified,,,,I,
0,Subjects with Amyotrophic Lateral Sclerosis (ALS),"Signed informed consent Subjects over 18 years of age and less than 70 years old Subjects with a possible, probable-lab supported, probable, or definite diagnosis of ALS, according to the revised El Escorial criteria Subjects having experienced their first ALS symptoms within 18 months prior to recruitment/consent Forced Vital Capacity > 70% Subjects must be medically suitable for study participation and willing to comply with all planned aspects of the protocol, including blood sampling, at the time of inclusion in the study.",F16029 GBI1501 NCT02872142 TrialTroveID-284798,Adults; Older Adults,year(s),year(s),284798,Delay Disease Progression,69.0,19.0,"Subjects with pre-existing clinically significant lung disease not attributable to ALS Subjects diagnosed with other neurodegenerative diseases or diseases associated with other motor neuron dysfunction Participation in another investigational product study within one month prior to screening Females who are pregnant, breastfeeding, or, if of child-bearing potential, unwilling to practice a highly effective method of contraception (oral, injectable or implanted hormonal methods of contraception, placement of an intrauterine device or intrauterine system, condom or occlusive cap with spermicidal foam/ gel/ film/ cream/ suppository, male sterilization, or true abstinence) throughout the study Difficult or problematic peripheral vein access and inability to implant a central catheter which would make continuous PE not feasible as per the visit protocol Contraindication to undergo PE or subject has abnormal coagulation parameters at the discretion of the Outpatient Apheresis Unit team, including but not limited to: Thrombocytopenia (platelets <100,000/µL) Fibrinogen <1.5 g/L International Normalized Ratio >1.5 Beta-blocker treatment and bradycardia <50 beats/min Treatment with angiotensin-converting enzyme inhibitors which may increase the risk of allergic reactions, unless a preventive change in hypotensive treatment occurs prior to enrollment History of anaphylaxis or severe systemic response to any plasma-derived albumin preparation, component of Albutein® 5%, or other blood product(s) Subjects unable to interrupt treatment with acetylsalicylic acid, other oral antiplatelet, or anticoagulant Renal dysfunction by elevated creatinine concentration >2 mg/dL Presence of heart disease that contraindicates PE treatment, including ischemic cardiopathy and congestive heart failure Presence of prior behavioral disorders requiring pharmacological intervention with less than 3 months of stable treatment Mentally challenged subject who cannot give independent informed consent Any condition that would complicate compliance with the study protocol (i.e., illness with the expectation of less than one year survival, abuse of drugs or alcohol, etc.)",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis.,"In order to be eligible for participation in the trial, the patients must meet the following requirements: Must give written informed consent. Age 18 and <70 years. Subjects with diagnosis of definitive, posible and probable ALS according El Escorial-Arlie criteria. Subjects with ALS symptom onset < 18 months from recruitment. FVC > 70%. Be medically able to undergo study procedures and to comply with the visits schedule at the time of inclusion in the study.",EudraCT Number: 2013-004842-40 IG1309 NCT02479802 TrialTroveID-209130,Adults; Older Adults,year(s),year(s),209130,Delay Disease Progression,70.0,18.0,"Patients meeting any of the following criteria will not be able to participate in the trial: Subjects with a clinically significant preexisting lung disease not attributable to ALS. Subjects with a diagnosis of other neurodegenerative diseases or diseases associated with dysfunction of the motor neurons that can confuse the diagnosis of ALS. Participation in other clinical trials, or the reception of any other investigational drug in the six months prior to the start of the study. Female subjects who are pregnant, currently breastfeeding, or attempting to conceive during the study. Difficult peripheral venous access precluding plasma exchange and inability to implement a viable alternative catheter to make continued performing plasma exchange visits according to protocol. Any contraindication for plasma exchange or abnormal coagulation parameters according clinical criteria from apheresis team (Banc de Sang i Teixits, BST Bellvitge). A history of frequent adverse reactions (serious or otherwise) to blood products. Hypersensitivity to albumin or allergies to any of the components of Albutein. Subjects that can not interrupt treatment with acetylsalicylic acid or oral anticoaguants. Plasma creatinine > 2mg/dl. Present a history of heart disease including ischemic heart disease or congestive heart failure. Presence of prior conduct disorders requiring pharmacologic intervention, with less than 3 months of stable treatment. Any condition that complicates adherence to study protocol (illness with less than one year of expected survival , drug or alcohol abuse, etc.)",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis,"Patient provides written informed consent, informed consent signature collection prior to any study procedure (patient has good acceptance and understanding of the informed consent); Definite, probable diagnosis according to the revised El Escorial criteria; Age: 18-65 years; FVC >70%; Onset ≤ 24 months; Patients with an ALSFRS-R score of at least 26; overall, including a score of at least 2 on each of the 1-9 ALSFRS-R individual component items and of at least 3 of the 10-12 individual components items; Evidence of fast progression of the disease. We exclude slow progressors at the time of screening defined as Patient with an ALSFRS-R total score progression between onset of the disease and screening of < 0.3 per month. We document the fast progression of the disease defined as ALSFRS-R total score decrease of ≥ 1 point per month during a 12 week run-in period between screening and randomization; Patient should be on a stable dose of Riluzole for > 30 days from pre-screening visit or not taking riluzole at all, nor plan to begin riluzole during the study period; Patient is medically able to tolerate transient immunosuppression regimen; Presence of a willing and able caregiver who understands the need to attend all follow-up visits, even if mobility declines.",hNSCALSII NCT06344260 STEMALS TrialTroveID-511096,Adults,year(s),year(s),511096,Delay Disease Progression,65.0,18.0,"Psychiatric disease or other neurological diseases different from ALS; Evidence of any concurrent illness or treatments limiting the safety to participate or any condition that the neurosurgeon feels may pose complications for the surgery; Cancer within the previous 10 years; Immunosuppressive therapy within 12 weeks of screening; active autoimmune disease or infection (including hepatitis B, hepatitis C, or HIV); Cognitive impairment; Contraindications to perform MRI scans, CSF withdrawal and Skin biopsy; Patient unable to understand informed consent form; Pregnancy and breast feeding; Patient has been treated previously with any stem cell or somatic cells therapy; Patient has participated in another clinical treatment trial or received other experimental medications outside of a clinical trial within 1 month prior to start of this study.",Ii,Both
1,Patients with Multifocal Motor Neuropathy,"1. Male or female patient aged 18 to 80 years. 2. Written informed consent obtained prior to any study-related procedures. 3. Diagnosis of definite or probable MMN according to the EFNS/PNS Guideline 2010, First revision made by neuromuscular disease specialists with specific electrodiagnostic expertise. 4. Patients treated with a stable maintenance dose within 15% of any brand of IVIg (Kiovig® excluded) at 1 g/kg for 1-3 days up to 2 g/Kg for 2-5 days every 4 to 8 weeks (+/- 7 days), according to the EFNS/PNS Guideline 2010, First revision for at least 3 months prior to enrolment. 5. Covered by national health care insurance system if required by local regulations.",EudraCT Number: 2012-001995-12 I10E-0901 LIME NCT01951924 TrialTroveID-231219,Adults; Older Adults,year(s),year(s),231219,Unspecified MMN,80.0,18.0,"1. Upper motor neuron, bulbar, cranial nerve or significant sensory deficit. 2. CSF protein >100 mg/dL (if available and done as part of a previous evaluation). 3. Any other ongoing disease that may cause neuropathy, such as toxin exposure, dietary difficency, uncontrolled diabetes, hyperthyroidism, cancer, systemic lupus erythematosus or other connective diseases, infection with HIV, hepatitis B virus (HBV), or hepatitis C (HCV), Lyme disease, multiple myeloma, Waldenström's macroglobulinemia, amyloid, and hereditary neuropathy. 4. BMI >= 40 kg/m2. 5. Known hypersensitivity to the active substance or to any of the excipients of I10E (glycine and polysorbate 80) or Kiovig(glycine). 6. Patient who have been treated with Kiovig shall not have received Kiovig during the last 6 months prior to enrolment. 7. History of IgA deficiency, except if the absence of anti-IgA antibodies is documented. 8. Protein-losing enteropathy characterised by serum protein levels <60 g/l and serum albumin levels <30 g/l or nephrotic syndrome characterised by proteinuria >=3.5 g/24 hours, serum protein levels <60 g/l and serum albumin levels <30 g/l. 9. History of cardiac insufficiency (New York Heart Association (NYHA) III/IV), uncontrolled cardiac arrythmia, unstable ischemic heart disease, or uncontrolled hypertension. 10. History of venous thrombo-embolic disease, myocardial infarction, or cerebrovascular accident. 11. Risk factor for blood hyperviscosity such as cryoglobulinemia or haematological malignancy with monoclonal gammopathy. 12. Glomerular filtration rate <80 ml/min/1.73m2 measured according to the Modified Diet in Renal Disease (MDRD) calculation. 13. Serum levels of AST, ALT >2 times upper limit of normal range. 14. Treatment within 12 months prior to screeening with immunomodulator or immunosuppressant agent (including but not limited to cyclophosphamide, cyclosporine, interferon-a, interferon-b 1a, anti-CD20, alemtuzumab, azathioprine, etanarcept, mycophenolate mofetil, methotrexate, haematopoietic stem cell transplantation). 15. Administration of another investigational product within the last month prior to inclusion. 16. Plasma exchange, blood products or derivatives administered with the last 3 months prior to screening. 17. Woman with positive results of pregnancy test or breast-feeding woman or woman of childbearing potential without an effective contraception. Effective contraception are injectible, patch or combined oestro-progestative or progestative contraceptives, Cooper T or levonorgest releasing intra-uterine devices, depot intramuscular medroxyprogesterone, subcutaneous progestative contraceptive implants, condoms or occlusive caps (diaphragm or cervical/vault caps) with spermicide, true abstinence (when this is in line with the preferred and usual lifestyle of the patient). 18. Any serious medical condition that would interfere with the clinical assessment of I10E or prevent the patient from complying with the protocol requirements. 19. Anticipated poor compliance of patient with study procedures during the 12 month duration of the study. 20. Drug or alcohol abuse.",Iii,Both
0,Subjects with treatment of amyotrophic lateral sclerosis.,,TrialTroveID-509880,,,,509880,Unspecified,,,,I,
0,Patients suffering from Amytrophic Lateral Sclerosis,"1. Patients must be over 18 years of age. 2. Patients diagnosed with laboratory supported, clinically probable or definite ALS according to the World Federation of Neurology Revised El Escorial criteria (Brooks, 1994). 3. Disease duration from symptoms onset no longer than 24 months at the screening visit. 4. Patient with a FVC (Forced Vital Capacity) equal to or more than 80% predicted normal value for gender, height, and age at the screening visit 5. Patients must have bulbar involvement (defined as clinically evident dysarthria or a > or =1 point drop on questions 1-3 of the revised version of the ALS functional rating scale (ALS-FRS-R). 6. Patient treated with a stable dose of riluzole (100 mg/day) for at least 30 days prior to screening.",EudraCT Number: 2017-001983-39 NL61931.041.17 PHALS TrialTroveID-310325,Adults; Older Adults,year(s),,310325,Delay Disease Progression,,18.0,"1. Patients with concomitant frontotemporal dementia (FTD). 2. Patients on non-invasive ventilation (NIV) or who underwent tracheotomy. 3. Patients with syphilis or a medical history of syphilis. 4. Patients with known penicillin allergy or patients with a positive penicillin allergy skin test. 5. Patients with a contra-indication for using penicillin (use of methotrexate, renal insufficiency). 6. Patients with a medical history of epilepsy. 7. Patients with a contra-indication for using hydrocortisone (uncontrolled hypertension or diabetes mellitus, ulcus ventriculi or ulcus duodeni, patients with acute infections) 8. In the case of a female with childbearing potential, the patient must not be pregnant or breast-feeding. Women of childbearing potential should use adequate contraception",Ii,Both
0,"Patients were enrolled with definite, probable, or laboratory supported probable ALS according to El Escorial Revised Criteria with an FVC w50% and disease duration < 5 years.",,TrialTroveID-122009,,,,122009,Delay Disease Progression,,,,I,
1,Patients with Niemann-Pick Disease Type C1,"Confirmed diagnosis of NPC1 Annual Severity Increment Score between 0.5 and 2.0 using the 17-domain NPC Severity Scale Treated or Not Treated with Miglustat (patients must be on a stable dose for at least 3 months prior to the Screening Visit, or have discontinued Miglustat for at least 3 months prior to Screening Visit). Body weight greater than 4.5 kg and less than or equal to 125 kg Presenting at least 1 neurological symptom of the disease Written informed consent Willing and capable to participate in all aspects of trial design Ability to travel to the trial site at scheduled times Contraception requirements per protocol Caregiver consent as appropriate to participate in all protocol-specified assessments for duration of trial Inclusion criteria for Open Label Extension are 1) Received double-blind treatment for at least 48 weeks with CGI-S deterioration by at least 2 levels for 2 consecutive assessment visits 12 weeks apart, or 2) completion of double-blind treatment and completed all assessments through week 96, or 3) Discontinued early from double-blind treatment but completed all assessments through week 96 Inclusion criteria for patients age 0 to 3 years in open-label sub-study in countries following EMA guidance only: Confirmed diagnosis of NPC1; treated or not with Miglustat per main study; body weight greater than 4.5kg; patient may be asymptomatic; written assent for child to participate in safety assessments; caregiver consent to participate in caregiver assessments; ability to travel to the trial site for all scheduled visits.",CTD-TCNPC-301 EudraCT Number: 2020-003136-25 NCT04860960 TransportNPC TrialTroveID-402637,Children; Adults; Older Adults,year(s),,402637,Niemann-Pick Type C,,3.0,"Recipient of a liver transplant within <12 months or planned liver transplantation Patients with active liver disease from any cause other than NPC1 Clinical evidence of acute liver disease including symptoms of jaundice or right upper quadrant pain or international normalized ratio > 1.8 Stage 3 chronic kidney disease or worse as indicated by an estimated glomerular filtration rate <60ml/min/1.73m2. Use of curcumin or fish oil within 12 weeks prior to enrollment Known or suspected allergy or intolerance to the study treatment In the opinion of the Investigator, the patient's clinical condition does not allow for the blood collection required as per protocol specific procedures. Treatment with any investigational drug during the 3 months prior to entering the study. If the investigational drug has a short half-life (<8 hours) and would be expected to be cleared from the body within 1 month, then the wash-out period is 1 month. Treatment with any form of leucine, whether as an investigational drug or other formulation is not allowed Treatment with any other investigational drug during the study Pregnancy or breastfeeding Current participation in another trial is not permitted unless it is a noninterventional study and the sole purpose of the trial is for long-term follow up describing clinical features or survival data (registry) Patients with uncontrolled, severe epileptic seizure periods (at least 3 consecutive severe epileptic seizures that required medication) within 2 months prior to completion of informed consent or assent, as applicable. Neurologically asymptomatic patients Inability to participate in the primary study assessment (4D-NPC-SS or 5D-NPC-SS) as determined by the Investigator Exclusion criteria for patients age 0 to 3 years in open-label sub-study in countries following EMA guidance only are similar to the main study with the addition of exclusion criterion of history of fetal hydrops or fetal ascites",Iii,Both
0,Patients with Niemann-Pick Disease Type C,"- Completion of study CTD-TCNPC-101 with no safety concerns at the final visit - Negative urine pregnancy test for females of child bearing potential - Patients must be legally resident in the USA with access to healthcare - Written, informed consent",CTD-TCNPC-102 NCT03893071 TrialTroveID-346391,Adults; Older Adults,year(s),,346391,Niemann-Pick Type C,,18.0,"- Inability to comply with the proposed protocol assessments or any uncertainty about their ability to give meaningful, informed consent (legal guardian may give consent with subject assent) - Concurrent medical conditions representing a contraindication to any of the study medications - Grade 3 renal impairment or worse as indicated by estimated Glomerular filtration rate (eGFR) < 60mL/min/1.73m2 - Clinical evidence of acute liver disease including symptoms of jaundice or right upper quadrant pain or International Normalised Ratio (INR) >1.8 - Male patients and female patients of childbearing potential who are not willing to use appropriate birth control (i.e. double barrier birth control) from enrollment until the follow-up visit",I,Both
0,Patients with confirmed diagnosis of NPC-1.,"1. Confirmed diagnosis of NPC-1 defined as one of the following 1. Two NPC-1 mutations on exome gene sequencing 2. One NPC-1 mutation and positive filipin staining (current or prior) 3. Vertical supranuclear gaze palsy [VSGP] plus either ??? one NPC-1 mutation or positive filipin staining and no NPC-2 mutations 2. NIH NPC Severity Score <30 and with no more than 4 individual domains with a score ??? 3. 3. Age range: 18 years upwards 4. At least one systemic manifestation of NPC disease defined as one or more of 1. Clinically detectable hepatomegaly and/or either ALT or AST outside the normal range for the study laboratory 2. Clinically detectable splenomegaly 3. Impaired respiratory function due to NPC or a history of pneumonia in the last 12 months 5. Negative urine pregnancy test for females of child bearing potential 6. Written, informed consent",CTD-TCNPC-101 NCT02939547 TrialTroveID-288905,Adults; Older Adults,year(s),,288905,Niemann-Pick Type C,,18.0,"1. The presence of NPC-2 mutations on exome gene sequencing 2. Previous receipt of cyclodextrin therapy within 3 months of baseline 3. Receipt of any of the following medications within 1 month of baseline: Coenzyme Q10, curcumin, cinnamon, fish oil supplements, high dose vitamin D (>500 milli-International unit (mIU)/day), acetyl leucine, or gingko biloba 4. Concurrent treatment with any therapy indicated for the lowering of cholesterol such as statins, fibrates, ezetimibe 5. Karnofsky score < 40 6. Inability to comply with the proposed protocol assessments or any uncertainty about their ability to give meaningful, informed consent (legal guardian may give consent with patient assent) 7. Concurrent medical conditions representing a contraindication to any of the study medications 8. Grade 3 renal impairment or worse as indicated by eGFR< 60mL/min/1.73m2 9. Clinical evidence of acute liver disease including symptoms of jaundice or right upper quadrant pain or INR >1.8 10. Involvement in another interventional clinical trial within the previous 6 months from baseline 11. Weight <40 kg or >100 kg 12. Male patients and female patients of childbearing potential who are not willing to use appropriate birth control (i.e. double barrier birth control) from enrolment until the follow-up visit",I,Both
0,Patients with confirmed diagnosis of NPC-1.,"1. Confirmed diagnosis of NPC-1 defined as one of the following - Two NPC-1 mutations on genotyping - One NPC-1 mutation and positive filipin staining (current or prior) - Vertical supranuclear gaze palsy [VSNGP] plus either ??? one NPC-1 mutation or positive filipin staining and no NPC-2 mutations 2. NIH NPC Severity Score <30 and with no more than 4 individual domains with a score ??? 3. 3. Age range: 2 years upwards - Inclusion of the first three paediatric patients will be restricted to individuals aged ??? 5 years. Once the first three paediatric patients have safely completed stage 1, study entry will be open to all ages ???2 years as per the protocol 4. Negative pregnancy test for females of child bearing potential 5. Written, informed consent -",CTD-TCNP-201 CTD-TCNPC-201 EudraCT Number:2015-005761-23 MOH_2017-09-17_000540 NCT02912793 TrialTroveID-287116,Children; Adults; Older Adults,year(s),,287116,Niemann-Pick Type C,,2.0,"1. The presence of NPC-2 mutations on genotyping 2. Previous receipt of cyclodextrin therapy 3. Lanksy score < 50 if aged ???16 or Karnofsky score < 40 if aged > 16. 4. Inability to comply with the proposed protocol assessments 5. Concurrent treatment with any type of cholesterol lowering agents such as statins, fibrates, ezetimibe 6. Concurrent medical conditions representing a contraindication to any of the study medications 7. Stage 3 renal impairment or worse as indicated by eGFR< 60mL/min using the MDRD equation 8. Clinical evidence of acute liver disease including symptoms of jaundice or right upper quadrant pain or INR >1. 8 9. Involvement in another interventional clinical trial within the previous 6 months 10. Weight >100 kg 11. Females of childbearing potential who are not willing to use a method of highly effective contraception (hormonal contraception, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner, or true abstinence) during the study and the follow-up period. True abstinence can only be in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a trial, and withdrawal are not acceptable methods of contraception. 12. Females who are breastfeeding -",Iii,Both
0,"Patients with With Niemann-Pick Disease, Type C1","Age greater than or equal to 3 and less than or equal to 60 years old at time of enrollment Diagnosis of NPC1 based upon one of the following: A. Two NPC1 mutations B. Biochemical Positive for NPC (oxysterol/bile acid and sphingomyelinase levels consistent with a diagnosis of NPC) and one NPC1 mutation NPC1 mutations will be interpreted using standards established for the interpretation of sequence variants [33]. Oxysterol/Bile Acid testing refers to cholestane-3beta,5 ,6beta-triol [7, 8] or 3beta,5alpha,6beta-trihydroxycholanic acid and its glycine conjugate [34]. Evidence of NPC1-related liver disease as defined by one of the following: A. Abnormal liver chemistries as defined by one of the following: i. Plasma aspartate aminotransferase (AST) greater than or equal to 1.5-times age-appropriate upper limit of normal ii. Plasma aspartate aminotransferase (AST) greater than or equal to 1.25-times age-appropriate upper limit of normal and plasma alanine aminotransferase (ALT) > 1.25-times age-appropriate upper limit of normal iii. Plasma aspartate aminotransferase (AST) greater than or equal to 1.25-times age-appropriate upper limit of normal and AST/ALT ratio greater than or equal to 2.0 AND Abnormal liver chemistries as defined above at least 8 weeks apart. B. Abnormal Liver Ultrasound* defined as one of the following: Intraparenchymal echogenic bands consistent with fibrosis Abnormal liver echogenicity with AST or ALT above the upper limit of normal. Hepatomegaly with AST or ALT above the upper limit of normal. To define hepatomegaly, we will use the suggested limit of normal of the longitudinal dimension of the right lobe of the liver. These values are approximately 2 standard deviations above the mean. C. Abnormal liver stiffness (FibroScan**) for age. To define Liver Stiffness Measurement we will use the normal age dependent ranges. Values above the 95th centile will be considered abnormal. Ability to travel to the NIH Clinical Center repeatedly for evaluation and follow-up. Willingness to discontinue all non-prescription supplements, except for an age-appropriate multivitamin/mineral supplement. Stable miglustat dose for 3 months prior to entry into the IV portion of the trial. Women of reproductive age must be willing to use an effective method of contraception for the duration of the trial if sexually active. Willingness to participate in all aspects of the IV trial",19-CH-0028 190028 NCT03887533 TrialTroveID-346005,Children; Adults,year(s),year(s),346005,Niemann-Pick Type C,60.0,3.0,"Age <3 or > 60 years of age at time of enrollment in the trial. Subjects who have received any form of parenteral cyclodextrin, an HDAC inhibitor, or an experimental therapy for NPC in the prior six months. Prior Intrathecal VTS-270 treatment is allowed. History of hypersensitivity reactions to cyclodextrin or components of the formulation. Pregnancy or breastfeeding. Females of childbearing potential unwilling to utilize a highly effective form of contraception (i.e., barrier method with spermicide, intrauterine device, steroidal contraceptive in conjunction with a barrier method, or abstinence if it is the patient s baseline preference) for the duration of the study and for 30 days after participation. Any systemic infection at the time of enrollment. Neutropenia, defined as an absolute neutrophil count (ANC) of less than 1,500 per microliter. Subjects with benign cyclic/ethnic neutropenia may be enrolled if not clinically symptomatic. Thrombocytopenia defined as a platelet count less than 75,000 per microliter. Established history of a chronic clotting or bleeding disorder. Use of anticoagulants within 3 months of enrollment Severe or acute liver disease as defined by one of the following: A. AST or ALT greater than 10-times age-appropriate upper limit of normal B. Jaundice or right upper quadrant pain C. International Normalized Ratio (INR) >1.8 Individuals with AST and ALT greater than 4-times the age-appropriate upper limit of normal will be excluded if they have a positive NIH Clinical Center Viral Markers Hepatitis Screen (HBsAG, anti-HCV and Anti-HAV IgM). This screening test will not be obtained unless AST and ALT are elevated. An equivalent panel from another laboratory may be used if this elevation is noted on screening. Individuals excluded under this criterion may be rescreened after the acute pathology resolves (e.g. Hepatitis A infection). Presence of anemia defined as two standard deviations below normal for age and gender. Serum creatinine level greater than 1.5 times the age-appropriate upper limit of normal OR FOR INDIVIDUALS >= 6 years of age an eGRF < 60 mL/min 1.73 m squared Hematuria on a single urinalysis, as defined by the American Urological Association (AUA) as five or more red blood cells per high-power field on microscopic evaluation of urinary sediment from a properly collected urinalysis specimen. The patient will not be excluded if two subsequent urine specimens are negative for hematuria as defined by the AUA. Proteinuria (1+ protein on repeat urinalysis) unless evaluated and classified as benign. Active pulmonary disease, oxygen requirement or clinically significant history of decreased blood oxygen saturation (SaO2 <95% on room air), pulmonary therapy, daily use of a cough assist device or pulmonary vest, requiring active suction, or with a tracheostomy. Patients with uncontrolled seizures per either of the criteria below. Unstable frequency, type or duration of seizures. Quantified by a seizure log over one month prior to enrollment. Subject requiring antiepileptic medication changes (other than dose adjustments for weight) in the month prior to enrollment. Individuals receiving parenteral nutrition will be excluded. Patients, who in the opinion of the investigators, are unable to comply with the protocol or have specific health concerns that would potentially increase the risk of participation. Additional exclusion criteria for intrathecal VTS-270 Neurologically asymptomatic. Determination made by the investigators based on history, neurological exam and consultant input. Suspected infection of the central nervous system Spinal deformity that would impact the ability to perform a lumbar puncture Skin infection in the lumbar region Prior use of anticoagulants or a bleeding disorder with increased risk of clinical bleeding. Patients unable to complete a behavioral audiological evaluation including pure-tone threshold assessment (500 Hz to 8000 Hz). In consultation with the medical monitor and audiologists, a sedated ABR may be utilized to monitor ototoxicity if the participant is being sedated to receive IT VTS-270. Patients, who in the opinion of the investigators, are unable to comply with the protocol or have specific health concerns that would potentially increase the risk of participation.",Iii,Both
0,"Infants With Niemann-Pick Disease, Type C","Age 0 to 6 months of age at time of enrollment, both genders, and any race/ethnicity. Diagnosis of NPC (either NPC1 or NPC2) based upon meeting any of the two following conditions: A. Two variants classified as pathogenic or likely pathogenic in NPC1/NPC2 on clinical laboratory testing, or B. One variant classified as pathogenic or likely pathogenic on clinical laboratory testing and a positive NPC biochemical marker (oxysterol or bile acid biomarker or PPCS/Lyso509) test, if acid sphingomyelinase deficiency and cholesterol ester storage disease have been excluded either by clinical molecular testing of the SMPD1 and LIPA genes or by clinical biochemical assay for acid sphingomyelinase and lysosomal acid lipase enzymes (or a combination of enzymatic and molecular testing). Variants will be interpreted using the American College of Medical Genetics guidelines for the interpretation of sequence variants (2015) and testing must be performed by a CLIA-certified laboratory. Subjects with evidence of NPC-related liver disease as defined by direct bilirubin (DB) >2mg/dL or DB/total bilirubin ratio >0.2. Ability to travel to a research site. Willing to participate in all aspects of trial design including serial blood collections. Parent / guardian must provide written informed consent to participate in the study. Because of the age range intended for inclusion, assent will not possible.",201708114 NCT03471143 TrialTroveID-321078,Children,,month(s),321078,Niemann-Pick Type C,6.0,,"Age > 6 months at time of enrollment in the trial. A medical condition (such as clinically significant bleeding diathesis or evidence of immune suppression) that in the opinion of the investigator precludes placement of an intravenous catheter An absolute neutrophil count (ANC) of less than 1,500 per microliter. A platelet count less than 75,000 per microliter. History of severe neonatal encephalopathy, per modified Sarnat including level of consciousness as stupor/coma, absent spontaneous activity, decerebrate posture, flaccid tone, absent suck, absent moro, diverted/nonreactive pupils, lack of heart rate variability, apnea. Subjects, who in the opinion of the investigators, are unable to comply with the protocol or have specific health concerns that would potentially increase the risk of participation. Examples of inability to comply include unwillingness to relocate or travel to a study site, suspected noncompliance with study procedures, behavior that jeopardizes the safety or security of the data or study staff, and other causes of inability to comply. Concurrent participation in another investigational drug trial. History of renal disease or evidence of acute kidney injury defined as serum creatinine greater than 1.5 mg/dL or an increase of at least 0.2-0.3 mg/dL per day.",Iii,Both
0,Patients with Niemann-Pick Type C1 Disease.,"Aged greater than or equal to 2 and less than or equal to 25 years old at time of enrollment, either gender and any ethnicity. Diagnosis of NPC1 based upon one of the following: Two NPC1 mutations; Positive filipin staining and at least one NPC1 mutation; Vertical supranuclear gaze palsy (VSNGP) in combination with either: i. One NPC1 mutation, or ii. Positive filipin staining and no Niemann-Pick Type 2 (NPC2) mutations. Patients with at least one neurological manifestation of NPC1. For example, but not limited to, hearing loss, vertical supranuclear gaze palsy, ataxia, dementia, dystonia, seizures, dysarthria, or dysphagia. Ability to travel to the National Institutes of Health Clinical Center (NIH CC) repeatedly for evaluation and follow-up. If taking miglustat, the patient must have been taking a constant dose of the medication for no less than 3 months prior to baseline evaluation and must be willing to maintain that dose level for the duration of the trial. Willing to discontinue all non-prescription supplements, with the exception of an age-appropriate multivitamin. Women of reproductive age must be willing to use an effective method of contraception for the duration of the trial. Willing to participate in all aspects of trial design including serial blood and cerebrospinal fluid (CSF) collections.",130001 NCT01747135 TrialTroveID-229710,Children; Adults,year(s),year(s),229710,Niemann-Pick Type C,25.0,2.0,"Aged below 2 or above 25 years of age at enrollment in the trial. Subjects will be excluded if their weight would result in an endotoxin level that would exceed 0.2 EU/kg for either the saline or drug dosing. Severe manifestations of NPC1 that would interfere with the patient's ability to comply with the requirements of this protocol. Neurologically asymptomatic patients. Patients who have received any form of cyclodextrin in an attempt to treat NPC1. Treatment with another drug preparation for another medical indication that contains cyclodextrin as an excipient, will not exclude a patient. History of hypersensitivity reactions to cyclodextrin or components of the formulation. Pregnancy or breastfeeding at any time during the study. Patients with suspected infection of the CNS or any systemic infection. Spinal deformity that would impact the ability to perform a lumbar puncture Skin infection in the lumbar region Neutropenia, defined as an absolute neutrophil count (ANC) of less than 1,500. Thrombocytopenia (a platelet count of less than 75,000 per cubic millimeter). Evidence of disturbed circulation of CSF. Contraindication for anesthesia. Prior use of anticoagulants or history/presence of a bleeding disorder with increased risk of clinical bleeding or an international normalized ratio (INR) greater than 2. Patients with clinical evidence of acute liver disease having symptoms of jaundice or right upper quadrant pain. Presence of anemia defined as two standard deviations below normal for age and gender. For subjects 18 years of age and older, the epidermal growth factor receptor (eGFR) is automatically calculated and reported by the NIH CC laboratory utilizing the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine 2009 equation. We will exclude subjects greater than or equal to 18 years of age if eGFR is less than or equal to 60 mL/min/1.73 m2. For subjects < 18 12 years of age, we will utilize the national kidney disease education program (NKDEP) calculator (http://www.nkdep.nih.gov/lab-evaluation/gfr-calculators/children-conventional-unit.shtml). Results are reported as > 75 mL/min/1.73 m2 or lower. We will exclude subjects < 18 years of age if eGFR is less than or equal to 75 15 mL/min/1.73 m2 19. Hematuria on a single urinalysis, as defined by the American Urological Association (AUA) as five or more red blood cells per high-power field (or > 25/micro L) on microscopic evaluation of urinary sediment from a properly collected urinalysis specimen. The patient will not be excluded if 2 subsequent urine specimens are negative for hematuria as defined by the AUA. 20. Proteinuria (1+ protein on urinalysis) unless evaluated and classified as benign by patient s primary medical provider or by NIH nephrology consult or in the context of normal urine protein creatinine ratio and in the absence of clinical symptoms (edema, hypertension). 21. Active pulmonary disease, oxygen requirement or clinically significant history of decreased blood oxygen saturation, pulmonary therapy, or requiring active suction. 22. Patients unable to complete a behavioral audiologic evaluation including pure-tone threshold assessment (500 Hz to 8000 Hz) to monitor for ototoxicity and for whom otoacoustic emissions (OAEs) cannot be reliably obtained at baseline. 23. Patients with ongoing seizures, that are not stable in frequency, type or duration over a 2 month period prior to enrollment, requiring change in dose of antiepileptic medication (other than adjustment for weight) over a 2 month period prior to enrollment, or requiring 3 or more antiepileptic medications to control seizures. 24. Patients, who in the opinion of the investigators are unable to comply with the protocol or have specific health concerns that would potentially increase the risk of participation.",Iii,Both
0,Patients with Amyotrophic Lateral Sclerosis,Patients between 25 and 80 years old Patients diagnosed as 'Possible with lab-supported' or 'Possible' or 'Probable' or 'Definite' ALS according to the World Federation of Neurology El Escorial criteria Patients whose duration of disease is within 5 years from the first diagnosis Patients with ALSFRS-R score within 21 to 46 at screening Patients who can visit to a hospital by walk personally or by protector's help Patients who provide the written consent by oneself or his/her legal representative Patients who has HLA-haplo matched Bone marrow donor,HYNR-CS-Allo-02 NCT03214146 TrialTroveID-305008,Adults; Older Adults,year(s),year(s),305008,Unspecified,80.0,25.0,"Patients who doesn't appropriate to the diagnostic criteria of ALS Patients who doesn't have HLA-haplo-matched bone marrow donor Patients suspected of adverse effect after stem cell injection(patients suspected of malignant tumor, risk group of psychogenic shock, patients with serious hypertension) Patients with ALSFRS-R score below 21 at screening Patients performed Tracheostomy at screening Patients with suspected 20% or less of Forced vital capacity(FVC) at screening Patients who doesn't agree with written consent form by oneself of his/her legal representative Patients who have taken any other drug for clinical trial within the past 3 months at screening entry Patients with epilepsy Patients with severe medical disease Pregnant woman, lactating woman, female patients who has a pregnancy planning or who doesn't agree with adoption of contraception methods proper medically, male patients who doesn't agree with adoption of contraception methods proper to his partner during participating this study Patients with hemorrhagic tendency at screening Patients with a known history of hypersensitivity/allergy to penicillin and streptomycin Patients with severe psychotic diseases (such as alzheimer, schizophrenia excepts slight cognitive dysfunction and secondary emotional disorder)",I,Both
0,Patients with amyotrophic lateral sclerosis(ALS).,"Ages Eligible for Study: 25 Years to 80 Years; Genders Eligible for Study: Both Inclusion Criteria: Patients between 25 and 80 years old Patients who have both signs of lower motor neuron(LMN) and upper motor neuron(UMN) degeneration by clinical, electrophysiological or neuropathologic examination Patients diagnosed as 'Probable' or 'Definite' ALS according to the World Federation of Neurology El Escorial criteria Patients whose duration of disease is within 5 years from the first diagnosis Patients with ALSFRS-R score within 21 to 46 at screening Patients who can visit to a hospital by walk personally or by protector's help Patients who provide the written consent by oneself or his/her legal representative Patients who has HLA-haplo matched Bone marrow donor",HYNR-CS-Allo-01 NCT01758510 TrialTroveID-179974,Adults; Older Adults,year(s),year(s),179974,Delay Disease Progression,80.0,25.0,"Exclusion Criteria: Patients who doesn't appropriate to the diagnostic criteria of ALS Patients who are diagnosed as primary lateral sclerosis(PLS) or progressive muscular atrophy(PMA) Patients suspected of adverse effect after stem cell injection(patients suspected of malignant tumor, risk group of psychogenic shock, patients with serious hypertension) Patients with ALSFRS-R score below 21 at screening Patients performed ventilator or tracheostomy at screening Patients performed gastrostomy at screening Patients unable to assess the efficacy of this clinical trial due to unattainable Pulmonary Functional Test(PFT) or patients with suspected 40% or less of Forced vital capacity(FVC) at screening Patients with finding of myocardial infarction or angina pectoris according to ECG, patients who have been performed Stenting or Bypass operation at screening Patients who have taken any other drug for clinical trial within the past 3 months at screening entry Patients with epilepsy Patients with severe renal dysfunction(serum creatinine=2.0mg/dl) Patients with severe liver dysfunction(ALT, AST, bilirubin=upper limit of normal X 2) Pregnant woman, lactating woman, female patients who has a pregnancy planning or who doesn't agree with adoption of contraception methods proper medically, male patients who doesn't agree with adoption of contraception methods proper to his partner during participating this study Patients with hemorrhagic tendency at screening Patients with virus infection at screening Patients with a known history of hypersensitivity/allergy to penicillin and streptomycin Patients with previous stem cell therapy Patients diagnosed with cancer Patients who have taken any drug that can effect to bone marrow function Patients with any other neurological disease except ALS Patients with psychotic diseases",I,Both
0,Healthy Volunteers,"Able to provide written informed consent. Healthy non-smoking male and female subjects aged 18 to 45 years, inclusive. Health status is determined by physical examination, medical history, no clinical abnormalities in laboratory and urine analyses, normal renal function, liver enzymes less than twice the upper limit of normal (ULN), and electrocardiogram (ECG) with QT interval adjusted for heart rate within normal limits at the screening visit. A body mass index (BMI) of 18 kg/m2 or greater, but less than 36 kg/m2. Agree to use barrier contraceptive methods during the course of the study (hormonal contraceptive alone is not acceptable). Females of child-bearing potential must have a negative urine pregnancy test on Day 1. If post-menopausal female, follicle stimulating hormone (FSH) level > 40 IU/L.",MN-166-HDT-002 NCT04054206 TrialTroveID-355238,Adults,year(s),year(s),355238,(N/A); Healthy subjects; Line of therapy N/A,45.0,18.0,"History of clinically significant drug allergy or anaphylaxis, including known hypersensitivity to Pinatos® or its components. History of any condition(s) which might affect drug absorption, metabolism or excretion. Clinical evidence or a history of clinically significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurologic, or other chronic disease as judged by the Investigator. History of severe psychiatric disease, especially major depression. Severe psychiatric disease is defined as treatment with an antidepressant medication or a major tranquilizer at therapeutic doses for major depression or psychosis, respectively, for at least 3 months at any previous time or any history of the following: a suicidal attempt, hospitalization for psychiatric disease, or a period of disability due to a psychiatric disease. History of severe cardiac disease [e.g., New York Heart Association (NYHA) Functional Class III or IV], myocardial infarction within 6 months, ventricular tachyarrhythmias requiring ongoing treatment, unstable angina or other significant cardiovascular diseases. Estimated creatinine clearance outside the normal range (</= 80 mL/min) at screening. History or other evidence of severe illness or any other conditions which would make the subject, in the opinion of the investigator, unsuitable for the study. Evidence of alcohol and/or drug abuse within one year of screening. Positive results on screen for drugs of abuse or alcohol at screening visit or Day 0. History within 1 year of screening visit, or current habit, of smoking more than 10 cigarettes per day or equivalent (>3 cigars or >3 pipes-full). Donated blood in the past 90 days or have poor peripheral venous access. Platelets < 100,000/mm3, history of thrombocytopenia. Confirmed diagnosis of chronic liver disease, for example, chronic Hepatitis B, Hepatitis C infection, auto-immune, alcoholic or neoplastic liver disease. Positive serostatus for HIV, HCV, or HBV. Currently pregnant or nursing. Male partners of females who are pregnant. History of clinically significant cardiovascular, pulmonary, endocrine, neurological, metabolic, or psychiatric disease. Participation in a clinical study with an investigational drug, biologic, or device within 3 months before receiving study drug. Used any systemic medications, including vitamins and over-the-counter items, during the 14 days (or five times the elimination half-life of the medication, whichever is longer) before receiving study drug or will require their use during the study. Metabolic inducers and herbal preparations, which have been shown to produce metabolic enzyme induction or inhibition, whether as teas or formulations, are prohibited 28 days before dosing. Paracetamol 3000 mg/day will be allowed up to 2 consecutive days before dosing and during the outpatient phase of the study, as needed. Unable to swallow large tablets.",I,Both
1,Patients with amyotrophic lateral sclerosis.,"Male or female subjects age 18 - 80 years, inclusive; Diagnosis of familial or sporadic ALS as defined by the El Escorial-Revised (2000) research diagnostic criteria for ALS [clinically definite, clinically probable, probable-laboratory-supported]; ALS onset of < or =18 months from first clinical signs of weakness prior to screening; If currently using riluzole, subject must be on a stable dose for at least 30 days prior to initiation of study drug; If currently using edaravone, subject should have completed at least 14 days of their initial treatment cycle prior to initiation of study drug; Last documented pulmonary function test result (i.e., slow vital capacity or forced vital capacity) must be greater than or equal to 70% predicted;; Able to swallow study medication capsules; No known allergies to the study drug or its excipients; Received pneumococcal vaccine within 6 years prior to starting clinical trial. Written or verbal informed consent is obtained and willing and able to comply with the protocol in the opinion of the Investigator; Diagnosis of familial or sporadic ALS as defined by the El Escorial-Revised (2000) research diagnostic criteria for ALS [clinically definite, clinically probable, probable-laboratory-supported]; ALS onset of < or = 18 months from first clinical signs of weakness prior to Screening; Documented ALS history of location of disease onset (i.e. bulbar onset, limb onset) A total ALSFRS-R score of at least 35 overall at screening and: a.No more than one of the 12 ALSFRS-R individual component items has a score of 1 or less at screening; b.For limb onset subjects, ALSFRS-R score of = 3 on item #1 (speech), # 2 (salivation) and # 3 (swallowing); ALSFRS-R score progression from onset of the first symptom of weakness to the ALSFRS-R score at Screening of > 0.3 points and < 1 point per month calculated as: ALSFRS-R score at Screening minus ALSFRS-R score at onset of first symptom of weakness divided by number of months since onset of first symptom of weakness. Slow vital capacity > or = 70% of predicted within at screening; Currently on a stable dose of riluzole for at least 30 days prior to initiation of study drug; Females of childbearing potential must use an effective method of contraception throughout the entire study period and for 30 days after study drug discontinuation; Males should practice contraception (e.g. condom use and contraception by female partner) throughout the entire study period and for 30 days after study drug discontinuation; Able to swallow study medication capsules; Subject is willing and able to comply with the protocol assessments and visits, in the opinion of the Investigator; Has no known allergies to the study drug or its excipients; Has received pneumococcal vaccine within 6 years prior to starting clinical trial.",CCR-19-137 COMBAT-ALS EudraCT Number: 2019-003549-14 MN-166-ALS-2301 NCT04057898 TrialTroveID-333564,Adults; Older Adults,year(s),year(s),333564,Delay Disease Progression,80.0,18.0,"Confirmed hepatic insufficiency or abnormal liver function (AST and/or ALT >3 times upper limit of normal); Currently diagnosed with a clinically significant psychiatric disorder or dementia that would preclude evaluation of symptoms; Currently use or treated with parenteral (intramuscular or intravenous) high dose (>25 mg/week) Vitamin B12 within 30 days prior to study drug administration; Poor peripheral venous access that will limit the ability to draw blood as judged by the Investigator; Currently participating, or has participated in a study with an investigational or marketed compound or device within 30 days or 5 half-lives, whichever is shorter, prior to signing the informed consent; Use of tracheostomy or >22/24-hour ventilatory support.",Ii/Iii,Both
0,Healthy Volunteers,"Able to provide written informed consent. Healthy non-smoking male and female subjects aged 18 to 65 years, inclusive. No clinical abnormalities in laboratory and urine analyses. Normal renal function (GFR > 90mL/min). Liver enzymes should be less than twice the upper limit of normal (ULN). Screening electrocardiogram (ECG) with QT interval adjusted for heart rate within normal limits. Agree to use barrier contraceptive methods during the course of the study (hormonal contraceptive alone is not acceptable). Females of child-bearing potential must have a negative pregnancy test on Study Day 1",MN-166-HDT-001 NCT03533387 TrialTroveID-324847,Adults,year(s),year(s),324847,(N/A); Healthy subjects,65.0,18.0,"Known hypersensitivity to Pinatos or its components. Condition(s) which might affect drug absorption, metabolism or excretion. Untreated mental illness, current drug addiction or abuse or alcoholism. Donated blood in the past 90 days or have poor peripheral venous access. Platelets < l00,000/mm3, history of thrombocytopenia. Confirmed diagnosis of chronic liver disease, e.g., chronic Hep. B, Hep. C infection, auto-immune, alcoholic or neoplastic liver disease. Positive serostatus for HIV. Currently pregnant or nursing. History of clinically significant cardiovascular, pulmonary, endocrine, neurological, metabolic, or psychiatric diseases. Received an investigational drug in the past 30 days. Unable to swallow tablets",I,Both
0,Subjects with Amyotrophic Lateral Sclerosis (ALS). ALS participants with upper motor neuron bur-den(UMNB) scores >=25 and mixed/ high binding affinity for (11 C)PBR28,"Subjects must be diagnosed as having possible, probable, probable-laboratory supported, or definite ALS, either sporadic or familial according to modified El Escorial criteria. Age 18 or above, able to provide informed consent, and safely comply with study procedures. Vital capacity (VC) of at least 50% predicted value for gender, height and age at screening visit, or in the opinion of the study physician, able to safely tolerate study procedures. (Not applicable to flexible arm) Subject must be able to swallow oral medication at the Baseline Visit and expected to be able to swallow the capsules throughout the course of the study. Subject must not have taken riluzole for at least 30 days, or be on a stable dose of riluzole for at least 30 days, prior to screening (riluzole-naïve participants are permitted in the study). (Not applicable to flexible arm) Women must not be able to become pregnant (e.g. post menopausal, surgically sterile, or using adequate birth control) for the duration of the study and 3 months after study completion. Males should practice contraception for the duration of the study and 3 months after completion. Ability to safely lie flat for 90 min for PET procedures in the opinion of the study physician. (Not applicable to flexible arm) High or mixed affinity to bind TSPO protein (Ala/Ala or Ala/Thr) (see section 7.2.1). (Not applicable to flexible arm) Upper motor Neuron Burden (UMNB) Score > or =25 (out of 45) at screening visit. (Not applicable to flexible arm)",MN-166-ALS-1202 NCT02714036 TrialTroveID-267747,Adults; Older Adults,year(s),,267747,Delay Disease Progression,,18.0,"Abnormal liver function defined as AST and/or ALT > 3 times the upper limit of the normal. Renal insufficiency as defined by a serum creatinine > 1.5 times the upper limit of normal. The presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair ability of the participant to provide informed consent, according to PI judgment. Clinically significant unstable medical condition (other than ALS) that would pose a risk to the participant if they were to participate in the study. History of HIV, clinically significant chronic hepatitis, or other active infection. Active inflammatory condition of autoimmune disorder (Not applicable to flexible arm). Females must not be lactating or pregnant. Active participation in another ALS clinical trial or exposure to an off label ALS experimental treatment within 30 days of the Baseline Visit (Not applicable to flexible arm) Exposure to immunomodulatory medications within 30 days of the Baseline Visit. (Not applicable to flexible arm) Any contraindication to undergo MRI studies such as History of a cardiac pacemaker or pacemaker wires Metallic particles in the body Vascular clips in the head Prosthetic heart valves Claustrophobia (Not applicable to flexible arm) Radiation exposure that exceeds the site's current guidelines (Not applicable to flexible arm) EKG finding of QTc prolongation > 450 ms for males and > 470 ms for females at screening or baseline. Not on any prohibitive medication or known QT prolonging medication.",Iii,Both
0,"Subjects with early advanced stage amyotrophic lateral sclerosis (ALS) with and without non-invasive ventilation (NIV). Per September 02, 2015 amendment: Advanced ALS patients with NIV support.","Ages Eligible for Study: 18 Years to 80 Years; Genders Eligible for Study: Both Inclusion Criteria: Written informed consent is obtained and willing and able to comply with the protocol in the opinion of the Investigator. Male or female subjects ages > or = 18 to 80 years, inclusive Diagnosis of familial or sporadic ALS as defined by the El Escorial-Revised (2000) research diagnostic criteria for ALS [Clinically Definite, Clinically Probable, Probable-Laboratory-Supported] Diagnosis of ALS with onset of less than or equal to 5 years from first clinical weakness Slow vital capacity > or = 60% of predicted within 1 month prior to Treatment Day 1 Currently on a stable dose of riluzole for at least 30 days prior to initiation of study drug. Subjects not currently taking riluzole will be started on 50 mg qd for the first 7 days followed by 50 mg bid for the following 21 days prior to screening. Patients may be screened during this time period but not started on study drug until they are on a stable dose of riluzole. All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (i.e., bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing). Females of childbearing potential must use an effective method of contraception throughout the entire study period and for 30 days after study drug discontinuation. Females must not be lactating or pregnant at Screening or Baseline (as documented by a negative beta-human chorionic gonadotropin [ß-hCG] (or human chorionic gonadotropin [hCG]). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug. Males should practice contraception as follows: condom use and contraception by female partner. Able to swallow study medication capsules. Subject is willing and able to comply with the protocol assessments and visits, in the opinion of the study nurse/coordinator and the Investigator. Has no known allergies to the study drug or its excipients. Has received 23-valent pneumococcal vaccine within 4 years prior to starting clinical trial. Advanced ALS group will follow the same inclusion as the early ALS subjects with the exception of the following: Diagnosis of ALS with onset of < or = 10 years from first clinical weakness On Non-invasive ventilator with Non-invasive pressure [P-NIV] or volume [V-NIV] cycled ventilation stable use for > or = 4 hours daily for 1 month prior to Treatment Day. Slow vital capacity > or = 20% of predicted (Knudsen 1983) within 1 month prior to Treatment Day 1 Able to swallow study medication capsules or have gastrostomy tube access for delivery of contents of medication capsule.",IBU-ALS-1201 MN-166-ALS-1201 NCT02238626 STEP-IBUDILAST-ALS-DB-OLE-1 TrialTroveID-215483,Adults; Older Adults,year(s),year(s),215483,Delay Disease Progression,80.0,18.0,"Exclusion Criteria: Use of tracheostomy, tracheostomy invasive mechanical ventilation [TIMV]. Greater than 3% predicted loss in post-diagnosis vital capacity per month or a greater than 1 unit loss in post diagnosis ALSFRS-R total score per month [ exclusive of loss due to beginning use of assistive devices] Confirmed hepatic insufficiency or abnormal liver function (AST and/or ALT greater than 3 times the upper limit of the normal range) Renal insufficiency as defined by a serum creatinine greater than 1.5 times the upper limit of normal range Currently has a clinically significant psychiatric disorder or dementia which would preclude evaluation of symptoms. Has a clinically significant medical condition (other than ALS) including the following: neurological, metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urological disorder, or central nervous system infection that would pose a risk to the subject if they were to participate in the study or that might confound the results of the study. History of malignancy < 5 years prior to signing the informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. ECG finding of QTcB prolongation > 450 ms for males and > 470 ms for females at screening History of HIV (human immunodeficiency virus), clinically significant chronic hepatitis, or other active infection Subject has a history of stomach or intestinal surgery or any other condition that could interfere with or is judged by the Investigator to interfere with absorption, distribution, metabolism, or excretion of study drug. Subject has a history of alcohol or substance abuse (DSM-IV-TR criteria) within 3 months prior to screening or alcohol or substance dependence (DSM-IV-TR criteria) within 12 months prior to screening. Subject has poor peripheral venous access that will limit the ability to draw blood as judged by the Investigator. Currently participating, or has participated in, a study with an investigational or marketed compound or device within 3 months prior to signing the informed consent. Unable to cooperate with any study procedures, unlikely to adhere to the study procedures and keep appointments, in the opinion of the Investigator. Advanced ALS group will follow the same exclusion as the early ALS subjects with the exception of the following: Use of tracheostomy, tracheostomy invasive mechanical ventilation [TIMV]. No rate of progression exclusion.",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis,"Diagnosis of ALS classified as Clinically Probable ALS or Clinically Definite ALS according to the El Escorial Revised Criteria4 ALS onset < or = 18 months from Screening Male or female aged 20 to 80 years old (inclusive) ALSFRS-R > or = 30 SVC > or = 60% of predicted at Screening Willing and able to provide informed consent Concurrent medications riluzole and edaravone are permitted as long as the regimen is stable for at least 4 weeks prior to randomization and is expected to remain unchanged during the course of the study Able to swallow tablets Has been stable on medications that affect the CNS, for at least 4 weeks (including antidepressants, hypnotics and antipsychotics) and dose is not expected to change during the trial Willing to abstain from benzodiazepine or other CNS depressant treatment for 24 hours prior to each clinic visit and night-time hypnotics for 8 hours prior to each clinic visit Negative serum pregnancy test at Screening, for female subjects of childbearing potential Male subjects: Male subjects with female partners of childbearing potential are eligible to participate if they agree to ONE of the following methods of contraception from 21 days before the first dose of IMP through 4 months after the last dose of the IMP: Abstinence from penile-vaginal intercourse as their usual and preferred lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent Use of a male condom plus partner use of a contraceptive method with a failure rate of < 1% per year when having penile-vaginal intercourse with a woman of childbearing potential who is not currently pregnant. In addition male subjects must refrain from donating sperm for the duration of the study and for 4 months after the last dose of the IMP. Female subjects: A female subject is eligible to participate if she is not pregnant and/or breastfeeding. Females of childbearing potential must agree to use a highly effective method of contraception consistently and correctly during the treatment period and for at least 3 months after the last dose of IMP. Highly effective methods of contraception include, combined hormonal (estrogen and progestogen containing) contraception, which may be oral, intravaginal, or transdermal, progestogen-only hormonal contraception associated with inhibition of ovulation, which may be oral, injectable, or implantable, placement of an intrauterine device, placement of an intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner and true sexual abstinence, if it is the chosen life style of the subject. Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only and the lactational amenorrhea method are not acceptable methods of contraception. Female condom and male condom should not be used together",NCT04505358 PU-AD-SD-0202 TrialTroveID-381048,Adults; Older Adults,year(s),year(s),381048,Delay Disease Progression,80.0,20.0,"Dependence on invasive or non-invasive mechanical ventilation (excluding continuous positive airway pressure for sleep apnea) Has current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterological, respiratory, endocrinologic, neurologic (other than ALS), psychiatric, infectious, immunologic or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses of safety and pharmacologic effect in this study Has a life expectancy of <1 years Has had a history within the last 5 years of a serious infectious disease affecting the brain or head trauma resulting in protracted loss of consciousness Has a history within the last 5 years of a primary or recurrent malignant disease with the exception of resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ or in situ prostate cancer with a normal prostate specific antigen post treatment Has a known history of human immunodeficiency virus, clinically significant multiple or severe drug allergies or severe post treatment hypersensitivity reactions Has a ""yes"" answer to Columbia Suicide Severity Rating Scale (C-SSRS) suicidal ideation item 4 or 5, or any suicidal behavior assessment within 6 months of Screening, or has been hospitalized or treated for suicidal behavior in the past 5 years before Screening Has a history of chronic alcohol or drug abuse/dependence within the past 5 years Transient ischemic attack or stroke or any unexplained loss of consciousness within 1 year prior to Screening History of bleeding disorder or predisposing conditions, blood clotting or clinically significant abnormal results on coagulation profile at Screening, as determined by the investigator History of unstable angina, myocardial infarction, chronic heart failure (New York Heart Association Class III or IV) or clinically significant conduction abnormalities (e.g., unstable atrial fibrillation) within 1 year prior to Screening Clinically significant 12 lead electrocardiogram (ECG) abnormalities, as determined by the investigator Indication of impaired liver function as shown by an abnormal liver function profile at Screening (e.g., repeated values of aspartate aminotransferase [AST] and alanine aminotransferase [ALT] > or = 2 x the upper limit of normal [ULN] and/or indication of impaired renal function at Screening) (e.g., repeated values of creatinine and blood urea nitrogen [BUN] > or =1.5 x ULN or estimated glomerular filtration rate [GFR] < 45 mL/minute/1.73 m2 and corroborating medical history and physical examination) Any contraindications to lumbar puncture (LP), e.g., increased bleeding risk (platelet count < 100,000/µL, coagulopathies, anticoagulant drugs, antiplatelet therapy), lumbar spine deformity that might interfere with the procedure, evidence on magnetic resonance imaging (MRI) contraindicating LP, risk for cerebral herniation, space occupying lesion with mass effect, abnormal intracranial pressure due to increased CSF pressure, Arnold Chiari malformation, local infections at the puncture site and subject refusal of LP; abnormalities in the Screening CSF profile that are considered by the investigator to be clinically significant are exclusionary Any major surgery or trauma within 12 weeks of Screening or during the Screening Period or any surgery planned during the study Has active ocular condition, that in the opinion of the investigator, may alter visual acuity during the course of the study Use of any drugs that are strong inhibitors of cytochrome (CYP) 450 (2D6 or 2C19) within 7 days or 5 half-lives of the inhibitor (whichever is longer), prior to administration of the first dose of IMP and/or plan to use throughout the study Has taken other investigational drugs or participated in any clinical study within 30 days or 5 half-lives (if known) of the investigational drug, whichever is longer, prior to first dose of IMP in this study or is currently participating in another clinical study Other unspecified reasons that, in the opinion of the investigator or Samus and/or its delegated medical monitor, place the subject at risk or make the subject unsuitable for the study or unable or unwilling to comply with the requirements of the study Female subject of childbearing potential with positive pregnancy test or who is lactating History or presence of conditions, which in the judgment of the investigator, are known to interfere with the absorption distribution, metabolism or excretion of drugs, such as prior surgery or gastrointestinal dysfunction that may affect drug absorption (e.g., gastric bypass surgery, gastrectomy) History of serious head injuries, unexplained syncope, loss of consciousness, CNS disease or dementia Prior exposure to PU-AD or related compounds Significant blood loss (> 450 mL) or has donated one or more units of blood or plasma within 6 weeks prior to study participation",Ii,Both
0,Patients with bulbar-onset amyotrophic lateral sclerosis (ALS),"1. Diagnosis of probable or definite ALS according to the revised El Escorial criteria, with bulbar onset of disease, familial or sporadic form, 2. Onset of symptoms = 18 months prior to screening, as reported by the patient, 3. Adult males or females, aged at least 18 years old, 4. SVC > 60% of predicted value for age and sex, 5. ALSFRS-R score ≥ 36 6. Treatment with riluzole 100 mg/day, at stable dose since at least one month and well tolerated, 7. Male or female patient of childbearing potential who agrees to use highly effective mechanical contraception methods (condom, sexual abstinence, intrauterine device, bilateral tubal occlusion, vasectomised partner) throughout the study, and for 3 months after the end of the treatment, 8. Patient who read, understood and signed the informed consent form (ICF), 9. Patient who is willing to adhere to the study visit schedule and is capable to understand and comply with protocol requirements.",EudraCT Number: 2021-003875-32 NCT05508074 P288ALS Study TRIALS TRIALS Protocol TRIALS study TrialTroveID-403590,Adults; Older Adults,year(s),,403590,Delay Disease Progression,,18.0,"Known other significant neurological disease(s), Serious illness(es) or medical condition(s) (e.g. unstable cardiac disease, cancer, hematologic disease, hepatitis or liver failure, renal failure) that is not stabilised or that could require hospitalisation and may jeopardise the participation in the study, Abnormal renal function at screening defined as estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m2, Abnormal liver function at screening defined as total bilirubin levels >1.5 ULN, and/or AST and/or ALT >3 ULN, Neutropenia (ANC <1.5 x 109/L) at screening, Other causes of neuromuscular weakness, Non progressive or very rapidly progressing ALS (ALSFRS-R decline from disease onset to randomisation ≤ 0.1 / month or ≥ 1.2 / month)11, Non-invasive ventilation, Tracheotomy, Weight loss ≥ 10% compared to weight at symptoms onset as declared by the patient or BMI <18 kg/m2 at screening, Dementia or other severe active psychiatric illness, including suicidal ideation assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS), Patient with a significant pulmonary disorder not attributed to ALS or who require treatments that might complicate the evaluation of the effect of ALS on respiratory function, Patient treated by edaravone for ALS, Patient using unauthorised concomitant treatments, namely moderate or strong inhibitors or inducers of CYP1A2, strong inhibitors or inducers of CYP2D6 or 2C19 and strong inhibitors of OCT2, as listed in Section 6.2. Combined oral contraceptives containing ethinylestradiol are forbidden concomitant medications, Smoker of > 10 cigarettes per day (e-cigarettes and nicotine patches are permitted), Known hypersensitivity to any of the ingredients or excipients of the IMPs, Pregnant, lactating women, Patient who participated in another trial of investigational drug(s) within 30 days prior to randomisation, or 5 half-lives of the previous investigational product, whichever is longer, Patient who has forfeited their freedom by administrative or legal award, or who is under guardianship or under limited judicial protection.",Ii,Both
0,Healthy male subjects,"Healthy male 18 to 40 years of age inclusive, Caucasian. Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests, vital signs and ECG. AST, ALT, alkaline phosphatase and bilirubin = 1.5xULN (isolated bilirubin>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%). ECG (12 leads) normal (120<PR<200ms; QRS<120ms; QTcF<450ms) and/or without clinically relevant impairments as judged by investigator. Non-smoker Negative screen for alcohol and drugs of abuse at screening and admission No history of psychiatric disorders assessed by the psychological interview and the Mini International Neuropsychiatric Interview (MINI). Body mass index (BMI) between 19 and 27 Subject with female partners of child bearing potential must agree to use one of the contraception methods listed in Section 6.6.1 (Contraception requirements). This criterion must be followed from the time of the first dose of study medication until the follow up visit (for female partners) and with an additional period of 90 days (for subjects themselves). Willing and able to understand and sign an approved Informed Consent Form, Able to understand the protocol and to come to the visits, Who is, in the judgement of the investigator likely to be compliant during the study, Subject registered in the VRB file (volontaires se prêtant à des recherches impliquant la personne humaine)",EudraCT Number: 2018-000443-29 NCT03610334 P188 TrialTroveID-329360,Adults,year(s),year(s),329360,Healthy subjects,40.0,18.0,"History of asthma, anaphylaxis or anaphylactoid reactions, severe allergic responses Known allergy to any component of IFB-088 oral capsule or its placebo (HPMC or cellulose microcrystalline) History of major medical, psychiatric illness or surgery which, in the judgment of the investigator, puts them 'at risk' or is likely to modify their handling of the study drug, Acute or chronic systemic disease or disorder (respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine) Renal insufficiency defined by a Glomerular Filtration Rate (GFR) < 80 ml/min/1.73m2 (according the definition of the renal function EMACHMP/EWP/225/02 History of nephritic colic and/or renal calculi History of drug abuse and/or regular use of tobacco- or nicotine-containing products > 5/day within three months of the study History of alcohol consumption exceeding, (on average 21 drinks/week for men) within 6 months of the first dose of study medication Drinking excessive amounts of tea, coffee, chocolate and/or beverage containing caffeine (> 4 cups / day) Vital signs with a clinically significant abnormality at screening, ECG with a clinically significant abnormality at screening, Laboratory test values outside the clinically acceptable 'normal range' for healthy volunteers at screening, Positive HIV, Hepatitis B or Hepatitis C at screening, Positive urine drug test or positive breath alcohol test at screening or at admission to the clinical unit Any medication (including St John's Wort) within 14 days before administration, or within 5 times the elimination half-life of that drug, whichever is the longest (except paracetamol) Have used any investigational drug or participated in any clinical trial within 90 days prior to screening Unable to refrain from consumption of grapefruit or grapefruit juice within 7 days prior to the first dose of study medication Unwillingness to abstain from sexual intercourse with pregnant or lactating women or to use a condom and spermicide and another form of contraception (e.g., IUD, birth control pills taken by female partner, diaphragm with spermicide) if engaging in sexual intercourse with a woman who could become pregnant until discharge from the study and during 90 additional days Subjects unlikely to co-operate in the study, and/or poor compliance anticipated by the investigator, Subject being in the exclusion period of a previous trial, Subject having exceeded the earnings for the last 12 months, Subject who could not be contacted in case of emergency, Subject refusing to give written informed consent, Subject who has received blood or plasma derivatives in the year preceding the study, Subject who has given blood within the past 3 months or has planned to give blood or sperm within the 90 days following the study, Subject who has forfeited their freedom by administrative or legal award, or who is under guardianship or under limited judicial protection.",I,Male
0,,"- Medical inferral, suspicion metabolic disease incl epilepsy and their relatives",2008/351-31 NCT06376279,,,,513537,,,,- Disease other than metabolic,Other,Both
0,Patients with amyotrophic lateral sclerosis (ALS).,"Patients > or =18 years and who have provided written informed consent to participate in the study Prior to trial entry patients will have a definite diagnosis of ALS according to El Escorial Criteria. All patients will demonstrate either: presence of Upper Motor Neuron (UMN) (increased tone, brisk reflexes) as well as Lower Motor Neuron (LMN) (weakness, wasting and fasciculation) signs in the bulbar region and at least two of the other spinal regions (cervical, thoracic or lumbosacral) or presence of UMN and LMN signs in all three spinal regions (cervical, thoracic or lumbosacral) Electrophysiological tests (Electromyography (EMG) / Nerve Conduction Study (NCS)) that supports the diagnosis of Motor Neurone Disease (MND) and to exclude mimic disorders Forced Vital Capacity (FVC) > or = 50% of predicted value for gender, height and age at screening and a mean Sniff Nasal Inspiratory Pressure (SNIP) > or = 50% of predicted value for age Adequate haematological function (Hb > or = 10g/dl absolute neutrophil count > or =1.5x109/L and a platelet count > or = 60 x109/L International Normalised Ratio (INR) < or = 1.5, Activated Partial Thromboplastin Time (aPTT) 30 - 40 seconds, Prothrombin Time (PT) 11-13.5 seconds Patient willing and able to comply with schedule visits, treatment plan and other study procedures. Patients taking Riluzole must have discontinued treatment > or = 28 days prior to study entry (and following consent to take part in the study) Women Of Child Bearing Potential (WOCBP) who agree to use highly effective means of contraception (as defined in the Heads of Medicines Agencies_Clinical Trials Facilitation Group (HMA_CTFG) guideline (see Appendix 8) and in combination with a barrier contraception method (condom, diaphragm or cap) for the entirety of the study",EudraCT Number: 2018-000668-28 ISRCTN83738603 NCT03705390 RG_17-250 TrialTroveID-331524,Adults; Older Adults,year(s),,331524,Unspecified,,18.0,"1. Patients classified as either probable or possible ALS according to El Escorial Criteria. 2. Subjects in whom other causes of neuromuscular weakness have not been excluded 3. Assisted ventilation of any type within 3 months before the screening visit or at screening 4 Patients requiring Radiologically Inserted Gastrostomy (RIG) or Percutaneous Endoscopic Gastroscopy (PEG) feeding 5. Involvement in any other interventional study involving use of another IMP or biological product, within 3 months of screening 6. Any use of antioxidants, edaravone, tirasemtiv or CK-2127107 within 1 month before the screening visit 7. Any botulinum toxin use within 3 months before the screening visit. 8. Any form of stem cell or gene therapy for the treatment of amyotrophic lateral sclerosis (ALS) 9. Neuroimaging of brain and cervical spine with Magnetic Resonance imaging (MRI) indicating compressive myelopathy as an alternate diagnosis 10. Laboratory examinations including Acetylcholine receptor (AChR) antibodies and Muscle Specific Kinase (MuSK) antibodies to exclude Bulbar onset Myasthenia gravis from Bulbar onset Motor neuron disease as an alternate diagnosis and Antinuclear Antibodies (ANA), Anti-neutrophil cytoplasmic antibodies (ANCA), Extractable Nuclear Antigen (ENA) antibodies, Creatine Kinase (CK), electrophoresis and immunoglobulin indicating an alternate diagnosis for muscle disease like Myositis 11. Abnormal liver function defined as Aspartate Transaminase (AST) and/or Alanine Transaminase (ALT) >3 times upper limit of normal 12. Any head trauma, intracranial or spinal surgery within 3 months of trial entry 13. Patients who have had recurrent falls will be excluded to reduce the risk of intracerebral haemorrhage with this IMP 14. Current use of an anticoagulant e.g Warfarin, Aspirin, Clopidogrel, any novel anticoagulants (NOAC)s or low molecular weight subcutaneous heparin 15. Uncontrolled severe hypertension defined as systolic blood pressure (SBP) > or = 220 mmHg or diastolic blood pressure (DBP) > or = 120 mmHg 16. Current or previous history of heparin-induced thrombocytopenia 17. Active peptic ulcer disease 18. Known hypersensitivity to sulphur 19. Severe liver insufficiency 20. Patients with evidence of major psychiatric illness, significant cognitive impairment or clinically evident dementia that may interfere with the patients' ability to comply with study procedures 21. Pulmonary illness (e.g asthma or Chronic Obstructive Pulmonary Disease (COPD)) requiring regular treatment 22. Patient judged to be actively suicidal by the investigator during 3 months before the screening visit 23. Subjects with a diagnosis of another neurodegenerative disease (e.g. Parkinson`s disease, Alzheimer's disease and Frontotemporal dementia)",Ii,Both
0,Subjects with Amyotrophic Lateral Sclerosis (ALS),"1. Willing and able to give informed consent for participation in the study. 2. Clinical diagnosis of Amyotrophic Lateral Sclerosis. 3. Male or female patients between 18-80 years of age (inclusive). 4. ALS of intermediate progression rate. 5. Forced Vital Capacity (FVC) > or = 65 % of predicted value for gender, height and age at screening. 6. Evaluated with ALSFRS-R and Norris clinical rating scales for at least the past 4 weeks before study drug administration 7. Laboratory analyses within normal ranges for PK-INR, fibrinogen, Von Willebrand factor and activated partial thromboplastin time (APTT) at screening.","1.2, 2018-05-15 1.5, 2019-06-25 EudraCT Number: 2017-005065-47 NCT03613571 TM-105 TrialTroveID-324533",Adults; Older Adults,year(s),year(s),324533,Delay Disease Progression,80.0,18.0,"Unable to understand information about the study or are expected not to collaborate with the study team. Concurrent serious disease, other than ALS. Pregnancy. Patients of child-bearing potential not willing to use adequate double contraception with <1% failure rate after the screening visit until the last visit. Addiction to drugs or alcohol. Confirmed HIV, hepatitis B or hepatitis C. Known bleeding disorders or abnormal bleeding events. Treatment with anticoagulant drugs warfarin and novel oral anticoagulants (NOAC) within the last 14 days prior to screening. Treatment with Riluzole or Lamotrigine within the last 28 days prior to study drug administration. Hypersensitivity to dextran sulfate. Poor venous access Patients with clinically significant abnormal prothrombin complex-international normalised ratio (PK-INR), fibrinogen, von Willebrand factor and APTT at screening",Ii,Both
1,Patients with amyotrophic lateral sclerosis.,"Patients diagnosed with sporadic or familial ALS corresponding to the Awaji criteria categories of possible, probable, or definite. Patients rated as 1, 2, or 3 according to Japan ALS severity classification. Patients within 2 years of the initial diagnosis. Patients whose age is from 30-80 years. Patients who have given written consent to participate in this study after receiving sufficient explanation.",ALSI vig CRB4180007 jRCTs041190028 TrialTroveID-411490,Adults; Older Adults,year(s),year(s),411490,Delay Disease Progression,80.0,30.0,"Patients diagnosed with multifocal motor neuropathy. Patients predominantly exhibiting bulbar symptoms. Patients with <70% forced vital capacity. Patients who refuse or are unable to undergo a lumbar puncture. Patients who started to take, Discontinued, Or Changed The Dosage Of Riluzole Within 4 Weeks Prior To Giving Informed Consent To Inclusion In The Study. Patients Receiving Or Discontinued Edaravone Therapy Within 4 Weeks Prior To Giving Informed Consent. Patients With A Neuroimmunological Disease, Including MS, MG, and CIDP. Patients with a past history of angina pectoris, myocardial infarction, or heart failure. Patients complicated by or receiving treatment for malignancy or infectious disease. Patients with a manual muscle testing score of 5 (normal strength) for 36 muscles. Patients with IgA deficiency. Patients with past history of hypersensitivity to Venoglobulin IH. Patients who received any other investigational agent within 12 weeks To Giving Informed Prior Consent. Patients Determined To Be Unsuitable For The Study By The Primary Investigator Or A Sub-Investigator.",Iv,Both
0,"31 consecutive patients with progressive, focal-onset LMN limb weakness, without evidence of clinical upper motor neuron signs, sensory, respiratory or bulbar involvement, or evidence of motor nerve conduction block on electrodiagnostic studies.",,TrialTroveID-198313,,,,198313,Delay Disease Progression,,,,Ii,
0,"Patients diagnosed with ALS by el-Escorial Criteria, ages 20-80 with troublesome sialorrhea","Inclusion criteria are as follows: For ALS: 1. Patients diagnosed with ALS by el-Escorial Criteria, ages 20-80 with troublesome sialorrhea as defined below**.**Troublesome sialorrhea is defined as grade 3 or more (grade 3 is marked excess of saliva with some drooling) or more on the UPDRS Part 2 Sialorrhea grading scale:[33] (Appendix 1) 1.Swallowing function: FOIS scale* 5 or greater (see appendix 1 for scale) 2.If patients have been treated with other medications for sialorrhea earlier, they should be off the medications at least 4 weeks prior to the baseline evaluation. 3.If they are on other medications for sialorrhea at the time of the baseline evaluation, the doses will be held stable throughout the period of the study. 4.Women of child bearing age will need to be on a reliable method of birth control for the duration of the study.",2011P-000304 2011P00304 NCT01565395 TrialTroveID-262397 Xeomin 2012,Adults; Older Adults,year(s),year(s),262397,Comorbidity in ALS,80.0,20.0,"For both PD and ALS: 1.Current use of Coumadin 2.Concurrent significant medical illness. 3.History of myasthenia gravis or Lambert-Eaton Syndrome 4.Ongoing substance abuse 5.History of unreliable follow-up 6.Past use of Xeomin or other botulinum toxin preparations 7.Cognitive impairment, defined as a score = 23/30 on the Mini Mental Status Exam.",Ii,Both
0,People with Advanced Cognitive Impairment,"Genders Eligible for Study: Both Inclusion Criteria: Severe cognitive impairment (complete dependency in all activities of daily living (ADLs) Diagnosis of Alzheimer's disease, vascular dementia,or frontotemporal dementia Score> 3 on the paratonic assessment instrument, with paratonic rigidity in an arm(s) interfering in the provision of care",NCT02212119 NT-036 TrialTroveID-214357,Older Adults,,,214357,Frontotemporal Dementia; Severe; Vascular Dementia,,,"Exclusion Criteria: Alternate etiologies for increased tone Botulinum toxin 6 months preceding the study Exclusion criteria included alternate etiologies for increased tone such as Parkinsonism, dystonia, territorial strokes or other focal neurological deficits, fixed contractures of the affected limb (assessed clinically as no mobility on passive range of motion), or injection with Botulinum toxin in the preceding 6 months",Ii,Both
0,"Patients with Parkinson's Disease (PD)/Parkinsonism, ALS, Multiple Systems Atrophy (MSA), or Progressive Supranuclear Palsy (PSP). Parkinson's Disease patients (n =10), with normal cognition, no severe dysphagia.","Ages Eligible for Study: 18 Years to 90 Years; Genders Eligible for Study: Both Inclusion Criteria: Hypothesis: Xeomin injections into the parotid and submandibular glands are safe and effective in the treatment of troublesome sialorrhea in patients with PD/Parkinsonism and ALS. Inclusion criteria are as follows: For ALS: 1. Patients diagnosed with ALS by el-Escorial Criteria, ages 20-80 with troublesome sialorrhea. For PD/ Parkinsonism: 1. PD, Multiple Systems Atrophy (MSA), or Progressive Supranuclear Palsy (PSP) diagnosed by clinical criteria, ages 20-80 with troublesome sialorrhea as defined below Sialorrhea that patients or their families or treating physicians think is troublesome -Swallowing function: Functional Oral Intake Scale (FOIS)* of 5 or greaterr. -If patients have been treated with other medications for sialorrhea earlier, they should be off the medications at least 4 weeks prior to the baseline evaluation -If they are on other medications for sialorrhea at the time of the baseline evaluation, the doses will be held stable throughout the period of the study. -Women of child bearing age will need to be on a reliable method of birth control for the duration of the study. - Normal cognition, no severe dysphagia were included.",2011P-000304 2011P00304 NCT01653132 TrialTroveID-164671 Xeomin 2012,Adults; Older Adults,year(s),year(s),164671,(N/A); Non-motor symptoms/comorbidities; Symptom relief; Unspecified PSP,90.0,18.0,"Exclusion criteria For PD: a.Current use of Coumadin b.Concurrent significant medical illness c.History of myasthenia gravis or Lambert-Eaton Syndrome d.Ongoing substance abuse e.History of unreliable follow-up f.Past use of Xeomin® or other botulinum toxin preparations g.Cognitive impairment, defined as a score = 23/30 on the Mini Mental Status Exam",Ii,Both
0,Patients with urate elevation in sporadic or familial amyotrophic lateral sclerosis,"Age 18-85. Sporadic or familial ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria (Appendix 1). Slow vital capacity (SVC) .> or = 60% of predicted for age, height, and gender at the Screening Visit. Capable of providing informed consent and following trial procedures. Serum urate < 5.5 mg/dL at screening (i.e. below the population median serum urate levels). Women must not be able to become pregnant (e.g. post menopausal, surgically sterile, or using adequate birth control methods) for the duration of the study and 3 months after study completion. Adequate contraception includes: abstinence, hormonal contraception (oral contraception, implanted contraception, injected contraception or other hormonal (patch or contraceptive ring, for example) contraception), intrauterine device (IUD) in place for > or = 3 months, barrier method in conjunction with spermicide, or another adequate method. Is able and willing to participate in the Mobile app study procedures.",NCT03168711 SURE-ALS2 TrialTroveID-294453,Adults; Older Adults,year(s),year(s),294453,Delay Disease Progression,85.0,18.0,"History of urolithiasis. Urine pH < 5.5 at screening (as acidic urine is a major determinant of uric acid urolithiasis). History of gout. History of stroke or myocardial infarction. History of symptomatic coronary artery disease (e.g. angina pectoris) or symptomatic peripheral arterial disease within 1 year prior to Screening. Symptomatic congestive heart failure with a documented ejection fraction below 45%. Poorly controlled arterial hypertension (SBP > 160mmHg or DBP > 100mmHg at Screening). Women who are pregnant or lactating. The presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair ability of the subject to provide informed consent, according to Site Investigator judgment, or a history of active substance abuse within the prior year. Anything that, in the opinion of the Site Investigator, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study. Use of the following within 30 days prior to Screening: inosine, allopurinol, probenecid, more than 300mg vitamin C daily (note that a subject may take a standard multivitamin up to one tablet or capsule daily). Use of thiazides is permissible as long as the subject is on a stable dose from 1 week prior to Screening. Known hypersensitivity or intolerability to inosine. Renal insufficiency as defined by eGFR < 60 mL/min/1.73m2 at the time of screening.",Ii,Both
0,"People who meet the El Escorial criteria of possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS.","Ages Eligible for Study: 18 Years and older; Genders Eligible for Study: Both Inclusion Criteria: Age 18 years or older. Sporadic or familial ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria (Appendix 1). Capable of providing informed consent and following trial procedures. Serum urate < or=5.5 mg/dl at screening (i.e. below the population median serum urate levels). Willingness to undergo magnetic resonance spectroscopy (MRS) at Baseline and at Week 12 of the study. Women must not be able to become pregnant (e.g. post menopausal, surgically sterile, or using adequate birth control methods) for the duration of the study and 3 months after study completion. Adequate contraception includes: abstinence, hormonal contraception (oral contraception, implanted contraception, injected contraception or other hormonal (patch or contraceptive ring, for example) contraception), intrauterine device (IUD) in place for >or= 3 months, barrier method in conjunction with spermicide, or another adequate method. Subjects on a stable dose of riluzole and those not taking riluzole, and women of child-bearing age at screening are eligible for inclusion as long as they meet specific protocol requirements.",701 NCT02288091 TrialTroveID-220578,Adults; Older Adults,year(s),year(s),220578,Unspecified,80.0,18.0,"Exclusion Criteria: History of urolithiasis. Urine pH <or= 5.5 at screening (as acidic urine is a major determinant of uric acid urolithiasis). Urate crystalluria at Screening. History of gout. History of stroke or myocardial infarction. History of symptomatic coronary artery disease (e.g. angina pectoris) or symptomatic peripheral arterial disease within 1 year prior to Screening. Symptomatic congestive heart failure with a documented ejection fraction below 45%. Poorly controlled arterial hypertension (SBP>or=160mmHg or DBP>or=100mmHg at Screening). Contraindications to undergo magnetic resonance spectroscopy (MRS) at Baseline and at Week 12 of the study such as history of claustrophobia, inability to lie flat for approximately one hour, or metal implants (metal pins or plates, extensive non-removable dental work, cerebral aneurysm clips, pacemaker). Women who are pregnant or lactating. The presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair ability of the subject to provide informed consent, according to PI judgment, or a history of active substance abuse within the prior year. Anything that, in the opinion of the investigator, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study. Use of the following within 30 days prior to Screening: inosine, allopurinol, probenecid, more than 300mg vitamin C daily (note that a subject may take a standard multivitamin up to one tablet or capsule daily). Use of thiazides is permissible as long as the subject is on a stable dose from 1 week prior to Screening. Known hypersensitivity or intolerability to inosine.",I,Both
0,"Patients diagnosed as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis","Japanese with 20 to 80 years of age Patients diagnosed as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis by specialist doctors.",TrialTroveID-303547 UMIN000024312,Adults; Older Adults,year(s),year(s),303547,(N/A); Unspecified; Unspecified MS,80.0,20.0,"Subjects taking azathioprine or mercaptopurine Subject who has or had renal function disorder. Subject with a history of gout, hyperuricemia or urolithiasis. Subject who has a history of renal disorder. Subject who has or had hypersensitivity, idiosyncracy (allergy) to drug. Subject who was judged not to be appropriate by the principal investigator or sub investigators by other reasons.",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis.,"18-70 years old; Clinically diagnosed with ALS syndrome, i.e., with ALS -like manifestations, consisting of a combination of upper and/or lower motor neuron damage; significant abnormalities with rheumatoid immune-related indicators, or diagnoses of immune-mediated ALS syndrome, including but not limited to multifocal motor neuropathy (MMN), Lewis-Sumner syndrome, and other ALS-like syndromes with an immune background that cannot be clearly classified; Poor treatment with conventional hormones or gamma globulin; Permitted concomitant treatment: oral prednisone or equivalent doses of other glucocorticoids ( < or = 1.0mg/kg/d); Oral routine dose of immunosuppressants or immunomodulators, such as cyclophosphamide, tacrolimus, etc.; Routine oral doses such as too much force; Doses and types of accompanying therapeutic drugs should not be changed from the trial enrollment to the end of follow-up. For women of reproductive age, contraception for at least 2 weeks at the time of enrolment and negative urine HCG; Reasonable and effective contraceptive measures should be taken by subjects of childbearing age from the time of trial enrollment to the end of follow-up; Signed informed consent.",M2020420 NCT04952155 TrialTroveID-408279,Adults; Older Adults,year(s),year(s),408279,Delay Disease Progression,70.0,18.0,"Allergic or intolerance to IL2; Receive non-standard treatment or use of excessive dose of glucocorticoids or gamma globulin intravenously within 2 months before enrollment; Vaccination within 6 months before enrolment or between enrolment and the end of follow-up; Peripheral venous white blood cells < 2000/mm3, lymphocytes < 600/mm3, platelets < 80,000 /mm3; Complicated with severe infection or inflammation, such as bacteremia, sepsis, etc.; Complicated blood system diseases, infectious diseases (hepatitis, HIV, tuberculosis, etc.), mental diseases, dementia, severe hypotension, substance abuse history, malignant tumor history, organ transplantation history, etc.; Severe liver, kidney, lung or heart dysfunction: heart failure ( > or = NYHA grade III), renal insufficiency (creatinine clearance < or = 30ml/min), abnormal liver function (3 times the upper limit of normal > ); Pregnant and lactating women; Currently participating in other clinical studies or using other investigational drugs.",Ii,Both
0,,- Clinical diagnosis of probable Frontotemporal Dementia or Pick's disease - Caregiver available to participate in all study visits,15398 NCT01002300 R-08-395,Adults; Older Adults,year(s),year(s),242035,,80.0,30.0,"- Severe language or memory deficits that preclude completion of the cognitive tasks - Females who are pregnant or breastfeeding (a pregnancy test will be done on females who have not completed menopause) - Uncontrolled hypertension - Bradycardia (rate <50 bpm) or tachycardia (rate > 100 bpm) - Current use of prostaglandins - Use of any investigational or experimental drug or device within the last 60 days prior to screening or within 5 half-lives of the experimental drug , whichever is longer",(N/A),Both
0,Patients with Sporadic Amyotrophic Lateral Sclerosis.,"Part 1: Ability of the participant to understand the purpose and risks of the study and indicate informed consent, and the ability of the participant or the participant's legally authorized representative, to provide signed and dated informed consent and authorization to use protected health information in accordance with national and local privacy regulations. No known presence or family history of mutations in the superoxide dismutase 1 (SOD1) or fused in sarcoma (FUS) genes. Participants in Cohorts A, B, C1 and D1, must meet the laboratory-supported probable, probable, or definite criteria for diagnosing ALS according to the World Federation of Neurology El Escorial criteria (revised according to the Airlie House Conference 1998 [Brooks 2000]). Participants in Cohort C2 and D2, must meet any of the prior conditions, but may also only meet clinically possible criteria for diagnosing ALS, or exhibit weakness attributable to ALS in the presence of ataxin-2 protein (ATXN2) intermediate repeats. In participants in Cohorts C2 and D2, confirmed intermediate cytosine-adenine-guanine/cytosine-adenine-adenine (CAG/CAA) repeat expansion in the ataxin-2 (ATXN2) gene as defined by at least 1 allele carrying 30 to 33 CAG/CAA repeats. Slow vital capacity (SVC) criteria: In participants in Cohorts A, B, C1, and D1, SVC ≥60% of predicted value as adjusted for sex, age, and height (from the sitting position). In participants in Cohort C2 and D2, SVC ≥50% of predicted value as adjusted for sex, age, and height (from the sitting position). If taking riluzole, participant must be on a stable dose for ≥30 days prior to Day 1 and expected to remain at that dose until the final study visit, unless the Investigator determines that it should be discontinued for medical reasons, in which case it may not be restarted during the study. Participants taking concomitant edaravone at study entry must be on a stable dose for ≥60 days prior to the first dose of study treatment (Day 1). Participants taking concomitant edaravone must be willing to continue with the same dose regimen throughout the study, unless the Investigator determines that edaravone should be discontinued for medical reasons, in which case it may not be restarted during the study. Edaravone may not be administered on dosing days of this study. Screening values of coagulation parameters including platelet count, international normalized ratio (INR), prothrombin time (PT), and activated partial thromboplastin time (aPTT) should be within normal ranges. Has an informant/caregiver who, in the Investigator's judgment, has frequent and sufficient contact with the participant as to be able to provide accurate information about the participant's cognitive and functional abilities at screening. Part 2: Ability of the participant to understand the purpose and risks of the study and indicate informed consent, and the ability of the participant or the participant's legally authorized representative to provide signed and dated informed consent and authorization to use protected health information in accordance with national and local privacy regulations Participants must have completed Study NCT04494256 Part 1 through Week 25 (Day 175 Visit for Cohorts A, B, C1, C2; Day 176 Visit for Cohorts D1, D2). This inclusion criterion does not apply to a participant if Part 1 was terminated by the Sponsor before the participant reached Week 25. Participants from Cohorts A, B, C1, and C2 must have a washout of ≥16 weeks between the last dose of study treatment received in Study NCT04494256 Part 1 and the first dose of BIIB105 received in Study NCT04494256 Part 2. Participants from Cohorts D1 and D2 do not require a washout period. If taking riluzole, participant must be on a stable dose for ≥30 days prior to Day 1 and expected to remain at that dose until the final study visit, unless the Investigator determines that it should be discontinued for medical reasons, in which case it may not be restarted during the study. Participants taking concomitant edaravone at study entry must be on a stable dose for ≥60 days prior to the first dose of study treatment (Day 1). Participants taking concomitant edaravone must be willing to continue with the same dose regimen throughout the study, unless the Investigator determines that edaravone should be discontinued for medical reasons, in which case it may not be restarted during the study. Edaravone may not be administered on dosing days of this study. Screening values of coagulation parameters including platelet count, INR, PT, and aPTT should be within normal ranges.",275AS101 ALSpire EudraCT Number: 2020-000207-36 NCT04494256 NL73598.000.20 TrialTroveID-374023,Adults; Older Adults,year(s),,374023,Unspecified,,18.0,"Part 1: History or positive test result at Screening for human immunodeficiency virus (HIV). Current hepatitis C infection. Current hepatitis B infection. History of alcohol or substance abuse ≤6 months of Screening that would limit participation in the study, as determined by the Investigator. Current or anticipated need, in the opinion of the Investigator, of a diaphragm pacing system during the study period. Presence of tracheostomy. In participants from Cohorts A, B, C1, and D1, history of myocardial infarction, as determined by the Investigator. In participants from Cohorts A, B, C1, and D1, poorly controlled type 1 or 2 diabetes mellitus defined as hemoglobin A1c (HbA1c) ≥8% during Screening. In participants in Cohorts A, B, and C1, prescreening ALSFRS-R slope >-0.4 points/month, where prescreening ALSFRS-R slope is defined as: (ALSFRS-R score at Screening - 48) / (months from date of symptom onset to date of Screening). This criterion is not applicable for Cohorts C2, D1, and D2. Treatment with another investigational drug (including investigational drugs for ALS through compassionate use programs) or biological agent within 1 month or 5 half-lives of study agent, whichever is longer, before Screening. Treatment with an approved disease-modifying therapy for ALS other than riluzole or edaravone within 1 month or 5 half-lives of therapy, whichever is longer, before completion of screening. Treatment with an antiplatelet or anticoagulant therapy that cannot safely be interrupted for lumbar puncture (LP) according to local standard of care and/or institutional guidelines, in the opinion of the Investigator or Prescriber. Female participants who are pregnant or currently breastfeeding and those intending to become pregnant during the study. Part 2: History or positive test result at Screening for HIV. If participants from Cohorts D1 and D2 who would seamlessly roll from Part 1 into Part 2 test positive for HIV during screening for Part 2 but are clinically asymptomatic, they may enroll in Part 2 at the discretion of the Investigator. Current hepatitis C infection. If participants from Cohorts D1 and D2 who would seamlessly roll from Part 1 into Part 2 test positive for hepatitis C during screening for Part 2 but are clinically asymptomatic, they may enroll in Part 2 at the discretion of the Investigator. Current hepatitis B infection. If participants from Cohorts D1 and D2 who would seamlessly roll from Part 1 into Part 2 test positive for hepatitis B during screening for Part 2 but are clinically asymptomatic, they may enroll in Part 2 at the discretion of the Investigator. History of alcohol or substance abuse ≤ 6 months of Screening that would limit participation in the study, as determined by the Investigator. Current or anticipated need, in the opinion of the Investigator, of a diaphragm pacing system during the study period. In participants from Cohorts A, B, C1, and D1, history of myocardial infarction, as determined by the Investigator. In participants from Cohorts A, B, C1, and D1, poorly controlled type 1 or 2 diabetes mellitus defined as HbA1c ≥8% during Screening. Treatment with another investigational drug (including investigational drugs for ALS through compassionate use programs; excluding BIIB105) or biological agent within 1 month or 5 half-lives of study agent, whichever is longer, before Screening. Treatment with an antiplatelet or anticoagulant therapy that cannot safely be interrupted for LP according to local standard of care and/or institutional guidelines, in the opinion of the Investigator or Prescriber. Female participants who are pregnant or currently breastfeeding and those intending to become pregnant during the study.",Iii,Both
0,Adults with C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS),"Participants must have completed study NCT03626012 through the first follow-up clinic visit that follows the final dosing visit without missing more than 1 dose of study treatment. Participants taking concomitant riluzole at study entry must be on a stable dose for > or = 30 days prior to the first dose of study treatment (Day 1). Participants taking concomitant riluzole must be willing to continue with the same dose regimen throughout the study, unless the Investigator determines that riluzole should be discontinued for medical reasons, in which case it may not be restarted during the study. Participants taking concomitant edaravone at study entry must be on a stable dose for =60 days prior to the first dose of study treatment (Day 1). Participants taking concomitant edaravone must be willing to continue with the same dose regimen throughout the study, unless the Investigator determines that edaravone should be discontinued for medical reasons, in which case it may not be restarted during the study. Edaravone may not be administered on dosing days of this study.",245AS102 BASEC2020-00921 EudraCT Number: 2019-004798-14 NCT04288856 NL73220.000.20 SNCTP000004138 TrialTroveID-368837,Adults; Older Adults,year(s),,368837,Delay Disease Progression,,18.0,"History of drug abuse or alcoholism =6 months before study enrollment that would limit participation in the study, as determined by the Investigator. Presence of an implanted shunt for the drainage of CSF or an implanted central nervous system (CNS) catheter. History of or positive test result at Screening for human immunodeficiency virus. The requirement for testing at Screening may be omitted if it is not permitted by local regulations. Treatment with another investigational drug (including investigational drugs for ALS through compassionate use programs) or biological agent within 1 month of Screening or 5 half-lives of study agent, whichever is longer. Note: Other protocol-specific inclusion/exclusion criteria may apply.",I,Both
0,Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis,"Ability of the participant to understand the purpose and risks of the study, to provide signed and dated informed consent, and to authorize the use of confidential health information in accordance with national and local participant privacy regulations; or, in the event of the participant's physical incapacity to sign, to confirm that understanding and consent orally to a legally authorized representative (LAR) for the express purpose of having said informed consent and authorization signed on his/her behalf. All participants of childbearing potential must agree to practice highly effective contraception during the study and be willing and able to continue contraception for 5 months after their last dose of study treatment. Must meet the possible, laboratory-supported probable, probable, or definite criteria for diagnosing ALS according to the World Federation of Neurology El Escorial criteria and have documentation of a clinical genetic test demonstrating the presence of a pathogenic mutation in C9ORF72. Slow vital capacity (SVC) = 50% of predicted value as adjusted for sex, age, and height (from the sitting position). Participants taking concomitant riluzole at study entry must be on a stable dose for = 30 days prior to the first dose of study treatment (Day 1). Participants taking concomitant edaravone at study entry must be on a stable dose for = 60 days prior to the first dose of study treatment (Day 1). ALS Cognitive Behavioral Screen (ALS-CBS) score = 11 for the cognitive portion; = 33 for the behavioral portion. Medically able to undergo the study procedures, and to adhere to the visit schedule at the time of study entry, as determined by the Investigator. Screening values of coagulation parameters including platelet count, international normalized ratio (INR), prothrombin time (PT), and activated partial thromboplastin time (APTT) should be within normal ranges. Has an informant/caregiver who, in the Investigator's judgment, has frequent and sufficient contact with the participant as to be able to provide accurate information about the participant's cognitive and functional abilities at Screening.",216409 245AS101 245AS101 - AS EudraCT Number: 2017-000294-36 NCT03626012 NL69083.000.19 SNCTP000003128 TrialTroveID-330208,Adults; Older Adults,year(s),,330208,Delay Disease Progression,,18.0,"History of drug abuse or alcoholism = 6 months of Screening that would limit participation in the study, as determined by the Investigator. Tracheostomy. Prescreening ALSFRS-R slope less than 0.4 points/month, where prescreening ALSFRS-R slope is defined as follows: (48 - ALSFRS-R score at Screening) / (months from date of symptom onset to date of Screening). History of or positive test result at Screening for human immunodeficiency virus. . History of, or positive test result at Screening for, hepatitis C virus antibody. Treatment with another investigational drug or biological agent within 1 month of Screening or 5 half-lives of study agent, whichever is longer. Treatment with an antiplatelet or anticoagulant therapy that cannot safely be interrupted for lumbar puncture (LP) according to local standard of care and/or institutional guidelines, in the opinion of the Investigator or Prescriber. Current or anticipated need, in the opinion of the Investigator, of a diaphragm pacing system during the study period. Female participants who are pregnant or currently breastfeeding. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",Iii,Both
0,Patients with Frontotemporal Dementia and Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease Dementia.,"Must meet all the clinical staging criteria for MCI due to AD (Stage 3) or mild AD dementia (Stage 4) according to the National Institute on Aging at National Institutes of Health and the Alzheimer's Association (NIA-AA) and must have the following at Screening Visit 1: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Delayed Memory Index score of ≤85, indicative of objective evidence of memory impairment. CDR global score of 0.5 for MCI due to AD or 0.5 or 1 for mild AD dementia MMSE score of 21 to 30 (inclusive). CDR Memory Box score of ≥0.5. Evidence of amyloid pathology as measured by positive emission tomography (PET) or cerebrospinal fluid (CSF) sampling. Must have 1 care partner who, in the Investigator's judgment, has frequent and sufficient contact with the participant (at least 10 hours/week) to be able to provide accurate information about the participant's cognitive and functional abilities. Key Inclusion Criteria for LTE Period Participants must have completed the placebo-controlled period of the study, including the Week 76 visit. Participants must have taken at least 5 doses of BIIB080 or placebo during the placebo-controlled period. MMSE score >10 at the Week 76 visit. Must have 1 care partner who, in the Investigator's judgment, has frequent and sufficient contact with the participant (at least 10 hours/week) to be able to provide accurate information about the participant's cognitive and functional abilities.",247AD201 CELIA EUCT Number: 2022-501644-15-01 EudraCT Number: 2022-501644-15 jRCT2031220635 NCT05399888 TrialTroveID-319730,Adults; Older Adults,year(s),year(s),319730,Cognitive Function; Frontotemporal Dementia; Mild; Mild Cognitive Impairment/Prodromal; Underlying Disease-Modifying,80.0,50.0,"Known allergy to BIIB080 or a history of hypersensitivity to any of the inactive ingredients in the drug product. Previous participation in this study or previous studies with BIIB080. Use of non-disease-modifying AD medications (including but not limited to donepezil, rivastigmine, galantamine, tacrine, and memantine) at doses that have not been stable for at least 8 weeks prior to Screening Visit 1 and during the screening period up to Day 1. Use of any commercially available disease-modifying AD medications such as anti-amyloid monoclonal antibodies. Prior participation in any active or passive immunotherapy study targeting Aβ, unless documentation of receipt of placebo is available. Prior participation in any passive immunotherapy study targeting tau, unless the last administration occurred 6 months or 5 half-lives, whichever is sooner, prior to Screening or documentation of receipt of placebo is available. Prior participation in any study involving an investigational treatment targeting tau that is not a passive immunotherapy, unless documentation of receipt of placebo is available. Prior participation in a study of any other agent(s) not included in exclusion criteria 5, 6, and 7 with a purported disease-modifying effect in AD within 12 months, unless documentation of receipt of placebo is available. Prior participation in a study of any gene therapy with a purported disease-modifying effect in AD, unless documentation of receipt of placebo is available. Current use or previous use of medications with a purported disease-modifying effect in AD, outside of investigational studies. Any vaccination given within 10 days prior to Day -1. Coronavirus disease 2019 (COVID-19) vaccinations using RNA or deoxyribonucleic acid (DNA) technology are allowed during the study, as well as other types of immunization/vaccination/booster, except during the 10 days before and after clinic visits. Contraindications to having a brain magnetic resonance imaging (MRI) [e.g., MRI-incompatible pacemaker; MRI-incompatible aneurysm clips, artificial heart valves, or other metal foreign body; claustrophobia that cannot be medically managed]. If the MRI compatibility of implanted devices is unknown, the participant must be excluded from the study. Current enrollment or a plan to enroll in any interventional clinical study in which an investigational treatment or approved therapy for investigational use is administered within 52 weeks prior to the Baseline Visit. Key Exclusion Criteria for LTE Period Any medical or psychiatric contraindication or clinically significant abnormality that, in the opinion of the Investigator, will substantially increase the risk associated with the participant's enrollment in and completion of the study. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",Ii,Both
0,Patients with Frontotemporal Dementia,,TrialTroveID-313920,,,,313920,Frontotemporal Dementia,,,,I,
0,Subjects with Amyotrophic Lateral Sclerosis,Male or female participants ages > or = 18 to 75 years. Participants that have completed study protocol #101/2 A written informed consent signed prior to any study procedure being performed Medically capable to undergo study procedures at the time of study entry,101/3 MOH_2018-06-17_002459 NCT03755167 TrialTroveID-337573,Adults; Older Adults,year(s),year(s),337573,Delay Disease Progression,75.0,18.0,"Participants that did not participate or did not complete 28 treatment days of study protocol #101/2. Concurrent therapy, that in the PI's opinion, would interfere with the evaluation of the safety or efficacy of the study medication Presence of any other condition or circumstance that, in the judgment of the Investigator, might contraindicate or increase the risk to the participant. Females must not be lactating or pregnant at Screening or Baseline (as documented by a negative serum pregnancy test from protocol 101/2) Women of child-bearing potential or males whose partners are women of child-bearing potential, unwilling or unable to use an effective method of contraception throughout the trial",Ii,Both
0,Subjects with Amyotrophic Lateral Sclerosis,"Male or female participants ages =18 to 80 years Consenting participants fulfilling the El Escorial criteria for probable and definite ALS (sporadic and familial) Participant has ALSFRS-R score >20, the latest ALSFRS-R test should be no more than 6 weeks before screening visit, AND: a disease progression rate greater than 0.55 ALSFRS-R point per month on average, over at least 4 months, prior to the latest ALSFRS-R test OR a decline of at least 3 points in ALSFRS-R score within the last 4 months prior to the latest ALSFRS-R test Previous data of Force Vital Capacity (FVC) of =60% at least 3 months before screening and not more than 12 months. Written informed consent consistent with ICH-GCP and local laws, signed prior to any study procedures being performed. BMI 18.5 to 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg. If taking riluzole or edaravone, the participant must be on a stable dose for =30 days prior to Day 1 and expected to remain at that dose until the final study visit. Medically able to undergo the study procedures, and to adhere to the visit schedule at the time of study entry. Medically is able and willing to undergo placement and maintain a central venous catheter as determined by the investigator. Participant has a competent caregiver or qualified individual who can and will be responsible for the administration of study drug and reporting home activities. Geographic accessibility to the study site Females must not be lactating or pregnant at Screening, as documented by a negative beta-human chorionic gonadotropin [ß-hCG] (or human chorionic gonadotropin [hCG]. Women of child-bearing potential or males whose partners are women of child-bearing potential use an effective method of contraception throughout the trial.",101/ 2 NCT03652805 TrialTroveID-331573,Adults; Older Adults,year(s),year(s),331573,Delay Disease Progression,80.0,18.0,"Concurrent therapy that, in the PI's opinion, would interfere with the evaluation of the safety or efficacy of the study medication. Co-existing psychiatric disorder excluding a depression disorder occurred after ALS diagnosis. Participant is a respiratory dependent. Subjects with a significant pulmonary disorder not attributed to ALS. Slow Vital Capacity (SVC) <60. Presence of any other condition or circumstance that, in the judgment of the Investigator, might contraindicate or increase the risk to the participant or decrease the chance of obtaining satisfactory data to achieve the objectives of the study. History of HIV, positive HBV or HCV serology. Participants suffering from significant cardiac, or any other disease that may endanger the participant or interfere with the ability to interpret the results. A participant with active infections. Documented active cancer. Treatment with another investigational drug, biological agent, or device within 2 months of the first dose, or investigational cell therapy within 6 months of the first dose.",Iii,Both
0,,,TrialTroveID-169886,,,,169886,Unspecified,,,,I,
0,Patients with ALS,"Non-smoking adults aged 21-80 years will be eligible to participate. - Upon screening, eligible patients will have an ALS diagnosis (El Escorial diagnostic classifications of probable/definite ALS), vital capacity (VC) > 60% of predicted value, and ALS Functional Rating Scale (ALSFRS-R) scores of 2 or greater for bulbar and respiratory items: swallowing, speech, salivation, dyspnea, orthopnea, and respiratory insufficiency. Additionally, patients taking riluzole and/or edaravone must be on a stable dose for >30 days. Unaffected control subjects will be eligible if they have a vital capacity (VC) > 60% of predicted value.",NCT05377424 OCR41682 TrialTroveID-432365,Adults; Older Adults,year(s),year(s),432365,Delay Disease Progression,80.0,21.0,"Patient and control are ineligible if they are pregnant have an active respiratory infection, took antibiotics within 4 weeks, are diagnosed with another neurodegenerative disease, have symptomatic cardiovascular disease or dysrhythmias (resting tachycardia and hypertension), exhibit history or presence of hypoxemia or hypercapnia, presence of rest tachypnea (RR ?30), have a BMI >35 kg/m2, have a seizure disorder, take respiratory inhalers daily for airway disease, or require external respiratory support while awake and upright, or supplemental oxygen at rest or at night. In addition, the following conditions are exclusionary for the use of istradefylline: routine use of CYP3A4 inducers (i.e. carbamazepine, phenobarbitol, rifampin, phenytoin, St. John's Wort, glucocorticoids) or medications that may suppress ventilation, history of moderate renal impairment or severe hepatic impairment, and history of hallucinations or psychosis. Patients who cannot safety swallow thin liquids (required for administration of istradefylline and placebo) will also be ineligible.",Iii,Both
0,Healthy Volunteers,"- Part A: male or female participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent - Part B: male participant only must be 18 to 55 years of age inclusive, at the time of signing the informed consent - Body weight between 50.0 and 100.0 kg, inclusive, if male, and between 40.0 and 90.0 kg, inclusive, if female, body mass index between 18.0 and 30.0 kg/m^2, inclusive - Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies",INT17470 NCT05797753 TrialTroveID-464741 U1111-1267-9023,Adults,year(s),year(s),464741,(N/A); Healthy subjects,55.0,18.0,"- Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness - Any medication (including St John's Wort) within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of the medication, with the exception of hormonal contraception or menopausal hormone replacement therapy; any non-live Covid-19 vaccine within the last 2 weeks before inclusion, any live attenuated vaccine within the last 28 days before inclusion and any other non-vaccine biological drugs given within 4 months before inclusion - Current enrollment in Part A (applicable for Part B) or past participation in previous clinical study on SAR443820 - Positive result for hepatitis B, C or human immunodeficiency virus (HIV) - Positive result on urine drug screen - Positive urine alcohol test - Any consumption of citrus fruits (grapefruit, orange, etc) or their juices within 5 days before inclusion The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial",I,Both
0,Amyotrophic lateral sclerosis (ALS) patients with FUS gene mutations,,TrialTroveID-370457,,,,370457,Unspecified,,,,I,Both
0,Patients with Amyotrophic Lateral Sclerosis,Patients with Amyotrophic Lateral Sclerosis,TrialTroveID-407441,,,,407441,Delay Disease Progression,,,,Ii,
0,Subjects with amyotrophic lateral sclerosis,"Diagnosed as ALS by Gold Coast criteria Patients visiting or admitted in our hospital, and can be followed up more than 3 months",jRCTs061230001 TrialTroveID-477476,Adults; Older Adults,year(s),,477476,Unspecified,,18.0,Arginase deficiency Lysineuric protein intolerance whose absorption inhibition of L-arginine hydrochloride is great in degree Taking Argi-U Using ventilator Scheduled for surgery at the time of registration,Ii,Both
1,Patients With Amyotrophic Lateral Sclerosis,"Diagnosis of probable or definite ALS ALSFRS-R score >25 and FVC score = 60% predicted If currently taking Riluzole and/or Edaravone/Radicava must be on stable dose for 3 months prior to Baseline/Screening. If the dosing has not been stable for 3 months prior to Baseline/Screening or if stopped due to an adverse event, the waiting period off the medication will be 7 days. If not on either of these medications may start if desired either or both medications after enrollment into study.",D18095 NCT03580616 TrialTroveID-297948,Adults; Older Adults,year(s),,297948,Delay Disease Progression,,18.0,"Diagnosis of probable or definite ALS more than 3 years prior to study enrollment Diagnosis or previous history of ischemic stroke, brain tumor, uncontrolled diabetes, renal insufficiency, or severe hypertension. Diagnosis or previous history of comorbid progressive neurodegenerative disease such as Alzheimer's disease, Parkinson's disease, Lewy Body disease, Pick's disease, Huntington's disease, Progressive Supranuclear palsy. ALS patients diagnosed with frontotemporal dementia will not be excluded from this study. Diagnosis or previous history of symptomatic peripheral neuropathy. Patients with findings of peripheral neuropathy on electrodiagnostic tests only but no clinical symptoms at the time of enrollment are eligible. Undergoing any chemotherapy or radiation therapy for any cancer Any medical condition likely to interfere with the conduct of the trial or survival of the patient during this study period Pregnant women or women who are breast feeding Has taken L-Serine supplement within 30 days prior to start of study drug",Ii/Iii,Both
0,Patients diagnosed with Sporadic Amyotrophic Lateral Sclerois on stable doses of riluzole were enrolled.,Age 18-85. Male or Female. Clinically diagnosed with probable or definite ALS based on El Escorial criteria. ALSFRS-R > 25. Able to provide informed consent to and comply with all medical procedures. FVC >60% predicted,L-Serine2013 NCT01835782 TrialTroveID-184975,Adults; Older Adults,year(s),year(s),184975,Unspecified,85.0,18.0,"Outside age range of 18-85. Subjects with forced vital capacity (FVC) below 60%. Evidence of any motor neuron disease for over 3 years. Symptoms present for more than three years; taking amphetamines or adrenergic agonists such as dopamine; presence of a comorbid condition that could make completion of the trial unlikely; a history of intolerance to L-serine; serum creatinine >2.0?mg/dl; taking any other investigational drug; and, for females of child-bearing age, pregnancy, breast-feeding, or unwillingness to prevent pregnancy during the trial.",Iii,Both
0,Patients with amyotrophic lateral sclerosis (ALS),1) Over 20 year old 2) Probable of definite ALS disease by Awaji electrophysiological criteria 3) Subjects provided informed consent.,G29007 jRCTs031180173 NCT03186040 TrialTroveID-303297 UMIN000027476,Adults; Older Adults,year(s),,303297,Symptom relief,,20.0,"1) Patient without ability to comprehend informed consent 2) Patient with uncompensated medical illness 3) Patient with cardiac disease (myocardial infarction, valvular disease and cardiomyopathy etc.) 4) Patient with arrhythmia (incomplet AV-block and bundle branch block etc.) 5) Patient with sodium channel disorders, like Brugada syndrome 6 )Patient already administered anti-arrhythmic drug which prolongs PR interval 7) Pregnant or breast-feeding women 8) Patient with forced vital capacity of< 60% predicted 9) Patient already performed tracheotomy or tube feeding 10) Patient take any other experimental agents 3 months before. 11) Not enough CMAP amplitude in the median nerve to be performed nerve excitability test 12) Patient plan to change medicine which affects nerve excitability 13) Familial ALS 14) Patient who is judged inappropriate for this trail by doctors responsible for this trial",Iii,Both
1,Participants With Neurodegenerative Disease,"- Written informed consent must be obtained and documented (from the participant or, where jurisdictions allow it, from their legal decision maker). - Has successfully completed participation in their parent latozinemab study. - Female participants must be nonpregnant and nonlactating. - Male participants must agree to acceptable contraception use.",2023-506805-20-00 AL001-CS-302 NCT06111014 TrialTroveID-490868,Adults; Older Adults,year(s),,490868,Frontotemporal Dementia,,18.0,"- Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins. - Clinically significant heart disease, liver disease or kidney disease. History or evidence of clinically significant brain disease other than FTD.",Iii,Both
0,Patients with amyotrophic lateral sclerosis (ALS) caused by C9orf72.,"Confirmation of C9orf72 mutation Diagnosis of ALS by revised El Escorial criteria Time since onset of muscle weakness due to ALS < or = 36 months at the time of the Screening Visit Slow Vital Capacity (VC) > or = 50% of predicted capacity at the time of the Screening Visit If taking riluzole, must be on a stable dose of riluzole for at least 30 days prior to the Screening Visit. Riluzole naive participants are allowed. If taking edaravone, must have completed at least one cycle of edaravone prior to the Screening Visit and plan to continue edaravone during the study. Edaravone naive participants are allowed. Females must not be pregnant, breastfeeding or planning to conceive within the study period. Males must agree to use acceptable contraception Capable of providing informed consent at the Screening visit and complying with study procedures throughout the study",AL001-ALS-201 NCT05053035 TrialTroveID-393792,Adults; Older Adults,year(s),,393792,Delay Disease Progression,,18.0,"Clinically significant, unstable, medical condition (other than ALS) Clinically significant heart disease, liver disease or kidney disease Cognitive impairment or dementia Current uncontrolled hypertension History of unresolved cancer Any experimental gene therapy Any experimental vaccine (any vaccine against COVID-19 either approved or administered under an Emergency Use Authorization is allowed)",Ii,Both
1,Patients with frontotemporal dementia with a progranulin mutation (FTD-GRN),"Part 1: 1. Is a known carrier of a heterozygous loss-of-function GRN mutation causative of FTD with a global CDR® plus NACC FTLD score of 0 to 2, and: • A CDR® plus NACC FTLD-SB score =0.5 with an elevated level of serum NfL, or • A CDR® plus NACC FTLD-SB score of >0.5 with 1 or more of the 6 behavioral/cognitive symptoms required for a diagnosis of possible bvFTD (Rascovsky 2011), or a diagnosis of PPA 2. Age 25 to 85 years of age, inclusive, at Screening. 3. At Screening, woman must be nonpregnant and nonlactating, and 1 of the following conditions must apply: a. Not a woman of childbearing potential (WOCBP) (either surgically sterilized or physiologically incapable of becoming pregnant, or at least 1-year postmenopausal [amenorrhea duration of 12 consecutive months with no identified cause other than menopause]). b. Is a WOCBP and agrees to use an acceptable contraceptive method from screening until 10 weeks after the last dose of study treatment. Acceptable contraception is defined as using hormonal contraceptives (e.g. combined oral contraceptive pill) or an intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm or cervical cap, or a condom. In addition, total abstinence, if in accordance with the lifestyle of the participant, is acceptable. c. A WOCBP must have a serum pregnancy test conducted at screening. Additional requirements for pregnancy testing during and after study intervention are described in the Schedules of Assessments. 4. Men must agree to use acceptable contraception and not donate sperm from Day 0 until 10 weeks after the last dose of study treatment. Acceptable contraception for the male participant when having sexual intercourse with a WOCBP who is not currently pregnant is defined as using a condom. In addition, WOCBP partners must use hormonal contraceptives (e.g. combined oral contraceptive pill) or an intrauterine device. 5. Agrees not to donate blood or blood products for transfusion for the duration of the study and for 1 year after the final dose of study treatment. 6. Willing to and can comply with the study protocol requirements, in the opinion of the investigator. 7. Willing and able to give informed consent. If the patient is not competent, a legally authorized representative must provide informed consent on their behalf, and the participant must provide assent, in accordance with the local regulations, guidelines, and institutional review board (IRB) or independent ethics committee (IEC). 8. Patient has the availability of a person (""study partner"") who has frequent and sufficient contact with the patient(at least 5 hours per week of in-person contact), and who can provide accurate information to the study site regarding the patient's behavior, cognitive, and functional abilities as well as their health throughout the study. Requirements for the study partner will include: a. Willing and able to provide informed consent to participate in the study as a study partner. b. The study partner must have sufficient cognitive capacity to accurately report upon the participant's behavior, cognitive, and functional abilities, in the opinion of the investigator. c. The study partner should be in sufficiently good general health to have a high likelihood of maintaining the same level of interaction with the participant and participation in study procedures throughout the study duration. d. The same study partner should participate throughout the duration of Part 1 of the study. If a change in study partner is necessary, the medical monitor must be contacted. e. Study partner agrees to provide information at investigational site visits that require partner input for COA completion. f. Study partner agrees to accompany the participant at COA visits Inclusion criteria applicable to those participants participating in the optional Winterlight Labs Speech Assessment (WLA) only: 1. Has available and willing study partner to administer the WLA. 2. Has WiFi access in their residence or WiFi access in a private area where the testing can take place. 3. Participants and study partners must be proficient in English, Spanish, French, or German in the investigator's opinion. Part 2: Patient must complete Part1, week 97: 1. Participant is willing and able to give informed consent to continue treatment with AL001. If the study participant is not competent, a legally authorized representative must provide informed consent on his or her behalf, and the participant must provide assent, in accordance with the local regulations, guidelines, and IRB/IEC. 2. Is willing and has the ability to comply with OLE requirements, in the opinion of the investigator. 3. Has availability of a person (""study partner"") who can continue to assist with assessments throughout the OLE evaluation period. (For more information please refer to the protocol or as described on PART 1, inclusion criteria number 8)",135892 AL001-3 BASEC2020-01901 EudraCT Number: 2019-004066-18 INFRONT-3 NCT04374136 NL72487.078.20 SNCTP000004097 TrialTroveID-371125,Adults; Older Adults,year(s),year(s),371125,Frontotemporal Dementia,85.0,25.0,"Part 1: 1.Dementia due to a condition other than FTD including, but not limited to, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, Huntington disease, or vascular dementia. 2.Known mutation causative of neurodegenerative disorder(s) other than heterozygous loss-of-function GRN mutations causative of FTD. 3.Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins. 4. Signs or symptoms of progressive supranuclear palsy or bulbar dysfunction, such as postural instability, eye problems, and swallowing difficulties. 5. History of moderate or severe substance use disorder within the past 2 years, with the exception of nicotine, as defined by the Diagnostic and Statistical Manual of Mental Disorders, fifth edition criteria 6. Currently has or has had an acute illness that requires or required systemic antibiotics within 30 days prior to first study treatment administration. 7. Clinically significant vitamin B12 or folate deficiency (if treated, must be on a stable regimen for at least 3 months prior to first study treatment administration). 8.Untreated hypothyroidism (if treated, thyroid supplementation dose must be stable for at least 3 months with a normal thyroid-stimulating hormone level prior to study treatment administration). 9.Insufficiently controlled diabetes mellitus (e.g., hemoglobin A1C =8%). 10.Any surgery (major or emergent) or hospitalization within 30 days prior to first study treatment administration. 11. History of cancer within the last 5 years with the exception of basal cell or squamous cell carcinoma. 12. Positive for hepatitis B surface antigen, human immunodeficiency virus-1 or -2 antibodies or antigen, or history of spirochetal infection of the CNS (e.g., syphilis, borreliosis, or Lyme disease). Participants with a positive hepatitis C virus antibody will be allowed if hepatitis C RNA is negative. 13. Significant kidney disease as indicated by either of the following: a. Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2, according to the re-expressed abbreviated (four-variable) MDRD Study equation b.Creatinine =2 mg/dL. 14. Impaired hepatic function as indicated by screening aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =2.5 the upper limit of normal (ULN), or total bilirubin =1.5 × ULN. Note: Participants with Gilbert's syndrome are eligible to participate if approved by the Medical Monitor. 15. Hematologic abnormalities as indicated by hemoglobin =10 g/dL; white blood cells (WBC) =3 000/mm3; absolute neutrophil count =1 1,000/mm3; or platelet count =150,000/mm3. 16. Has or has had unstable or clinically significant cardiovascular disease within the past 2 years. 17. Uncontrolled hypertension (e.g., repeated supine diastolic blood pressure [BP] >95 mm Hg or systolic BP >150 mm Hg) at screening. 18. History or presence of an abnormal ECG that is clinically significant, or evidence of acute or subacute myocardial infarction or ischemia. 19. History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease or clinically significant electrolyte abnormalities Note: Participants with premature ventricular contractions are eligible to participate. 20. For participants who consent to lumbar puncture, participant has contraindication to lumbar dural puncture, including coagulopathy, concomitant anticoagulation medication (except for a platelet inhibitor such as aspirin), thrombocytopenia, or other factor(s) that precludes safe lumbar puncture. 21. History or presence of clinically evident vascular disease potentially affecting the brain 22. History of a clinically significant, persistent neurologic deficit, structural brain damage, or CNS trauma. 23. Resides in a skilled nursing facility, convalescent home, or long-term care facility at screening; or requires continuous nursing care (i.e., >3 months). 24. Unable to tolerate MRI procedures (e.g., due to anxiety or claustrophobia) or has a contraindication to MRI. 25. Has a medical condition or extenuating circumstance that, in the opinion of the investigator, might compromise their ability to comply with the protocol-required testing or procedures, or compromise the participant's well-being, safety, or clinical interpretability Part 2: Part 1 participants are not eligible for continued treatment with AL001 OLE if any of the following apply: 1. Part 1 participant has been admitted to a skilled nursing facility, convalescent home, or long-term care facility at screening and requires continuous nursing care (i.e., >3 months). 2. Part 1 participant has a medical condition or extenuating circumstance that, in the opinion of the investigator, continued treatment with AL001 at the conclusion of Part 1 is not beneficial or safe for the participant.",Iii,Both
0,"Patients with a Granulin mutation or C9orf72 mutation causative of frontotemporal dementia. INFRONT-2 included three cohorts of FTD patients: asymptomatic FTD-GRN mutation carriers, symptomatic FTD-GRN patients, and FTD-C9orf72 patients.","At screening, female participants must be nonpregnant and nonlactating In good physical health on the basis of no clinically significant findings from medical history, physical examinations (PEs), laboratory tests, ECGs, and vital signs. Participant is a carrier of a loss of function progranulin gene (GRN) mutation or carrier of a hexanucleotide repeat expansion C9orf72 mutation Participants must meet all of the key inclusion criteria specific to their applicable participant category. These bullet points are some of the important criteria within each category: 1) Participant completed Study AL001-1 through the Day 57 visit and did not experience AEs that the investigator deems would prevent safe participation in Study AL001-2. 2) Participant completed Study AL001-1 through the Day 43 visit and did not experience AEs that the investigator deems would prevent safe participation in Study AL001-2. 3) Participant is a carrier of a loss of function GRN mutation causative of FTD-GRN 4) Participant is a carrier of a hexanucleotide repeat expansion C9orf72 mutation causative of FTD-C9orf72 Participant is not a woman of childbearing potential (WOCBP) (either surgically sterilized or physiologically incapable of becoming pregnant, or at least 1 year postmenopausal (amenorrhea duration of 12 consecutive months with no identified cause other than menopause). - Participant is a WOCBP and using an acceptable contraceptive method from screening until 90 days after the follow up visit. Acceptable contraception is defined as using hormonal contraceptives or an intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm or cervical cap, or a condom. In addition, total abstinence, in accordance with the lifestyle of the participant, is acceptable. - A WOCBP must have a serum pregnancy test conducted at screening. Additional requirements for pregnancy testing during and after study intervention are located in the Schedule of Assessments (Table 14-1 in the protocol). Male participants, if not surgically sterilized, must agree to use acceptable contraception and not donate sperm from Day 1 until 90 days after the follow up visit. Acceptable contraception for the male patient (and his female partner) is defined as using hormonal contraceptives or an intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm or cervical cap, or a condom. In addition, total abstinence, in accordance with the lifestyle of the participant, is acceptable. Participant is in good physical health on the basis of no clinically significant findings from medical history, PEs, laboratory tests, ECGs, and vital signs. Participant agrees not to donate blood or blood products for transfusion for the duration of the study and for 1 year after final dose of study drug. Participant is willing and able to comply with the study protocol. Participant is willing and able to give informed consent. If the study participant is not competent, a legally authorized representative must provide informed consent on their behalf, and the participant must provide assent, in accordance with the local regulations, guidelines, and institutional review board (IRB) or independent ethics committee (IEC). Participant has availability of a person (“study partner”)",AL001-2 EudraCT Number: 2019-000138-20 INFRONT INFRONT-2 NCT03987295 NL70050.078.19 TrialTroveID-351601,Adults; Older Adults,year(s),year(s),351601,Frontotemporal Dementia,85.0,18.0,"Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins. History of alcohol abuse or substance abuse Participant resides in a skilled nursing facility, convalescent home, or long term care facility Participant has donated or lost more than 100 mL of blood within 30 days prior to Day 1. Participant has had a blood transfusion within 30 days prior to screening. Participant has had clinically significant and/or acute illness within 5 days prior to drug administration that may affect safety assessments. Participant had surgery, hospitalization, or clinically significant infection requiring oral or IV antibiotics during the 30 days prior to screening. Participant has planned procedure or surgery during the study that would interfere with the ability to perform study assessments. Participant has past history of seizures, with the exception of childhood febrile seizures. Participant has clinically, significant systemic immunocompromised condition because of continuing effects of immune suppressing medication. Participant has major depressive disorder or history of schizophrenia, schizoaffective disorder, or bipolar disorder. Participant has history of cancer Participant has history or presence of intracranial tumor that is clinically relevant. Participant has any clinically significant medical condition or laboratory abnormality that precludes the participant’s safe participation in and completion of the study. Participant is positive for hepatitis B surface antigen, hepatitis C virus antibodies, or human immunodeficiency virus 1 and 2 antibodies or antigen, or history of spirochetal infection of the CNS. Participant has significant kidney disease as indicated by a screening creatinine clearance < 30 mL/min as calculated by the central laboratory using the Cockcroft Gault formula, which remains < 30 mL/min if retested. Participant has impaired hepatic function as indicated by screening aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > or = 2 the upper limit of normal (ULN) or total bilirubin > or =1.5 × ULN, which remains above either of these limits if retested or other abnormalities in synthetic function that are clinically significant. The participant has, within the last 2 years, had unstable or clinically significant cardiovascular disease. Participant has uncontrolled hypertension. Participant has history or presence of an abnormal ECG that is clinically significant. Participant has QT interval corrected using Fridericia formula (QTcF) > 450 ms for male participants and > 470 ms for female participants. Participant has history of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease, coronary heart disease, clinically significant electrolyte abnormalities, or family history of sudden unexplained death or long QT syndrome. Participant has contraindication to lumbar dural puncture. Participant has dementia or a milder, symptomatic syndrome (eg, mild cognitive impairment, mild behavioral impairment, or mild motor impairment) due to a condition other than FTD, including, but not limited to, Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, Huntington disease, or vascular dementia. Participant has history or presence of clinically evident vascular disease potentially affecting the brain that has the potential to affect cognitive function. A drug from a clinical trial (other than AL001-1) within 30 days prior to drug administration in the current study (Day 1); Use of any experimental oral therapy within 30 days or 5 half-lives prior to Day 1, whichever is greater; Use of any biologic therapy within 12 weeks or 5 half-lives prior to Day 1, whichever is greater; or any other investigational treatment within 5 half-lives or 3 months of screening, whichever is longer. Participants who have received an experimental therapy that has no half-life, like a vaccine, should have completed that therapy at least 12 weeks prior to Day 1.",Ii,Both
0,Healthy volunteers and participants with frontotemporal dementia with granulin mutation. participants with FTD‐GRN were enrolled in the study,"BMI 18.0-35.0 kg/m^2 45-120 kg, inclusive At screening, females must be non-pregnant and non-lactating, or of nonchildbearing potential (either surgically sterilized or physiologically incapable of becoming pregnant, or at least 1-year postmenopausal (amenorrhoea duration of 12 consecutive months); nonpregnancy will be confirmed for all females by a pregnancy test conducted at screening, (each) admission, and at follow-up. Female participants of child-bearing potential must agree to use adequate contraception from screening until 90 days after the follow-up visit. In good physical health on the basis of no clinically significant findings from medical history, physical examination (PE), laboratory tests, 12 lead ECG, and vital signs, as judged by the Investigator. Willingness and able to comply with the study protocol, in the investigator's judgement. Participants had to be symptomatic and meet diagnostic criteria for possible behavioral variant frontotemporal dementia (bvFTD) or probable bvFTD or primary progressive aphasia. 29 , 30 Additional inclusion criteria included being in good physical health and being a heterozygous carrier of a loss‐of‐function GRN mutation. Participants were eligible for inclusion if they were males or non‐pregnant females using adequate contraception throughout the study duration.",AL001-1 INFRONT NCT03636204 TrialTroveID-330789,Adults; Older Adults,year(s),year(s),330789,Frontotemporal Dementia; Healthy subjects,80.0,18.0,"Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins. Positive drug or alcohol at screening and prior to first dose History of alcohol abuse or substance abuse",I,Both
1,Patient With Dementia and insomnia.,- Identified by clinician investigator to have early-onset dementia and a significant component of insomnia.,LembN01 NCT06093126 TrialTroveID-489507,Adults,,,489507,Comorbidities in insomnia; Mild Cognitive Impairment/Dementia Risk,,,- Known sleep disorders that are contraindications for orexin antagonist therapy.,Iv,Both
0,Patients with amyotrophic lateral sclerosis.,"Inclusion criteria Age 40-65, disease duration < or = 12 months, FVC > or = 80%. 15 men, 11 women; mean age, 54.2 years. The median baseline CD34+ level was 2.15/L. Patients with a ‘definite’, ‘probable’ or ‘probable with laboratory support’ ALS diagnosis according to the revised El Escorial criteria Mild or moderate disability, with a minimum score of 3 according to the revised ALS functional rating scale, plus acceptable respiratory function Signs of disease progression over the previous 3 months Ability to provide signed informed consent to participate in the study.",EudraCT Number: 2005-003248-75 EudraCT-number 2005-03248-75 STEMALS STEMALS 01 TrialTroveID-087353,Adults,year(s),year(s),87353,Delay Disease Progression,65.0,40.0,"Patients with familial ALS were excluded from the study Concomitant or previous neoplasia History of myeloproliferative disorder; Splenomegaly with a spleen diameter larger then 180 mm Severe renal, cardiac or liver dysfunction.",Iii,Both
1,Patients with Amyotrophic Lateral Sclerosis,"Subjects who show both upper motor neuron signs and lower motor neuron signs at the same time in neurological tests. Among subjects diagnosed with familial or sporadic ALS, subjects falling into clinically definite ALS, probable ALS and probable ALS-lab supported according to The revised World Federation of Neurology El Escorial Criteria[Rix Brooks, 2000], during 17-weeks period prior to the administration and ALSFRS-R score (progression rate) of 1.03 + or - 50%/month (meaning mean value in that total period). For subjects who are under Riluzole treatment, those who have received stable dose of Riluzole for more than 28 days before screening visit. Subjects with duration of disease of no more than 2 years from the first diagnosis date. Subjects whose ALSFRS-R scores are in the range of 31~46 at the time of screening (P-V0).",ALSummit ALSUMMIT HYUH-2018-09-025 KCT0005954 NCT04745299 NEURONATA-R_ALS301 TrialTroveID-393116,Adults; Older Adults,year(s),year(s),393116,Delay Disease Progression,75.0,25.0,"Subjects who received tracheostomy or use ventilators (including positive pressure ventilators; subjects who use non-invasive ventilation for sleep apnea may be allowed after review) at the time of screening (P-V0). Subjects who received gastrotomy at the time of screening (P-V0). Subjects for whom clinical efficacy evaluation is not possible because pulmonary functional tests cannot be conducted at the time of screening (P-V0) or subjects whose forced vital capacity is found to be not greater than 40%of the expected value. Subjects who fall into above Class II according to the New York Heart Association's functional classification, who have showed myocardial infarction, unstable arrhythmia and/or other significant cardiovascular diseases such as unstable angina in the past 3 months, or who show electrocardiographic signs of myocardial infarction or angina at the time of screening (P-V0) or who received stent insertion or coronary artery bypass grafting. Subjects who have received other investigational products or edaravone within 3 month or 5 half-lives at the time of screening (P-V0) and lead in period visit L-V1 (evaluated by whichever is longer). Subjects who have experienced epileptic seizure. Subjects with severe renal disorder (serum creatinine: not less than 2.0 mg/dL). Subjects with severe hepatic disorder (ALT, AST, or bilirubin: over 2.0 times of the normal upper limit). Subjects who show hemorrhagic tendency at the time of screening (PT and aPTT > 1.5 x ULN) Subjects who are found to have active viral infections (HBsAg, HCV Ab, HIV Ab, CMV IgM, EBV IgM, HSV IgM and Treponema pallidum) at the time of screening. Subjects with hypersensitivity to antibiotics (penicillin or streptomycin). Subjects who have ever received any cell therapy product for the same disease. Subjects with any malignant tumor in the past 5 years before screening, except malignant tumors with very low risk of metastasis or death.",Iii,Both
0,Patients with Amyotrophic Lateral Sclerosis.,Inclusion Criteria: Patients diagnosed with probable ALS according to the World Federation of Neurology Revised El Escorial criteria. Age: 25-80 years ALS functional rating scale-revised (ALSFRS-R): 20 points,TrialTroveID-147469,Adults; Older Adults,year(s),year(s),147469,Delay Disease Progression,80.0,25.0,"Exclusion Criteria: Malignancy or are at risk of cardiogenic shock. Patients with severe medical illness complications.. El Escorial revised criteria, suspicious below. Patients who received surgery. Forced vital capacity 20% or less.",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis (ALS).,"Ages Eligible for Study: 25 Years to 75 Years Genders Eligible for Study: Both Inclusion Criteria: Patients between 25 and 75 years old Patients who have both signs of lower motor neuron(LMN) and upper motor neuron(UMN) degeneration by clinical, electrophysiological or neuropathologic examination Patients diagnosed as 'Probable' or 'Definite' ALS according to the World Federation of Neurology El Escorial criteria. Patients who have taken Rilutek at stable background dose from 3 months ago at least before screening entry. Patients whose duration of disease is within 5 years from the first diagnosis. Patients with ALSFRS-R score within 31 to 46 at screening. Patients who can visit to a hospital by walk personally or by protector's help. Patients who provide the written consent by oneself or his/her legal representative.",HYNR_CS_ALS201 NCT01363401 TrialTroveID-147370,Adults; Older Adults,year(s),year(s),147370,Delay Disease Progression,75.0,25.0,"Exclusion Criteria: Patients who doesn't appropriate to the diagnostic criteria of ALS. Patients who are diagnosed as primary lateral sclerosis(PLS) or progressive muscular atrophy(PMA). Patients suspected of adverse effect after stem cell injection(patients suspected of malignant tumor, risk group of psychogenic shock, patients with serious hypertension). Patients with ALSFRS-R score below 30 at screening. Patients performed ventilator or tracheostomy at screening. Patients performed gastrostomy at screening. Patients unable to assess the efficacy of this clinical trial due to unattainable PFT(Pulmonary Functional Test) or patients with suspected 40% or less of FVC at screening. Patients with finding of myocardial infarction or angina pectoris according to ECG, patients who have been performed Stenting or Bypass operation at screening. Patients who have taken any other drug for clinical trial within the past 3 months at screening entry. Patients with epilepsy. Patients with severe renal dysfunction(serum creatinine > or =2.0mg/dl). Patients with severe liver dysfunction(ALT, AST, bilirubin> or = upper limit of normal X 2). Pregnant woman, lactating woman, female patients who has a pregnancy planning or who doesn't agree with adoption of contraception methods proper medically, male patients who doesn't agree with adoption of contraception methods proper to his partner during participating this study. Patients with hemorrhagic tendency at screening. Patients with virus infection at screening. Patients with a known history of hypersensitivity/allergy to penicillin and streptomycin Patients with previous stem cell therapy Patients diagnosed with cancer Patients who have taken any drug thag can effect to bone marrow function Patients with any other neurological disease except ALS Patients with psychotic diseases",Iii,Both
1,Subjects with Frontotemporal Dementia,,TrialTroveID-376264,,,,376264,Frontotemporal Dementia,,,,Iii,
1,Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD),"1. Diagnosis of probable bvFTD according to the International Consensus Criteria for bvFTD 2. Centrally rated frontotemporal atrophy score of 2 or greater, taken as the maximum of right or left frontal or anterior temporal lobes on brain MRI of sufficient quality obtained at Screening or within a maximum of 42 days before Baseline, irrespective of pre-existing structural or functional imaging evidence supporting a diagnosis of bvFTD 3. MMSE > or = 20 at the Screening visit 4. Age <80 years at the Screening visit 5. Modified Hachinski ischemic score of < or = 4 at the Screening visit 6. Females must meet one of the following: Surgically sterile (hysterectomy, bilateral salpingectomy / oophorectomy) for at least 6 months minimum Have undergone bilateral tubal occlusion / ligation at least 6 months prior Post-menopausal for at least 1 year Using adequate contraception (a barrier method [such as condom,diaphragm, or cervical/vault cap] with spermicidal foam, gel, film, cream, or suppository; intrauterine device [IUD] or system, or oral or long-acting injected or implanted hormonal contraceptives for at least 3 months prior to Baseline; or vasectomized partner [with the appropriate post-vasectomy documentation of the absence of spermatozoa in the ejaculate]), or true abstinence (when this is in line with the preferred and usual lifestyle of the subject); subjects must be competent to use adequate contraception and to agree to continue to maintain adequate contraception throughout participation in the study OR In Italy, have avoided a pregnancy for at least 3 months prior to Baseline and accept to avoid a pregnancy throughout participation in the study 7. Subject and/or, in the case of reduced decision-making capacity, legally acceptable representative(s) consistent with national law is/are able to read, understand, and provide written informed consent in the designated language of the study site 8. Has one or more identified adult caregivers who meet the following criteria: Either lives with the subject or sees the subject on average for > or = 2 hours/day > or = 3 days/week, or in the investigator's opinion, the extent of contact is sufficient to provide meaningful assessment of changes in subject behavior and function over time and provide information on safety and tolerability Is willing to provide written informed consent for his/her own participation Is able to read, understand, and speak the designated language at the study site Agrees to accompany the subject to each study visit Is able to verify daily compliance with study drug 9. If currently taking an AChEI (i.e., donepezil, galantamine, or rivastigmine) and/or memantine, at the time of Screening: The subject must have been taking such medication(s) for > or = 3 months The current dosage regimen and dosage form must be within the locally approved dose range and must have remained stable for > or = 6 weeks It must be planned that the dosage regimen will remain stable throughout participation in the study Subjects not being treated with an AChEI or memantine (for > or = 6 weeks before Screening) may also be enrolled if initiation of an AChEI or memantine is not planned for the time period during which the subject will be participating in this study 10. Able to comply with the study procedures in the view of the Investigator",EudraCT Number: 2011-005529-34 NCT01626378 NL41019.078.12 TrialTroveID-228848 TRx-237-007,Children; Adults; Older Adults,,year(s),228848,Frontotemporal Dementia,79.0,,"1.Significant CNS disorder other than bvFTD 2.Other significant intracranial pathology seen on brain MRI scan that would lead to a diagnosis other than probable bvFTD or that puts the subject at risk of Amyloid Related Imaging Abnormalities including: large confluent white matter hyperintense lesions, other focal brain lesion(s), a single area of superficial siderosis, >4 cerebral microhemorrhages,evidence of a prior macrohemorrhage. 3.Biomarker evidence of underlying AD pathology as etiology of dementia 4.Expressive language deficits such that the subject is too severely impaired to allow testing at Baseline 5.Meets research criteria for Amyotrophic Lateral Sclerosis or motor;evidence of mild motor neuron disease on examination is allowed if not expected to interfere with subject's completion of study but prominent bulbar symptoms would be exclusionary 6.Meets diagnostic criteria for probable bvFTD but has a proven mutation producing non-tau,non-TDP-43 pathology 7.Clinical evidence or history of: Cerebrovascular accident (2 years) Transient ischemic attack (6 months) Significant head injury with associated loss of consciousness,skull fracture or persisting cognitive impairment (2 years) Other unexplained or recurrent loss of consciousness > or =15 minutes (2 years) 8.Epilepsy (a single prior seizure is considered acceptable) 9.Rapid eye movement sleep behavior disorder 10.DSM IV-TR criteria met for the following within specified period: Major depressive disorder (current) Schizophrenia (lifetime) Other psychotic disorders, bipolar disorder (within the past 5 years),or substance related disorders (within the past 2 years) 11.Metal implants in the head (except dental),pacemaker, any other non-removable items that are contraindications to MR imaging; any device proven to be MR compatible will be allowed 12.Resides in hospital or moderate to high dependency continuous care facility 13.History of swallowing difficulties 14.Pregnant or breastfeeding 15.G6PD deficiency 16.History of significant hematological abnormality or current acute or chronic clinically significant abnormality, including: Hereditary or acquired methemoglobinemia or Baseline measurement of MetHb >2.0% Hemoglobinopathy, myelodysplastic syndrome, hemolytic anemia,or splenectomy Screening value below normal range for hemoglobin and vitamin B12 or folate 17.Abnormal serum chemistry laboratory value at Screening clinically relevant.In addition, subjects with the following abnormalities must be excluded: Creatinine clearance <50 mL/min at Screening Thyroid stimulating hormone above laboratory normal range 18.Clinically significant cardiovascular disease or abnormal assessments such as: Hospitalization for acute coronary syndrome or symptoms consistent with angina pectoris, within the 12 months preceding Baseline Signs or symptoms of clinical heart failure within the 12 months preceding Baseline Evidence of uncontrolled atrial fibrillation on Screening ECG or history of atrial fibrillation that is not currently controlled or where the QT interval cannot be assessed by triplicate ECGs QTcF at Screening >460 msec in males or >470 msec in females, or low or flat T waves making measurement of QT interval unreliable Recent history of poorly controlled hypertension Hypotension Heart rate <48 bpm or >96 bpm by measurement of vital signs or by ECG at Screening 19.Preexisting or current signs or symptoms of respiratory failure. Subjects with previously diagnosed moderate to severe sleep apnea not adequately controlled should be excluded 20.Concurrent acute or chronic clinically significant immunologic, hepatic,or endocrine disease and/or other unstable or major disease other than bvFTD Subjects with hepatitis or primary biliary cirrhosis should be excluded HTLV-III, LAV (incl.any mutants/derivatives),any condition associated with Acquired Immunodeficiency Syndrome 21.Diagnosis of cancer within the past 2 years prior to Baseline (other than basal cell or squamous cell skin cancer or Stage 1 prostate cancer) unless treatment has resulted in complete freedom from disease for at least 2 years 22.Prior intolerance or hypersensitivity to MT-containing drug, similar organic dyes, or any of the excipients 23.Treatment currently or within 3 months before Baseline with the following medications: Tacrine Amphetamine or dexamphetamine Antipsychotics: clozapine, olanzapine (other antipsychotics are allowable if they have not been initiated within 3 months before Baseline and are used in a stable dose and regimen) Carbamazepine, primidone Other mood stabilizers Drugs associated with methemoglobinemia 24.Current or prior participation in a clinical trial Clinical trial of a product for cognition with last dose received within 90 days prior to Screening (unless randomized to placebo) Clinical trial of a drug, biologic,device, or medical food with last dose received within 28 days prior to Baseline",Iii,Both
1,Patients with alzheimer's disease or behavioral Variant frontotemporal dementia.,"Genders Eligible for Study: Both Inclusion Criteria: Subjects with all cause dementia and probable Alzheimer's disease at enrollment and who completed participation in one of the following three TauRx studies (inclusive of the 4-week post-treatment follow-up visit): TRx-237-005, TRx-237-008, or TRx-237-015. Subjects with a diagnosis of probable bvFTD at enrollment and who completed participation in TauRx study TRx-237-007 through Visit 9 (Week 52). Females, if of child-bearing potential, must practice true abstinence or continue to use adequate contraception and agree to maintain this throughout the study - Barrier method (such as condom, diaphragm or cervical/vault cap) with spermicidal foam, gel, film, cream, or suppository - Intrauterine device [IUD] or system - Oral or long-acting injected or implanted contraceptives for at least 3 months prior to Baseline - Vasectomized partner (with the appropriate post-vasectomy documentation of the absence of spermatozoa in the ejaculate) - True abstinence (when this is in line with the preferred and usual lifestyle of the subject) Subjects must agree to continue to maintain adequate contraception throughout participation in the study. Subject, and/or, in the case of reduced decision-making capacity, legally acceptable representative(s) consistent with national law and ethics approval is/are able to read, understand, and provide written informed consent Has an identified adult caregiver who is willing to provide written informed consent for his/her own participation; is able to read, understand, and speak the designated language at the study site; either lives with the subject or sees the subject for =1 hour/day =3 days/week; agrees to accompany the subject to each study visit; and is able to verify daily compliance with study drug - Is willing to provide written informed consent for his/her own participation - Is able to read, understand, and speak the designated language at the study site - Agrees to accompany the subject to each study visit - Is able to verify daily compliance with study drug Able to comply with the study procedures",EudraCT Number: 2014-002013-37 NCT02245568 NL52155.078.15 NMRR-14-1486-23103 REec-2015-1385 TrialTroveID-217397 TRx-237-020 TRx-237-020 23103,Adults,,,217397,Behavioral Symptoms - Other; Frontotemporal Dementia; Mild; Moderate,,,"Exclusion Criteria: History of swallowing difficulties (note: study drug should be swallowed whole and MUST NOT be broken, crushed or chewed or dissolved in fluids prior to ingestion) Pregnant or breastfeeding. Clinically significant laboratory, pulse co-oximetry, electrocardiogram, or imaging abnormality (in originating study) or emergent intercurrent illness that, in the judgment of the principal investigator, could result in the risk of participation outweighing the potential benefit. Current participation in, or intent to enroll in, another clinical trial of a drug, biologic, device, or medical food. In Germany, subjects mandated to reside in a continuous care or assisted living facility or those whose willingness to participate in the clinical trial may be unduly influenced",Iii,Both
0,Patients With Motor Neurons Diseases.,"Ages Eligible for Study 18 Years and above, Inclusion Criteria Patients with MNDs (ALS, PLS or PMA) who have cramps with average severity 50/100 points, are able to provide informed consent, have normal renal function and are on a stable riluzole dose.",8380-06-3R0 NCT00324454 TrialTroveID-078777,Adults; Older Adults,year(s),year(s),78777,Delay Disease Progression; Spasticity; Symptom relief,78.0,38.0,"Exclusion Criteria Pregnancy; unstable medical illness, dementia; drug abuse or non-compliance.",Ii,Both
1,Patients with amyotrophic lateral sclerosis.,Written or verbal informed consent (IC) for participation in the study. Subjects who completed 48 weeks of treatment according to the REFALS study protocol. Able to swallow study treatment capsules at the time of completing 48 weeks dosing in the REFALS study.,3119003 EudraCT Number: 2018-004180-31 NCT03948178 REFALS-ES TrialTroveID-342659,Adults; Older Adults,year(s),year(s),342659,Delay Disease Progression,120.0,18.0,"Development (or significant worsening from baseline of the REFALS study) of serious cardiovascular disease (e.g.: myocardial infarction, heart failure, arrhythmia, stroke, or second or third degree atrioventricular (AV) block). Pulse/heart rate repeatedly > 100 bpm after 5-minute rest at baseline. If the pulse/heart rate is > 100 bpm in the first recording, then a second recording must be done after another 5 min rest to confirm pulse/heart rate >100 bpm. Systolic blood pressure (SBP) < 90 mmHg. Severe renal impairment (creatinine clearance < 30ml/min or creatine >170 µmol/l at 48 week visit of the REFALS study, or on dialysis. Severe hepatic impairment at the discretion of the investigator. Women of reproductive age without a negative pregnancy test and without a commitment to using a highly effective method of contraception (e.g.: oral hormonal contraceptive associated with inhibition of ovulation, intrauterine devices and long acting progestin agent), if sexually active during the study, and for 1 month after the last dose of the study treatment. Women who are postmenopausal (1 year since last menstrual cycle), surgically sterilised or who have undergone a hysterectomy are considered not to be reproductive and can be included. Subject judged to be actively suicidal by the investigator. Any other clinical significant cardiovascular, gastrointestinal, hepatic, renal, neurological or psychiatric disorder or any other major concurrent illness that in the opinion of the investigator could interfere with the interpretation of the study results or constitute a health risk for the subject if he/she took part in the study.",Iii,Both
1,Patients with Amyotrophic Lateral Sclerosis.,"Written or verbal informed consent (IC) for participation in the study Male or female subjects with diagnosis of laboratory supported probable, probable or definite ALS according to El Escorial revised criteria. Full electromyogram (EMG) report available consistent with ALS (but not necessarily fulfilling the electrodiagnostic criteria for ALS) from an experienced neurophysiologist Able to swallow study treatment capsules, and in the opinion of the investigator, is expected to continue to do so during the study Sitting SVC between 60-90% of the predicted value for age, height and sex at screening visit Disease duration from symptom onset (defined by first muscle weakness or dysarthria) 12-48 months at the time of visit 1 (baseline) Able to perform supine SVC in an adequate and reliable way at screening and baseline visits as judged by the investigator Subjects with or without riluzole and/or edaravone. If using riluzole (any daily dose up to 100 mg), the dose must have been stable for at least 4 weeks before the screening visit and should not be changed during the study. If using edaravone, the treatment should have been started at least 4 weeks before the screening visit (at least one 28-day treatment cycle as indicated) and should not be changed during the study. If not on riluzole and/or edaravone, the respective treatments should not be started during the study.",134169 3119002 EudraCT Number: 2017-002754-36 NCT03505021 NL64706.041.18 REFALS TrialTroveID-322838,Adults; Older Adults,year(s),year(s),322838,Delay Disease Progression,120.0,18.0,"Subject in whom other causes of neuromuscular weakness have not been excluded Subject with a diagnosis of another neurodegenerative disease (e.g. Parkinson's or Alzheimer's disease) Assisted ventilation of any type within 3 months before the screening visit or at screening Any use of a diaphragm pacing system (DPS) within 3 months before the screening visit Any form of stem cell or gene therapy for the treatment of ALS Known hypersensitivity to levosimendan Administration of levosimendan within 3 months before the screening visit or previous participation in the present phase III study or earlier study with oral levosimendan in ALS patients (LEVALS) Any use of tirasemtiv or reldesemtiv within 1 month before the screening visit. Participation in a clinical trial with any experimental treatment within 30 days or within 5 half-lives of that treatment (whichever is longer) before the screening visit Any botulinum toxin use within 3 months before the screening visit Recorded diagnosis or evidence of major psychiatric diagnosis, significant cognitive impairment or clinically evident dementia that may interfere with the patient's ability to comply with study procedures Pulmonary illness (e.g. asthma or COPD) requiring regular treatment Haemodynamically significant uncorrected valve disease or hypertrophic cardiomyopathy or restrictive cardiomyopathy Any cardiovascular event (e.g. myocardial infarction, HF, arrhythmia or stroke) requiring hospitalisation within 3 months before the screening visit History of Torsades de Pointes (TdP) or diagnosed long QT-syndrome History of life-threatening ventricular arrhythmia, unless treated with reliable measures to prevent recurrence (e.g. with placement of implantable cardioverter defibrillator [ICD] or catheter ablation) History of second or third degree atrioventricular (AV) block or sinus node disease at screening, if not treated with pacemaker HR repeatedly > 100 bpm in the 12-lead ECG after a 5-minute rest at screening. If the HR is > 100 bpm in the first recording, then the second recording must be done after another 5 min rest to confirm HR > 100 bpm Systolic blood pressure (SBP) < 90 mmHg at screening Potassium < 3.7 mmol/l or > 5.5 mmol/l at screening Severe renal impairment (creatinine clearance < 30 ml/min at screening), creatinine > 170 µmol/l at screening or on dialysis Blood haemoglobin < 10 g/dl at screening or blood donation or loss of significant amount of blood within 60 days before the screening visit Clinically significant hepatic impairment at the discretion of the investigator Body mass index (BMI) < or = 18.5kg/m2 (BMI = weight/height2) Women who are lactating or of reproductive age without a negative pregnancy test and without a commitment to using a highly effective method of contraception (e.g. oral hormonal contraceptives associated with inhibition of ovulation, intrauterine devices and long acting progestin agents), if sexually active during the study, and for 1 month after the last dose of the study treatment. Women who are postmenopausal (1 year since last menstrual cycle), surgically sterilised or who have undergone a hysterectomy are considered not to be reproductive and can be included Patient judged to be actively suicidal by the investigator during 3 months before the screening visit Patients with known history of human immunodeficiency virus (HIV) infection Any other clinically significant cardiovascular, gastrointestinal, hepatic, renal, neurological or psychiatric disorder or any other major concurrent illness that in the opinion of the investigator could interfere with the interpretation of the study results or constitute a health risk for the subject if he/she took part in the study",Iii,Both
0,Patients with Amyotrophic Lateral Sclerosis,"-Written informed consent (IC) for participation in the study will be obtained from the subject (or from the subject's next of kin, caregiver, or other legally acceptable representative in case the study subject him/herself cannot sign the IC due to severe muscle weakness). -Male or female subjects with diagnosis of laboratory supported probable, probable or definite ALS according to El Escorial revised criteria (Brooks BR et al., 2000). Full electromyogram (EMG) report available compatible with ALS according to an experienced neurophysiologist. -Ability to swallow the study treatment capsules. -An upright (sitting position) SVC between 60-90% of the predicted value for age, height and sex at screening visit. -Normal oxygen saturation during daytime (measure of = 95% when steady state has been reached with a reliable read) in sitting position measured by pulse oximetry. -Disease duration from symptom onset (defined by first muscle weakness or dysarthria) of 12-48 months. -Using riluzole. The dose must have been stable for at least 4 weeks prior to screening at a dose of 50 mg b.i.d.",3119001 EudraCT Number: 2014-004567-21 LEVALS NCT02487407 TrialTroveID-261530 UKCRN ID: 18646,Adults; Older Adults,year(s),,261530,Delay Disease Progression,,18.0,"-Subject in whom other causes of neuromuscular weakness have not been excluded. -Subject with a diagnosis of another neurodegenerative disease (e.g. Parkinson's or Alzheimer's disease). -Assisted ventilation or gastrostomy of any type during the preceding 3 months prior to screening or predicted to be required within the randomised, double-blind cross-over part of the study. -Recorded diagnosis or evidence of major psychiatric diagnosis, significant cognitive impairment or clinically evident dementia. -Any major surgery within 1 month before the screening visit or patients who are scheduled for any major surgery during the planned study period. -Potassium less than 3.7 mmol/l or more than 5.5 mmol/l at screening. -Creatinine more than 170 µmol/l at screening or on dialysis. -Blood haemoglobin less than 10 g/dl at screening. -Clinically significant hepatic impairment at the discretion of the investigator. -Women of reproductive age without a negative pregnancy test and without a commitment to using an acceptable method of barrier or hormonal contraception (e.g. condoms, diaphragms, oral contraceptives and long acting progestin agents), if sexually active during the study, and for 1 month after the last dose of the study treatment. Women who are postmenopausal (1 year since last menstrual cycle), surgically sterilised or who have undergone a hysterectomy are considered not to be reproductive and can be included. -Known hypersensitivity to levosimendan. -Administration of levosimendan within 30 days prior to screening visit. -Patients with history of botulinum toxin treatment for any reason. -Patients with known history of human immunodeficiency virus infection. -History of significant arrhythmias or other cardiac events -Any other clinically significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, neurological or psychiatric disorder or any other major concurrent illness that in the opinion of the investigator could interfere with the interpretation of the study results or constitute a health risk for the subject if he/she took part in the study. -Blood donation or loss of significant amount of blood within 60 days prior to screening. -Participation in a clinical trial with any experimental treatment within 30 days prior to the screening visit or previous participation in the present study. -Any other condition that in the opinion of the investigator could interfere with the interpretation of the study results or constitute a health risk for the subject if he/she took part in the study.",Ii,Both
0,Subjects with Amyotrophic lateral sclerosis.,"1 45-70 years old, no gender limit (including 45 and 70 years old); 2 The diagnosis meets the ALS diagnosed and proposed in the Revised Criteria of the World Federation of Neurology (Revised Criteria of the World Federation of Neurology, 1998); 3 The duration of the disease from the onset of the subject to random is < or = 2 years; 4 Before randomization, all items of ALSFRS-R score were > or = 2 points, and the items of respiratory function were 4 points; 5 ALSFRS-R decreased by 1-4 points (> or = 1 and < or = 4 ) within 3 months of the screening period; 6 Forced Vital Capacity (%FVC) > or = 80% before random; 7 Understand and abide by the test procedure, participate voluntarily, and sign the informed consent form (the informed consent form is voluntarily signed by the person or guardian).",CTR20202126 MP-2019-004 TrialTroveID-389004,Adults; Older Adults,year(s),year(s),389004,Delay Disease Progression,70.0,45.0,"1 Familial ALS (judged based on family history); 2 People with obvious cognitive impairment (MMSE scale: illiteracy group < or = 19 points, elementary school group < or = 22 points, junior high school and above group (more than 8 years of education) < or = 26 points); 3 Have obvious difficulty swallowing; 4 Severe renal insufficiency: creatinine clearance <30 mL/min (Cockcroft-Gault formula), or other known severe renal insufficiency diseases; 5 Severe liver damage: ALT, AST> 3 times the upper limit of normal, or other known liver diseases such as acute and chronic active hepatitis, cirrhosis, etc.; 6 In the screening period, patients with acute myocardial infarction or interventional therapy in the past 6 months and heart failure (patients with grade III-IV according to NYHA classification); 7 Combined with malignant tumor, blood, digestive or other serious diseases of the system. 8 Those who are allergic to experimental drugs or ligustrazine; 9 During pregnancy and lactation; 10 Participated in other drug clinical trials within 30 days before screening, or are participating in other clinical trials; 11 The researcher thinks it is not suitable to participate in this trial.",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis (ALS).,"Study Population: Patients Adults (18 to 64 years), elderly (65 years) Females and males Inclusion criteria: ALS Defined or Probable Age 'Between 30 And 70 Years Duration Of Illness Of Less Than 18 Months.",ALALS EudraCT Number: 2005-005152-40 TrialTroveID-109559,Adults; Older Adults,year(s),year(s),109559,Unspecified,70.0,18.0,"Exclusion criteria: Family ALS, Internist serious clinical conditions, malignancy, diabetes mellitus",Ii,Both
0,Patients with amyotrophic lateral sclerosis.,,TrialTroveID-261108,,,,261108,Unspecified,,,,Ii,
1,Patient with Amyotrophic Lateral Sclerosis.,"Inclusion Criteria: Participants who have completed week 77 of the LICALS double blind trial. Age > or = 18 years (inclusive). In the case of a female with childbearing potential, the patient must not be pregnant or breast-feeding. Women of childbearing potential will have a urine pregnancy test before randomisation; and at each clinic visit. The results of those must be negative. Women of childbearing potential should use adequate contraception. Capable of understanding the information given and giving fully informed consent prior to any study specific procedures.",EudraCT Number: 2008-006891-31 LICALS Extension TrialTroveID-137565 UKCRN ID: 9349,Adults; Older Adults,year(s),,137565,Delay Disease Progression,,18.0,"Exclusion Criteria: Any laboratory abnormal values considered by the local physician to contraindicate lithium. Recorded diagnosis or evidence of major psychiatric disorder or clinically evident dementia. Known allergy or hypersensitivity to lithium, or its excipients. Likely to be uncooperative or to fail to comply with the trial requirements or to be inaccessible in the event of an emergency. Subjects with significant haematological, biochemical and autoimmune abnormalities, as judged by the study physician. If a woman of childbearing potential, unable or unwilling to use effective contraception during the study. Patients already taking lithium in any form outside the LICALS trial. Presence of a medical condition contra-indicative to the use of lithium, according to the BNF (http://www.bnf.org/bnf/)",Iv,Both
0,"Patients (n = 11) with amyotrophic lateral sclerosis (4 females, mean age 66 yr +/- 8) and control patients (n = 10) (6 females, mean age 71 yr +/- 13).",,TrialTroveID-135873,Adults; Older Adults,year(s),year(s),135873,Delay Disease Progression,84.0,58.0,,Ii,Both
0,"Sporadic ALS patients (mean +or-SD age: 64.3 +or -7.0 years; mean +or- SD duration of the disease 15.3 +or-9.4 months). Enrolled patients (20% bulbar, 30% cervical and 50% pseudopolyneuritic form).",,TrialTroveID-111253,Adults; Older Adults,year(s),year(s),111253,Unspecified,71.0,57.0,,Ii,
0,Patients with amyotrophic lateral sclerosis (ALS).,,TrialTroveID-111182,,,,111182,Delay Disease Progression,,,,Ii,Both
0,Patients with amyotrophic lateral sclerosis.,"Inclusion Criteria: ALS, sporadic or familial, definite, probable or likely to support laboratory. Age > 18 years. Disease duration less than 36 months. The patient should be treated with riluzole in combination with cycles of thirty days every three months of vitamin E (400 mg / day) as an antioxidant. Disable mild or moderate. Patients should be able to understand and adhere to the requirements of the study protocol, and must provide written informed consent. Negativity of the pregnancy test in women age fertile.",2707/2009 EudraCT Number: 2009-010060-41 TrialTroveID-109390,Adults; Older Adults,year(s),,109390,Delay Disease Progression,,18.0,"Exclusion Criteria: Patients with serious psychiatric disorders (Axis 1 or 2 of the DSM IV). Patients with severe or profound mental retardation (IQ in the WAIS <45). Patients with uncorrected hypothyroidism (serum TSH values greater than 20% compared to the upper limits of normal, and patients taking medications for thyroid disorders should be in a euthyroid for at least three months before the screening visit). Patients with drug therapy (thiazide diuretics, potassium-sparing diuretics, nonsteroidal anti-inflammatory drugs, COX-2 inhibitors, ACE inhibitors, receptor angiotensin system, iodine salts and any other potential inhibitor activity 'IP3) are inconsistent with treatment with lithium salts. Previous allergic or hypersensitive state 'to the lithium. Cardiac patients (all conduction abnormalities ECG) and / or renal failure. Patients on diuretics. Epileptic patients. Motor neuron diseases other than ALS (progressive bulbar palsy, progressive muscular atrophy, primary lateral sclerosis). Clinical involvement of other neurological systems (sensory, extrapyramidal, oculomotor, cerebellar, vegetative). Poor compliance with previous treatments. Subjects with PEG or tracheostomy. Pregnancy and lactation.",Ii,Both
1,Adults of both sexes with a diagnosis of ALS.,"SLA defined, probable, or likely to support laboratory Age '> 18 years Disease duration of less than 36 months The patient should be treated with riluzole in combination with 30-day cycles every 3 months of vitamin E (400 mg / day) as an antioxidant; Disable 'mild or moderate, documented by a spinal or bulbar function is still satisfactory (average score of 3 to ALS-FSR-R scale, with a score of at least 3 for swallowing) and features a' satisfactory breathing (FVC >or= 60% ) Patients should be able to understand and adhere to the requirements of the study protocol, and must provide written informed consent; Negativity 'of the pregnancy test in women age' fertile.",2327/2007 EudraCT Number: 2008-001879-30 TrialTroveID-109383,Adults,year(s),year(s),109383,Delay Disease Progression,64.0,18.0,"Patients with serious psychiatric disorders (Axis 1 or 2 of DMS IV) Patients with severe or profound mental retardation (IQ in the WAIS <45); Patients with hypothyroidism is not compensated; Patients with drug regimens incompatible with treatment with lithium salts; Previous allergic or hypersensitive state 'to the lithium? Patients with cardiac disease and / or renal failure; Patients treated with diuretics Epileptic patients; Motor neuron diseases other than ALS (progressive bulbar palsy, progressive muscular atrophy, primary lateral sclerosis) Clinical involvement of other neurological systems (sensory, extrapyramidal, oculomotor, cerebellar, vegetation) Poor compliance with previous treatments; Subjects with PEG or tracheotomy.",Iii,Both
1,"Patients with Amyotrophic Lateral Sclerosis. (100 men, 71 women; mean age 58.3 years)","a. SLA defined, probable, or likely to support the laboratory. b. Age 'between 18 and 75 years; c. Disease duration less than 36 months; d. Score of at least 2 for the Swallowing scale ALS-FRS-R score of at least 2 under the stairs walking ALS-FRS-R score of at least 3 respiratory failure at the scale under ALS-FRS-R e. Disease progression documented over the past 3 months; f. Patients should be able to understand and adhere to the requirements of the study protocol and provide written informed consent. g. Patients should be treated with riluzole stabilized dose of 50 mg twice daily for at least two months or should not be treated with riluzole throughout the study period. Diagnosis of clinically definitive, probable or probabile laboratory-supported, possible ALS Concomitant standard Riluzole therapy 50 mg twice daily for at least 2 months or without standard Riluzole therapy during the period of the study. Value more than 2 at the point Swallowing in the ALS-FRS-R scale, value more than 2 at the point walking in the ALS-FRS-R scale, value more than 3 at the point respiratory function at the ALS-FRS- R scale",EudraCT Number: 2008-001094-15 LitALS TrialTroveID-108793,Adults; Older Adults,year(s),year(s),108793,Delay Disease Progression,75.0,18.0,"a. Previous infection poliomyelitis, motor neuron b.Malattie other than ALS (progressive bulbar palsy, progressive muscular atrophy, primary lateral sclerosis); c.Coinvolgimento other clinical neurological systems (sensory, extrapyramidal, oculomotor, cerebellar, vegetative); d.Gravi conditions internistic clinics, such as cardiovascular disease, hypertension, renal failure or liver, thyroid, e.Creatininemia> 1.6 mg / dl f. Pregresse cardiovascular disease, cerebrovascular or peripheral circulation disorder inherited. g.Neoplasie malignant h.Serious deterioration in mental i.Poor compliance with previous treatments; j. Pregnant or breast-feeding or during the study may become pregnant. The state of pregnancy will not 'confirmed by a negative test for beta-HCG performed 7 days before Start of treatment. The lack of risk of pregnancy and 'indicated by (1) be in menopause, (2) have undergone surgery isteroannessiectomia, (3) contraceptive use, (4) to be sexually inactive.",Iii,Both
0,Patients with amyotrophic lateral sclerosis.,,TrialTroveID-107925,,,,107925,Unspecified,,,,Ii,Both
1,Patients with amyotrophic lateral sclerosis.,"Patients with possible, laboratory-supported probable, probable or definite ALS according to the revised version of the El Escorial World Federation of Neurology criteriaThe Airlie House Statement). These criteria are internationally accepted research diagnostic criteria with high specificity and sensitivity. The onset form (bulbar or limb) and disease type (familial or sporadic) will be recorded; source documents will include a full report of an electromyogram (EMG) reported by an experienced neurophysiologist as compatible with ALS. The neurological exam should be performed by a physician. Disease duration > or =6 months and < or = 36 calendar months (inclusive), with disease onset defined as date of first muscle weakness, or dysarthria. Age > or = 18 years (inclusive). FVC > or = 60% of predicted within 1 month prior to randomisation SVC greater than or equal to 60% of predicted within 1 month prior to randomisation. Sex: male or female. In the case of a female with childbearing potential, the patient must not be pregnant or breast-feeding. Women of childbearing potential will have a urine pregnancy test before randomisation and at each clinic visit. The results of those must be negative. Women of childbearing potential should use adequate contraception. Continuously treated with riluzole for at least 4 weeks prior to screening (28 days inclusive) and stabilised at 100 mg/day (50 mg twice daily [bid]) without significant adverse drug reactions Capable of understanding the information given and giving fully informed consent prior to any study specific procedures.",6345 EudraCT Number: 2008-006891-31 ISRCTN83178718 LiCALS RAA/2008/013 TrialTroveID-104757 UKCRN ID 5745,Adults; Older Adults,year(s),,104757,Delay Disease Progression,,18.0,"Participation in another therapeutic study within the preceding 12 weeks or use of other investigational drugs or agents. Tracheostomy, or assisted ventilation of any type during the preceding three months. Existing gastrostomy. unless elective and not currently used for nutritional support or hydration Any medical condition known to have an association with motor neuron dysfunction which might confound or obscure the diagnosis of ALS. Presence of any concomitant life-threatening disease or any disease or impairment likely to interfere with functional assessment. Confirmed hepatic insufficiency or abnormal liver function (aspartate aminotransferase [AST] or alanine aminotransferase [ALT] greater than 1.5 times the upper limit of the normal range) within one month of randomisation. That blood test may be repeated in the case of initial abnormal results; if the levels return to normal, the patient may then be included in the study. Renal insufficiency (serum creatinine greater than upper limit of normal [ULN] for the centre/local laboratory) within one month of randomisation. That blood test may be repeated in the case of initial abnormal results; if the level returns to normal, the patient may then be included in the study. Evidence of major psychiatric disorder or clinically evident dementia precluding evaluation of symptoms. Known allergy or hypersensitivity to lithium, or its excipients Likely to be uncooperative or to fail to comply with the trial requirements or to be inaccessible in the event of an emergency. Subjects with significant haematological, biochemical and autoimmune abnormalities, as judged by the study physician If a woman of childbearing potential, unable or unwilling to use effective contraception during the study Patients with active inflammation/infection at screening or baseline (day 0). Patients presenting with active inflammation/infection can be reassessed at a later date, and included in the trial if the infection/inflammation has cleared. Patients already taking lithium in any form. Presence of a medical condition contra-indicative to the use of lithium, according to the British National Formulary (BNF). Use of PEG of non-invasive ventilation.",Iii,Both
0,Amyotrophic lateral sclerosis patients,"Inclusion criteria: Definite, probable, or probable-laboratory supported ALS according to the revised El Escorial World Federation of Neurology criteria. Intake of riluzole 2dd 50 mg. A disease duration (at inclusion) of more than 6 months and less than 36 months (disease onset is defined as the date of first symptoms excluding muscle cramps and fasciculations). Vital capacity (VC%) 70 % of normal value (slow expiration, best of a minimum of three and a maximum of five measurements, with a respiratory function validly assessable and spontaneous, non-assisted ventilation). Age 18 - 85 years (inclusive). Capable of thoroughly understanding the trial information given; has signed the informed consent.",08-192 METC UMC Utrecht LITRA NTR1448 TrialTroveID-100377,Adults; Older Adults,year(s),year(s),100377,Delay Disease Progression,85.0,18.0,"Exclusion criteria Tracheostomy, tracheostomal ventilation of any type, non-invasive ventilation more than 16 hours/ day, or supplemental oxygen during the last three months prior to inclusion. Any medical condition or intoxication known to have an association with motor neuron dysfunction, which might confound or obscure the diagnosis of ALS. Presence of any concomitant life-threatening disease or any disease or impairment likely to interfere with functional assessment. Contra indications for lithium therapy Interaction of lithium with other medication (like NSAID's and thiazide diuretics) that increase the chance of intoxication.",Ii,
0,Patients with Amyotrophic Lateral Sclerosis.,"Age 18 - 85 years Inclusion criteria: Definite, probable, or probable-laboratory supported ALS according to the revised El Escorial World Federation of Neurology criteria. Intake of riluzole 2dd 50 mg. A disease duration (at inclusion) of more than 6 months and less than 36 months. Vital capacity (VC%) is 70 % of normal value. Capable of thoroughly understanding the trial information given; has signed the informed consent.",LTA-2-2008 LTA-2-2008 UMC Utrecht NTR1432 TrialTroveID-097749,Adults; Older Adults,year(s),year(s),97749,Delay Disease Progression,85.0,18.0,"Exclusion criteria: Tracheostomy, tracheostomal ventilation of any type, non-invasive ventilation more than 16 hours/ day, or supplemental oxygen during the last three months prior to inclusion. Any medical condition or intoxication known to have an association with motor neuron dysfunction, which might confound or obscure the diagnosis of ALS. Presence of any concomitant life-threatening disease or any disease or impairment likely to interfere with functional assessment. Contra indications for lithium therapy. Interaction of lithium with other medication.",Ii,
1,Volunteers with Amyotrophic Lateral Sclerosis (ALS).,"Ages Eligible for Study: 18 Years and older Inclusion Criteria Familial or sporadic ALS. Participants diagnosed with laboratory supported probable, clinically possible, probable or definite ALS according to the World Federation of Neurology Revised El Escorial criteria. Disease duration from symptom onset no greater than 36 months at the Screening Visit. Age 18 years or older. Capable of providing informed consent and complying with trial procedures. On a stable dose of riluzole 50mg bid for at least 30 days prior to screening. Vital capacity (VC) equal to or more than 60% predicted value for gender, height and age at the Screening Visit. Creatinine <1.5 mg/dl (133 umol/L). Participants maintained on thyroid medication must be euthyroid for at least 3 months before the Screening Visit. Participants with psoriasis must have inactive disease for at least 30 days before the Screening Visit. Women must not be able to become pregnant (e.g., post menopausal for at least one year, surgically sterile, or practicing adequate birth control methods) for the duration of the study. Women of childbearing potential must have a negative serum pregnancy test at the Screening Visit and be non-lactating. Geographic accessibility to the study site. Patients may be included if they are within three years of their diagnosis and are not already taking lithium.",3U01NS049640-04S1 CRC LALS-001 NCT00818389 TrialTroveID-096325 U01NS049640,Adults; Older Adults,year(s),,96325,Delay Disease Progression,,18.0,"Exclusion Criteria History of known sensitivity or intolerability to lithium or to any other related compound. Prior exposure to lithium within 90 days of the Screening Visit. Exposure to any investigational agent within 30 days of the Screening Visit. Participants who are malnourished, dehydrated or on a sodium-free diet will be excluded due to the potential side effects of lithium carbonate. Use of digoxin or iodide salts [e.g. calcium iodide, hydrogen iodide (hydriodic acid), iodide, iodinated glycerol (Organidin), iodine, potassium iodide (SSKI), and sodium iodide supplementation beyond table salt]. Presence of any of the following clinical conditions: Substance abuse within the past year; Unstable cardiac, pulmonary, renal, hepatic, endocrine, hematologic, or active malignancy or infectious disease; AIDS or AIDS-related complex; Clinically active psoriasis within 30 days of the Screening Visit; Unstable psychiatric illness defined as psychosis (hallucinations or delusions) or untreated major depression within 90 days of the Screening Visit; Screening serum creatinine greater than or equal to 1.5 mg/dL (133 umol/L), TSH > 20% above the upper limit; Presence of any clinically significant conduction abnormalities on ECG; or Lactating or have a positive serum pregnancy test at the Screening Visit.",Ii/Iii,Both
0,Subjects with Amyotrophic Lateral Sclerosis (ALS). 107 patients and 249 control patients were included.,"Ages Eligible for Study: 21 Years to 80 Years Inclusion Criteria Clinical diagnosis of laboratory-supported probable, probable, or definite ALS. Vital capacity of at least 75% of predicted. Onset of weakness within 3 years prior to enrollment. If patients are on riluzole, they must be on a stable dose for at least 30 days prior to baseline visit. Women of childbearing potential must be surgically sterile or using an effective method of birth. control and have a negative pregnancy test. Willing and able to give informed consent. Participants must: -Have a diagnosis of ALS, which has been confirmed at the local study site. -Have a breathing (FVC) test score of 75 percent of normal or better. -Be in good general health. -Meet other requirements to be discussed at the study site.",28.013 NCT00790582 TrialTroveID-091425,Adults; Older Adults,year(s),year(s),91425,Delay Disease Progression,80.0,21.0,Exclusion criteria: Diagnosis of other neurodegenerative disease. Need tracheotomy ventilation or non-invasive ventilation 23 or more hours/day. Clinically significant history of any unstable medical condition in past 30 days. History of renal. History of liver disease. Current pregnancy or lactation. Use of lithium within thirty days of enrollment. Significantly limited mental capacity. History of recent drug or alcohol abuse. Use of any investigational drug within 30 days prior to enrollment.,Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis.,Amyotrophic Lateral Sclerosis (ALS) patients.,TrialTroveID-121167,,,,121167,Delay Disease Progression,,,,Ii,
0,Patients with amyotrophic lateral sclerosis (ALS).,"Ages Eligible for Study; 18 Years and older Inclusion Criteria: Diagnosis of clinically possible, clinically probable laboratory-supported, clinically probable or clinically definite ALS (according to WNF EL Escorial diagnostic criteria, revised according to the AIRLIE House Conference 1998). Concomitant standard Riluzole therapy (50mg twice daily). Patients included in ALS reference center. Women of childbearing age be non-lactating and surgically sterile or using a highly effective method of birth control and have a negative pregnancy test Capable of thoroughly understanding all information given and giving full informed consent according to GCP. Patients with gastrostomy.",EudraCT Number: 2008-003707-32 LISLA NCT00925847 P080401 TrialTroveID-110858,Adults; Older Adults,year(s),,110858,Delay Disease Progression,,18.0,"Exclusion Criteria: Evidence of major psychiatric disorder or clinically evident dementia precluding evaluation of symptoms. Any medical condition known to contre-indicate lithium treatment (dysthyroid, cardiopathy, renal insufficiency). Presence of any concomitant life-threatening disease or impairment likely to interfere with functional assessment. Hypersensitivity to any component of Teralithe (lithium carbonate, hypromellose, stearic acid, magnesium stearate, silica colloidal anhydrous) Existence of biological criteria reflecting even moderate renal insufficiency (creatinine clearance <85 ml / min) or sodium depletion. Heart disease leading to impaired ventricular function, arrhythmias or chronic paroxysmal. Induced disorder uncorrected. Women pregnant or of childbearing age without effective contraception, breastfeeding. Decision-treatment incompatible with co-prescription of lithium. Getting past lithium or lithium not previously treated with lithium including homeopathic oligosol, positive blood test and whatever the plasma concentration of lithium obtained. Patients with dementia of frontotemporal type, major psychiatric disorder, a condition inconsistent with evolving medical prescription of lithium and / or the constraints of the study. Patients gastrostomises. Patients tracheotomized.",Ii,Both
0,"Eleven patients presented the bulbar form of the disease, and the remaining presented the classic onset. Lithium-treated patients and control patients were carefully matched for bulbar forms and FVC at the time of their inclusion in the study.","Inclusion Criteria - Male or female aged >30 years with definite or probable sporadic ALS (El Escorial revised criteria); disease duration <5 years. - On therapy with riluzole >6 months. - Forced vital capacity (FVC) >70% of predicted value. - ALS functional rating scale-revised (ALSFRS-R) score >20 and Medical Research Council (MRC) score never <4 in each muscle groups (neck flexors/extensors, shoulder adductors/abductors, forearm flexors/extensors, wrist flexors/extensors, first dorsal interosseus, hip flexors/extensors and adductors/abductors, thigh flexors/extensors, foot flexors/extensors).",TrialTroveID-096403,Older Adults,year(s),year(s),96403,Delay Disease Progression,72.0,65.0,"Exclusion criteria - Cardiological diseases, renal or hepatic failure, hypothyroidism, severe endocrine or hematologic diseases, history of intolerance to lithium, concomitant therapies not compatible with lithium and diagnosis of motor neuron diseases other than ALS, the presence of life-supporting therapies. - Multifocal motor conduction blocks were excluded both in the ulnar (axilla, elbow, and wrist) and deep peroneal nerve (caput fibulae and ankle). - Abnormal blood levels of antibodies against Borrelia burgdorferi, gangliosides GM1, GM2, GD1a, GD1b, sulphatides, myelin associated glycoprotein, glutamate decarboxylase, kappa and lamba antibody light chains (also in urine), monoclonal immunoglobulins, neurooncogene and paraneoplastic antigens were also excluded.",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis.,"Patients aged 40 to 70 years. Of both genders. Female patients who are either postmenopausal for at least 24 months or who are able to practice 2 methods of contraception. Clinical diagnosis of definite ALS supported by neurophysiological studies, according to El Escorial reviewed criteria and Awaji criteria. Sporadic ALS, a priori. Onset of weakness for 1 year + or - 6 months Vital capacity of at least 60 % of the predicted value Other treatment (with riluzole or not) at fixed dosis 2 months before and during all the clinical trial. Patients who are willing to give informed consent. Without gastrostomy. Without jejunostomy. Without traqueostomy.",CONACYT234154 NCT03204500 TrialTroveID-304621,Adults; Older Adults,year(s),year(s),304621,Unspecified,70.0,40.0,"Age less than 25 years. Patients with uncontrolled diabetes. Patient with heart failure. Patient with respiratory vital capacity < 60%. Hepatic failure. Dysthyroidism. Do not give or sign informed consent. Women in lactation, pregnancy or possibility of pregnancy. Patients with significant sensory abnormalities and uncompensated medical illnesses. Laboratory abnormalities consistent with clinically significant cardiovascular, respiratory, haematological, metabolic, hepatic and renal disease. Patients with gastrostomy. With jejunostomy. With nasogastric tube. Tracheotomy and invasive ventilation. Treatment with investigational drug within 3 months prior to screening. Patients aged 26 to 39 years can be included at the discretion of medical researchers.",Ii,Both
0,,,TrialTroveID-508358,,,,508358,Unspecified,,,,I,
0,Patients with Amyotrophic Lateral Sclerosis (ALS).,"Male or female, aged at least 18 years. Sporadic or familial ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria. Patient is able to understand and express informed consent (in the opinion of the site investigator). Patient has access to the Internet on a desktop computer, laptop, or tablet and has a working email address. Patient or caregiver is willing and able to use a computer and enter data on a secure website. Patient is able to read and write English. Women must not be able to become pregnant (e.g., post-menopausal, surgically sterile, or using adequate birth control methods) for the duration of the study and three months after study completion. Adequate contraception includes: abstinence, hormonal contraception (oral contraception, implanted contraception, injected contraception or other hormonal contraception, for example patch or contraceptive ring), intrauterine device (IUD) in place for = 3 months, barrier method in conjunction with spermicide, or another adequate method.",NCT02709330 TrialTroveID-274942,Adults; Older Adults,year(s),,274942,Delay Disease Progression,,18.0,Patient is taking other experimental treatments for ALS. Prior side effects from Lunasin. Known soy allergy. Patient has a medical or psychiatric illness that could in the investigator's opinion interfere with the patient's ability to participate in this study. Pregnant women or women currently breastfeeding.,Ii,Both
0,Patients with frontotemporal dementia (FTD) with a GRN mutation.,"Men or women aged 30 to 85 years (inclusive), at the time of informed consent. Body weight range of ≥40 kg (88 lbs) to ≤110 kg (242 lb) and a BMI of 18 to 34 kg/m2. Has symptomatic frontotemporal dementia (FTD), including mild behavioral, cognitive, motor or language impairment per Investigator's assessment (behavioral-variant FTD, primary progressive aphasia-FTD, FTD with corticobasal syndrome, or a combination of syndromes are allowed for enrollment). Score ≥0.5 and ≤15 on CDR plus NACC FTLD sum of boxes. Stable use of background medications at least 8 weeks prior to LY3884963 dosing. Carrier of a pathogenic progranulin gene (GRN) mutation. Negative screening test for Mycobacterium tuberculosis (MTB) or documented negative MTB test within 1year prior to screening. Age- and gender-appropriate cancer screenings are up-to-date and completed. Patient and/or patient's legally authorized representative has the ability to understand the purpose and risks of the study, and provide written informed consent and authorization to use protected health information. Patient has a reliable study partner/informant (e.g. family member, friend) willing and able to participate in the study as a source of information on the patient's health status and cognitive and functional abilities. Patient is not dependent on a walker or wheelchair. Patient is living in the community (i.e. not in nursing home); some levels of assisted living may be permitted at the discretion of the investigator. Pneumococcal pneumonia and shingles vaccines are required within 10 years of Screening (allowed to be performed during Screening but must be given at least 4 weeks prior to initiation of immunosuppressant regimen).",019511 EudraCT Number: 2019-003159-12 J4B-MC-OKAA NCT04408625 PROCLAIM PRV-FTD101 TrialTroveID-363569,Adults; Older Adults,year(s),year(s),363569,Frontotemporal Dementia,85.0,30.0,"Diagnosis of a significant CNS (central nervous system) disease other than frontotemporal dementia (FTD) that may cause FTD symptoms or confound study objectives. Brain or cervical spine magnetic resonance image (MRI)/MRA imaging showing clinically significant abnormality considered to prevent intracisternal magna (ICM) injection. Hypersensitivity or contraindications to corticosteroid, and/or sirolimus use. Clinical evidence of peripheral symmetric sensory polyneuropathy (stable sensory mononeuropathies and radiculopathies are not exclusionary). Concomitant disease or condition within 6 months of screening that could interfere with, or treatment of which might interfere with, the conduct of the study or that would, in the opinion of the investigator, pose an unacceptable safety risk to the patient or interfere with the patient's ability to comply with study procedures Clinically significant laboratory test result abnormalities assessed at screening. Participation within 3 months prior to screening in another therapeutic investigational drug or device study with purported disease-modifying effects on FTD, unless it can be documented that the patient received placebo only. Any type of prior gene or cell therapy. Live vaccines in the 4 weeks prior to Screening. NOTE: Pneumococcal vaccine and/or shingles vaccine administration is allowed at least 4 weeks prior to initiation of immunosuppressant regimen. Use of blood thinners in the 2 weeks prior to screening, or anticipated use of blood thinners during the study. Antiplatelet therapies are acceptable if the patient is medically able to temporarily stop 48 hours to 7 days (depending on the antiplatelet medication used) prior to and at least 48 hours after ICM injection and LP. Note: the use of blood thinners as part of prophylaxis or treatment of an emergent VTE or another AE during the study does not exclude the patient, unless there is a baseline high risk of thromboembolic events, and use of blood thinners is highly anticipated in the opinion of the Investigator. Contraindications or intolerance to imaging methods (MRA, MRI, and/or computed tomography [CT]), including claustrophobia and intolerance to contrast agents used for MRI, MRA, or CT (including, but not limited to, gadolinium contrast agents and iohexol). Contraindications to general anesthesia or deep sedation. Positive urine test for drugs of abuse (including opiates, amphetamines, cocaine, barbiturates, and phencyclidine) without prescription at Screening and on Day 1. Other protocol-defined inclusion/exclusion criteria may apply",Iii,Both
0,,,TrialTroveID-388278,,,,388278,Delay Disease Progression,,,,I,
0,Subjects with Amyotrophic lateral sclerosis (ALS),"Male or female subjects aged between18 and 80 years ALS meeting the revised El Escorial criteria for possible, probable, laboratory-supported probable, or definite ALS (familial or sporadic) Time since first motor deficit at screening: at least 6 months, up to 24 months Slope of progression of ALS Functional Rating Scale - revised (ALSFRS-R) from date of symptom onset to date of screening test (ΔFS/number of months) between [0.4 and 1.1] Able to swallow study treatments (including capsules without opening or chewing them) as per the investigator's assessment SVC (Slow Vital Capacity) equal to or greater than 70% of the predicted normal value for sex, height, and age at the screening visit If taking riluzole, subject must be on a stable dose for ≥30 days Signature of written informed consent by subject",IASO MPNS01 NCT05889572 TrialTroveID-458533,Adults; Older Adults,year(s),year(s),458533,Delay Disease Progression,80.0,18.0,"Subjects with a non-invasive ventilation, a tracheotomy and /or a gastrostomy Known autoimmune diseases, inflammatory disorders (SLE, Rheumatoid arthritis, connective tissue disorder) or chronic infections (HIV, hepatitis B, or C infection, Tuberculosis) Known hypersensitivity to rifaximin or macrogol or any of its components Known allergy or intolerance to trehalose, maltodextrin or Polyethylene Glycol (PEG) Documented hepatic impairment (Alanine Transaminase/ Aspartate Transaminase > 5N) Subject with white blood cells < 4000/ mm3; Polynuclear neutrophils < 1.5 G/ L Active infection requiring systemic antimicrobial therapy within 2-week prior to screening visit Active infection requiring systemic antimicrobial therapy between screening and baseline Medical condition requiring proton pump inhibitors (PPIs) Gastrointestinal obstruction or perforation Any gastro-intestinal bleeding in the past 3 months Gastric emptying disorders (gastroparesis) Toxic megacolon Severe forms of inflammation of the intestinal tract, including Crohn's disease and ulcerative colitis Severe vital organ dysfunctions unrelated to ALS and not compatible with experimental treatment, as per the investigator's assessment Subjects with negative IgG serology for Epstein Barr virus (EBV) Women of childbearing potential1 without effective contraceptive protection Nursing or pregnant women Any condition that, in the opinion of the investigator, may interfere with full participation in the study, including administration of study drug (and its preparation procedure) and attendance at required study visits; represent a significant risk to the subject; or interfere with the interpretation of study data Enrollment in another trial or expanded access program that may interfere with this study Guardianship/legal protection/curatorship of subjects Vulnerable subjects such as: persons deprived of liberty, persons in intensive care units unable to provide informed consent prior to the procedure",I,Both
0,Patients with Amyotrophic Lateral Sclerosis.,"Principal inclusion criteria: Patients with definite, probable, probable laboratory-supported or possible ALS age 20-75 years. Disease duration <or=24 months; Respiratory function (FVC) >or= 65% of expected. Patients must understand and accept the protocol requirements, and must give a written informed consent.",EudraCT Number: 2014-002228-28 STEMALS-II TrialTroveID-217484,Adults; Older Adults,year(s),year(s),217484,Delay Disease Progression,75.0,20.0,"Principal exclusion criteria: Previous polio infection . Motor neuron diseases other than ALS (progressive bulbar palsy , progressive muscular atrophy , primary lateral sclerosis ). Clinical involvement of other neurological systems (sensory, extrapyramidal , oculomotor, cerebellar). Serious clinical conditions such as cardiovascular disease, uncontrolled hypertension, renal or hepatic impairment , dysthyroidism , Respiratory Distress Syndrome (ARDS), sickle-cell anaemia. Subjects who have participated in any drug trial within 12 weeks prior to recruitment. concomitant malignancy, present or past, with the exception of different melanoma skin cancers and carcinoma in situ of the cervix. Patients with severe congenital neutropaenia syndrome with abnormal cytogenetics; Patients with rare hereditary problems of fructose intolerance. Present or past malignant myeloproliferative diseases, secondary polycythemia, splenomegaly with a diameter> 14 cm, thrombophilia was found. Presence of percutaneous gastrostomy at the time of recruitment . Presence of NIV at the time of recruitment; Subjects who have participated in any drug trial within 12 weeks prior to recruitment; drug addiction , alcoholism, or psychiatric disorders. women who are pregnant or breastfeeding.",Ii,Both
1,Patients with a familial or sporadic Amyotrophic Lateral Sclerosis who have mild or moderate (non severe) impairment of functionality at baseline.,"1. Patient, male or female, diagnosed with laboratory supported probable, clinically probable or definite ALS according to the World Federation of Neurology Revised El Escorial criteria [52] 2. Patient with a familial or sporadic ALS 3. Patient aged between 18 and 75 years old inclusive at screening 4. Patient treated with a stable dose of Riluzole (100 mg/day) for at least 12 weeks prior to baseline visit 5. Patient with an ALS disease duration from diagnosis no longer than 24 months at screening 6. Patient with an ALSFRS-R total score progression between onset of the disease and screening of > 0.3 and < 1.1 point/month 7. Patient with an ALSFRS-R total score decrease of > or = 1 point between screening and baseline 8. Patient with an ALSFRS-R total score of at least 26 at screening following rules below: - at least 3 on item #3 and - at least 2 on each of the other 11 items (i.e. item #1, #2, #4, #5a or #5b, #6, #7, #8, #9, #10, #11 and #12) 9. Patient with an ALSFRS-R total score of at least 25 at randomization following rules below: - at least 3 on item #3 and - at least 2 on each of the other 11 items (i.e. item #1, #2, #4, #5a or #5b, #6, #7, #8, #9, #10, #11 and #12) 10. Contraception: - Female patient of childbearing potential (entering the study after a menstrual period and who has a negative pregnancy test), who agrees to use a highly effective method of contraception and an effective method of contraception by her male partner during the study and for 3 months and a half after the last treatment intake - Male patient with a female partner of childbearing potential who agrees to use a highly effective method of contraception and an effective method of contraception by his female partner during the study and for 3 months and a half after the last treatment intake OR who agrees to use an effective method of contraception and a highly effective method of contraception by his female partner during the study and for 3 months and a half after the last treatment intake Highly effective and effective methods of contraception are detailed in appendix 15.1 11. Patient able to understand, and willing to sign, and date the written informed consent form prior to any protocol-specific procedures. If patients are duly capable of study consent but are unable to sign by themselves due to aggravation of disease condition, written informed consent can be obtained from a legally authorized representative who can sign on behalf of the patients after confirming the patients' agreement to study participation. 12. Patient able and willing to comply with study protocol and to come on-site as per protocol visits schedule 13. Patient able to understand, and willing to follow the safety procedures mentioned on the patient card in case of signs or symptoms of severe neutropenia or severe cutaneous toxicity",AB14008 AB19001 CCR-20-90 EudraCT Number: 2019-001862-13 MOH_2017-07-09_000594 NCT03127267 NL71135.041.19 TrialTroveID-300123,Adults; Older Adults,year(s),year(s),300123,Delay Disease Progression,81.0,18.0,"1. Patient with dementia or significant neurological, psychiatric, systemic or organic disease, uncontrolled or that may interfere with the conduct of the trial or its results 2. Patient with hypersensitivity to masitinib excipients 3. Patient with an FVC < 60% predicted normal value for gender, height, and age at screening 4. Patient with a weight < 41 kg and a BMI < 21 or > 30 kg/m² at screening and at baseline 5. Pregnant, or nursing female patient 6. Patient with history (or family history) of severe skin toxicities or reactions 7. Patients treated by drugs known to be at high risk for Stevens-Johnson Syndrome or for Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome 8. Patient with history of severe bone marrow disorders such as agranulocytosis or aplasia, or with abnormal laboratory results from local laboratory assessments at screening and baseline: - Neutropenia with ANC < 1.5 x 109/L - Anemia with Hgb < LLN and red blood cell count below the LLN - Thrombocytopenia with platelets counts < 150 x 109/L 9. Patient with history of hepatic disorders, with a known liver disease or alcohol abuse, or with abnormal laboratory results from local laboratory assessments defined as: - hepatic transaminase levels > 2 ULN at baseline, or - total bilirubin level > 1.5 ULN at baseline, or - both hepatic transaminase levels and total bilirubin level outside of the normal ranges at screening and baseline, or - albuminemia < 1 x LLN at screening and baseline 10. Patient with pre-existing severe renal impairment, or with abnormal laboratory results from local laboratory assessments at screening and baseline: - Creatinine clearance < 60 mL/min (Cockcroft and Gault formula) - Proteinuria > 30 mg/dL (1+) on dipstick; in case of the proteinuria > or = 1+ on the dipstick, 24 hours proteinuria must be > 1.5g/24 hours 11. Patient with active severe infection such as herpes, tuberculosis, viral hepatitis, human immunodeficiency virus infection 12. Patient with autoimmune conditions such as systemic lupus erythematosus 13. Patient with a diagnosis of cancer or evidence of continued disease within five years before screening 14. Patient with severe cardiac conditions: - Patient with recent history of severe cardiovascular conditions including acute myocardial infarction, unstable angina pectoris, coronary revascularization procedure, congestive heart failure of NYHA Class III or IV, stroke, including a transient ischemic attack - Patient with cardiac conduction abnormalities at study entry including a QTc Fredericia interval > 450 milliseconds for males and > 470 milliseconds for females, a second- or third-degree atrioventricular block not successfully treated with a pacemaker - Patient presenting with edema of cardiac origin and left ventricular ejection fraction < or = 50% 15. Patient with risk factors for sudden unexpected death of cardiovascular origin 16. Patient who has been exposed to an investigational treatment within 3 months prior to screening 17. Patient who has been exposed to Edaravone within at least 30 days prior to screening 18. Patient treated concomitantly with drugs known to interact with cytochrome P450 (CYP450) isoenzymes (2C9, 2D6 and 3A4)",Iii,Both
0,Healthy Male Subjects.,"Healthy Male as determined by a physician, based on a medical evaluation including medical history, physical examination, clinical laboratory tests and 12-lead ECG. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the Sponsor Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. Male between 18 and 65 years old inclusive, at the time of signing the informed consent. Body mass index of 18.0 to 32.0 kg/m2, inclusive at screening Body weight between 60 and 90 kg Normal blood pressure and heart rate or, if abnormal, considered not clinically significant by the principal Investigator or sub-investigator. Neutrophils count should be within normal range or deemed as not clinically significant by the PI Must have regular bowel movements (ie, average stool production of > or =1 and < or =3 stools per day)",AB17001 EudraCT Number: 2017-001948-34 NCT05200169 QCL118054 TrialTroveID-316619,Adults,year(s),year(s),316619,(N/A); Healthy subjects; Line of therapy N/A,65.0,18.0,"Any clinically significant cardio vascular diseases such as but not limited to the common reported below: History or presence or suspect of Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery bypass graft surgery or stent procedure; History or presence or suspect of Angina Pectoris; History or presence or suspect, heart failure; Abnormal vital signs Clinically significant abnormal Blood Pressure according to investigator's opinion Abnormal resting ECG according investigator's opinion. Clinically significant, abnormal medical history, physical findings, ECG, or laboratory values at the screening visit that could interfere with the objectives of the study or the safety of the volunteer. A history of clinically significant acute illness (resolved within 4 weeks of screening), or history of significant cardiac arrhythmias or unexplained syncope or presence of cardiovascular, gastrointestinal, renal, hepatic, neurologic, haematologic, endocrine, oncologic, pulmonary, immunologic, dermatologic or psychiatric disease or any other condition which, in the opinion of the Principal Investigator (PI), would jeopardize the safety of the subject or impact the validity of the study results. Subject has an uncontrolled intercurrent illness (i.e., active infection) or fever (oral temperature > 38 degrees Celsius) at screening. Clinically significant history of or current seizure disorder or history of syncope, unexplained loss of consciousness or clinically significant history of Central Nervous System (CNS) disorders Failure to satisfy the investigator of fitness to participate for any other reason",I,Male
1,"Patients suffering from Amyotrophic Lateral Sclerosis (ALS). Per November 04, 2013 AB Science SA PR, Phase III: Patients who have been treated with a stable dose of riluzole.","Female or male patient aged between 18 and 75 years of age Female or male patient aged between 18 and below 80 and whose weight > or = 50 kg and and BMI between 18 and 35 kg/m^2 Familial or sporadic ALS Patient with a verifiable diagnosis of probable or definite ALS Disease duration no longer than 36 months Patient treated with a steady regimen of riluzole (100 mg/day) for a minimum of 1 month before study entry Patient with a FVC (Forced Vital Capacity) > or = 60% Patient with life expectancy > or = 6 months Patient with adequate organ function at screening and baseline: · Absolute Neutrophils Count (ANC) > or = 2 x 109/L · Hemoglobin > or = 10 g/dL · Platelets (PTL) > or = 100 x 109/L · AST/ALT < or = 2.5 ULN · . Bilirubin < or = 1.5 ULN · Albuminemia > or = 1 x LLN · Urea < or = 1.5 x ULN · Creatinine clearance > or = 50 mL/min (Cockcroft and Gault formula) · Proteinuria < 30 mg/dL on dipstick; in case of the proteinuria > or = 30 mg/dL, 24 hours proteinuria < 1.5g/24 hours Man or woman of child bearing potential, (entering the study after a menstrual period and who have a negative pregnancy test) who agree to use two methods (one for the patient and one for the partner) of medically acceptable forms of contraception during the study and for three months after the last treatment intake Patient able and willing to comply with study procedures as per protocol Patient able to understand, and willing to sign, and date the written informed consent form at screening visit prior to any protocol-specific procedures Patient able to understand and willing to folow the safety procedures mentioned on the patient card Patient affiliated to a social security system Patient diagnosed with laboratory supported, clinically probable or definite ALS according to the World Federation of Neurology Revised El Escorial criteria Patients who had already lost certain physical functioning or with very severely affected physical function (i.e. respectively, scores of 0 or 1 at inclusion on any of the individual component subscores of ALSFRS-R).",AB10015 EudraCT Number: 2010-024423-24 MOH_2020-12-07_008659 NCT02588677 REec-2013-0211 TrialTroveID-181957,Adults; Older Adults,year(s),year(s),181957,Delay Disease Progression,75.0,18.0,"Patient who underwent tracheotomy and /or gastrostomy Patient with a diagnosis of cancer or evidence of continued disease within five years before starting study treatment Patient with significant sensory abnormalities, dementia, other neurologic diseases, uncompensated medical illness, substance abuse and psychiatric illness Patient who have participated in a clinical trial within 3 months prior to screening Pregnant, or nursing female patient Patient having cardiac disorders defined by at least one of the following conditions: · Patient with recent cardiac history (within 6 months) of: - Acute coronary syndrome - Acute heart failure (class III or IV of the NYHA classification) - Significant ventricular arrhythmia (persistent ventricular tachycardia, ventricular fibrillation, resuscitated sudden death) · Patient with cardiac failure class III or IV of the NYHA classification · Patient with severe conduction disorders which are not prevented by permanent pacing (atrioventricular block 2 and 3, sino-atrial block) · Syncope without known aetiology within 3 months · Uncontrolled severe hypertension, according to the judgment of the investigator, or symptomatic hypertension Patient with history of poor compliance or history of drug/alcohol abuse, or excessive alcohol beverage consumption that would interfere with the ability to comply with the study protocol, or current or past psychiatric disease that might interfere with the ability to comply with the study protocol or give informed consent PREVIOUS TREATMENTS: Patient treated with any investigational agent within 3 months of screening",Ii/Iii,Both
0,Healthy volunteers and hepatic impaired patients. 16 subjects (8 impaired patients and 8 healthy subjects).,"For eligibility into the trial, subjects and patients must meet all the following inclusion criteria: Male or female subjects, aged 18 to 75 years inclusive; Females participating in this study must be of non-childbearing potential or using acceptable contraception for the full duration of the study and for 1 month after the end of treatment, as described below: Cessation of menses for at least 12 months due to ovarian failure; Surgical sterilization such as bilateral oophorectomy, hysterectomy, or medically documented ovarian failure; Using an acceptable effective non-hormonal method of contraception (bilateral tubal occlusion, vasectomized partner or intra-uterine device, sexual abstinence, male or female condom with spermicide); Negative serum pregnancy test at screening (if applicable); Normal renal function according to the age Non-smoker subject or smoker of not more than 5 cigarettes a day; Signing a written informed consent prior to selection; Covered by Health Insurance System and / or in compliance with the recommendations of National Law in force relating to biomedical research. For hepatic impaired patients: Hepatic impairment of moderate Child Pugh category determined at screening (Class B: 7 to 9 points); Stable Hepatic dysfunction e.g. no clinical significant change in disease status within the last 30 days documented by recent medical history, including no worsening of clinical signs of hepatic impairment or no worsening of total Bilirubin or Prothrombin time>50%. Stable treatment regimen or dose of medication Supine blood pressure < or = 170/110 mmHg; Body Mass Index (BMI) between 20 and 34 kg/m² inclusive. For healthy subject with normal hepatic function: Considered as healthy after a comprehensive clinical assessment (detailed medical history and complete physical examination); Body Mass Index (BMI) between 20 and 30 kg/m2 inclusive and body weight (BW) not lower than 55kg; Normal Blood Pressure (BP) and Heart Rate (HR) at the screening visit after 10 minutes in supine position: 90 mmHg < or = Systolic Blood Pressure (SBP) < or = 145 mmHg, 50 mmHg < or = Diastolic Blood Pressure (DBP) < or = 90 mmHg, 45 bpm < or = HR < or = 90 bpm, Or considered NCs by investigators; Normal ECG recording on a 12-lead ECG at the screening visit: 120 < PR < 220 ms, QRS < 110 ms, QTcf < or = 430 ms for male and < 450 ms for female, No sign of any trouble of sinusal automatism, Or considered NCs by investigators; Laboratory parameters within the normal range of the laboratory (hematological, blood chemistry tests, urinalysis). Individual values out of the normal range can be accepted if judged clinically non relevant by the Investigator. In particular, the hepatic function should be considered as normal; Normal dietary habits; Matched to at least 1 hepatic impaired patient by ethnic group, sex, age (+/- 10 years) and BMI (+/- 20%).",EudraCT Number: 2019-002315-26 MD1003CT201901HI NCT04252417 TrialTroveID-366994,Adults; Older Adults,year(s),year(s),366994,(N/A); Healthy subjects,75.0,18.0,"Subjects or Patients meeting any of the following criteria will not be included into the trial: Positive Hepatitis B surface (HBs) antigen or anti Hepatitis C Virus (HCV) antibody, or positive results for Human Immunodeficiency Virus (HIV) 1 or 2 tests); Subject/Patient who, in the judgment of the Investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development; Subject/Patient who cannot be contacted in case of emergency; History or presence of allergy or unusual reactions to some drugs or anesthetics or known hypersensitivity to the investigation product or its excipients (including lactose); Any medications intake within 3 months that may interfere with absorption, distribution, metabolism or excretion of the study drug, or any medication that may result in induction or inhibition of microsomal enzymes; Subject/Patient who is in the exclusion period of a previous study; Administrative or legal supervision; Blood donation (including in the frame of a clinical trial) within 2 months before administration or blood donation planned during the study or within 2 months following participation to the study; Subjects/Patients who are pregnant or breastfeeding. Subjects/Patients should not be enrolled if they plan to become pregnant during the time of study participation; Excessive consumption of beverages with xanthine bases (> 4 cups or glasses / day); History or presence of drug abuse; Positive results of screening for drugs of abuse; Intake of any food or any beverage containing grapefruit or grapefruit juice within 48h prior to the first dosing and the inability to stop such intake during the study. Evidence or history of clinically significant hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, renal, psychiatric, neurologic, metabolic, systemic, infectious, or allergic disease (including drug hypersensitivity or allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing); General anesthesia within 3 months before administration; Major surgery within 28 days prior to inclusionor major surgery planned during the next 6 months. For hepatic impaired patients: Other underlying diseases that may alter Child Pugh components like metastatic cancer to the brain or peritoneal surface or cancer cachexia (hypoalbuminemia, encephalopathy, ascites); History of liver transplant; The patient has an acute exacerbation or unstable hepatic function, as indicated by worsening of clinical and/or laboratory signs of hepatic impairment, within the 4 weeks before study drug administration; Hepatocellular carcinoma confirmed by alpha-fetoprotein rate < 50 mg/dL no longer than 3 months before inclusion; Signs of encephalopathy (grade 1 to 4 e.g. moderate to severe); Presence of clinical ascites (slight to severe); Drug addict patients treated with methadone or buprenorphine; Presence of clinical ascites and/or pleural effusion. According to the investigator's judgement, small ascites radiologically detected but not clinically relevant could be accepted; Severe hepatic encephalopathy, (Grade > 2, portal systemic encephalopathy score); Recent history of gastrointestinal bleeding due to esophageal varices. According to the investigator's judgement, patient who had esophageal varices can be included if surgically treated by ligation, or sclerosis and with a prophylactic treatment by non-selective ß-blockers (e.g., propranolol) and after checking by echography. History of hepatic cytolysis due to medication; Disorders or surgery of the gastrointestinal tract which may interfere with drug absorption or may otherwise influence the pharmacokinetics of the investigational medicinal product (e.g., inflammatory bowel disease, resections of the small or large intestine, etc.); History of febrile illness within 5 days prior to dosing; Any forbidden drug (as defined in protocol) intake during the 2 weeks or 5 half-lives of the drug preceding the first administration. For Healthy Subjects with normal hepatic function: Any history or presence of cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, hematological, neurologic, psychiatric, systemic, infectious or allergic disease Frequent headaches (> twice a month) and / or migraines, recurrent nausea and / or vomiting; Symptomatic hypotension whatever the decrease of blood pressure or asymptomatic postural hypotension defined by a decrease in SBP or DBP equal to or greater than 20 mmHg within two minutes when changing from the supine to the standing position; Inability to abstain from intensive muscular effort; History or presence of alcohol abuse (alcohol consumption > 40 grams/day); Any drug intake (except paracetamol 3g/d) during the 2 weeks or 5 half-lives of the drug preceding the first administration; Subject who would receive more than 4500 euros as indemnities for his participation in biomedical research within the 12 last months, including the indemnities for the present study.",I,Both
0,Healthy volunteers and renal impaired patients.,"For eligibility into the trial, subjects and patients must meet all the following inclusion criteria: Male or female subjects, aged 18 to 75 years inclusive Females participating in this study must be of non-childbearing potential or using highly effective contraception for the full duration of the study and for 1 month after the end of treatment, as described below: Cessation of menses for at least 12 months due to ovarian failure; Surgical sterilization such as bilateral oophorectomy, hysterectomy, or medically documented ovarian failure; Using an highly effective non-hormonal method of contraception (bilateral tubal occlusion, vasectomized partner or intra-uterine device); Double contraception with barrier AND highly effective hormonal method of contraception (oral, intravaginal or transdermal combined estrogen and progestogen hormonal contraception associated with inhibition of ovulation, oral, injectable or implantable progestogen-only hormonal contraception associated with inhibition of ovulation or intrauterine hormone-releasing system). The hormonal contraception must be started at least one month prior to inclusion. Negative serum pregnancy test at screening (if applicable); Normal hepatic function; Non-smoker subject or smoker of not more than 5 cigarettes a day; Signing a written informed consent prior to selection; Covered by Health Insurance System and / or in compliance with the recommendations of National Law in force relating to biomedical research. For renal impaired patients: Renal impairment patients with mild decrease in estimated creatinine clearance (CLcr) (60 < or = CLcr < or = 89 mL.min) or with moderate decrease of CLcr (30 = CLcr = 59 mL.min) or severe decrease of CLcr (15 < or = CLcr < or = 29 mL.min) using the Cockcroft-Gault equation; Supine blood pressure < or = 170/110 mmHg; Documented renal impairment indicated by reduced estimated creatinine clearance within 12 months of screening or longer; Stable renal function as evidenced by < or = 30% difference in two evaluation of estimated creatinine clearance on two separate occasions separated by at least 28 days with one measurement being the value at screening; Body Mass Index (BMI) between 20 and 34 kg/m2 inclusive. For healthy subjects with normal renal function: Considered as healthy after a comprehensive clinical assessment (detailed medical history and complete physical examination); Estimated creatinine clearance (CLcr) > or = 90 mL/min; No proteinuria (< 0.15 g/L determined by urinalysis); Body Mass Index (BMI) between 20 and 30 kg/m2 inclusive and body weight (BW) not lower than 55 kg; Normal Blood Pressure (BP) and Heart Rate (HR) at the screening visit after 10 minutes in supine position: 90 mmHg < or = Systolic Blood Pressure (SBP) < or = 145 mmHg, 50 mmHg < or = Diastolic Blood Pressure (DBP) < or = 90 mmHg, 45 bpm < or = HR < or = 90 bpm, Or considered NCs by investigators; Normal ECG recording on a 12-lead ECG at the screening visit: 120 < PR < 220 ms, QRS < 110 ms, QTcf < or = 430 ms for male and < 450 ms for female, No sign of any trouble of sinusal automatism, Or considered NCs by investigators; Laboratory parameters within the normal range of the laboratory (hematological, blood chemistry tests, urinalysis). Individual values out of the normal range can be accepted if judged clinically non relevant by the Investigator; Normal dietary habits; Matched to at least 1 renal impaired patient by ethnic group, sex, age (+/- 10 years) and BMI (+/- 20%).",EudraCT Number: 2019-002315-26 MD1003CT2019602RI NCT04252430 TrialTroveID-366993,Adults; Older Adults,year(s),year(s),366993,(N/A); Healthy subjects,75.0,18.0,"Positive Hepatitis B surface (HBs) antigen or anti Hepatitis C Virus (HCV) antibody, or positive results for Human Immunodeficiency Virus (HIV) 1 or 2 tests); History or presence of drug or alcohol abuse (alcohol consumption > 40 grams/day); Subject/Patient who, in the judgment of the Investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development; Subject/Patient who cannot be contacted in case of emergency; History or presence of allergy or unusual reactions to some drugs or anesthetics or known hypersensitivity to the investigation product or its excipients (including lactose intolerance); Any medications intake within 3 months that may interfere with absorption, distribution, metabolism or excretion of the study drug, or any medication that may result in induction or inhibition of microsomal enzymes; Subject/Patient who is in the exclusion period of a previous study; Administrative or legal supervision; Blood donation (including in the frame of a clinical trial) within 2 months before administration or blood donation planned during the study or within 2 months following participation to the study; Subject/Patient who is pregnant or breastfeeding. Subject/Patient should not be enrolled if she plans to become pregnant during the time of study participation; Excessive consumption of beverages with xanthine bases (> 4 cups or glasses / day); Positive results of screening for drugs of abuse; Intake of any food or any beverage containing grapefruit or grapefruit juice within 48h prior to the first dosing and the inability to stop such intake during the study; Evidence or history of clinically significant uncontrolled hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, metabolic, systemic, infectious, or allergic disease (including drug hypersensitivity or allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing); General anesthesia within 3 months before administration; Major surgery within 28 days prior to inclusion or major surgery planned during the next 6 months. For renal impaired patients: History of renal transplant; The patient has evidence of an unstable clinically important medical condition other than impaired renal function; The patient has an acute exacerbation or unstable renal function, as indicated by worsening of clinical and/or laboratory signs of renal impairment, within the 4 weeks before study drug administration; Patients undergoing any method of dialysis or hemofiltration; Disorders or surgery of the gastrointestinal tract which may interfere with drug absorption or may otherwise influence the pharmacokinetics of the investigational medicinal product (e.g., inflammatory bowel disease, resections of the small or large intestine, etc.); History of febrile illness within 5 days prior to dosing; Evidence of clinically significant liver disease or liver damage (e.g., hepatitis B or C, autoimmune hepatitis, primary biliary cirrhosis, non-alcoholic fatty liver disease, elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) that is considered clinically significant by the Investigator, etc.). Presence or history of protein drug hypersensitivity, or allergic disease diagnosed and treated by a physician; Any drug intake during the 2 weeks or 5 half-lives of the drug preceding the first administration. For Healthy subjects with normal renal function: Any history or presence of renal disease Frequent headaches (> twice a month) and / or migraines, recurrent nausea and / or vomiting; Symptomatic hypotension whatever the decrease of blood pressure or asymptomatic postural hypotension defined by a decrease in SBP ( > or = 20 mmHg) or DBP (> or =20 mmHg) within two minutes when changing from the supine to the standing position; Inability to abstain from intensive muscular effort; Any drug intake (except paracetamol 3g/d or contraception) during the 2 weeks or 5 half-lives of the drug preceding the first administration; Subject who would receive more than 4500 euros as indemnities for his participation in biomedical research within the 12 last months, including the indemnities for the present study.",I,Both
0,Healthy male volunteers.,Healthy males Age 30 to 65 years of age at the time of signing informed consent Body mass index (BMI) of 18.0 to 30.0 kg/m2 as measured at screening Must be willing and able to communicate and participate in the whole study Must have regular bowel movements (ie average stool production of > or = 1 and < or = 3 stools per day) Must provide written informed consent Must agree to adhere to the contraception requirements of the protocol.,MD1003CT2019-03MB NCT04223232 TrialTroveID-365234,Adults,year(s),year(s),365234,(N/A); Healthy subjects,65.0,30.0,"Subjects who have received any IMP in a clinical research study within the 90 days prior to Day 1 Subjects who are study site employees, or immediate family members of a study site or sponsor employee Subjects who have previously been enrolled in this study History of any drug or alcohol abuse in the past 2 years Regular alcohol consumption in males >21 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 Units = 125 mL glass of wine, depending on type) A confirmed positive alcohol breath test at screening or admission Current smokers and those who have smoked within the last 12 months. A confirmed breath carbon monoxide reading of greater than 10 ppm at screening or admission Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months Subjects with pregnant or lactating partners Radiation exposure, including that from the present study, excluding background radiation but including diagnostic X-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017, shall participate in the study Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator or delegate at screening Clinically significant abnormal clinical chemistry, haematology or urinalysis as judged by the investigator. Subjects with Gilbert's Syndrome are allowed Confirmed positive drugs of abuse test result (drugs of abuse tests are listed in the protocol) Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results Evidence of renal impairment at screening, as indicated by an estimated creatinine clearance of <80 mL/min using the Cockcroft-Gault equation History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder, as judged by the investigator Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active Donation or loss of greater than 400 mL of blood within the previous 3 months Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other than 4 g of paracetamol per day), herbal remedies, vitamin B5 or dietary supplements containing lipoic acid in the 14 days before IMP administration. Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as determined by the PI Subjects who have had any intake of biotin (including as a nutritional supplement) in the 14 days before IMP administration Failure to satisfy the investigator of fitness to participate for any other reason.",I,Male
0,Healthy Adult Subjects,"1. Subject voluntarily agrees to participate in this study and signs an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent form prior to performing any of the Screening Visit procedures. 2. Males and females between 18 to 55 years of age, inclusive, at the Screening Visit. 3. Female subjects of childbearing potential must not be planning to become pregnant, must not be breastfeeding, and must have a negative serum pregnancy test at Screening and negative urine pregnancy test on Day-2. 4. Sexually active female subjects of childbearing potential (i.e. women who are not post-menopausal [12 months of spontaneous amenorrhea without an alternative medical cause and follicle stimulating hormone (FSH) levels in the post-menopausal range for the laboratory involved] or who have not had a documented hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) and all male subjects (who have not been surgically sterilized by documented vasectomy) must agree to use highly effective methods of contraception during the study and for 8 weeks after the last dose of study drug. Please refer to Section 5.4.4 for acceptable methods of contraception. 5. Continuous non-smoker who has not used nicotine-containing products for at least 3 months prior to the screening. 6. Body mass index (BMI) between 18.0 and 30.0 kg/m^2, inclusive, at the Screening Visit. 7. Healthy adult subjects with suitable veins for cannulation. 8. Healthy, determined by pre-study medical evaluation (medical history, renal function, physical examination, vital signs, 12-lead ECG, and clinical laboratory evaluations). 9. Supine vital signs should be within the normal range at Screening and Day -2: a. oral body temperature between 35.0°C - 37.5°C; b. systolic BP, 90 - 140 mm Hg; c. diastolic BP, 40 - 90 mm Hg; d. pulse rate, 40 - 100 bpm. 10. Subjects should have serum potassium, calcium, and magnesium levels within the normal range at Screening and at admission on Day -2 (morning in fasted condition). 11.Subjects should fulfil the following ECG parameters criteria at Screening and Day -2: a. Normal sinus rhythm (HR between 40 beats per minute [bpm] and 100 bpm, inclusive); b. Fridericia QTc interval corrected (QTcF) < or = 450 msec; c. QRS interval < or = 110 msec; and confirmed by manual over-read if > 110 msec; d. PR interval < or = 220 msec.",Eudract Number: 2019-003121-19 MD1003CT2019-04TQT2 NCT04168723 TQT2 TrialTroveID-361599,Adults,year(s),year(s),361599,(N/A); Healthy subjects,55.0,18.0,"1. Subject has clinically significant history or evidence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological or psychiatric disorder(s) as determined by the Principal Investigator or designee. 2. Subject has any disorder that would interfere with the absorption, distribution, metabolism or excretion of drugs. 3. Subject has any concurrent disease or condition that, in the opinion of the Principal Investigator, would make the subject unsuitable for participation in the clinical study. 4. History or presence of: a. risk factors for Torsades de Pointes (e.g., heart failure, cardiomyopathy, or family history of Long QT Syndrome); b. sick sinus syndrome, Mobitz 2second, or third-degree atrioventricular block, myocardial infarction, pulmonary congestion, cardiac arrhythmia, prolonged QT interval QTc>450 male/470 female), or conduction abnormalities; c. repeated or frequent syncope or vasovagal episodes; d. hypertension, angina, bradycardia, or severe peripheral arterial circulatory disorders. 5. Subjects with serum creatinine clearance below 90 mL/min. 6. Subject has history of alcohol and/or illicit drug abuse within 2 years prior to the first dose of study drug. 7. Subject has positive test for Hepatitis B surface antigen, Hepatitis C antibody or human immunodeficiency virus antibody at the screening visit. 8. Subject has positive urine drug (e.g., cocaine, amphetamines, barbiturates, opiates, benzodiazepines, cannabinoids), alcohol or cotinine test at the Screening Visit or Day -2. Consumption of alcohol and alcohol-containing foods, medications or beverages 48 hours prior to the screening visit. 9. Female subjects are breastfeeding or female subjects with a positive serum pregnancy test at the Screening Visit or positive urine pregnancy test on Day -2. 10. Has had surgery or any medical condition which may affect the absorption, distribution, metabolism, or elimination of the study drugs within 6 months prior to the first dose, in the opinion of the Principal Investigator. 11. Plasma donation within 7 days prior to the first dose of study drug. 12. Subject has donated > 500 mL blood or blood products within 2 months (56 days) prior to admission. 13. Subject is unwilling to avoid consumption of coffee and caffeine containing beverages from 48 hours prior to admission until discharge from the clinical site. 14. Use of any prescription or over-the-counter medication including antacids, herbal remedies, or vitamin or nutritional supplements (especially those containing biotin, magnesium, aluminum, iron, or zinc), excluding contraceptive pill, and intermittent use of paracetamol, ibuprofen, or acetylic salicylic acid within 14 days prior to Screening and throughout the study, unless approved by both the Investigator and the Sponsor. 15. Subject has used an investigational drug, or device within 3 months or 5 half-lives of the investigational drug (whichever is longer) prior to Screening. 16. Participation in a previous clinical trial where subject received MD1003. 17. Subject has been on a diet incompatible with the on study diet (including an extreme diet which resulted in a significant weight change for whatever reason), in the opinion of the Principal Investigator, within the 28 days prior to the first dose of study drug, and throughout the study. 18.Subject is unwilling to abstain from vigorous exercise from 48 hours prior to admission until the End of Study Visit. 19. Subject has a history of hypersensitivity to the study drug or any of the excipients (incl. lactose), or to medicinal products with similar chemical structures. 20. Subject is unlikely to comply with the protocol requirements, instructions and study related restrictions; e.g., uncooperative attitude, inability to return for follow-up visits and improbability of completing the clinical study. 21. Vulnerable subjects defined as individuals whose willingness to volunteer in a clinical study may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate (e.g., persons in detention, minors and those incapable of giving consent).",I,Both
0,Patients with Amyotrophic lateral sclerosis.,"Age: 25 to 80 years, inclusive. Male or female subjects with probable or confirmed ALS (revised international El Escorial criteria, Forbes et al., 2001). Patients presenting first motor deficits due to ALS for a maximum of three years at the first consultation in an ALS centre. Patients monitored for at least 6 months in an ALS centre or for whom the previous monitoring parameters are available (excepted for MIP and SNIP). Patients who have lost at least 5 points on the ALSFRS-R during the last 12 months or at least 2 points during the preceding 6 months Patients who have been treated with riluzole for at least 3 months at a stable dose. In case of intolerance to this product or refusal for this treatment, patients who have not been treated with riluzole for at least 1 month. For patients with spinal form (onset of the disease affecting limbs) or respiratory form, slow vital capacity > 60% of predicted value. For patients with a bulbar form, slow vital capacity > 60% of theoretical value or, if spirometry not assessable (severe bulbar disability), patient should not have significant abnormality in both nocturnal capnography and nocturnal oximetry (median pCO2 < 52 mmHg, SaO2 < 90% less than 5% of the time during night) less than 3 months prior inclusion. Patients who are willing to give written consent (or oral consent in the presence of a trusted person if the patient is no longer able to write) Patients likely to be able to participate in all scheduled evaluation and complete all required study procedures (except for spirometry in bulbar patients with severe disability).",EudraCT Number: 2015-005810-31 MD1003-ALS MD1003CT2015-02-ALS NCT03114215 TrialTroveID-289178,Adults; Older Adults,year(s),year(s),289178,Delay Disease Progression,80.0,25.0,"Patients on non-invasive ventilation for respiratory insufficiency due to ALS for more than 10 hours a day Patients with an ALSFRS-R score at inclusion of < 20 (maximum score without disability = 48) Patients who have lost less than 5 points on the ALSFRS-R during the last year or less than 2 points during the preceding 6 months Patients with a gastrostomy Patients who have lost more than 15% of their ideal weight Patient with dyspnoea at rest or with the least effort (score < 3 on the dyspnoea item of the ALSFRS-R) Patients with dementia Patient with severe or rapidly progressive form of ALS for whom the investigator estimates the life expectancy less than 3 months Patients with another progressive disease that has not been stabilized at the time of inclusion Patients with cancer, except basal cell carcinoma, for less than 5 years, or who require continuous treatment for cancer even if it is older Pregnant women. Subject who are not covered by a social security scheme. Subject under temporary or permanent Judicial Protection. Contraception: Both male subjects, and female subjects who are not either surgically sterile (tubal ligation/obstruction or removal of ovaries or uterus) or post-menopausal (no spontaneous menstrual periods for at least one year confirmed by a negative hormone panel), must commit to using two highly effective method of birth control for the duration of the study and for two months after the treatment termination.",Ii,Both
0,Patients with ALS.,,TrialTroveID-083026,Adults; Older Adults,year(s),year(s),83026,Delay Disease Progression,68.0,45.0,,Ii,Both
1,Patients with Amyotrophic Lateral Sclerosis.,"Ages Eligible for Study: 18 Years to 80 Years Inclusion Criteria Patients entering this study: Are between the ages of 18-80 years old. Legal residents of the United States or Canada. Have a history of a chronic onset of a progressive motor weakness of less than 24 months duration. Fulfill El Escorial criteria of probable or definite ALS. If female, are surgically sterile, two years postmenopausal, or if of child-bearing potential, must be using a medically acceptable method of birth control and agree to continue use of this method for the duration of the study. Acceptable methods include a barrier method with spermicide, oral contraceptives (normal doses are acceptable; low dose oral contraceptives or contraceptive implants must be used with a barrier method), IUD, or abstinence. Have a negative pregnancy test. Are able to comply with protocol requirements. Can provide written informed consent. Have a manual muscle testing score of less than 8. Have a forced vital capacity by pulmonary function testing 60% predicted.",IGF-1/ALS Trial NCT00035815 TrialTroveID-078710,Adults; Older Adults,year(s),year(s),78710,Delay Disease Progression,80.0,18.0,"Exclusion Criteria Patients entering this study will not: Have any of the following conditions:renal disease (Creatine > 2.0) or other active systemic disease Have any clinically significant abnormalities on the prestudy laboratory evaluation, physical examination, ECG, chest x-ray or ophthalmologic exam. Have any clinically significant medical condition (e.g., within six months of baseline, had myocardial infarction, angina pectoris, and/or congestive heart failure) that, in the opinion of the investigator, would compromise the safety of patient. Have Type I or Type II diabetes. Have a history of cancer including melanoma with the exception of localized skin cancers (with no evidence of metastasis, significant invasion, or re-occurrence within three years of baseline) and carcinoma in-situ of the cervix (women only). Have used an investigational drug within 30 days of baseline visit. Have had a tracheostomy. Have a Beck's Depression Inventory score 12. Have legal residency outside of the United States or Canada. Be pregnant or breast-feeding.",Iii,Both
1,Patients with Amyotrophic Lateral Sclerosis (ALS),"Definite, probable or probable-laboratory supported in the Updated Awaji criteria. Within 1-year elapsed time period from disease onset at the start of observation period. Total ALSFRS-R score was lowered by 1-2 points during the observation period (12 weeks). Stage 1 or 2 of the severity criteria for ALS. Able to visit study site for out-patient treatment. Japanese Clinical Severity Scale 1 or 2 ALS patients within 12 months after clinical onset at the entry Updated Awaji combined with El Escorial criteria: definite, probably or laboratory supported probable",763 E0302-J081-763 JET-ALS JETALS NCT03548311 TrialTroveID-311980 UMIN000029588,Adults; Older Adults,year(s),,311980,Delay Disease Progression,,20.0,Tracheostomy. Experienced non-invasive positive pressure ventilation. %FVC > or = 60%. Chronic obstructive pulmonary disease. Edaravone use within 4weeks before starting the observation period. Initiated newly introduced riluzole therapy after starting the observation period. Or received dose escalation or resumed administration of riluzole therapy after previous down titration or discontinuation. Cognitive impairment. Participated in another clinical study within 12 weeks before starting the observation period. Those who have dementia Those who have the possibility of pregnancy Those who have serious respiratory or cardiac diseases Those who have malignancies Those who participated other clinical trials within 12 weeks Those who have allergies to B12 and related compounds,Iii,Both
1,Patients with Amyotrophic Lateral Sclerosis (ALS).,"Ages Eligible for Study: 20 Years and above, Genders Eligible for Study: Both Inclusion Criteria: Patients who have completed Phase II/III study of E0302 (E0302-J081-761, hereafter referred to as Study 761) except for those patients who discontinued the treatment of Study 761. Completed patients are defined as those who completed the treatment period of Study 761, those on 24-hour use of non-invasive positive pressure ventilation (NIPPV), or those who eventually resulted in the use of NIPPV. Patients who are able to submit written informed consent. If patients are duly capable of study consent but are unable to sign (or affix a seal) by themselves due to aggravation of disease condition, written informed consent can be obtained from a legally authorized representative who can sign on behalf of the patients after confirming the patients' agreement to study participation.",E0302-J081-762 JapicCTI-070434 NCT00445172 TrialTroveID-078774,Adults; Older Adults,year(s),,78774,Delay Disease Progression,,20.0,"Exclusion Criteria Patients with cognitive impairment. Pregnant women or women who may have a possibility of becoming pregnant. Patients or their partners who are not willing to use reliable contraception. Patients with severe disease in the renal, cardiovascular, hematological, or hepatic system (severe disease will be judged referring to ""Ministry of Health, Labor and Welfare (MHLW) Drug Safety Dept. Notification No. 80, Drug Safety Classification Criteria for Severity of Adverse Drug Reaction by Medicinal Products, Grade 3."" However, an event due to the primary disease will be precluded). Patients with malignant tumor. Patients who participated in another clinical study after the completion of Study 761. Patients with present illness or history of drug allergy or severe allergic disease (anaphylactic shock). Patients who are judged to be ineligible for study entry by the investigator or subinvestigator.",Ii/Iii,Both
1,"Patients with Amyotrophic Lateral Sclerosis (ALS). Patients (373) who were diagnosed with definite, probable, or probable-laboratory-supported Amyotrophic Lateral Sclerosis (ALS)","Ages Eligible for Study: 20 Years and above, Genders Eligible for Study: Both Inclusion Criteria: Patients who are able to submit written informed consent. If patients are duly capable of study consent but are unable to sign (or affix a seal) by themselves due to aggravation of disease condition, written informed consent can be obtained from a legally authorized representative who can sign on behalf of the patients after confirming the patients' agreement to study participation. Patients who are aged 20 years or older at the time of obtaining informed consent. Patients who have clinically definite ALS, clinically probable ALS, or clinically probable-laboratory supported ALS as specified in the revised El Escorial Airlie House diagnostic criteria. Patients who are at stage 1 or 2 of the severity criteria for ALS. Patients within 3-year elapsed time period from disease onset at the start of observation period. Patients who can visit study site for out-patient treatment.",E0302-J081-761 JapicCTI-070433 NCT00444613 TrialTroveID-078715,Adults; Older Adults,year(s),,78715,Delay Disease Progression,,20.0,"Exclusion Criteria: Patients who underwent tracheostomy. Patients who experienced non-invasive positive pressure ventilation. Patients whose percent-predicted forced vital capacity (%FVC) is > or = 60%. Patients with multiple disturbances of conduction detected by nerve conduction test. Patients with neurological symptom(s) due to vitamin B12 deficiency. Patients who initiated newly introduced riluzole therapy after starting the observation period. Or those who received dose escalation or resumed administration of riluzole therapy after previous down titration or discontinuation. Patients with cognitive impairment. Pregnant women or women with a possibility of becoming pregnant. Patients or their partners who are not willing to use reliable contraception. Patients with severe disease in the renal, cardiovascular, hematological, or hepatic system (severe disease will be judged referring to ""Ministry of Health, Labor and Welfare"" (MHLW) Drug Safety Dept. Notification No. 80, Drug Safety Classification Criteria for Severity of Adverse Drug Reaction by Medicinal Products, Grade 3.""). Patients with malignant tumor. Patients who participated in another clinical study within 12 weeks before starting the observation period. Patients with present illness or history of drug allergy or severe allergic disease (anaphylactic shock). Patients who are judged to be ineligible for study entry by the investigator or subinvestigator.",Ii/Iii,Both
0,Adult Healthy Subjects,"Participants must meet all of the following criteria to be included in this study: Body mass index (BMI) of 18 to 30 kilogram per meter square [kg/m2], inclusive at Screening",E0302-J064-003 NCT03885882 TrialTroveID-345883,Adults,year(s),year(s),345883,(N/A); Healthy subjects,59.0,18.0,"Participants who meet any of the following criteria will be excluded from this study: History of drug or alcohol dependency or abuse within the 2 years before Screening, or those who have a positive urine drug test or breath alcohol test at Screening or Baseline Subjects who contravene the restrictions on concomitant medications, food and beverages Currently enrolled in another clinical study or used any investigational drug or device within 3 months preceding informed consent",I,Both
1,Patients with amyotrophic lateral sclerosis.,"(1) Participants diagnosed as familial or sporadic ALS, according to the World Federation of Neurology Standards; (2) male or female participants aged 18-70 years; (3) Participants must be able to provide informed consent and follow the test procedure; (4) Participants must have qualified nursing staff to assist in tube feeding; (5) The participants receiving the gastric fistula or stoma tube must be able to receive tube feeding; (6) The subjects were able to carry out non-invasive ventilation for less than 10 hours a day",ChiCTR1800016626 TrialTroveID-326456,Adults; Older Adults,year(s),year(s),326456,Symptom relief,70.0,18.0,"(1) Patients with unstable mental illness, including mental depression; (2) Women during pregnancy and who breastfeed after pregnancy; (3) History of hepatitis, including Nonalcoholic steatohepatitis (NASH), cholecystectomy, previous biliary diseases such as gallstones, diabetes, previous myocardial infarction, stroke and thromboembolism, liver and kidney insufficiency, breast tumor, uterine fibroids, hypertension, galactose or hyperglycemia patients; (4) Laboratory examination value: Alanine transaminase (ALT) or aspartate transaminase (AST) is greater than the normal range of 2.2 times or total bilirubin greater than the normal limit of twice times; (5) allergic to soybeans, fish or dairy products; (6) intolerance of nutritional supplements.",Iv,Both
1,Patients with senile dementia and Alzheimer's dementia.,"(1) Age ≥50 years old; (2) Patients with senile dementia, including Alzheimer's dementia, vascular dementia, frontotemporal dementia; (3) MMSE score ≤20 points; (4) Newly diagnosed patients with more than moderate dementia, or patients with more than moderate dementia who have been clearly diagnosed but have not been treated with memantine before; (5) A reliable caregiver.",ChiCTR2300071719 TrialTroveID-470911,Adults; Older Adults,year(s),year(s),470911,Frontotemporal Dementia; Moderate; Severe; Vascular Dementia,90.0,50.0,"(1) Allergic to the test drug or its related ingredients; (2) Patients with severe liver function impairment (ALT or AST level more than 3 times the upper limit of normal value); (3) Patients with severe renal function impairment (serum creatinine more than 3 times the upper limit of normal value); (4) previous diagnosis of depression, bipolar disorder or other mental disorders; (5) Patients with poor compliance who cannot be treated according to the prescribed program; (6) Patients considered unsuitable for inclusion by other researchers.",Iv,Both
0,Patients with mild and moderate-to-severe stage behavioral variant frontotemporal dementia,"Patients were 53–84 years old with Montreal Cognitive Assessment (MoCA) scores between 4 and 29 at the initial screening during enrollment. All participants were required to have an MRI or brain CT scan within 1 year to confirm the bvFTD diagnosis, and a number of patients received 18F-fluorodeoxyglucose (18F-FDG) positron emission (PET)/CT in order to further confirm the diagnosis.",TrialTroveID-315916,Adults; Older Adults,year(s),year(s),315916,Frontotemporal Dementia,84.0,53.0,"Patients that were prescribed oxiracetam (10 patients, 0.8 g thrice daily), a memory-improving agent widely used in senile dementia patients, or a cholinesterase inhibitor (8 patients, 5 mg once daily) were excluded from the present study. Other exclusion criteria were as follows: i) Aphasia, severe illness and difficulty completing procedures of the study; ii) the pattern of deficits was better accounted for by other non-degenerative neurological or psychiatric disorders; iii) serious chronic conditions within the previous year; iv) magnetic resonance imaging (MRI) or computed tomography (CT) findings inconsistent with bvFTD diagnosis criteria; v) biomarker results that strongly indicated a diagnosis of AD or other forms of dementia; vi) acetylcholinesterase inhibitor treatment and other nootropic or antipsychotic medications taken within 4 weeks of baseline measurement recording; vii) metabolic or inflammatory brain disorders.",Ii,Both
1,,"- Must meet criteria for frontotemporal lobar degeneration (FTD) by Neary et al. criteria. 28 Subjects may have either the behavioural or the aphasic variant of FTD. - Able to undergo psychometric testing. - Must have reliable informant with daily contact with patient - May be taking concurrent psychotropic medications, but must be on stable dosing regimen for 3 months prior to trial enrollment - On the basis of a physical examination, medical history (including psychiatric and neurological), and results of blood chemistry carried out at screening visit, the patient in the investigator's opinion is considered healthy. - Signed Informed Consent must be obtained from the patient or legally responsible representative and the informant prior to initiating any study specific procedures.",Baycrest.Ebixa.FTD-001 Lundbeck 11627A NCT00594737,Adults; Older Adults,year(s),year(s),238709,,80.0,40.0,"- Complaint of recurrent or persistent dizziness or constipation - Abnormal chemistry panel particular with respect to ruling out renal insufficiency or failure. We will exclude those patients with creatinine clearance (CLcr) < 50ml/min, per the Sakana equations for men and women. - Angina, myocardial infarction, severe hypertension, severe cardiac arrhythmia, unstable diabetes mellitus, or new abnormalities on EKG within the past year. - Any current malignancy, or any clinically significant hematological, endocrine, renal, hepatic, gastrointestinal or non-dementia neurological disease. If the condition has been stable for at least the past year and is judged by the investigators not to interfere with the patient's participation in the study, the patient may be included. Basal cell carcinoma is an exception. - Non-English speaking, as cognitive tests will be in English. - Evidence of other neurological or psychiatric disorders which preclude diagnosis of FTD (including, but not limited to, stroke, Parkinson's disease, any psychotic disorder, severe bipolar or unipolar depression) within the past year - Current or prior history of uncontrolled seizure disorder, due to seizures reported as adverse events with memantine. - Patients with suspected alcohol or substance abuse within last 1 year. If past history of abuse or dependence must have been abstinent for 1 year with continuing progression of dementia despite abstinence. - Patients with active delusions or hallucinations at the time of screening. - Female patients who are not at least two years post-menopausal or surgically sterile. Pre-menopausal women will be excluded; because almost all women are post-menopausal at the age of onset of FTD, we do not anticipate having to exclude more than one potential subject on the basis of this one exclusion criterion. - Use of investigational drugs or participation in another investigational drug study within 3 months of screening. - Patients who have previously been treated with memantine or have participated in an investigational study with memantine. - Patients with history of severe drug allergy or hypersensitivity or known hypersensitivity to amantadine or memantine.",Iii,Both
1,Patients with Frontotemporal dementia (FTD) or Semantic dementia (SD).,"A subject must meet ALL of the following criteria to be considered for enrollment in this study: Signed and dated written informed consent obtained from the subject and the subject's caregiver in accordance with local IRB regulations. Must meet criteria Neary et al. criteria for frontotemporal dementia (FTD) or semantic dementia (SD) Age: 40-80 CT or MRI of brain within 12 months consistent with a diagnosis of FTD or SD. MMSE > or = 15 at screening visit. Judged by investigator to be able to comply with neuropsychological evaluation at baseline. Must have reliable caregiver accompany subject to all study visits. Caregiver must read, understand and speak English fluently in order to ensure comprehension of informed consent form and informant-based assessments of subject. Caregiver must also have frequent contact with subject (at least 3 times per week for one hour) and be willing to monitor study medication compliance and the subject's health and concomitant medications throughout the study. In the opinion of the investigator, the patient and the caregiver will be compliant with the protocol and have a high probability of completing the study.",NAM-53:memantineplacebo NCT00545974 TrialTroveID-238316,Adults; Older Adults,year(s),year(s),238316,Frontotemporal Dementia,80.0,40.0,"Any one of the following will exclude a subject from being enrolled into the study: Insufficient fluency in English to complete neuropsychological and functional assessments. Concurrent Motor Neuron Disease judged by investigator to have bulbar or upper extremity impairments at baseline that would interfere with neuropsychological assessment, or that are expected to lead to such impairments within one month. Exclusion criteria as listed in Neary criteria. Diagnosis of progressive nonfluent aphasia by Neary criteria. Use of memantine within 4 weeks prior to randomization. Evidence of other neurological or psychiatric disorders which preclude diagnosis of FTD (including, but not limited to, stroke, Parkinson's disease, any psychotic disorder, severe bipolar or unipolar depression, seizure disorder, or head injury with loss of consciousness) within the past year. Concurrent treatment with acetylcholinesterase inhibitors, antipsychotic agents, mood stabilizers (valproate or lithium) or benzodiazepines (other than temazepam or zolpidem), or use of any of these agents within 4 weeks prior to randomization. Atypical antipsychotic agents may be started after the baseline visit if felt to be medically necessary by the investigator and will be recorded as a secondary outcome measure. History of alcohol or substance abuse within 1 year prior to screening, if deemed clinically significant by investigator. Any current malignancy, or any clinically significant hematological, endocrine, cardiovascular, renal, hepatic, gastrointestinal or neurological disease. If the condition has been stable for at least the past year and is judged by the investigator not to interfere with the patient's participation in the study, the patient may be included. Clinically significant lab abnormalities at screening, including Creatinine = 1.7, B12 below laboratory normal reference range or TSH above site's laboratory normal reference range. Subjects with abnormal B12 or TSH levels at screening may be included per investigator's discretion. 9. CT or MRI evidence of any of the following: hydrocephalus, stroke, space-occupying lesion, cerebral infection or any clinically significant CNS disease other than FTD. 10.Systolic blood pressure greater than 180 or less than 90 mm Hg. Diastolic blood pressure greater than 105 or less than 50 mm Hg. 11. Abnormal ECG at screening judged to be clinically significant by the investigator. 12. Use of investigational drugs or participation in investigational drug study within 60 days of screening. Written informed consent was obtained from the subject and the subject’s caregiver in accordance with local IRB regulations",Iv,Both
0,,"- Patients with FTD based on the criteria defined by the Lund and Manchester groups' consensus statement (revised in 1998), whose disease has been progressing during the last year. - MMSE score of 19 or higher - Men and women aged 45 to 75 years - Without speech, visuospatial, or episodic memory impairments",BRD 05/1-E NCT00200538,Adults; Older Adults,year(s),year(s),235151,,75.0,45.0,"- Age > 76 years - Illiterate or misunderstanding patients - Patients with cancer, heart disease, lung disease, kidney disease (creatinine > 200 mg/dL), or epilepsy",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis.,"Age 18-85 Male or Female Clinically definite, probable, probable lab-supported, or possible ALS by El Escorial criteria ALSFRS-R > 25 Must be willing to undergo longitudinal blood draws for biomarker analysis Availability and willingness to complete the study Capable of providing informed consent and complying with trial procedures If patients are taking riluzole and/or Radicava, they must be a on a stable dose for at least thirty days prior to the baseline. Remote Inclusion Criteria: Age 18-85 Male or Female Clinically definite, probable, probable lab-supported, or possible ALS by El Escorial criteria ALSFRS-R > 25 Must be willing to undergo longitudinal blood draws for biomarker analysis. This may be foregone during the screening visit Availability and willingness to complete the study Capable of providing informed consent and complying with trial procedures If patients are taking riluzole and/or Radicava, they must be a on a stable dose for at least thirty days prior to the baseline Documentation of not clinically significant liver enzymes within the previous 6 months",NCT02118727 TAME TAME-ALS TAME-ALS FD003937-01 TrialTroveID-207406,Adults; Older Adults,year(s),year(s),207406,Delay Disease Progression,85.0,18.0,"Exclusion Criteria: Patients with forced vital capacity (FVC) ≤ 60% History of liver disease Severe renal failure History of intolerance to memantine Onset of weakness for greater than 3 years Any other co-morbid condition which would make completion of the trial unlikely If female, pregnant or breast-feeding; or, if of childbearing age, an unwillingness to use birth control. Taking any investigational medications. If the patient was previously on investigational medications, a 30-day washout period is required before the baseline visit. Non-trial medications are not cause for exclusion. Unwillingness to provide consent Remote Exclusion Criteria: Patients with FVC < or =60%* History of liver disease Severe renal failure History of intolerance to memantine Onset of weakness for greater than 3 years Any other co-morbid condition which would make completion of the trial unlikely If female, pregnant or breast-feeding; or, if of childbearing age, an unwillingness to use birth control. Taking any investigational medications. If the patient was previously on investigational medications, a 30-day washout period is required before the baseline visit. Non-trial medications are not cause for exclusion. Unwillingness to provide consent Since FVC cannot be captured during a remote screening visit, and acceptable FVC performed within the previous 90 days is acceptable. If an FVC is not available within the previous 90 days, the subject may be enrolled if the local site PI believes the subject has no significant shortness of breath or respiratory issues.",Ii,Both
0,Patients with amyotrophic lateral sclerosis.,"Inclusion Criteria: Clinically probable or definite ALS according to El Escorial criteria (World Federation of Neurology, 1994. Age <80 years. Matattia duration between 3 and 36 months. Degree of disability to max moderate bulbar function satisfactorily documented and the ability to stand up without support. Capacity forced vital > 50%. Progression of symptoms during the 3 months preceding study entry. Capacity 'to understand and follow the mode' of the study and sign informed consent.",EudraCT Number: 2005-004329-24 MEM-ALS/05 TrialTroveID-109620,Children; Adults; Older Adults,,year(s),109620,Delay Disease Progression,80.0,,"Exclusion Criteria: Case of familial ALS. Case of progressive bulbar palsy, or SL primary progressive muscular atrophy. Case of ALS-like syndrome second Brooks et al. (1994). Use of other investigational drugs within 4 weeks before. Hypersensitivity documented against memantine or any other ingredients used in the formulation.",Ii,
0,Patients with a diagnosis of Amyotrophic Lateral Sclerosis.,"Ages Eligible for Study: 18 Years to 85 Years, Genders Eligible for Study: Both Inclusion Criteria: Age 18-85. Male or Female. Clinically definite ALS by El Escorial criteria. To be included in the study, patients had an elevated level of Tau, greater than 144 ng/L.",Memantine in ALS NCT01020331 TAME TrialTroveID-079841,Adults; Older Adults,year(s),year(s),79841,Delay Disease Progression,85.0,18.0,"Exclusion Criteria: Patients with FVC below 1.5 L or who require respiratory assistance. History of liver disease. Severe renal failure. History of intolerance to Riluzole or Memantine. Any other co morbid condition which would make completion of trial unlikely. If female, pregnant or breast-feeding; or, if of childbearing age, an unwillingness to use birth control. Taking any trial medications. Non-trial medications are not cause for exclusion. Unwillingness to provide consent.",Ii,Both
0,Patients With ALS.,"Ages Eligible for Study: 18 Years - 80 Years Inclusion Criteria El Escorial Classification of laboratory supported probable, probable,or definite ALS. Age 18 - 80 years. ALS symptoms for no more than 3 years. FVC greater than or equal to 70% predicted. Riluzole naive or have been on a stable dose of Riluzole for at least 2 months. Patients must have the ability to attend monthly study visits in Edmonton or Calgary, Alberta.",1204 EB2006ALS NCT00409721 TrialTroveID-078838,Adults; Older Adults,year(s),year(s),78838,Delay Disease Progression,80.0,18.0,"Exclusion Criteria Presence of significant sensory abnormalities, dementia, other neurologic diseases, uncompensated medical illness and psychiatric illness. Female patients who are breastfeeding. Use of concurrent investigational drugs. Patient unlikely to comply with study requirements. Poor adherence to study protocol during run-in phase.",Ii,Both
1,Patients with Amyotrophic Lateral Sclerosis.,Ages Eligible for Study: 20 Years to 75 Years Inclusion criteria < 75 years at disease onset. < 3 years of disease progression. ALS-FRS > 24. FVC > 60. Probable or definite disease (revised El Escorial criteria). Normal blood tests. Riluzole treatment during 1 month or more. Regular medication on riluzole > 1 month. Nerve conduction studies ruling out conduction block. EMG with widespread loss of motor units (revised El Escorial criteria). At least one hand with ADM strength > 2 on MRC scale.,002-04 MEDALS NCT00353665 TrialTroveID-078800,Adults; Older Adults,year(s),year(s),78800,Delay Disease Progression,75.0,20.0,Exclusion Criteria Other diseases (such as PNP). Both ADM muscles < 3 on MRC scale. Conduction block on nerve conduction tests. Disease duration > 3 years. ALS-FRS < 25. Forced vital capacity - <60%.,Ii/Iii,Both
1,Patients with Motor Neurone Disease,"Confirmed diagnosis of MND (including the following subtypes: ALS by El Escorial Criteria (possible, probable, and definite), Primary Lateral Sclerosis, and Progressive Muscular Atrophy) Over 18 Women of childbearing potential according to CTFG guidelines (http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf) must have a negative pregnancy test within 7 days prior to the baseline visit Women of childbearing potential and fertile men (according to CTFG guidelines) must be using an appropriate method of contraception to avoid any unlikely teratogenic effects of the selected drugs from time of consent, to 4 weeks after treatment inclusive Willing and able to comply with the trial protocol and ability to understand and complete questionnaires Written informed consent (this can be signed by a proxy in the case of limb dysfunction)",AC18082 EudraCT Number: 2019-000099-41 MND-SMART NCT04302870 TrialTroveID-360994,Adults; Older Adults,year(s),,360994,Delay Disease Progression,,18.0,"Patients diagnosed with Frontotemporal Dementia (FTD-MND) or any other significant psychiatric disorder that prevents informed consent being given. Patients in the manic phase of bipolar disorder. Alcoholism (self-reported) Active suicide ideation assessed using the Columbia-Suicide Severity Rating Scale On concurrent investigational medication (including biological therapy) Known hypersensitivity, including hereditary fructose intolerance, or adverse reaction to the active substances and their excipients (SPCs section 6.1) or any past medical history contraindicating use of any of the IMPs Pregnancy or breast-feeding females If ALT, ALP, bilirubin or GGT >3 times the upper limit of normal. If creatinine clearance (creatinine clearance or eGFR) <35 ml/min. If TSH <0.2mU/l (if possible to test free T4, then Serum free T4 >25pmol/l) corrected QT interval on 12 lead ECG >500 ms Active Epilepsy History of proven peptic ulcer confirmed on endoscopy Patient's diagnosed with ventricular arrhythmias, significant heart block (at the investigator's discretion) or in the immediate recovery period after myocardial infarction (< 6 weeks). Already taking any of the IMPs in this protocol Patient's contraindicated to any of the IMPs according to SPC section 4.3 Taking a medication that interacts with the active substances and their excipients according to the SPCs, including but not limited to; Dextromethorphan, Amantadine; Ketamine, Monoamineoxidase inhibitors ((MAOIs), Rasagiline, Selegiline, Safinamide, Tranylcypromine, Phenelzine, Isocarboxazid, Moclobemide). Patients who the PI considers will not be able to comply with the study protocol.",Ii/Iii,Both
1,Patients with amyotrophic lateral sclerosis.,,TrialTroveID-277187,Adults; Older Adults,year(s),year(s),277187,Delay Disease Progression,67.0,25.0,,Iv,
0,Patients with Amyotrophic lateral sclerosis (ALS).,"1. Aged 18 -70 years old men and women; 2. Meet the diagnostic criteria for Amyotrophic Lateral Sclerosis (ALS); 3. There are no other neurologic related diseases except ALS; 4. fail to respond to conventional therapy; 5. The eligible patients are with no severe non-reversible cardiopulmonary function impairment; No pulmonary and systemic infection; 6. Non tumor patients; 7. The eligible patients are with no history of severe allergy to drugs; 8. Non immunodeficiency patients; 9. Sign informed consent; 10. Good compliance, Family members agreed to cooperate follow up.",ChiCTR1800017734 TrialTroveID-330370,Adults; Older Adults,year(s),year(s),330370,Delay Disease Progression; Symptom relief,70.0,18.0,"1. With other neurologic related diseases except ALS . 2. ALS patients with severe non-reversible cardiopulmonary, liver, brain function impairment; 3. ALS patients with mental illness or severe neurosis; 4. ALS patients who cannot express the symptoms of subjective discomfort; 5. Participation in other clinical trials in latest 6 months; 6. ALS patients with malignant tumor; 7. Suffering from immunodeficiency disease; 8. Pregnant woman,Breast-feeding women; 9. ALS patients with a history of drug allergy; 10. Any factors that may affect the compliance, safety and test results of this study.",Iii,Both
0,Patients affected by early stage or progressive ALS.,,TrialTroveID-260001,,,,260001,Unspecified,,,,Iii,
0,Subjects with diagnosis of probable or definite C9orf72 positive ALS/FTD,"Subjects have a diagnosis of probable or definite ALS in accordance with the Revisited El-Escorial Criteria. Subjects have a likely diagnosis of C9orf72 positive ALS/FTD. Subjects must be currently on an oral diet and able to take foods, pills and liquids by mouth equivalent to a score of 4 or above on the Functional Oral Intake Scale Subjects must have no known allergy to barium sulfate or Metformin. Subjects or subject's legally authorized representative must be willing and able to complete informed consent/assent and HIPAA authorization. Ability to comprehend and be informed of the nature of the study, as assessed by the PI or Co-Investigators. Subjects prescribed to take Metformin at or before the time of first dosing. (The study is open to subjects currently taking Metformin or subjects who have taken Metformin in the past). Availability to participate for the entire study duration. Female subjects of childbearing potential must have a negative urine pregnancy test prior to Videofluoroscopic Swallow Study (VFSS) exam during Visit 1, 3, and 4.",NCT04220021 OCR20620 TrialTroveID-364983 UF2019-001,Adults; Older Adults,year(s),year(s),364983,Unspecified,80.0,18.0,"Subjects who score 3 or below on the Functional Oral Intake Scale Subjects who do not carry the C9ORF72 hexanucleotide repeat expansion as determined by laboratory analysis. Subjects with a history of clinically significant liver disease, renal disease, or any other medical condition judged to be exclusionary by the investigator. Subjects who are unwilling to sign informed consent or subjects who for any other reason in the judgment of investigator are unable to complete the study. Female subjects who have a positive urine pregnancy test (ßhCG) at screening or visit 1, are trying to become pregnant or are breastfeeding. Subjects with active cancer within the previous 2 years, except treated basal cell carcinoma of the skin. Subjects who have taken any experimental drug within 30 days prior to enrollment or within 5 half-lives of the investigational drug -whichever is the longer period. Subjects with known history or presence of moderate or severe renal impairment as defined by an estimated glomerular filtration rate (eGFR) value below 30 mL/min/1.73 m2. Subjects with hepatic impairment as defined by baseline elevations of serum aminotransferases greater than 5 times upper limit of normal or evidence of liver dysfunction (e.g., elevated bilirubin). Use of potentially hepatotoxic drugs: (e.g., allopurinol, methyldopa, sulfasalazine). Subjects with clinically significant abnormal laboratory values in the judgment of the investigator. Subject with implanted electrical device (i.e. cardiac pacemaker or a neurostimulator), metal or metallic clip(s) in their body (i.e. an aneurysm clip in the brain) that will be damaged by participation in the MRI portion of the study. Anything else that, in the opinion of the investigator, would place the subject at increased risk or preclude the subject's full compliance with or completion of the stud",Ii,Both
0,Patients with Amyotrophic lateral sclerosis (ALS),,TrialTroveID-339228,,,,339228,Delay Disease Progression,,,,Ii,
0,"Patients with Frontotemporal Dementia, Progressive Supranuclear Palsy or Related Dementia Syndromes","Patients of either sex supervised by a carer competent and willing to ensure compliance with medication and who is willing to participate in completing the various assessments. Female patients should not be pregnant at the start of the study or planning a pregnancy during the course of the study. Patients must be able to either give written informed consent to participation in the study, with additional assent to their participation being provided by a competent carer. Patients must meet either: Consensus Clinical Diagnostic Criteria for Frontotemporal Lobar Degeneration (Neary et al 1998) including MRI and HMPAO SPECT imaging consistent with the diagnosis NINDS –SPSP Clinical Criteria for Diagnosis of Probable Progressive Supranuclear Palsy including MRI and HMPAO SPECT imaging consistent with that diagnosis (Litvan et al 1996a) Diagnostic Criteria for Corticobasal Degeneration including MRI and HMPAO SPECT consistent with the diagnosis (Boeve et al 2003) In addition to meeting the above criteria patients additionally must have significant cognitive impairment with a CAMCOG score of < 85.",EudraCT Number: 2005-005915-13 TrialTroveID-313456 TRx-014-002,,,,313456,Frontotemporal Dementia; Unspecified PSP,,,"The patient is not eligible to participate in the study in any of the following circumstances: The patient has a known sensitivity to MTC or similar agents. The patient has known glucose-6-phosphate dehydrogenase deficiency. The patient has known hereditary methaemoglobinaemia, has been known to have suffered an attack of acquired methaemoglobinaemia or has a blood level of methaemoglobin at screening which is above the upper limit of normal for age and laboratory. The patient has significant impairment of renal, hepatic or haematological function for the age of the patient. The patient has started taking prescribed medication known to have an effect on mood, cognition or motor function within the previous six weeks or has changed the dose of such medication within the same period (e.g.cholinesterase inhibitors, memantine, anticholinergics, hypnotics, sedatives, anxiolytics, neuroleptics antidepressants, antiepileptics or antiparkinsonian drugs). The patient has started taking an alternative anti dementia therapy (e.g. ginkgo biloba or HRT) within six weeks or has changed their dose within that period. The patient is receiving warfarin or digitalis or any other medication that has a narrow margin between effective dose and toxic dose or between effective dose and ineffective dose, where the subject would be at risk if the levels were to rise or fall due to interaction with MTC. Patients who are unlikely to comply with the study procedures or with study medication. Patients with significant intercurrent illness which in the opinion of the investigator may compromise either the safety of the patient or the validity of the data. Females who, in the opinion of the investigator, have the potential of childbearing and are not using adequate contraception or females who are breastfeeding. Patients with a history of alcohol or drug abuse defined as meeting DSM-IV criteria for substance dependence. This applies to alcohol and /or any illicit drug including cannabis within the last six months. The patient has participated in a clinical investigation of a medication or device within the previous three months.",Ii,Both
0,Patients with Sporadic Amyotrophic Lateral Sclerosis (SALS).,"Sporadic ALS diagnosed as possible, laboratory-supported probable, probable, or definite ALS as defined by revised El Escorial criteria. Age 18 years or older. Symptom onset of weakness or spasticity due to ALS = 60 months prior to Screening Visit. Slow vital capacity (SVC) measure =50% of predicted for gender, height, and age at the screening visit. Must be able to swallow capsules throughout the course of the study, according to Site Investigator judgment. Capable of providing informed consent and following trial procedures. For TMS: a resting motor threshold defined as 50% of pulses eliciting a motor evoked potential (MEP) of amplitude = 50 µV. For TTNCS: median Compound Muscle Action Potential (CMAP) = 1.5 mV. Subjects must not have taken riluzole for at least 30 days or be on a stable dose of riluzole for at least 30 days prior to the Screening Visit and continue on the stable dose throughout the course of the study (riluzole-naïve subjects are permitted in the study). Subjects must not have taken medication for muscle cramping such as cyclobenzaprine, baclofen, carisoprodol, or methocarbamol, for at least 30 days prior to screening or be on a stable dose for at least 60 days prior to screening. Geographic accessibility to the site. Women must not become pregnant for the duration of the study and must be willing to use two contraceptive therapies and have a negative pregnancy test throughout the course of the study. Use of medications known to affect the neurophysiology measures in the study must be scheduled, not as needed (pro re nata, PRN). A subject must have been on a fixed dose for 30 days prior to the Screening Visit, and there must be no reason to believe that a subsequent change would be necessary during the course of the study. These medications include: benzodiazepines, muscle relaxants, tricyclic antidepressants, selective serotonin reuptake inhibitors, non-selective serotonin reuptake inhibitors, hypnotics (including anti-histamines) and anti-cholinergics.",Mexiletine-2 MX-ALS-002 NCT02781454 TrialTroveID-279460,Adults; Older Adults,year(s),,279460,Delay Disease Progression,,18.0,"Invasive ventilator dependence, such as tracheostomy. Creatinine level greater than 1.5 mg/dL at screening. Serum Glutamic-Oxaloacetic (SGOT/AST) / Serum Glutamic-Pyruvic (SGPT/ALT) greater than 3 times the upper limit of normal at screening. History of known sensitivity or intolerability to mexiletine or lidocaine. Any history of either substance abuse within the past year, unstable psychiatric disease, cognitive impairment, or dementia. Clinically significant conduction abnormalities on electrocardiogram or a known history of cardiac arrhythmia. Known history of epilepsy. Known history of congestive heart failure (CHF) or history of myocardial infarction within the past 24 months. Use of mexiletine for 30 days prior to Screening Visit. Exposure to any other experimental agent (off-label use or investigational) including high dose creatine (>10 grams a day) within 30 days prior to Screening Visit. Metal in the head and neck region, cardiac pacemaker or brain stimulator, cochlear implants, implanted infusion device or personal history of epilepsy. Use of amiodarone, flecainide, duloxetine, tizanidine, or clozapine. Pregnant women or women currently breastfeeding. Placement of Diaphragm Pacing System (DPS) device < 60 days prior to Screening Visit. Planned DPS device implantation during study participation",Ii,Both
0,Patients With Sporadic Amyotrophic Lateral Sclerosis (SALS).,"Sporadic Amyotrophic Lateral Sclerosis (SALS) diagnosed as possible, laboratory-supported probable, probable, or definite ALS as defined by revised El Escorial criteria. Age 18 years or older. Disease duration <or= 36 months from ALS symptom onset. Capable of providing informed consent and following trial procedures. Subjects must not have taken riluzole for at least 30 days or be on a 50 milligrams twice daily dose of riluzole for at least 60 days prior to randomization (riluzole-naïve subjects are permitted in the study). Subjects must not have taken medication for muscle cramping such as cyclobenzaprine, baclofen, carisoprodol, or methocarbamol, for at least 30 days prior to randomization or be on a stable dose for at least 60 days prior to randomization. Geographic accessibility to the site. Women must not become pregnant for the duration of the study and must be willing to use two contraceptive therapies and have a negative pregnancy test throughout the course of the study. Slow vital capacity (SVC) measure greater than or equal to 50% of predicted for gender, height, and age at the screening visit. Subjects medically able to undergo lumbar puncture (LP) as determined by the investigator (for example, no bleeding disorder, allergy to local anesthetics, a skin infection at or near the LP site, or evidence of high intracranial pressure). Must be able to swallow capsules throughout the course of the study, according to Principal Investigator (PI) judgment. Must have a caregiver assist with dispensing the study drug.",43708-A MX-ALS-001 NCT01849770 TrialTroveID-186024,Adults; Older Adults,year(s),,186024,Delay Disease Progression,,18.0,"Invasive ventilator dependence, such as tracheostomy. Creatinine level greater than 1.5 milligram/deciliter. Serum glutamic oxaloacetic transaminase or (aspartate transaminase) / serum glutamic pyruvic transaminase (alanine aminotransferase) greater than 3 times the upper limit of normal at screening. History of known sensitivity or intolerability to mexiletine or lidocaine. Any history of either substance abuse within the past year, unstable psychiatric disease, cognitive impairment, or dementia. Clinically significant conduction abnormalities on electrocardiogram or a known history of cardiac arrhythmia. Known history of epilepsy. Known history of congestive heart failure (CHF) or history of myocardial infarction within the past 24 months. Use of mexiletine for 60 days prior to Baseline Visit. Exposure to any other experimental agent (off-label use or investigational) including high dose creatine (greater than 10 grams a day) within 30 days prior to Baseline Visit. Use of amiodarone, flecainide, duloxetine, tizanidine, or clozapine. Pregnant women or women currently breastfeeding. Placement of Diaphragm Pacing System (DPS) device less than 60 days prior to Baseline Visit. Planned DPS device implantation after Baseline Visit.",Ii,Both
1,ALS patients with severe muscle cramps.,"Ages Eligible for Study: 21 Years to 89 Years; Genders Eligible for Study: Both Inclusion Criteria: ALS diagnosed according to El Escorial criteria (Awaji version) as: Possible, Probable, or Definite. Experiencing cramps as a moderate or severe symptom as defined by willingness to take a medication for the symptom. >or=2 cramps per week during run in week Life expectancy >or=6 months, estimated by clinician. Able to take drug capsule by mouth. No significant EKG abnormality on screening. Aspartate aminotransferase / alanine aminotransferase / alkaline phosphatase <or=2x upper limit of normal measured at screening. Having successfully filled out the cramp diary and cramp and fasciculation scales on six out of the last seven days of run in period.",378164 NCT01811355 TrialTroveID-183284,Adults; Older Adults,year(s),year(s),183284,Symptom relief,89.0,21.0,"Exclusion Criteria: Inability to communicate by telephone or email Allergy/ known sensitivity to mexiletine Prior use of mexiletine AV block unless subject has pacemaker Cardiac arrhythmia Prior myocardial infarction Other significant EKG abnormality Liver disease History of leucopenia (WBC <or=3,500/mm^3) Epilepsy Other serious and unstable medical condition Pregnant woman Breastfeeding woman Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements Use of quinidine (alone or as a component of Nuedexta) during the study Inability or unwillingness of subject to give written informed consent Woman of childbearing potential, not willing to use at least two approved methods of contraception Use of a prohibited medication during study.",Iv,Both
0,Patient had probable or definite amyotrophic lateral sclerosis.,"Age-lower limit 20 years-old < = Age-upper limit Not applicable Inclusion criteria: Over 20 years old. Patient had probable or definite ALS disease, as defined in the Awaji electrophysiological criteria. Subjects provided informed consent.",TrialTroveID-154059 UMIN000006423,Adults; Older Adults,year(s),,154059,Delay Disease Progression,,20.0,"Exclusion criteria: Patient did not have ability to comprehend informed consent Patient had uncompensated medical illness Patient had cardiac disease (myocardial infarction, valvular disease and cardiomyopathy etc.) Patient had arrhythmia (incomplet AV-block and bundle branch block etc.) Significant sinus bradycardia 6)Hypotension Hypokalemia Patient already administered anti-arrhythmic drug Woman is pregnant or is breast-feeding Subjects had forced vital capacity of< 60% predicted Subjects were not allowed to take any other experimental agents 3 months before. Subjects had concomitant disease effects peripheral nerve (diabetic peripheral neuropathy, hyperglycemia, ypercapnia etc.) Not evoled CMAP amplitude in median nerve Patient already performed tracheotomy or tube feeding. Patient with disease duration of less than 36 months at study entry. Patient had family history of amyotorphic lateral sclerosis. Patient already administered other drug (procaine amide, quinidine, aprindine, amoxapine, antiepileptic drug). If patient suspend the administration of these drugs, they had possibility to exacerbate illness.",Ii,Both
0,Patients With Niemann-Pick Type C Disease,Patients with NPC disease confirmed by abnormal cholesterol esterification and abnormal filipin staining. Patients aged 12 and over. Body weight must not be less than 14 kg. Patients who can ingest a capsule.,03-EI-0011 030011 NCT00316498 TrialTroveID-236246,Children; Adults; Older Adults,year(s),,236246,Niemann-Pick Type C,,12.0,"Patients younger than 18 who are unable to give informed assent and/or whose legal guardian is unable to provide informed consent. Patients aged 18 and over who cannot provide informed consent and/or whose legal guardian is unable to provide witnessed informed consent. Fertile patients who do not agree to use adequate contraception throughout the study and for three months after cessation of OGT 918 treatment. Patients who cannot tolerate the study procedures or who are unable to travel to the study center as required by this protocol. Patients currently undergoing therapy with other investigational agents or patients taking drugs or food supplements which may interfere with gastrointestinal absorption or motility. Patients suffering from clinically significant diarrhoea (greater than 3 liquid stools per day for greater than 7 days) without definable cause within 3 months of Screening Visit, or who have a history of significant gastrointestinal disorders. Patients with an intercurrent medical condition that would render them unsuitable for the study e.g. HIV, hepatitis infection. Patients who in the opinion of the investigator (for whatever reason) are thought to be unsuitable for the study.",I,Both
1,Patients with Niemann-Pick C disease.,Confirm diagnosis of Niemann-Pick C disease Symptomatic including motor or mental symptoms,200802043M NCT01760564 TrialTroveID-229819,,,,229819,Niemann-Pick Type C,,,Unknown severe diarrhea for more than 7 day Allergy to miglustat,Iii,Both
0,Newly diagnosed ALS patients (62.5 +or- 10.3 years) were recruited,,TrialTroveID-121809,Adults; Older Adults,year(s),year(s),121809,Unspecified,73.0,52.0,,Other,
1,Continuously treated with riluzole for at least 3 months and stabilised at 100 mg/day (50 mg twice a day) without significant adverse drug reactions. Capable of understanding the information given and giving fully informed consent.,"Age >or=18 years (inclusive). Participants - inclusion criteria Possible, probable (clinically or laboratory) or definite ALS according to the revised version of the El Escorial World Federation of Neurology criteria (The Ã‚Â¿Airlie House StatementÃ‚Â¿: http://www.wfnals.org/). The onset form (bulbar or limb) and disease type (familial or sporadic) will be recorded; source documents will include a full report of an electromyogram (EMG) reported by an experienced neurophysiologist as compatible with ALS. Disease duration more than 6 months (required by the El Escorial Criteria as the minimum time required to determine that there has been progression) and less than 5 years (inclusive); disease onset defined as date of first muscle weakness. Vital Capacity (VC) >or=40 % of predicted. Sex male or female. In the case of a female with childbearing potential, the patient must use adequate contraceptive measures and must not be pregnant or breast-feeding.",EMINALS ISRCTN72727460 TrialTroveID-079881,Adults; Older Adults,year(s),,79881,Delay Disease Progression,,18.0,"Participants - exclusion criteria Previous participation in another clinical study within the preceding 12 weeks. Tracheostomy, assisted ventilation of any type during the preceding three months. Existing gastrostomy. Any medical condition known to have an association with motor neuron dysfunction which might confound or obscure the diagnosis of ALS. Presence of any concomitant life-threatening disease or any disease or impairment likely to interfere with functional assessment. Confirmed hepatic insufficiency or abnormal liver function (ASpartate aminoTransferase [AST] and/or ALanine aminoTransferase [ALT] greater than 1.5 the upper limit of the normal range). Renal insufficiency (serum creatinine >200 Âµmol/L [2.26 mg/dL]). Evidence of major psychiatric disorder or clinically evident dementia precluding evaluation of symptoms. Known hypersensitivity to any component of the study drugs or to drugs in this class. Likely to be unco-operative or to fail to comply with the trial requirements or to be inaccessible in the event of an emergency. Unable or unwilling to use an effective method of contraception if a woman of childbearing age.",Iii,
1,Patients early in the course of Amyotrophic Lateral Sclerosis (ALS).,"Ages Eligible for Study: 21 Years to 85 Years; Genders Eligible for Study: Both To be eligible for enrollment in this study, subjects must meet the following eligibility criteria within fourteen days prior to randomization: Inclusion criteria: A clinical diagnosis of laboratory-supported probable, probable or definite ALS, according to modified EL Escorial criteria. FVC greater or equal to 75% of predicted. Onset of weakness within 3 years prior to enrollment. If patients are receiving riluzole they must be on a stable dose for at least the past thirty days. Women of childbearing age must be non-lactating and surgically sterile or using an effective method of birth control and have a negative pregnancy test (adequate birth control includes use of intra-uterine device or oral contraceptives plus a barrier method, e.g. condom, diaphragm). Willing and able to give signed informed consent that has been approved by your Institutional Review Board (IRB).",NCT00047723 R01NS45294 TrialTroveID-079057,Adults; Older Adults,year(s),year(s),79057,Delay Disease Progression,85.0,21.0,"Exclusion criteria: Requirement for tracheotomy ventilation (or non-invasive ventilation > 23 hours/day). Diagnosis of other neurodegenerative diseases (Parkinson's disease, Alzheimer's disease, etc). FVC < 75% of predicted. A clinically significant history of unstable medical illness (unstable angina, advanced cancer, etc) over the last 30 days. History of renal disease (screening creatinine greater than 1.5). History of liver disease (screening alanine aminotransferase greater than 3 times the upper limit of normal). History of hematologic disease (screening white blood cell count less than 3,800/mm3). History of system lupus erythematosis (or screening ANA of 1:160 or greater). Treatment with any medications that may cause lupus-like symptoms within 4 weeks of baseline visit (e.g. procainamide, hydralazine). History of vestibular disease (excluding benign position vertigo). Pregnancy or lactation. Allergy to tetracycline antibiotics. Use of minocycline within thirty days of enrollment (baseline visit). Use of anti-epileptic medications other than gabapentin. Limited mental capacity rendering the subject unable to provide written informed consent or comply with evaluation procedures. History of recent alcohol or drug abuse or noncompliance with treatment or other experimental protocols. Use of any investigational drug within the past 30 days (Creatine, Vioxx, Celebrex, Topiramate). Women with the potential to become pregnant who are not practicing effective birth control.",Iii,Both
0,"ALS patients. Patients with a diagnosis of probable or definite ALS, according to the El Escorial revised criteria of the World Federation of Neurology were recruited. There were 12 males and 8 females (mean age 60 +or - 11 years, range 38–76; mean disease duration 16 + or - 6 months, range 8–27).",,TrialTroveID-078907,Adults; Older Adults,year(s),year(s),78907,Delay Disease Progression,76.0,38.0,,Ii,Both
0,,,TrialTroveID-102300,,,,102300,(N/A); Healthy subjects,,,,I,
1,Patients with amyotrophic lateral sclerosis (ALS).,"Ages Eligible for Study: 18 Years to 80 Years; Genders Eligible for Study: Both Inclusion Criteria Be 18 to 80 years old. Have a clinical diagnosis of possible, laboratory-supported probable, probable or definite ALS, according to modified El Escorial criteria. Have a forced vital capacity (respiratory measurement) of more than 50 percent. Clinically significant fatigue (4.5+ on Fatigue Severity Scale with duration 3+ months plus impairment in 1+ categories of role function). Be able to swallow capsules. Be able to communicate verbally, with or without an assistive device. Speaks English. Able and willing to give informed consent.",IRB5178 NCT00614926 TrialTroveID-080449,Adults; Older Adults,year(s),year(s),80449,Symptom relief,80.0,18.0,Exclusion Criteria Untreated hypothyroidism (TSH > 4.25 UIU/ML). Untreated and uncontrolled hypertension. Clinically significant anemia (HCT < 33%). Untreated or under-treated major depressive disorder. Current clinically significant suicidal ideation. Started antidepressant medication for treatment of depression during past 6 weeks. Currently taking psychostimulant medication. History or current psychosis or bipolar disorder. Fecund women not currently using barrier methods of contraception. Untreated major depressive disorder.,Iv,Both
0,Patients with ALS.,,TrialTroveID-079830,,,,79830,Symptom relief,,,,Ii,
0,Patients with ALS/MND,"1. Signed informed consent obtained prior to initiation of any study specific procedures and treatment. 2. Individuals who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. 3. Able to swallow study drug tablets. 4. Individuals must have completed Study MON-2021-001 and, in the opinion of the investigator, have been compliant with the study procedures and study treatment. 5. Diagnosis of ALS/MND defined as clinically possible, probable, or definite according to Awaji-shima Consensus Recommendations. 6. Not taking riluzole or on a stable dose of riluzole for at least 4 weeks prior to the screening visit; subjects are not allowed to start taking riluzole during the study. 7. Individual has a competent caregiver/support person who can and will be able to support the individual's participation in the study, including assisting with the administration of study drug. 8. Adequate bone marrow reserve, renal and liver function: - absolute neutrophil count ≥ 1500/µl. - platelet count ≥ 120,000/µl. - hemoglobin ≥ 11 g/dL. - creatinine clearance ≥ 60 mL/min (Cockroft & Gault formula). - alanine aminotransferase and/or aspartate aminotransferase ≤ 3 x upper limit of normal. - total bilirubin ≤ 2.0 x ULN. - serum albumin ≥ 2.8 g/dL. 9. Women and men with partners of childbearing potential must use effective contraception while on study treatment and women of childbearing potential must be non-lactating.",MON-2023-001 NCT06177431 TrialTroveID-496830,Adults; Older Adults,year(s),year(s),496830,Delay Disease Progression,75.0,18.0,"Inability to swallow oral medications or presence of a gastrointestinal disorder (e.g., malabsorption) deemed to jeopardize intestinal absorption of study drug. Participated in another investigational drug research study within 4 weeks (28 days) of the Baseline Visit or five half-lives of the drug, whichever is longer. Any other significant illness or condition that in the opinion of the study investigator would interfere with the study conduct. Dementia that may affect either outcome measures or subject understanding and/or compliance with study requirements and procedures. Women and men of childbearing potential not using effective contraception while on study treatment. Women who are breast feeding. Individuals at risk of or are known to carry a SOD1 mutation or VCP mutation.",I,Both
0,People with Amyotrophic lateral sclerosis/ Motor Neurone Disease.,"Signed informed consent obtained prior to initiation of any study-specific procedures and treatment Familial or sporadic ALS/MND diagnosed as clinically possible, probable, or definite according to Awaji-shima Consensus Recommendations Seated slow vital capacity (SVC) >/= 3L in males and >/= 2.5L in females at screening Not taking riluzole or on a stable dose of riluzole for at least 4 weeks prior to the screening visit. While on study, subjects are not allowed to start taking riluzole during the study Patient has a competent caregiver who can support the patient's involvement in the study, including assisting the administration of study drug Adequate bone marrow reserve, renal and liver function: absolute neutrophil count (ANC) >/=1500/µL; platelet count >/= 100,000/µL; hemoglobin >/= 9 g/dL; creatinine clearance >/= 60 mL/min (Cockroft & Gault formula); alanine aminotransferase ALT, SGPT) and/or aspartate aminotransferase (AST, SGOT) </= 2 x upper limit of normal (ULN); total bilirubin </= 1.5 x ULN; serum albumin >/= 2.8 g/dL Women and men with partners of childbearing potential must use effective contraception while on study treatment and women of childbearing potential must have a negative pregnancy test at screening",MON-2021-001 NCT04894240 TrialTroveID-385362,Adults; Older Adults,year(s),year(s),385362,Delay Disease Progression,75.0,18.0,"Inability to swallow oral medications or presence of a gastrointestinal disorder (e.g., malabsorption) deemed to jeopardize intestinal absorption of study drug Dependence on mechanical ventilation (invasive or non-invasive, including Continuous Positive Airway Pressure (CPAP) or Bi-level Positive Airway Pressure (BiPAP) for any part of day or night prior to the screening visit. Dependence on mechanical ventilation is defined as being unable to lie flat (supine) without it, unable to sleep without it, or daytime use Exposure to any other investigational agent within 3 months prior to the screening visit Active gastrointestinal disease within 30 days of the screening visit. Gastro-esophageal reflux disease (GERD) is not considered active gastrointestinal disease and is not exclusionary Known immune compromising illness or treatment Presence of any of the following clinical conditions: drug abuse or alcoholism; unstable cardiac, pulmonary, renal, hepatic, endocrine, or hematologic disease; active infectious disease; AIDS or AIDS-related complex; diagnosis of malignancy within 2 years of screening (adequately treated basal cell or squamous cell carcinoma of skin or non-invasive bladder cancer or carcinoma in situ of the bladder, breast or cervix are allowed; unstable psychiatric illness defined as psychosis or untreated major depression within 90 days of the screening visit; neuromuscular disease other than ALS/MND Dementia that may affect either outcome measures or patient understanding and/or compliance with study requirements and procedures Women and men of childbearing potential not using effective contraception while on study treatment Women who are breast-feeding Patients at risk of or known to carry a SOD1 mutation or VCP mutation",Iii,Both
1,Amyotrophic Lateral Sclerosis Patients.,,TrialTroveID-220888,,,,220888,Unspecified,,,,Iv,
0,Patients with terminal amyotrophic lateral sclerosis (ALS).,,TrialTroveID-128316,,,,128316,Symptom relief,,,,Ii,
0,Patients with Alzheimer`s disease psychosis,"Females must be of non-childbearing potential, defined as women greater than or equal to (> =) 60 years of age, postmenopausal women > =50 and less than(<) 60 years of age who have had a cessation of menses for at least 12 months, or women who are congenitally or surgically sterile. Males must agree to use 2 forms of highly effective birth control with female partners of childbearing potential while enrolled in the study, and for at least 28 days following the last dose. Ambulatory (with or without walking device) with a stable gait. Have an Mini-Mental State Examination (MMSE) score of 10 to 24. Meet clinical criteria for one of the following disorders: dementia associated with Parkinson's disease, dementia with Lewy bodies, possible or probable Alzheimer's disease, frontotemporal degeneration spectrum disorders, vascular dementia Able to communicate verbally. Have an NPI score of > or =4 on either individual item (delusions or hallucinations) or > or =6 on the Psychosis Subscale (combined delusions and hallucinations), or an NPI score of > or =4 on agitation/aggression domain. Have a reliable caregiver who provides written informed consent to participate and who is in frequent contact with the patient (defined as spending at least 4 hours/day at least 4 days/week with the patient and who is knowledgeable about the patient's daytime and nighttime behaviors). The caregiver must be able to communicate with site personnel, and opinion of the investigator, must understand the written protocol-specified questionnaires. If a caregiver cannot continue, one replacement caregiver will be allowed if the above criterion is met. Must be on a stable dose of cholinesterase inhibitor and/or memantine, if applicable. If taking antipsychotic drugs or any drug intended to treat psychosis, must be on a stable treatment regimen for > or =1 month prior to the study. Have venous access sufficient to allow for blood sampling per the protocol. Have clinical laboratory test results within normal reference range for the population or investigative site. Are capable of participating in all study assessments. Are able and willing to provide consent (patients and caregivers).",MP-101-01 NCT03044249 TrialTroveID-281496,Adults; Older Adults,year(s),,281496,Behavioral Symptoms - Psychosis; Frontotemporal Dementia; Lewy Body Dementia; Mild; Moderate; Severe; Vascular Dementia,,50.0,"Have a history of significant psychotic disorders (including, schizophrenia, delusional disorder, substance abuse psychosis that lasted over 6 months, major depressive disorder or bipolar disorder with psychotic episodes). Has a history of ischemic stroke within the last 12 months or any evidence of hemorrhagic stroke. Have renal impairment as defined by Estimated Glomerular Filtration Rate (eGFR) <45 milliliters per minute per 1.73 square meters (ml/min/1.73m^2). Have significant cardiovascular, respiratory, gastrointestinal, renal, hematologic, or oncologic comorbidities that could impact patient safety and study participation over 10 weeks. Have a history of seizures or other condition that would place the patient at increased risk of seizures. Are, in the investigator's judgment, at risk for suicide, or as indicated by the Columbia Suicide Severity Rating Scale (C-SSRS). Have a Fridericia's corrected QT interval (QTcF) greater than (>) 450 milliseconds (ms) for males or 470 ms for females. Are currently enrolled in any other clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study. Have participated, within the last 30 days, in a clinical trial involving an investigational product. If the previous investigational product has a long half-life, at least 3 months (or more) must have passed. In the opinion of the investigator or sponsor, are unsuitable for inclusion in the study.",Ii,Both
0,Patients With Amyotrophic Lateral Sclerosis,"- Able to provide written informed consent (either from patient or patient's legally acceptable representative and complying with study procedures, in the PI's opinion. - Male or female patients between 18-75 years. - Sporadic or familial ALS diagnosed as clinically possible, probable, lab-supported probable, or definite ALS defined by revised El Escorial criteria. - Time since onset of weakness due to ALS ≤ 48 months at the time of the Screening Visit - Vital Capacity ≥ 50% of predicted capacity for age, height, and sex at the time of the Screening Visit measured by Slow Vital Capacity (SVC), or Forced Vital Capacity (FVC). - Patients must either not take Riluzole or be on a stable dose of Riluzole for ≥ 30 days prior to the Master Protocol Screening Visit. Riluzole-naïve participants are permitted in the study. - Participants must either not take Edaravone or have completed at least one cycle of edaravone prior to the Master Protocol Screening Visit. Edaravone-naïve participants are permitted in the study. - Participants must either not take Relyvrio (AMX0035) or be on a stable dose of Relyvrio for ≥ 30 days prior to the Master Protocol Screening Visit. Relyvrio-naïve participants are permitted in the study. - Women of child-bearing potential (defined as females who are not surgically sterile or who are not over the age of 52 and amenorrhoeic for at least 12 months) must utilize appropriate birth control throughout the study duration. - Male patients must agree to use a medically acceptable method of contraception /birth control throughout the study duration.",MRG24ALS NCT06315608 TrialTroveID-508439,Adults; Older Adults,year(s),year(s),508439,Delay Disease Progression,75.0,18.0,"- Subjects who meet one or more of the following criteria will not be considered eligible to participate in the clinical study: - Participation in another interventional clinical trial (drug or device) within 30 days of Screening and at any time during the study. - Significant pre-existing organ dysfunction prior to randomization: - Lung: Receiving supplemental home oxygen therapy at baseline for pre-existing medical condition (other than COVID-19), as documented in medical record. - Heart: Pre-existing congestive heart failure defined as an ejection fraction <20% as documented in the medical record. Clinically significant ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation), unstable angina, myocardial infarction (past 3 months), heart and coronary vessel surgery (past 3 months), significant valvular heart disease, uncontrolled arterial hypertension with systolic blood pressure >180 mm Hg and diastolic blood pressure >110 mm Hg. - Renal: End-stage renal disease requiring renal replacement therapy or creatinine clearance <50 mL/min. - Hematologic: Baseline platelet count <30,000/mm3 or hemoglobin levels <6.0 g/dL. - Neurological: Stage ≥3 hepatic encephalopathy by West Haven criteria. - History of splenectomy or splenomegaly (spleen weighing > 750 g). - Active cancer or history of cancer, except for the following: basal cell carcinoma or successfully treated squamous cell carcinoma of the skin, cervical carcinoma in situ, prostatic carcinoma in situ, or other malignancies curatively treated and with no evidence of disease recurrence for at least 3 years. - Presence of unstable psychiatric disease, cognitive impairment, dementia or substance abuse that would impair ability of the participant to provide informed consent, in the SI's opinion. - Exposure at any time to any gene therapies under investigation for the treatment of ALS (off-label use or investigational) including tofersen (Qalsody). - History of splenectomy or splenomegaly (spleen weighing >750 g). - Co-infection with human immunodeficiency virus (HIV). - History of organ or bone marrow transplantation, other than a corneal transplant. or recent (within 3 months) chronic use of immunosuppressive drugs (tacrolimus, mycofenolate mofetil, cyclosporine, rapamycine, hydrochloroquine, azathiopurine, methotrexate), e.g., biologicals, JAK1/2 inhibitors, interferons, interleukins or (prednisone or related corticosteroids are allowed). - Hypersensitivity to either of the components of MRG-001. - If female, known pregnancy, or has a positive serum pregnancy test, or lactating/breastfeeding. - Underlying diseases that, in the opinion of the site investigator, might be complicated or exacerbated by proposed treatments or might confound assessment of study drug.",Ii,Both
0,Patients with Amyotrophic lateral sclerosis,Definite ALS Severe fatigue (defined by FSS > 4.0) Expanded Disability Status Scale (EDSS) (measure of neurological impairment) 0 - 7.5 Able to comply with study procedures Stable medication for the past month prior to enrollment.,2022342 NCT04557410 TrialTroveID-384923,,,,384923,Symptom relief,,,,I,Both
0,Sporadic Amyotrophic Lateral Sclerosis Patients.,,TrialTroveID-121794,,,,121794,Unspecified,,,,Ii,
0,Healthy subjects under fasting and postprandial conditions,"Sign an informed consent form before research, and fully understand the research content, process and possible adverse reactions; 2 Able to complete the research according to the requirements of the research plan; 3 Subjects have no reproductive plans (or sperm/egg donation plans) within 6 months from screening to the end of the study and voluntarily take effective contraceptive measures; 4 Healthy Chinese male or female subjects aged 18 years and above (including 18 years old); 5 The weight of male subjects should not be less than 50.0kg, and the weight of female subjects should not be less than 45.0kg. Body mass index (BMI) = weight (kg)/height 2 (m2), and the body mass index is in the range of 19.0~26.0kg/m2 (including the boundary value).",CTR20240913 TrialTroveID-513758 YYAA1-BLZ-24008,Adults; Older Adults,year(s),,513758,(N/A); Healthy subjects,,18.0,"1 Those who are allergic to any ingredients in baclofen and its related compounds and excipients, or those who are allergic to two or more drugs (or foods), or those who have allergic constitution; 2 Have clinical abnormalities in physical examination, electrocardiogram, vital signs and laboratory tests (blood cell analysis, comprehensive urine analysis, blood biochemistry, coagulation function, etiological examination, blood pregnancy test (females only)) within 14 days before taking the study drug for the first time. meaning (subject to the judgment of the research doctor); 3 Female subjects are lactating or have a positive pregnancy test; 4 Have a history of important diseases such as the nervous system, mental system, cardiovascular and cerebrovascular systems, endocrine system, digestive system, urinary system, reproductive system, immune system, respiratory system, or existing diseases of the above systems or any clinically significant persistent chronic diseases (including But not limited to epilepsy, Parkinson's disease, nystagmus, ataxia, schizophrenia, depression, mania, peptic ulcer, urinary retention, etc.); 5 Those who have undergone surgery within 3 months before screening, or plan to have surgery during the study period, and those who have undergone surgery that will affect drug absorption, distribution, metabolism, and excretion; 6 Those who have started a significantly abnormal diet (such as dieting, low sodium) within 4 weeks before screening, or have special requirements for diet and cannot adhere to a unified diet; 7 Those with difficulty swallowing or lactose intolerance; 8 Smoking more than 5 cigarettes per day in the 3 months before screening, and regular drinkers in the 6 months before screening, that is, drinking more than 14 units of alcohol per week (1 unit = 360 mL of beer with an alcohol content of 5% or 45 mL of alcohol) 40% spirits or 150mL of wine with an alcohol content of 12%), or those who are unable to stop ingesting alcohol or any tobacco products during the study; 9 Drinking excessive amounts of tea, coffee and/or caffeinated beverages (more than 8 cups, 1 cup is about 250mL) every day within 3 months before screening, or drinking or taking tea, coffee and/or caffeinated beverages within 48 hours before taking the study drug for the first time / Or those who consume caffeinated beverages and foods (including chocolate, coffee, cola and any xanthine-rich foods), or those who do not agree to be prohibited from consuming these foods or beverages during the study; 10 Those who have used drugs within 3 months before screening or have a history of drug abuse within 12 months before screening; 11 Those who have participated in other clinical studies of drugs or devices within 3 months before screening; 12 Have taken any drug that changes the gastrointestinal environment within 30 days before screening (such as proton pump inhibitors Tytoprazole, omeprazole, lansoprazole, esoprazole, etc.; histamine receptor (H2) antagonist ranib Tidine, cimetidine, famotidine, etc.; antacids sodium bicarbonate, magnesium oxide, aluminum hydroxide, magnesium trisilicate, etc.; gastric mucosa protective agent sucralfate, etc.) or drugs with liver enzyme activity ( Such as: Inducers - barbiturates, carbamazepine, phenytoin, dexamethasone, etc.; inhibitors - SSRI antidepressants, ciprofloxacin, cimetidine, diltiazem, macrolides? (such as metronidazole, ketoconazole, verapamil, fluoroquinolones, omeprazole, etc.); 13 Have used baclofen or any drug that interacts with baclofen (such as levodopa/dopa decarboxylase (DDC) inhibitors, central nervous system (CNS) depressants, antidepressants) within 30 days before screening , lithium, antihypertensive drugs, drugs that damage kidney function, etc.); 14 Those who have taken any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health products within 2 weeks before screening; 15 Those who have donated blood (including blood components) or lost a large amount of blood (≥400mL) within 3 months before screening, or those who have received blood transfusions or used blood products, or those who plan to donate blood during the trial or within one month after the end of the trial; 16 Those who have received the COVID-19 vaccine less than 4 weeks before screening (3 months for other vaccines), and those who do not agree to be prohibited from receiving the vaccine during the study; 17 Those who cannot tolerate venipuncture, or those who have difficulty in blood collection or faint from needles (such as unqualified vein assessment); 18 Those who develop acute illness before randomization are not suitable to participate in the study (subject to the judgment of the study doctor); 19 Those who have eaten dragon fruit, mango, grapefruit, lime, star fruit, pomegranate, grapefruit, or foods or beverages prepared therefrom within 48 hours before taking the study drug for the first time, or who do not agree to be prohibited from consuming the above foods or beverages during the study; 20 Those with a positive drug abuse screen (urine drug screen) or those with alcohol breath test results >0mg/100mL; twenty one Subjects may be unable to complete the study due to other reasons or the researcher may not consider them to be included.",I,Both
0,Patients with Frontotemporal Dementia,"- Men and women over 18 years - Major neurocognitive disorder due to probable behavioural variant FTD (Rascovsky criteria)17 or primary progressive aphasia (Gorno-Tempini criteria)18. All ages and severity levels will be included. - Meets International Psychogeriatric Association criteria for agitation in cognitive disorders19 - CMAI score of 39 or above - Stable psychoactive medication for 1 month prior to screening (all medications allowed) with no intention to change dose during treatment period - Available study partner with ≥10 hours per week in-person contact with the patient. This can either be a friend/family member or a staff member at an assisted living facility. - Capacity to provide written consent in English or French, or consent from official surrogate decision maker in case of incapacity Rationale for The inclusion criteria are designed to enroll patients with FTD with the behaviours of interest, with a range of disease severity that will permit assessment of all outcome measures.",AgiNab Nabilone-FTD NCT05742698 TrialTroveID-460012,Adults; Older Adults,year(s),,460012,Frontotemporal Dementia,,18.0,"- Clinically significant psychotic symptoms (Neuropsychiatric Inventory domain score (severity x frequency) ≥4 on the delusions or hallucinations subscale) - Clinically significant orthostatic hypotension (a decrease in systolic blood pressure of 20 mm Hg or in diastolic blood pressure of 10 mm Hg within three minutes of standing compared to blood pressure in a seated position) - Symptomatic orthostatic tachycardia (heart rate increase from of at least 30 beats per minute within the first 5 minutes of standing compared to a seated position IF orthostatic hypotension is not a problem) - Unstable cardiovascular condition in the opinion of the investigator - Known or suspected history of drug or alcohol dependence or abuse in the past 12 months, including use of any psychomimetic drugs (e.g. ketamine, lysergic acid diethylamide, psilocybin). - Allergy, or significant adverse reaction to cannabinoids. If the adverse reaction involved psychological symptoms that are indicative of psychosis or severe anxiety the patient will be excluded. Their treating clinician may be consulted for a clinical opinion on the severity of the response to cannabis and whether this justifies exclusion from the trial. - Major depressive episode within 6 months of screening - Women who are breast feeding or pregnant - Severe liver dysfunction, as determined by their treating clinician - Other psychiatric or neurological condition that could cause significant agitation - Ongoing use of any cannabinoid-related products. This includes any THC or CBD based products, regardless of administration method (oral, inhalation, topical, etc…) Rationale for The exclusion criteria are designed to avoid inclusion of patients who may have medical comorbidities that would increase their risk of serious side effects from repeated nabilone administration.",Ii,Both
1,Patients affected by spasticity due to motor neuron disease ( Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis).,"Subjects must fulfil ALL of the following criteria: Written informed consent Subject able and willing to comply with all study requirements Affected by ALS, either of definite, probable or possible category according to the El Escorial revised criteria or by primary lateral sclerosis (Pringle's criteria) Affected of spasticity, equal or above 1 in the Ashworth Scale for spasticity in 2 or more muscle groups Who will judge spasticity a relevant cause of movements impairment Subject has spasticity due to MND of at least three months duration, which is not wholly relieved with current anti-spasticity therapy Subject fulfils at least one of the two criteria below. Subject must be either: Currently established on a regular dose of anti-spasticity therapy, or Previously tried and failed, or could not tolerate suitable anti-spasticity therapy Stabilization of factors affecting spasticity: any physiotherapy regimen or medication likely to affect spasticity will be optimised before the study and not altered in the 3 weeks before start of treatment Subject is willing for his or her name to be notified to the responsible authorities for participation in this study, as applicable. Additional inclusion Criteria to be met at baseline Subjects have registered spasticity NRS scores via the personal clinical diary over the 6 days (day 2 to day 7) before randomization",CANALS EudraCT Number: 2010-022808-40 NCT01776970 TrialTroveID-181182,Adults; Older Adults,year(s),year(s),181182,Comorbidity in ALS; Spasticity; Symptom relief,80.0,18.0,"Any concomitant disease or disorder that has spasticity-like symptoms or that may influence the subject's level of spasticity Subjects receiving Botulinum Toxin during the preceding 6 months Bedridden and tracheotomised patients Fixed-tendon contractures Severe cognitive impairment Currently using or has used cannabis, cannabinoid-based medications or Acomplia (Rimonabant) within 30 days of study entry and unwilling to abstain for the duration of the study Any history or immediate family history of schizophrenia, other psychotic illness, severe personality disorder or other significant psychiatric disorder other than depression associated with their underlying condition Any known or suspected history of a diagnosed dependence disorder, current heavy alcohol consumption, current use of an illicit drug or current non-prescribed use of any prescription drug Subjects with poorly controlled epilepsy or recurrent seizures (Subjects who have had one or more fits in the year prior to Visit 1 will be excluded) Any known or suspected hypersensitivity to cannabinoids or any of the excipients Subject has experienced myocardial infarction or clinically relevant cardiac dysfunction within the last 12 months or has a cardiac disorder that, in the opinion of the investigator would put the subject at risk of a clinically relevant arrhythmia or myocardial infarction Subject has a diastolic blood pressure of <50 mmHg or >105 mmHg (when measured in a sitting position at rest for five minutes) or a postural drop in the systolic blood pressure of greater than 20 mmHg Personal history suggestive of relevant impaired renal or hepatic function Female subjects of child bearing potential, unless willing to ensure that they or their partner use effective contraception during the study and for three months thereafter Female subject who is pregnant, lactating or planning pregnancy during the course of the study and for three months thereafter Subjects who have received any IMP within the 8 weeks before Visit 1 Any other significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the result of the study, or the subject's ability to participate in the study Unwilling to abstain from donation of blood during the study Patients will be asked not to drive while they will be receiving medication",Ii/Iii,Both
1,Patients with amyotrophic lateral sclerosis.,,TrialTroveID-294461,Adults; Older Adults,year(s),year(s),294461,Unspecified,78.0,30.0,,Iv,Both
0,Patients with amyotrophic lateral sclerosis,"1 Meet the Western medical diagnostic criteria for amyotrophic lateral sclerosis (ALS) (clinically confirmed ALS, clinically probable ALS, clinically probable ALS—laboratory support); 2 It complies with the TCM syndrome differentiation standard of Duyuan deficiency syndrome for impotence disease; 3 Age 45-70 years old (both ends included), gender not limited; 4 Modified amyotrophic lateral sclerosis functional scale score (ALSFRS-R) is ≥2 points for each item (including dyspnea, orthopnea, and respiratory insufficiency are all 4 points; 5 Forced vital capacity as a percentage of predicted value (FVC%) ≥70%, and non-invasive ventilator is not used; 6 The duration of the disease is 2 years or less (from the first appearance of any symptoms of ALS); 7 Patients may or may not receive medication (edaravone and/or riluzole) before enrollment, and the treatment regimen is expected to remain unchanged throughout the study period; 8 Voluntarily sign written informed consent",ChiCTR2400083114 CTR20240243 SRKL-ALS-Ⅱ-2023 TrialTroveID-502302,Adults; Older Adults,year(s),year(s),502302,Unspecified,70.0,45.0,"1 The diagnosis is consistent with progressive bulbar palsy and primary lateral sclerosis; combined with other neurological diseases that have symptoms similar to ALS and affect the evaluation of drug efficacy, such as cervical spondylotic myelopathy, syringomyelia, spinal cord and brainstem tumors, Hirayama disease, Multifocal motor neuropathy, multiple sclerosis, Guillain-Barré syndrome, Parkinson's disease and dementia; 2 Those who have undergone gastrostomy at the time of enrollment, or those who have dysphagia and cannot ensure normal diet and drug intake; 3 If the condition is severe and the possibility of survival within 1 year is expected to be extremely small (for example: using non-invasive ventilation for more than 10 hours a day, finger pulse oxygen continuously lower than 95%, or unable to tolerate nasogastric enteral nutritional support), it is difficult to evaluate the experimental drugs. Those who make accurate assessments of effectiveness and safety; 4 Those with a history of spinal surgery within six months; 5 Those who are accompanied by other serious lung diseases, or the required treatment may affect the assessment of respiratory function; 6 Those with serious heart, liver, kidney, blood, tumor and other diseases, or severe active mental illness; 7 Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≥ 1.5 times the upper limit of normal value, and/or serum creatinine (Scr) ≥ the upper limit of normal value; 8 Pregnant or lactating women, and those who have a childbirth plan within 6 months from enrollment to the end of the trial or who are unwilling to take effective contraceptive measures; 9 Those who are suspected or have a history of alcohol or drug abuse; 10 Allergy to the test drug or test drug ingredients; 11 Participated in other clinical trials within the past 3 months; 12 Any other relevant disease or condition that, in the opinion of the investigator, may limit or prevent study participation or affect study results.",Ii,Both
0,Subjects with amyotrophic lateral sclerosis,"(1) Subsequent patients diagnosed with amyotrophic lateral sclerosis (ALS); (2) Male and female, age 18-70 years old; (3) Mild, moderate patients, with a certain swallowing function; (4) Provide blood glucose, blood routine, liver and kidney function, immune function (CD3,CD4,CD8, interleukin-6) test reports within one week before enrollment; (5) Voluntarily participate in this clinical trial, give informed consent and sign informed consent.",ChiCTR2300077387 TrialTroveID-491734,Adults; Older Adults,year(s),year(s),491734,Delay Disease Progression,70.0,18.0,"(1) Severe renal insufficiency: creatinine clearance <30 mL/min (Cockcroft-Gault formula), or other known severe renal insufficiency; (2) Severe liver function damage: ALT, AST >3 times the upper limit of normal, or other known liver diseases such as acute and chronic active hepatitis, cirrhosis, diabetes, etc; (3) During the screening period, patients with heart failure (Class III-IV patients according to NYHA classification) developed acute myocardial infarction or underwent interventional therapy within the last 6 months; (4) Complicated with malignant tumors, serious diseases of blood, digestion or other systems; (5) Allergic constitution.",I,Both
1,Patients with amyotrophic lateral sclerosis,"Part I (1) Patients aged 18-80 years, regardless of gender. (2) Meet Gold Coast diagnostic criteria, disease stage 1-4, and severity grading 1-4. Part II Phase I 1.Patient inclusion criteria. (1) Patients diagnosed with ALS by Gold Coast criteria. (2) Patients aged 18-80 years, regardless of gender. (3) Patients with normal interpretative and expressive abilities and no other serious mental illness. (4) Voluntary participation in this study, and family members agreed to participate. 2. Patient's family members inclusion criteria. (1) Being the primary caregiver of the patient during treatment. (2) have normal understanding of expression. (3) Completed at least 3 time points of follow-up assessment in the Phase I longitudinal study. (4) Voluntary participation in this study. Part II Phase II Patient inclusion criteria. (1) Patients with a confirmed diagnosis of ALS. (2) Patients with normal comprehension and expression and no other serious mental illness. (3) Voluntary participation in this study, and family members agree to the patient's participation. Inclusion criteria for patient's family members. (1) being the primary caregiver of the patient during treatment. (2) Normal comprehension and expression ability. (3) Voluntary participation in this study.",ChiCTR2300068650 TrialTroveID-460826,Adults; Older Adults,year(s),year(s),460826,Delay Disease Progression,80.0,18.0,"Part I (1) Patients diagnosed with other neurodegenerative diseases during the trial. (2) Patients with severe psychiatric or cognitive disorders and other diseases who cannot cooperate to complete the study. (3) Patients with comorbid heart, brain, liver, kidney and other organ diseases. Part II Same exclusion criteria as Phase I",Iv,Both
0,Patients with Mild Neurocognitive Disorder,"1.Age between 50 -70 years of either sex. 2.Diagnosed as Mild Neurocognitive Disorder as per DSM V criteria {Possible sub types of Alzheimer’s disease, Frontotemporal lobar degeneration, Lewy body disease, vascular disease}. 3.Monteral cognitive assessment scale (MOCA) score between 18 and 25",CTRI/2022/12/047965 TrialTroveID-451102,Adults; Older Adults,year(s),year(s),451102,Frontotemporal Dementia; Lewy Body Dementia; Mild Cognitive Impairment/Prodromal; Vascular Dementia,70.0,50.0,"1.Other Neuro cognitive disorders due to Parkinson’s disease, trauma, medical conditions etc. 2.Neuropsychiatric disorders such as Schizophrenia, Bipolar disorder, Major depressive disorder 3.Patients with severe or uncontrolled Diabetes mellitus Hypertension and Thyroid disorders. 4.Patients with clinically relevant depression. [ Cornell Scale for Depression in Dementia (CSDD) >10]. 5.Patient on any other medications like psychotropic, neurotropic etc since 4 weeks.",Ii,Both
0,Participants with Amyotrophic Lateral Sclerosis,"Diagnosed with laboratory supported probable, clinically possible, probable or definite ALS according to the World Federation of Neurology Revised El Escorial criteria (83) (Appendix A) Disease duration from symptom onset no greater than 36 months at the Screening Visit Aged 18 years or older Capable of providing informed consent and complying with study procedures If taking riluzole, on a stable dose for at least 30 days prior to Screening Visit If taking edaravone, on a stable dose for at least one cycle prior to Screening Visit If on BiPAP, average usage of no more than 12 hours per day at time of Screening Visit Able to swallow a capsule at Baseline Visit Fluency in English or French",032-2017 NCT05031351 NIALS TrialTroveID-412810,Adults; Older Adults,year(s),,412810,Delay Disease Progression,,18.0,"Exposure to any investigational agent or Withania somnifera (Ashwagandha) within 30 days prior to the Screening Visit; simultaneous participation in other observational studies is allowed upon Site Investigator approval Presence of any of the following clinical conditions: Substance abuse within the past year Unstable cardiac, pulmonary, renal, hepatic, endocrine, hematologic, or active malignancy or infectious disease Acquired Immunodeficiency Syndrome (AIDS) or AIDS-related complex Unstable psychiatric illness defined as psychosis (hallucinations or delusions) or untreated major depression within 90 days prior to the Screening Visit Hypersensitivity or allergy to Withania somnifera Uncontrolled diabetes with severe associated complications (such as neuropathy) Untreated hypertension, active stomach ulcers, or untreated thyroid disorder Previously diagnosed auto-immune condition with or without neurological manifestations (e.g. multiple sclerosis (MS), systemic lupus erythematosus (SLE), rheumatoid arthritis, etc.) Current or planned use of oral, intramuscular or intravenous steroid drugs (such as prednisone, prednisolone, dexamethasone, triamcinolone, methylprednisolone, oxandrolone, and others) or immunosuppressant drugs (azathioprine, mycophenolate, tacrolimus, sirolimus, cyclophosphamide, and others) for more than 7 days Planned consumption of alcohol, other drugs or natural health products with sedative and anxiolytics properties while taking study drugs (8 week duration) Current or planned use of continuous subcutaneous, intravenous or oral anticoagulant drugs Scheduled for surgery under general anesthetic within 14 days of Screening Visit Pregnancy or planned pregnancy. Women of childbearing potential must have a negative pregnancy test and be non-lactating at the Screening Visit Insertion of a diaphragm pacing system",Ii,Both
0,Subjects with amyotrophic lateral sclerosis (ALS),"Meet the diagnostic criteria of Western medicine for amyotrophic lateral sclerosis (ALS) (Clinically confirmed ALS, clinically likely to suffer from ALS or clinically likely to suffer from ALS-laboratory support); The modified amyotrophic lateral sclerosis function scale score (ALSFRS-R) each item is =2 points (including dyspnea, orthopedic breathing and respiratory insufficiency must all be 4 points); Forced vital capacity as a percentage of predicted value (FVC%) > or = 70%; The course of the disease is 3 years or less (calculated from the first appearance of any symptoms of ALS); TCM syndrome differentiation is insufficiency of spleen-qi and deficiency of kidney-yang; 45~70 years old (including 45 and 70 years old), no gender limit; Volunteer to participate in this clinical trial, informed consent and signed informed consent.",CTR20202518 D2020076 NCT04950933 TrialTroveID-397296 Z-HLSJ-GR-2020-KCYY-01,Adults; Older Adults,year(s),year(s),397296,Delay Disease Progression,70.0,45.0,"Those diagnosed as familial ALS; Those who have undergone gastrostomy; Patients with other neurological diseases that have similar symptoms to ALS or that affect the evaluation of drug effectiveness, such as cervical spondylotic myelopathy, lumbar spondylosis, dementia, etc.; Those who found motor nerve conduction block or sensory nerve conduction abnormality on electromyography examination, and those who found substantial lesions that could explain clinical manifestations on imaging examination (CT or MRI); Those who have been treated with riluzole or edaravone within 3 months before enrollment; Patients with a history of spinal surgery after the onset of ALS; Aspartate aminotransferase (AST) or alanine aminotransferase (ALT)> 1.5 times the upper limit of the normal reference value, or blood creatinine (Scr)> the upper limit of the normal reference value; Accompanied by other primary diseases of the nervous system, heart, lungs, hematopoietic system or endocrine system and mental illness; Suspected or did have a history of alcohol or drug abuse; Pregnant women or lactating women, subjects of childbearing age (including male subjects with heterosexual sex and their female partners with reproductive potential) have a pregnancy plan or not within 3 months after the start of the screening to the drug withdrawal Those willing to take effective contraceptive measures; Those who are known or suspected of having a history of allergies to the test drug and its excipients; Those who have participated in other clinical trials within 3 months before screening; Researchers believe that it is not suitable to participate in this clinical trial.",Ii,Both
1,Patients with Amyotrophic Lateral Sclerosis,"All voluntarily registered patients with Amyotrophic lateral sclerosis of muscular dystrophy. There must be: A: evidence of clinical, electrophysiological or neuropathic degeneration of inferior motor neurons; B: Clinical examination confirmed the degeneration of upper motor neurons; C: Symptoms that develop gradually in one area or from one area to another are detected by history or examination. At the same time: A: signs of degeneration of lower motor neurons and/or upper motor neurons that can be explained by electrophysiological or pathological evidence of other diseases; B: Neuroimaging evidence of other diseases can explain the clinical and electrophysiological characteristics. Clinical diagnostic study of ALS: Medical history, physical examination and neurological examination should detect clinical evidence of upper and lower motor neuron injury in four areas of the central nervous system (brain stem, neck, chest and lumbosacral medulla), and perform neuroelectrophysiological, neuroimaging and clinical laboratory tests according to clinical indications, excluding other diseases.",ChiCTR2000037353 TrialTroveID-383507,,,,383507,Delay Disease Progression,,,Patients who do not meet the diagnosis of sclerosis on the side of muscular atrophy,Iv,Both
0,Patients with amyotrophic lateral sclerosis,"Meet the diagnostic criteria of Western medicine for amyotrophic lateral sclerosis (ALS) (Clinically confirmed ALS, clinically likely to suffer from ALS or clinically likely to suffer from ALS-laboratory support); The modified amyotrophic lateral sclerosis function scale score (ALSFRS-R) each item is =2 points; Forced vital capacity accounts for at least 80% of the predicted value percentage (FVC%); The course of the disease is 3 years or less (calculated from the first appearance of any symptoms of ALS); Comply with the syndrome differentiation standard of liver and kidney loss syndrome of fistula; Age 20~75 years (including 20 and 75 years old) at the time of informed consent, regardless of gender; Volunteer to participate in this clinical trial, informed consent and signed informed consent.",CTR20192373 CTR20200929 TrialTroveID-379874 Z-HLSJ-GR-2019-KCYY-01,Adults; Older Adults,year(s),year(s),379874,Delay Disease Progression,75.0,20.0,"Patients with other neurological diseases that have similar symptoms to ALS and affect the evaluation of drug efficacy, such as cervical spondylotic myelopathy, syringomyelia, spinal cord and brainstem tumors, Hirayama disease, multifocal motor neuropathy, multiple sclerosis, Guillain-Barre syndrome Symptoms, Parkinson’s disease and dementia; During the study period, those who refused nasogastric feeding food and drugs due to swallowing dysfunction; Patients with a history of spinal surgery after the onset of ALS; Aspartate aminotransferase (AST) or alanine aminotransferase (ALT)> 1.5 times the upper limit of the normal reference value, or blood creatinine (Scr)> the upper limit of the normal reference value; Accompanied by other neurological diseases or severe heart, lung, hematopoietic or endocrine system and other primary diseases and mental illness; Those who suspect or have a history of alcohol and drug abuse; Pregnant or lactating women, subjects of childbearing age (including heterosexual male subjects and female partners with reproductive potential) who have pregnancy plans or are unwilling to take effective contraceptive measures during the study period; Those who are known or suspected of having a history of allergies to the test drug and its excipients; Those who have participated in other clinical trials within 3 months before screening; Researchers believe that it is not suitable to participate in this clinical trial.",Ii,Both
0,Patients With Amyotrophic Lateral Sclerosis (ALS).,"Males aged 18 to 75 years, Females > 50 years Diagnosis of ""probable"" or ""definite"" ALS according to the El Escorial revised criteria A documented history of ALS symptoms for more than 6 month prior to study enrolment, and no more than 40 month. Patients capable of understanding and signing Informed Consent.",0015-14-CMC ALS-PHL NCT02588807 TrialTroveID-266962,Adults; Older Adults,year(s),year(s),266962,Delay Disease Progression,75.0,18.0,"Patients allergic to seafood Patients with forced vital capacity < 75% Patients who are respiratory dependent, underwent tracheostomy, or cannot swallow. Patients with cardiovascular diseases Patients with diabetes Patients with active peptic ulcers Diagnosis of other neurodegenerative diseases (Parkinson disease, Alzheimer disease, etc). Patients suffering from other chronic significant disease, malignant diseases or any other disease that may risk the patient or interfere with the ability to interpret the results. Patients that can not sign/understand the Informed Consent Form. Female patients who are pregnant or lactating Patients who have received and experimental drug or have participated in a clinical trial within 1 month prior to screening",I,Both
0,Patients with amyotrophic lateral sclerosis.,"At the age of 18 years old and above, not limited to men and women. Meet the diagnostic criteria for ALS diagnosis / probable. The patients' informed consent to accept the trial Women must not be able to become pregnant for the duration of the study. Women of childbearing potential must have a negative pregnancy test at screening and be non-lactating.",ChiCTR-IOR-14005674 TrialTroveID-255509,Adults; Older Adults,year(s),year(s),255509,Unspecified,80.0,18.0,"Have allergy history of Jianpi Yifei Decoction. Associated with other serious diseases including liver, kidney, cardiovascular disease. Combined with mental illness or severe neurosis patients. Unable to express subjective symptoms. Clinical evidence of unstable medical or psychiatric illness in the investigator's judgment.",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis.,"Ages Eligible for Study: 18 Years to 65 Years Inclusion Criteria: All subjects must have a verifiable diagnosis of ALS of 0.5 to 2 years' duration. The diagnosis must be supported by the Revised Criteria of the World Federation of Neurology. The grades of diagnosis must be clinically definite ALS or clinically probable ALS. All subjects must be over age 18 and below 65. The ALS is mildly to moderate based on ALS Health State Scale. Electrophysiological features show CMAP amplitude of motor nerve normal or mild declining. Serum creatine kinase is normal or mild upper, less than 500U/L.",NCT00753571 PUTH-1 TrialTroveID-097484,Adults,year(s),year(s),97484,Unspecified,65.0,18.0,"Exclusion Criteria: If anyone of the above eligibility requirements is not met. Use of any other investigational agent within 30 days beginning the treatment phase of this study. Severe cardiac, pulmonary, hepatic or/and hematic disease. HIV positivity or signs and symptoms consistent with HIV infection. Pregnant or nursing women. History of cancer with less than 5 years documentation of a disease-free state. History of anaphylactic reaction or hypersensitivity to G-CSF or proteins derived from E.coli. Alcohol or drug abuse in recent 1 year. Can't understand or obey the rules of treatment. Blood donor in recent 30 days.",Ii,Both
0,"Amyotrophic Lateral Sclerosis patients, three males and one female, age 55-62 years.",,TrialTroveID-080362,Adults,year(s),year(s),80362,Unspecified,62.0,55.0,,Ii,Both
0,Healthy subjects,"- Male and post-menopausal females aged >/=18 years and < /=65 years old at the time of signing informed consent. - Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring (ECG). - Nonsmoker and/or ex-smoker who has discontinued smoking and/or the use of nicotine containing products for at least 3 months prior to first dose of study drug. - Body mass index within the range 18 to 30 kg/m2 inclusive. - Females must be either postmenopausal for >/=1 year (or with FSH >/=40 mIU/mL at screening if postmenopausal for < 1 year) or surgically sterile (having undergone bilateral tubal ligation, hysterectomy, or bilateral oophorectomy) for at least 6 months. However, to protect against the transfer of the study drug in any bodily fluids, male partners of female subjects (whether postmenopausal or surgically sterile) must use a barrier form (e.g., condom) of contraception until the end of the study visit (EOS) or 7 days after the last dose of study drug in case of early termination. - Males with female partners of childbearing potential will agree to use barrier contraceptive (i.e., condom) and their female partners must use a highly effective method of contraception from screening to 90 days after the last dose of study drug. Males must also refrain from sperm donations during this time period. Males who are abstinent will not be required to use a contraceptive method unless they become sexually active. Males in a same sex relationship must also use a barrier form of contraception against the transfer of the study drug in any bodily fluids until the end of the study visit (EOS) or 7 days after the last dose of study drug in case of early termination.",ACTRN12623000476639 CL-4746-23-01 TrialTroveID-471337,Adults,year(s),year(s),471337,Healthy subjects,65.0,18.0,"- History or presence of significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data. - Subjects with a history of pancreatitis or with prior cholecystectomy. - Any significant chronic medical illness, as determined by the investigator. - Mentally or legally incapacitated, has significant emotional problems at screening or expected during the conduct of the study, or has a history of a clinically significant psychiatric disorder within the last 5 years. Note: normal healthy volunteers who have had situational depression may be enrolled in the study at the discretion of the Investigator. - The subject has a history of severe drug allergy or hypersensitivity or food allergy, including anaphylaxis. - The subject has had surgery or trauma with significant blood loss within the last 3 months prior to the first dose of study drug. - The subject has donated more than 1 unit (500 mL) of blood within 4 weeks prior to the first dose of study drug. . - Abnormal vital signs that are considered to be clinically significant by the investigator. - Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years. Fully resected basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) with no evidence of recurrence for 1 year are permitted. - Breast cancer within the past 10 years. - Clinically significant laboratory abnormality at the screening visit or before the administration of the first dose of study drug. - Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of asymptomatic gallstones). - QTcF interval (QT with Fredericia’s correction) > 450 msec in males and > 470 msec in females (based on the mean of triplicate measurements taken at screening). - Females of childbearing potential, irrespective of contraceptive measures taken. - Inability to tolerate oral medications. - Past or intended use of over-the-counter or prescription medication (including herbal medications) within 14 days before dosing. - Live vaccine(s) within 1 month before Screening or plans to receive such vaccines during the study. - Treatment with biologic agents (such as monoclonal antibodies including marketed drugs) within 3 months or 5 half-lives (whichever is longer) before dosing. - Current participation in any other investigational drug study or receipt of an investigational drug within 30 days or 5 half-lives (whichever is longer) before Screening. - Positive prestudy drug or alcohol screen. - Positive human immunodeficiency virus (HIV) or hepatitis C antibody test (HCV), or hepatitis B surface antigen (HBsAg) at screening or 3 months before enrollment. - Regular alcohol consumption within 6 months before the study defined, current evidence of substance dependence or self-reported alcoholic intake > 2 drinks/day for female subjects and > 3 drinks/day for male subjects. - Use of tobacco products (e.g., cigarettes, e-cigarettes, cigars, smokeless tobacco) confirmed by a positive cotinine test on Day -1. - Regular use of known drugs of abuse or a history of drug abuse within 12 months prior to screening.",I,Both
1,,,TrialTroveID-148984,,,,148984,Unspecified,,,,Ii/Iii,
1,,"1. 18-80 years old; 2. Confirmed or possible familial or sporadic ALS diagnosed according to the revised El Escorial criteria; 3. 6 months ≤disease duration ≤ 3 years, (onset time is defined as the time of the first occurrence of myasthenia); 4. Forced vital capacity (FVC) ≥ 85% of predicted value (based on gender, height and age); 5. Informed consent signed.",HX-A-2023027 NATURAL NCT06391645,Adults; Older Adults,year(s),year(s),514860,,80.0,18.0,"1. Patients undergoing endotracheal intubation, non-invasive or mechanical ventilation; 2. Patients with diaphragmatic pacemakers; 3. Allergy to any component of the investigational medication, or any other allergic history that researchers deem necessary to be vigilant about; 4. Local skin infection or other suspicious signs of infection at the injection site; 5. Known hemorrhagic tendency (including but not limited to: platelet count <100×109/ L; on therapy of heparin, activated partial thromboplastin time (APTT) ≥35s; on therapy of warfarin, international normalized ratio (INR) >1.7; on therapy of novel oral anticoagulants; with direct thrombin or factor Xa inhibitor; accompanied with coagulopathy such as hemophilia); 6. Severe cardiac insufficiency before randomization (comply with New York College of Cardiology (NYHA) Cardiac Function Class III, IV); 7. Suffering from infectious diseases: hepatitis, tuberculosis, acquired immunodeficiency syndrome, etc; 8. Psychiatric disorders diagnosed according to Diagnostic and Statistical Manual of Mental Disorders (DSM-V) diagnostic criteria; or with suicidal intentions; 9. Women/men with desire to conceive during the experiment, and patients with pregnancy and lactation; 10. Difficulty in verbal communication, inability to communicate, understand or follow instructions, inability to cooperate with treatment and evaluation; 11. Combining with history of alcohol and drug abuse; 12. Unable to cooperate in follow-up due to geographical or other reasons; 13. Patients participated in other clinical trials or used other biologics, drugs, or devices under study.",Ii/Iii,Both
0,Subjects with Amyotrophic Lateral Sclerosis,,TrialTroveID-373815,,,,373815,Unspecified,,,,Ii,
0,,"All groups: - Ability to give informed consent for study procedures - Ability to understand study instructions and to realize the cognitive tasks - Person with health insurance Patients: - MMS>20 - Absence of another neurological or psychiatric disease - Presence of a caregiver - We will recruit three groups of patients: - diagnosed with behavioral variant frontotemporal dementia (bvFTD) according to the Rascovsky criteria (Rascovsky et al. 2011) - diagnosed with idiopathic Parkinson's disease (Hughes et al. 1992) - Sub-group 1: Parkinson's disease with Impulse Control Disorders (ICDs) - Sub-group 2: Parkinson's disease without Impulse Control Disorders (ICDs) - diagnosed with depression (Major Depressive Disorder, DSM-IV) Healthy age,sex, education-matched controls: - MMS>27 - Absence of neurological or psychiatric disease",2017-A00416-47 C16-87 ECOCAPTURE NCT03272230,Adults; Older Adults,year(s),year(s),308450,,85.0,40.0,- Standard contraindications to MRI - Inability to understand study instructions - Person mentioned in the article L.1121-5 to L. 1121-8 and L. 1122-12 of the French Public Health Code,Other,Both
0,Patients with frontotemporal dementia,"(all must be met): - Signed and dated written informed consent obtained from the subject and/or the subject's caregiver in accordance with local IRB regulations - Symptomatic GRN mutation carrier as defined by presence of known disease-associated GRN mutation confirmed by genetic testing and meeting international (2011) criteria for FTD (Rascovsky et al., 2011), Boeve (2003) criteria (B. F. Boeve, Lang, & Litvan, 2003) for CBS, or Gorno-Tempini criteria (2011) for primary progressive aphasia (Gorno-Tempini et al., 2011) (gene carrier status known) OR - Asymptomatic GRN mutation carrier (gene carrier status known) from family with known disease-associated mutation; - Age: >30 - MMSE ??? 10 at screening visit. - Judged by investigator to be able to comply with all study procedures - In the opinion of the investigator, the patient will be compliant with the protocol and have a high probability of completing the study - Lack of other recent, severe medical conditions.",CHR12-09098 NCT01835665 TrialTroveID-245133,Adults; Older Adults,year(s),,245133,Frontotemporal Dementia,,30.0,"(Any one of the following will exclude a subject from being enrolled into the study): - Hypersensitivity or other contra-indication to nimodipine use - Systemic autoimmune disease (such as rheumatoid arthritis, thyroid disease, or diabetes) that might alter progranulin levels. - Regular use of systemic corticosteroids or other anti-inflammatory medication. NSAID use acceptable if on a stable dose for 30 days prior to screening and agrees to remain on same dose for duration of trial. - Subject is pregnant, plans to become pregnant during course of study or has a positive urine pregnancy test. - Unwilling to use two forms of contraception if not surgically sterile for duration of study. - History of cancer (other than basal cell CA of skin) within 5 years. - History of myocardial infarction, cardiac conduction block, arrhythmia or other significant cardiac illness in the opinion of the investigator (in consultation with a board certified cardiologist). - History of peptic ulcer. - Metabolic disease such as gout or poorly controlled diabetes. - History of alcohol or substance abuse within 1 year prior to screening, if deemed clinically significant by investigator. - Any current malignancy, or any clinically significant hematological, endocrine, cardiovascular, renal, hepatic, gastrointestinal or neurological disease. If the condition has been stable for at least the past year and is judged by the investigator not to interfere with the patient's participation in the study, the patient may be included. - CT or MRI evidence of any of the following: hydrocephalus, stroke, space-occupying lesion, cerebral infection or any clinically significant CNS disease other than FTD, CBS, or progressive aphasia. - Systolic blood pressure greater than 180 or less than 90 mm Hg. Diastolic blood pressure greater than 105 or less than 50 mm Hg. - Abnormal ECG at screening and judged to be clinically significant by the investigator and/or board certified cardiologist. - Use of investigational drugs or participation in investigational drug study within 30 days of screening or 5 half lives of the previous investigational drug, whichever is longer. - Use of nimodipine within the 4 weeks prior to start of trial. - Within 4 weeks of beginning or during the course of the study, concurrent treatment with calcium channel antagonists, blood thinners (e.g. clopidogrel, warfarin), or statin medication in combination with niacin. - Clinically significant lab abnormalities at screening, including creatinine ??? 1.7, B12 below laboratory normal reference range, or TSH above site's laboratory normal reference range. Subjects with abnormal B12 or TSH levels at screening may be included per investigator's discretion. - Contraindication to MRI examination for any reason (e.g., severe claustrophobia, ferromagnetic metal in body).",I,Both
0,Subjects with Amyotrophic Lateral Sclerosis,"Age 45-70, gender unlimited (including 45 and 70); diagnoses in accordance with the confirmed and proposed ALS diagnostic standards ofthe Revised World Federation of Neurology (1998); The duration of disease from onset to randomization of subjects is less than 2 years; Before randomization, ALSFRS-R scores were > or =2 points, and respiratory function items were 4 points; ALSFRS-R decreased by 1-4 points in screening period 3A (> or =1 and lt; 4); Random pre-respiratory function Forced Vital Capacity (%FVC) > or =80%; Understand and abide by the test procedures, participate voluntarily, and sign the informed consent (the informed consent should be signed by the person or the guardian voluntarily).",D2020109 NCT04950647 TrialTroveID-408143,Adults; Older Adults,year(s),year(s),408143,Delay Disease Progression,70.0,45.0,"Familial ALS (judged by family history); Patients with significant cognitive impairment (MMSE: illiteracy group < 19 points, elementary school. 22 points, S26 points in the junior high school and above group (more than 8 years of education); obvious dysphagia; Severe renal insufficiency: creatinine clearance. 30 mL/min (Cockcroft-Gault formula), or other known severe renal insufficiency; Severe liver function impairment: ALT, AST&GT; 3 times the upper limit of normal value, or other known liver diseases such as acute or chronic active hepatitis, cirrhosis, etc.; In the screening stage, patients with heart failure who developed acute myocardial infarction or underwent interventional therapy within the last 6 months (grade II1-IV according to NYHA); Complicated with malignant tumors, serious diseases of blood, digestion or other systems. Allergic to experimental drugs or ligustrazine; Pregnancy and lactation; Participated in, or is participating in, other clinical trials within 30 days prior to screening; The investigator did not consider it appropriate to participate in this study.",Ii,Both
0,,"- Informed consent/assent provided by the participant (when appropriate), and/or participant's parent(s) or legally authorized representative(s). - Ability to travel to the study site and adhere to study-related follow-up examinations and/or procedures and provide access to participant's medical records. - Genetically confirmed neurological disorder.",23-011476 NCT06392126,Adults; Older Adults,year(s),,514876,,,48.0,"- Participant has any condition that in the opinion of the Site Investigator, would ultimately prevent the completion of study procedures. - Use of an investigational medication within less than 5 half-lives of the drug at enrollment",Iii,Male
0,,,TrialTroveID-355173,,,,355173,Unspecified,,,,I,
0,,,TrialTroveID-254932,,,,254932,Unspecified,,,,I,
0,Subjects with behavioral variant frontotemporal dementia or semantic dementia and healthy subjects,"Male or female subject meeting international consensus criteria for probable behavioral variant frontotemporal dementia or criteria for semantic dementia (Gorno-Tempini et al., 2011; Rascovsky et al., 2011) Subject has a Mini-Mental State Exam (MMSE) score > or = 18. Subject is > 40 and <90 years of age. Female subjects are post-menopausal or have a negative pregnancy test The subject must be proficient in speaking, reading and understanding English in order to comply with procedural testing of cognitive function, memory and physiology. Subject has a dedicated family member/caregiver, who will be able to attend all visits and report on subject's status. Subject and family member/caregiver have both provided fully informed written consent prior to participation. In the event that subject is legally unable to provide informed written consent due to deterioration in cognitive abilities, fully informed written consent must be provided by a legally authorized representative. Subject must have undergone a brain computed tomography (CT) scan or magnetic resonance imaging (MRI) scan as part of receiving frontotemporal dementia (FTD) diagnosis",A18-305 NCT04115384 TrialTroveID-358557,Adults; Older Adults,year(s),year(s),358557,Frontotemporal Dementia; Healthy subjects,89.0,41.0,"Subject has medical history and/or clinically determined evidence of other central nervous system (CNS) disorders including, but not limited to brain tumor, active subdural hematoma, seizure disorder, multiple sclerosis, Alzheimer's disease, vascular dementia, corticobasal syndrome, progressive supranuclear palsy, Parkinson's disease, multiple system atrophy, Lewy body dementia, normal pressure hydrocephalus, Huntington's disease, or Jakob-Creutzfeldt disease presenting as dementia. Subject has medical history and/or clinically determined disorders: current B12 deficiency, chronic sinusitis, untreated thyroid disease, or significant head trauma. Subject has history of any of the following: moderate to severe pulmonary disease, poorly controlled congestive heart failure, significant cardiovascular and/or cerebrovascular events within previous 6 months, condition known to affect absorption, distribution, metabolism, or excretion of drugs such as any hepatic, renal or gastrointestinal disease or any other clinically relevant abnormality that inclusion would pose a safety risk to the subject as determined by investigator. Subject has had previous nasal and/or oto-pharyngeal surgery and severe deviated septum and/or other anomalies. Subject has a history of any psychiatric illness that would pose a safety risk to the subject as determined by investigator. Subject is currently taking any medications (anticholinergics, antihistamines, benzodiazepines, barbiturates, or insulin) that are clinically contraindicated as determined by investigator. Subject has undergone a recent change (<1 month) in their selective serotonin reuptake inhibitors (SSRI) or anti-depressant medication. Subject has current or recent drug or alcohol abuse or dependence as defined by the Diagnostic and Statistical Manual of Mental Disorders 5, Text Revision (DSM-IV TR). Screening laboratory results that are medically relevant, in which inclusion would pose a safety risk to the subject as determined by investigator. The subject has participated in a clinical trial investigation within 1 month of this study. The subject has an insulin allergy.",Ii,Both
0,Patients with amyotrophic lateral sclerosis.,,TrialTroveID-264899,,,,264899,Unspecified,,,,Ii,
1,Patients with amyotrophic lateral sclerosis,,TrialTroveID-260821,,,,260821,Unspecified,,,,Iii,
0,Patients with amyotrophic lateral sclerosis (ALS) and evidence of systemic inflammation.,"Diagnosis of clinically possible, clinically probable (with or without laboratory support), or clinically definite ALS (using the revised El Escorial Criteria) Forced vital capacity greater than or equal to 65% of that predicted for age and height Onset of ALS-related weakness less than 3 years prior to first dose of study drug Plasma high sensitivity C-reactive protein (hs-CRP) concentration of greater than or equal to 0.113 mg/dL at pre-screening/screening Stable dose (greater than 30 days) of riluzole if undergoing treatment with this agent For females: Not be of childbearing potential or agree to use adequate birth control during the study",20160522 NCT02794857 NP001-10-003 TrialTroveID-176786,Adults; Older Adults,year(s),year(s),176786,Delay Disease Progression,80.0,21.0,"Life expectancy of less than 6 months Tracheotomy or be using ventilatory assistance, including Bi-level Positive Airway Pressure (BiPAP) or Continuous Positive Airway Pressure (CPAP) Active pulmonary disease Gastrostomy Stem cell therapy Immune modulator therapy or participation in studies of other agents within 12 weeks of pre-screening/screening Unstable medical condition other than ALS",Ii,Both
0,Subjects with Amyotrophic Lateral Sclerosis (ALS).,"Ages Eligible for Study: 21 Years to 80 Years, Genders Eligible for Study: Both Subjects with sporadic or familial ALS classified as definite, probable, or laboratory-supported probable ALS according to the revised El Escorial criteria. Inclusion Criteria: Onset of symptoms less than 2 years prior to study entry. Forced Vital Capacity (FVC) at least 70% of that predicted for age and height. Stable dose of riluzole if undergoing treatment with this agent. For females: Not be of childbearing potential or agree to use adequate birth control during the study. Onset of weakness < 3 years, and no immune modulator therapy within 3 months. Entry criteria were: FVC 70%, and onset of weakness < 3 years",NCT01281631 NP001-10-002 TrialTroveID-141255,Adults; Older Adults,year(s),year(s),141255,Delay Disease Progression,80.0,21.0,Exclusion Criteria: Unstable medical condition(s) other than ALS. Life expectancy of less than 6 months. Require life-sustaining interventions for the 6 months following randomization; have a tracheotomy or require ventilatory assistance [including Bi-level Positive Airway Pressure (BiPAP) or Continuous Positive Airway Pressure (CPAP)] for ALS. Active pulmonary disease. Immune modulator therapy within 12 weeks of study entry or participation in studies of other agents within the last 4 weeks prior to the randomization.,Ii,Both
0,Subjects with Amyotrophic Lateral Sclerosis.,"Ages Eligible for Study: 21 Years to 75 Years, Genders Eligible for Study: Both Inclusion Criteria: Males and females, age 21 years - 75 years Subjects must be in generally sound health as appropriate for their ALS diagnosis. Subjects must have a clinical diagnosis of laboratory-supported probable or definite ALS, according to modified El Escorial criteria. Subjects receiving riluzole must be on a stable dose for at least 30 days prior to enrollment. Women of childbearing age must be non-lactating and surgically sterile or using an effective method of birth control and have a negative pregnancy test prior to dosing with study medication. Subjects must understand the study and be willing to adhere to protocol requirements as evidenced by provision of written informed consent. Subject must be willing and able to give signed informed consent that has been approved by the Institutional Review Board (IRB). Subjects must be willing to have an intravenous infusion. Subjects must have suitable veins for IV access as determined by examination.",NCT01091142 NP001 Single Dose - ALS TrialTroveID-124600,Adults; Older Adults,year(s),year(s),124600,Unspecified,75.0,21.0,"Exclusion Criteria: Subjects should not require nor are expected to require life sustaining interventions for the next six months or longer. (e.g. invasive ventilation). Subjects must not have: -Presence of a tracheotomy or invasive ventilation. Nocturnal non-invasive ventilation system (e.g. C-PAP) is allowed. -A diagnosis of neurologic disease known to mimic the muscle atrophy or weakness seen in ALS including MS, muscular dystrophy, spinal stenosis, peripheral neuropathy, inherited neuropathies or neuromuscular diseases, foramen magnum or brainstem tumor, or toxic conditions. -An active pulmonary disease under treatment including uncontrolled asthma, chronic obstructive pulmonary disease (pneumonia, bronchitis, etc.), pulmonary fibrosis, pulmonary infection in the last 2 months, or history of aspiration that may expose the subject to increased risk by participating in this trial as determined by the Investigator. -A history of unstable medical illness in the 3 months prior to screening including any emergent hospitalizations. -Renal disease based on screening estimated creatinine clearance (eCcr) < 50 mL/minute (Cockcroft Gault estimate using ideal body weight) where: -Evidence of elevated alanine aminotransferase greater than 3 times the upper limit of normal. -Evidence of anemia, thrombocytopenia, or neutropenia (screening hematocrit <33%, platelet count < lower limit of normal for the site laboratory, or neutrophil count less than 1,500/mm3). -Any condition that requires periodic red blood cell transfusions, erythropoietin or any blood dyscrasias undergoing active treatment in the past year. -Clinical laboratory parameters that are clinically significant in the opinion of the Investigator. -Systolic blood pressure in excess of 160 mmHg nor less than 100 mmHG or a diastolic blood pressure above 98 mmHg. -A history of G6PD deficiency (Glucose-6-phosphate dehydrogenase deficiency) determined by subject report. -A current history of hepatitis or HIV determined by subject report. Subjects must not be using systemic immunosuppressants including steroids and chemotherapeutic agents. Inhaled steroids, eye drops and local topical use are permitted with concurrence of Medical Monitor. Subjects must not have a hematologic disorder such as autoimmune anemia, or hemolytic anemia of any type including paroxysmal nocturnal hemoglobinuria or myoglobinuria. Subjects must not have a history of unexplained jaundice determined by subject report. Subjects must not have received IV Immunoglobulin (IG) within 30 days of the planned initial dose of study drug. Subjects must not be participating in another drug study or have participated in a drug study within the last 30 days prior to enrollment. Observational trials with no intervention are acceptable provided permission for the other study Sponsor is obtained in writing. Subjects must not have any other condition which in the Investigator's opinion would put the subject at risk by participating in this study.",I,Both
0,Healthy volunteers,,TrialTroveID-432126,,,,432126,Healthy subjects,,,,I,
0,Patients with amyotrophic lateral sclerosis and Parkinson's disease.,,TrialTroveID-365379,,,,365379,(N/A); Unspecified,,,,I,
0,Healthy Volunteers.,"nformed of, and willing and able to comply with, all of the protocol requirements and the investigational nature of the study, and have signed an informed consent form in accordance with institutional and regulatory guidelines; male or female adults between 18 and 55 years of age, inclusive; female subjects must be of non-childbearing potential (i.e. post-menopausal for at least 2 years) or surgically sterile (hysterectomy, bilateral oophorectomy, tubal ligation) or nonsurgically sterile (hysteroscopic sterilization, i.e. Essure); male subjects must be willing to use an adequate barrier method of contraception for the duration of the study and for 90 days after dosing and no sperm donations for the duration of the study and for 90 days after dosing. Male subjects who are surgically sterile (16 weeks post-surgery, or documented proof of Post-Vasectomy Semen Analysis (PVSA) with negative sperm results) need not employ a method of contraception; non-smokers for at least six months; BMI = 18.0 - 32.0 kg/m^2 inclusive; in good health, in the judgment of the Investigator, as determined by: 7a. medical history indicative of no serious or severe chronic conditions requiring frequent medical intervention or continual pharmacologic management, and no medical or social conditions that would potentially interfere with the subject's ability to comply with the study visit schedule or the study assessments; 7b. no clinically significant abnormalities in body temperature, heart rate, respiratory rate, blood pressure; 7c. no clinically significant abnormalities in the 12-lead electrocardiogram (ECG); 7d. no clinically significant abnormalities in clinical chemistry (ALT, AST, total bilirubin must be at or below the upper limit of normal and eGFR must be > or = 90 mL/min), hematology (hemoglobin > or = 11.5 g/dL for females and > or = 13 g/dL for males), coagulation and urinalysis; lab tests may be repeated, if necessary (details are provided in the attached flow chart of study assessments). negative results on the following screening laboratory tests: urine drug screen, urine alcohol screen, serum pregnancy test, hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus antibody.",NCT03954600 NPT520-34-001 TrialTroveID-349330,Adults,year(s),year(s),349330,(N/A); Healthy subjects,55.0,18.0,"females of child bearing potential history of a significant medical condition, including cholecystectomy or clinically significant GI tract resection, that may interfere with absorption, distribution or elimination of NPT520-34, or with the clinical and laboratory safety assessments in this study; history of pre-existing thyroid abnormalities, such as hyper or hypothyroidism; history of lactose intolerance; history of drug hypersensitivity and disorders affecting respiratory function (e.g., COPD, asthma) and cardiac disorders predisposing to cardiac adverse events history of or current alcohol abuse and/or other drug addiction < 2 years prior to screening, or a positive urine drug or alcohol screen (e.g., amphetamines, barbiturates, benzodiazepines, opiates, cannabinoids, alcohol and cocaine); positive for HBVsAg, HCV Ab, HIV Ab; 12 lead ECG showing the following: having a corrected QTc interval > 450 msec or <340 msec (Fridericia's correction); sustained supine systolic blood pressure > 140 or < 90 mm Hg or supine diastolic blood pressure > 90 or < 50 mm Hg at Screening or Day -1. The average of the 2 assessments of BP taken at each visit will be used to exclude a subject; resting pulse rate at screening of > 100 or < 45. donated or lost > 500 mL of blood < 56 days prior to enrollment into this study; plasma donation within 7 days prior to enrollment into this study; active infection or febrile illness < 14 days prior to the first dose of study medication; use of prescription (including hormone replacement therapy) or over-the-counter medications or herbal supplements = 14 days prior to dosing and until completion of follow-up visit on Day 7 for the SAD subjects and Day 21 for the MAD subjects; excessive regular caffeine intake (>250 mg of caffeine per day); have participated in other clinical studies of a new chemical entity within 30 days prior to admission to the CRU.",I,Both
0,Healthy volunteers,"Male, non-smokers (no use of tobacco or nicotine products within 6 months prior to screening), > or =18 and < or =55 years of age, with BMI >18.5 and <30.0 kg/m2 and body weight > or =50.0 kg for males. Healthy as defined by: the absence of clinically significant illness and surgery within 4 weeks prior to dosing. the absence of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease. Subject's score on the Sheehan Suicidality Tracking Scale (S-STS) at screening must be 0.",NCT05143463 NS101_P1_01 TrialTroveID-419841,Adults,year(s),year(s),419841,(N/A); Healthy subjects,55.0,18.0,"Any clinically significant abnormality at physical examination, clinically significant abnormal laboratory test results or positive test for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C found during medical screening. Positive urine drug screen or alcohol breath test at screening or admission. History of asthma, allergic rhinitis or urticaria, anaphylactic reactions, or any other clinically significant allergic reactions to any medication, including biologics, or food, or allergy to any excipient in the formulation.",I,Male
1,Patients with amyotrophic lateral sclerosis (ALS).,,TrialTroveID-371996,,,,371996,Unspecified,,,,Iii,
0,,,TrialTroveID-254064,,,,254064,Delay Disease Progression,,,,Ii,
0,Patients with Amyotrophic Lateral Sclerosis.,"Ages Eligible for Study: 18 Years and older; Genders Eligible for Study: Both Inclusion Criteria: Have the ability to understand the requirements of the study, provide written informed consent, understand and provide written authorization for the use and disclosure of Protected Health Information (PHI) [per Health Insurance Portability and Accountability Act (HIPAA) Privacy Ruling] and comply with the study procedures. Subjects with sporadic or familial ALS with symptom onset within the last two years as laboratory-supported probable, probable or definite according to the World Federation of Neurology El Escorial Criteria (Appendix A), based on examination by the site PI. Age 18 years or older. Females must have a negative serum pregnancy test and practice an acceptable method of contraception or be of non-childbearing potential (post-menopausal for at least 2 years or surgically sterile [hysterectomy, oophorectomy or surgical sterilization]). Geographic accessibility to the study center and the ability to travel to the clinic for study visits. Presence of a willing and able caregiver. Medically able to undergo lumbar and/or cervical laminectomy or laminoplasty as determined by the site Principal Investigator and neurosurgeon. Medically able to tolerate the immunosuppression regimen consisting of basiliximab, tacrolimus, mycophenolate mofetil, prednisone and methylprednisolone as determined by the site PI. Agrees to the visit schedule as outlined in the informed consent. Not taking riluzole (Rilutek) or on a stable dose for > or = 30 days. Vital capacity > or = 60% of predicted normal for age, height and gender measured in the seated position and > or =50% in supine position during the 7 days prior to surgery. Ambulatory subjects with extremity weakness and/or spasticity due to ALS. Patients undergoing lumbar surgery must have demonstrable weakness or spasticity in one or both lower extremities. Patients undergoing cervical surgery must have demonstrable weakness or spasticity in one or both upper extremities, with at least antigravity strength. Subjects must have normal neck extensor and flexor strength.",NCT01730716 NS2012-3 TrialTroveID-180626,Adults; Older Adults,year(s),,180626,Delay Disease Progression,,18.0,"Exclusion Criteria: Etiology of paraplegia or weakness is due to causes other than ALS. A positive result on the Panel Reactive Antibody (PRA) test, with the presence of specific HLA antibodies matching the HLA DNA profile of the donor cells. Any known immunodeficiency syndrome. Receipt of any investigational drug, device or biologic within 30 days of surgery. Any concomitant medical disease or condition limiting the safety to participate: Coagulopathy Active uncontrolled infection Hypotension requiring vasopressor therapy Previous spinal surgery that the neurosurgeon deems to be an obstacle to the planned transplantation Skin breakdown over the site of surgery Malignancy (except for non-melanoma skin cancer) Spinal stenosis severe enough to preclude surgery (as determined by the neurosurgeon) Pre-existing kyphosis by preoperative MRI or X-ray Less than 5/5 grade in neck extension and strength test at the time of surgery. Creatinine >1.5, liver function tests (SGOT/SGPT, Bilirubin, Alk Phos) > 2x upper limit of normal, hematocrit/hemoglobin < 30/10, total WBC < 4000, uncontrolled hypertension (systolic > 180 or diastolic > 100) or uncontrolled diabetes (defined as hemoglobin A1C >8), evidence of GI bleeding by hemoccult test, tuberculosis (TB test: PPD), serologic evidence of current infection with a hepatitis virus or human immunodeficiency virus (HIV). Presence of any of the following conditions: -Current drug abuse or alcoholism -Unstable medical conditions -Unstable psychiatric illness including psychosis and untreated major depression within 90 days of screening Any condition or ALS disease phenotype that the site PI feels may interfere with participation in the study or in the interpretation of study endpoints. Any condition that the neurosurgeon feels may pose complications for the surgery. Known hypersensitivity to basiliximab, tacrolimus, mycophenolate mofetil, prednisone or methylprednisolone. Inability to provide informed consent as determined by the site PI. Inadequate family or caregiver support as determined by the site PI.",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis,,TrialTroveID-168164,,,,168164,Unspecified,,,,Iii,
0,Patients with amyotrophic lateral sclerosis with varying degrees of the disease. AAN 2011: Subjects are males (37-66 years of age) with limb onset ALS and an average disease duration of 4.4 years Enrolled subjects included 13 males and 2 females ranging in age from 35-66 years old. Disease duration ranged between 1.3-13 years at the time of surgery.,"Ages Eligible for Study: 18 Years and older Genders Eligible for Study: Both Inclusion Criteria: Have the ability to understand the requirements of the study, provide written informed consent, understand and provide written authorization for the use and disclosure of Protected Health Information (PHI) [per Health Insurance Portability and Accountability Act (HIPAA) Privacy Ruling] and comply with the study procedures. Subjects with sporadic or familial ALS diagnosed as laboratory-supported probable,probable or definite according to the World Federation of Neurology El Escorial Criteria (Appendix A), based on examination by the site PI. Age 18 years or older. Females must have a negative serum pregnancy test and practice an acceptable method of contraception or be of non-childbearing potential (post-menopausal for at least 2 years or surgically sterile [hysterectomy, oophorectomy or surgical sterilization]). Geographic accessibility to the study center and the ability to travel to the clinic for study visits. Presence of a willing and able caregiver. Medically able to undergo lumbar or cervical laminectomy as determined by the Investigator, surgeon and anesthesiologist. Medically able to tolerate immunosuppression regimen consisting of basiliximab, tacrolimus, mycophenolate mofetil, and methylprednisolone as determined by the site Investigator. Agrees to the visit schedule as outlined in the informed consent. Not taking riluzole (Rilutek) or on a stable dose for > or = 30 days. All required vaccinations current: tetanus/diptheria (TDAP), herpes zoster/shingles(Vostavax®: within last 10 years and must be prior to surgery), pneumonia (Pneumovax),seasonal/H1N1 flu vaccines (as appropriate for season) for Groups B-E. In addition, for Group A: Inability to ambulate for > 2 weeks secondary to lower extremity weakness and/or spasticity; the ALS Functional Rating Scale - Revised (ALSFRS-R) lower extremity subscore must be 1 or less. Patients who are non-ambulatory because of severe spasticity must have failed standard antispasticity treatment with baclofen (up to 120 mg/day) and/or tizanidine (up to 12 mg/day), physical therapy (PT), and occupational therapy (OT). Failure of antispasticity medications is defined as continued inability to walk unassisted even at the highest tolerated doses of these medications. Failure of PT and OT means continued inability to walk independently after maximum PT and OT intervention. Vital capacity > or = 60% of predicted normal for age, height and gender measured in the supine position at the time of screening and > or = 50% of predicted normal for age,height and gender measured supine during the 7 days prior to surgery OR stable for at least 3 months with tracheostomy and invasive ventilation. In addition, for groups B and C: Ambulatory subjects with impaired gait and approximately symmetrical lower extremity weakness and/or spasticity due to ALS and an ALSFRS-R gate subscore > 2. Vital capacity > or = 60% of predicted for age, height and gender measured in the supine position at the time of screening and > or = 50% of predicted for age, height and gender measured supine during the 7 days prior to surgery In addition, for groups D and E: Ambulatory subjects with impaired gait and symmetrical lower extremity weakness and/or spasticity due to ALS and an ALSFRS-R gate subscore > 2. Upper extremity weakness affecting function with an ALSFRS-R arm subscale between 1 and 3. Vital capacity > or = 60% of predicted normal for age, height and gender measured in the supine position at the time of screening and > or = 50% of predicted normal for age, height and gender measured supine during the 7 days prior to surgery. Group 1A and Group 2A (up to 3 patients in each group): Eligibility Criteria: - Confirmed diagnosis of ALS by a neurologist. - Has tracheostomy and is ventilator dependent for greater than 3 months OR a vital capacity greater than 60% predicted value. - Unable to walk due to ALS. - Lack of complicating medical conditions. - Live in geographic proximity to Emory University Hospital. - Ability to communicate vocally or with low-tech tools (writing or letter board). - A willing and able caregiver who is committed to the study.",NCT01348451 NS2008-1 Study No.: 00020318 TrialTroveID-102165,Adults; Older Adults,year(s),year(s),102165,Delay Disease Progression,66.0,18.0,"Exclusion Criteria: Etiology of paraplegia or weakness is due to causes other than ALS such as spinal ischemia, traumatic spinal injury, traumatic brain injury, multiple sclerosis, cerebral stroke, cerebral palsy, or infection. VC < 60% predicted normal by standard nomogram at the time of screening and VC < 50% predicted normal measured supine for age at the time of surgery. Current or peak Panel Reactive Antibody (PRA) due to alloantibodies > 20% receiving their first allograft. Any known immunodeficiency syndrome. Receipt of any investigational drug,device or biologic within 30 days of surgery. Any concomitant medical disease or condition limiting the safety to participate: Coagulopathy Active uncontrolled infection Hypotension requiring vasopressor therapy Previous spinal surgery at the site of planned transplantation except for anterior cervical dissection fusion (ACDF) Skin breakdown over the site of surgery Malignancy (except for non-melanoma skin cancer) Primary or secondary immune deficiency Spinal stenosis. Creatinine >1.5, liver function tests (SGOT/SGPT, Bilirubin, Alk Phos) > 2x the upper limit of normal, hematocrit/hemoglobin < 30/10, total WBC < 4000, uncontrolled hypertension (defined as systolic >180 or diastolic >100) or uncontrolled diabetes(defined as hemoglobin A1C >8), evidence of GI bleeding by hemoccult test, positive tuberculosis (TB test: PPD/Mantoux), hepatitis B or C, or human immunodeficiency virus (HIV). Presence of any of the following conditions: Current drug abuse or alcoholism Unstable medical conditions Unstable psychiatric illness including psychosis and untreated major depression within 90 days of screening Positive blood test for hepatitis B or C. Any condition that the site PI feels may interfere with participation in the study. Any condition that the surgeon feels may pose complications for the surgery. Known hypersensitivity to basiliximab, tacrolimus, mycophenolate mofetil, or methylprednisolone. Inability to provide informed consent as determined by screening protocol. Inadequate family or caregiver support as determined by the site PI. Are pregnant or might get pregnant. Have taken an experimental drug in the last 30 days. Have had previous spinal surgery in the area where the transplant will go. Are unable to undergo MRI. Have been taking Riluzole (rilutek) for less than 30 days. Have a positive blood test for Hepatitis B or C, or HIV. Are not a patient at the Emory ALS Center and are not geographically accessible and able to travel to Emory for study visits.",I,Both
1,Patients With Hyperkinetic movement disorders in Disease of Motor Neurons.,"Patients with SMA type I, II, III, and IV and patients with ''clinically definite ALS'' or ''clinically probable ALS'' or ''clinically probable ALS - laboratory supported'' according to the revised El Escorial diagnostic criteria or with the diagnosis of PMA or PLS will be included. Genetically proven SMA patients treated with Nusinersen ''clinically definite ALS'' or ''clinically probable ALS'' or ''clinically probable ALS - laboratory supported'' according to the revised El Escorial diagnostic criteria or diagnosis of PMA or PLS",0120-293/2019/8/1 NCT04825119 TrialTroveID-400683,,,,400683,(N/A); Myoclonus; Spinal Muscular Atrophy Type 1; Spinal Muscular Atrophy Type 2; Spinal Muscular Atrophy Type 3; Symptom relief,,,,Iv,Both
1,Patients with amyotrophic lateral sclerosis (ALS),"Possible, probable (clinically or laboratory supported) or definite amyotrophic lateral sclerosis according to the revised version of the El Escorial criteria Disease duration (onset of first paresis or bulbar symptoms) < 24 months Loss of amyotrophic lateral sclerosis functional rating scale revised of ≥ 0.33 points/month based on the formula: (48 - myotrophic lateral sclerosis functional rating scale revised score at screening visit) / (months between onset and screening visit) Age ≥18 years. Either continuously treated with a stable dose of riluzole, OR not treated with riluzole for the last 4 weeks prior to inclusion Either continuously treated with a stable dose of edaravone, OR not treated with edaravone for the last 4 weeks prior to inclusion Either continuously treated with a stable dose of sodium-phenylbutyrate/taurursodiol, OR not treated with sodium-phenylbutyrate/taurursodiol for the last 4 weeks prior to inclusion Capable of thoroughly understanding all information given full written informed consent according to good clinical practice",LIPCAL-ALS II 1.1 NCT06280079 TrialTroveID-506213,Adults; Older Adults,year(s),,506213,Unspecified,,18.0,"Previous participation in another interventional study involving an active treatment within the preceding 4 weeks Tracheostomy or continuous permanent ventilator dependence (>22 hours per day) Pregnancy or breastfeeding Any medical condition known to have an association with motor neuron dysfunction which might confound or obscure the diagnosis of ALS Presence of any concomitant life-threatening disease or impairment likely to interfere with functional assessment. Evidence of a major psychiatric disorder or clinically evident dementia precluding evaluation of symptoms. Liable to be not cooperative or comply with study requirements as assessed by the investigator, or unable to be reached in the case of emergency",Iv,Both
0,Subjects with amyotrophic lateral sclerosis (ALS).,"Ages Eligible for Study: 18 Years and older Genders Eligible for Study: Both Inclusion Criteria: Clinical diagnosis of ALS. Male or female subjects aged 18 years or older. Must already be tolerating tube feedings through either a gastrostomy tube (G-tube or PEG) or jejunostomy tube (J-tube). Must require non-invasive ventilation (BIPAP) for less than 10 hours/day. Women of childbearing potential must have a negative pregnancy test at screening and be non-lactating. Eligible participants were aged 18 years or older with no history of diabetes or liver or cardiovascular disease, and who were already receiving percutaneous enteral nutrition.",2009-P-001132 MDA136152 NCT00983983 TrialTroveID-116123,Adults; Older Adults,year(s),,116123,Symptom relief,,18.0,"Exclusion Criteria: History of hepatitis including non-alcoholic steatohepatitis (NASH), cholecystectomy, prior biliary disease such as gallstones. History of diabetes. History of prior myocardial infarction or stroke. Laboratory values: Screening alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 2.0 times the upper limit of normal or total bilirubin greater than 1.5 times the upper limit of normal. Allergy to soy, fish, or milk products.",Ii,Both
1,"Patients with amyotrophic lateral sclerosis. 80 female, 121 male",,LIPCAL-ALS study TrialTroveID-365911,,,,365911,Delay Disease Progression,,,,Iv,Both
0,Patients With Amyotrophic Lateral Sclerosis,"- Patients diagnosed as having possible, probable, probable laboratory-supported, or definite ALS according to El Escorial Revised criteria. - Aged ≥ 18 years, inclusive at screening. - King's Clinical Staging Stage ≤3, disease duration of ≤ 36 calendar months and estimated life expectancy > 6 months at baseline.",AXO-CLI-210c-03 EUCT number: 2023-508895-13-00 NCT06365216 SEALS TrialtroveID-512705,Adults; Older Adults,year(s),,512705,Delay Disease Progression,,18.0,"- Patients with any cognitive or psychological disorder, intellectual disability or other significant impairment that would result in an inability to understand and sign the informed consent. - History of any clinically significant or unstable medical, neurological, psychiatric condition, disorder or disease (other than ALS) or social circumstances that, based on the investigator's judgment, would interfere with the conduct of the study or pose a risk to the patient if they were to participate.",Ii,Both
1,Patients with Amyotrophic Lateral Sclerosis (ALS).,"Ages Eligible for Study: 18 Years to 80 Years; Genders Eligible for Study: Both Inclusion Criteria: Patients between the ages of 18 and 80 years old. Clinical diagnosis of definitive, probable, and possible ALS (revised El Escorial Criteria) or diagnosis of the clinical ALS-variants of Progressive Muscle Atrophy (PMA). Sporadic and familial ALS. Beginning of symptoms of paralysis at least 6 months prior. Treatment with a steady dose of RIL 100 mg/day for at least 1 month. A score of < or = 28 in the symptom-oriented Council on Nutrition appetite questionnaire (CNAQ) by which appetite is evaluated. Patient consent.",NCT00876772 OLN-ALS01 TrialTroveID-106947,Adults; Older Adults,year(s),year(s),106947,Symptom relief,80.0,18.0,"Exclusion Criteria: Patients with known hypersensitivity to OLN, RIL, or one of the active ingredients. Percutaneous Endoscopic Gastronomy (PEG). Clinically significant eating disorder. Deliberate weight loss. Underlying consumptive disease with undesired weight loss. Overweight with BMI > or = 25 kg/m2. Clinically significant hypotonia and history of recurrent syncopes (> 1 syncope). Clinically severe concomitant illnesses, including psychiatric illnesses. Pregnant or nursing women. Severe neutropenia (< 750/mm3). Open angle glaucoma. Diabetes mellitus. Prostatic hyperplasia. Extrapyramidal movement disorders including from late dyskinesia. Dementia and incompetence to grant informed consent. Clinically significant EKG changes. EKG proof of a QT time corrected according to Fridericia (QTcF) > 500 ms. Treatment with substances that are metabolized by the Cytochrom-P450-System CYP1A2 (e. g. Carbamazepine, Fluvoxamin, and Ciprofloxacin). Treatment with Mirtazapine within the past 3 months. Treatment with steroids or appetite-stimulating substances including anabolics within the past 3 months. Treatment with Valproat within the past 3 months. Treatment with hepatotoxic medicines. Treatment with tetrahydrocannabinol within the past 3 months. Treatment with another atypical or typical neuroleptic within the past 3 months. Treatment with any other study medication < 1 month before the beginning of the study. Destructive use of psychotropic substances within the past 3 months. Destructive use of alcohol. Laboratory parameters outside the normal range that are associated with a clinically significant cardiovascular, pulmonologic, hematologic, hepatological, metabolic, or renal disease or that interfere with interpretation of the clinical study or that require medications that are not permitted in the study protocol. Elevation of the serum transaminase levels (ALT/AST) to more than 3-times of the upper normal value. Elevation of the bilirubin and gamma glutamyl transferase levels (GGT) to beyond the maximum normal value. History of a cardiopulmonary reanimation und prevention of sudden cardiac death. History of clinically significant EKG changes. History of thrombotic events including deep leg vein thrombosis and pulmonary artery embolism. History of a paralytic ileus. History of epilepsy or an episodic seizure.",Ii/Iii,Both
1,Amyotrophic Lateral Sclerosis (ALS) Patients.,"Genders Eligible for Study: Both Inclusion Criteria: Patients must have completed the 18-month safety and efficacy study of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) patients treated with riluzole (Protocol TRO19622 CL E Q 1015-1). Both the investigator and the patient will decide based on previous good tolerance and other clinical grounds whether or not to participate to the open-label extension. If patients were on anti-vitamin K during the double-blind period, when entering the open-label extension, coagulation tests should be monitored in exactly the same conditions as if a new anticoagulant treatment was initiated and the dose of anti-vitamin K should be adjusted accordingly. Patients enrolling from this prior safety and efficacy study must: - If female of childbearing age of potential, continue to use adequate birth control methods and have a negative serum pregnancy test at the preceding double-blind protocol termination visit. Male and female partners must agree to use an effective method of birth control during their participation in the trial and for at least 15 days after the last IMP dose. Both partners must use reliable methods of contraception with 2 independent methods. The following measures are acceptable: Hormone contraceptives (e.g. oral contraceptives or comparable methods), intrauterine device, condoms with spermicidal coating or in combination with spermicidal creams, total abstinence or sterilisation performed in the past. -Be able to follow the investigator's instructions and be able to comply with the visit schedule and visit requirements; and -Sign a written informed consent.",DeNDRoN 035ext EudraCT Number: 2010-021179-10 NCT01285583 TrialTroveID-141399 TRO19622 CL E Q 1425-1 TRO19622 OLE TRO19622CLEQ1425 UKCRN ID: 10407 WN29852,Adults; Older Adults,year(s),year(s),141399,Delay Disease Progression,80.0,18.0,"Exclusion Criteria: Patients may not participate in this study if they have an ongoing, unresolved, clinically significant medical problem (including patients having experienced serious adverse events or non-serious, but medically significant adverse events during the preceding safety and efficacy study that was assessed to be related to the study medication by the investigator) that in the judgment of the investigator would make it unsafe for the patient to participate in the trial.",Ii/Iii,Both
0,18 males and 18 post-menopausal females (mean age 59 years) with a probable/definite diagnosis of amyotrophic lateral sclerosis.,,TrialTroveID-122013,,,,122013,Unspecified,,,,I,Both
1,Patients diagnosed with amyotrophic lateral sclerosis (ALS) between 6 and 36 months before enrolment who were already treated with riluzole.,"Ages Eligible for Study: 18 Years to 80 Years, Genders Eligible for Study: Both Inclusion Criteria: Patients with sporadic or familial Amyotrophic Lateral Sclerosis. Patients with a clinical diagnosis of laboratory-supported probable, probable, or definite ALS according to the modified El Escorial criteria8. Have signed an Informed Consent to participate to the trial before any study related procedure has taken place. Be of age > 18 (exclusive) and < 80 years (inclusive). If a female, not lactating, has a negative pregnancy test and agrees to use an effective method of birth control. Onset of ALS Symptoms (weakness) for more than 6 months (inclusive) and less than 36 months(inclusive). Slow vital capacity (SVC), measured three times, one of the measure being > or = 70% of that predicted. Treated with riluzole at the stable dose of 50 mg bid for at least 30 days before enrolment. Received swallowing function and ability of oral medication.",DeNDRoN 035 DeNDRoN 035 (Trophos CL E Q 1015-1) EudraCT Number: 2008-007320-25 MITOTARGET MREC N° : 09/H0706/47 NCT00868166 TrialTroveID-080568 TRO19622 CL E Q 1015-1 Trophos CL E Q 1015-1 UKCRN ID: 6706 WN29853,Adults; Older Adults,year(s),year(s),80568,Delay Disease Progression,80.0,18.0,"Exclusion Criteria: Tracheostomy, invasive ventilation, or non invasive positive pressure ventilation (NIPPV). Gastrostomy. Evidence of major psychiatric disorder or clinically evident dementia. Diagnosis of a neurodegenerative disease in addition to ALS. Have a current medication that could interfere with TRO19622 pharmacokinetics: tamoxifene. Have current medications that could interfere with TRO19622 absorption such as ezetimibe, bile salts chelators (cholesteramine), fibrates, phytosterols, niacin (vitamin B3),fish oils. Have a current medication of lipid lowering agents other than statins. Known hypersensitivity to any component of the study drug. Patients with known intolerance or contra-indication to riluzole. Have a recent history (within the previous 6 months) or current evidence of alcohol or drug abuse. Have concurrent unstable disease involving any system eg, carcinoma other than basal cell carcinoma, any cardiac dysrhythmia, myocardial infarction, clinical or ECG signs of myocardial ischemia, cardiac insufficiency, angina symptoms, current symptoms of Coronary Artery Disease, or any other condition that in the opinion of the Investigator would make the patient unsuitable for study participation. Having a baseline QTc (Bazett) > 450 msec for males and > 470 msec for females. Patients with known hepatitis B/C or HIV positive serology. Be pregnant female or lactating. Have renal impairment defined as blood creatinine > 1:5 X upper limit of normal. Have hepatic impairment and/or liver enzymes (ALAT or ASAT) > 3 X ULN. Hemostasis disorders or current treatment with oral anticoagulants. Be possibly dependent on the Investigator or the Sponsor (eg, including, but not limited to, affiliated employee). Participated in any other investigational drug or therapy study with a non approved medication, within the previous 3 months. Patients without Social Security Insurance (France).",Ii/Iii,Both
0,Healthy male Caucasian subjects.,,TrialTroveID-080017,,,,80017,Healthy subjects,,,,I,Male
0,Adults With Acid Sphingomyelinase Deficiency,"Signed, informed consent by the patient or legal guardian prior to performing any study-related procedures; Have ≤ 0.2 nmol/hr/mg protein ASM activity in peripheral leukocytes, as measured by the reference laboratory; Have a diffusing capacity (DLco) > 30% of the predicted normal value; Have a spleen volume ≥ 2x normal Female patients of childbearing potential must have a serum pregnancy test negative for β-hCG and agree to use a reliable birth control method for the duration of the study.",NCT00410566 SPHINGO00605 TrialTroveID-237122,Adults,year(s),year(s),237122,Acid sphingomyelinase deficiency,65.0,18.0,"- Is pregnant or lactating; - Has received an investigational drug within 30 days prior to study enrollment; - Has a medical condition, including serious intercurrent illness, active hepatitis B or C or human immunodeficiency virus (HIV) infection, cirrhosis, > stage 3 liver fibrosis, INR >1.5, platelet count < 60.0x10^3/??L, significant cardiac disease (e.g. pulmonary artery pressure > 40 mm Hg, moderate or severe valvular dysfunction, or < 40% left ventricular ejection fraction by echocardiography (ECHO)), or any other extenuating circumstances that may significantly interfere with study compliance including all prescribed evaluations and follow-up activities; - Has had a major organ transplant (e.g. bone marrow or liver); - Has had a total splenectomy; - Has an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value >250 IU/L or a total bilirubin >3.6 mg/dL; - Is unwilling or unable to avoid the use of alcohol, medications that may decrease rhASM activity, medications or herbal supplements that may cause or prolong bleeding, and the use of medications or herbal supplements with potential hepatoxicity within 14 days prior to and 28 days afte the rhASM infusion.",I,Both
0,"Patients with clinically significant sensory abnormalities, dementia, other neurological disease, psychiatric illness, uncompensated medical illness, malignancy or clinically significant laboratory abnormalities were exclude from the study. Approximately 150 patients (30b patients per treatment group) at selected centers were to participate in abbreviated pharmaco kinetic profiling of TCH346 on day 1, at week 24 and week 40.","Ages Eligible for Study 21 Years to 80 Years; Inclusion criteria Clinical diagnosis of laboratory-supported probable, probable, or definite ALS; Sporadic or familial ALS; ALS symptom onset for no more than 3 yrs at study entry; FVC equal to or more than 70%; Patients who are either riluzole naive or patients who are receiving concomitant treatment with riluzole at a stable dose of riluzole (50 mg bid) at study start.",CTCH346A2211 NCT00072709 TCH346A2211 TrialTroveID-079099,Adults; Older Adults,year(s),year(s),79099,Delay Disease Progression,80.0,21.0,"Exclusion criteria Known or suspected chronic infectious disease including HIV, hepatitis B, or hepatitis C. Clinically significant ECG abnormalities. Known hypersensitivity to study drug or related drugs (e.g. selegiline, MAO-A and B inhibitors, or tricyclic antidepressants). Patients treated with potent inhibitors of CYP1A2 or CYP3A4 (a list of such inhibitors will be provided to the investigator). Treatment with MAO-A and B inhibitors (including selegiline) within the past 30 days.",Ii,Both
0,,"Ages Eligible for Study: 21 Years - 80 Years, Inclusion Criteria: Completed original protocol, Study No. CTCH346A2211. Be capable of satisfying the requirements of the extension protocol and must sign informed consent after the nature of the extension protocol has been fully explained. This study recruited males and females aged 21-80 years, inclusive suffering from clinical diagnosis of laboratory supported probable, probable or definite ALS (conforming to WFN E1 Escoral Revisited; Revised Criteria for the Diagnosis of Amyotrophic Lateral Sclerosis with ALS onset of symptoms for no more than 3.0 years at the study start. Patients could have been riluzole naive or have been on a stable dose of riluzole (50 mg b.i.d) at study start. A vital capacity equal to or no more than 70% of the theoretical value (% predicted value) was required.",CTCH346A2211E1 EudraCT Number: 2004-002855-15 NCT00230074 TCH346A2211E1 TrialTroveID-078690,Adults; Older Adults,year(s),year(s),78690,Delay Disease Progression,80.0,21.0,"Exclusion Criteria Exclusion criteria as described in the original protocol will remain applicable into the extension protocol. Other protocol-defined exclusion criteria may apply. Patients were excluded from the study with clinically significant sensory abnormalities, dementia, other neurologic diseases, uncompensated medical illness and or psychiatric illness, know or suspected chronic infectious disease including HIV, hepatitis B or C, and or clinically significant ECG abnormalities.",Ii,Both
0,Patient affected by Amyotrophic Lateral Sclerosis (ALS).,Age > 18 years Obtaining of a written consent after information. Diagnosis of probable or certain ALS according to the El Escorial criteria of the World Federation and Neurology Committee on Neuromuscular Diseases. Patient having a follow-up in an ALS center. Sialorrhea with VAS functional embarrassment > or equal at 50/100. Patient beneficiary of Social Security regime.,2010.607/11 ALS-TOX NCT01551940 TrialTroveID-163934,Adults; Older Adults,year(s),,163934,Symptom relief,,18.0,"Evolving disease associated with predictable survival < 1 month. Patient having previously received an injection of botulinum toxin in the salivary glands. Patient taking the other medical treatments for sialorrhea in the 7 days before the inclusion in the study (scopoderm, trihexyph'nidyle, atropine, ipatropium, amitriptyline, clomipramine, oxybutinine, diphenhydramine, beta-blockers). Patient having benefited from radiotherapy or from surgery on the salivary glands. Behavioral problems, dementia or other psychiatric problems. Myasthenia. Known Pregnancy or absence of contraception recognized as effective, breast feeding.",Ii,Both
1,Cohort of 26 patients (15 PD and 11 ALS) who were referred for treatment because suffering severe drooling and other therapies had failed.,,TrialTroveID-152703,,,,152703,Healthy subjects; Non-motor symptoms/comorbidities,,,,Iv,
1,Patients with amyotrophic lateral sclerosis and three with Parkinson's disease,,TrialTroveID-140851,,,,140851,Non-motor symptoms/comorbidities; Symptom relief,,,,Iv,
1,Patients with bulbar ALS and socially disabling sialorrhea.,,TrialTroveID-079862,,,,79862,Symptom relief,,,,Iv,
1,Children and adolescents with disabilities 5–18 years of age with a history of excessive drooling,"Inclusion criteria were children belonging to group 1–2 (healthy or minor disease) according to the ASA (American Society of Anaesthesiologists) Physical Status Classification System with no allergy to atropine eyedrops or other medical conditions contraindicating the use of atropine. Previous inclusion criteria: Principal inclusion criteria: Adults and juvenile patients with a severe drooling secondary to a neurologic medical condition, as e.g. cerebral palsy, ALS, Mb Parkinson",132998 EudraCT Number: 2007-003017-14 TrialTroveID-169479,Children,year(s),year(s),169479,(N/A); Advanced-stage; Non-motor symptoms/comorbidities; Spastic CP; Symptom relief,18.0,5.0,Principal exclusion criteria: Poor dental status. ASA 3 or more. Children who can´t undergo general anaesthesia. Hypersensitivity to Botox and/or Atropine w. ingredients. Children with untreated dentine caries and insufficient oral hygiene were excluded from the study as they were considered to have an increased caries risk if their salivary secretion would decrease.,Iv,Both
0,Patients with amyotrophic lateral sclerosis.,"Adult males and females aged over 18years. Previous randomisation in clinical study ONO-2506PO/EU0106. Completion of all visits in clinical study ONO-2506PO/EU0106. Ability to swallow ONO-2506PO capsules. Ability to comply with the dosing regimen and visit schedule. Agreement for themselves or their partner to use an adequate method of contraception throughout the study and for 2 weeks post-study. Adequate methods of contraception for themselves or their partner include condoms, diaphragm with spermicidal gel, coil (intra-uterine device), surgical sterilisation, vasectomy and abstinence. Able and willing to give written informed consent.",EudraCT Number: 2004-002912-27 ONO-2506PO E011 TrialTroveID-336561,Adults,year(s),year(s),336561,Delay Disease Progression,64.0,18.0,"Requirement for any medications metabolised via the cytochrome P450 2C9 pathway and may compromise subject safety due to elevated plasma levels, or those listed in section 7.6.2. A clinically relevant medical history or presence of cardiovascular, gastrointestinal, renal, hepatic, endocrine/metabolic, neurologic, lymphatic, haematologic, immunologic, musculoskeletal, connective tissue, dermatologic, genito/urinary, psychiatric diseases or disorders that, in the opinion of the Investigator, may pose an unwarranted risk to the subject. Previous participation in any ONO-2506 study, with the exception of ONO-2506PO/EU0106. Previous participation in any other study since their participation in study ONO-2506PO/EU0106. Presence or intention of pregnancy and breast-feeding (female subjects only). Males with the intention of fathering a child during the study period.",Ii,Both
0,Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS).,"Adult male and female patients with diagnosis of ALS over the age of 18 years. Previous randomization and completion of the last visits in ONO-2506POE014 study. Patients whom the investigator has no concern and judges tolerable for the continued treatment with ONO-2506PO and Riluzole from a risk and benefit point of view. Who had completed 18 months treatment (1200 mg ONO-2506PO and standard riluzole therapy) in ONO-2506POE014 study and were willing to provide written informed consent, were included in this study. Subjects had to have the ability to swallow study medication without the requirement for nasogastric or Percutaneous endoscopic gastrostomy (PEG) feeding as evidenced by a score of > or = 3 on ALS functional rating scale (ALSFRS-R) question # c (swallowing).",EudraCT Number: 2007-004723-37 NCT00694941 ONO-2506POE015 TrialTroveID-091503,Adults; Older Adults,year(s),,91503,Delay Disease Progression,,18.0,"A clinically relevant medical history or presence of cardiovascular, gastrointestinal, renal, hepatic, endocrine/metabolic, neurologic, lymphatic, haematologic, immunologic, musculoskeletal, connective tissue, dermatologic, genito/urinary, psychiatric diseases or disorders that, in the opinion of the investigator may pose an unwarranted risk to the patient.",Ii,Both
0,Patients with ALS.,,2506PO/EU0106 N0059122206 TrialTroveID-079013,,,,79013,Delay Disease Progression,,,,Ii,
0,Patients With Amyotrophic Lateral Sclerosis (ALS).,"Ages Eligible for Study: 18 Years - 74 Years Inclusion Criteria: Adult males and females aged 18 to 75 years. Diagnosis of clinically possible, clinically probable laboratory-supported, clinically probable, or clinically definite ALS (according to WNF EL Escorial diagnostic criteria, revised according to the Airlie House Conference 1998) Onset of muscle weakness within 14 months of randomisation Baseline SVC greater than or equal to 70% of predicted normal at Visit 1 (screening visit) Concomitant standard Riluzole therapy (50mg twice daily) for at least 2 weeks prior to Visit 1(screening visit), with liver function test (LFT) results within two times the upper limit of the normal range Ability to swallow without the requirement for nasogastric or PEG feeding as evidenced by a score of = 3 on ALSFRS-R question # c (swallowing) at Visit 1 (screening visit) Agreement for themselves or their partner to use an adequate method of contraception throughout the study and for 2 weeks after post study visit. Adequate methods of contraception for themselves or their partner include but are not limited to barrier method (i.e. condoms, diaphragm with spermicide gel), surgical sterilisation, vasectomy and abstinence. Able and willing to give written informed consent, personally or via their legally authorised representative",EudraCT Number: 2006-002660-26 NCT00403104 NL15677.041.06 ONO-2506POE014 SIRONA TrialTroveID-078967,Adults; Older Adults,year(s),year(s),78967,Delay Disease Progression,74.0,18.0,"Exclusion Criteria: Presence of a tracheotomy, mechanical ventilation or non-invasive ventilation as evidenced by a score of = 3 on ALSFRS-R question # i (respiratory insufficiency) at Visit 1 (screening visit) Requirement for prescription drugs used for potential neuroprotective benefit listed in section 10.5.3.1, for one month prior to Visit 1 (screening visit) Requirement for prescription drugs that are metabolised via the cytochrome P450 2C9 listed in section 10.5.3.2, for one week prior to Visit 1 (screening visit). A clinically relevant medical history or presence of respiratory diseases or disorders (such as moderate-to-severe asthma and chronic obstructive pulmonary disease) that, in the opinion of the Investigator, may pose an unwarranted risk to the subject or confound the results of the study. A history or presence of malignancy within the past 3 years. A history or presence of other life threatening diseases within the past 3 years. A clinically relevant medical history or presence of cardiovascular, gastrointestinal, renal, hepatic, endocrine/metabolic, neurologic, lymphatic, haematologic, immunologic, musculoskeletal, connective tissue, dermatologic, genito/urinary, psychiatric diseases or disorders that, in the opinion of the investigator, may pose an unwarranted risk to the subject or confound the results of the study. Presence or intention of pregnancy and breast feeding (female subjects only). Males with the intention of fathering a child during the study period. A history of drug or alcohol abuse (alcoholic subjects who are recovered for at least 2 years will be allowed to enrol in the study). Subjects who have used any investigational drug and /or participated in any clinical trial within 3 months of entry to this study. Subjects who have previously received ONO-2506PO",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis (ALS).,"[Interim Registration] Subjects who are Diagnosed as ""Clinically Definite ALS"", ""Clinically Probable ALS"" or ""Clinically Possible-Laboratory-supported ALS"" according to the El Escorial revised Criteria, and within 30 months after onset of the disease Classified as class 1 or 2 in ALS severity classification Aged 20 or older and 70 or younger at the time of obtaining informed consent (IC) With 2 points or more in every question of ALSFRS-R (in writing and eating action (1), both sides should be 2 points or more) %FVC is not less than 70 Two points or more in every question of bulbar symptom scale in the modified Norris Scale Agreed by written IC for entry in the trial [Registration] Subjects who meet the following criteria in addition to the inclusion criteria for the interim registration Change in ALSFRS-R score during 12 weeks-preobsevation period is within the range between -1 and -3 Can come into hospital by the day before the day of NP022 implantation and can stay hospital until the next day of the first administration",TrialTroveID-279278 UMIN000022050,Adults; Older Adults,year(s),year(s),279278,Delay Disease Progression,70.0,20.0,"Have serious hepatic disorder, renal disorder, cardiovascular disease, pulmonary disorder, hematological disorder or metabolism disorder, and are judged by the investigators to be improper for entry in the trial With HbA1c (NGSP scale) of 6.5% or higher at the check of screening period Participated in clinical trials of INDs or clinical studies receiving treatment within a month before interim registration (30 days including interim registration date) With the following diseases or symptoms which might affect safety: malignant tumor, intrathecal infection, intrathecal tumor, proliferative retinopathy, depressed respiratory function (less than 70 of %FVC) Have a medical history of cancer Have a drug allergy Newly started taking of Riluzole after obtaining IC Participated in the Phase I Trial (protocol KP-100-ND001) With allergy to antibiotics or intolerance for devices implantation With allergy to the material of NP022, and including suspected above Have an anatomical difficulty in intrathecal catheterization Have an abnormality other than ALS in the spinal cord, the spine, the subarachnoidal cavity, or cerebrospinal fluid circulation, and are judged to be inappropriate for this trial With infectious diseases requiring a systemic therapy, meningitis, sepsis, bacteremia, peritonitis, or cutaneous infection, and including suspected above With bleeding diathesis With impaired coagulation-fibrinolysis, or taking anticoagulant or antiplatelet drugs Diagnosed as dementia Mentally impaired or have psychiatric disorders, and are judged to be inappropriate for the trial Pregnant (including suspected), nursing, wishing to become pregnant, or unable to prevent conception during the trial period using contraceptive methods Judged by the investigators to be inappropriate for any reason.",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis (ALS).,"Clinically Definite ALS,'Clinically Probable ALS or Clinically Possible-Laboratory-supported ALS by El Escorial Criteria Within 2 years after onset of the disease Stage I or II in ALS severity classification",JPRN-UMIN000007062 TrialTroveID-149387 UMIN000007062,Adults,year(s),year(s),149387,Unspecified,64.0,20.0,"Exclusion criteria: Have a serious disorder in any systems or have a serious metabolic defect, so that the investigators decide to be unsuitable for participation in the trial. Have hemoglobin A1c 6.1 (JDS value) or more. Any observation of diseases/symptomes below; malignant neoplasm, intrathecal infection/mass, proliferative retinopathy, %VC less than 70% in spirogram Have a history of intolerance to transplantation of medical devices Have received an investigational drugs or devices within a month before onformed consent Be unsuitable for participation in the trial for any reason, according to the investigators.",I,Both
1,Patients diagnosed with Frontotemporal Dementia,"1.Be within 40 to 75 years of age 2.Have a diagnosis of behavioural variant frontotemporal dementia, semantic dementia, or progressive non-fluent aphasia 3.Have a carer who will be able to live with the participant during the study",ACTRN12618001807246 TrialTroveID-336701 U1111-1218-4356,Adults; Older Adults,year(s),year(s),336701,Frontotemporal Dementia,75.0,40.0,"1.Severely compromised cardiac, hepatic or renal function 2.Severe nasal obstruction/blockage 3.Sensitivity to preservatives (in particular benzyl alcohol 0.9%), which are present in the nasal spray formulation 4.Upcoming surgery, due to concerns of interactions with other medications 5.Prior history of psychiatric disorders (e.g. major depression, schizophrenia, bipolar disorder) 6.Prescribed an anticholinesterase medication for less than three months or are experiencing side effects secondary to this class of medication. 7.Have prior history of neurological disorder other than dementia (e.g., head injury, stroke or transient ischemic attack, epilepsy) 8.Have a diagnosis of another neurodegenerative disease (e.g., Dementia with Lewy Bodies, Alzheimer’s Disease, Parkinson’ Disease) 9.Have an intellectual disability 10. Have a current history of substance abuse",Iii,Both
0,Patients with Frontotemporal Dementia and Healthy controls.,Patients: Ages 30-85 meet consensus criteria for probable behavioural variant FTD (bvFTD) Controls: Age and sex matched with patients Mini-Mental State Exam (MMSE) scores >27,FTDOXY13EF IEMO NCT01937013 R-13-270 TrialTroveID-231106,Adults; Older Adults,year(s),year(s),231106,Frontotemporal Dementia; Healthy subjects,85.0,30.0,Patients: history of stroke intracranial haemorrhage or other medical or neurological disorder apart from FTD that could affect cognition diagnosis of bipolar disorder or schizophrenia not better accounted for by the diagnosis of FTD cognitive impairment that precludes comprehension of task instructions contraindication to MRI scanning severe language or memory deficits that preclude participation in the study visits and measures females who are pregnant or breastfeeding (a pregnancy test will be done on females who have not completed menopause). uncontrolled hypertension bradycardia (rate <48 bpm) or tachycardia (rate > 100 bpm) current use of prostaglandins Controls: history of stroke intracranial haemorrhage or other medical or neurological disorder diagnosis of bipolar disorder or schizophrenia cognitive impairment that precludes comprehension of task instructions contraindication to MRI scanning severe language or memory deficits that preclude participation in the study visits and measures females who are pregnant or breastfeeding (a pregnancy test will be done on females who have not completed menopause). uncontrolled hypertension bradycardia (rate <48 bpm) or tachycardia (rate > 100 bpm) current use of prostaglandins,Ii,Both
0,Participants with Frontotemporal Dementia/Pick's disease.,"Diagnosis of probable FTD (behavioural variant FTD, FTD-semantic subtype or FTD-Progressive Nonfluent Aphasia) with supportive brain imaging (centrally rated frontotemporal atrophy score of 2 or greater on brain MRI or CT) or known FTD causing genetic mutation.68 Current symptoms of social apathy/indifference as measured by NPI apathy/indifference severity subscale score > or = 2 indicating the presence of moderate to marked levels of apathy/indifference. Study partner who consents to study participation and who cares for/visits the patient daily for at least 3 hours/day and who can administer all trial medications. FTLD-CDR score 0-2. MMSE >10. Stable baseline medications related to cognition or behaviour for >=30 days such as acetylcholinesterase inhibitors, memantine, anti-depressants, antipsychotic agents, other mood stabilizers, benzodiazepines. Written informed consent must be obtained and documented (from the patient or, where jurisdictions allow it, from their substitute decision maker).",FOXY FTDOXY17EF NCT03260920 TrialTroveID-307719,Adults; Older Adults,year(s),year(s),307719,Frontotemporal Dementia,80.0,30.0,"History of stroke, other neurologic or psychiatric disorder other than FTD that is considered to better account for behavioural symptoms. History of a myocardial infarction within the last two years or congestive heart failure. Current uncontrolled hypertension Current bradycardia (rate < 50 beats per minute/bpm) or tachycardia (rate > 100 bpm) Current hyponatremia (Na <135 mEq/L) Current use of topical prostaglandin medications applied to the cervix. Females who are pregnant or breastfeeding, or planning to conceive within the study period. Use of any investigational or experimental drug or device within the last 60 days prior to screening or within 5 half-lives of the experimental drug, whichever is longer. Participant has speech difficulties that in the opinion of the investigator would be incompatible with neuropsychology and safety assessments History of cancer except: If considered to be cured If not being actively treated with anti-cancer therapy or radiotherapy and, in the opinion of the investigator, not likely to require treatment in the ensuing 5 years For prostate cancer or basal cell carcinoma, no significant progression over the previous 2 years Any clinically significant hematological, endocrine, cardiovascular, renal, hepatic, gastrointestinal or neurological disease. If the condition has been stable for at least the past year and is judged by the investigator not to interfere with the patient's participation in the study, the patient may be included. For the CSF sub-study, current use of anticoagulant medications (warfarin, rivaroxaban, etc.). Plan for FTD patient to be placed into long-term care or plan for hospital admission for any kind of treatment within study period or if caregiver plans for holidays/respite care > 3 days during study period.",Ii,Both
0,Patients with frontotemporal dementia.,"- diagnosis of possible and probable behavioral variant FTD (bvFTD) based on clinical assessment, standard neuropsychological, functional, and neurobehavioral tests; - early and mild bvFTD (MMSE score=20); - stable (i.e., more than 2 months) medical treatment related to cognition or behaviour traditionally used for bvFTD, such as acetylcholinesterase inhibitors, memantine, anti-depressants, antipsychotic agents, other mood stabilizers, benzodiazepines. - ages 40-80; - both genders (women in menopausal status: females with amenorrhea for 12 months without an alternative medical cause. A high follicle stimulating hormone, FSH, level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy) - Males participants with female premenopausal partners must agree to use a double barrier method of contraception i.e., condom + diaphragm, condom or diaphragm + spermicidal gel or foam, and agree to maintain this throughout the study. Oxytocin nasal sprays has not been studied in pregnant or lactating women. - normal or correct-to normal vision - to be able to read and understand Italian language (the language used for the study instructions and Consent Form); - to be able to sign the consent form (MMSE=20, the semantic fluency, TMT A-B, and Digit Span scores should not be below 2SD from the mean scores); - availability of a caregiver who consents to participate into all study sessions and complete specific tests. (We consider a caregiver the person who spends at least 8 hours a day with the patient).",EudraCT Number: 2018-000143-12 ORBIS-DE-UNIBO001 TrialTroveID-473607,Adults; Older Adults,year(s),year(s),473607,Frontotemporal Dementia; Mild Cognitive Impairment/Dementia Risk,80.0,40.0,"- Severe bvFTD (MMSE < 20) - Speech difficulties that in the opinion of the investigator would be incompatible with neuropsychology and safety assessments - Inability to sign the consent form - Medical or neurological disorders of the central nervous system apart from FTD - Any clinically significant hematological, endocrine, cardiovascular, renal, hepatic, gastrointestinal or neurological disease. If the condition has been stable for at least the past year and is judged by the investigator not to interfere with the patient's participation in the study, the patient may be included. - History of a myocardial infarction within the last two years or congestive heart failure. - Current uncontrolled hypertension - Current bradycardia (rate < 50 beats per minute/bpm) or tachycardia (rate > 100 bpm) - Current hyponatremia (Na <135 mEq/L) - Psychiatric disorders (depression, bipolar disorder or schizophrenia) - Hormonal therapy - Premenopausal women - Males refusing to use a double barrier method of contraception throughout the study. - Abuse of alcohol and drugs during the last 6 months - Severe hepatic or renal impairment - Ischemic cardiomyopathy - Diagnosis of cancer not in remission since at least 10 years - Known allergy to food additive and preservatives used for nasal sprays (E 216, E 218 and chlorobutanol hemihydrate) - Use of any investigational or experimental drug or device within the last 60 days prior to screening or within 5 half-lives of the experimental drug, whichever is longer.",Ii,Both
0,Patients with Frontotemporal Dementia,"Age 30-80 years Meets ""Neary criteria"" for diagnosis of probable frontotemporal dementia Neuroimaging (CT, MRI or SPECT scan) supports diagnosis of frontotemporal dementia Provides written informed consent and has a caregiver or legally acceptable representative who provides written informed consent.",17783 FTDOXY10EF NCT01386333 R-11-232 TrialTroveID-226952,Adults; Older Adults,year(s),year(s),226952,Frontotemporal Dementia,80.0,30.0,"Has a history of a myocardial infarction within the last two years or congestive heart failure. Current uncontrolled hypertension Current bradycardia (rate < 50 beats per minute/bpm) or tachycardia (rate > 100 bpm) Current hyponatremia Current use of prostaglandin medications Females who are pregnant or breastfeeding Use of any investigational or experimental drug or device within the last 60 days prior to screening or within 5 half-lives of the experimental drug , whichever is longer.",I,Both
0,Subjects with Amyotrophic Lateral Sclerosis.,"Minimum Age: 18 Year; Maximum Age: 80 Year Gender: Both Inclusion Criteria: Patients with diagnosis of familial or sporadic ALS. Onset of muscle weakness no more than 30 months before screening visit. Slow Vital Capacity (SVC) of at least 65% predicted for gender, age, ethnicity and height at Screening. If on riluzole, the dose must have been stable for at least 28 days prior to Baseline visit. Age 18 – 80 years inclusive. Female subjects may participate if they are of non-child-bearing potential or if they are of child-bearing potential they must agree to use the approved contraceptive methods. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < or =2x upper limit of normal (ULN); alkaline phosphatase and bilirubin < or =1.5xULN. QTc (both QTcB and QTcF) <450 milliseconds (msec) or <480 msec for subjects with Bundle Branch Block at Screening and Baseline (average from triplicate ECGs). French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category. Eligible participants will be ALS patients, aged 18 - 80 years, with onset of muscle weakness within the last 30 months. They should not have any other nerve or muscle problems or any severe lung problems.",112 264 112264 DeNDRoN 083 GSK EudraCT Number: 2012-003349-13 JapicCTI-132047 NCT01753076 NL42366.041.12 NOG112264 TrialTroveID-159001 UKCRN ID: 12921,Adults; Older Adults,year(s),year(s),159001,Delay Disease Progression,80.0,18.0,"Exclusion Criteria: Patients with other neuromuscular disorders (including a history of polio) which in the opinion of the investigator could have contributed to the muscular atrophy or weakness caused by ALS. Patients with primary lateral sclerosis, monomelic ALS, ALS Parkinsonism dementia complex. Patients requiring non-invasive or mechanical ventilation (non-invasive ventilation for sleep apnoea is allowed subject to discussion with Medical Monitor). Patients on diaphragmatic pacing. Presence of any of the following clinical conditions: Drug abuse or alcoholism, uncontrolled hypertension, active major infectious disease, unstable psychiatric illness within 90 days of the Screening visit. Subjects, who in the investigator's judgement, pose a significant suicide risk. Current or chronic history of liver disease, known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones), positive Hepatitis B surface antigen or Hepatitis C antibody test. Subjects who have participated in a clinical trial involving receipt of a biopharmaceutical product within 6 months prior to the first dosing day. Exposure to non-biological experimental agents 1 month or 5 half-lives prior to Baseline visit (whichever is longer). History of sensitivity to ozanezumab, or components thereof, or a history of other allergies that, in the opinion of the investigator, contraindicates participation in the study. Chronic (>3 months) use of systemic immunosuppressants including systemic steroids. Vaccination within 2 weeks. Pregnancy or breastfeeding.",Ii,Both
0,"Patients with amyotrophic lateral sclerosis (ALS) Across all subjects, the mean age was 58 years, mean body mass index was 26.2 kg/m2 , and the majority of subjects were white males The majority of subjects had sporadic ALS (69/76; 91%) with a mean time from diagnosis of 11.1 months and a mean time from onset of muscle weakness of 19.4 months; the mean time from onset of muscle weakness varied considerably between these cohorts.","Ages Eligible for Study: 18 Years to 80 Years Inclusion Criteria Patients with diagnosis of familial or sporadic ALS, defined as meeting the possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS according to the revised World Federation of Neurology El Escorial criteria [Rix Brooks 2000]. Onset of muscle weakness within 36 months of study entry. Slow Inspiratory Vital Capacity (SVC) greater than or equal to 70% predicted for age and sex. If on any medication (including riluzole), these must have been stable within the previous one month. Age 18 - 80 years inclusive. Male or Female of non-childbearing potential (NCBP) defined as follows: Pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous iollicle stimulating hormone (FSH) > 40 MlU/ml and oestradiol < 40 pg/ml (<140 pmol/L) is confirmatory]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods in Section 7.1.1, if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method. Male subjects must agree to use one of the contraception methods listed in Section 7.1.2. This criterion must be followed from the time of the first dose of study medication until the last follow-up visit. QTcB < 500 msec or uncorrected QT <600msec (machine or manual overread). If subject has bundle branch block then criteria is QTcB < 530 msec. Body Mass Index >19.0 kgm2. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form. Each subject was only allowed to participate in one part of the study.",111330 DeNDRoN 036 EudraCT Number: 2008-005040-16 FTIH NOG111330 MREC N°: 09/H0804/1 NCT00875446 NOG111330 NOGO-A NOGO111330 TrialTroveID-106808 UKCRN ID: 6600,Adults; Older Adults,year(s),year(s),106808,Delay Disease Progression,80.0,18.0,"Exclusion Criteria: Patients with other neuromuscular disorders (in addition to their ALS diagnosis), unless the investigator determines that such additional disorder will not affect safety or other measures in this study. Patients with evidence of dementia or psychiatric illness which, in the investigator's opinion, is likely to prevent them from a full understanding of and/or compliance with the study requirements and rocedures. Patients with abnormalities detected during the screening evaluations which, in the investigator's medical judgement, are sufficiently significant to exclude them from participation in the study. Patients who have participated in a clinical trial involving receipt of a biopharmaceutical product within 6 months prior to the first dosing day. Exposure to more than four new investigational products within 12 months prior to the first dosing day. The subject has a positive drugs of abuse test at the screening or pre dose visit. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates and benzodiazepines. Subjects who are on any of these drugs by prescription for medical reasons may be considered by the investigator for inclusion if they fulfil other entry criteria. The subject has a positive alcohol test at the pre-dose visit. History of regular excessive alcohol consumption within 6 months of the study defined as: For European sites: an average weekly intake of > 28 units for males or >21 units for females. One unit is equivalent to 8g of alcohol: a half-pint (~240mL) of beer, 1 glass (125mL) of wine or 1 (25mL) measure of spirits. For North American sites: an average weekly intake of >21 drinks for males or >14 drinks for women. One drink is equivalent to 12 g alcohol: 12 ounces (360mL) of beer, 5 ounces (150mL) of wine or 1.5 ounces (45mL) of 80 proof distilled spirits. History of sensitivity to GSK1223249, or components thereof, or a history of drugs or other allergies that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation. Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period. Females of childbearing potential, pregnant females as determined by positive serum or urine beta hCG test at screening or prior to dosing, or lactating females. Patients who have received any type of vaccination in the last two months before study entry. Subject will not be eligible for inclusion in Part 1 (in the cohorts receiving 1 and 15 mg/kg only) and Part 2 of the study if any of the following criteria apply: Patients with wasted deltoids (MRC score = 2) and patients with normal deltoids (MRC score 5). Patients who cannot achieve normal coagulation in the peri-operative period and those who may otherwise be at higher risk of bleeding complications.",Iii,Both
0,Adult Subjects with Frontotemporal Dementia and Heterozygous Mutations in the Granulin Precursor GRN Gene Patients with early symptomatic FTD-GRN,"Documented to be a pathogenic GRN mutation carrier Clinical diagnosis of frontotemporal dementia Have a reliable informant / caregiver (and back-up informant / caregiver) who personally speaks with or sees the subject at least weekly Living in the community (i.e., not in a nursing home); assisted living may be permitted at the discretion of the investigator",EudraCT Number: 2020-004499-17 FTD-GRN NCT04747431 PBFT02-001 TrialTroveID-374688 upliFT-D,Adults; Older Adults,year(s),year(s),374688,Frontotemporal Dementia,75.0,35.0,"Classification of the GRN mutation as ""not pathogenic,"" ""likely benign variant,"" ""benign variant,"" or ""pathogenic nature unclear"" Previous treatment with any gene therapy. Any other therapies with the potential to alter PGRN levels must be washed out for at least 5 half-lives prior to entry into this study Homozygous GRN mutation carrier Rosen-modified Hachinski Ischemic Scale score > 7 Known presence of a structural brain lesion (eg, tumor, cortical infarct) that could reasonably explain symptoms in a symptomatic subject Known presence of an AD-causing mutation in PSEN1, PSEN2 or APP based on genetic testing history (if performed) Previous history of Korsakoff encephalopathy, severe alcohol or substance dependence (within 5 years of onset of dementia), except where onset of increased alcohol consumption occurs at the time of FTD disease onset History of untreated vitamin B12 deficiency Presence of untreated hypothyroidism (thyroid stimulating hormone [TSH] > ULN and free T4 < LLN) eGFR < or = 30 ml/min (as calculated using the CKD-EPI equation) Alanine aminotransferase [ALT] or aspartate aminotransferase [AST] > 2 × ULN, or total bilirubin > ULN) Respiratory failure that requires supplemental oxygen Inability to provide full consent or the lack of a legally authorized caregiver with adequate contact who can provide consent Any contraindication to MRI or lumbar puncture (LP) (eg, local infection, history of thrombocytopenia, coagulopathy) Any contraindication to the ICM administration procedure Medical conditions or laboratory or vital sign abnormalities that would increase risk of complications from intra-cisterna magna injection, anesthesia, LP, and/or MRI (e.g., fever, hypoxia, tachycardia, or evidence of active infection) Immunocompromised status Peripheral axonal sensory neuropathy Receipt of a vaccine within 14 days of dosing A positive test result for human immunodeficiency virus (HIV), human T cell leukemia virus (HTLV) type 1 or type 2, or Hepatitis B or C; a Mycobacterium tuberculosis positive test within 1 year of or determined at screening Malignant neoplasia (except localized skin cancer) or a documented history of hereditary cancer syndrome Any concurrent disease that, in the opinion of the investigator, may cause cognitive impairment unrelated to GRN mutations, including other causes of dementia, neurosyphilis, hydrocephalus, stroke, small vessel ischemic disease, uncontrolled hypothyroidism, or vitamin deficiency Current or recent history of clinically significant suicidal ideation within the past 6 months For females of childbearing potential, a positive serum pregnancy test at the screening visit, a positive serum result on Day 1 prior to administration of the investigational product, or unwillingness to have additional pregnancy tests during the study. Females of childbearing potential must use a highly effective method of birth control or engage in abstinence until 90 days postdose Women who are breastfeeding For sexually active men, unwillingness to use a medically accepted method of double-barrier contraception (such as a condom/diaphragm used with spermicide) or engage in abstinence from the date of screening until 90 days postdose Any condition (eg, history of any disease, evidence of any current disease, any finding upon physical examination, or any laboratory abnormality) that, in the opinion of the investigator, would put the subject at undue risk or would interfere with evaluation of the investigational product or interpretation of subject safety or study results Any acute illness requiring hospitalization within 30 days of enrollment Failure to meet the protocol-specified coagulation test criteria: Platelet count over 100,000 per uL INR less than 1.5 aPTT less than 40 seconds Use of anticoagulants in the 2 weeks prior to screening, or anticipated use of anticoagulants during the study. Antiplatelet therapies may be acceptable Hypersensitivity or contraindications to corticosteroid use Known or suspected intolerance or hypersensitivity to PBFT02 or any of its ingredients or to closely related compounds",Iii,Both
0,,"- all subjects had a verifiable diagnosis of ALS for 0.5 to 2 years based on a diagnosis using the Revised Criteria of the World Federation of Neurology. The grades of diagnosis were clinically definite ALS or clinically probable ALS; - ALS was mild-to-moderate based on the ALS Functional Rating Scale-Revised. Electrophysiological features showed compound muscle action potential (CMAP) amplitude of motor nerve normal or mild declining; - serum creatine kinase was normal or mild upper, less than 500 U/L.",LCKY2016-58 NCT03085706,Adults; Older Adults,year(s),year(s),298030,,75.0,31.0,"- use of any other investigational agent within 30 days before treatment; - severe cardiac, pulmonary, hepatic or/and hematic disease; - human immunodeficiency virus positivity or signs and symptoms consistent with human immunodeficiency virus infection; - pregnant or nursing women; - history of cancer with less than 5 years documentation of a disease-free state; - history of anaphylactic reaction or hypersensitivity to granulocyte colony- stimulating factor (G-CSF); - alcohol or drug abuse in recent 1 year; - cannot understand or obey the rules of treatment; - blood donor in recent 30 days.",(N/A),Both
0,Subjects with Frontotemporal dementia,"The patient has a diagnosis of probable Frontotemporal dementia behavioural variant (bv-FTD) based on the International consensus clinical diagnostic criteria described by Rascovsky et al., 2011. The patient is a man or a woman, aged from 40 to 85 years. The patient has a Clinical Dementia Rating-FTD (CDR-FTD) total score of =2 at Screening. The patient has not been treated with acetylcholinesterase inhibitor (AChEI), i.e., donepezil, galantamine, or rivastigmine, at the time of screening. The patient is able to comply with the study procedures in the view of the investigator. Evidence of frontotemporal hypometabolism at PET imaging. Evidence of amyloid markers excluding Alzheimer's disease (cerebrospinal fluid Abeta/Tau dosages or amyloid PET imaging).",NCT04489017 PEA-FTD SPE.107 TrialTroveID-380926,Adults; Older Adults,year(s),year(s),380926,Frontotemporal Dementia,85.0,40.0,"Significant neurodegenerative disorder of the central nervous system other than FTD e.g., Alzheimer's disease, Lewy body dementia, Parkinson's disease, multiple sclerosis, progressive supranuclear palsy, normal pressure hydrocephalus, Huntington's disease, any condition directly or indirectly caused by Transmissible Spongiform Encephalopathy (TSE), Creutzfeldt-Jakob Disease (CJD), variant Creutzfeldt-Jakob Disease (vCJD), or new variant Creutzfeldt-Jakob Disease (nvCJD) Significant intracranial focal or vascular pathology seen on brain MRI scan within a maximum of 6 months before Baseline leading to a diagnosis other than probable FTD. The patients has history of seizure (with the exception of febrile seizures in childhood). Metal implants in the head (except dental), pacemaker, cochlear implants, or any other non-removable items that are contraindications to MR imaging. Treatment currently or within 3 months before Baseline with any of the following medications: Typical and Atypical antipsychotics (i.e., Clozapine, Olanzapine); Antiepileptics drugs (i.e., Carbamazepine, Primidone, Pregabalin, Gabapentin); Antidepressants (i.e., Citalopram, Duolxetine, Paroxetine).",Ii,Both
0,Adult subjects with Amyotrophic Lateral Sclerosis (ALS),"At least 18 years of age Sporadic ALS diagnosed as definite, probable, or laboratory-supported probable as defined by the revised El Escorial criteria Slow vital capacity (SVC) >or= 60% of the predicted value at screening Onset of ALS symptoms within 72 weeks (18 months) prior to screening Total ALSFRS-R score of >or= 30 at screening Have vaccination within 5 years against Streptococcus pneumoniae, Neisseria meningitidis (types A, C, W, Y, and B), and Haemophilus influenzae (type B) or agree to receive vaccination Women of childbearing potential defined as any woman who has experienced menarche and who is NOT permanently sterile or postmenopausal a.must have a negative pregnancy test at screening and b.must agree to use protocol defined methods of contraception for the duration of the study and 90 days after their last dose of investigational product. i.Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause. Males must agree to a.use protocol defined methods of contraception and b.refrain from donating sperm for the duration of the study and 90 days after their last dose of investigational product. Willing and able to give informed consent and comply with study procedure and assessments (including at-home assessments)",APL2-ALS-206 EudraCT Number: 2019-003797-10 jRCT2031230170 MERIDIAN NCT04579666 NL74696.041.20 TrialTroveID-386281,Adults; Older Adults,year(s),,386281,Delay Disease Progression,,18.0,"Confirmed or suspected other causes of neuromuscular weakness Diagnosed with another neurodegenerative disease (examples include Parkinson's disease and Huntington's disease) Significant pulmonary disorder not attributed to ALS (eg, chronic obstructive pulmonary disease, pulmonary fibrosis, cystic fibrosis, pulmonary arterial hypertension) If taking riluzole, participant must be on a stable dose for 30 days prior to the start of the screening period. Use of riluzole is not required for participation. If taking edaravone, participant must be on a stable dose for 60 days prior to the start of the screening period. Use of edaravone is not required for participation. Participation in any other investigational drug trial or exposure to other investigational agent, device, or procedure within 30 days or within 5-half lives of the treatment (whichever is longer) prior to the start of the screening period or during study participation Use of any other complement inhibitor within 30 days or within 5-half lives of the treatment (whichever is longer) prior to the start of the screening period or during study participation Subject with significant cognitive impairment, clinical dementia, or psychiatric illness that in the opinion of the investigator may increase subject’s risk by participating in the study or confound the outcome of the study Current use or anticipated need, in the opinion of the investigator, of a diaphragm pacing system during the randomized treatment period Positive response to Item 4 or 5 of the Columbia Suicide Severity Rating Scale Subjects with detectable hepatitis C by polymerase chain reaction at screening Subjects with chronic inactive hepatitis B with viral loads >1000 IU/mL (>5000 copies/mL) at screening. Eligible subjects who are chronic active carriers (< or = 1000 IU/mL) must receive prophylactic antiviral treatment according to local country guidelines (eg, entecavir, tenofovir, lamivudine) History of an aggressive lymphoma or presence of a lymphoma requiring therapy by itself Active or overt malignant disease other than basal cell carcinoma or cutaneous squamous cell carcinoma Received organ transplant Presence or suspicion of liver dysfunction as indicated by elevated alanine aminotransferase, aspartate aminotransferase, or bilirubin levels >2 × the upper limit of normal Presence or suspicion of severe recurrent or chronic infections that, in the opinion of the investigator, increase the subject’s risk by participating in the study Inability to cooperate or any condition that, in the opinion of the investigator, could increase the subject’s risk by participating in the study or confound the outcome of the study",Ii,Both
0,Patients with probable or definite Amyotrophic Lateral Sclerosis and vital capacity less than 100%.,,N0059115937 TrialTroveID-079170,,,,79170,Delay Disease Progression,,,,Ii,
0,Patients with Amyotrophic Lateral Sclerosis,"Amyotrophic Lateral Sclerosis (ALS) volunteers must be diagnosed within the 3 years prior to participation as having possible, probable, or definite ALS, either sporadic or familial according to modified El Escorial criteria Age 18-80, able to provide informed consent, and comply with study procedures Participants must not have started riluzole for at least 30 days, or be on a stable dose of riluzole for at least 30 days, prior to screening (riluzole-naïve participants are permitted in the study) Slow VC test equal to or greater than 50% of the predicted value",IM.JS.03 NCT03377309 TrialTroveID-314973,Adults; Older Adults,year(s),year(s),314973,Delay Disease Progression,80.0,18.0,"The presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair ability of the participant to provide informed consent Exposure to any experimental agent within 30 days of entry or at any time during the trial or enrollment in another research study within 30 days of or during this trial Women who are breastfeeding, who are pregnant or are planning to become pregnant Renal insufficiency as defined by a serum creatinine > 1.5 times the upper limit of normal Hepatic insufficiency or abnormal liver function (AST and/or ALT greater than 3 times the upper limit of the normal range) Slow VC test less than 50% of the predicted value ECG finding of QTc prolongation > 450 ms Patients who had already undergone tracheostomy",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis.,"1. Patients (male or female) who are aged over 20 years old. 2. Patients who are diagnosed as definite or probalble (including ""laboratory supported-"") ALS based on the revised El Escorial diagnostic criteria or the Awaji criteria. 3. Patients who are able to submit written informed consent.",TrialTroveID-297732 UMIN000026221,Adults; Older Adults,year(s),,297732,Unspecified,,20.0,1. Patients who are expected to show rapid symptomatic progression. 2. Patients with severe complications. 3. Patients with malignancy. 4. Patients with severe psychiatric symptoms. 5. Patients who participated in another cliniccal trial within 12 weeks. 6. Patients who are judged to be ineligible for study entry by the investigators.,I,Both
1,Subjects With Amyotrophic Lateral Sclerosis (ALS),"diagnosis of ALS first clinical weakness within past 3 years slow vital capacity >= 60% of predicted within 1 month of treatment may be on stable dose of riluzole for at least 30 days, or otherwise agree to not initiate riluzole for duration of the trial may be on stable dose of edaravone for at least 30 days, otherwise agree to not initiate edaravone for duration of the trial can travel to Stony Brook to receive medical care must have a monitor who can be contacted at regular intervals to report on subject's clinical/psychiatric status",Eisai-01 NCT03020797 TrialTroveID-294165,Adults; Older Adults,year(s),year(s),294165,Unspecified,80.0,18.0,"use of tracheostomy or mechanical ventilation within last 3 months hepatic insufficiency or abnormal liver function renal insufficiency clinically significant psychiatric disorder active malignancy history of HIV, clinically significant chronic hepatitis, or other active infection history of stomach or intestinal surgery or condition that could interfere with absorption, distribution, metabolism or secretion of study drug history of alcohol or substance abuse within 3 months prior to entry (subjects will be instructed to refrain from alcohol during the study) use of strong cytochrome P4503A inhibitors or inducers, anticonvulsants or other drugs known to interact strongly with perampanel. pregnancy or lactation clinically significant medical condition (other than ALS) that would pose a risk to the subject if they were to participate know hypersensitivity to perampanel currently participating, or has participated in a study with an investigation or marketed compound within 3 months of entry",Iv,Both
0,Patients with sporadic amyotrophic lateral sclerosis Patients with probable or definite ALS as defined by revised El Escorial criteria were enrolled,"[Eligibility Criteria for Interim Registration] Patients who are able to submit written informed consent. If patients are duly capable of study consent but are unable to sign by themselves due to aggravation of disease condition, written informed consent can be obtained from a legally authorized representative who can sign on behalf of the patients after confirming the patients' agreement to study participation. Patients who are male or female aged 40 years to 78 years at the time of obtaining informed consent Patients who have clinically definite ALS, clinically probable ALS, or clinically probable-laboratory supported ALS as specified in the revised El Escorial Airlie House diagnostic criteria. The sum of the 3 respiratory items of the ALSFRS-R must total 12 points or more Patients within 2-year elapsed time period from disease onset at the time of obtaining informed consent Patients who can visit study site for out-patient treatment [Eligibility Criteria for Registration] Subjects who meet the following criteria in addition to the inclusion criteria for the interim registration The progression on score of ALSFRS-R during 12 weeks of observation period must be between -2 and -5 Patients who has not initiated newly introduced riluzole therapy after starting the observation period. Or those who has not received dose escalation or resumed administration of riluzole therapy after previous down titration or discontinuation Patients who has not initiated newly introduced edaravone therapy after starting the observation period Patients who are judged to be eligible for continuation of the study by the investigators",A2016-J000-001 NCT03019419 TrialTroveID-294056 UMIN000025614,Adults; Older Adults,year(s),year(s),294056,Delay Disease Progression,78.0,40.0,"Patients who underwent tracheostomy. Patients who experienced non-invasive positive pressure ventilation. Patients whose percent-predicted forced vital capacity (%FVC) is =80%. Patients with progressive bulbar palsy type. Patients with cognitive impairment, severe disease in the renal, cardiovascular, or hematological system. Patients with hepatic disease. Patients with malignant tumor. Pregnant women or women with a possibility of becoming pregnant. Patients who participated in another clinical study within 12 weeks before starting the observation period. Patients who has initiated perampanel therapy in the past or at present. Patients who are judged to be ineligible for study entry by the investigators",Ii,Both
0,Patients with amyotrophic lateral sclerosis,"A probable laboratory supported, probable or definitive ALS diagnosis by revised El Escorial criteria. Sporadic or familial ALS. Ages of 18-70. Agree to use reliable contraception Randomization will occur after a baseline MT has been established; any subject in whom a MT cannot be established will be excluded. Caregiver willing to report adverse behavioral events. -",17-002396 NCT03793868 TrialTroveID-340225,Adults; Older Adults,year(s),year(s),340225,Unspecified,70.0,18.0,"History of epilepsy. Significant laboratory abnormality (AST or alanine aminotransferase >3x upper limit of normal, or glomerular filtration rate <60) History of aggressive behavior. Subject unwilling to abstain from alcohol for 2 weeks after each dosing. History of drug abuse in the last 5 years Other severe medical conditions, including psychiatric conditions, which would cause an increased risk in the opinion of the investigator, including but not limited to renal failure and liver failure. Skull defect or other physical contraindication for TMS Pacemaker or implanted defibrillator Inability to take study capsule by mouth Females only: Subject is pregnant [as confirmed by a positive serum human chorionic gonadotropin (hCG) test for females of reproductive potential (FRP) only], subject is breastfeeding, or subject is of reproductive potential and does not agree to follow use of reliable contraception.",I,Both
0,Patients With SOD1 ALS Treated,"Confirmed diagnosis of ALS with an SOD1 mutation Current enrollment in the tofersen expanded access program Age greater than 18 years Medically able to participate in outpatient physical therapy and/or home-based rehabilitation, as determined by the treating health care provider",202208170 NCT05725759 TrialTroveID-459178,Adults; Older Adults,year(s),,459178,Delay Disease Progression; Symptom relief,,18.0,"Any comorbidities or conditions that, in the opinion of the treating healthcare provider, would unacceptably increase the risk of participation in outpatient physical therapy and/or home-based rehabilitation",Ii,Both
1,"Patients with diagnosis of Parkinson disease, diffuse Lewy body disease, multiple systems atrophy, Huntington's Disease, Frontotemporal Dementia, and other variants","Patient arm - clinical diagnosis of Parkinson disease, diffuse Lewy body disease, multiple systems atrophy, Huntington's Disease, Frontotemporal Dementia, and other variants Healthy arm - age and gender matched to patient arm Psychosis (presence of hallucinations or delusions) starting after the diagnosis of Parkinson's disease, occurring at least weekly for 4 weeks, severe enough to warrant treatment. Study partner available for study visits",212028 NCT05357612 TrialTroveID-431238,Adults; Older Adults,year(s),year(s),431238,(N/A); Frontotemporal Dementia; Lewy Body Dementia; Non-motor symptoms/comorbidities,85.0,50.0,"Prior stroke or other uncontrolled serious neurological or medical illness Contra-indication or inability to tolerate MRI scan Use of serotonergic medications in the last 6 weeks Incapable of providing independent consent. Pregnant or breastfeeding women psychosis due to a metabolic, toxic, or primary psychiatric disease Deemed unable to complete neurocognitive testing For PD Participants: current or prior use of pimavanserin Use of antipsychotics in the last 2 weeks",Iv,Both
1,Adult and elderly subjects experiencing neuropsychiatric symptoms.,"Can understand the nature of the trial and protocol requirements and provide written informed consent. If the subject is deemed not competent to provide informed consent, the following requirements for consent must be met: The subject's legally acceptable representative (LAR) (or study partner/caregiver, if local regulations allow) must provide written informed consent The subject must provide written (if capable) informed assent Subject requires some or complete assistance with one or more of the following: Instrumental activities of daily living (communication, transportation, meal preparation, shopping, housework, managing medications, managing personal finances) OR Basic activities of daily living (personal hygiene, dressing, eating, maintaining continence or transferring) Meets clinical criteria for at least one of the following disorders, with or without cerebrovascular disease (CVD): Parkinson's disease with or without dementia as defined by the Movement Disorder Society's Task Force Dementia with Lewy bodies (DLB) All-cause dementia, possible or probable Alzheimer's disease (AD) Frontotemporal degeneration spectrum disorders, including possible or probable: i. Behavioral variant frontotemporal dementia ii. Progressive supranuclear palsy iii. Corticobasal degeneration e. Vascular dementia, including post-stroke dementia multi-infarct dementia and/or subcortical ischemic vascular dementia (SIVD) Has a designated study partner/caregiver Can come to the clinic for study visits with a study partner/caregiver If the subject is female, she must not be pregnant or breastfeeding. She must also be of non-childbearing potential (defined as either surgically sterilized or at least 1 year postmenopausal) or must agree to use a clinically acceptable method of contraception or be abstinent. If the subject is taking an antipsychotic medication at the time of screening, the antipsychotic medication must be discontinued 2 weeks or 5 half-lives (whichever is longer) Has a designated study partner/caregiver who meets the following requirements: a. In the Investigator’s opinion, is in contact with the subject frequently enough to accurately report on the subject’s symptoms and whether or not the subject is taking the study drug. Subjects with moderate or severe dementia, as evaluated by the Investigator, must live with a responsible adult who can provide direct supervision and monitoring of study medication administration. Subjects with mild dementia, as evaluated by the Investigator, must have close monitoring of study drug administration. b. In the Investigator’s opinion, is considered reliable in providing support to the subject to help ensure compliance with study treatment, study visits, and protocol procedures. c. Is fluent in the local language in which study assessments will be administered. d. Agrees to participate in study assessments, has the capacity to provide informed consent, and provides written consent to participate in the study. If the subject is taking an antipsychotic medication at the time of screening, the antipsychotic medication must be discontinued 2 weeks or 5 half-lives (whichever is longer) prior to Visit 2. Investigators should not withdraw a subject’s prohibited medication for the purpose of enrolling them into the study unless discontinuation of the medication is deemed to be clinically appropriate (e.g. symptoms are not well-controlled or the subject cannot tolerate the current medication) If the subject is female, she must not be pregnant or breastfeeding. She must also be of non-childbearing potential (defined as either surgically sterilized or at least 1 year postmenopausal) or must agree to use a clinically acceptable method of contraception or be abstinent for at least 1 month prior to Visit 2 during the study, and 1 month following completion of the study Abstinence as a method of contraception is defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. This option is usually made for a specific moral, religious, legal, or health reason. If heterosexual intercourse does occur, an acceptable method of birth control is required. Acceptable methods of birth control include the following: Condom, diaphragm, or cervical cap with spermicide. Hormonal contraception, including oral, injectable, transdermal, or implantable methods. Intrauterine device (IUD)",ACP-103-046 EudraCT Number: 2017-003536-36 NCT03575052 PMC 3069-2 Study 046 TrialTroveID-327273,Adults; Older Adults,year(s),,327273,Behavioral Symptoms - Other; Frontotemporal Dementia; Lewy Body Dementia; Non-motor symptoms/comorbidities; Parkinson's Disease Dementia; Unspecified PSP; Vascular Dementia,,60.0,"Is in hospice, is receiving end-of-life palliative care, or is bedridden Has psychotic symptoms that are primarily attributable to delirium or substance abuse (i.e., neuropsychiatric symptoms not related to neurodegenerative disease) Has current evidence of an unstable neurological, cardiovascular, respiratory, gastrointestinal, renal, hepatic, hematologic, or other medical disorder, including cancer or malignancies that, in the judgment of the Investigator, would jeopardize the safe participation of the subject in the study or significantly interfere with the conduct or interpretation of the study Has a known personal or family history of long QT syndrome or family history of sudden cardiac death Has a clinical significant CNS abnormality that is most likely contributing to the dementia or findings on MRI or CT including: intracranial mass lesion vascular malformation evidence of >4 hemosiderin deposits The urine drug screen result at Visit 1 (Screening) indicates the presence of amphetamine/methamphetamine, barbiturates, cocaine, or phencyclidine (PCP). Subjects who test positive for amphetamines and who have a valid prescription may be retested if they agree to abstain from the medication for the length of their participation in the study. The presence of benzodiazepines, marijuana (THC), or opiates does not necessarily exclude the subject from the study, as assessed by the Investigator in consultation with the Medical Monitor. Has previously been enrolled in any prior clinical study with pimavanserin or is currently taking pimavanserinIs judged by the Investigator or the Medical Monitor to be inappropriate for the study for any reason Additional inclusion/exclusion criteria apply. Patients will be evaluated at screening to ensure that all criteria for study participation are met. Patients may be excluded from the study based on these assessments (and specifically, if it is determined that their baseline health and psychiatric condition do not meet all pre-specified entry criteria). Has a history of myocardial infarction, unstable angina, acute coronary syndrome, or cerebrovascular accident within the last 6 months prior to V1 Has any of the following: a. greater than New York Heart Association (NYHA) Class 2 congestive heart failure b. Grade 2 or greater angina pectoris (by Canadian CV Society Angina Grading Scale) c. sustained ventricular tachycardia d. ventricular fibrillation e. torsades de pointes f. syncope due to an arrhythmia g. an implantable cardiac defibrillator Has a history of human immunodeficiency virus (HIV) or hepatitis C infection Has a history of neuroleptic malignant syndrome or serotonin syndrome Has a known personal or family history of long QT syndrome or family history of sudden cardiac death Has a heart rate <50 or >100 beats per minute, and/or a blood pressure of >165 mmHg (systolic) or >95 mmHg (diastolic). Corrections to medication or underlying cause of bradycardia or tachycardia and/or hypertension may be made during the Screening period and repeat measurement is permitted within the Screening window. Has a clinically significant CNS abnormality that is most likely contributing to the dementia or findings on MRI or CT including: a. intracranial mass lesion (including but not limited to meningioma [>1 cm3 with evidence of peritumoral edema] or glioma) b. vascular malformation c. evidence of >4 hemosiderin deposits (definite microhemorrhage or superficial siderosis) Has clinically significant neuroimaging or laboratory abnormalities during Screening that in the judgment of the Investigator would jeopardize the safe participation of the subject in the study. In consultation with the Medical Monitor, these subjects may be rescreened after appropriate treatment of their medical condition Requires treatment with a medication or other substance that is prohibited by the protocol The urine drug screen result at Visit 1 indicates the presence of amphetamine/methamphetamine, barbiturates, cocaine, or phencyclidine (PCP) Subjects who test positive for amphetamines may be retested during Screening if they agree to abstain from the medication for the length of their participation in he study and if abstinence from medication usage is achieved at least 7 days prior to Visit 2 Is suicidal at Screening or Baseline as defined below: a. If the subject can complete the Columbia Suicide Severity Rating Scale (C-SSRS), he or she must not be actively suicidal at Visit 1 or Visit 2 (including, an answer of “yes” to C-SSRS questions 4 or 5 [current or over the last 6 months]) and must not have attempted suicide in the 2 years prior to Visit 1 OR b. If the subject is not able to reliably complete the C-SSRS in the Investigator’s judgment, the subject must not be suicidal as assessed by the Global Clinician Assessment of Suicidality (GCAS) score (i.e. a score of 3 or 4) based on Investigator’s assessment of behavior within the 3 months prior to Visit 1 or since-last-visit at Visit 2 OR c. The subject is actively suicidal in the Investigator’s judgment Has participated in or is participating in a clinical trial of any investigational drug, device, or intervention, within 30 days or 5 half-lives, whichever is longer, of Visit 2 Has previously been enrolled in any prior clinical study with pimavanserin or is currently taking pimavanserin. Has a significant sensitivity or allergic reaction to pimavanserin or its excipients. Is an employee or is a family member of an employee of ACADIA Pharmaceuticals Inc. Is judged by the Investigator or the Medical Monitor to be inappropriate for the study for any reason, including if the subject is judged to be a danger to self or others.",Iii,Both
1,"Patients with Alzheimer’s disease, dementia with lewy bodies, Parkinson’s disease dementia, vascular dementia, and frontotemporal dementia Patients with dementia and moderate to severe psychosis","Meets criteria for All-cause Dementia according to NIA-AA guidelines Meets clinical criteria for one of the following disorders: Dementia associated with Parkinson's disease, Dementia with Lewy bodies, Possible or probable Alzheimer's disease, Frontotemporal degeneration spectrum disorders, Vascular dementia Has an MMSE score > or = 6 and < or = 24 Has had psychotic symptoms for at least 2 months Must be on a stable does of cholinesterase inhibitor or memantine, if applicable If the subject is female, she must not be pregnant or breastfeeding. She must also be of non-childbearing potential or must agree to use a clinically acceptable method of contraception for the duration of the study Can understand the nature of the trial and protocol requirements and provide written informed consent If the subject is deemed not competent to provide informed consent, the following requirements for consent must be met: a. The subject’s legally acceptable representative (LAR) (or study partner/caregiver, if local regulations allow) must provide written informed consent b. The subject must provide written (if capable) informed assent Frontotemporal degeneration spectrum disorders, including possible or probable: i Behavioral variant frontotemporal dementia (Appendix D) ii Progressive supranuclear palsy (Appendix E) iii Corticobasal degeneration (Appendix F) Has sufficient verbal and written ability to understand and answer questions and comply with procedures, with corrective measures such as hearing aids and reading glasses if necessary, and is willing and able to participate in all scheduled evaluations and complete all required tests Has all of the following scores at Visit 1 (Screening) and Visit 2 (open-label Baseline): a. SAPS-H+D total score =10; AND b. CGI-S =4 (moderately ill); AND c. SAPS-H+D global item (H7 or D13) score =4 (marked) Has lived at the current place of residence for at least 3 weeks prior to Visit 1 (Screening) and there are no plans to move to a different location Has a designated study partner/caregiver who meets the following requirements: a. In the Investigator’s opinion, is in contact with the subject frequently enough to accurately report on the subject’s symptoms and whether or not the subject is taking the study drug b. Is fluent in the local language in which study assessments will be administered c. Agrees to participate in study assessments and provides written consent to participate in the study Can come to the clinic for study visits with a study partner/caregiver Has an MRI or CT scan of the brain (completed within past 3 years) taken during or subsequent to the onset of dementia. If not available, a non-contrast brain MRI or non-contrast head CT must be done during screening. If the subject is taking an antipsychotic medication at the time of screening, the antipsychotic must be discontinued 2 weeks or 5 half-lives (whichever is longer) prior to Visit 2. Investigators should not withdraw a subject’s prohibited medication for the purpose of enrolling them into the study unless discontinuation of the medication is deemed to be clinically appropriate (e.g., symptoms are not well-controlled or the subject cannot tolerate the current medication).",ACP-103-045 EudraCT Number: 2017-002227-13 HARMONY NCT03325556 TrialTroveID-301631,Adults; Older Adults,year(s),year(s),301631,Behavioral Symptoms - Psychosis; Frontotemporal Dementia; Lewy Body Dementia; Mild; Moderate; Non-motor symptoms/comorbidities; Parkinson's Disease Dementia; Severe; Vascular Dementia,90.0,50.0,"Has psychotic symptoms that are primarily attributable to a condition other than dementia Has had a recent major depressive episode Has experienced suicidal ideation or behavior within 3 months prior to study enrollment Has evidence of a non-neurologic medical comorbidity or medication use that could substantially impair cognition Has a history of ischemic stroke within the last 12 months or any evidence of hemorrhagic stroke Has a known history of cerebral amyloid angiopathy (CAA), epilepsy, CNS neoplasm, or unexplained syncope Has any of the following: greater than New York Heart Association (NYHA) Class 2 congestive heart failure, Grade 2 or greater angina pectoris, sustained ventricular tachycardia, ventricular fibrillation, torsade de pointes, syncope due to an arrhythmia, an implantable cardiac defibrillator Had a myocardial infarction within the last 6 months Has a known personal or family history or symptoms of long QT syndrome Has a significant unstable medical condition that could interfere with subject's ability to complete the study or comply with study procedures Requires treatment with a medication or other substance that is prohibited by the protocol Additional inclusion/exclusion criteria apply. Subjects will be evaluated at screening to ensure that all criteria for study participation are met. Is in hospice or end-of-life care Is confined to bed (subjects who can attend clinic visits using a wheelchair or other ambulatory assistive device are permitted) Requires skilled nursing care (procedures that can only be administered by a registered nurse or doctor, such as but not limited to, intravenous administration of medication, procedures related to insertion or care of suprapubic catheters, and nasopharyngeal/tracheostomy aspiration) Has a Global Clinician Assessment of Suicidality (GCAS) score of 3 or 4 based on Investigator’s assessment of behavior within the 3 months prior to Visit 1 (Screening) or since-last-visit at Visit 2 (open-label Baseline) Has any of the following ECG results at Visit 1 (Screening) or Visit 2 (open-label Baseline): a. QTcF >450 ms, if QRS duration <120 ms b. QTcF >470 ms, if QRS duration =120 ms Has a heart rate <50 beats per minute Has a significant unstable medical condition that could interfere with subject’s ability to complete the study or comply with study procedures Has a clinically significant laboratory abnormality that in the judgment of the Investigator or Medical Monitor will interfere with the conduct or interpretation of safety or efficacy evaluations in the study Has one of the following screening laboratory results: a. Platelets =75,000/mm3 b. Hemoglobin =9.5 g/dL if male, or =8.5 g/dL if female c. Neutrophils, absolute =1000/mm3 d. Aspartate aminotransferase (AST) >2×upper limit of normal e. Alanine aminotransferase (ALT) >2×upper limit of normal f. Creatinine =2 mg/dL g. Hemoglobin A1c (HbA1c) =8.5% h. Abnormal free thyroxine (T4) i. Vitamin B12 deficiency Has a history of a positive test result for HIV or hepatitis C Has a clinically significant CNS abnormality that is most likely contributing to the dementia or findings on MRI or CT including: a. intracranial mass lesion (including but not limited to meningioma [>1 cm3 with evidence of peritumoral edema] or glioma) b. vascular malformation c. evidence of >4 hemosiderin deposits (definite microhemorrhage or superficial siderosis) Requires treatment with a medication or other substance that is prohibited by the protocol Has a body mass index (BMI) <18.5 or known unintentional weight loss =7% of body weight over past 6 months The urine drug screen result at Visit 1 (Screening) or Visit 2 (open-label Baseline) indicates the presence of amphetamine/methamphetamine, barbiturates, cocaine, or phencyclidine (PCP). The presence of benzodiazepines, marijuana (THC), or opiates may not exclude the subject from the study. Has participated in or is participating in a clinical trial of any investigational drug, device, or intervention, within 30 days or 5 half-lives, whichever is longer, of Visit 1 (Screening) OR has participated in a clinical trial for disease-modifying therapy within 6 months of Visit 1 Has previously been enrolled in any prior clinical study with pimavanserin or is currently taking pimavanserin Has a significant sensitivity or allergic reaction to pimavanserin or its excipients Is an employee or is a family member of an employee of ACADIA Pharmaceuticals Inc. Is judged by the Investigator or the Medical Monitor to be inappropriate for the study for any reason",Iii,Both
1,Adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease,"1. Subject satisfied all entry criteria for the antecedent pimavanserin study 2. The subject may benefit from longer term therapy with open-label pimavanserin treatment in the judgment of the Investigator 3. Subject completed the antecedent study; or was participating in a pimavanserin study that the Sponsor ended early 4. Has a designated study partner/caregiver who meets the following requirements: a. In the Investigator’s opinion, is in contact with the subject frequently enough to accurately report on the subject’s symptoms and whether or not the subject is taking the study drug. Subjects with moderate or severe dementia, as evaluated by the Investigator, must live with a responsible adult who can provide direct supervision and monitoring of study medication administration. Subjects with mild dementia, as evaluated by the Investigator, must have close monitoring of study drug administration. b. In the Investigator’s opinion, is considered reliable in providing support to the subject to help ensure compliance with study treatment, study visits, and protocol procedures c. Is fluent in the local language in which study assessments will be administered d. Agrees to participate in study assessments, has the capacity to provide informed consent, and provides written consent to participate in the study 5. Subject can come to the clinic for study visits with a study partner/caregiver 6. Subject is willing and able to provide informed consent. Consent for the present study must be obtained prior to the final procedures being performed at antecedent study’s EOT visit or ET visit (if the study was ended early by the Sponsor). If the subject is deemed not competent to provide informed consent, the following requirements for consent must be met: a. The subject’s legally acceptable representative (LAR) (or study partner/caregiver, if local regulations allow) must provide written informed consent b. The subject must provide written (if capable) informed assent 7. If the subject is female, she must not be pregnant or breastfeeding. She must also be of non-childbearing potential (defined as either surgically sterilized or at least 1 year postmenopausal) or must agree to use a clinically acceptable method of contraception or be abstinent during the study and 1 month following completion of the study. Abstinence as a method of contraception is defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. This option is usually made for a specific moral, religious, legal, or health reason. If heterosexual intercourse does occur, an acceptable method of birth control is required. Acceptable methods of birth control include the following: a. Condom, diaphragm, or cervical cap with spermicide b. Hormonal contraception, including oral, injectable, transdermal, or implantable methods c. Intrauterine device (IUD)",ACP-103-047 EudraCT Number: 2017-004439-36 NCT03623321 TrialTroveID-330120,Adults; Older Adults,year(s),,330120,Behavioral Symptoms - Other; Frontotemporal Dementia; Lewy Body Dementia; Non-motor symptoms/comorbidities; Parkinson's Disease Dementia; Vascular Dementia,,60.0,"1. Subject is judged by the Investigator or the Medical Monitor to be inappropriate for the study, due to AEs, medical condition, or noncompliance with investigational product or study procedures in the antecedent study, or is judged to be a danger to self or others 2. Is in hospice, is receiving end-of-life palliative care, or has become bedridden 3. Has any of the following ECG results at the EOT/ET visit of the antecedent study: a. If the subject is not on citalopram, escitalopram, or venlafaxine: i. QTcF > 450 ms, if QRS duration < 120 ms ii. QTcF > 470 ms, if QRS duration > or = 120 ms b. If the subject is on citalopram, escitalopram, or venlafaxine: i. QTcF > 425 ms, if QRS duration < 120 ms ii. QTcF > 450 ms, if QRS duration > or = 120 ms 4. Has a heart rate < 50 or > 100 beats per minute, and/or a blood pressure of > 165 mmHg (systolic) or > 95 mmHg (diastolic) 5. Has a body mass index (BMI) < 18.5 kg/m2 or known unintentional clinically significant weight loss (i.e., > or = 7% of body weight) over past 6 months 6. Has clinically significant laboratory abnormalities in the antecedent study that, in the judgment of the Investigator or Medical Monitor, would either: a. jeopardize the safe participation of the subject in the study; OR b. would interfere with the conduct or interpretation of safety or efficacy evaluations in the study 7. Is suicidal as defined below at Visit 1 (Baseline) of the ACP-103-047 study: a. If the subject was assessed in the antecedent study using the Columbia-Suicide Severity Rating Scale (C-SSRS), he or she must not be actively suicidal at Visit 1 (Baseline) (including an answer of “yes” to C-SSRS questions 4 or 5) and must not have attempted suicide (using the “Since Last Visit” version) prior to Visit 1 (Baseline) of the present study; OR b. If the subject is not able to reliably complete the C-SSRS in the Investigator’s judgment or if the Global Clinician Assessment of Suicidality (GCAS) scale was used in the antecedent study, the subject must not be suicidal as assessed by the GCAS score (i.e., a score of 3 or 4) based on Investigator’s assessment of behavior since-last-visit at Visit 1 (Baseline); OR c. The subject is actively suicidal in the Investigator’s judgment 8. Has developed a neurologic, cardiovascular, respiratory, gastrointestinal, renal, hepatic, hematologic, or other medical or mental disorder, including cancer or malignancies that, in the judgment of the Investigator, would increase the risk associated with taking study medication or significantly interfere with the conduct or interpretation of the study 9. Requires treatment with a medication or other substance that is prohibited by the protocol 10. Has a significant sensitivity or allergic reaction to pimavanserin or its excipients 11. Is an employee of ACADIA, or has a family member who is an employee of ACADIA",Iii,Both
0,Patients with Amyotrophic lateral sclerosis.,"Patients classified as having clinically definite, clinically probable, clinically probable (laboratory-supported) or clinically possible ALS according to the El-Escorial diagnostic criteria for ALS (see Appendix 2). Able to comprehend and willing to sign Informed Consent Form (ICF). Age 18 years of age or greater. ALS Symptom onset of muscle weakness or speech impairment no more than 48 months prior to screen visit. Fasiculations should not be considered. Slow Vital Capacity (SVC) greater than or equal to 50% predicted for sex, age and height at screen. Has the ability to swallow tablets/capsules whole at study entry. Subject with clinical laboratory findings within the normal range or, if outside the normal range, determined by the Investigator at the Screening visit to be not clinically significant. If the subject is taking Riluzole the dose must be stable for 30 days prior to the randomization visit. Riluzole cannot be initiated during the study. If the subject is receiving Edaravone therapy, the dose must be stable for at least 1 cycle of infusion treatments before the randomization visit.",NCT03272503 Pimozide2 Pimozide2_ALS-002 TrialTroveID-308441,Adults; Older Adults,year(s),,308441,Delay Disease Progression,,18.0,"History of laryngeal spasm, dystonia, or akathisia. Diagnosis of ongoing symptomatic Restless Leg Syndrome or undergoing current treatment for Restless Leg Syndrome. If subject has symptoms that resemble or have the potential to be Restless Leg Syndrome, then further investigation should be undertaken to confirm or rule out diagnosis of Restless Leg Syndrome. Any history of moderate or severe traumatic brain injury as defined by a Glasgow Coma Scale Score of less than 13/15 at any time point following a head injury without sedation or other reason for a decreased level of consciousness. History of neuroleptic malignant syndrome. History of hypersensitivity or serious adverse reaction(s) to a neuroleptic medication. History of hyponatremia < 130 mmol/L Subject with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) value >3.0 times the upper limit of normal at the Screening visit. Current heparin or warfarin use. History of hepatic and/or renal impairment that may affect pimozide metabolism History of current pregnancy, or breastfeeding women, or women planning to become pregnant. Female subjects of childbearing potential (sexually mature female who has not undergone a hysterectomy or who has not been post-menopausal for 12 consecutive months), must practise effective contraception during the study and be willing and able to continue contraception until the Follow-up phone visit after discontinuing study medication. Abstinence can be considered an acceptable method of contraception at the discretion of the investigator. Current antipsychotic use Presence of central nervous system depression, comatose states, liver disorders, renal insufficiency, and blood dyscrasias Presence of Parkinson's syndrome Presence of major depressive disorders as determined by site Investigator. History of clinically significant ECG abnormalities at screen visit, including QTc>500ms. History of congenital long QT syndrome or with a family history of this syndrome and in patients with a history of cardiac arrhythmias or Torsade de Pointes. Presence of acquired long QT interval, and/or concomitant use of drugs known to prolong the QT interval (TCAs, opioids such as methodone, quinolone antibiotics (ciprofloxacin), antimalarials (quinine), Detrol, azole antifungals, Class 1A, III and 1C antiarrhythmics, and macrolide antibiotics. Presence of clinically significant bradycardia (heart rate < 50 beats per minute) Presence of hypokalemia or hypomagnesemia. The concomitant use of CYP 3A4-inhibiting drugs such as azole antimycotics, antiviral protease inhibitors, macrolide antibiotics and nefazodone. The concomitant use of CYP 2D6-inhibiting drugs such as quinidine is also contraindicated. Concomitant use of serotonin reuptake inhibitors, such as, sertraline, paroxetine, citalopram and escitalopram.* Has taken any compound under current or known future study as a potential therapy (including Withania) for ALS less than 30 days prior to dosing OR history of exposure to stem cell therapy for treatment of ALS at any time. Current Neurological impairment due to a condition other than ALS: Subject in whom causes of neuromuscular weakness other than ALS have not been excluded. Subject with a diagnosis of other neurodegenerative diseases (e.g., Parkinson's disease, Frontotemporal dementia, Alzheimer's disease, etc.) Use of non-invasive ventilation (BiPAP or CPAP) prior to Baseline visit at any time. Cognitive impairment as determined by the Site Investigator, subject must not have an impaired ability to provide informed consent and must be able to understand study processes and comply with study procedures. Extrapyramidal Symptom Rating Scale (ESRS) Parkinsonism score of 2 on 2 items or a score > 3 on 1 item; OR Dystonia score of >3 on at least 1 item or a score of 2 on 2 items; OR Tardive Dyskinesia score of >3 on at least 1 item or a score of 2 on 2 items. Do not consider scores greater than 3 for Tremor in any region if due to Benign Essential, Exaggerated, or Physiological Tremor. The concomitant use of SSRIs and tricyclic antidepressants (e.g. amitriptyline, amoxaprine, desipramine, doxepin, imipramine, nortriptyline, protripyline, trimipramine) - and Tolterodine (Detrol) CYP2D6 inhibitor. Prohibited medications such as tricyclic antidepressants, antimalarials, and serotonin reuptake inhibitors,(ie sertraline, paroxetine, citalopram, fluoxetine, vilazodone and escitalopram) may be weaned to full discontinuation at the screening visit after consent has been signed (no study procedures including adjustments to medication may occur until informed consent has been provided).",Ii,Both
0,Patients With Neuromuscular Junction Transmission Dysfunction Due to ALS.,"Patients classified as having clinically definite, clinically probable, or clinically probable (laboratory-supported) ALS according to the El-Escorial diagnostic criteria for ALS Evidence of decremental response greater or equal to 5.0% in at least one nerve-muscle pair at the initial screening visit Age 18 years or greater Consent to participate in the Canadian Neuromuscular Disease Registry (CNDR) (follow-up study component only).",NCT02463825 PIMOZIDE_ALS-001 REB14-0617 TrialTroveID-259065,Adults; Older Adults,year(s),,259065,Comorbidity in ALS; Delay Disease Progression,,18.0,"Diagnosis of clinically possible or clinically suspected ALS as defined by the El-Escorial diagnostic criteria for ALS If the subject is taking riluzole the dose must be stable for 30 days prior to randomization visit. Riluzole cannot be initiated during the study. History of Parkinson's disease History of traumatic brain injury History of neuroleptic malignant syndrome History of hypersensitivity or serious adverse reaction(s) to a neuroleptic medication History of prolonged QTc interval more than 500 ms History of hyponatremia less than 130 mmol/L History of current heparin or warfarin use History of hepatic and/or renal impairment that may affect pimozide metabolism History of current pregnancy or breastfeeding Current antipsychotic use Presence of central nervous system depression, comatose states, liver disorders, renal insufficiency, and blood dyscrasias Presence of depressive disorders or Parkinson's syndrome History of congenital long QT syndrome or with a family history of this syndrome and in patients with a history of cardiac arrhythmias or Torsade de Pointes Presence of acquired long QT interval, such as associated with concomitant use of drugs known to prolong the QT interval Presence of hypokalemia or hypomagnesemia Presence of clinically significant bradycardia (heart rate less than 50 beats per minute) The concomitant use of CYP 3A4-inhibiting drugs such as azole antimycotics, antiviral protease inhibitors, macrolide antibiotics and nefazodone The concomitant use of CYP 2D6-inhibiting drugs such as quinidine is also contraindicated Concomitant use of serotonin reuptake inhibitors, such as, sertraline, paroxetine, citalopram and escitalopram Severe dysphagia with risk of aspiration Has taken any compound under current or known future study as a potential therapy for ALS less than 30 days prior to dosing OR history of exposure to stem cell therapy for treatment of ALS at any time",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis (ALS),"Ages Eligible for Study: 18 Years and older; Inclusion Criteria: Diagnsis of ALS Possible, probable (clinically or laboratory) or definite ALS according to the revised version of the El Escorial World Federation of Neurology criteria. Disease duration more than 6 months and less than 3 years. Best-sitting FVC between 50% and 95% of predicted normal. Continuously treated with 100 mg riluzole daily, for at least one month. Onset of progression weakness within 36 months prior to study. Women of childbearing age be non-lactating and surgically sterile or using a highly effective. method of birth control and have a negative pregnancy test. Capable of thoroughly understanding all information given and giving full informed consent according to GCP. Muscle weakness at least 6 months show more than 18 years old. An adequate lung function and have the ability to swallow tablets. Patients with serious co-morbidities may not be included in the study be included.",EudraCT Number: 2006-005410-13 FARM7MFFEB GERP ALS NCT00690118 TrialTroveID-091599,Adults; Older Adults,year(s),,91599,Delay Disease Progression,,18.0,"Exclusion Criteria Previous participation in another clinical study within the preceding three months. Tracheotomy or assisted ventilation of any type during the preceding three months. Gastrostomy. Any medical condition known to have an association with motor neuron dysfunction which might confound or obscure the diagnosis of ALS. Presence of any concomitant life-threatening disease or impairment likely to interfere with functional assessment. Confirmed hepatic insufficiency or abnormal liver function (ASAT and/or ALAT more than 1.5 upper limit of normal). Renal insufficiency (serum creatinine more than 2.26 mg/dl). Evidence of major psychiatric disorder or clinically evident dementia precluding evaluation of symptoms. Known hypersensitivity to any component of the study drugs. Likely to be not cooperative or comply with the trial requirements (as assessed by the investigator), or unable to be reached in the case of an emergency. Other antidiabetics. Heart failure or heart failure in the patients history (NYHA I to IV). History of macular oedema. Treatment with thiazolidinediones within 3 months prior to screening. Known or suspected history of alcohol and/or drug abuse. Treatment with gemfibrozil within 3 months prior to screening. Percutaneous endoscopic gastrostomy (PEG) .",Ii,Both
0,Patients with dementia (except mild Alzheimer's disease),1.Informed consents are obtained in writing from patients or one of their caretakers 2.Those who regularly go to hospitals conducting this study and are 60 or older and 85 or younger Japanese (as of obtaining informed consent) 3.Those who showed 19 or less of Mini Mental State Examination at the beginning of this study 4.Those who are judged as suitable for participation in this study by responsible doctors at the beginning of the study,TrialTroveID-313547 UMIN000016008,Adults; Older Adults,year(s),year(s),313547,Cognitive Function; Frontotemporal Dementia; Lewy Body Dementia; Moderate; Severe; Vascular Dementia,85.0,60.0,1. Those who have scallop allergy 2. Those who are judged as not suitable for participation in this study by responsible doctors at the beginning of the study,Ii,Both
0,Patients with amyotrophic lateral sclerosis,"1. Male and female patients ≥18 years of age with sporadic or familial ALS 2. If taking riluzole and/or edaravone, must be on a stable dose prior to screening",CA-18-08 ISRCTN13974483 TrialTroveID-464630,Adults; Older Adults,year(s),,464630,Delay Disease Progression,,18.0,"1. History of a clinically significant non-ALS neurologic disorder 2. Inability to swallow capsules. 3. Human immunodeficiency virus (HIV) or current chronic/active infection with hepatitis C virus or hepatitis B virus 4. Women who are pregnant, planning to become pregnant, or are breastfeeding. 5. Use of non-invasive ventilation (NIV) or mechanical ventilation via tracheostomy, or any form of oxygen supplementation. 6. Current or anticipated need for a diaphragm pacing system (DPS). 7. Currently using glucocorticoids or have a history of regular systemic glucocorticoid use within the last 12 months. 8. Previous exposure or treatment with glucocorticoid receptor modulators or antagonists.",I,Both
0,Patients with Amyotrophic lateral sclerosis.,"Male or female study subjects fulfilling the probable or higher criteria for ALS according to the revised El-Escorial criteria. First documented symptom of ALS < or = 24 months before screening. The sum of the 3 respiratory items on the ALSFRS-R, 10: dyspnoea, 11: orthopnoea and 12: respiratory insufficiency, must total at least 10 points. Ability to walk without other walking aids than a crutch. 18 – 80 years at the time of screening. FEV% > or = 70%. Study subjects with or without pharmacological treatment, i.e. Riluzole for ALS (study subjects with ongoing pharmacological treatment for ALS shall have received unchanged treatment as regards drug(s) and dose(s) for at least 1 month).",APOCT-001 EudraCT Number: 2012-002099-15 TrialTroveID-217137,Adults; Older Adults,year(s),year(s),217137,Delay Disease Progression,80.0,18.0,"Women in fertile age with a positive pregnancy blood test, or planning to become pregnant during the period of the trial. Fertile women include any female who has experienced menarche, who has not undergone tubal ligation, and who is not postmenopausal. Postmenopausal is defined as amenorrhea = 12 consecutive months without another cause. Sexually active men and women without highly effective contraceptive treatment, e.g. sterilisation, condoms and diaphragms with spermicide; oral contraceptives (including Progesterone-only pills in high dose) in combination with a barrier method; hormonal contraceptives alone are not sufficient. Active hepatitis B, active hepatitis C, or HIV infection. Serious cardiac disease including unstable or uncontrolled cardiac disease during the last 6 months and/or a previous history or present clinical signs of deep venous thrombosis Major surgical procedure within 4 weeks prior to start of treatment. Participation in any other clinical trial within 30 days of inclusion (randomisation) in the trial or patients with unresolved investigational treatment-related adverse events. Other chronic disease or previous organ transplantation judged by the Investigator to interfere with the assessment of treatment success and/or ability to fully participate in the trial. Impaired kidney function with an absolute GFR calculated from cystatin C <60 mL/min. Known blood disease or Anaemia Haemoglobin <120 g/L for women and <130 g/L for men. Known haemoglobinopathy (e.g. thalassemia and sickle cell anaemia). Patients that require immunosuppressive treatments including azathioprine, cyclosporine, systemic steroid treatment (e.g. prednisolone at doses of =10 mg/day or hydrocortisone) or has received such treatment within the last 6 months prior to randomization. Patients that are treated with drugs that can interact significantly with APO-P001; ethinylestradiol and/or ribavirin; azathioprine, didanosine, zidovudine, mercaptopurine, stavudine. Lack of suitability for participation in the trial, for any reason, as judged by the Investigator. Patients with clinical or other signs of frontal temporal lobe dementia (FTLD) or known heredity for FTLD.",Ii,Both
0,,,TrialTroveID-211260,,,,211260,Unspecified,,,,I,
0,"Patients with various pathological conditions, such as ALS, ADHD and bronchial asthma.","Age at enrollment ≥18 years; ALS diagnosis defined or probable according to El Escorial criteria (Brooks et al., 2000); Respiratory function with FVC% >50% Population 2: ADHD Inclusion Criteria: children between 6 and 16 years old children with ADHD, diagnosed with DSM-5 criteria and in accordance with the protocol shared by the Regional ADHD Reference Centers Lombardy. Population 3: Bronchial Ashtma Inclusion Criteria: adults above 18 years of age diagnosed with Bronchial Ashtma following ERS-ETS criteria",NCT06005506 NM102_SPATIALS3 sPATIALS3 TrialTroveID-482616,Adults,,,482616,Adolescents; Adults; Children; Comorbidities in ADHD; Comorbidity in ALS; Delay Disease Progression; Hyperactive/Impulsive type; Symptom relief,,,"Subjects unable to give informed consent to the study; presence of psychiatric disease or severe cognitive impairment; presence of tracheotomy; presence of severe pre-existing gastrointestinal disease (e.g., ulcerative rectocolitis; Crohn's disease). presence of intellectual disability (QIT<70), presence of neurological diseases, epilepsy presence of genetic syndromes treatment with drug therapies. Co-diagnosis with other psychiatric or neurodevelopmental disorders (i.e. Autism, Anxiety, Depression etc) will not be considered a criterion of exclusion. life expectancy less than 18 months active respiratory infections cognitive disorders that prevent participation to the study (MMS <24)",Ii,Both
0,Subjects with Amyotrophic Lateral Sclerosis (ALS).,"Male or female patients 18-65 years of age. ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial Criteria. Symptom onset < or = 24 months from screening visit. A score of > or =38 on the Revised ALS Functional Rating Scale. Slow vital capacity (SVC) measure >80% of predicted for gender, height and age at screening. Subjects must not have taken riluzole for at least 30 days, or be on a stable dose of riluzole for at least 30 days, prior to the screening visit (riluzole-naïve subjects are permitted in the study). Negative tuberculosis (TB) test within 3 months of Screening Visit. Subjects medically able to undergo lumbar puncture (LP) as determined by the investigator (i.e., no bleeding disorder, allergy to local anesthetics, or a skin infection at or near the LP site). Capable of providing informed consent and following study procedures. Women must not be able to become pregnant (e.g. post menopausal, surgically sterile, or using adequate birth control methods) for the duration of the study. Women of childbearing potential must have a negative pregnancy test at screening and be non-lactating. Geographic accessibility to the study site. Inclusion Criteria for participants with symptom onset greater than 24 months before screening: Male or female patients age 18 or older. ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial Criteria. Symptom onset >24 months from screening visit. Subjects must not have taken riluzole for at least 30 days, or be on a stable dose of riluzole for at least 30 days, prior to the screening visit (riluzole-naïve subjects are permitted in the study). Negative tuberculosis (TB) test within 3 months of Screening Visit. Subjects medically able to undergo lumbar puncture (LP) as determined by the investigator (i.e., no bleeding disorder, allergy to local anesthetics, or a skin infection at or near the LP site). Capable of providing informed consent and following study procedures. Geographic accessibility to the study site. Women must not be able to become pregnant (e.g. post menopausal, surgically sterile, or using adequate birth control methods) for the duration of the study. Women of childbearing potential must have a negative pregnancy test at screening and be non-lactating.",2013P000981 NCT01884571 NIP-ALS-2013 NIPALS2013 TrialTroveID-188964,Adults,year(s),year(s),188964,Delay Disease Progression,65.0,18.0,"Prior use of basiliximab, solumedrol, prednisone, tacrolimus or mycophenolate mofetil within 30 days of the Screening Visit. Known allergy or sensitivity to basiliximab, solumedrol, prednisone, tacrolimus or mycophenolate mofetil or a formulation of one of these drugs. Treatment with an immunosuppressant medication within 30 days of the Screening Visit. Active peptic ulcer disease. Any medical disorder that would make immunosuppression contraindicated including, but not limited to, human immunodeficiency virus (HIV), tuberculosis, or evidence of active cytomegalovirus (CMV) or infection. Subjects who have a diaphragm pacing system (DPS). Women who are pregnant, breastfeeding, or planning to become pregnant in the next 12 months. Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. Use of invasive or non-invasive mechanical ventilation (including Continuous Positive Airway Pressure (CPAP) or Bi-level Positive Airway Pressure (BiPAP)) for any part of the day or night prior to the Screening Visit (participants with symptom onset within past 24 months only). Exposure to any other agent currently under investigation for the treatment of patients with ALS (off-label use or investigational) within 30 days of the Screening Visit. Inability to safely complete study activities based on the discretion of the site investigator.",Ii,Both
1,,,TrialTroveID-513721,,,,513721,Unspecified,,,,Iii,
1,Patients With Amyotrophic Lateral Sclerosis.,- Sporadic or familial ALS. - Patient does not qualify for clinical trials of pridopidine or other clinical trials for the treatment of ALS at the enrolling site - Capable of providing informed consent and complying with study procedures - Patient has established care with a physician at the specialized ALS center involved in the study and will maintain this clinical care throughout the duration of the EAP - Life expectancy of at least 6 months.,EAP 2 NCT06069934 PL101-ALS501 TrialTroveID-487837,Adults; Older Adults,year(s),,487837,Unspecified,,18.0,"- Confirmed prolonged Fridericia-corrected QT (QTcF) interval (>450 ms for men; >470 ms for women). - Clinically significant heart disease, clinically significant history of arrhythmia, symptomatic or uncontrolled atrial fibrillation despite treatment, asymptomatic sustained ventricular tachycardia, or left bundle branch block. - Known history of long QT syndrome or a first degree relative with long QT syndrome. - Use of Nuedexta (>20 mg dextromethorphan and >10 mg quinidine twice daily); citalopram >20 mg/day; escitalopram >10 mg/day. - Known allergy to pridopidine or any of the exipients (silicified microcrystalline cellulose, magnesium stearate). - History of any clinically significant or unstable medical condition or laboratory abnormality that may interfere with assessment of the study objectives. - Female who is pregnant or nursing or who plans to get pregnant during the course of the EAP - Female of child-bearing potential or male unwilling or unable to use accepted methods of birth control. - Use of investigational treatments for ALS (as part of participation in a clinical trial or another EAP) within 5 half-lives (if known) or 30 days (whichever is longer) prior to screening (other than pridopidine). - Patient receives or has received any gene therapy - Active cancer or history of cancer, except for basal cell carcinoma or successfully treated squamous cell carcinoma of the skin, cervical carcinoma in situ, prostatic carcinoma in situ, or other malignancies curatively treated and with no evidence of disease recurrence for at least 3 years - Patients who chose to take experimental medications and/or supplements, and for whom this is the only reason they are not eligible for trials.",Iv,Both
1,Patients with Amyotrophic Lateral Sclerosis.,No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT NCT04297683).,2019P003518D HEALEY ALS Platform Trial - Regimen D NCT04615923 TrialTroveID-388613,Adults; Older Adults,year(s),,388613,Delay Disease Progression,,18.0,"The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683). Participants with a confirmed prolonged Fridericia-corrected QT (QTcF) interval (defined as a QTcF interval of >450 ms for men and >470 ms for women). Participants with clinically significant heart disease, clinically significant history of arrhythmia, symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia, or presence of left bundle branch block. Participants with known history of long QT syndrome or a first degree relative with this condition. Participants using prohibited medications within the 4 weeks prior to the Regimen Specific Screening Visit, as detailed in section 5.9. Participants using the following medications at the time of the Regimen Specific Screening Visit: Nuedexta - at a dosage higher than 20 mg dextromethorphan + 10 mg quinidine BID Citalopram - at a dosage higher than 20 mg/day Escitalopram - at a dosage higher than 10 mg/day Participants with a known allergy to any ingredient of the study intervention (pridopidine, silicified microcrystalline cellulose, and magnesium stearate).",Ii/Iii,Both
1,Patients with amyotrophic lateral sclerosis (ALS),"Sporadic or familial ALS diagnosed as clinically possible, probable, lab-supported probable, or definite ALS defined by revised El Escorial criteria. Age 18 years or older. Capable of providing informed consent and complying with study procedures, in the SI's opinion. Time since onset of weakness due to ALS ≤ 36 months at the time of the Master Protocol Screening Visit. Vital Capacity ≥ 50% of predicted capacity at the time of the Master Protocol Screening Visit measured by Slow Vital Capacity (SVC), or, if required due to pandemic-related restrictions, Forced Vital Capacity (FVC) measured in person. Participants must either not take riluzole or be on a stable dose of riluzole for ≥ 30 days prior to the Master Protocol Screening Visit. Participants must either not take edaravone or have completed at least one cycle (typically 14 days) of edaravone prior to the Master Protocol Screening Visit. Participants must have the ability to swallow pills and liquids at the time of the Master Protocol Screening Visit and, in the SI's opinion, have the ability to swallow for the duration of the study. Geographically accessible to the site. Participants must either not take Relyvrio/ Albrioza or have started Relyvrio/ Albrioza ≥ 30 days prior to the Master Protocol Screening Visit.",2019P003518 CCR-20-43 Healey ALS Platform Trial NCT04297683 TrialTroveID-358229,Adults; Older Adults,year(s),,358229,Delay Disease Progression,,18.0,"Clinically significant unstable medical condition (other than ALS) that would pose a risk to the participant, according to SI's judgment (e.g., cardiovascular instability, systemic infection, untreated thyroid dysfunction, or clinically significant laboratory abnormality or EKG changes). Lab abnormalities include, but are not limited to: Hemoglobin < 10 g/dL, White Blood Cells < 3.0 x 103/mm3, Neutrophils, Absolute ≤ 1000/mm3, Eosinophilia (absolute eosinophil count of ≥ 500 eosinophils per microliter), low platelet counts (< 150 x 109 per liter), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3 times the upper limit of normal (ULN), eGFR < 30 mL/min/1.73m2, thyroid-stimulating hormone (TSH) levels >10 mIU/L or <0.01 mIU/L. Presence of unstable psychiatric disease, cognitive impairment, dementia or substance abuse that would impair ability of the participant to provide informed consent, in the SI's opinion. Active cancer or history of cancer, except for the following: basal cell carcinoma or successfully treated squamous cell carcinoma of the skin, cervical carcinoma in situ, prostatic carcinoma in situ, or other malignancies curatively treated and with no evidence of disease recurrence for at least 3 years. Use of investigational treatments for ALS (off-label use or active participation in a clinical trial) within 5 half-lives (if known) or 30 days (whichever is longer) prior to the Master Protocol Screening Visit. Exposure at any time to any gene therapies under investigation for the treatment of ALS (off-label use or investigational). If female, breastfeeding, known to be pregnant, planning to become pregnant during the study, or of child-bearing potential and unwilling to use effective contraception for the duration of the trial and for 3 months, or longer as specified in each RSA, after discontinuing study treatment. If male of reproductive capacity, unwilling to use effective contraception for the duration of the trial and for 3 months, or longer as specified in each RSA, after discontinuing study treatment. Anything that would place the participant at increased risk or preclude the participant's full compliance with or completion of the study, in the SI's opinion. If a participant is being re-screened, the disqualifying condition has not been resolved, or the mandatory wash-out duration has not occurred.",Ii/Iii,Both
0,Patients with Amyotrophic Lateral Sclerosis.,"(1) Age > or = 18; (2) Clinically confirmed, probable and probable ALS in compliance with IE Escorial criteria revised in 1998; (3) medulla oblongata dysfunction; (4) CNS-BFS scores range from 50 to 90 points (the scoring criteria are shown in Attached Table 1); (5) subjects who can or receive oral medication; (6) Informed consent has been signed; (7) If patients are taking riluzole, they must take it for at least 30 days prior to randomization; (8) Patients who are taking medications to control salivation, such as Nuedexta (DMQ), Dextromethorphan, or Quinidine, must stop taking them within 30 days of enrollment to be eligible for the study.",ChiCTR2200058224 TrialTroveID-430014,Adults; Older Adults,year(s),,430014,Delay Disease Progression; Symptom relief,,18.0,"(1) Participated in other clinical studies within 3 months; (2) Endotracheal intubation or invasive assisted ventilation; (3) Pregnant women and lactating women; (4) People allergic to primidone; (5) ALT or AST was 3 times higher than normal; (6) Creatinine clearance rate was less than 50ml/min; (7) Disease or injury that interferes with functional assessment or endangers life; (8) any known motor neurone disease unrelated to ALS; (9) Major mental illness, cognitive dysfunction; (10) Irregular history of taking medicine in the past 3 years; (11) Patients with vision change, diplopia, nystagmus or ataxia; (12) Patients with porphyria; (13) Patients with asthma, chronic obstructive pulmonary disease or other respiratory disease that may aggravate breathing difficulties or obstructed airways. (14) People with coagulation dysfunction; (15) Patients with impaired liver and kidney function; Albuminuria showed ++ and above; (16) Systolic blood pressure less than 90 mmHg, diastolic pressure less than 50 mmHg, heart rate less than 50 beats per minute; (17) Unwilling or unable to participate in and complete the study.",Ii,Both
0,Subjects with amyotrophic lateral sclerosis,"(1) Age > or = 18 years; (2) Comply with clinically affirmative, probable and possible ALS in the IE Escorial criteria revised in 1998; (3) Course of disease < or = 24 months from onset to enrollment (date of onset is the first Muscle weakness, excluding fasciculations and spasms); (4) Subjects who can or receive oral medications; (5) Have signed informed consent.",ChiCTR2100045741 TrialTroveID-402290,Adults; Older Adults,year(s),,402290,Delay Disease Progression,,18.0,"(1) Participated in other clinical studies within 3 months; (2) Tracheal intubation or invasive assisted ventilation; (3) Gastrostomy or dysphagia; (4) Pregnant women and lactating women; People who are allergic to Miconazole; (6) ALT or AST is greater than 3 times the normal value; (7) Creatinine clearance rate <50ml/min; (8) Diseases or injuries that interfere with functional assessment or life-threatening; (9) Any known Non-ALS-related motor neuron disease; (10) Major mental illness, cognitive dysfunction; (11) Irregular medication history in the past 3 years; (12) Suffering from visual changes, diplopia, nystagmus, and People with dysfunction; (13) with porphyria; (14) with asthma, chronic obstructive pulmonary disease, or other respiratory diseases that may aggravate breathing difficulties or airway insufficiency. (15) Those with coagulation dysfunction; (16) those with impaired liver and kidney function; those with proteinuria ++ and above; (17) the systolic blood pressure is less than 90mmhg, or the diastolic blood pressure is less than 50 mmHg, and the heart rate is less than 50 per minute Second; (18) Unwilling or unable to participate in and complete this research",Ii,Both
0,Healthy adult subjects and participants with ALS.,"Adults between 18 and 65 years of age, inclusive BMI within 18.0 to 32.0 kg/m2, inclusive In good health, in the opinion of the Investigator, as determined by a physical examination, vital signs, 12-lead ECG, and clinical laboratory assessments Females of childbearing potential must agree to an approved method of contraception",5027513 NCT05279755 PRO-101 TrialTroveID-427532,Adults,year(s),year(s),427532,Healthy subjects; Unspecified,65.0,18.0,"History or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, musculoskeletal, neurological, or psychiatric disorder Any episodes of vertigo in the previous 12 months prior to screening or any medical history of seizures Active autoimmune conditions such as systemic lupus erythematosus A diagnosis of cancer or evidence of continued disease within five years before screening",I,Both
0,Patients with Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder,"Inclusion Criteria: ALS participants: Aged 18 years old or greater. Diagnosis of ALS by El Escorial Criteria revised (possible, probable, probable with lab support and definite). Onset of weakness or speech impairment no more than 24 months before randomization. ALSFRS-R equal or superior to 24/48 at screening, with no more than one subscore under 2/4. ALSFRS-R slope of decline of at least 0.5 points per month on the ALSFRS- R, calculated as (48-score at screening)/ (months since onset of weakness). SVC greater than or equal to 60% predicted for sex, age and height at screening. Note on FTD Symptoms: The presence of FTD symptoms is not a requirement for inclusion in this study. Participants with a diagnosis of ALS, whether or not accompanied by FTD symptoms, are eligible for inclusion. No prior or screening diagnosis of FTDSD is required. Subject has an informant/caregiver who has frequent and sufficient contact to provide accurate information about the patient's cognitive abilities and behaviors to complete the ALS-CBS. Participants apt to comprehend and sign the ICF. Participants of child-bearing potential must have a negative urine pregnancy test at screening and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include: Abstinence or agrees to use contraception if planning to become sexually active. Hormonal contraceptives including oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormone implant Double-barrier method Intrauterine devices Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s) Vasectomy of partner at least 6 months prior to screening Willing to maintain eating habits throughout the study. Willing to refrain from consuming probiotic supplements and food containing added probiotics and/or prebiotics (e.g., yogurts with live, active cultures or supplements) from the moment of screening until the end of the study. Healthy controls: Aged 18 years old or greater. Able to comprehend and willing to sign ICF. Participants of child-bearing potential must have a negative urine pregnancy test at screening and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include: Abstinence or agrees to use contraception if planning to become sexually active. Hormonal contraceptives including oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormone implant Double-barrier method Intrauterine devices Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s) Vasectomy of partner at least 6 months prior to screening Willing to maintain eating habits throughout the study. Willing to refrain from consuming probiotic supplements and food containing added probiotics and/or prebiotics (e.g., yogurts with live, active cultures or supplements) from the moment of screening until the end of the study Informants/caregivers: Aged 18 years old or greater. Has frequent and sufficient contact to provide accurate information about the patient's cognitive abilities and behaviors to complete the ALS-CBS. Able to comprehend and willing to sign ICF.",2024-11453 NCT06051123 PROBIO_HA114 TrialTroveID-486787,Adults; Older Adults,year(s),,486787,Comorbidity in ALS; Frontotemporal Dementia; Healthy subjects,,18.0,"Exclusion Criteria: ALS Participants: Use of respiratory support (non-invasive ventilation or mechanical respiratory support) at screening. Significant medical condition or behavioral issues that could interfere with participation in the clinical trial in the principal investigator's opinion. Use of a feeding tube at randomization. Use of lipid-lowering drugs for less than 3 months before randomization. Introduction of lipid-lowering drug unless it is due to the event of acute coronary syndrome or stroke as per Canadian guidelines. Use of edaravone with stable dosage for less than 2 months before randomization. Use of riluzole, or ALBRIOZA™ with stable dosage for less than 1 month before randomization. Introduction of edaravone, riluzole or ALBRIOZA™ during the clinical trial. Immunodeficiency (immune-compromised and immune-suppressed participants, e.g., AIDS, lymphoma, participants undergoing long-term corticosteroid treatment, chemotherapy and allograft participants). Pregnancy (as per serum HCG pregnancy test at screening), planning to be pregnant or currently breastfeeding. Use of probiotics other than the study medication in the month prior to randomization. Note: participants could be eligible to participate after a 4-week washout period. Use of any antibiotic drug in the month prior to randomization. Note: participants could be eligible to participate after a 4-week washout period. Milk and soy allergy, or severe lactose intolerance. Currently enrolled in another clinical trial. Healthy Participants: Use of lipid-lowering drugs for less than 3 months before randomization. Introduction of lipid-lowering drug unless it is due to the event of acute coronary syndrome or stroke as per Canadian guidelines. Pregnancy (as per serum HCG pregnancy test at screening), planning to be pregnant or currently breastfeeding. Note: participants will not take the IP or placebo, but pregnancy is a major factor that could affect lipidomic profiling. Use of probiotics in the month prior to day 0 of the study (visit 2). Note: participants could be eligible to participate after a 4-week washout period. Although participants will not consume any study product, we aim to maintain environmental factors comparable to the ALS-FTDSD group. Use of any antibiotic drug in the month prior to day 0 of the study (visit 2). Note: participants could be eligible to participate after a 4-week washout period. Although participants will not consume any study product, we aim to maintain environmental factors comparable to the ALS-FTDSD group. Milk and soy allergy, or severe lactose intolerance. Note: Although participants will not consume any study product, we aim to maintain environmental factors comparable to the ALS-FTDSD group. We aim to exclude allergies, so participants are maintained on standard diet. Currently enrolled in another clinical trial.",Ii,Both
1,Patients with Amyotrophic Lateral Sclerosis (ALS).,"Diagnosis of sporadic ALS, definite or probable disease,-revised El Escorial criteria Patient must be able to understand the purpose and procedures of the study, sign informed consent and comply with requirements of the protocol. Age 18 and older. Normal serum Magnesium (1.7 - 2.3 mg/dL) and Manganese (4.7 - 18.3 ng/mL) levels or adequate supplement to obtain normal serum Mg (if Manganese levels are low (<1.7 mg/dL), Hair Manganese will be evaluated before starting probiotic, and inclusion to the protocol will be at the principal investigators discretion).",AIHG-2017.004-ALS NCT03324399 TrialTroveID-311856,Adults; Older Adults,year(s),,311856,Delay Disease Progression,,18.0,"Need for consumption of frequent antibiotics, gut pH increasing medications, and/or alkaline water. Patient unable to maintain regular follow up or submit to informed consent Stool pH >7.5 - The ideal stool pH for growth and function of the investigational probiotic is 6-6.5. Patients who are judged to be ineligible for study entry by investigator or sub-investigator.",Iv,Both
0,,- 1. Age: 50 and older - 2. Primary Progressive Aphasia diagnosis - 3. Native English speaker,2097152 NCT06066710,Adults; Older Adults,year(s),,487672,,,50.0,"- 1. Unable to provide consent - 2. Taking alpha 2 agonists (clonidine and guanfacine) - 3. Other major psychological or neurological diagnosis - 4. Major head trauma that contributed to their condition - 5. Allergic reaction to adhesives - 6. Uncorrected vision/hearing impairments - 7. Diabetes - 8. Reactive airway disease - 9. Untreated hypothyroidism - 10. Bradyarrhythmia - 11. Unexplained syncope - 12. Pregnancy (assessed verbally on the days of MR imaging) - 13. Drugs that interact with propranolol, such as alpha 2 agonists - 14. Claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign bodies in eye, pacemaker or other contraindication to MR scanning. Subjects with any implanted device that cannot be verified as MRI compliant will be excluded.",I,Both
0,Patients with motor neurone disease (ALS).,,TrialTroveID-079599,,,,79599,Unspecified,,,,Ii,
0,Healthy adult subjects.,,TrialTroveID-079588,Adults,,,79588,Healthy subjects,,,,I,
0,"Patients with mild to moderate FALS and SOD1 mutations, diagnosed as probable, laboratory supported probable or definite according to the World Federation of Neurology El Escorial criteria","Ages Eligible for Study: 18 Years and older, Genders Eligible for Study: Both Inclusion Criteria: Subjects with definite, probable, or laboratory supported probable ALS will be eligible. ALS diagnosed as probable, laboratory supported probable or definite according to the World Federation of Neurology El Escorial criteria Age 18 or older. Capable of providing informed consent and complying with trial procedures. SOD1 mutation confirmation by study team. Not taking Riluzole (Rilutek) or on a stable dose for 30 days. Not taking Coenzyme QR10R or on a stable dose and brand for 30 days. Absence of exclusion criteria. No evidence of any of the following conditions: malabsorption syndromes, alcoholism, dementia, seizure disorder, folate deficiency, megaloblastic anemia, and impaired kidney function or liver function.",0903010259 EudraCT Number: 2011-004798-99 NCT01083667 TrialTroveID-123945,Adults; Older Adults,year(s),,123945,Unspecified,,18.0,"Exclusion Criteria: History or evidence of malabsorption syndromes Exposure to any experimental agent within 30 days of onset of this protocol Women who are pregnant or planning to become pregnant Women of childbearing potential not practicing contraception Women who are breastfeeding Enrollment in another research study within 30 days of or during this trial Alcoholism Patients taking phenytoin (Dilantin) or other therapy affecting folate levels Dementia (MMSE <22) Seizure disorder Folate deficiency Megaloblastic anemia Cardiovascular disorder/arrhythmia Impaired kidney function, defined as creatinine levels of 2.5 x ULN Impaired liver function, defined as AST or ALT of 3 X ULN Advanced ALS patients, defined as those with any of the following: forced vital capacity <60% (use of BIPAP is allowed); tracheostomy; or mechanical ventilation Use of any of the following medications: cytosine, arabinoside, methotrexate, daunorubicin, sulfonamides, zidovudine, lorazepam, coumadin, sulfamethoxazole, and trimethoprim Patients taking Lithium within 30 days of or during this trial Any previous medical history that, in the opinion of PI, could interfere with the patient being able to complete the study Incapable of providing informed consent and complying with trial procedures",Iii,Both
0,"Patients had El Escorial definite ALS associated with an SOD1 mutation (FALS). Two patients with weakness and an SOD1 mutation. Four different SOD1 mutations were identified in seven patients: D90A (2: 1 man; 1 woman), A4V (2: 1 man; 1 woman), L144F (2 men), N65S (1 woman).",,TrialTroveID-087390,,,,87390,Delay Disease Progression,,,,Ii,Both
0,Patients with SOD1-mediated Amyotrophic Lateral Sclerosis.,,740 TrialTroveID-080417,,,,80417,Unspecified,,,,Ii,
0,Adults living with ALS.,,QRL-101-02 TrialTroveID-501748,Adults,,,501748,Unspecified,,,,I,
0,Healthy Volunteers,"Age 18 to 70 years of age inclusive at the time of signing the informed consent. Clinical chemistry laboratory values within acceptable range for the population, as per investigator judgment. Body mass index of 18 to 32 kg/m2 (inclusive). Willing and able to practice effective contraception.",EudraCT Number: 2022-002484-30 NCT05667779 QRL-101-01 TrialTroveID-394416,Adults; Older Adults,year(s),year(s),394416,Healthy subjects,70.0,18.0,"Currently enrolled in any other clinical trial involving a study drug or off-label use of a drug or device, or any other type of medical research judged not to be scientifically or medically compatible with this study. Any participant in >4 studies a year and/or has participated in a clinical trial within 1 month of expected dosing date. History or presence of medical illness including, but not limited to, any cardiovascular, hepatic, respiratory, hematological, endocrine, psychiatric, or neurological disease, convulsions, or any clinically significant laboratory abnormality that, in the judgment of the investigator, indicate a medical problem that would preclude study participation. *Other inclusion and exclusion criteria may apply*",I,Both
0,Patients with Amyotrophic Lateral Sclerosis,"Male or female participants aged 18 to 80 years diagnosed with ALS ALS symptom onset within 24 months of Screening Slow vital capacity >50% Clinical evidence of lower motor neuron involvement Not pregnant and not nursing Willing and able to practice effective contraception Able to tolerate lumbar puncture If on approved therapies for the treatment of ALS during the course of the study, must be on a stable dose (at the Sponsor's discretion)",ANQUR NCT05633459 QRL-201-01 TrialTroveID-414440,Adults; Older Adults,year(s),year(s),414440,Unspecified,80.0,18.0,"Pathogenic variant, likely pathogenic variant, or variant of uncertain significance in the superoxide dismutase 1 (SOD1) and/or fused in sarcoma (FUS) genes Currently enrolled in any other clinical study involving either an investigational product (IP) or off-label use of a drug or device Prior exposure to stem cell or gene therapy products Any contraindication to intrathecal drug administration Abnormal laboratory values deemed clinically significant by the Investigator Significant infection, or known inflammatory process",I,Both
0,Subjects with Amyotrophic Lateral Sclerosis.,"Ages Eligible for Study:30 Years to 80 Years Inclusion Criteria Definite ALS no prior exposure to R(+)PPX. Have an established diagnosis of ALS. Have a forced vital capacity (respiratory measurement) of more than 60 percent of normal without being ventilated. Be able to swallow. Be able to walk, with or without assistive devices.",13023 NCT00600873 TrialTroveID-082481,Adults; Older Adults,year(s),year(s),82481,Delay Disease Progression,80.0,30.0,"Exclusion Criteria ALSFRS at baseline <40 FVC at baseline <70%. Have had ALS for more than three years. Have advanced ALS with a predicted survival time of less than six months. Have active cardiovascular disease. Have dementia (disorientation, poor thinking ability) Have a history of psychosis or hallucinations. Have had prior exposure to R(+) pramipexole. Have orthostatic hypotension (a significant drop in blood pressure when assuming a standing position). Have abnormal baseline lab values that would jeopardize safety.",Iii,Both
0,Patients with ALS,Ages Eligible for Study: 30 Years to 80 Years Genders Eligible for Study: Both Inclusion Criteria Definite diagnosis of ALS.,12316 NCT00596115 TrialTroveID-082468,Adults; Older Adults,year(s),year(s),82468,Delay Disease Progression,80.0,30.0,Exclusion Criteria No prior participation in R(+)PPX clinical studies.,Iii,Both
0,,Ages Eligible for Study 21 Years to 85 Years; Inclusion Criteria Established diagnosis of ALS FVC>60% of predicted not being ventilated no difficulty swallowing ambulatory (can use assistance devices),11736 Futility Study NCT00140218 TrialTroveID-078793,Adults; Older Adults,year(s),year(s),78793,Delay Disease Progression,85.0,21.0,Exclusion Criteria ALS duration >3 years advanced ALS with survival predicted <6 months dementia (MMSE<22) prior exposure to R(+) pramipexole orthostatic hypotension >30 mmHg history of psychosis or hallucinations abnormal baseline safety lab values.,Iii,Both
0,Patients with Amyotrophic Lateral Sclerosis (ALS).,,TrialTroveID-121605,,,,121605,Symptom relief,,,,Ii,
0,Amyotrophic Lateral Sclerosis patients with SOD1 gene mutation,"- Patients who are judged by professional medical staff to still be able to carry out the clinical trial project cycle; - 18 years old < or = age < or = 75 years old, males or females; - ALS patients with confirmed SOD1 gene mutations document (known SOD1 mutation sites and related disease progression have been reported); - Forced vital capacity > or = 80% of predicted vital capacity during the screening period; - Diagnosis of confirmed or probable familial or sporadic ALS in accordance with the revised EI Escorial diagnostic criteria for amyotrophic lateral sclerosis of the World Federation of Neurology; - The patient or patient's legal representative clearly understands and voluntarily participates in the study and signs the informed consent form; - Subjects (including male subjects) are willing to have no birth plan and voluntarily take effective contraceptive measures during the entire study period and within 3 months after the end of the study, and have no plan to donate sperm or eggs.",HX-A-2023004 NCT05903690 TrialTroveID-473953,Adults; Older Adults,year(s),year(s),473953,Delay Disease Progression; Symptom relief,75.0,18.0,"- Patients with SOD1 mutations occurring at nucleotides 44 to 66 (calculated from the start of SOD1 protein translation), patients with P.F21C mutation; - Patients who have previously received or are currently receiving Tofersen treatment; - HIV test positive or history of positive tests; - Positive hepatitis C virus antibody or history of positive tests; - Active hepatitis B infection (positive hepatitis B surface antigen and/or positive hepatitis B core antibody); - Have used other investigational drugs within 1 month or within 5 drug half-lives; - Diseases and deformities of the lumbar spine; - Have other conditions known to be associated with motor neuron dysfunction that may confuse or obscure an ALS diagnosis; - Other psychiatric disorders diagnosed according to DSM-V diagnostic criteria, or significant suicide intent; - With severe hepatic insufficiency, renal insufficiency or severe cardiac insufficiency (severe hepatic insufficiency refers to ALT value> or =2.0 times the upper limit of normal value or AST value > or = 2.0 times the upper limit of normal value; severe renal insufficiency refers to CRE > or = 1.5 times the upper limit of normal value or eGFR<40mL/min/1.73m2; severe cardiac insufficiency refers to NYHA class 3-4); - Permanently dependent on ventilator-assisted ventilation; - History of alcohol and drug abuse; - Patients who are pregnant, breast-feeding, or who are likely to become pregnant and plan to become pregnant; - Patients participating in other clinical trials or using other biological agents, drugs or devices under investigation; - Patients who have received any vaccinations within 28 days; - Contraindications to MRI (eg, claustrophobia); - Unable to be cooperative and complete the follow-up due to other reasons.",I,Both
0,Healthy postmenopausal women.,Ages Eligible for Study: 45 Years to 75 Years Inclusion Criteria: Postmenopausal. Body mass index (BMI) of = or > 18.5 to < 32.,A031-02 NCT00952887 TrialTroveID-113404,Adults; Older Adults,year(s),year(s),113404,Cachexia; Healthy subjects,75.0,45.0,"Exclusion Criteria: History of malignancy, except excised or treated basal cell carcinoma, cervical carcinoma in-situ, or = 2 squamous cell carcinomas History of clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease. History of opportunistic infection (e.g. invasive candidiasis or pneumocystis pneumonia) within 6 months prior to screening or serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., septicemia) within 3 months prior to screening. Surgery within 3 months prior to Day 1 (other than minor cosmetic or dental procedures). Fever or symptomatic viral or bacterial infection within 7 days prior to Day 1. Donation or significant loss of blood within 2 months prior to Day 1. Hormone replacement therapy within 3 months prior to Day 1. Treatment with erythropoiesis stimulating agents (Epogen, Procrit, Aranesp, etc) within 2 months prior to Day 1. Systemic glucocorticoid therapy within 6 months prior to Day 1. Treatment with another investigational drug or approved therapy for investigational use within 1 month prior to Day 1. Previous treatment with ACE-031.",I,Female
0,Healthy postmenopausal women.,"Ages Eligible for Study: 45 Years to 75 Years Inclusion Criteria: Subject is a postmenopausal woman, 45-75 years old (inclusive). Subject has a body mass index (BMI) of > 18.5 to < 30. Subject must give written informed consent.",A031-01 NCT00755638 TrialTroveID-099252,Adults; Older Adults,year(s),year(s),99252,Cachexia; Duchenne; Healthy subjects,75.0,45.0,"Exclusion Criteria: Subject has a history of malignancy. However, a subject with a history of excised or treated basal cell carcinoma, cervical carcinoma in-situ, or less than or equal to 2 squamous cell carcinomas is eligible to participate in this study. Subject has a history of clinically significant (as determined by the Investigator) cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease. Subjects with chronic stable diseases including migraines, hypertension, hyperthyroid disorder, hypothyroid disorder, gastroesophageal reflux disease, or mild depression/anxiety will be excluded unless the investigator does not have safety or compliance concerns at study entry. Subject has a history of opportunistic infection (e.g. invasive candidiasis or pneumocystis pneumonia). Subject has had a serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., septicemia) within the 3 months prior to screening. Subject has a history of severe allergic or anaphylactic reactions. Subject had surgery within the previous 3 months (other than minor cosmetic surgery or minor dental procedures). Subject had a fever (body temperature > 38°C) or symptomatic viral or bacterial infection within 2 weeks prior to dosing. Subject has a positive Tuberculin skin test (Mantoux) Subject has a history of hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV), or human immunodeficiency virus (HIV). Subject has a recent or clinically significant history of drug or alcohol abuse, or tests positive in a urine screen for alcohol or drugs of abuse. Subject consumed any alcohol within 48 hours prior to dosing. Subject has donated or lost = 499 mL of whole blood within 56 days prior to study drug administration. Subject has taken any hormone replacement therapy within 3 months prior to study enrollment, or plans to begin hormone replacement therapy at any time during the study.",I,Female
0,"Patients with Amyotrophic Lateral Sclerosis (ALS) 10 patients enrolled at the time of this report were mostly male (81%), and middle aged (median 53 years)","Patients with clinically definite, probable, laboratory supported probable, or possible ALS per revised El Escorial criteria Cramp frequency greater than 4 cramps per week during 2 week run in ALS functional rating scale-revised (ALSFRS-R) score of greater than 24 Able to lie on back for study procedures",NCT03472950 STUDY00141491 TrialTroveID-320844,Adults; Older Adults,year(s),,320844,Delay Disease Progression; Symptom relief,,18.0,"Tracheostomy invasive ventilation, or use of non-invasive ventilation greater than 12 hours per day Pregnant or lactating Participation in a prior experimental drug trial less than 30 days prior to screening Patients taking ranolazine Patients taking medications which are contraindicated for use with ranolazine such as strong CYP3 inhibitors (ketoconazole, clarithromycin, nelfinavir), and CYP3 inducers (rifampin, phenobarbital) Patients with clinically significant medical comorbidities (hepatic, renal, cardiac, etc) Patients with baseline QT interval prolongation on Electrocardiography (ECG) Patients pre-disposed to secondary QT prolongation for other health conditions like family history of congenital long QT syndrome, heart failure, bradycardia, or cardiomyopathies",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis,"1. Male or female patients > or = 18 years of age. 2. Patients with sporadic or familial amyotrophic lateral sclerosis (ALS) diagnosed as laboratory-supported possible, probable, or definite according to World Federation of Neurology El Escorial Criteria. 3. Pulmonary slow vital capacity (SVC) < 50% of predicted normal. 4. Must have a source of autologous T cells potentially sufficient to manufacture RAPA-501 cells, as defined by a peripheral CD3+ T cell count ≥ 500 cells per μl. 5. Patients who are taking riluzole (Rilutek), edaravone (Radicava), and/or sodium phenylbutyrate/taurursodial (Relyvrio) are eligible if taking the drug for at least 30 days prior to the screening visit. 6. Patients must be ≥ two (2) weeks removed from major surgery, or investigational therapy. 7. Patients must have no ongoing, unstable serious illness other than ALS, as determined by the Site Investigator. 8. Serum creatinine less than or equal to 2.0 mg/dL. 9. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x upper limit of normal (ULN). 10. Bilirubin ≤ 1.5 (except if due to Gilbert's disease). 11. No history of abnormal bleeding tendency. 12. Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.",NCT06169176 RAPA-501-ALS Expanded Access TrialTroveID-495926,Adults; Older Adults,year(s),,495926,Unspecified,,18.0,"1. Active uncontrolled infection. 2. Hypertension not adequately controlled by ≤ 3 medications. 3. History of documented pulmonary embolus within 6 months of enrollment. 4. Clinically significant cardiac pathology, as defined by: myocardial infarction within 6 months prior to enrollment, Class III or IV heart failure according to NYHA, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. 5. HIV, hepatitis B, or hepatitis C seropositive. 6. Pregnant or breastfeeding subjects. 7. Subjects of childbearing age, or males who have a partner of childbearing potential, who are unwilling to practice contraception. 8. Subjects may be excluded at the Principal Investigator discretion or if it is deemed that allowing participation would represent an unacceptable medical or psychiatric risk.",Ii,Both
1,Subjects with Amyotrophic lateral sclerosis (ALS).,"Male or female patients ≥ 18 years of age. Patients with sporadic or familial amyotrophic lateral sclerosis (ALS) diagnosed as laboratory-supported possible, probable, or definite according to World Federation of Neurology El Escorial Criteria. . Less than or equal to 24 months since ALS symptom onset. Total ALSFRS-R score between 34 and 45. Must have a source of autologous T cells potentially sufficient to manufacture RAPA-501 cells, as defined by a peripheral CD3+ T cell count ≥ 500 cells per μl. Patients may continue riluzole (Rilutek®), and/or edaravone (Radicava®), and/or sodium phenylbutyrate/taurusodial (Relyvrio™) if on a stable dose for at least 30 days prior to the screening visit. Patients must be ≥ 2 two weeks removed from major surgery or investigational therapy. Patients must have recovered from clinical toxicities ([resolution of CTCAE(v5) [version 5] toxicity to a value of ≤ 2].). Serum creatinine ≤ less than or equal to 2.0 mg/dL. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x upper limit of normal (ULN). Bilirubin ≤ 1.5 (except if due to Gilbert's disease). Pulmonary slow vital capacity (SVC) ≥ 70% of predicted normal. No history of abnormal bleeding tendency. Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient participant at any time without prejudice to future medical care.",NCT04220190 RAPA-501-ALS TrialTroveID-364979,Adults; Older Adults,year(s),,364979,Delay Disease Progression,,18.0,"Active uncontrolled infection. Hypertension not adequately controlled by ≤ 3 medications. History of documented pulmonary embolus within 6 months of enrollment. Clinically significant cardiac pathology, as defined by: myocardial infarction within 6 months prior to enrollment, Class III or IV heart failure according to NYHA, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Patients with history of coronary artery bypass grafting or angioplasty will receive a cardiology evaluation and be considered on a case-by-case basis. HIV, hepatitis B, or hepatitis C seropositive. Pregnancy or breastfeeding patients. Patients of Subjects of childbearing age, or males who have a partner of childbearing potential, who are unwilling to practice contraception. Patients Subjects may be excluded at the Principal Investigator discretion of the PI or if it is deemed that allowing participation would represent an unacceptable medical or psychiatric risk.",Ii/Iii,Both
0,Patients with Amyotrophic Lateral Sclerosis.,"Possible, probable (clinically or laboratory) or definite ALS according to the revised version of the El Escorial World Federation of Neurology criteria Disease duration more than 6 months and less than 3 years (inclusive). Disease onset defined as date of first muscle weakness, excluding fasciculations and cramps Vital capacity more than 50% of normal (slow vital capacity; best of three measurements) Age: > or = 18 years Continuously treated with 100 mg riluzole for at least four weeks Capable of thoroughly understanding all information given and giving full informed consent according to GCP Women of childbearing age must be non-lactating and surgically sterile or using a highly effective method of birth control and have a negative pregnancy test. Acceptable methods of birth control with a low failure rate i.e. less than 1% per year) when used consistently and correct are such as implants, injectables, combined oral contraceptives, hormonal intrauterine devices (IUDs), or double-barrier methods (condom or diaphragm with spermicidal agent or IUD), sexual abstinence or vasectomized partner",Eudract Number: 2011-004482-32 NCT01879241 RAS-ALS TrialTroveID-188612,Adults; Older Adults,year(s),,188612,Delay Disease Progression,,18.0,"Previous participation in another clinical study within the preceding 12 weeks Tracheostomy or assisted ventilation of any type during the preceding three months Gastrostomy Any medical condition known to have an association with motor neuron dysfunction which might confound or obscure the diagnosis of ALS Presence of any concomitant life-threatening disease or impairment likely to interfere with functional assessment Patients on sympathomimetic agents. This includes pseudoephedrine, phenylephrine, phenylpropanolamine, and ephedrine. Patients on analgesics with serotoninergic properties such as meperidine, tramadol, methadone and propoxyphene. Patients on serotonin reuptake inhibitors (SSRIs). This includes fluoxetine or fluvoxamine. Patients on dextromethorphan, St. John's wort, cyclobenzaprine or other MAO inhibitors (selective or non-selective) Patients taking Antidepressants Confirmed hepatic insufficiency or abnormal liver function (ASAT and/or ALAT greater than 3 times the upper limit of the normal range) Renal insufficiency (serum creatinine more than 2.26 mg/dL) Evidence of major psychiatric disorder or clinically evident dementia precluding evaluation of symptoms Known hypersensitivity to any component of the study drug Liable to be not cooperative or comply with the trial requirements (as assessed by the investigator), or unable to be reached in the case of emergency Female with childbearing potential, if no adequate contraceptive measures are used Pregnancy or breast-feeding females",Ii,Both
0,Subjects with Amyotrophic Lateral Sclerosis (ALS),"Ages Eligible for Study: 21 Years to 80 Years; Genders Eligible for Study: Both Inclusion Criteria: A clinical diagnosis of laboratory-supported probable, probable, or definite ALS, according to a modified El Escorial criteria, by the study investigator. 21 to 80 years of age inclusive. VC greater or equal to 75% of predicted at screening and baseline. Onset of weakness within 2 years prior to enrollment. If patients are taking riluzole for ALS, they must be on a stable dose for at least thirty days prior to the baseline visit. Women of childbearing age must be non-lactating and surgically sterile or using an effective method of birth control and have a negative pregnancy test. Willing and able to give signed informed consent that has been approved by the Institutional Review Board (IRB). Patients with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease who have had symptoms for less than 24 months?",12312 NCT01786603 TrialTroveID-181697,Adults; Older Adults,year(s),year(s),181697,Delay Disease Progression,80.0,21.0,"Exclusion criteria: Requirement for tracheotomy ventilation or non-invasive ventilation for > 23 hours per day. Patients on sympathomimetic agents. This includes pseudoephedrine, phenylephrine, phenylpropanolamine, and ephedrine. Patients on analgesics with serotoninergic properties such as meperidine, tramadol, methadone and propoxyphene, flexeril. Patients on fluoxetine or fluvoxamine. Patients taking amitriptyline > 50 mg/d, trazodone and sertraline > 100 mg/d, citalopram > 20 mg/d or paroxetine > 30 mg/d. Diagnosis of other neurodegenerative diseases (Parkinson disease, Alzheimer disease, etc). Clinically significant history of unstable medical illness (unstable angina, advanced cancer, etc) over the last 30 days. Has a diaphragm pacing device or plan on obtaining a diaphragm pacing device during the course of the study. History of renal disease. History of liver disease. Current pregnancy or lactation. Limited mental capacity such that the patient cannot provide written informed consent or comply with evaluation procedures. History of recent alcohol or drug abuse or noncompliance with treatment or other experimental protocols. Vital Capacity (VC) < 75% of predicted. Receipt of any investigational drug within the past 30 days. Women with the potential to become pregnant who are not practicing effective birth control. Poorly controlled hypertensive subjects or resting systolic blood pressure (SBP) > 160 mmHg and/or diastolic (DBP) > 95 mmHg Use of BiPAP at screening.",Ii,Both
0,"Patients with Amyotrophic Lateral Sclerosis (ALS). There were 18 men and 17 women, with a mean age at entry of 61 years (59-82), and mean disease duration was 1.5 years (0.5-3).","Ages Eligible for Study: 21 Years to 80 Years; Genders Eligible for Study: Both Inclusion Criteria: A clinical diagnosis of laboratory-supported probable, probable, or definite ALS, according to a modified El Escorial criteria, by the study investigator (Appendix IV). 21 to 80 years of age inclusive. VC greater or equal to 75% of predicted at screening and baseline. Onset of weakness within 3 years prior to enrollment. If patients are taking riluzole for ALS, they must be on a stable dose for at least thirty days prior to the baseline visit. Women of childbearing age must be non-lactating and surgically sterile or using an effective method of birth control and have a negative pregnancy test. Willing and able to give signed informed consent that has been approved by the Institutional Review Board (IRB). Patients diagnosed with Amyotrophic Lateral Sclerosis who are currently being treated with or without Riluzole, with no history of liver disease, heart disease or diabetes.",11922 NCT01232738 TrialTroveID-137311,Adults; Older Adults,year(s),year(s),137311,Delay Disease Progression,80.0,21.0,"Exclusion criteria Requirement for tracheotomy ventilation or non-invasive ventilation for > 23 hours per day. Patients on sympathomimetic agents. This includes pseudoephedrine, phenylephrine, phenylpropanolamine, and ephedrine. Patients on analgesics with serotoninergic properties such as meperidine, tramadol, methadone and propoxyphen, flexeril. Patients on fluoxetine or fluvoxamine. Patients taking amitriptyline > 50 mg/d, trazodone and sertraline > 100 mg/d, citalogram > 20 mg/d or paroxetine > 30 mg/d. Diagnosis of other neurodegenerative diseases (Parkinson disease, Alzheimer disease, etc). Clinically significant history of unstable medical illness (unstable angina, advanced cancer, etc) over the last 30 days. History of renal disease. History of liver disease. Current pregnancy or lactation. Limited mental capacity such that the patient cannot provide written informed consent or comply with evaluation procedures. History of recent alcohol or drug abuse or noncompliance with treatment or other experimental protocols. VC < 75% of predicted. Receipt of any investigational drug within the past 30 days. Women with the potential to become pregnant who are not practicing effective birth control.",Ii,Both
1,Adults with Amyotrophic Lateral Sclerosis (ALS),"A diagnosis of sporadic or familial ALS, defined by the El Escorial criteria (possible, laboratory-supported probable, probable, or definite ALS). ALS onset < or = 36 months from Screening. Documented meningococcal vaccination not more than 3 years prior to, or at the time of, initiating study treatment. Upright slow vital capacity > or = 65% predicted at Screening. If on riluzole, participant must be on a stable dose for 30 days; if on edaravone, participant must be on a stable dose for 60 days (2 cycles). Body weight > or = 40 kilograms at Screening. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Not dependent on respiratory support",145660 ALXN1210-ALS-308 CHAMPION-ALS EudraCT Number: 2019-004619-30 JapicCTI-205395 jRCT2080225299 MOH_2020-11-09_009024 NCT04248465 NL72466.056.20 SNCTP000004075 TrialTroveID-365466,Adults; Older Adults,year(s),,365466,Delay Disease Progression,,18.0,"1. History of N. meningitidis infection. 2. Human immunodeficiency virus (HIV) infection (evidenced by HIV-1 or HIV-2 antibody titer). 3. History of unexplained infections. 4. Active systemic bacterial, viral, or fungal infection within 14 days prior to study drug administration on Day 1. 5. Presence of fever > or = 38°C (100.4°F) within 7 days prior to study drug administration on Day 1. 6. Hypersensitivity to murine proteins or to 1 of the excipients of ravulizumab. 7. Dependence on invasive or non-invasive mechanical ventilation. Dependence on mechanical ventilation is defined as being unable to lie flat (supine) without it, unable to sleep without it, or daytime use > 6 hours per day for > 3 days per week. Non-invasive ventilation for sleep apnea is allowed subject to discussion with Medical Monitor. 8. Any medical condition that, in the opinion of the Investigator, might interfere with the patient’s participation in the trial, poses any added risk for the patient, or confounds the assessment of the patient. 9. The presence of unstable psychiatric disease or dementia that might interfere with the patient’s participation in the trial, poses any added risk for the patient, or confounds the assessment of the patient. 10. History of drug and/or alcohol abuse (according to Diagnostic and Statistical Manual of Mental Disorders) within 1 year of screening that would limit patient participation in the study as determined by the Investigator. 11. History of Parkinson’s disease, myasthenia gravis, multiple sclerosis, or any other neurological disorder that may confound the diagnosis or assessment of the patient as determined by the Investigator. 12. Previously or currently treated with a complement inhibitor. 13. Use of IV immunoglobulin (IVIg) within 3 weeks prior to screening. 14. Has a diaphragm pacing system (DPS) at study entry or anticipate DPS placement during the course of the study. 15. Participation in any other investigational product study or exposure to an investigational drug or device within 30 days of screening or 5 half-lives of the study drug, whichever is greater or any prior exposure to gene therapy. 16. Pregnant, breastfeeding, or intending to conceive during the course of the study.",Iii,Both
0,Amyotrophic lateral sclerosis patients.,,TrialTroveID-330489,,,,330489,Unspecified,,,,Ii,
0,,,TrialTroveID-215210,,,,215210,(N/A); Unspecified,,,,I,
0,Healthy volunteers.,Ages Eligible for Study: 18 Years to 55 Years; Genders Eligible for Study: Male Inclusion Criteria: Willing to use effective method of contraception Non smoker or ex-smoker within the previous 6 months,EudraCT Number: 2013-003335-29 NCT02016742 RDC5-1-01 TrialTroveID-199562,Adults,year(s),year(s),199562,(N/A); Healthy subjects,55.0,18.0,Exclusion Criteria: History or presence of any clinically significant findings upon screening Participation in a New Chemical Entity clinical study within the previous 124 days or a marketed drug clinical study within the previous 93 days Positive result for human immunodeficiency virus (HIV) and/or hepatitis B or C test Positive result for urine alcohol and drug screen Blood donation = 450 mL in the previous 12 weeks Receipt of prescription medicines and/or St John's Wort in the previous 2 weeks,I,Male
1,Subjects with Amyotrophic Lateral Sclerosis Completed dosing in CY 5031 study,"- Able to comprehend and willing to sign an ICF and willing to comply with all study procedures and restrictions for the duration specified in the Schedule of Activities. If non-written consent is given, a Legal Designee of the patient must sign the ICF form. - Completed dosing in CY 5031",COURAGE OLE COURAGE-ALS OLE CY 5032 CY5032 EudraCT Number: 2021-004727-33 NCT05442775 TrialTroveID-436214,Adults; Older Adults,year(s),,436214,Delay Disease Progression,,18.0,"- Has taken investigational study drug (other than reldesemtiv) prior to dosing, within 30 days or five half-lives of the prior agent, whichever is greater - Presence on Day 1 of any medically significant cardiac, pulmonary, gastrointestinal, musculoskeletal, or psychiatric illness that might interfere with the patient's ability to comply with study procedures or that might confound the interpretation of clinical safety or efficacy data. - Use of a strong cytochrome P450 (CYP) 3A4 inhibitor within 7 days prior to first dose of reldesemtiv in CY 5032 or a strong CYP3A4 inducer within 14 days prior to first dose of reldesemtiv in CY 5032 - Use of a medication that is an OCT1/OCT2 substrate within 7 days prior to first dose of reldesemtiv in CY 5032 - Currently participating in another trial, managed access program, open label extension, early access program, or through the right to try act is receiving an investigational drug or received an investigational drug or device within 30 days (or 5 half-lives for drugs, whichever is longer) prior to Day 1. Patients also cannot be taking outside of a clinical trial certain investigational drugs (which includes drugs, supplements, and nutraceuticals) that are currently being studied or have been studied for the treatment of ALS.",Iii,Both
1,Patients with Amyotrophic lateral sclerosis.,"Males or Females between the ages of 18 and 80 years of age, inclusive Diagnosis of familial or sporadic ALS (defined as meeting the laboratory-supported probable, probable, or definite criteria for ALS according to the World Federation of Neurology El Escorial criteria published in 2000 [Brooks 2000]). Patients who meet the possible criteria are eligible if they have lower motor neuron findings; those who have purely upper motor neuron findings are ineligible. First symptom of ALS < or = 24 months prior to screening. The qualifying first symptoms of ALS are limited to manifestations of weakness in extremity, bulbar, or respiratory muscles. Cramps, fasciculations, or fatigue should not be taken in isolation as a first symptom of ALS. ALSFRS-R total score < or = 44 at screening. Patients with a total score of 45 or higher may be rescreened 60 + or - 7 days following the original screening date and be deemed eligible if their ALSFRS-R total score is < or = 44 or if their score is 2 or more points less than at initial screening. Such patients must continue to meet all other inclusion/exclusion criteria at the time of rescreening. Upright FVC > or = 65.0% of predicted for age, height, sex and ethnicity at screening according to Global Lung Initiative equation Able to perform reproducible pulmonary function tests defined as being able to perform FVC at screening with variability of the 2 highest raw values of less than 10% with a maximum of 5 trials permitted. Screening FVC results must be reviewed and approved by the central review process prior to randomization. Must be either on riluzole for > or = 30 days prior to screening or have not taken it for at least 30 days prior to screening Must have completed at least 2 cycles of edaravone at the time of screening or have not received it for at least 30 days prior to screening Able to swallow whole tablets Clinical laboratory findings within the normal range, or if outside the normal range, not deemed clinically significant by the Investigator, except as specifically indicated as laboratory exclusion",CCR-20-145 COURAGE-ALS CY 5031 CY5031 EudraCT Number: 2020-004040-29 NCT04944784 NL77133.041.21 SNCTP000004651 TrialTroveID-369035,Adults; Older Adults,year(s),year(s),369035,Delay Disease Progression,80.0,18.0,"eGFRCysC < 45.0 mL/min/1.73 m2 at screening Urine protein/creatinine ratio > 1 mg/mg (113 mg/mmol) at screening Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > or = 3-times the upper limit of normal (ULN) Total bilirubin (TBL), direct or indirect bilirubin above the ULN. Cognitive impairment, related to ALS or otherwise that impairs the patient’s ability to understand and/or comply with study procedures and provide informed consent Other medically significant neurological conditions that could interfere with the assessment of ALS symptoms, signs or progression. Presence at screening of any medically significant cardiac, pulmonary, gastrointestinal, musculoskeletal, or psychiatric illness that might interfere with the patient’s ability to comply with study procedures or that might confound the interpretation of clinical safety or efficacy data Has a tracheostomy",Iii,Both
0,Patients with Amyotrophic lateral sclerosis.,"Diagnosis of familial or sporadic ALS < or = 24 months prior to screening Upright Slow Vital Capacity (SVC) > or = 60% of predicted for age, height and sex at screening Able to swallow tablets A caregiver (if one is needed) Able to perform reproducible pulmonary function tests Pre-study clinical laboratory findings within the normal range or, if outside the normal range, deemed not clinically significant by the Investigator Male patients who have not had a vasectomy and confirmed zero sperm count must agree after receiving the first dose of study drug until 10 weeks after the last dose to either use acceptable methods of contraception or abstain from sex use a condom during sexual intercourse with female partners who are of reproductive potential AND to have female partners use an additional highly effective means of contraception. Highly effective birth control methods include: – combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral intravaginal transdermal – progestogen-only hormonal contraception associated with inhibition of ovulation: oral injectable implantable – intrauterine device (IUD) – intrauterine hormone-releasing system (IUS) - bilateral tubal occlusion OR - practice true abstinence when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a trial, and withdrawal are not acceptable methods of contraception. Female patients must be post-menopausal or sterilized or must not be breastfeeding, have a negative pregnancy test, have no intention to become pregnant during the study and use acceptable methods of contraception or abstain from heterosexual intercourse from Screening until 10 weeks after last dose of study drug Patients must be either on riluzole for at least 30 days prior to screening or have not taken riluzole for at least 30 days prior to screening and not planning to start riluzole during the course of the study. Patients on edaravone must have completed at least 2 cycles of dosing with edaravone at the time of screening or have not taken edaravone for at least 30 days prior to screening and not planning to start edaravone during the course of the study. Two cycles of dosing are defined as having completed Cycle 1 infusion, which is 14 consecutive days of intravenous (IV) edaravone followed by 14 days off edaravone, and Cycle 2, which is 10 out of 14 days of IV edaravone 1. Able to comprehend and willing to sign an Informed Consent Form (ICF) 2. Males or females between the ages of 18 and 80 years of age, inclusive 3. Diagnosis of familial or sporadic ALS (defined as meeting the possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS according to the World Federation of Neurology El Escorial criteria published in 2000 (Brooks, Miller et al. 2000) < or = 24 months prior to screening 4. Upright SVC > or = 60% of predicted for age, height and sex at screening 5. Able to swallow tablets 6. A caregiver (if one is needed) 7. Able to perform reproducible pulmonary function tests 8. Pre-study clinical laboratory findings within the normal range or, if outside the normal range, deemed not clinically significant by the Investigator 9. Male patients, who have not had a vasectomy and a confirmed zero sperm count, must agree after receiving the first dose of study drug and until 10 weeks after the last dose to do either of the following: - use a condom during sexual intercourse with female partners who are of reproductive potential AND to have female partners use an additional effective means of contraception (e.g., diaphragm plus spermicide, or oral contraceptives) OR - abstain from heterosexual intercourse 10. Female patients must be post-menopausal (> or = 1 year) OR sterilized, OR if of childbearing potential (i.e., females who have had their first period unless they are anatomically and physiologically incapable to become pregnant), must: not be breastfeeding, have a negative pregnancy test, have no intention of becoming pregnant during the course of the study, AND do either of the following: - use contraceptive drugs or devices as detailed in item number 9 from Screening until 10 weeks after the last dose of study drug AND require male partners to use a condom during sexual intercourse OR - abstain from heterosexual intercourse from Screening until 10 weeks after the last dose of study drug 11. Patients must be either on riluzole for at least 30 days prior to screening or have not taken riluzole for at least 30 days prior to screening and not planning to start riluzole during the course of the study. 12. Patients on edaravone must have completed at least 2 cycles of dosing with edaravone at the time of screening or have not taken edaravone for at least 30 days prior to screening and not planning to start edaravone during the course of the study. Two cycles of dosing are defined as having completed Cycle 1 infusion, which is 14 consecutive days of intravenous (IV) edaravone followed by 14 days off edaravone, and Cycle 2, which is 10 out of 14 days of IV edaravone.",CY 5022 EudraCT Number: 2018-000586-37 FORTITUDE-ALS NCT03160898 NL65920.041.18 TrialTroveID-296218,Adults; Older Adults,year(s),year(s),296218,Delay Disease Progression,80.0,18.0,"At the time of screening, any use of non-invasive ventilation (NIV), e.g. continuous positive airway pressure [CPAP], noninvasive bi-level positive airway pressure [NPPV] or noninvasive volume ventilation [NVV]for any portion of the day, or mechanical ventilation via tracheostomy, or on any form of oxygen supplementation Neurological impairment due to a condition other than ALS Presence at screening of any medically significant cardiac, pulmonary, GI, musculoskeletal, or psychiatric illness that might interfere with the patient's ability to comply with study procedures or that might confound the interpretation of clinical safety or efficacy data Has taken any investigational study drug within 30 days or five half-lives of the prior agent, whichever is longer, prior to dosing Known to have received CK-2127107 or tirasemtiv in any previous clinical trial Has received or is considering receiving during the course of the study any form of stem cell therapy for the treatment of ALS Has received or is considering receiving during the course of the study any form of gene therapy for the treatment of ALS Has received or is considering obtaining during the course of the study a diaphragmatic pacing system History of substance abuse within the past 2 years 1. At the time of screening, any use of non-invasive ventilation, e.g. continuous positive airway pressure, noninvasive bi-level positive airway pressure or noninvasive volume ventilation, for any portion of the day, or mechanical ventilation via tracheostomy, or on any form of oxygen supplementation 2. Neurological impairment due to a condition other than ALS 3. Presence at screening of any medically significant cardiac, pulmonary, gastrointestinal, musculoskeletal, or psychiatric illness that might interfere with the patient’s ability to comply with study procedures or that might confound the interpretation of clinical safety or efficacy data, including, but not limited to: a. A pulse <40 or >100 bpm; mean systolic blood pressure >180 mm Hg; mean diastolic blood pressure >100 mm Hg (based on measurements taken after rest for 3 minutes) that persist on 3 successive measurements taken at least 2 minutes apart. b. Clinically significant ECG abnormalities that require medical attention (i.e., persistent atrioventricular conduction block >first degree, or acute myocardial ischemic changes) c. New York Heart Association Class II or greater congestive heart failure d. Chronic obstructive pulmonary disease or asthma requiring daily use of bronchodilator medications e. Gastrointestinal disorder that is likely to impair absorption of study drug from the gastrointestinal tract f. ALT or aspartate aminotransferase (AST) greater than or equal to 3-times the upper limit of normal (ULN) or has total bilirubin (TBL) greater than or equal to 2-times the ULN at screening. These assessments may be repeated at the Investigator’s discretion (within the screening window). g. Poorly controlled or brittle diabetes mellitus h. Amputation of a limb i. Cognitive impairment, related to ALS or otherwise, sufficient to impair the patient’s ability to understand and/or comply with study procedures and provide informed consent j. Cancer with metastatic potential (other than basal cell carcinoma, carcinoma in situ of the cervix, or squamous cell carcinoma of the skin excised with clean margins) diagnosed and treated within the last five years k. Any other condition, impairment or social circumstance that, in the opinion of the Investigator, would render the patient not suitable to participate in the study l. Patient judged to be actively suicidal or a suicide risk by the Investigator m. Patient has estimated glomerular filtration rate (eGFR) less than 40 mL/min/1.73 m2 calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) cystatin equation based on a cystatin C measurement at baseline 4. Has taken any investigational study drug within 30 days or five half-lives of the prior agent, whichever is longer, prior to dosing 5. Known to have received CK-2127107 or tirasemtiv in any previous clinical trial 6. Has received or is considering receiving during the course of the study any form of stem cell therapy for the treatment of ALS 7. Has received or is considering receiving during the course of the study any form of gene therapy for the treatment of ALS 8. Has received or is considering obtaining during the course of the study a diaphragmatic pacing system 9. History of substance abuse within the past 2 years 10. Use of a strong cytochrome P450 (CYP) 3A4 inhibitor within 7 days prior to first dose of study drug or a strong CYP3A4 inducer within 14 days prior to first dose of study drug 11. Use of a medication that is an OCT1/OCT2 substrate within 7 days.",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis.,"All ALS patients, over 18 years of age and with a clear diagnosis and symptomatology of ALS since at least 6 months.",EudraCT Number: 2020-005143-23 NCT04654689 TrialTroveID-390990 UCV/2020-2021/018,Adults; Older Adults,year(s),year(s),390990,Delay Disease Progression,75.0,18.0,"Exclusion Criteria: Women under 50 years of age and childbearing age. Tracheotomy patients. Patients with invasive or non-invasive ventilation with positive ventilatory pressure Patients with evidence of dementia. Patients with alcohol or drug abuse dependency. Patients infected with B or C hepatitis, or HIV positive Renal patients with creatinine levels twice as high as normal markers. Liver patients with liver markers (ALT, AST) elevated 3 times above normal levels. Patients included in other research with drugs or therapies in the experimental phase. Patients treated with anticoagulants or with haemostatic problems",Ii,Both
0,,,TrialTroveID-107545,,,,107545,Unspecified,,,,I,
0,Healthy Volunteers.,"Informed consent: signed written informed consent before inclusion in the study Sex and Age: men/women, 18-55 years old inclusive Tobacco: non-smokers for at least 6 months prior to study screening Body Mass Index (BMI): 18.5-29 kg/m2 inclusive Vital signs: systolic blood pressure (SBP) 100-139 mmHg, diastolic blood pressure (DBP) 50-89 mmHg, heart rate 50-90 bpm, measured after 5 min at rest in the sitting position Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the investigator and to comply with the requirements of the entire study Contraception and fertility (women only): women of child-bearing potential must be using at least one of the following reliable methods of contraception: A non-hormonal intrauterine device or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit A male sexual partner who agrees to use a male condom with spermicide A sterile sexual partner Female participants of non-child-bearing potential or in post-menopausal status for at least 1 year will be admitted. For all women, pregnancy test result must be negative at screening.",BASEC2020-01406 NCT04819438 SNCTP000004338 TrialTroveID-400359 Z7251J01,Adults,year(s),year(s),400359,Healthy subjects,55.0,18.0,"Electrocardiogram (ECG) 12-leads: (supine position) clinically significant abnormalities; corrected QT interval > 450 msec Physical findings: clinically significant abnormal physical findings which could interfere with the objectives of the study Laboratory analyses: clinically significant abnormal laboratory values indicative of physical illness Cotinine: positive cotinine test at screening Allergy: ascertained or presumptive hypersensitivity to the active principle and/or formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the investigator considers may affect the outcome of the study Diseases: clinically significant history or presence of renal, hepatic, gastrointestinal, cardiovascular, cerebrovascular, immunological, musculoskeletal, respiratory, skin, haematological, endocrine, psychiatric or neurological diseases or surgeries that may interfere with the aim of the study. Gastrointestinal pathologies include any clinically significant disorder of the mouth, e.g. impairment of swallowing, lesions, ulcerations, deformities, untreated dental caries Dentures: presence of mouth jewellery, dentures, braces, piercings that may interfere with successful completion of the dosing Medications: medications, including over the counter medications and herbal remedies for 2 weeks before study screening; central nervous system depressants, including opioids, benzodiazepines, general anaesthetics and anticonvulsants, or cytochrome C inhibitors, including cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and antiretroviral agents, or strong cytochrome C inducers, including barbiturates, carbamazepine, glucocorticoids, phenytoin, St John's wort and rifampin, or hormonal oral or transdermal contraceptives for 30 days before study screening; implanted, injected, intravaginal or intrauterine hormonal contraceptives for 6 months before study screening Investigative drug studies: participation in the evaluation of any investigational product for 3 months before this study. The 3-month interval is calculated as the time between the first calendar day of the month that follows the last visit of the previous study and the first day of the present study Blood donation: blood donations for 3 months before this study Drug, alcohol, caffeine, tobacco: history of drug, alcohol [>1 drink/day for females and >2 drinks/day for males, defined according to the Dietary Guidelines 2015 ], caffeine (>5 cups coffee/tea/day) or tobacco use including any tobacco product like e-cigarettes and vamping products Drug test: positive result at the drug test at screening or Day -1 Alcohol test: positive alcohol breath test at Day -1 Diet: abnormal diets (<1600 or >3500 kcal/day) or substantial changes in eating habits in the 4 weeks before this study; vegetarians and vegans Pregnancy (women only): positive or missing pregnancy test at screening or Day -1, pregnant or lactating women",I,Both
1,Consecutive amyotrophic lateral sclerosis (ALS) patients.,,TrialTroveID-374406,,,,374406,Delay Disease Progression,,,,Iv,
1,Subjects with Amyotrophic Lateral Sclerosis,Nine male patients (mean age +or- SD: 57.3 +or- 9.5 yrs) with defi ned ALS according to the El Escorial criteria were enrolled in our study.,TrialTroveID-220907,Adults; Older Adults,year(s),year(s),220907,Unspecified,69.0,47.0,,Iv,Male
1,Patients with Amyotrophic Lateral Sclerosis,,TrialTroveID-171267,,,,171267,Delay Disease Progression,,,,Iv,
1,"Patients with definite or probable amyotrophic lateral sclerosis. Group 1, age: 56.2 yr, Group 2: 57.4 yr.",,TrialTroveID-125254,,,,125254,Unspecified,,,,Iv,
0,Amyotrophic Lateral Sclerosis Patients.,,TrialTroveID-122005,Adults; Older Adults,year(s),year(s),122005,Unspecified,70.0,48.0,,Other,
1,The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.,"Ages Eligible for Study 18 Years - 75 Years, Inclusion Criteria Diagnosis of ALS confirmed by the following definition: -""Probable"" or ""Definite"" Amyotrophic Lateral Sclerosis (ALS) according to the El Escorial criteria. -""Peripheral"" onset form (limb involvement) or a ""Bulbar"" form of ALS with a duration of five years, based on inquiry for the earliest symptoms of the disease. A subject who simultaneously presents with bulbar and peripheral signs at onset of ALS disease should be stratified to the bulbar onset group. The neurologic progression of such subjects matches that of the bulbar onset ALS subjects. Pulmonary Function: forced vital capacity (FVC) must be 3 60% at study entry. Females of childbearing potential must be documented to be using acceptable birth control methods such as an IUD or oral contraceptives.",CARE NCT00542412 RIL_CA1_401 RP54274/CA1.401 TrialTroveID-078766,Adults; Older Adults,year(s),year(s),78766,Delay Disease Progression,75.0,18.0,"Exclusion Criteria Previous treatment with riluzole. Tracheostomy, or expected to undergo a tracheostomy within two months after study inclusion. Signs of clinical dementia and/or major psychiatric disorders. Serious concomitant disease or handicap likely to interfere with the subject's assessments or impact on the subject's survival. A multiple conduction block has been shown on nerve conduction studies by electromyogram.",Iv,Both
1,Patients With Amyotrophic Lateral Sclerosis,"Age range from 20 to 75 (including 20 and 75 years old), regardless of ethnic group or gender; The subjects should meet the diagnostic criteria for ALS by El Escorial revised criteria: ""Definite ALS"", ""Probable ALS"" and ""Probable, laboratory-supported ALS"". ALS Functional Rating Scale-Revised (ALSFRS-R 12 items) each item score =2 points; The onset (the symptoms of limbs weakness, muscle atrophy or bulbar involvement ) of the disease is less than 2 years Baseline breath function: Forced Vital Capacity> or =70% . Disease Progression Rate FS=(48- ALSFRS-R at ""time of diagnosis"")/duration from onset to diagnosis (month), progression rate FS< or =1;",2020-375 NCT04518540 TrialTroveID-382354,Adults; Older Adults,year(s),year(s),382354,Delay Disease Progression,75.0,20.0,"Combined with one of cerebrovascular disease, spinal cord disease, spinal muscular atrophy, juvenile myoatrophy of distal upper extremity, multifocal motor neuropathy, Kennedy disease, epilepsy, etc; Severe renal insufficiency: creatinine clearance rate <30 mL/min (Cockcroft-Gault formula, urea nitrogen and (or) blood creatinine> 1.5 times the upper limit of normal, or other known severe renal insufficiency diseases; Severe liver damage: ALT, AST> 3 times the upper limit of normal, or other known liver diseases such as acute and chronic hepatitis, cirrhosis, etc.; Obvious tachycardia or bradycardia; patients with acute myocardial infarction or interventional therapy in the past 6 months (patients with grade III-IV according to NYHA classification); Combined with malignant tumor, blood, digestion or other serious diseases; Female patients during pregnancy and lactation; Participated in other clinical trials within 30 days before randomization, or are participating in other clinical trials;",Iv,Both
0,Patients With Amyotrophic Lateral Sclerosis.,"Probable (clinically or laboratory) or definite ALS according to the revised version of the El Escorial World Federation of Neurology criteria loss of Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) of > or = 0.33 points per month since onset (first paresis), based on the formula: (48 - score at screening visit) / (months between onset and screening visit) age > or = 18 years continuously treated with 100 mg riluzole per day for at least 4 weeks capable of thoroughly understanding all information given and giving full informed consent according to good clinical practice (GCP)",KETO-ALS KETO-ALS V 1.41 NCT04820478 TrialTroveID-400961,Adults; Older Adults,year(s),,400961,Delay Disease Progression,,18.0,hyperinsulinism pyruvate decarboxylase deficit disturbance of fatty acid oxidation disturbance of gluconeogenesis acute porphyria metabolism disorders which prevent utilization or degradation of ketone bodies severe gastro-esophageal reflux severe renal insufficiency previous participation in another interventional study within the preceding 4 weeks tracheostomy pregnancy or breast-feeding females evidence of a major psychiatric disorder or clinically evident dementia,Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis,"Patients diagnosed with a laboratory supported, clinically ""probable"" or ""definite"" amyotrophic lateral sclerosis according to the Revised El Escorial criteria (Brooks, 2000) Sporadic ALS ALS phenotypes: classic or bulbar Female or male patients aged between 18 and 80 years old Disease duration from symptoms onset no longer than 18 months at the screening visit Patients treated with a stable dose of Riluzole (100 mg/day) for at least 30 days prior to screening Patients with a weight > 50 kg and a BMI > or =18 Patients with a FVC (Forced Vital Capacity) equal or more than 65 % predicted normal value for gender, height, and age at the screening visit Patients able and willing to comply with study procedures as per protocol Patients able to understand, and capable of providing informed consent at screening visit prior to any protocol-specific procedures Use of highly effective contraception",Co-ALS EudraCT Number: 2017-004459-21 NCT03693781 TrialTroveID-333946,Adults; Older Adults,year(s),year(s),333946,Delay Disease Progression,80.0,18.0,"Prior use of Colchicine Prior allergy/sensitivity to Colchicine Receiving Colchicine or other anti-inflammatory drugs (such as corticosteroids, methotrexate, anti-neoplastic, Interleukin 1-1b antagonist, Tumor necrosis factor-alpha inhibitor) Receiving food or co-medications such as strong-moderate cytochrome P450 3A4 inhibitors that will result in elevated plasma level of Colchicine Inflammatory disorders (SLE, Rheumatoid arthritis, connective tissue disorder) or chronic infections (HIV, hepatitis B or C infection) or significant history of malignancy Severe renal (eGFR< 30ml/min/1.73m2), or liver failure or liver aminotransferase (ALT/AST > 2x Upper limit of normal), Existing blood dyscrasia (e.g., myelodysplasia) White blood cells<4,000/mm3, platelets count<100,000/mm3, hematocrit<30% Severe comorbidities (heart, renal, liver failure), autoimmune diseases or any type of interstitial lung disease Patients who underwent non invasive ventilation, tracheotomy and /or gastrostomy Women who are pregnant or breastfeeding Participation in pharmacological studies within the last 30 days before screening Patients with the following ALS phenotypes: flail arm, flail leg, UMN-p, respiratory, PLS, progressive muscular atrophy. Patients with familial ALS defined as presence of at least one first degree family member (parents/son/daughter/brother/sister) affected by ALS. Patients with known pathogenic mutations (SOD1, TARDBP, FUS, C9ORF72).",Ii,Both
1,"Seven male and 5 female healthy controls were recruited from the New Haven area (6 African-Americans, 4 Caucasians, and 2 Hispanics).","The average age (SD) of the subjects was 27.7 years (6.9). Subjects were required to have normal physical, laboratory and psychiatric examinations. None of the subjects were dependent on alcohol or on any drugs except nicotine.",TrialTroveID-133693,Adults,year(s),year(s),133693,Healthy subjects; Unspecified,35.0,21.0,"To minimize any confounding effects from nicotine or caffeine withdrawal, those who smoked over 5 cigarettes per day and drank more than 3 cups of coffee or caffeinated beverages per day were excluded from the study.",Iii,Both
1,Bulbar type amyotrophic lateral sclerosis (ALS) patients.,Patients (ALS + PBP) according to El-Escorial criteria,TrialTroveID-294459,Adults; Older Adults,year(s),year(s),294459,Delay Disease Progression,84.0,30.0,,Iv,Both
0,Patients with Amyotrophic lateral sclerosis,"Male patients over 18 years of age or female patients over 50 years of age who are not fertile, and between 18 and 50 years of age who have accepted the use of contraceptives if they are of childbearing age and renounce becoming pregnant during the intervention. Patients diagnosed and symptomatic of ALS for at least 6 months prior to inclusion in the study. Patients treated with Riluzole at least one month before inclusion in the study. Acceptance of participation in the study by signing the IC form. At the discretion of the investigator, the patient must be able to meet the requirements of the study",EudraCT Number: 2021-001989-38 IMCRELA TrialTroveID-408677,Adults,year(s),year(s),408677,Delay Disease Progression,64.0,18.0,"Patients with tracheostomy. Patients with invasive or non-invasive ventilation with positive ventilatory pressure. Participation in any other trial or in the 4 weeks prior to inclusion. Gastro-stomized patients. We are ill with evidence of dementia. We are ill with dependence on alcohol or drug abuse. Patients infected with hepatitis B or C, or HIV positive. Kidney patients with creatinine 2 times higher than normal markers 30 days before inclusion. Hepatic patients with hepatic markers (ALT, AST) elevated 3 times above normal levels 30 days prior to enrollment. Patients treated with anticoagulants or with hemostatic problems 30 days before inclusion.",Ii,Both
0,Patients diagnosed with amyotrphic lateral sclerosis.,"Probable (clinically or laboratory) or definite ALS according to the revised version of the El Escorial World Federation of Neurology criteria Disease duration more than 6 months and less than 24 months (inclusive). Disease onset defined as date of first muscle weakness, excluding fasciculations and cramps Vital capacity more than 65% of normal (slow vital capacity; best of three measurements) Age: = 18 years Patients have to be treated with Riluzole (2 x 50mg/d), must be stable for at least four weeks before randomization Patients who have started on Edaravone therapy shall continue Edaravone treatment. Edaravone treatment must not be discontinued for reasons of trial participation. Women of childbearing age must be non-lactating and surgically sterile or using a highly effective method of birth control and have a negative pregnancy test. Acceptable methods of birth control with a low failure rate i.e. less than 1% per year) when used consistently and correct are such as implants, injectables, combined oral contraceptives, hormonal intrauterine devices (IUDs), sexual abstinence or vasectomized partner Capable of thoroughly understanding all information given and giving full informed consent according to good clinical practice (GCP) Patients have to have a valid health insurance, when recruited in a center in France",00013948 01742 BASEC2018-02001 DRKS00013948 EudraCT Number: 2017-003676-31 NCT03792490 ROCK-ALS SNCTP000003245 TrialTroveID-340147,Adults; Older Adults,year(s),,340147,Delay Disease Progression,,18.0,"Previous participation in another clinical study involving trial medication within the preceding 12 weeks or five terminal half times of the longest to be eliminated trial medications (whichever is longer) or previous participation in this trial Tracheostomy or continuous assisted ventilation of any type during the preceding three months before randomization or a significant pulmonary disorder not attributed to ALS, which may complicate the evaluation of respiratory function, intermittent non-invasive ventilation is permitted, Patients with a history of intracranial bleeding, known intracerebral aneurysms or Moyamoya disease, or positive family history for the above. If only family history positive, magnetic resonance (MR)- or x-ray-based cranial imaging not older than 24 months must confirm absence of bleeding, aneurysms or Moyamoya. Gastrostomy Any medical condition known to have an association with motor neuron dysfunction or involving neuromuscular weakness or another neurodegenerative disease, e.g. Parkinson's disease (PD) or Alzheimer's disease (AD), which might confound or obscure the diagnosis of ALS Presence of any concomitant life-threatening disease or impairment likely to interfere with functional assessment Patients with known arterial hypotension (resting blood pressure <90/60 mmHg) or previous hypotensive episodes or requiring treatment for increasing of blood pressure, such as fludrocortisone, midodrine, etilefrine, cafedrine or theodrenaline Patients with an uncontrollable or unstable arterial hypertensive disease (resting blood pressure >180 mmHg systolic and/or >120 mmHg diastolic under current antihypertensive medication) Known pulmonary hypertension and any medication prescribed for treatment of pulmonary hypertension Confirmed hepatic insufficiency or abnormal liver function (stable aspartate transaminase (ASAT) and/or alanine aminotransferase (ALAT) greater than 3 times the upper limit of the normal range) and determined to be non-transient through repeat testing Renal insufficiency with a glomerular filtration rate (GFR) <60 ml/min/1,73m^2 (calculated by Modification of Diet in Renal Disease (MDRD) equation) and determined to be non-transient through repeat testing Major psychiatric disorder, significant cognitive impairment or clinically evident dementia precluding evaluation of symptoms Hypersensitivity to any component of the study drug Liable to be not cooperative or comply with the trial requirements (as assessed by the investigator), or unable to be reached in the case of emergency Pregnant or breast-feeding females or females with childbearing potential, if no adequate contraceptive measures are used Prisoners or subjects who are involuntary incarcerated Patients subject to legal protection measures",Ii,Both
1,Patients with mild or moderate amyotrophic lateral sclerosis (ALS).,Patients diagnosed as definite or probable ALS according to El Escorial Criteria. ALS patients who are graded as mild or moderate according to ALS Health State Scale. Forced vital capacity of at least 80% Desire of the patient to participate in this study and Signing Written Informed Consent. The patient gets at least 2 points on all 12 items of the ALSFRS-R.,IRCT20190324043105N1 Isfahan ALS Registery NCT03272802 TrialTroveID-308554,Adults; Older Adults,year(s),year(s),308554,Delay Disease Progression,75.0,18.0,"Incidence of drug's side effects that requires discontinuation of the drug (Edaravone's side effects: Acute kidney injury, Acute allergic reactions, DIC, Thrombocytopenia, Leukopenia). Desire of the patient to discontinue participating in this study. The patient starts another drug or herb for ALS during the study. Patients diagnosed as possible ALS disease according to El Escorial Criteria ALS Patients who are graded as severe or terminal according to ALS Health State Scale. The patient can't get at least 2 points on all 12 items of the ALSFRS-R.",Ii/Iii,Both
1,Patients with sporadic Amyotrophic Lateral Sclerosis (ALS).,Diagnosis of ALS according to the El-Escorial criteria; Age> or =18 years; ALS Functional Rating Scale-Revised (ALSFRS- r) score> or = 20; Forced Vital Capacity (FVC)> or =30%; Treatment with Riluzole.,3314 NCT02645461 TrialTroveID-270826,Adults; Older Adults,year(s),,270826,Delay Disease Progression,,18.0,"Other diseases motor neurons; Experimental treatments in the previous three months; Pregnant or breast-feeding; Contraindications to the use of riluzole; Patients undergoing tracheostomy, enteral or parenteral supply; Severe psychiatric disorders.",Iii,Both
0,Patients with Amyotrophic Lateral Sclerosis (ALS) and a median nerve CMAP > 1 mV.,"Ability to understand the purpose and risks of the study and provide signed and dated informed consent. Aged 18 to 80 years old, inclusive, at the time of informed consent. Women of childbearing potential must practice effective contraception for the duration of the study. Willing to limit the intake of alcohol to no more than 2 units per day from the screening visit to the the last scheduled visit and to refrain from alcohol intake 48 hours prior to each study visit until their stay in the clinical research unit. One unit of alcohol is defined as 1 pint of beer (350 mL), 1 glass of wine (150 mL) or 1 shot of liquor (30 mL). Willing to refrain from marijuana use throughout the study. Willing to refrain from vigorous exercise within 48 hours prior to each study visit. Must have a diagnosis of “definite”, “probable”, or “probable laboratory-supported”, ALS according to the World Federation of Neurology El Escorial criteria (revised according to the Airlie House Conference 1998 [Brooks 1999]) Hyperexcitability of motor neurons as assessed by the neurophysiologist. Fasciculations in the arms observed by the treating neurologist",CHDR1417 EudraCT Number: 2015-001431-20 NL53042.056.15 NTR6278 TrialTroveID-263701,Adults; Older Adults,year(s),year(s),263701,Delay Disease Progression,80.0,18.0,"History of diabetes or neuropathy. History of neuromuscular disorders (other than ALS) including but not limited to ALS mimic syndromes, myopathy, myasthenia gravis, and other motor neuron diseases. Vital Capacity less than 50%. Median nerve CMAP less than 1 mV. Unstable cardiac , pulmonary, renal, hepatic disease or active malignancy. History of or positive screening test for hepatitis C infection (defined as positive for hepatitis C virus antibody), hepatitis B infection (defined as positive for hepatitis B surface antigen [HBsAg] and/or positive for hepatitis B core antibody [HBcAb] at Screening), or positive for human immunodeficiency virus (HIV) antibody. Subjects who are HBsAg negative and HBcAb positive are allowed to participate if they are positive for HBsAb immunoglobulin G (see the Centers for Disease Control and Prevention's interpretation of the hepatitis B serology panel)). Clinically significant abnormalities in laboratory test results as judged by the investigator. In the case of uncertain or questionable results, laboratory tests performed during the screening visit may be repeated 1 time before participation in the study to confirm eligibility or may be judged to be clinically irrelevant. History or symptoms of any clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and ophthalmologic or other major disease, as determined by the investigator (with the exception of the neurological syndrome listed in the inclusion criteria section). 12-lead ECG demonstrating QTc >450 msec at Screening. Concomitant disease or condition that can interfere with the conduct of the study, or that in the opinion of the investigator, would pose an unacceptable risk to the subject in this study. History of trauma to the upper extremities or other orthopaedic conditions that, in the opinion of the investigator, could affect the electrophysiological measurements. Use of medications including but not limited to anticholinergics and muscle relaxants that, in the opinion of the investigator, could affect the electrophysiological measurements. Current enrolment in any interventional clinical study in which treatment with an investigational drug or approved therapy for investigational use is administered within 30 days prior to the screening or participation in an interventional study for an investigational drug or device within 3 months prior to Screening. Pregnant, breastfeeding, or a positive pregnancy test result at Screening. History of alcohol or drugs of abuse dependence or a positive urine test for drugs of abuse at Screening. Unwillingness or inability to comply with study requirements. Unspecified reasons that, in the opinion of the Investigator, make the subject unsuitable for enrollment.",I,Both
0,"Patients with Amyotrophic Lateral Sclerosis (14 males and 7 females with mean age 48 yrs (24-74yrs)) 23 ALS patients (15 male, 8 female, mean age 51, 4 yrs.) 23 ALS patients (15 male, 8 female, mean age 51,4 yrs. (+ or -13.2), mean ALS-FRS-r at start 36.75 (+ or - 6.84))",,TrialTroveID-205567,Adults; Older Adults,year(s),year(s),205567,Delay Disease Progression,74.0,24.0,,Ii,Both
1,Patients with amyotrophic lateral sclerosis (ALS).,"Inclusion criteria: Patients ALS, sporadic or familial, diagnosed according to El Escorial revised criteria as definite, probable or likely to support laboratory and a history of disease between 6 and 36 months. Ages between 18 and 75 years. Patients should be able to understand and adhere to the provisions of the study protocol and must provide a written informed consent. Patients receiving stable dose of riluzole 50 mg twice daily for at least 30 days and without any serious adverse events. Value capacity of 'vital force measured at the time of study entry equal to or greater than 60% of the predicted value. Creatininemia < or = 1.5 mg / dl. The women should be able to avoid pregnancy for the duration of the study (at least one year physiological menopause, infertility 'surgical or adoption of appropriate contraceptive methods). Pegnant women should have a negative serological test for the screening and must not be breast-feeding stage",EudraCT Number: 2008-006722-34 SLA_Litio TrialTroveID-110113,Adults; Older Adults,year(s),year(s),110113,Delay Disease Progression,75.0,18.0,"Exclusion criteria: Medical History of positive hypersensitivity 'lithium or related compounds. Previous intake for therapy of lithium carbonate. Recruitment to any other investigational drug during the 30 days preceding the screening visit. Presence of any of the following medical conditions: -substance abuse in the previous year. -Severe compromise character of cardiac, pulmonary, renal, hepatic, endocrine or haematological, chronic infectious diseases or neoplasms malignant behavior. -Diagnosis of acquired immunodeficiency syndrome or HIV seroconversion. -Diagnosis confirmed psychiatric illnesses such as psychosis (hallucinations or delusions), untreated major depression during the 90 days preceding the screening visit -Value serum TSH greater than 20% compared to the upper limits of normal (patients taking drugs for thyroid disorders should be in a euthyroid for at least three months before the screening visit). -Treatment of chronic diuretic. Presence of conduction abnormalities to Electrocardiogram. Involvement of other clinical neurological systems (sensory, extrapyramidal, oculomotor, cerebellar, vegetative). Tracheostomy or assisted ventilation of any kind in the three months preceding the study, gastrostomy.",Iii,Both
0,Patients diagnosed with ALS,"Adult men and women aged 20 years or older and under 80 years of age, A person who has been diagnosed with ALS only after an EMG (Electroelectricity), MRI, biopsy, cerebral spinal fluid test, blood test, urine test, genetic test, and comprehensive medical examination at medical and general hospitals, ALSFRS score greater than 20, A person taking 100 milligrams of lychel a day from one month before screening, who can visit a hospital alone or visit a hospital with the help of a guardian, who voluntarily agrees to participate in this clinical trial after hearing the purpose, methods, and effects of the clinical trial",HP_MECASIN-02 KCT0003792 TrialTroveID-364650,Adults; Older Adults,year(s),year(s),364650,Unspecified,80.0,20.0,"Less than 30% of patients with forced lung capacity,Patients with severe mental illness and difficulty communicating with dementia, Patients with myocardial infarction or angina in electrocardiogram, Patients with heart disease who underwent stenting or vascular bypass, Patients with liver disease such as liver cirrhosis, liver cancer, active hepatitis, or patients whose transaminase level is more than three times the normal upper limit, patients with cholecystitis or bile duct obstruction, patients with renal dysfunction and renal dialysis, Patients with organs such as liver and kidney, Patients with interstitial lung disease on chest X-ray examination, Patients suffering from post-operative complications, Persons with previous history of hypersensitivity to components of the test drug and similar classes,A person diagnosed with motor neuron disease due to hereditary diseases (Caneti's disease, SMA4, etc.) or heavy metal poisoning, Women who have not received consent to the choice of oral contraceptives (contraceptives, hormonal implants, intrauterine devices, condoms, spermicides, etc.) in addition to medically appropriate contraceptive methods, pregnancy, breastfeeding, or pregnancy planning (hysterectomy within 2 years of menopause, , A woman who has not undergone bilateral ovariectomy), or a male patient who does not consent to use the appropriate method of contraception to prevent the partner from becoming pregnant while participating in the trial, In patients with progressive muscular atrophy (PMA) with only primary motor sclerosis (PLS) or lower motor neuron symptoms, A person with a bleeding tendency,A person with a malignant tumor,Patients who were found to have active viral infection (Hbs Ag, HCV (hepatitis C virus) Ab, HIV (human immunodeficiency virus)Ab, CMV(Cytomegalovirus) IgM, EBV(Epstein-barr virus) IgM, HSV (herpes simplex virus)IgM, VDRL(Venereal Disease Research Laboratory ), etc.), Patients judged to be inadequate to participate in clinical trials by other clinical investigators",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis.,"Men and women between the ages of 20 and 80; Diagnosis of ALS(Amyotrophic Lateral Sclerosis) based on EMG(Electromyography) findings after comprehensive examinations including EMG(Electromyography), MRI(magnetic resonance imageing), biopsy, CSF(cerebrospinal fluid) tests, blood tests, urine tests, and genetic tests at either a university or general hospital; Probable diagnosis of ALS(Amyotrophic Lateral Sclerosis); ALSFRS(Amyotrophic Lateral Sclerosis Functional Rating Scale) score greater than 20; (5) ability to communicate in cases of ALS with frontal lobe dementia; Ability to walk in cases of ALS with Parkinson’s disease; Treatment with 100 mg riluzole up to 3 months prior to screening; Ability to visit the hospital alone or with the assistance of a caregiver. Ability to provide voluntary, written informed consent.",2016/5-1 KCT0001984 TrialTroveID-288935,Adults; Older Adults,year(s),year(s),288935,Delay Disease Progression,80.0,20.0,"Patients with <OR=30% forced vital capacity; Patients with severe mental disorders or dementia with communication difficulties; Patients with cardiovascular disease including ischemic heart disease; Patients with hepatic diseases such as hepatic cirrhosis, hepatic cancer, and active hepatitis, or AST/ALT(aspartateaminotransferase/alanine aminotransaminase) greater than three times the upper normal limit; Patients with cholecystitis or biliary obstruction; Patients with renal failure or undergoing renal dialysis; Patients who have had liver or kidney transplants; Patients with interstitial lung disease as observed on chest x-ray; Patients who have experienced post-operative complications; Patients with a history of hypersensitivity to any component of the experimental medication or similar class of medication; Patients with genetic disorders (Kennedy’s disease, SMA4(Spinal muscular atrophy type IV)) or diagnosis of motor neuron disease due to heavy metal poisoning; Patients who have received other experimental medication/procedures within four weeks of participating in this trial; Pregnant women, lactating women, and women of childbearing age who plan on becoming pregnant (i.e., no hysterectomy, bilateral tubal ligation, or bilateral oophorectomy within 2 years of menopause) who do not agree to use medically appropriate contraceptives (oral medication, hormone implants, intrauterine devices, condoms, or spermicides) or men who do not agree to use appropriate contraceptives with female partners; Patients with PLS(primary lateral sclerosis) experiencing only upper motor neuron symptoms or PMA(progressive muscular atrophy) experiencing only lower motor neuron symptoms; Patients with bleeding diathesis; Patients with malignant tumors; Patients who have undergone mechanical ventilation or tracheostomy and PEG(percutaneous endoscopic gastrostomy); Patients with active viral infections (Hbs Ag, HCV(hepatitis C virus) Ab, HIV(human immunodeficiency virus) Ab, CMV(Cytomegalovirus) lgM, EBV(Epstein-Barr Virus) lgM, HSV(Herpes Simplex Virus) lgM, VDRL(Venereal Disease Research Laboratory)); and Patients who have been determined inappropriate to participate in clinical trials by a clinical examiner.",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis,"Meet the following diagnosis standard: confirmed, proposed and laboratory supported diagnosis; Age 50-70 years old ; 3-18 months course of disease; Forced vital capacity (FVC) > or =70% predicted value; Total amyotrophic lateral sclerosis Functional Rating Scale score > or =36, scores of respiratory related items > or =10; Take Riluzole regularly before participate in this trial (25~50mg twice a day for at least 30 days continuously) without obvious side effects and can continue to take for 22 months; Participants of childbearing age take reasonable and effective contraceptive measures from the time of enrollment to the end of follow-up; Signed informed consent.",NCT04454840 PUTH2017118 TrialTroveID-378475,Adults; Older Adults,year(s),year(s),378475,Delay Disease Progression,70.0,50.0,"Familial amyotrophic lateral sclerosis; Female during pregnancy and lactation; Positive hepatitis B, hepatitis C or HIV in screening History of cytomegalovirus and malaria infection; After tracheotomy and ventilator-dependent state (daily use of non-invasive ventilator = 22 hours for 7 consecutive days); After percutaneous gastrostomy (PEG) operation; Has had allergic reactions and other adverse reactions during blood transfusion; Have diseases of the blood system (including Immunoglobulin A deficiency); alanine transaminase, Aspartate transaminase= 3 times the upper limit of normal; Abnormal renal function (Cr, BUN); History of malignant tumors; Combining severe cardiopulmonary diseases, autoimmune diseases, mental diseases, substance abuse history, etc; Currently participating in other clinical studies or using other drugs in researching.",I,Both
0,Subjects with Amyotrophic Lateral Sclerosis,"Male or female subjects between 18-80 years of age, inclusive Subjects with a diagnosis of probable or definite ALS in accordance with the Revised El-Escorial Criteria Subjects must be currently on an oral diet and able to take foods and liquids by mouth equivalent to a score of 3 or above on the Functional Oral Intake Scale. Subjects with no known allergy to barium, riluzole or inactive ingredients in ROSF Subject or subject's legally authorized representative must be willing and able to give informed consent/assent and HIPAA authorization. Subject must have the ability to comprehend and be informed of the nature of the study, as assessed by the Principal Investigator or Sub-Investigator. Subjects prescribed riluzole at or before the dose of study drug. (The study was open to subjects currently taking riluzole at screening, subjects who were not currently taking riluzole at screening who had taken riluzole in the past, and subjects to be newly started on riluzole (given as ROSF in this study). Availability to volunteer for the entire study duration and willing to adhere to all protocol requirements Female subjects of childbearing potential (i.e. not surgically sterile, not 2 years postmenopausal, or not with a sterile partner) must have a negative pregnancy test at Screening and Visit 1, agree to abstinence, be practicing double barrier contraception or using an FDA approved barrier method contraceptive (e.g., licensed hormonal or barrier methods) for more than 2 months prior to the screening visit and commit to an acceptable form of birth control for the duration of the study and for 30 days after participation in the study.",17MO1R-0012 NCT03679975 TrialTroveID-333447,Adults; Older Adults,year(s),year(s),333447,Unspecified,80.0,18.0,"Subjects who score 2 or below on the Functional Oral Intake Scale. Subjects with a prior swallowing study that has shown a Penetration Aspiration Scale score of 3 or greater Subjects with a history of 2 or more episodes of aspiration pneumonia requiring hospitalization Subjects with a history of clinically significant liver disease, renal disease, or any other medical condition judged to be exclusionary by the Investigator Subjects who were unwilling to sign informed consent or subjects who for any other reason in the judgment of investigator were unable to complete the study Female subjects who had a positive urine pregnancy test (ßhCG) at screening or Visit 1, were trying to become pregnant, or were breastfeeding. Subjects with active cancer within the previous 2 years, except treated basal cell carcinoma of the skin Subjects who had taken any experimental drug within 30 days prior to enrollment or within 5 half-lives of the investigational drug -whichever was the longer period. However, subjects who had previously completed other Aquestive Therapeutics-sponsored ROSF clinical studies within the last 30 days prior to enrollment could be eligible for consideration for entry into this study. Subjects with known history of moderate or severe renal impairment as defined by a calculated creatinine clearance of =50 mL/minute Subjects currently taking riluzole with alanine aminotransferase levels greater than 5 times upper limit of normal or with evidence of clinical jaundice. (Riluzole should be discontinued in these patients.) Subjects who would be receiving riluzole for the first time who exhibited baseline elevations of several liver function tests (especially elevated bilirubin). (These findings at baseline should preclude the use of riluzole including ROSF). Use of potentially hepatotoxic drugs: (e.g., allopurinol, methyldopa, sulfasalazine). Subjects with clinically significant abnormal laboratory values in the judgment of the Investigator Use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, thiabendazole, vemurafenib, zileuton) and CYP1A2 inducers (e.g. rifampin and barbiturates) in the previous 30 days before first drug administration. Anything else that, in the opinion of the Investigator, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study. Employee or immediate relative of an employee of the investigator, Aquestive Therapeutics, any of its affiliates or partners, or inVentiv Health.",Ii,Both
0,Subjects With Amyotrophic Lateral Sclerosis.,"Male or female subjects, between 18-80 years of age, inclusive. Subjects having a diagnosis of probable or definite ALS in accordance with the Revisited El-Escorial Criteria. Subjects must have no known allergy to riluzole or inactive ingredients in ROSF. Subjects or subject's legally authorized representative must be willing and able to complete informed consent/assent and HIPAA authorization. Ability to comprehend and be informed of the nature of the study, as assessed by the Primary or Sub-Investigator. Subjects prescribed to take riluzole at or before the time of first dose. (The study is open to subjects currently taking riluzole at screening, subjects who are not currently taking riluzole at screening but who have taken riluzole in the past, and subjects to be newly started on riluzole (given as ROSF in the course of this study). Availability to volunteer for the entire study duration and willing to adhere to all protocol requirements. Female subjects of childbearing potential must have a negative urine pregnancy test at Screening and Visit 1-3. Female subjects of childbearing potential (i.e. not surgically sterile, not 2 years postmenopausal, or not with a sterile partner) must have a negative pregnancy test at screening and Visit 1-3, agree to abstinence, practicing double barrier contraception or using an FDA approved barrier method contraceptive (e.g., licensed hormonal or barrier methods) for greater than 2 months prior to screening visit and commit to an acceptable form of birth control for the duration of the study and for 30 days after participation in the study. Subjects, in the judgment of the investigator, must be suitable candidates for administration of ROSF (riluzole oral soluble film).",17MO1R-0016 NCT03457753 TrialTroveID-320012,Adults; Older Adults,year(s),year(s),320012,Unspecified,80.0,18.0,"Subjects with a history of clinically significant liver disease, renal disease, or any other medical condition judged to be exclusionary by the investigator. Subjects who are unwilling to sign informed consent or subjects who for any other reason in the judgment of investigator are unable to complete the study. Female subjects who have a positive urine pregnancy test (ßhCG) at screening or visit 1, are trying to become pregnant or are breastfeeding. Subjects with active cancer within the previous 2 years, except treated basal cell carcinoma of the skin. Subjects who have taken any experimental drug within 30 days prior to enrollment or within 5 half-lives of the investigational drug -whichever is the longer period. However, subjects who have previously completed other Aquestive sponsored ROSF clinical studies within the last 30 days prior to enrollment may be eligible for consideration for entry into this study. Subjects with known history or presence of moderate or severe renal impairment as defined by a calculated creatinine clearance of < or = 50 mL/minute. Subjects currently taking riluzole with alanine aminotransferase (ALT) levels greater than 5 times upper limit of normal or with evidence of clinical jaundice. (Riluzole should be discontinued in these patients.) Subjects who will be receiving riluzole for the first time who exhibit baseline elevations of several liver function tests (especially elevated bilirubin). (These findings at baseline should preclude the use of riluzole including ROSF.) Use of potentially hepatotoxic drugs: (e.g., allopurinol, methyldopa, sulfasalazine). Subjects with clinically significant abnormal laboratory values in the judgment of the investigator. Use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, thiabendazole, vemurafenib, zileuton) and CYP1A2 inducers (e.g. rifampin and barbiturates) in the previous 30 days before first drug administration. Employee or immediate relative of an employee of the investigator, MonoSol Rx LLC, any of its affiliates or partners, or inVentiv Health. Anything else that, in the opinion of the investigator, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study.",Ii,Both
1,"Patients with Amyotrophic Lateral Sclerosis 33 patients four are bulbar onset; 3 women and 1 man. 29 are limb-onset, 11 of which are women, 18 are men.","Patients with diagnosed ALS of any type or duration Current or previous treatment with oral riluzole tablets, or patients who have never taken riluzole oral tablets, or patients who have successfully completed a clinical trial with BHV-0223 and were not withdrawn prematurely due to adverse events Swallowing difficulties, or patient or caregiver report choking one or more times per week, or investigator deems appropriate to treat with sublingual BHV-0223 because (s)he deems the patient cannot be satisfactorily treated with Rilutek Adequate hepatic function",BHV0223-401 NCT03537807 TrialTroveID-325007,Adults; Older Adults,year(s),,325007,Unspecified,,18.0,Patient with history of severe hypersensitivity reaction to riluzole oral tablets or BHV-0223 Patient is known to have any other acute or chronic liver disease,Iii,Both
0,Subjects With Amyotrophic Lateral Sclerosis,"Subjects with diagnosed ALS by the revised El Escorial diagnostic criteria, including laboratory supported probable, probable, or definite ALS; Subjects who have never taken riluzole tablets, OR Subjects who previously took riluzole tablets but discontinued at least 1 month prior to the screening visit. Subjects must not have had ALT or AST > 5 x ULN while taking riluzole tablets, or any other clinically significant tolerability issues (e.g., hypersensitivity reactions) in the judgement of the investigator; Subjects determined by the investigator to be medically stable; Subjects determined by the investigator to be willing and physically able to complete the study as designed, with or without caregiver assistance.",BHV0223-103 NCT03520517 TrialTroveID-323953,Adults; Older Adults,year(s),,323953,Unspecified,,18.0,"Target Disease Exceptions Medical History Exceptions Subject is known to have a current diagnosis of acute or chronic viral hepatitis; Subject is known to have any other acute or chronic liver disease that is clinically significant in the investigator's judgment; Subject has a history of a clinically significant medical condition that would interfere with the subject's ability to comply with study instructions, would place the subject at increased risk, or might confound the interpretation of the study results in the investigator's judgment; Any other sound medical, psychiatric and/or social reason in the investigator's judgment; Physical and Laboratory Test Findings Positive urine pregnancy test in WOCBP at screening; Subject has evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, or other determinations beyond what is consistent with the target population, in the investigator's judgment; Subject has liver function testing abnormalities (ALT, AST , or total bilirubin) that are > 1 x ULN; Other Exclusions a. Subjects who are unable to be compliant with the visit schedule or protocol procedures.",I,Both
0,Healthy volunteers.,,TrialTroveID-273966,,,,273966,Healthy subjects,,,,I,
0,Healthy volunteers.,,BHV223-101 TrialTroveID-254299,,,,254299,(N/A); Healthy subjects,,,,I,
0,Chinese healthy subjects,"Chinese healthy subjects aged 18 and over (including 18 years old), both male and female; The weight of male subjects is not less than 50 kg, the weight of female subjects is not less than 45 kg, and the body mass index (BMI) is within the range of 19.0~26.0 kg/m2 (including the critical value); Subjects fully understand the purpose, nature, methods and possible adverse reactions of the test, and voluntarily sign the informed consent, and can complete the study in accordance with the requirements of the test protocol; The subjects were able to communicate smoothly with the researchers, and fully understood and complied with the requirements of the research.",CTR20230637 LLZ-BE-202301 TrialTroveID-461741,Adults; Older Adults,year(s),,461741,Healthy subjects,,18.0,"Those who are known to be allergic to the test drug or preparation excipients, or have allergic constitution (allergic to two or more drugs, environment or food), or those who are prone to asthma, rash, urticaria and other allergic symptoms; Those with a history of chronic or severe diseases such as cardiovascular system, cerebrovascular system, blood and lymphatic system, respiratory system (especially interstitial lung disease), immune system, endocrine system, skin, nerve or spirit; Combining diseases or medical history that may affect the interpretation of drug absorption, distribution, metabolism, excretion and safety data; Physical examination, vital signs, blood routine, urine routine, blood biochemistry (among them alanine aminotransferase, aspartate aminotransferase, total bilirubin, glutamyl transaminase > 1.2 times the normal range), coagulation function, female blood pregnancy, 12 Abnormal lead electrocardiogram results with clinical significance; Hepatitis B virus surface antigen, hepatitis C virus antibody, Treponema pallidum specific antibody or human immunodeficiency virus antigen antibody test results are abnormal and have clinical significance; Difficulty swallowing; Positive drug abuse screening; Those with a history of drug abuse within 6 months before screening; Those who used drugs within 3 months before screening; Positive alcohol breath test results; Those who drank more than 14 units of alcohol per week (1 unit of alcohol ≈ 360 mL of beer or 45 mL of spirits with an alcohol content of > 40% or 150 mL of wine) within 3 months before screening, or those who could not abstain from alcohol during the test; Those who smoked more than 5 cigarettes a day within 3 months before screening or who could not quit smoking during the test; Those who drank excessive amounts (more than 8 cups a day, 1 cup = 250 mL) of tea, coffee and/or caffeinated beverages within 3 months before screening; Cannot promise not to eat dragon fruit, mango, grapefruit or food or drink prepared from them from 3 days before the first period of admission to the Phase I ward, and not to eat chocolate and any caffeine (such as coffee, strong tea, cola, etc. ) drinkers; Blood donation or blood loss ≥ 400 mL within 3 months before screening (excluding blood loss during female physiological period) or blood donation during the planned test period and within 3 months after the end of the test; Participated in other clinical trials within 3 months before screening; Those who have used any prescription drugs, over-the-counter drugs, vitamins, Chinese herbal medicines or health products within 2 weeks before screening; Those who have difficulty in venipuncture, those who have a history of haemorrhage and needling, and those who cannot tolerate venipuncture; Pregnant or lactating women; Those who have special requirements for diet or lactose intolerance (those who have had milk-drinking diarrhea) cannot follow a unified diet during the test; Male subjects (or their partners) or female subjects who have family planning or sperm and egg donation plans within 3 months from the screening date to the end of the trial, or those who are unwilling to take non-drug contraceptive measures (drug-based contraceptives) Contraceptive measures include oral contraceptives, contraceptive injections, subcutaneous implants, local contraceptives such as spermicides, etc.); According to the investigator's judgment, those who are not suitable to participate in this experiment.",I,Both
0,Healthy Subjects,"Volunteer to participate and sign an informed consent form 18 years old and above Male weight =50.0Kg, female weight =45.0Kg. Body mass index (BMI) = weight (Kg)/height 2 (m2), the body mass index is 19.0-26.0Kg/m2, including the critical value Those who have been proved healthy through medical history inquiry, full physical examination and laboratory examination The subject had no pregnancy plan and voluntarily adopted effective contraceptive measures from the signing of the informed consent form to 6 months after the last administration, so as to prevent the subject or his spouse from getting pregnant and had no sperm or egg donation plan.",BT-XYL-T-BE01 CTR20212516 TrialTroveID-419924,Adults; Older Adults,year(s),,419924,Healthy subjects,,18.0,"The results of blood routine, blood biochemistry, urine routine, 12-lead electrocardiogram, blood transfusion, blood coagulation function test and other results are judged by the investigator as abnormal and clinically significant (examination) Those who have a history of heart, lung, liver, kidney, blood, gastrointestinal, endocrine, immune, dermatological, neurological or mental diseases, or existing diseases of the above-mentioned systems, who are judged by the researcher to be unsuitable to participate in this research (inquiry) Those with elevated alanine aminotransferase, aspartate aminotransferase, bilirubin, and glutamyl transpeptidase (check) Allergic physique (such as those who are allergic to two or more drugs, foods such as milk and pollen) or have a history of allergies to riluzole or similar drugs (inquiry) Those who have a history of drug abuse or a positive drug screening test in the past 5 years (inquiry, examination); Those who have a positive alcohol breath test result (check) Subjects who have undergone surgery within 3 months before screening, or plan to undergo surgery during the study period, or who have undergone surgery that will affect drug absorption, distribution, metabolism, and excretion (inquiry) Alcoholics in the 3 months before screening (drinking =14 units of alcohol per week: 1 unit ˜200 mL of beer with 5% alcohol content or 25 mL of spirits with 40% alcohol content or 85 mL of wine with 12% alcohol content) , Or those who cannot give up drinking until the end of the study 48h before the first dose (inquiry) Those who have consumed excessive amounts of tea, coffee or caffeinated beverages for a long period of time in the 3 months before screening (more than 8 cups a day, 1 cup = 250mL) (inquiry) Those who smoked =5 cigarettes per day within 3 months before screening, or who could not give up smoking until the end of the study 48h before the first dose (ask for consultation); Subjects who participated in other clinical trials and took medications within 3 months before screening (system inquiry, consultation) Those who donated blood (including donated blood components) or other causes of bleeding caused the total blood loss = 400 mL (except for female physiological blood loss) within 3 months before screening (inquiry) Those who have used any prescription drugs, over-the-counter drugs, Chinese herbal medicines, health care products, etc., for the treatment and/or prevention of their own diseases in the 14 days before screening (inquiry) Those who received the vaccine within 14 days before the first dose (including the 14th day) or planned to be vaccinated during the trial period (inquiry); It is not possible to avoid eating xanthine-rich beverages (coffee, tea, etc.) or food (chocolate, animal liver, etc.), or eating grapefruit, grapefruit, mango, dragon fruit and other fruits that may affect metabolism until the end of the study. Fruit juice (for consultation); People who have difficulty in blood collection or have a history of fainting needles or fainting blood (inquiry) Those who cannot follow a unified diet (such as intolerance to standard meals, etc.) or who have difficulty swallowing tablets (ask a doctor) Women who are pregnant or breastfeeding (within one year after delivery or have not stopped breastfeeding) (inquiries, examinations) The investigator believes that it is not suitable for other subjects into the group",I,Both
0,Healthy volunteers.,,TrialTroveID-294455,,,,294455,Healthy subjects,,,,Ii,
1,"Adult patients with Parkinson’s disease, amyotrophic lateral sclerosis, medication-induced, stroke and other disorders",,TrialTroveID-374396,Adults,,,374396,Non-motor symptoms/comorbidities; Symptom relief,,,,Iv,
1,"Bulbar-onset Amyotrophic Lateral Sclerosis patients (9 men, 7 women; mean age and SD of 69.2 + or - 8.0 years) with clinical and socially disabling sialorrhea for at least three months prior to screening. All patients considered that this condition required treatment. They had bulbar symptoms for a mean duration of 21.8 + or - 7.1 months (range, 6 to 33) and drooling for 10.5 + or - 7.0 months (range, 3 to 24). Mean ALS severity in the revised ALS Functional Rating Scale (ALSFRS) was 26.3 + or - 7.9 (range, 14 to 40). Eleven patients had previously undergone percutaneous endoscopic gastrostomy and 9 patients were on stable dose pharmacotherapy for sialorrhea (amytriptyline, up to 75 mg daily). None had prior exposure to BTX or salivary gland surgery,or had evidence of any clinically significant neurological disease (other than ALS), or other systemic disease or condition.",,TrialTroveID-080389,Adults; Older Adults,year(s),year(s),80389,Symptom relief,77.0,61.0,,Iv,Both
1,Patients with Amyotrophic Lateral Sclerosis (ALS).,"Ages Eligible for Study: 21 Years - 85 Years Inclusion Criteria Diagnosis of probable or definite ALS based on current World Federation of Neurology criteria. Between the ages of 21-85, inclusive. Sialorrhea refractory to treatment with at least two anticholinergic medications OR has been intolerant of anticholinergic medications due to side effects. Capable of giving informed consent. Must be able to attend all study visits.",BB-IND 11090 NCT00125203 TrialTroveID-078863,Adults; Older Adults,year(s),year(s),78863,Symptom relief,85.0,21.0,"Exclusion Criteria Patient has any uncontrolled significant medical, psychiatric or neurological disease (other than ALS) over the past 30 days. History of ongoing substance abuse. History of non-compliance with treatment. Cannot provide informed consent or comply with evaluation procedures. Has received any form of botulinum toxin in the past for any indication. Women who are pregnant, lactating, or of child bearing potential not using an adequate form of birth control. Currently being treated with coumadin. Forced vital capacity (FVC) <40% of predicted unless the tidal volume is > 600cc, as patients with significant bulbar weakness may show a falsely low FVC due to bulbar muscle spasticity.",Ii/Iii,Both
0,Patients with Parkinson’s disease and amyotrophic lateral sclerosis accompanied by severe drooling.,,TrialTroveID-115413,,,,115413,Non-motor symptoms/comorbidities; Symptom relief,,,,Ii,
0,Patients with Amyotrophic Lateral Sclerosis.,"1 Disease duration of sporadic ALS is ≤ 24 months after symptom onset and symptoms have not progressed to a permanent need of assisted ventilation of any kind (including non-invasive ventilation). 2 Age ≥ 18 years 3 Written consent to participate in the study 4 The patient is capable to attend study visits 5 Medication with riluzole at a stable dose of 50 mg BID for ≥ 30 days prior to the screening visit and if possible, throughout the study. 6 Slow vital capacity (VC) equal to or more than 75% of the predicted normal value for gender, height and age at the screening visit 7 Recommended vaccination according to STIKO (incl. COVID-19 vaccination) 8 Patients with the capacity to give informed consent",ABCD DRKS00030948 EUCT Number: 2022-502743-35-00 RituxALS01 TrialTroveID-488284,Adults; Older Adults,year(s),,488284,Delay Disease Progression; Symptom relief,,18.0,"1 Dysfunction (other than ALS) that could distort or obscure the diagnosis of ALS. 3 The patient has used edaravone or sodium phenylbutyrate–taurursodiol in the first week before the baseline visit 4 Sexually active male and female patients of reproductive potential (female patients/ female partners of patients less than 12 months postmenopausal) who do not use highly effective contraception methods (pearl index <1) during and up to 12 months after treatment 5 Patients with HIV infections 6 Active severe infections (e.g. tuberculosis, sepsis and opportunistic infections) 7 History of chronically active hepatitis including active or chronic hepatitis B, acute or chronic hepatitis C 8 History of a tuberculosis (TB) infection, signs/symptoms of TB or close contact with a person with an active TB infection 9 Clinically significant infection involving intravenous administration of antibiotics and hospitalization in the 4 weeks prior to the screening visit 10 Patients with a serious impairment of the immune system 11 Severe heart failure (New York Heart Association Class IV) or severe, uncontrolled heart disease 12 Patients having severe disease in the renal, cardiovascular or hematological system 13 Patients with neutrophils < 1000 cells per µl and/or platelet counts 75.000 cells per µl 14 Any medical condition that, in the opinion of the Investigator, might interfere with the patient’s participation in the trial or poses any added risk for the patient 15 Patients with other causes of neuromuscular weakness 16 Patients with severe active psychiatric illness 17 Patients with a diagnosis of another neurodegenerative disease (e.g. Parkinson disease, Alzheimer’s disease) 18 Participation in any other investigational drug study or exposure to an investigational drug within 5 half-lives of the study drug at baseline 19 Patients with a history of recurrent or chronic infections or with underlying diseases which may further predispose patients to serious infection",Ii,Both
0,"Patients with Amyotrophic Lateral Sclerosis Participants diagnosed with Definite, Probable, or Probable lab-supported ALS, with satisfactory respiratory function (FVC 80% of predicted normal value) and self-sufficiency","Age 18 through 70 years inclusive; Geographically accessible to the site and able to come to the site once a week for 24 weeks; Definite or probable ALS diagnosis according to the revised El Escorial criteria; 4) Disease duration 6 to 24 months from symptom onset; 5) Self sufficiency: Satisfactory bulbar and spinal function (score 3+ on the ALSFRS-R for swallowing, cutting food and handling utensils, and walking); 6) Satisfactory respiratory function (FVC > or = 80% of predicted); 7) Documented progression of symptoms in the last three months, as measured by the ALSFRS-R scale; 8) Ability to understand and comply with the study requirements and to give written informed consent personally or via a legally authorized representative; 9) Treatment with riluzole 50 mg twice/day for at least 1 month prior to screening visit. Self sufficiency: this term reflect independence in daily living activities. It is an intuitive parameter to indicate preservation of key functional activities, and - not least - it has shown to be a valid and reliable measure",EudraCT Number: 2016-002382-62 NCT03456882 RNS60 RNS60-ALS TrialTroveID-297026,Adults; Older Adults,year(s),year(s),297026,Delay Disease Progression,80.0,18.0,"History of HIV, clinically significant chronic hepatitis, antecedent polio infection, or other active infection; Motor neuron disease (MND) other than ALS; Involvement of systems other than motor possibly determining a functional impairment (as measured by the end-points) for the entire duration of the study; Other severe clinical conditions (e.g., cardiovascular disorders, neoplasms) with impact on survival or functional disability in the next 12 months; Renal insufficiency as defined by a serum creatinine > 1.5 times the upper limit of normal; Poor compliance with previous treatments; Other experimental treatments in the preceding 3 months; Women who are lactating or able to become pregnant (e.g. who are not post menopausal, surgically sterile, or using inadequate birth control) and men unable to practice contraception for the duration of the treatment and 3 months after its completion; Unwillingness or inability to take riluzole; 10) Poor capability to use an inhalation device; Abnormal liver function defined as AST and/or ALT > 3 times the upper limit of the normal.",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis,"Probable, probable-laboratory supported, or definite ALS, either sporadic or familial according to modified El Escorial criteria Disease duration < 3 years Age 18 to 80 Able to provide informed consent and to comply with study procedures Subjects must not have taken riluzole for at least 30 days, or be on a stable dose of riluzole for at least 30 days, prior to screening (riluzole-naïve participants are permitted in the study) Women must not be lactating or able to become pregnant (e.g. post menopausal, surgically sterile, or using adequate birth control) for the duration of the study, and for 3 months after study completion Men should practice contraception for the duration of the study and for 3 months after completion",06.2.1.H6 NCT02988297 TrialTroveID-292121,Adults; Older Adults,year(s),year(s),292121,Delay Disease Progression,80.0,18.0,"Diagnosis of a motor neuron disease other than ALS (e.g., primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy) Clinically significant unstable medical condition (other than ALS) that would pose a risk to the participant if they were to participate in the study or that would impact survival or functional disability in the next 12 months Abnormal liver function defined as aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 3 times the upper limit of the normal Renal insufficiency (Glomerular Filtration Rate < 60) Active pulmonary disease Prior poor compliance with an inhalation device The presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair ability of the participant to provide informed consent, according to judgment by the principal investigator. History of human immunodeficiency virus (HIV) infection, clinically significant chronic hepatitis, or other active infection. Active participation in another ALS clinical trial within 30 days of the Screening Visit Other experimental treatments or anti-inflammatory/immunomodulatory medications used in the preceding 3 months",Ii,Both
0,People with amyotrophic lateral sclerosis who are not eligible for controlled clinical trials.,,TrialTroveID-423266,,,,423266,Delay Disease Progression,,,,Ii,
0,Patients with Amyotrophic Lateral Sclerosis (ALS),"Amyotrophic Lateral Sclerosis (ALS) volunteers must be diagnosed as having possible, probable, probable-laboratory supported, or definite ALS, either sporadic or familial according to modified El Escorial criteria. Age 18-80, able to provide informed consent, and comply with study procedures. Participants must not have taken riluzole for at least 30 days, or be on a stable dose of riluzole for at least 30 days, prior to screening (riluzole-naïve participants are permitted in the study). Women must not be able to become pregnant (e.g. post menopausal, surgically sterile, or using adequate birth control) for the duration of the study and 3 months after study completion. Males should practice contraception for the duration of the study and 3 months after completion. Ability to safely lie flat for 90 min for Positron Emission Tomography (PET) procedures in the opinion of the study physician. High or mixed affinity to bind translocator (TSPO) protein (Ala/Ala or Ala/Thr) Participants will undergo MRI/PET scans at two time points to look at inflammation in the brain. These participants should have no metal or electrically powered implants in their body, and should be able to lie flat for at least 90 minutes. A score of 25 or greater (out of 45) on the Upper Motor Neuron Burden Scale (UMN-B). The UMN-B assesses deep tendon reflexes as well as pathological reflexes and will be administered during screening.",NCT02525471 RNS60-01 TrialTroveID-263140,Adults; Older Adults,year(s),year(s),263140,Delay Disease Progression,80.0,18.0,"Abnormal liver function defined as aspartate aminotransferase (AST) and/or alanine transaminase (ALT) > 3 times the upper limit of the normal. Renal insufficiency as defined by a serum creatinine > 1.5 times the upper limit of normal. The presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair ability of the participant to provide informed consent, according to PI judgment. Clinically significant unstable medical condition (other than ALS) that would pose a risk to the participant if they were to participate in the study. History of HIV, clinically significant chronic hepatitis, or other active infection. Females must not be lactating or pregnant. Active participation in another ALS clinical trial within 30 days of the Screening Visit Exposure to immunomodulatory medications within 30 days of the Screening Visit. Any contraindication to undergo MRI studies such as History of a cardiac pacemaker or pacemaker wires Metallic particles in the body Vascular clips in the head Prosthetic heart valves Claustrophobia Radiation exposure that exceeds the site's current guidelines Current use of tobacco products including cigarettes, cigars, snuff and chewing tobacco, or nicotine replacement products such as gum or patch",I,Both
0,Patients with Amyotrophic Lateral Sclerosis (ALS).,"(At provisional registration) Patients falling under probable laboratory-supported ALS, Clinically probable ALS or Clinically definite ALS in ALS diagnostic criteria (revised El Escorial criteria by the World Federation of Neurology), and within 60 months after onset Patients with severity classification of ALS (Ministry of Health, Labor and Welfare Specific Disease Research 2007.1.1) of 1 or 2 Japanese patients who aged 20 to 80 years old. Patients with the all items in ALSFRS-R (patients with the item in writing and feeding behavior (1) on one or both sides of 2 or more points) of 2 or more points. Patients with percent FVC more than 70. Patients who can submit written informed consent. If patients are duly capable of study consent but are unable to sign by themselves due to aggravation of disease condition, written informed consent can be obtained from a legally authorized representative who can sign on behalf of the patients after confirming the patients' agreement to study participation. Patients eligible for outpatient visit (and hospitalization) during trial period. (At definitive registration) Patients whose change in ALSFRS-R score is between -2 to -5 during 12 weeks of observation phase. Patients who have not newly introduced riluzole since the start of observation phase, and who have not changed or discontinued the dose of riluzole. Patients who did not administered edaravone and high-dose mecobalamin (25 mg or 50 mg) since the start of observation phase. Patients eligible for outpatient visit (and hospitalization) during trial period.",JMA-IIA00397 jRCT2091220397 ROPALS trial TrialTroveID-339079 UMIN000034954,Adults; Older Adults,year(s),year(s),339079,Unspecified,80.0,20.0,"Patients with severe diseases such as hepatic disorder, kidney disorder, heart disease, lung disease, blood disorder, metabolic disorder and whom investigators judged inappropriate for trial. Patients who participated in other clinical trials within 30 days prior to provisional registration. Patients with cancer complicated, or not more than 5 years after cure. Patients who have used ropinirole hydrochloride. Patients with family history of ALS with SOD-1 mutation or who have previously been diagnosed with ALS with SOD-1 mutations. Pregnant women or women who may be pregnant, lactating women. Patients with orthostatic hypotension with subjective symptoms (dizziness, syncope etc.) Patients who have psychiatric disorders or psychiatric symptoms and are considered difficult to participate in this trial. Patients whom investigators judged as inappropriate for trial.",Iii,Both
0,Patients with newly diagnosed behavioural Frontotemporal dementia,"The patient has a diagnosis of probable Frontotemporal dementia behavioural variant (bv-FTD) based on the International consensus clinical diagnostic criteria described by Rascovsky et al., 2011. The patient is a man or a woman, aged from 40 to 80 years. The patient has a Clinical Dementia Rating-FTD (CDR-FTD) total score of =2 at Screening. The patient has not been treated with acetylcholinesterase inhibitor (AChEI), i.e., donepezil, galantamine, or rivastigmine, at the time of screening. The patient is able to comply with the study procedures in the view of the investigator. Evidence of frontotemporal hypometabolism at PET imaging. Evidence of amyloid markers excluding Alzheimer's disease (cerebrospinal fluid Abeta/Tau dosages or amyloid PET imaging). Signature and date of written ICF prior to entering in the study Female patient must be neither pregnant nor breastfeeding. Women of childbearing potential should be willing to use contraception while receiving Rotigotine and for six months after its last assumption",EudraCT Number: 2019-002997-30 NCT04937452 TrialTroveID-407255,Adults; Older Adults,year(s),year(s),407255,Frontotemporal Dementia,80.0,40.0,"Significant neurodegenerative disorder of the central nervous system other than FTD e.g., Alzheimer's disease, Lewy body dementia, Parkinson's disease, multiple sclerosis, progressive supranuclear palsy, normal pressure hydrocephalus, Huntington's disease, any condition directly or indirectly caused by Transmissible Spongiform Encephalopathy (TSE), Creutzfeldt-Jakob Disease (CJD), variant Creutzfeldt-Jakob Disease (vCJD), or new variant Creutzfeldt-Jakob Disease (nvCJD) Significant intracranial focal or vascular pathology seen on brain MRI scan within a maximum of 6 months before Baseline leading to a diagnosis other than probable FTD. The patients has history of seizure (with the exception of febrile seizures in childhood). Metal implants in the head (except dental), pacemaker, cochlear implants, or any other non-removable items that are contraindications to MR imaging. Treatment currently or within 3 months before Baseline with any of the following medications: Typical and Atypical antipsychotics (i.e., Clozapine, Olanzapine); Antiepileptics drugs (i.e., Carbamazepine, Primidone, Pregabalin, Gabapentin); Antidepressants (i.e., Citalopram, Duolxetine, Paroxetine).",Ii,Both
0,Patients with amyotrophic lateral sclerosis.,,TrialTroveID-120002,,,,120002,Delay Disease Progression,,,,Ii,
0,Patients with Amyotrophic Lateral Sclerosis.,Main Criteria for inclusion was confirmatory diagnosis of ALS by two neurologists.,TrialTroveID-119994,,,,119994,Delay Disease Progression,,,,Ii,
0,Subjects with Amyotrophic Lateral Sclerosis,"- Subjects who meet the revised El Escorial criteria for probable or definite sporadic ALS - Adult patients between 18 and 75 years of age - Patients who are ambulatory and able to perform the 6MWT and quantitative muscle testing at screening (ALSFRS-R-walking = 3) - Patients able and willing to travel to the site, and, in the investigator's opinion, who are likely to attend visits for at least 6 months - Patients who signed written informed consent - Stable dose of riluzole for a minimum of 4 weeks prior to baseline or has not taken it for 4 weeks prior to baseline - For child-bearing aged women, efficient contraception (cf protocol p32) - Forced vital capacity (fVC) in a sitting position > 70 %",APHP190724 EUCT number: 2022-501624-14-00 NCT05860244 TrialTroveID-469676 WALKALS,Adults; Older Adults,year(s),year(s),469676,Delay Disease Progression,75.0,18.0,"- Patients with significant spasticity of the lower limbs interfering with walking capacity (Ashworth scale score > 2) - Patients with fronto-temporal dementia associated with ALS - Patients presenting respiratory insufficiency causing dyspnea during walking - Patients taking drugs that could interfere with NMJ function (anticholinesterase …) or muscle function (steroids, statins…) - Patients taking any forbidden drugs (see list in annex) - Hypersensitivity to salbutamol or to excipients of the drug and placebo - Known contraindication for the studied drug such as ischemic cardiomyopathy or risk of ischemic cardiomyopathy: history of ischemic heart disease or coronaropathy or/and significant ischemic ECG alterations at screening visit - Any clinically significant alterations in the following biological parameters glycemia, kalemia, creatinemia and hematology in the month prior to inclusion according to local laboratory threshold (cf protocol page 33) - Vulnerable persons defined in Articles L1121-5 to L 1121-8-1 and L1122-1-2 of the Code de la Santé Publique* (*CSP) - Participation in another interventional trial up to 3 months before inclusion - Patients having any relevant concomitant disease considered at risk of interfering with study procedures in the opinion of the investigator",Ii,Both
0,,,TrialTroveID-507499,,,,507499,(N/A); Unspecified,,,,I,
0,"Part 1: 56 healthy male subjects, smoking , or = 5 cigarettes / day Part 2: 8 healthy male subjects, smoking < or = 5 cigarettes / day Part 3: 36 healthy male subjects, smoking < or = 5 cigarettes / day Part 4: 24 healthy elderly male and female elderly subjects (at least 5 of each gender in each dose group)","Inclusion criteria: Healthy male subjects, between 18 and 45 years inclusive. Body weight between 50.0 and 95.0 kg inclusive, body mass index between 18.0 and 28.0 kg/m2 inclusive Healthy male or post-menopausal female subjects, between 60 and 75 years of age inclusive. Body weight between 50 kg and 105 kg if male, between 40 kg and 95 kg if female, body mass index between 18 and 33 kg/m2.",EudraCT Number: 2008-001627-65 NL23897.056.08 TrialTroveID-104996,Adults; Older Adults,year(s),year(s),104996,Healthy subjects,75.0,18.0,"Exclusion criteria: Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, psychiatric, systemic, ocular or infectious disease, or signs of acute illness. Frequent headaches and / or migraine, recurrent nausea and / or vomiting (more than twice a month).",I,Both
0,Subjects with non-bulbar onset amyotrophic lateral sclerosis.,"Ages Eligible for Study: 18 Years to 85 Years; Genders Eligible for Study: Both Inclusion Criteria: Male or female between the ages of 18 and 85 with clinical diagnosis of ALS. Forced Vital Capacity (FVC) > 60% of predicted. Less than 3 years of ALS since the onset of the first symptom with clinical evidence of limb muscle atrophy and weakness. Subjects taking Riluzole must have been at a stable dose for at least 30 days with no evidence of toxicity. Female of childbearing potential and male of child-creating potential must agree to use a medically acceptable physical barrier (condom, diaphragm, and cervical cap) through the treatment phase and for at least 30 days after the last study treatment.",NCT00748501 SB-509-0801 SB-509-801 TrialTroveID-080566,Adults; Older Adults,year(s),year(s),80566,Delay Disease Progression,85.0,18.0,"Exclusion Criteria: Women who are pregnant or currently breast-feeding. Dependent upon invasive or non-invasive artificial ventilation. Patients with bulbar onset ALS or with other active neuromuscular/ neurodegenerative diseases. Type 1 or Type 2 diabetes. Evidence of chronic or active heart, liver, kidney, or lung diseases, or Age-related macular degeneration. Current or history of known immune or immunodeficiency disorders. Patients with cognitive impairment with significant decision making incapacity, or major depression, or schizophrenia, or dementia (e.g. Alzheimer's disease). Malignancy or history of malignancy, except it has been in complete remission for at least 5 years. Pre-cancerous conditions (e.g. Barrett's Esophagus, dysplasias) or benign tumors which have the potential for significant growth due to VEGF stimulation.",Ii,Both
0,,,TrialTroveID-389934,,,,389934,Unspecified,,,,Ii,
0,Healthy subjects.,,TrialTroveID-365692,,,,365692,Healthy subjects,,,,I,
1,Cases include 91 ALS; 27 Parkinson’s disease-related disease; 7 multiple system atrophy; 5 spinocerebellar degeneration; 4 cerebral palsy; 4 SBMA; 3 muscular disorder; 3 cerebral vascular disorder; 3 cortico-basal degeneration; and 9 other neurodegenerative disease.,,TrialTroveID-220908,,,,220908,(N/A); Non-motor symptoms/comorbidities; Spastic CP; Symptom relief,,,,Iv,
0,Healthy male subjects.,"Inclusion criteria: Subjects eligible for inclusion in this study have to fulfill all of following criteria and be judged eligible for the study by the investigator Subjects must be able to understand the requirement of the study and must give a written, signed and dated informed consent before any study related activity is performed Male subjects aged older than 20 and younger than 40 years old at timing of giving written informed consent Subjects must be 50-100kg in weight and 18-27kg/m2 in BMI Subjects must be judged eligible for inclusion in the study by the investigator after examining the investigators interview, physical and laboratory test",TrialTroveID-199178 UMIN000012570,Adults,year(s),year(s),199178,Healthy subjects,39.0,20.0,"Exclusion criteria: Subjects will be excluded from enrollment by the following criteria. The investigator must ensure the criteria basically at the timing of screening. Subjects who have history of hypersensitivity to Scopolamin /Atropin (Belladonna alcaloid) Subjects who are prohibited the use of Scopolamin hydrobromide as follows ; -glaucoma -Prostatic hypertorophy with dysuria -Clinical significant heart disease -Paralytic ileus -A known hypersensitivity to the study drug or the ingredient of the study drug -History or clinical evidence of Asthma -History or clinical evidence of Hepatitis Subjects with underlyimg condition (renal or hepatic ) that need treatment Subjects may be administrated anticholinergic agent or dopaminergic antagonist during this study, the opinion of the investigator would not be judged eligible for the enrollment of this study Subjects that in the opinion of the investigator would not be judged eligible for the enrollment of the study based on the mode of action of the investigational drug Subjects took a drug containing Scopolamin or health food containing St.Johns wort within 14days before dosing and be judged not eligible for the enrollment of the study by the investigator Subjects who took food and drink containing grapfruits 7 days prior to dosing Use of investigational treatment within 3 months before the time of enrollment Domation or loss of 200 mL or more blood within a month prior to participation, domation or loss of 400 mL or more blood within 3 months prior to participation A positive Syphilis test result, Hepatitis B surface antigen or Hepatitis C History of drug or alcohol abuse or evidence of such abuse as indicated by the laboratory assays conducted the screening or baseline evaluations. Subjects that in the opinion of the investigator would not be judged eligible for the enrollment of the study",I,Male
1,ALS patients with drooling .,"Inclusion criteria: ALS patients with drooling who were diagnosed by EI Escorial revised Airlie House criteria as clinically definite,clinically probable or clinically pssible ALS. The patients who consented to commit to this research in writing after sufficient informed consent",SCOPOLA-D TrialTroveID-193085 UMIN000011494,,,,193085,Symptom relief,,,Exclusion criteria: 1.diagnosed as glaucoma 2.diagnosed as benign prostatic hypertrophy 3.past history of intestinal obstruction 4.allergy to this drug 5.pregnant or expecting to be pregnant 6.judged as an inadequate patient by responsible doctors,Iv,Both
0,Patients with Amyotrophic Lateral Sclerosis,"The Japanese ALS patients who meet all inclusion criteria (1) Patients who have provided their own written informed consent, who have complied with the requirements for participation in the study, who have undergone the medical examinations and tests specified in the study protocol, and who are able to report their symptoms, etc. (2) Patients aged =>20 and =<80 years at the time of imformed consent, regardless of gender (3) Patients who meet either ""definite"" or ""probable"" of the revised Airlie House diagnostic criteria for El Escorial (4) Patients with drooling (salivary secretion below 3 on ALSFRS-R for more than 28 days) whose volume can be measured",jRCT2031210612 TrialTroveID-460208,Adults; Older Adults,year(s),year(s),460208,Symptom relief,80.0,20.0,"(1) Patients with malignant tumors undergoing treatment (2) Patients who are suffering or have a history of any skin disease or skin abnormality at the site of study drug administration (postauricular area) that may prevent evaluation or are receiving treatment at the site of study drug administration that may prevent evaluation (e.g., topical corticosteroids) (3) Patients who have previously received treatment that affects the salivary glands (botulinum toxin injection, surgery, or radiation therapy) (4) Patients who have received medication to treat drooling within 14 days (Day-14) prior to the start of study drug administration (5) Patients with significant dental or oral lesions. (6) Patients who are hypersensitive to scopolamine or atropine (belladonna alkaloid) or have a complication or a history of drug allergy (7) Patients with any concurrent illnesses such as angle closure glaucoma, open angle glaucoma, benign prostatic hyperplasia, urinary retention, severe heart disease, congestive heart failure, arrhythmia, paralytic ileus, pyloric stenosis, ileus, ulcerative colitis, asthma, hyperthyroidism, epilepsy, hepatitis who are judged by the investigator or sub-investigator to be ineligible for participation in the study (8) Patients with infectious diseases requiring treatment who are judged by the investigator or sub-investigator to be ineligible for participation in the study. (9) Patients who are unable to cooperate with contraception from the time of obtaining consent until the end of observation (10) Patients who are premenopausal (Menopause is defined here as the absence of menstruation for more than 12 months without any other medical reason) (11) Patients who received another study drug within 12 weeks prior to the start of study drug administration (12) Patients who are unsuitable as a subject in this study in the judgement of the principal investigator or a sub-investigator due to other reasons",Iii,Both
0,"Patients With Amyotrophic Lateral Sclerosis (ALS), PMA or PLS and Muscle Cramps","\Diagnosed with ALS, PMA or PLS based on the El Escorial ALS Diagnostic Criteria or based on more recently revised Gold Coast ALS diagnostic criteria Experiences at least one muscle cramp in any muscle per day Age 20 to 84 years old Forced vital capacity is 45% of normal or greater in a seated position Able to swallow liquid via the mouth or be given via a feeding tube Caregiver available to assist with speaking or writing on behalf of the participant if they are not able to speak or write due to the disease Able to comprehend and willing to give (sign) the informed consent Willing to commute to the study site for the frequent visits, including a screening visit (study visits at the end of week 2, 5, 8 and 11) Taking a stable dose of Riluzole (Rilutek), Edaravone (Radicava), and/or sodium phenylbutyrate/taurursodiol (Relyvrio) for at least a month before randomization and not expected to require dose titration or initiation of these medications during the study period Willing to discontinue over-the-counter (OTC) products containing any peony root, Glycyrrhiza, or both Willing to discontinue Mexiletine, Quinine sulfate, or Ranolazine during the study period Willing to avoid food, beverages, and medications that may induce or inhibit metabolism of enzyme of transporters. Willing to refrain from initiation or dose adjustment of baclofen, gabapentin, pregabalin, and/or memantine during the study period (stable dosing of these medications is allowed). Willing to practice contraceptive measures for male and female patients.",AAAT0610 NCT04998305 TrialTroveID-410978,Adults; Older Adults,year(s),year(s),410978,Symptom relief,84.0,20.0,"History of allergic reactions to peony root, Glycyrrhiza, or FD&C Yellow No. 5 (tartrazine) Takes any medication known to increase the risk of pseudoaldosteronism or hypokalemia, including corticosteroids and diuretics (except potassium sparing diuretics, such as spironolactone or amiloride) History of pseudoaldosteronism or hypokalemia or current use of potassium supplementation Screening potassium level 3.4 mEq/L or less Screening diastolic blood pressure (DBP) more than 90 mmHg or systolic blood pressure (SBP) more than 150 mmHg after sufficient rest Screening albumin below normal laboratory level either at the Columbia or Mayo Clinic laboratory Screening bicarbonate or carbon dioxide level less than 29 mmol/L, suggesting metabolic alkalosis Screening sodium level greater than 145 mmol/L, suggesting hypernatremia Unstable or active medical or neurological (other than ALS) diseases which require treatment Failure of Capacity Assessment Not able and/or willing to comprehend and sign the informed consent Not able to speak or write English to complete the primary outcome measure, MCS Taking any experimental medication or unapproved medications directed at treating muscle cramps Those who are pregnant or breast feeding Those who have renal or hepatic impairment",Iii,Both
0,Patients with Amyotrophic Lateral Sclerosis (ALS).,"Patient diagnosed with a laboratory supported , clinically ""probable"" or ""definite"" amyotrophic lateral sclerosis according to the Revised El Escorial criteria (Brooks, 2000). Familial or sporadic ALS. Female or male patients aged between 18 and 75 years old. Disease duration from symptoms onset no longer than 18 months at the screening visit. Patient treated with a stable dose of Riluzole (100 mg/day) for at least 30 days prior to screening. Patients with a weight > 50 kg and a BMI > or = 18 Patient with a FVC > or = 70 % predicted normal value for gender, height, and age at the screening visit Patient able and willing to comply with study procedures as per protocol Patient able to understand, and capable of providing informed consent at screening visit prior to any protocol-specific procedures Use of effective contraception both for males and females",EudraCT Number: 2016-002399-28 NCT03359538 RAP-ALS TrialTroveID-313795,Adults; Older Adults,year(s),year(s),313795,Delay Disease Progression,75.0,18.0,"Prior use of Sirolimus. Prior allergy/sensitivity to Sirolimus or macrolides. Any medical disorder that would make immunosuppression contraindicated, including but not limited to, acute infections requiring antibiotics, patients with known diagnosis of HIV, tuberculosis, hepatitis B or C infection or history of malignancy. Severe comorbidities (heart, renal, liver failure), autoimmune diseases or any type of interstitial lung disease. White blood cells <4,000/mm^3, platelets count<100,000/mm^3, hematocrit <30%. Patient who underwent non invasive ventilation, tracheotomy and /or gastrostomy. Women who are pregnant or breastfeeding. Participation in pharmacological studies within the last 30 days before screening. Patients with known superoxide dismutase 1 (SOD1) mutation or with familial ALS and a family member carrying SOD1 mutation.",Ii,Both
0,Patients with amyotrophic lateral sclerosis,,TrialTroveID-501284,,,,501284,Unspecified,,,,I,
0,The mean age was 59 years and 85% of the sample was male.,"Ages Eligible for Study 18 Years and older; Inclusion Criteria Diagnosed with ALS. At least 18 years of age. Women, who can become pregnant, must actively use effective birth control measures. Veterans only are eligible to participate at VA sites.",0015 NCT00107770 TrialTroveID-078808,Adults; Older Adults,year(s),,78808,Unspecified,,18.0,Exclusion Criteria Must not have any other neurological (nervous system) disease.,Iii,Both
0,"15 healthy Japanese (JAP) (7 male [M], 8 female [F]) and 14 Caucasian (CAU) participants (8 M, 6 F)",,TrialTroveID-507036,,,,507036,Healthy subjects,,,,I,Both
0,Subjects with normal renal function,,PMR 4346-7 TrialTroveID-505764,,,,505764,Healthy subjects,,,,I,
1,Subjects with amyotrophic lateral sclerosis,"1. Previous participation in Study A35-004 (PHOENIX), including completion of the randomized controlled phase through Week 48 (this timepoint may be upcoming at the time of screening). Participants who do not complete randomized-controlled phase through Week 48 for medical reasons may be included on a case-by-case basis, in consultation with the Sponsor; 2. Capable of providing informed consent; 3. Capable and willing to follow trial procedures including visits to the trial clinic, remote visits, and survival status reporting requirements; 4. Women of childbearing potential (WOCBP; e.g., not post-menopausal for at least one year or surgically sterile must agree to use adequate birth control for the duration of the trial and 3 months after the last dose of AMX0035; 1. 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum Follicle-stimulating hormone (FSH) levels > 40 mIU/ml (milli-international units per milliliter) or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy. 2. Acceptable contraception methods for use in this trial are: Hormonal methods, such as birth control pills, patches, injections, vaginal ring, or implants; Barrier methods (such as a condom or diaphragm) used with a spermicide (a foam, cream, or gel that kills sperm); Intrauterine device (IUD); Abstinence (no heterosexual sex); Unique partner who is surgically sterile (men) or not of childbearing potential (female). 5. Women must not be pregnant or planning to become pregnant for the duration of the trial and 3 months after last dose of AMX0035; 6. Men must agree to practice contraception for the duration of the trial and for at least 3 months after last dose of AMX0035; 7. Men must not plan to father a child or to provide sperm for donation for the duration of the trial and 3 months after the last dose of AMX0035",A35-011 EudraCT Number:2022-002348-33 NCT05619783 PHOENIX TrialTroveID-448068,Adults; Older Adults,year(s),,448068,Delay Disease Progression,,18.0,"1. History of known allergy to phenyl butyrate or bile salts; 2. Abnormal liver function defined as bilirubin levels and/or aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 5 times the upper limit of the normal (obtained within 12 weeks from first dose); 3. Renal insufficiency as defined by estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2 normal (obtained within 12 weeks from first dose); 4. Pregnant women or women currently breastfeeding; 5. Current severe biliary disease which may result in the Investigator medical judgement in biliary obstruction including for example active cholecystitis, primary biliary cirrhosis, sclerosing cholangitis, gallbladder cancer, gangrene of the gallbladder, abscess of the gallbladder; 6. History of Class III/IV heart failure (per New York Heart Association - NYHA); 7. Participant under severe salt restriction where the added salt intake due to treatment would put the participant at risk, in the Investigator clinical judgment; 8. Presence of unstable psychiatric disease, cognitive impairment, dementia or substance abuse that would impair ability of the participant to provide informed consent, according to Investigator judgment; 9. Clinically significant unstable medical condition (other than ALS) (e.g., cardiovascular instability, systemic infection, untreated thyroid dysfunction, severe laboratory test anomaly or clinically significant electrocardiogram [ECG] changes) that would pose a risk to the participant if he/she were to participate in the trial, according to Investigator judgment; 10. Currently enrolled in another trial (excluding Study A35-004 (PHOENIX)) involving use of an investigational therapy (or within 5 plasma half-lives) prior to first dose at Baseline Visit; 11. Implantation of Diaphragm Pacing System (DPS); 12. Currently or previously treated within the last 30 days (or 5 half-lives, whichever is longer) from first dose at the Baseline Visit or planned exposure during the treatment period to any prohibited medications listed in Section 6.7 of the protocol.",Iii,Both
1,Adult Patients With Amyotrophic Lateral Sclerosis,"Male or female, at least 18 years of age (inclusive); Diagnosis of ALS made by a physician experienced with the management of ALS; >36 months from symptom onset defined as first weakness Capable of providing informed consent; Capable of and willing to follow program procedures. Participants who have established care with a physician experienced in treating patients with ALS involved in the program and will maintain this clinical care throughout the duration of their time in the program. Women of childbearing potential (e.g., not post-menopausal for at least one year or surgically sterile) must agree to use adequate birth control for the duration of the program and 3 months after last dose of AMX0035; Women must not be planning to become pregnant for the duration of the program and 3 months after last dose of study drug Men must agree to practice contraception for the duration of the program and for at least 3 months after last dose of program drug; Men must not plan to father a child or provide sperm",A35-006 NCT05286372 TrialTroveID-427740,Adults; Older Adults,year(s),,427740,Unspecified,,18.0,"Currently enrolled in a therapeutic study involving the use of an investigational therapy; Dependence on invasive mechanical ventilation, defined as being unable to lay supine without it, unable to sleep without it, or continuous daytime use; presence of tracheostomy at Screening; No current need for tracheostomy or PAV (defined as more than 22 hours daily of mechanical ventilation for more than one week (7 days) or based on the site investigator's judgment; no need anticipated for the next 12 weeks In the judgment of the Investigator, the participant's expected survival is less than 6 months History of known allergy to the following: PB, bile salts, excipient/constituents of the formulation; Abnormal liver function defined as AST and/or ALT >3 times the upper limit of the normal (obtained within 12 weeks from first dose); Renal insufficiency as defined by eGFR <60 mL/min/1.73m2 (obtained within 12 weeks from first dose); Pregnant women or women currently breastfeeding; Current severe biliary disease which may result in the investigator medical judgement in biliary obstruction including for example active cholecystitis, primary biliary cirrhosis, sclerosing cholangitis, gallbladder cancer, gallbladder polyps, gangrene of the gallbladder, abscess of the gallbladder; History of Class III/IV heart failure (per New York Heart Association - NYHA); Participant under severe salt restriction where the added salt intake due to treatment would put the participant at risk, in the Site Investigator clinical judgment; Presence of unstable psychiatric disease, cognitive impairment, dementia or substance abuse that would impair ability of the participant to provide informed c consent, according to Site Investigator judgment; Clinically significant unstable medical condition (other than ALS) that would pose a risk to the participant if they were to participate in the program, according to Site Investigator judgment; Treatment, current or within 90 days from screening with any cell therapies or gene therapies; Implantation of Diaphragm Pacing System (DPS); Anything that, in the opinion of the Site Investigator, would place the participant at increased risk or preclude the participant's full compliance with or completion of the program; Current or planned exposure to any prohibited medications listed in Section 6.8.1 of the protocol",Iv,Both
0,Patients With Amyotrophic Lateral Sclerosis,"Male or female, > or =18years of age; Diagnosis of sporadic ALS (definite, probable, laboratory probable, possible) made by physician experienced with management of ALS as defined by the World Federation of Neurology revised El Escorial criteria; If taking riluzole, must be on a stable dose for >30 days prior to Day 1 and anticipated to remain at that dose until the final study visit. If taking edaravone, must be on a stable regimen for > 30 days prior to Day 1 and infusion(s) can be scheduled to be performed at no less than 48 hours prior or after the planned pharmacokinetic and pharmacodynamic (PK/PD) sampling. Capable of providing informed consent and following trial procedures; Geographically accessible to the site; Able to undergo the study procedures (including planned sampling on 3 occasions) and to adhere to the visit schedule, as determined by Investigator; Women of child bearing potential (e.g. not post-menopausal for at least one year or surgically sterile) must agree to use adequate birth control for the duration of the study and 3 months after last dose of study drug; a. Women must not be planning to become pregnant for the duration of the study and 3 months after last dose of study drug Men must agree to practice contraception for the duration of the study and for at least 3 months after last dose of study drug; Men must not plan to father a child or provide sperm for donation for the duration of the study and 3 months after last dose of study drug Acceptable birth control methods for use in this study are: Hormonal methods, such as birth control pills, patches, injections, vaginal ring, or implants Barrier methods (such as a condom or diaphragm) used with a spermicide (a foam, cream, or gel that kills sperm) Intrauterine device (IUD) Abstinence (no heterosexual sex) Unique partner who is surgically sterile (men) or not of child bearing potential (female)",A35-005 NCT04987671 TrialTroveID-410485,Adults; Older Adults,year(s),,410485,Unspecified,,18.0,"Familial ALS Forced vital capacity < 50% (or alternatively SVC) or presence of tracheostomy or under PAV (PAV is defined as more than 22 hours daily of non-invasive mechanical ventilation for more than 7 days); Planned elective surgery (such as feeding tube or edaravone access port placement) during the duration of the study; History of known allergy to PB or bile salts; Abnormal liver function defined as aspartate aminotransferase and/or alanine aminotransferase (AST and/or ALT) > 3 times the upper limit of the normal; Renal insufficiency as defined by eGFR < 60 mL/min/1.73m2; Ongoing Anemia with Hg concentration < 10.0 g/dL Pregnant women or women currently breastfeeding; Current biliary disease which may lead to biliary obstruction or impedes biliary flow including active cholecystitis, primary biliary cirrhosis, sclerosing cholangitis, gallbladder cancer, gallbladder polyps, gangrene of the gallbladder, abscess of the gallbladder; History of Class III/IV heart failure (per New York Heart Association - NYHA); Patient under severe salt restriction where the added salt intake due to treatment would put the patient at risk, in the Site Investigator clinical judgement; Presence of unstable psychiatric disease, cognitive impairment, dementia or substance abuse that would impair ability of the subject to provide informed consent, according to Site Investigator judgment; Presence of an active infection requiring systemic antiviral or antimicrobial therapy at any time during the screening period. Clinically significant unstable medical condition (other than ALS) that would pose a risk to the subject if they were to participate in the study, according to Site Investigator judgment. Clinically significant, as determined by the Investigator, 12-lead ECG abnormalities at screening. Treatment, current or within 90 days from start of study treatment, with any cell therapies or gene therapies; Treatment, current or within 90 days from start of study treatment, with experimental medication (for ALS or other indications) Current or anticipated need for a Diaphragm Pacing System (DPS); Anything that, in the opinion of the Site Investigator preclude the subject's full compliance with or completion of the study; Exposure to any disallowed medications listed below: HDAC Inhibitors including: Valproate Vorinostat (Zolinza) Romidepsin Chidamide Panobinostat Lithium Butyrate Suramin Probenecid Bile Acid Sequestrants including: Cholestyramine and Cholestyramine Light Questran and Questran Light Welchol Colestid and Colestid Flavored Prevalite Product that may interact with sterol absorption or excretion Ezetimibe Note on Antacids within Two Hours of AMX0035 Administration: Antacids containing aluminum hydroxide or smectite (aluminum oxide) may not be taken within two hours of administration of MX0035 as they inhibit absorption of taurursodiol. These include: Alamag Alumina and Magnesia Antacid, Antacid M and Antacid Suspension Gen-Alox Kudrox M.A.H. Maalox HRF and Maalox TC Magnalox Maldroxal Mylanta and Mylanta Ultimate Ri-Mox Rulox Clinically significant, in the opinion of the Investigator, infection or inflammation at time of screening or admission. Acute gastrointestinal symptoms (eg, nausea, vomiting, diarrhea) at time of screening or admission or a or clinical diagnosis of irritable bowel syndrome (IBS) per ROME criteria (Appendix 7). Any current or previous illicit use of Class A drugs such as opiates, cocaine, ecstasy, LSD, and amphetamines (Class B). An alcoholic intake greater than 14 units per week or unwillingness to stop alcohol consumption for the duration of the study. Note: 1 unit = 8 g ethanol (250 mL of beer or approximately 10 oz, 1 glass wine [100 mL or approximately 3 oz], 1 measure spirits [30 mL or approximately 1 oz]). Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to the first administration of investigational product. History of plasma/blood donation in the last 2 months. Any condition, which compromises ability to give informed consent or to communicate with the Investigator as required for the completion of this study. Unwilling to conform to all lifestyle considerations and restrictions mandated by the protocol.",Iii,Both
1,Patients with amyotrophic lateral sclerosis,"1. Male or female, at least 18 years of age. 2. Diagnosis of ALS (definite or clinically probable), made by a physician who is experienced with management of ALS, as defined by the World Federation of Neurology revised El Escorial criteria. 3. Time since onset of first symptom of ALS should be < 24 months. 4. If the participant is to be treated with riluzole and/or edaravone during the course of the trial, then treatment with riluzole and/or edaravone was, at the time of the screening visit, started and maintained at a stable regimen for at least 14 days for riluzole and/or for a full treatment cycle for edaravone. 5. Capable of providing informed consent. 6. Capable and willing to follow trial procedures including visits to the trial clinic and visit requirements. 7. Women of childbearing potential (WOCBP; e.g., not post-menopausal for at least one year or surgically sterile*) must agree to use adequate birth control** for the duration of the trial and 3 months after the last dose of study drug. 8. Women must not be pregnant or planning to become pregnant for the duration of the trial and 3 months after last dose of study drug. 9. Men must agree to practice contraception for the duration of the trial and for at least 3 months after last dose of study drug; 10. Men must not plan to father a child or to provide sperm for donation for the duration of the trial and 3 months after the last dose of study drug. * 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone (FSH) levels > 40 mIU/ml or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy. ** Acceptable contraception for use in this trial are: - Hormonal methods, such as birth control pills, patches, injections, vaginal ring, or implants; - Barrier methods (such as a condom or diaphragm) used with a spermicide (a foam, cream, or gel that kills sperm); - Intrauterine device (IUD); - Abstinence (no heterosexual sex); - Unique partner who is surgically sterile (men) or not of childbearing potential (female).",A35- 004 PHOENIX A35-004 EudraCT Number: 2021-000250-26 NCT05021536 NL78255.100.21 PHOENIX TrialTroveID-401791,Adults; Older Adults,year(s),,401791,Delay Disease Progression,,18.0,"1. Presence of tracheostomy or PAV. 2. Slow Vital Capacity (SVC) less than 55%. 3. History of known allergy to PB or bile salts. 4. Abnormal liver function defined as bilirubin levels and/or aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 5 times the upper limit of the normal (obtained within 12 weeks from first dose). 5. Renal insufficiency as defined by estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m2 (obtained within 12 weeks from first dose). 6. Pregnant women (confirmed by a pregnancy test within 7 days of first dose) or women currently breastfeeding. 7. Current severe biliary disease which may result in the Investigator medical judgment in biliary obstruction including for example active cholecystitis, primary biliary cirrhosis, sclerosing cholangitis, gallbladder cancer, gangrene of the gallbladder, abscess of the gallbladder. 8. History of Class III/IV heart failure (per New York Heart Association – NYHA). 9. Participant under severe salt restriction where the added salt intake due to treatment would put the participant at risk, in the Investigator clinical judgment. 10. Presence of unstable psychiatric disease, cognitive impairment, dementia or substance abuse that would impair ability of the participant to provide informed consent, according to Investigator judgment. 11. Clinically significant unstable medical condition (other than ALS) (e.g., cardiovascular instability, systemic infection, untreated thyroid dysfunction, clinically significant laboratory test or ECG abnormality) that would pose a risk to the participant if he/she were to participate in the trial, according to Investigator judgment; 12. Previous treatment for ALS with cellular therapies or gene therapies; 13. Currently enrolled on another trial involving use of an investigational therapy; 14. Previous treatment with PB or taurursodiol within 30 days from Screening; 15. Implantation of Diaphragm Pacing System (DPS); 16. Currently or previously treated within the last 30 days or planned exposure to any prohibited medications listed in Section 6.8 of the protocol.",Iii,Both
1,Patients with Amyotrophic Lateral Sclerosis,"Any patient who has completed follow-up in an Amylyx sponsored trial of AMX0035 for the treatment of ALS will be eligible to enroll into this Protocol Capable of providing informed consent Capable and willing to follow trial procedures Capable and willing of travelling to the site at regular intervals for interim site visits and to return and collect study drug or able to attend telemedicine remote site visits if such are currently in use at the site Participants who have established care with a neurologist at the specialized ALS center involved in the study and will maintain this clinical care throughout the duration of the protocol. Women of child bearing potential (e.g. not post-menopausal for at least one year or surgically sterile) must agree to use adequate birth control for the duration of the study and 3 months after last dose of study drug. Women must not be nursing, be pregnant or planning to become pregnant for the duration of the study and 3 months after last dose of study drug Men must agree to practice contraception for the duration of the study and 3 months after last dose of study drug. Men must not plan to father a child or provide sperm for donation for the duration of the study and 3 months after last dose of study drug",A35-003 NCT04516096 TrialTroveID-382605,Adults; Older Adults,year(s),,382605,Delay Disease Progression,,18.0,"Ongoing severe adverse events that in the opinion of the Site Investigator are contraindication to the study drug, including severe renal or liver insufficiency or Class III/IV heart failure (per New York Heart Association) Ongoing serious adverse event that was assessed as related to study drug per the Site Investigator Presence of unstable psychiatric disease, cognitive impairment, dementia or substance abuse that would impair ability of the patient to provide informed consent, according to Site Investigator judgment; Current severe biliary disease which may result in the investigator medical judgement in biliary obstruction including for example active cholecystitis, primary biliary cirrhosis, sclerosing cholangitis, gallbladder cancer, gallbladder polyps, gangrene of the gallbladder, abscess of the gallbladder; Clinically significant unstable medical condition (other than ALS) that would pose a risk to the patient if they were to participate in the study, according to Site Investigator judgment; Treatment, current or within 90 days from screening with any cell therapies or gene therapies; Implantation of Diaphragm Pacing System (DPS); Current or planned exposure to any prohibited medications listed in Section",Ii/Iii,Both
0,Patients with amyotrophic lateral sclerosis (ALS).,"Completion of all visits in the randomized, double blind AMX0035 study.Subjects that receive tracheostomy or PAV during the course of the main study will still be followed as ITT until the week 24 visit before enrollment in the OLE. Must enroll in the OLE within 28 days of the Week 24 visit of the main study. Signed informed consent to enter the open label extension phase. All patients who complete the main phase of the CENTAUR phase II clinical study will be eligible for this extension.",AMX-3500-OLE CENTAUR-OLE NCT03488524 TrialTroveID-321850,,,,321850,Delay Disease Progression,,,"Discontinued study drug prematurely in the double-blind phase of the study for reasons other than tracheostomy or PAV. Exposure to or anticipated requirement for any disallowed medication listed below. Any ongoing adverse events that in the opinion of the Site Investigator are clear contraindications to the study drug. Unstable cardiac or other life-threatening disease emergent during the randomized, double blind study Any major medical condition that in the opinion of the Site Investigator would interfere with the study and place the subject at increased risk.",Ii,Both
1,Patients with sporadic or familial ALS. Patients with definite ALS and within 18 months of symptom onset.,"Male or female, aged 18-80 years of age Sporadic or familial ALS diagnosed as definite as defined by the World Federation of Neurology revised El Escorial criteria Less than or equal to 18 months since ALS symptom onset Capable of providing informed consent and following trial procedures Slow Vital Capacity (SVC) >60% of predicted value for gender, height, and age at the Screening Visit Subjects must either not take riluzole or be on a stable dose of riluzole for at least 30 days prior to the Screening Visit. Riluzole-naïve subjects are permitted in the study. Women of child bearing potential (e.g. not post-menopausal for at least one year study and 3 months after last dose of study drug. Women must not be planning to become pregnant for the duration of the study and 3 months after last dose of study drug. Men must agree to practice contraception for the duration of the study and 3 months after last dose of study drug. Men must not plan to father a child or provide for sperm donation for the duration of the study and 3 months after last dose of study drug",AMX-3500 CENTAUR CENTAUR ALS NCT03127514 TrialTroveID-282879,Adults; Older Adults,year(s),year(s),282879,Delay Disease Progression,80.0,18.0,"Presence of tracheostomy Exposure to PB, Taurursodiol or UDCA within 3 months prior to the Screening Visit or planning to use these medications during the course of the study History of known allergy to PB or bile salts Abnormal liver function defined as AST and/or ALT > 3 times the upper limit of the normal Renal insufficiency as defined by a serum creatinine > 1.5 times the upper limit of normal Poorly controlled arterial hypertension (SBP>160mmHg or DBP>100mmHg) at the Screening Visit Pregnant women or women currently breastfeeding History of cholecystectomy Biliary disease which impedes biliary flow including active cholecystitis, primary biliary cirrhosis, sclerosing cholangitis, gallbladder cancer, gallbladder polyps, gangrene of the gallbladder, abscess of the gallbladder. History of Class III/IV heart failure (per New York Heart Association - NYHA) Severe pancreatic or intestinal disorders that may alter the enterohepatic circulation and absorption of TUDCA including biliary infections, pancreatitis and ileal resection The presence of unstable psychiatric disease, cognitive impairment, dementia or substance abuse that would impair ability of the subject to provide informed consent, according to Site Investigator judgment Clinically significant unstable medical condition (other than ALS) that would pose a risk to the subject if they were to participate in the study Active participation in an ALS clinical trial evaluating a small molecule within 30 days of the Screening Visit Exposure at any time to any biologic under investigation for the treatment of subjects with ALS (off-label use or investigational) including cell therapies, gene therapies, and monoclonal antibodies. Implantation of Diaphragm Pacing System (DPS)",Ii/Iii,Both
0,,,TrialTroveID-090292,,,,90292,Unspecified,,,,I,
0,Subjects with Behavioural Variant Fronto-temporal Dementia,"1. Male or female (age 35 years or older). All participants must be using effective contraception for the duration of the trial and for 4 weeks following cessation of the investigational medicinal product (IMP). Female participants of non-childbearing potential must be either surgically sterile (hysterectomy and/or oophorectomy) or postmenopausal at least 1 year. All female participants must have a negative plasma hCG pregnancy test at screening. 2. Modified Hachinski Ischaemia Score less than or equal to 4 (Moroney et al., 1997) 3. Subjects must have a diagnosis of possible or probable bvFTD established in accordance with the recommendations from the International Behavioural Variant FTD Criteria Consortium (Rascovsky et al., 2011). 4. Subjects must have a lumbar puncture performed within 14 days prior to Baseline (Visit 2). 5. Subject must have an MRI scan during the screening period and prior to Baseline (Visit 2), with no gross structural abnormality indicative of a neurological disorder other than bvFTD. 6. Subject must be living in the community and have at least 10 contact hours per week with a responsible carer. The carer should be capable of ensuring the subject's compliance with the medication, be prepared to attend with the subject for assessment and be willing to participate in completing the various assessments throughout the period of the subject’s involvement in the Study. 7. Written informed consent must be obtained from the subject or legally authorised representative (as required by local laws and regulations), and the participant’s carer. 8. Subjects must have a negative amyloid-binding PET scan. Historical scans will be accepted. In patients who have not previously had an amyloid-PET this will be performed during the screening period and prior to Baseline (Visit 2).",ACTRN12620000236998 SEL002 TrialTroveID-369700 U1111-1248-2724,Adults; Older Adults,year(s),,369700,Frontotemporal Dementia,,35.0,"1.Subject has participated in a clinical investigation of a medication or device within the 3 months prior to the Screening Visit (Visit 1), with the exception of prior exposure to sodium selenate. 2.Subject in whom a lumbar puncture is contra-indicated. 3.Subject with a history of alcohol and/or drug abuse, defined as meeting DSM-V criteria for substance use disorder. This applies to alcohol and/or any illicit drug, including cannabis within the 6 months prior to the Screening Visit (Visit 1). 4.Subject who is unlikely to comply with trial visit schedule or with trial medication. 5.Subject has a known sensitivity to selenium, sodium selenate, any medicine or vitamin containing sodium selenate, similar agents or any of the excipients (including microcrystalline cellulose) used. 6.Subject has a primary, secondary or pseudodementia condition other than possible bvFTD, or has current evidence or history of neurological, psychiatric or any other illness that could contribute to cognitive impairment. 7.Subject has a known history of familial Alzheimer’s Disease. 8.Subject has a known genetic form of frontotemporal dementia that is not considered a primary tauopathy (e.g. positive for the C9ORF72 gene). 9.Subject has a significant medical or neurological disease, with the exception of bvFTD that: is not adequately controlled by therapy; and/or in the opinion of the investigator may interfere with the patient’s ability to complete the study or might impact on the patient’s cognitive performance. 10.Subject has current evidence of unstable diabetes. 11.Subject has significant impairment of any of the following for the age of the subject, which may compromise safety of the subject/validity of the data: Renal function (i.e. estimated glomerular filtration rate (eGFR) <30 ml/min) Hepatic function (i.e. abnormal liver function tests greater than 2 x upper limit of normal) Haematological function. 12.Subject in whom it is anticipated that there will be a definite indication for the commencement of other licensed anti-dementia drug treatment within the 64-week period of trial participation. 13.Subject is currently taking one of the following drugs, or has taken one of the following drugs within the 6 weeks prior to the Screening Visit (Visit 1): Memantine, or other NMDA receptor antagonists (such as amantadine, ketamine, dextromethorphan or nitrous oxide) Oral and/or injectable steroids, for example dexamethasone, fludrocortisone , methylprednisolone, prednisolone or prednisone 14.Subject is currently taking any of the following: Digoxin, phenobarbitone, warfarin or any other medication that has a narrow margin between effective dose and toxic dose or between effective dose and ineffective dose, where the subject would be at risk if the levels were elevated or fell due to interaction with sodium selenate. 15.Subject has started taking or changed their dose of other medication known to have an effect on mood or cognition within the 4 weeks prior to the Screening Visit (Visit 1). Examples of such drugs include: Anticholinergics, for example ipratropium, oxitropium or tiotropium bromide Hypnotics, sedatives and anxiolytics, for example barbiturates, benzodiazepines, serotonin 1A agonists, hydroxyzine, zolpidem or zopiclone Antidepressants, for example tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitor (MAOIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), noradrenergic and specific serotonergic antidepressants, buspirone, reboxetine or trazodone Antiepileptics, for example barbiturates, benzodiazepines, ethosuximide, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, primidone, topiramate, valproate or vigabatrin Antipsychotics, for example butyrophenones, phenothiazines, thioxanthenes, amisulpride, aripiprazole, clozapine, olanzapine, paliperidone or quetiapine Memory-enhancing drugs, for example aniracetam, oxiracetam, piracetam or pramiracetam Nutraceutical such as Souvenaid, and other supplements which contain selenium",Ii,Both
0,Patients with Behavioural Variant Fronto-Temporal Dementia,Diagnosis of possible behavioural variant FTD MRI not inconsistent with FTD Responsible caregiver who can ensure participants compliance with study procedures and dosing of drug,ACTRN12617001218381 SEL001 TrialTroveID-314139,Adults; Older Adults,year(s),,314139,Frontotemporal Dementia,,35.0,Contra-indication to lumbar puncture Positive amyloid PET scan Known family history of Alzheimer's Disease Significant uncontrolled medical condition Known sensitivity to sodium selenate or related compounds,Iii,Both
1,"Patients with Amyotrophic Lateral Sclerosis. Patients with probable, probable-laboratory supported or definite ALS.","Ages Eligible for Study 18 Years - 85 Years Inclusion Criteria Definite, probable, or probable-laboratory supported ALS according to the revised El Escorial World Federation of Neurology criteria. Intake of riluzole 50 mg twice a day (bid). A disease duration at inclusion of more than 6 months and less than 36 months [inclusive] (disease onset is defined as the date of first symptoms excluding muscle cramps and fasciculations). Vital capacity (VC%) > or = 70% of normal value (slow expiration, best of a minimum of three and a maximum of five measurements, with a respiratory function validly assessable and a spontaneous, non-assisted ventilation). Ages 18 - 85 years (inclusive). Capable of thoroughly understanding the trial information given; has signed the informed consent.",04/182-0 NCT00136110 TrialTroveID-079100,Adults; Older Adults,year(s),year(s),79100,Delay Disease Progression,85.0,18.0,"Exclusion Criteria Tracheostomy, tracheostomal ventilation of any type, non-invasive ventilation more than 16 hours/ day, or supplemental oxygen during the last three months prior to inclusion. Any medical condition or intoxication known to have an association with motor neuron dysfunction, which might confound or obscure the diagnosis of ALS. Presence of any concomitant life-threatening disease or any disease or impairment likely to interfere with functional assessment. Confirmed hepatic insufficiency or abnormal liver function (ASAT, ALAT greater than twice the upper limit of normal range).",Iii,Both
0,,,TrialTroveID-480959,,,,480959,Unspecified,,,,I,
0,Patients with amyotrophic lateral sclerosis.,"Ages Eligible for Study: 40 Years to 85 Years Inclusion Criteria: Definite/probable ALS according to El Escorial criteria. Aged >40, <85 years. Progression from onset. Disease duration < or = 3 years. Treatment with Riluzole.",FARM53XBKT NCT00635960 SLA_GH_1 TrialTroveID-086066,Adults; Older Adults,year(s),year(s),86066,Delay Disease Progression,85.0,40.0,Exclusion Criteria: Rapid disease progression in the first 6 months after diagnosis. Patients with tracheostomy and/or Gastrostomy. Disease duration >3 years. Patient with exclusive bulbar or 2 motorneuron involvement. Hepatic/renal failure. Pregnant or breastfeeding. Signs of active neoplasia. Complicated Diabetes. Severe hypertension. Unable to undergo MRI exams.,Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis,"Able to communicate well with the investigator, to understand and comply with the study visits and procedures of the study Written informed consent must be obtained before any assessment is performed. Male and female participants who are 18 years old or older at screening, and who are diagnosed with familial or sporadic ALS according to the World Federation of Neurology Revised El Escorial criteria of either bulbar or limb onset. Disease duration from symptoms onset no longer than 48 months at the screening visit. Females of childbearing potential must have a negative pregnancy test at screening and/or baseline. Treatment with approved ALS therapies is allowed, but participants need to be on a stable dose and regimen for at least 30 days prior to baseline. Having completed the Core Treatment Period to be able to continue in the Extended Treatment Period.",CBLZ945C12201 EudraCT Number: 2019-000826-22 NCT04066244 TrialTroveID-355943,Adults; Older Adults,year(s),,355943,Unspecified,,18.0,"A history of clinically significant ECG abnormalities Active medical or neurologic diseases other than ALS, that in the opinion of the investigator would limit their participation in the current study. Use of other investigational drugs within 5 half-lives of screening, or until the expected PD effect has returned to baseline, whichever is longer; or longer if required by local regulations. History of hypersensitivity to any of the study treatments or excipients or to drugs of similar chemical classes. Presence of human immunodeficiency virus (HIV) infection based on screening lab results. Evidence of active or latent tuberculosis as assessed by Quantiferon testing at the screening visit. Positive serology for hepatitis B surface antigen, or hepatitis C antibodies confirmed by an appropriate licensed test at screening. Signs or symptoms, in the judgement of the investigator, of a clinically significant systemic viral, bacterial or fungal infection within 30 days prior to the screening visit. Cardiac disorders, such as recent cardiac history (within 6 months of screening) of acute coronary syndrome, acute heart failure, or significant ventricular arrhythmia at the screening visit or participants with a history of severe pulmonary hypertension. Participants with cardiac failure class 3 or 4 of the NYHA classification, or history of reduced LVEF or individuals with implanted cardiac pacemaker, or defibrillator. Significant hematological laboratory abnormalities. Clinical evidence of liver disease or liver injury or any of the following hepatic conditions at the screening visit: Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 14 days after last dose of BLZ945. Pregnant or nursing female participants Sexually active males unless they use a condom during intercourse while taking the drug during treatment, for 14 days after stopping BLZ945 and should not father a child in this period. History or presence of impaired renal function at the screening visit. Active suicidal ideation. History of drug abuse or harmful alcohol use within the 12 months prior to dosing within the judgement of the investigator, or evidence of such abuse as indicated by the laboratory assays conducted during screening. Active GI conditions such as Barrett's esophagus, achalasia, esophageal varices and active or history of esophageal cancer, pre-existing pancreatic disease at screening visit. History of active vasculitis or history of autoimmune disease autoimmune disease associated with vasculitis (eg., RA, SLE, Sjögrens disease, scleroderma). History or active cardiac valve disorder, congenital valve disease, or other clinical condition that might affect cardiac valve function Use of systemic anticoagulation that cannot be temporarily paused before study procedures Abnormal values on CT scan or echocardiography, signs of vasculitis, or evidence of a significant medical condition meeting treatment discontinuation criteria will be exclusionary for continuation in the extended treatment period. Participants who are planning to initiate treatment with an additional approved ALS therapy in the next 24 weeks are not allowed to continue in the extended treatment period.",Ii,Both
0,Subjects with the behavioral variant of frontotemporal dementia (bv-FTD).,All patients and caregivers gave written informed consent for the study,TrialTroveID-315798,,,,315798,Frontotemporal Dementia,,,,Ii,
0,,,TrialTroveID-184617,,,,184617,Unspecified,,,,I,
1,,"1. Patients (men or women) - between 39 (exclusive) and 66 (inclusive) years old - with a sporadic ALS, defined, probable or laboratory possible - with a disease duration between 3 months (inclusive) and 5 years (exclusive) - treated with rilutek at 100 mg/ day since at least 1 month 2. Patients will be assigned in three groups in relation with the clinical phenotypes: - 20 patients without stiffness - 20 patients with pyramidal stiffness (spasticity patients). - 20 patients with mixed stiffness (both spasticity and rigidity). 3. Patients have to be capable of thoroughly understanding the information given; have signed the informed consent form (signature of spouse or family relative or acceptable third party is acceptable if the patient is physically unable to sign). 4. To have social insurance",AOM 07225 DOSERAL NCT01160263 P080402,Adults; Older Adults,year(s),year(s),225247,,66.0,39.0,"1. Patients with a FRONTO temporal dementia (according to NEARY' criteria) 2. Patients with any concomitant life-threatening disease or any disease or impairment likely to interfere with functional assessment; 3. Patients with any major evolving psychiatric disorder or major anxiety disorder according to DSM-IV criteria (APA, 1996) 4. Patients receiving treatments which could interfere with the serotonin or dopamine metabolism 5. Patients with contraindications for the dat-scan and /or ADAM scan 6. Patients with contraindications for the MRI scan. 7. Patients with previous vascular, traumatic or tumoral cerebral lesions making impossible the quantification of the tracer 8. Patients with a cancer within the past 5 9. Patients child bearing, breast feeding or in the second part of their cycle without any efficient contraceptive device or treatment 10. Patients liable not to be co-operative or comply with the trial requirements (as assessed by the investigator), or unable to be reached in the event of an emergency;",Iii,Both
0,Patients with amyotrophic lateral sclerosis and healthy subjects,Age 18-55 Must be in good health with no significant medical history Clinical laboratory values within normal range BMI 18-32 (inclusive) Contraceptive use by men or women consistent with local regulations Able and willing to provide written informed consent ALS Cohort Inclusion Criteria: Age 18-80 ALS FVC>80% ALSFRS-R >=12 points Stable dose of standard of care treatment Contraception use by men or women consistent with local regulations Able and willing to provide written informed consent,NCT05882695 SPG302-ALS-001 TrialTroveID-405962,Adults; Older Adults,year(s),year(s),405962,Healthy subjects,80.0,18.0,"Any physical or psychological condition that prohibits study completion Known cardiac disease Active or history of malignancy in the past 5 years Serious infection within 1 month of screening Acute illness within 30 days of Day 1 Surgery, bone fracture, or major musculoskeletal injury in the past 3 months History of suicidal behavior or suicidal ideation Active cigarette smokers and users of nicotine-containing products HIV, hepatitis B and hepatitis C positive SBP >140 or <90 DBP >90 or <40 HR <40 or >100 QTcF >450ms, cardiac arrhythmia, or clinically significant abnormal ECG Prescriptions, over-the-counter, or herbal medication within 7 days Vaccines within 14 days Other investigational products within 30 days Blood donation within 30 days Plasma donation within 7 days Pregnant or breastfeeding Otherwise unfit, on metabolic-altering lifestyle/diet, positive urine drug screen or intake of alcohol or caffeine-containing products ALS Cohort Exclusion Criteria: Underlying physical or psychological condition prohibiting study completion Known cardiac disease Active or history of malignancy in the past 5 years Serious infection within 1 month of screening Acute illness within 30 days of Day 1 Surgery, bone fracture, or major musculoskeletal injury in the past 3 months History of suicidal behavior or suicidal ideation Active cigarette smokers and users of nicotine-containing products Neurodegenerative disease External respiratory support or supplemental oxygen requirement HIV, hepatitis B and hepatitis C positive SBP >140 or <90 DBP >90 or <40 HR <40 or >100 QTcF >450ms, cardiac arrhythmia, or clinically significant abnormal ECG Vaccines within 14 days Other investigational products within 30 days Blood donation within 30 days Plasma donation within 7 days Pregnant or breastfeeding Otherwise unfit",I,Both
0,,,TrialTroveID-495558,,,,495558,Unspecified,,,,I,
0,,"- Patients with the diagnoses of definite amyotrophic lateral sclerosis. - Clear information about date of onset of symptoms, documented contact information and follow up information",NCT01984814 NGBSI-04,Adults; Older Adults,year(s),year(s),231463,,76.0,26.0,"- Patients with diagnoses of Progressive Lateral sclerosis, Progressive bulbar plasy, Progressive spinal muscular atrophy, Progressive muscular atrophy, monomelicamyotrophy or madras motor neuron disease. - patients with co-morbidities like presence of acute infections such as Human Immunodeficiency Virus/Hepatitis B Virus/Hepatitis C Virus, malignancies, bleeding tendencies, renal failure, severe liver dysfunction and other acute medical conditions such as respiratory infection and pyrexia.",Ii,Both
1,"78 Patients with ALS, thirty five patients exhibited high IgG titres to toxoplasmosis.",,TrialTroveID-182938,,,,182938,Delay Disease Progression,,,,Iv,
0,Healthy Volunteers,,TrialTroveID-283348,,,,283348,Healthy subjects,,,,I,
0,Subjects with Amyotrophic Lateral Sclerosis (ALS).,"Ages Eligible for Study: 18 Years to 80 Years Genders Eligible for Study: Both Inclusion Criteria: Patients must have completed 52 weeks of treatment of the double blind placebo-controlled phase of ALS-TAL-201. Women must be postmenopausal, surgically sterile, or using adequate birth control methods. Patients must be willing and able to give written informed consent prior to performing any open-label study procedures.",ALS-TAL-201-OL ALSTAR OL NCT00982150 TrialTroveID-115972,Adults; Older Adults,year(s),year(s),115972,Delay Disease Progression,80.0,18.0,"Exclusion Criteria: Patients with ECG signs of Brugada syndrome and/ or complete or incomplete Right Bundle Branch Block. Patients using any of the following: Chronic use of lithium carbonate. Chronic use of mecasermin (rhIGF-1). Chronic use of minocycline. Chronic use of more than 600mg/day coenzyme Q10. Chronic use of any marketed drug, if its use was not clearly indicated for any underlying medical condition other than ALS (symptomatic drugs for ALS and supplements allowed). Patients participating in any other investigational drug study and use of any other investigational drug Patients taking drugs that may interact with Talampanel Females who are pregnant or nursing. Females of child-bearing potential who do not practice medically acceptable methods of contraception. Any condition of the patient which the investigator feels may interfere with participation in the study.",Ii,Both
0,Healthy male and female volunteers.,"Ages Eligible for Study: 18 Years to 50 Years Inclusion Criteria: Healthy volunteers aged 18 to 50 years of age inclusive. Body mass index: Between 18 and 30 kg/m2 and weight of at least 50 kg. Female volunteers must have either a negative pregnancy test and be willing to use birth control, be post-menopausal evidenced by lab test, or be surgically sterile. Volunteers must be able to understand the requirements of the study and must be willing to comply with the requirements of the study and provide their written informed consents to participate in the study prior to the conduct of study procedures.",NCT00964730 R09-0539 TAL-TQT-101 TrialTroveID-114416,Adults,year(s),year(s),114416,Healthy subjects,50.0,18.0,"Exclusion Criteria: Male and female volunteers with a resting QT interval of < 320 msec or > 450 msec (males) or > 470 msec (females Volunteers with ECG abnormalities that may interfere with the accurate assessment of the QT interval Volunteers with known cardiovascular disorders, including coronary artery disease, valvular heart disease, cardiomyopathies, or ECG abnormalities suggestive of prior myocardial infarction, chamber enlargement or hypertrophy. Volunteers with known clinically significant arrhythmias or rhythm disturbances observed on ECG Volunteers who have a history of, or risk factors for, Torsades de Pointes (e.g. heart failure, abnormal serum electrolytes), including a history of family history of arrhythmia, sudden death, long QT syndrome, Brugada complex, or personal history of syncope. Volunteers who have a heart rate outside 40-90 beats per minute Volunteers who have a blood pressure outside 90-140 mmHg systolic or 45-90 mmHg diastolic Volunteers with history of uncontrolled hypertension, impaired glucose tolerance, diabetes mellitus, kidney disease, edema, stroke or neurological disorder, rheumatological disorder, lung disease, heart disease, liver disease, or a history of any illness that pose additional risk to the volunteer Volunteers with a history of psychiatric disorders, including bipolar disorder, psychosis, previous episode(s) of major depression, history of suicidality or suicidal ideation. Volunteers who have history of surgeries or conditions that affect the way drugs are absorbed or distributed in the body such as intestinal surgery, stomach surgery. Volunteers with impaired liver function and elevated liver enzymes Volunteers with major trauma or surgery in the past 2 months, acute infection within 2 weeks, cancer within the last 5 years (excluding non-melanoma skin cancers), History of tuberculosis, abnormal lab tests Female volunteers who are lactating or intend to become pregnant during the study period. Volunteers with a known allergy or sensitivity to moxifloxacin or its derivatives, benzodiazepines, talampanel or its derivatives, or any contraindications to moxifloxacin, benzodiazepines, or talampanel. Volunteers with significant food or drug allergies Volunteers that have used an investigational drug (new chemical entity) 3 months prior to the start of the study,.who have consumed any medications (including over-the-counter medications, prescription medications, investigational drugs, vitamins, or herbal remedies) within 30 days prior to check-in (with the exception of hormonal contraceptives [females only] and occasional use of acetaminophen and ibuprofens, who have consumed amiodarone and chloroquine within 4 months prior to screening, who have consumed excessive amounts of alcohol or are unwilling to comply with the restricted use of alcohol during the study, who have consumed excessive amounts of coffee, tea, coke, or other caffeinated beverages within 2 weeks prior to check-in, who have consumed quinine (tonic water) within 7 days prior to study start, who have consumed grapefruit, grapefruit juice, or Seville orange juice within the 7 days prior to study start, who smoke, have smoked in the last 3 months, or are planning to start smoking during the study, tobacco users, subjects currently using nicotine products, or subjects with a positive urine cotinine test at study start Volunteers who are currently regular users (including recreational use) of any illicit drugs or who have a history of drug (including alcohol) abuse within 1 year of study start. Volunteers with positive urine test for drugs of abuse at screening or check-in. Volunteers who have donated or received any blood, plasma, or platelet transfusions in the 3 months prior to study start, or who have made donations on more than two occasions within the 12 months preceding the first dose administration, or who have planned donations during the study or during the 3 months following the study. Volunteers with a positive screening test for Hepatitis B, Hepatitis C or HIV Volunteers not willing to refrain from changing level of activity during the study and from jogging and strenuous exercise of all types while at the research unit.",I,Both
0,Healthy human volunteers.,"Ages Eligible for Study: 18 Years to 55 Years Inclusion Criteria Males, between 18 and 55 years of age, inclusive. Body Mass Index range 18.0 to 30.0 kg/m2, inclusive. Have NAT2 slow or rapid acetylator genotype. In good health as determined by the investigator. Sterile or agrees to use an approved method of contraception from Check-in until 45 days following Clinic Discharge. Able to comprehend and willing to sign an Informed Consent Form. Have 1 to 2 bowel movements per day.",NCT00868361 TAL-MB-100 TrialTroveID-106544,Adults,year(s),year(s),106544,Healthy subjects,55.0,18.0,"Exclusion Criteria Positive test for selected drugs of abuse at screening. Positive screens for Hepatitis B, Hepatitis C and HIV. Significant history or clinical manifestation of any significant metabolic, allergic, skin, liver, kidney, blood, heart or blood vessel, digestive system, brain or psychiatric disorder. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance. History of stomach or intestinal surgery or resection. History or presence of an abnormal ECG, History of clinically significant alcohol or drug use within 1 year prior to Check-in. Participation in more than 1 other radiolabeled investigational study drug trial within 12 months prior to Check-in. Exposure to significant radiation within 12 months prior to Check-in -Use of any tobacco- or nicotine-containing within 6 months prior to Check- in. Use of any drugs which may interact with the study drug within 30 days prior to Check-in. Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 30 days prior to Check-in. Use of any prescription medications/products within 14 days prior to Check in. Use of any over-the-counter, non-prescription drugs within 7 days prior to Check-in. Use of grapefruit or grapefruit-containing foods or beverages within 7 days prior to Check-in. Use of alcohol- or caffeine-containing foods or beverages within 72 hours prior to Check-in. Donation of blood from 30 days prior to Screening through Study Completion, inclusive, or of plasma from 2 weeks prior to Screening through Study Completion. Receipt of blood products within 2 months prior to Check-in. Any acute or chronic condition that would limit the subject's ability to complete and/or participate in this clinical study.",I,Male
0,"Subjects with sporadic or familial ALS classified as definite, probable, or laboratory-supported probable ALS according to the revised El Escorial criteria. In yet another test of inclusion and exclusion criteria defined in the personal patient contact recorded. During the visits in our outpatient clinic, the following analysis steps: Physical examination. Electrocardiography (ECG). Structured Interview for the Quality of Life. Structured Interview for ALS severity. Laboratory Investigation. Measurement of respiratory capacity (SVC). Determination of body weight. Determination of blood pressure and heart rate. Detection of possible adverse events (side effects).",Ages Eligible for Study: 18 Years to 80 Years Inclusion Criteria Diagnosis of definite or probable ALS in accordance with the El-Escorial criteria. Subject has experienced his/her first ALS symptoms within 3 years prior to the screening visit. Slow VC test equal to or greater than 70% of the predicted value. The sum of the 3 respiratory items on the ALSFRS-R must total at least 10 points. Subject taking riluzole must be on a stable dose for at least 8 weeks prior to screening visit. Age - 18-80 (inclusive).,AL-STAR201 ALS-TAL-201 ALS-TAL-201 (ALSTAR) ALSTAR EudraCT Number: 2008-002062-62 NCT00696332 TrialTroveID-080706,Adults; Older Adults,year(s),year(s),80706,Delay Disease Progression,80.0,18.0,Exclusion Criteria: The use of invasive or non-invasive ventilation. Subject having undergone gastrostomy. Subject with any clinically significant or unstable medical condition. Subject participating in any other investigational drug trial or using investigational drug (within 12 weeks prior to screening and thereafter). Females who are pregnant or nursing. Ingestion of lithium carbonate to 4 weeks before study start.,Ii,Both
0,Patients with amyotrophic lateral sclerosis.,Eligible subjects were 18–85 years of age and had definite or probable ALS as described by the World Federation of Neurology ad hoc committee. They were symptomatic for two years or less at the time of entry into this study and had at least four of eight testable upper extremity muscle groups (extensors and flexors of the shoulder and elbow) at Medical Research Council grade 3 (antigravity) strength or better. Subjects had forced vital capacity of >60% predicted and were considered stable by the investigator. Riluzole was allowed providing subjects had been on a stable dose for at least 30 days. Subjects were not allowed to take any other experimental agents. Subjects provided informed consent.,TrialTroveID-080705,Adults; Older Adults,year(s),year(s),80705,Delay Disease Progression,85.0,18.0,,Ii,Both
0,,,TrialTroveID-405146,,,,405146,Unspecified,,,,I,
0,Subjects with Parkinson’s disease,Informed consent as documented by signature. Confirmed Parkinson's disease according to British brain bank criteria. Hoehn and Yahr Stage 0 - 2.5 on medication. Stable on PD treatment for a month at least. Absence of dementia confirmed by cognitive testing (MoCA >25),BASEC2021-01141 NCT04976127 NEON SNCTP000004631 TLN/PD/1 TrialTroveID-387494,Adults; Older Adults,year(s),year(s),387494,Mild to Moderate; Non-motor symptoms/comorbidities,85.0,30.0,"Contraindications to the class of drugs under study, e.g., known hypersensitivity or allergy to class of drugs or the investigational product. Women who are pregnant or breast feeding, or planning to become pregnant during the course of the trial or in the 3 months following the trial. Lack of safe contraception in women with childbearing potential Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc) that is not under stable control. Subject has an atypical parkinsonian syndrome or secondary parkinsonism. Patients with comorbidity that may interfere with the course of the trial.",I,Both
0,Subjects with Amyotrophic Lateral Sclerosis [ALS],"Ages Eligible for Study: 18 Years - 90 Years, Genders Eligible for Study: Both. Inclusion Criteria: Clinically probable-laboratory supported, clinically probable, or clinically definite amyotrophic lateral sclerosis.",2000-486 NCT00214110 TrialTroveID-079072,Adults; Older Adults,year(s),year(s),79072,Delay Disease Progression,90.0,18.0,"Exclusion Criteria: Allergic or idiosyncratic response to tamoxifen. Other active neurologic diseases that may produce weakness, sensory loss, or autonomic symptoms. Psychiatric, psychological, or behavioral symptoms that would interfere with the subject’s ability to participate in the trial. Clinically significant cardiac, pulmonary, gastrointestinal, hematologic, or endocrine (poorly controlled insulin-dependent diabetes mellitus or hyperthyroidism) disease that may confound interpretation of the study results. Previous kidney or pancreas transplants. Significant hepatic or renal disease (AST > 5 times normal, serum creatinine > 2.0 mg/dL for males or > 1.8 mg/dL for females).",Ii,Both
0,Patients with Amyotrophic Lateral Sclerosis (ALS).,"Ages Eligible for Study: 18 Years and older Genders Eligible for Study: Both Inclusion Criteria: Familial or sporadic ALS. Disease duration from diagnosis no greater than 36 months at Screening Visit. Aged 18 years or older. Capable of providing informed consent and complying with trial procedures. Vital capacity (VC) equal to or more than 50% predicted normal value for gender, height and age at the Screening Visit. Not taking, or on a stable dose of riluzole (50mg bid) for at least 30 days prior to the Screening Visit. Women must not be able to become pregnant for the duration of the study (e.g., post menopausal for at least one year, surgically sterile, or practicing adequate birth control methods) for the duration of the study. Women of childbearing potential must have a negative serum pregnancy test at the Screening Visit and be non-lactating.",NCT01257581 SDALS-001 TrialTroveID-139062,Adults; Older Adults,year(s),,139062,Delay Disease Progression,,18.0,"Exclusion Criteria: History of known sensitivity or intolerability to creatine monohydrate or tamoxifen citrate or to any other related compound. Prior exposure to creatine or tamoxifen within 30 days of the Screening Visit. Exposure to any investigational agent within 30 days of the Screening Visit. Use of coumarin anticoagulants (warfarin sodium), rifampin, aminoglutethimide, medroxyprogesterone, letrozole, or bromocriptine. Presence of any of the following clinical conditions: Clinical evidence of unstable medical or psychiatric illness at the Screening Visit; Screening AST > 3 times the upper limit of normal or serum creatinine > 1.5 mg/dl (133 umol/L); Permanent assisted ventilation or mechanical ventilation; or Lactating or have a positive serum pregnancy test at the Screening Visit. History of any of the following: blood clots including deep vein thrombosis, pulmonary embolism, and stroke, cataracts, renal problems, endometrial cancer, uterine sarcoma, or diabetes mellitus.",Ii,Both
0,Motor neuron disease patients have disabilities,"After two specialist neurologist diagnosed with amyotrophic lateral sclerosis, or patients taking sharp edge in (Rilutek) is about to take it; aged >or= 20 years old.",201306028 TrialTroveID-260538,Adults; Older Adults,year(s),,260538,Delay Disease Progression,,20.0,"Nova was a scholar for ingot or Motor Neuron Disease of similar allergy;. for any reason in the past, now have to use Nova disabilities ingots Motor Neuron Disease; maintain respiratory function of motor neurone disease through the use of a respirator Patients; refusal to accept the recommendations of neurologists treat patients. SOD-1 or FUS / TLS gene mutation. CA-125 concentration or abnormal uterine ultrasound. Nova have disabilities ingot (Tamoxifen) have been reported, although in a foreign country over the long-term use with endometrial hyperplasia and cancer of somewhat relevant, but in the subsequent study found that in a short time, the use of low-dose (20mg / day Use less than two years) is not prone to cancer than the control group trend.",Ii,
0,Patients With Motor Neuron Disease.,"Ages Eligible for Study: 20 Years to 80 Years; Genders Eligible for Study: Both Inclusion Criteria: Clinical diagnosed and confirmed ALS patients, with regular follow up and oral form riluzole at National Taiwan University or Shuang- Ho Hospital for more than 6 months. Age > or =20 years old",201307022 NCT02166944 TrialTroveID-211170,Adults; Older Adults,year(s),year(s),211170,Delay Disease Progression,80.0,20.0,"Exclusion Criteria: Patients who had already ventilator dependent, not regular followed up for more than 6 months or against medical advice, refuse to follow up at neurology department will be excluded in this study. Patients with now or previous usage of Tamoxifen Patients with any contraindications of Tamoxifen usage Patients with other internal medicine illiness",Iii,Both
1,Patients With Amyotrophic Lateral Sclerosis,- Completion of the visit M18 (Month 18) of the TUDCA-ALS clinical trial. - Signed informed consent for participation in the TUDCA-ALS Extension sub-study,H2020/755094/2017/OLE NCT05753852 TrialTroveID-460915 TUDCA-ALS OLE,Adults; Older Adults,year(s),,460915,Delay Disease Progression,,18.0,"- Treatment with edaravone or other unaccepted concomitant therapy - Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive TUDCA or that the subject is unable or unlikely to comply with the dosing schedule or study evaluations - The patient of reproductive potential is sexually active and is not willing to use highly effective contraception during the study and up to 90 days after the day of last dose - The patient is pregnant or breast feeding",Iii,Both
1,Patients affected by Amyotrophic lateral sclerosis,"Probable laboratory-supported, probable, or definite ALS, as defined by El Escorial Revised ALS diagnostic criteria at screening visit (month -3) Disease duration ≤ 18 months at screening visit (month -3) Able to perform reproducible pulmonary function tests at screening visit (month -3) Forced vital capacity or slow vital capacity ≥70% of normal at screening visit (month -3) Stable on riluzole treatment for 3 months in the lead-in period Signed informed consent at screening visit (month -3)",EudraCT Number: 2018-002722-22 H2020/755094/2017/IT-01 NCT03800524 NL69414.041.19 TrialTroveID-327506 TUDCA-ALS,Adults; Older Adults,year(s),year(s),327506,Delay Disease Progression,80.0,18.0,"Treatment with edaravone Other causes of neuromuscular weakness Presence of other neurodegenerative diseases Significant cognitive impairment, clinical dementia or psychiatric illness Severe cardiac or pulmonary disease Other diseases precluding functional assessments Other life-threatening diseases Any use of non-invasive ventilation (e.g. continuous positive airway pressure, non-invasive bi-level positive airway pressure or non-invasive volume ventilation) for any portion of the day, or mechanical ventilation via tracheostomy, or on any form of oxygen supplementation Gastrointestinal disorder that is likely to impair absorption of study drug from the gastrointestinal tract Has taken any investigational study drug within 30 days or five half-lives of the prior agent, whichever is longer, prior to dosing Any clinically significant laboratory abnormality Other concurrent investigational medications Active peptic ulcer Previous surgery or infections of small intestine Patients unable to easily swallow the treatment pills Acute inflammation of the gallbladder or bile ducts Occurrence of frequent biliary colic, biliary infections, severe pancreatic abnormalities Bile duct obstruction, calcified X-ray opaque gallstones and reduced mobility of the gallbladder Subjects who weigh 88 lbs (40 kg) or less Aspartate aminotransferase or alanine aminotransferase concentrations more than 3 times the upper limit of normal Creatinine clearance 50 ml/min or less Any clinically significant neurological, haematological, autoimmune, endocrine, cardiovascular, neoplastic, renal, gastrointestinal, or other disorder that, in the Investigator's opinion, could interfere with the subject's participation in the study, place the subject at increased risk, or confound interpretation of study results Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive TUDCA or that the subject is unable or unlikely to comply with the dosing schedule or study evaluations The patient of reproductive potential is sexually active and is not willing to use highly effective contraception during the study and up to 90 days after the day of last dose The patient is pregnant or breast feeding",Iii,Both
0,Patients Affected by Amyotrophic Lateral Sclerosis.,"Ages Eligible for Study: 18 Years to 75 Years, Genders Eligible for Study: Both Inclusion Criteria: Caucasian male or female out-patients. Aged 18 to 75 years inclusive. Diagnosis of ""probable"" or ""definite"" amyotrophic lateral sclerosis according to the El Escorial revised criteria (1). First symptoms of ALS by no more than 1.5 years. in treatment with steady regimen of riluzole for a minimum of 3 months before study entry, and desiring its continuation; FVC > or = 75% of predicted. No conditions known to be contraindications to the use of TUDCA Written informed consent. Patients affected by ALS with site of onset in the limbs.",EudraCT Number: 2007-001592-10 NCT00877604 TrialTroveID-107044 TUDCA 20071 TUDCA-ALS TUDCA200701,Adults; Older Adults,year(s),year(s),107044,Delay Disease Progression,75.0,18.0,"Exclusion Criteria: Subjects who underwent tracheostomy. Subjects who underwent resection of gall bladder. Subjects with signs of conduction blocks of motor nerves, sensory nerves or both on nerve conduction study. Subjects with clinical signs of dementia. Subjects with active peptic ulcer. Subjects with active malignancy. subjects with bulbar onset Female subjects who are pregnant or lactating. Subjects who have received an experimental drug or have participated in a clinical trial within 3 months prior to screening. Employees of the investigator or study centre with direct involvement in the proposed study or other studies under the direction of that investigator or study centre.",Ii,Both
1,Subjects with amyotrophic lateral sclerosis.,"Completed a multicenter, randomized, double-blind, placebo-controlled study The single arm long-term safety study must be conducted within 28 days of the 24th week visit of the multicenter, randomized, double-blind and placebo study (including the day of the 24th week visit).",ChiCTR2100054894 TrialTroveID-421812,Adults; Older Adults,year(s),year(s),421812,Delay Disease Progression,80.0,18.0,"Subjects using prohibited medications in a multicenter, randomized, double-blind, placebo-controlled study Subjects who, in the opinion of the investigator, cannot be enrolled in a single arm long-term safety study for any reason",Iv,Both
0,,,CTCH346 0102 NCT00036413,Adults; Older Adults,year(s),year(s),224775,,75.0,40.0,,Ii,Both
0,,- diagnosed with PPA by neurologist or speech-language pathologist - speech-language deficit arising from PPA - native speaker of English Language or equivalent - adequate vision (normal or corrected to normal) - adequate hearing,2103570362 NCT04920318 PPA,Adults; Older Adults,year(s),year(s),435690,,80.0,45.0,"- meeting (Diagnostic and Statistical Manual) DSM-IV criteria for Axis I mood, anxiety, psychotic or substance abuse disorders. - highly magnetizable metallic implants, including certain dental work - neurological disorders besides the ones of interest for the study (e.g., epilepsy) - Multiple Sclerosis - Parkinson's Disease - contraindications for MRI - pacemakers - metallic cardiac pumps - valves - magnetic materials such as surgical clips, implanted electronic perfusion pumps, or any other condition that would preclude proximity to a strong magnetic field. - clinically significant claustrophobia - severe systemic disease (e.g., renal failure) - poor health - pregnancy - epileptic activity in the past 12 months - family history of epilepsy or other seizure disorders - brain surgery in the past - metallic skull plates or implants - skin lesions or skull damage - excessive use of alcohol or drugs - premorbid psychiatric disease affecting communication - severe non-linguistic cognitive disturbances impeding language therapy",Other,Both
0,Adults with diagnosis of ALS Participants with a definite or probable diagnosis of ALS by El Escorial Criteria-revised,"ALS diagnosed as possible, laboratory supported probable, probable, or definite as defined by revised El Escorial criteria ALSFRS-R Aggregate score of 37 or greater No more than 24 months from diagnosis",AT-1501-A201 NCT04322149 TrialTroveID-370517,Adults; Older Adults,year(s),,370517,Unspecified,,18.0,"Exclusion Criteria: Any other central or peripheral nervous system disease that may interfere with the evaluation of ALS or its progression Presence of a tracheostomy, or use of permanent assistive ventilation (ventilatory support for 23 hours per day or more) History of malignancy within the previous 5 years, except for localized non-melanoma skin cancers Abnormal function of the immune system resulting from: Clinical conditions affecting the immune system (e.g. HIV infection, agammaglobulinemia), Systemic administration of corticosteroids (PO/IV/IM) at a dose equivalent to 20 mg/day of prednisone for more than 14 consecutive days within 90 days prior to screening, Administration of anti-neoplastic and/or immunomodulating agents (e.g. Tumor necrosis factor alpha (TNF α) antagonists or anti-B cell antibodies) or radiotherapy within 1 year prior to screening. Recipient of Stem Cell or Gene Therapy Positive test for Hepatitis B surface antigen, Hepatitis C antibody, or HIV. History of deep venous thrombosis or pulmonary embolism History of active substance abuse within the past 2 years History of stroke, poorly controlled or significant cardiovascular disease, diabetes",Ii,Both
0,Healthy Volunteers and Patients with Amyotrophic Lateral Sclerosis ATC 2021: Adults with ALS,,TrialTroveID-321213,Adults,,,321213,Delay Disease Progression; Healthy subjects,,,,I,
0,Patients with Amyotrophic Lateral Sclerosis.,"Ages Eligible for Study: 18 Years to 75 Years; Genders Eligible for Study: Both Inclusion Criteria: Previous participation in sNN0029-003 with completion of 12 weeks study without clinically significant safety concerns Intact continuity of the Medtronic SynchroMed II Infusion System as judged by X-ray of head and abdominal area Clinical diagnosis of ALS classified as definite, or probable with or without additional laboratory evidence, according to the revised WFN El Escorial criteria Patient has been given written and verbal information about the continuation study, has had the opportunity to ask questions about the study, and understands the time and procedural commitments Patient has given oral and / or signed consent (written) to participate in the study. In the event that a patient who gives oral informed consent is not physically able to sign the informed consent form (ICF) due to disease progression, a witness may sign the informed consent form on the patient's behalf",EudraCT Number: 2012-005034-11 NCT02269436 NL51030.041.14 sNN0029-004 TrialTroveID-219300,Adults; Older Adults,year(s),year(s),219300,Unspecified,75.0,18.0,"Exclusion Criteria: Hypertension defined as blood pressure >160 mmHg systolic or >90 mmHg diastolic Ophthalmological examination (fundus photography, visual acuity and perimetry) with any clinically significant findings that imply safety concerns for this study. Diagnosis of diabetes mellitus Presence of risk for increased or uncontrolled bleeding and/or risk of bleeding that cannot be not managed optimally due to: Anatomical factors at or near the implant site (e.g., vascular abnormalities, neoplasms, or other abnormalities) Underlying disorders of the coagulation cascade, platelet function, or platelet count (e.g., haemophilia, Von Willebrand's disease, liver disease, or other medical conditions) Presence of additional risk factors for thromboembolism such as obesity (Body mass index [BMI] > 35) or use of oestrogens including combined contraceptive pills Clinically significant abnormalities in haematology or clinical chemistry parameters as assessed by the investigator Ongoing medical condition that according to the investigator would interfere with the conduct and assessments in the study. Examples are medical disability (e.g., severe degenerative arthritis, compromised nutritional state, peripheral neuropathy) that would interfere with the assessment of safety and efficacy of investigational product or device performance, or would compromise the ability of the patient to undergo study procedures (e.g., MRI), or to give informed consent For women only: pregnant, breast feeding and/or for fecund women unwillingness to use adequate contraception during the trial such as: Established use of oral, injected or implanted hormonal methods of contraception that do NOT contain oestrogens Placement of an intrauterine device Barrier methods of contraception: Condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository",I,Both
0,Patients with Amyotrophic Lateral Sclerosis.,"Ages Eligible for Study: 18 Years to 75 Years, Genders Eligible for Study: Both Clinical diagnosis of ALS classified as definite, or probable with or without additional laboratory evidence, according to the revised World Federation of Neurology (WFN) El Escorial criteria. If patients are being treated with riluzole, they must have been on a stable dose for at least the past 30 days prior to screening. The patient is, in the opinion of the investigator, medically fit to undergo the surgery required for stereotactic implantation of the catheter and infusion pump.",EudraCT Number: 2012-001026-10 NCT01999803 NL45580.041.13 sNN0029-003 TrialTroveID-182767,Adults; Older Adults,year(s),year(s),182767,Unspecified,75.0,18.0,"Impaired respiratory function judged to pose a risk to the patient during anaesthesia for the device implantation. Hypertension defined as blood pressure >160 mmHg systolic or >90 mmHg diastolic. Values for coagulation parameters including platelet count, normalised prothrombin complex (PK-INR), activated partial thromboplastin time (APTT) outside normal ranges. Ophthalmological examination (fundus photography, visual acuity and perimetry) with any clinically significant findings that imply safety concerns for this study. Diagnosis of diabetes mellitus. History of structural brain disease other than ALS, including tumours and hyperplasia. An MRI of the brain and cervical spine, and an Magnetic Resonance Angiography (MRA) of the brain with findings of tumours or potential sources of pathological bleedings, or abnormality that may interfere with the assessments of safety or efficacy or that would, in the judgment of the investigator, represent a surgical risk to the patient. If an MRI and/or MRA has been performed within 1 month prior to screening, the results from that examination can be used. Any disorder that precludes a surgical procedure (e.g., signs of sepsis or inadequately treated infection), alters wound healing (e.g., including bleeding disorders), or renders chronic i.c.v. delivery or device implants medically unsuitable. Presence of risk for increased or uncontrolled bleeding and/or risk of bleeding that cannot be not managed optimally due to: i. anatomical factors at or near the implant site (e.g., vascular abnormalities, neoplasms, or other abnormalities), ii. underlying disorders of the coagulation cascade, platelet function, or platelet count (e.g., haemophilia, Von Willebrand's disease, liver disease, or other medical conditions) iii. administration of any antiplatelet or anticoagulant medication in the preoperative period A personal history of thromboembolic disease. A family history of thromboembolic disease will prompt a laboratory assessment to exclude hereditary liability before the patient is declared eligible. Presence of additional risk factors for thromboembolism such as obesity (BMI > 35) or use of oestrogens including combined contraceptive pills. Presence of an implanted shunt for the drainage of CSF or an implanted Central Nervous System (CNS) catheter. Clinically significant abnormalities in haematology or clinical chemistry parameters as assessed by the investigator. Serological evidence of Hepatitis B virus (HBV), Hepatitis C virus (HCV) or Human immunodeficiency virus (HIV) Ongoing medical condition that according to the investigator would interfere with the conduct and assessments in the study. Examples are medical disability (e.g., severe degenerative arthritis, compromised nutritional state, peripheral neuropathy) that would interfere with the assessment of safety and efficacy of investigational product or device performance, or would compromise the ability of the patient to undergo study procedures (e.g., MRI), or to give informed consent. Participation in another clinical trial with an investigational drug or device within 3 months prior to screening visit. For women only: pregnant, breast feeding and/or for fecund women unwillingness to use adequate contraception during the trial such as: Established use of oral, injected or implanted hormonal methods of contraception that do NOT contain oestrogens. Placement of an intrauterine device. Barrier methods of contraception: Condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.",Iii,Both
0,Patients with Amyotrophic Lateral Sclerosis.,"Ages Eligible for Study: 18 Years to 75 Years, Genders Eligible for Study: Both Inclusion Criteria: Clinical diagnosis of ALS classified as definite, or probable with or without additional laboratory evidence, according to the revised WFN El Escorial criteria (Appendix B). Previous participation in study sNN0029-001 with completion of 12 weeks study drug administration. To have completed the investigations associated with safety in study sNN0029-001 without development of clinically significant safety concerns. Patient has been given written and verbal information about the continuation study, has had the opportunity to ask questions about the study, and understands the time and procedural commitments. Patient has given oral and / or signed consent (written) to participate in the study. In the event that a patient who gives oral informed consent is not physically able to sign the informed consent form (ICF) due to disease progression, a witness may sign the ICF on the patient's behalf.",NCT01384162 sNN0029-002 TrialTroveID-148779,Adults; Older Adults,year(s),year(s),148779,Delay Disease Progression,75.0,18.0,"Exclusion Criteria: Hypertension defined as blood pressure >160 mmHg systolic or >90 mmHg diastolic. Proliferative retinopathy. Non-proliferative retinopathy of moderate severity or higher. Concurrent clinically significant dementia as determined by the investigator. Concurrent clinically significant depression as determined by the investigator. Need for administration of any antiplatelet or anticoagulant medication (e.g. aspirin, Plavix, non-steroidal anti-inflammatory drugs [NSAIDs]). Low dose aspirin or occasional use of NSAIDs is allowed (See Appendix E). Clinically significant abnormalities in haematology or clinical chemistry parameters as assessed by the investigator. For female patients, ongoing pregnancy or planned pregnancy Breast feeding",Iii,Both
1,Patients with Amyotrophic Lateral Sclerosis.,,TrialTroveID-119257,,,,119257,Delay Disease Progression,,,,Ii/Iii,
0,Patients with Amyotrophic Lateral Sclerosis.,"Ages Eligible for Study: 18 Years to 75 Years Inclusion Criteria: Clinical diagnosis of ALS classified as definite, or probable with or without additional laboratory evidence, according to the revised WFN El Escorial criteria. Age 18 to 75 years inclusive. If patients are being treated with riluzole, they must have been on a stable dose for at least 30 days. Ophthalmological examination at screening with normal findings regarding vascular structure and function. MRI/magnetic resonance angiography (MRA) examination of the brain and cervical spinal cord at screening with no findings of tumors or potential sources of pathological bleedings, or abnormality that may interfere with the assessments of safety or efficacy or that would, in the judgement of the investigator, represent a surgical risk to the subject. Values of coagulation parameters including platelet count, bleeding time, normalized prothrombin complex (PK-INR), activated partial thromboplastin time (APTT) within normal ranges. Patient is medically able to undergo the surgery required for stereotactic implantation of the catheter and infusion pump. Patient has been given written and verbal information, has had the opportunity to ask questions about the study, and understands the time and procedural commitments. Patient has given signed consent (written) to participate in the study. In the event that a patient who gives oral informed consent is not physically able to sign the informed consent form (ICF) due to disease progression, a witness may sign the ICF on the patient's behalf.",NCT00800501 sNN0029-001 TrialTroveID-101532,Adults; Older Adults,year(s),year(s),101532,Delay Disease Progression,75.0,18.0,"Exclusion Criteria: Impaired respiratory function judged to pose a risk to the patient during anaesthesia for the device implantation. Hypertension defined as blood pressure >160 mmHg systolic or >90 mmHg diastolic. Diagnosis of diabetes mellitus. Proliferative retinopathy. Non-proliferative retinopathy of moderate severity or higher. Concurrent clinically significant dementia as determined by the investigator. Concurrent clinically significant depression as determined by the investigator. History of structural brain disease other than ALS, including tumours and hyperplasia. Any disorder that precludes a surgical procedure (e.g., signs of sepsis or inadequately treated infection), alters wound healing (e.g., including bleeding disorders), or renders chronic ICV delivery or device implants medically unsuitable. Presence of risk for increased or uncontrolled bleeding and/or risk of bleeding that is not managed optimally. Physicians should specifically investigate anatomical factors at or near the implant site (e.g., vascular abnormalities, neoplasms, or other abnormalities), underlying disorders of the coagulation cascade, platelet function, or platelet count (e.g., haemophilia, Von Willebrand's disease, liver disease, or other medical conditions), and the administration of any antiplatelet or anticoagulant medication (e.g., aspirin, Plavix, NSAIDs) in the pre- or perioperative period. Any of those conditions or drugs could place a patient at an increased risk for intraoperative or postoperative bleeding. Presence of an implanted shunt for the drainage of CSF or an implanted CNS catheter. Presence of cardiac pacemakers, spinal cord stimulators, implantable programmable intraspinal drug pumps, or any other device that may interfere or interact with the programmer, without prior approval by Medtronic. Clinically significant abnormalities in hematology or clinical chemistry parameters as assessed by the investigator. Ongoing medical condition that according to the investigator would interfere with the conduct and assessments in the study. Examples are medical disability (e.g., severe degenerative arthritis, compromised nutritional state, peripheral neuropathy) that would interfere with the assessment of safety and efficacy of investigational product or device performance, or would compromise the ability of the subject to undergo study procedures (e.g., MRI), or to give informed consent. Participation in another clinical trial with an investigational drug or device within 3 months prior to Screening visit. For female subjects, ongoing pregnancy or planned pregnancy during the period of treatment with study drug. Breast feeding during the period of treatment with study drug.",Iii,Both
0,Patients with Amyotrophic Lateral Sclerosis.,"Participant is willing and able to give informed consent for participation in the study Male or female, aged 18 years or above Diagnosed with ALS (Gold Coast Criteria) Symptom onset (first weakness) 9-24 months (inclusive) at enrolment Taking riluzole at a stable dose for at least 4 weeks prior to enrolment, or will refrain from starting riluzole for the duration of the study, or have never taken riluzole Able to swallow tablets safely Willing to use highly effective contraception for the duration of trial treatment and for a duration of 80 days after the last dose",15775 301752 CPMS 51286 EudraCT number: 2021-003345-38 ISRCTN45028842 PID 15775 TrialTroveID-422412 TRUST,Adults; Older Adults,year(s),,422412,Delay Disease Progression,,18.0,"Using non-invasive ventilation (NIV) Pregnancy Any other significant disease, disorder, or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data Hypersensitivity to the IMP or any of its excipients (including lactose) Taking terazosin or other alpha adrenergic blockers (doxazosin, prazosin, tamsulosin, silodosin, trazodone, tolazoline, phentolamine, phenoxybenzamine) at time of screening visit or within the 3 months prior to baseline visit Ongoing use of sildenafil, tadalafil, or vardenafil Taking anti-coagulant medication, e.g. warfarin or apixaban Symptomatic postural hypotension or history of postural hypotension Systemic hypotension (systolic BP =90mmHg or diastolic BP=60mmHg) History of micturition syncope Contraindications to lumbar puncture Taking part in a current CTIMP or have taken part in any CTIMP in the 3 months prior to recruitment",I,Both
0,,,199/11792 NCT00004771 OSU-92H0325,Adults; Older Adults,year(s),,224330,,,18.0,,Ii,Male
0,Patients With Amyotrophic Lateral Sclerosis,"1)Age 45 to 70 years old (inclusive), gender is not limited; 2)Diagnosis in accordance with ALS Revised Criteria of the World Federation of Neurology, 1998, diagnosis of definite or probable ALS. 3)Subjects has a disease duration of < or = 2 years when enrolling; 4)The ALSFRS-R scores ARE all > 2 points when enroll, and the respiratory function in ALSFRS-R is 4 points; 5)ALSFRS-R score decreases by 1-4 points (inclusive) during the screening period; 6)Forced Vital Capacity (%FVC) > or = 80% before randomization; 7)Subjects must understand and be will to compliant with the study rules, voluntarily participate, and sign an informed consent form (informed consent form is voluntarily signed by the subject himself/herself or his/her legal representative).",ChiCTR2000039689 TrialTroveID-388768,Adults; Older Adults,year(s),year(s),388768,Delay Disease Progression,70.0,45.0,"1)Patients with familial amyotrophic lateral sclerosis(according to family history) 2)Patients with obvious cognitive impairment (MMSE scale: illiterate group < 19 points, primary school level group < 22 points, junior high school and above group (receiving education>8 years) < 26 points; 3)Obvious dysphagia; 4)Severe renal insufficiency: creatinine clearance < 30 mL/min (Cockcroft-Gault formula), or other identified severe renal insufficiency disease; 5)Severe liver damage: ALT or AST > 3 times ULN, or other identified liver diseases such as acute and chronic hepatitis, cirrhosis, etc.; 6)From the screening period, in the past 6 months, patients come up with acute myocardial infarction or interventional therapy, heart failure (NYHA CLASS III-IV); 7)Combined with malignant tumors or other systematic diseases such as digestive system disease and hematological system diseases. 8)Patients who are allergic to the investigational product or tetramethylpyrazine; 9)Female patients in pregnancy or lactation; 10)Having participated in other clinical studies within 30 days before randomization, or is participating in other clinical studies; 11)Patients that the investigator considers unsuitable for participation in the study.",Ii,Both
0,Patients with clinically proven amyotrophic lateral sclerosis.,"Ages Eligible for Study 18 Years - 80 Years Inclusion Criteria: Clinically proven ALS. Disease duration less than or equal to 5 years. ALSFRS-R score equal to or greater then 30. Have a forced vital capacity greater than or equal to 65 percent of the predicted value. Have adequate bone marrow, hepatic (liver) and renal (kidney) function. Give informed consent. State willingness to comply with the STEPS (System for Thalidomide Education and Prescribing Safety) program. If female, use two methods of contraception, unless surgically sterilized or postmenopausal for 24 consecutive months. If female, have a negative pregnancy test within 24 hours prior to the start of the study medication and in followup tests throughout the study. If male, either completely abstain from sexual contact or use latex condoms. Remain on any medications being taken for ALS throughout the study.",ALS-001 NCT00140452 TrialTroveID-078850,Adults; Older Adults,year(s),year(s),78850,Delay Disease Progression,80.0,18.0,"Exclusion Criteria: Patients with known deep venous thrombosis or hyper coagulable state will be excluded. Patients with FVC less than 80%. Participants may not donate blood or sperm while being treated with thalidomide. Have gastrointestinal abnormalities. Be on investigational medications other than the study drug. Have pulmonary disorders not attributed to ALS. If female, be pregnant or breast-feeding. Have a known hypersensitivity to thalidomide. Have pulmonary disorders not attributed to ALS. Have an uncontrolled medical disorder or active infection. Have significant sensory abnormalities, dementia, debilitating psychiatric illness, substance abuse history, or any serious neurological disease other than ALS.",Ii,Both
0,,Ages Eligible for Study 25 Years to 80 Years. Inclusion Criteria Patients aged 25 and 80 years. Female patients who are either postmenopausal for at least 24 month or who are willing and able to practice the methods of contraception following the Pharmion-Risk Managment Program (PRMP). Male patients who are willing and able to practice the methods of contraception along with their female partners of childbearing potential following the PRMP. Clinical diagnosis of probable and definite ALS. Sporadic or familial ALS. Onset of pareses for no more than 4 years. Vital capacity equal to or more than 65% of the predicted value. Treatment with riluzole 100mg/day. Patients who are willing to give informed consent.,NCT00231140 THL-ALS01 TrialTroveID-078683,Adults; Older Adults,year(s),year(s),78683,Delay Disease Progression,80.0,25.0,"Exclusion Criteria Pregnancy or breast feeding. Female patients who are unwilling or unable to practice the methods of contraception following the Pharmion-Risk Managment Program (PRMP). Male patients who are willing and able to practice the methods of contraception along with their female partners of childbearing potential following the PRMP. Patients unlikely to comply with the PRMP and other study requirements. Patients with significant sensory abnormalities, dementia, uncompensated medical illnesses and psychiatric disorders. Laboratory abnormalities consistent with clinically significant cardiovascular, respiratory, haematological, metabolic, hepatic and renal disease. Infectious disease including HIV, hepatitis B and C. Monoclonal gammopathy of unknown significance (MGUS). History of substance abuse within the past year. History of recurrent thrombosis. Continuous non-invasive ventilation (ventilation-free interval equal to or less than 2 hours daily). Tracheotomy and invasive ventilation. Treatment with investigational drug within 3 months prior to screening. Patients with clinically signifikant sensory polyneuropathy (inflammatory neuropathy cause and treatment sensory sum score - ISS > or = 2). Patients with sleep disorder (Epworth Sleeping Scale-ESS > or = 10).",Ii,Both
0,Subjects with Amyotrophic Lateral Sclerosis,"Possible, probable (clinically or laboratory supported) or definite ALS according to the revised version of the El Escorial criteria Disease duration < 18 months Vital capacity of more than 60% of normal (defined as slow vital capacity, best of three measurements) Age more than 18 years On a stable dose of riluzole for at least four weeks or not taking riluzole On a stable dose of edaravone for at least four weeks or not taking edaravone Capable of thoroughly understanding all information given and giving full informed consent according to GCP",NCT05105958 TIDALS TIDALS_01 TrialTroveID-417476,Adults; Older Adults,year(s),,417476,Delay Disease Progression,,18.0,"Previous participation in another clinical study within the preceding 12 weeks Proven SOD1- or FUS - mutation Tracheostomy or assisted ventilation of any type during the preceding three months Pregnancy or breast-feeding females Any medical condition known to have an association with motor neuron dysfunction which might confound or obscure the diagnosis of ALS Presence of any concomitant life-threatening disease or impairment likely to interfere with functional assessment Evidence of a major psychiatric disorder or clinically evident dementia precluding evaluation of symptoms Alcoholism Cardiovascular disorder/arrhythmia Impaired kidney function, defined as creatinine levels of 2.5 x upper limit of normal (ULN) Impaired liver function, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) of 3 x ULN Liable to be not cooperative or comply with trial requirements as assessed by the investigator, or unable to be reached in the case of emergency",Ii,Both
0,"Patients with amyotrophic lateral sclerosis. Patients in earlier stages of disease, shortly after diagnosis is confirmed.","Ages Eligible for Study: 18 Years and older Inclusion Criteria: For enrollment, patients were required to satisfy all of the following criteria at baseline: 1. Able to comprehend and willing to sign an Informed Consent Form (ICF) A diagnosis of familial or sporadic ALS (defined as meeting the possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS according to the World Federation of Neurology El Escorial criteria) (Brooks, Miller et al. 2000) Males or females 18 years of age or older Body Mass Index (BMI) of 18.0 to 30.0 kg/m2, inclusive Maximum voluntary grip strength in at least one hand between 10 and 40 pounds (females) or 10 and 60 pounds (males) Able to swallow capsules with water Upright Slow Vital Capacity (SVC) > 40% of predicted for age, height, and sex [See Appendix 16.6.1] Able to perform pulmonary function tests Pre-study clinical laboratory findings (including troponin I [TnI] and creatine phosphokinase [CPK]) within normal range, or, if outside of the normal range, deemed not clinically significant by the Investigator For female patients only: The patient is post-menopausal (= 1 year) or sterilized, or if she is of childbearing potential, she is not breastfeeding, her pregnancy test is negative, she has no intention to become pregnant during the course of the study, and she is using contraceptive drugs or devices for the duration of the study and for 10 weeks after the end of the study. For male patients only: Male patients agree for the duration of the study and 10 weeks after the end of the study to use a condom during sexual intercourse with female partners who are of reproductive potential and to have female partners use an additional effective means of contraception (e.g., diaphragm plus spermicide or oral contraceptives) or the male patient must agree to abstain from sexual intercourse for 10 weeks after the end of the study.",CY 4021 NCT01089010 TrialTroveID-122346,Adults; Older Adults,year(s),,122346,Delay Disease Progression,,18.0,"Exclusion Criteria: Patients satisfying any of the following criteria at baseline were excluded from enrollment: Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 times the upper limit of normal (ULN) Life expectancy < 3 months Participation in any trial in which receipt of investigational study drug occurred within 30 days prior to dosing Any prior treatment with CK-2017357 In the opinion of the Investigator, the patient is not suitable to participate in the study",Ii,Both
0,Healthy male volunteers.,,CY 4012 TrialTroveID-118382,,,,118382,Cachexia; Healthy subjects,,,,I,Male
0,Healthy male volunteers.,,CY 4011 TrialTroveID-108007,,,,108007,Cachexia; Healthy subjects,,,,I,Male
1,Patients with amyotrophic lateral sclerosis who participated in VITALITY-ALS study.,"Able to comprehend and willing to sign an Informed Consent Form (ICF). If verbal consent is given, a Legal Designee of the patient must sign the ICF form Completed participation on study drug and the Follow-Up Visit in the CY 4031 study Male patients, who have not had a vasectomy AND confirmed zero sperm count, must agree for the duration of their participation in the study to either: Use a condom during sexual intercourse with female partners who are of childbearing potential AND to have female partners use a highly effective means of contraception OR Abstain from sexual intercourse during participation in the study Female patients who are not post-menopausal (> or = 1 year) or sterilized, must: Not be breastfeeding Have a negative pregnancy test Have no intention to become pregnant during participation in the study AND Practice sexual abstinence, defined as refraining from intercourse during the duration of the study OR if male partners are not vasectomized with a confirmed zero sperm count, require use of a condom AND use of a highly effective contraceptive measure Combined (estrogen and progestogen containing) oral, intravaginal, or transdermal hormonal contraception associated with inhibition of ovulation - Progestogen-only oral, injectable, or implantable hormonal contraception associated with inhibition of ovulation - Intrauterine device (IUD) - Intrauterine hormone-releasing system (IUS) - Bilateral tubal occlusion",20160683 CY 4033 EudraCT Number: 2016-002629-13 F17004 NCT02936635 NL59871.041.17 TrialTroveID-284709 VIGOR-ALS VITALITY-ALS- EXT,Adults; Older Adults,year(s),year(s),284709,Delay Disease Progression,84.0,18.0,"Has a diaphragm pacing system (DPS) at study entry or anticipate DPS placement during the course of the study Has taken an investigational study drug (other than tirasemtiv) prior to dosing, within 30 days or five half-lives of the prior agent, whichever is greater Use of tizanidine and theophylline-containing medications during study participation Participation or planning to participate in any form of stem cell therapy for the treatment of ALS or another investigational drug",Iii,Both
1,"Patients with familial or sporadic amyotrophic lateral sclerosis (ALS) Patients may be enrolled whether or not they are on riluzole therapy. Patients with possible, probable or definite amyotrophic lateral sclerosis (ALS). December 09, 2016 PR: Patients are on average 57.6 years of age, 65 percent male, 7.7 months from diagnosis, 20.6 months from their first symptom and had an average percent predicted SVC of 90.7 percent.","A diagnosis of familial or sporadic ALS (defined as meeting the possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS according to the World Federation of Neurology El Escorial criteria) < or = 24 months prior to screening Upright SVC > or = 70 % of predicted for age, height and sex Able to swallow tablets without crushing, and in the opinion of the Investigator, is expected to continue to be able to do so during the trial A caregiver if one is needed Clinical laboratory findings within the normal range or, if outside the normal range, deemed not clinically significant by the Investigator Male patients must agree for the duration of the study and 10 weeks after the end of the study to use a condom during sexual intercourse with female partners who are of childbearing potential (i.e., following menarche until post-menopausal if not anatomically and physiologically incapable of becoming pregnant) and to have female partners use an additional effective means of contraception (e.g., diaphragm plus spermicide, or oral contraceptives) or the male patient must agree to abstain from sexual intercourse during and for 10 weeks after the end of the study, unless the male patient has had a vasectomy and confirmed sperm count is zero Female patients must be post-menopausal (> or = 1 year) or sterilized, or, if of childbearing potential, not be breastfeeding, have a negative pregnancy test, have no intention to become pregnant during the course of the study, and use effective contraceptive drugs or devices while requiring male partner to use a condom for the duration of the study and for 10 weeks after the end of the study Patients must be either on a stable dose of riluzole 50 mg twice daily for at least 30 days prior to screening or have not taken riluzole for at least 30 days prior to screening and are willing not to begin riluzole use until they complete study drug dosing Able to comprehend and willing to sign an Informed Consent Form (ICF).",20150619 CY 4031 EudraCT Number: 2014-005413-23 NCT02496767 NL54137.041.15 REec-2016-2095 TrialTroveID-261308 VITALITY-ALS,Adults; Older Adults,year(s),,261308,Delay Disease Progression,,18.0,"At the time of screening, any use of non-invasive positive pressure ventilation (NIPPV, e.g. continuous positive airway pressure [CPAP] or bi-level positive airway pressure [BiPAP]) for any portion of the day, or mechanical ventilation via tracheostomy, or on any form of oxygen supplementation Patients with a diaphragm pacing system (DPS) at study entry or who anticipate DPS placement during the course of the study BMI of 20.0 kg/m 2 or lower Unwilling or unable to discontinue tizanidine and theophylline-containing medications during study participation Serum chloride outside the normal reference range Neurological impairment due to a condition other than ALS, including history of transient ischemic attack within the past year Presence at screening of any medically significant cardiac, pulmonary, GI, musculoskeletal, or psychiatric illness that might interfere with the patient's ability to comply with study procedures or that might confound the interpretation of clinical safety or efficacy data, including, but not limited to: Poorly controlled hypertension NYHA Class II or greater congestive heart failure Chronic obstructive pulmonary disease or asthma requiring daily use bronchodilator medications GI disorder that might impair absorption of study drug History of significant liver disease defined by bilirubin > 2 times the upper limit of normal (ULN) or ALT or AST > 3 times the ULN on repeat testing Poorly controlled diabetes mellitus History of vertigo within three months of study entry History of syncope without an explainable or treated cause History of untreated intracranial aneurysm or poorly controlled seizure disorder Amputation of a limb Cognitive impairment, related to ALS or otherwise, sufficient to impair the patient's ability to give informed consent and to understand and/or comply with study procedures Cancer with metastatic potential (other than basal cell carcinoma, carcinoma in situ of the cervix, or squamous cell carcinoma of the skin excised with clean margins) diagnosed and treated within the last two years Any other condition, impairment or social circumstance that, in the opinion of the Investigator, would render the patient not suitable to participate in the study Patient judged to be actively suicidal or a suicide risk by the Investigator Has taken any investigational study drug within 30 days or five half-lives of the prior agent, whichever is greater, prior to dosing Prior participation in any form of stem cell therapy for the treatment of ALS Previously received tirasemtiv in any previous clinical trial",Iii,Both
0,Patients with Amyotrophic Lateral Sclerosis (ALS) receiving riluzole at the reduced dose of 50 mg daily.,"Ages Eligible for Study: 18 Years and older; Genders Eligible for Study: Both Inclusion Criteria: Able to comprehend and willing to sign an Informed Consent Form (ICF) Male or female 18 years of age or older A diagnosis of familial or sporadic ALS (defined as meeting the possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS according to the World Federation of Neurology El Escorial criteria) Upright Slow Vital Capacity (SVC) >60 % of predicted for age, height and sex At least 4 of the 12 ALSFRS-R questions must be scored 2 or 3 Diminished but measurable maximum voluntary grip strength in at least one hand; i.e., between 10 and 40 pounds (females) and 10 and 60 pounds (males) Able to swallow tablets without crushing, and in the opinion of the Investigator, is expected to do so for the duration of the study A caregiver (if one is needed) who can and will observe and report the patient's status Pre-study clinical laboratory findings within normal range or, if outside of the normal range, deemed not clinically significant by the Investigator Male patients must agree for the duration of the study and 10 weeks after the end of the study to use a condom during sexual intercourse with female partners who are of reproductive potential and to have female partners use an additional effective means of contraception (e.g., diaphragm plus spermicide, or oral contraceptives) or the male patient must agree to abstain from sexual intercourse during and for 10 weeks after the end of the study Female patients must be post-menopausal (> or = 1 year) or sterilized, or, if of childbearing potential, not be breastfeeding, have a negative pregnancy test, have no intention to become pregnant during the course of the study, and use contraceptive drugs or devices as detailed in item 10 for the duration of the study and for 10 weeks after the end of the study Patients must be either on a stable dose of riluzole 50 mg twice daily for at least 30 days prior to screening or have not taken riluzole for at least 30 days prior to screening and are willing not to begin riluzole use during the conduct of this study. Patients who do NOT use CPAP or BiPAP. Patients without diaphragm pacing system (DPS). Patients with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease who have moderate hand grip weakness. Races: White, African American, Asian, American Indian or Alaska Native, Native Hawaiian or Pacific Islander, All Ethnicities",BENEFIT-ALS C_FN_Cyto 4026 CY 4026 CY4026 DeNDRoN 098 EudraCT Number: 2012-004987-23 NCT01709149 NL42947.041.12 TrialTroveID-166541 UKCRN ID: 13984,Adults; Older Adults,year(s),,166541,Delay Disease Progression,,18.0,"Exclusion Criteria: Any use of non-invasive positive pressure ventilation (NIPPV, e.g. continuous positive airway pressure [CPAP] or bilevel positive airway pressure [BiPAP]) for any portion of the day, or mechanical ventilation via tracheostomy, or on any form of oxygen supplementation Patients with a diaphragm pacing system (DPS) at study entry or who anticipate DPS placement during the course of the study Body Mass Index (BMI) of 19.0 kg/m2 or lower Unwilling to discontinue theophylline-containing medications during study participation Serum chloride < 100 mg/deciliter (dL) Neurological impairment due to a condition other than ALS, including history of transient ischemic attack (TIA) within the past year Presence at screening of any medically significant cardiac, pulmonary, gastrointestinal (GI), musculoskeletal, or psychiatric illness that might interfere with the patient's ability to comply with study procedures or that might confound the interpretation of clinical safety or efficacy data: -Poorly controlled hypertension -NYHA Class II or greater congestive heart failure -Clinically significant ECG abnormalities -Chronic obstructive pulmonary disease or asthma requiring bronchodilator medications -History of sleep apnea requiring CPAP or oxygen supplementation -GI disorder that might impair absorption of study drug from the gastorintestinal tract -History of significant liver disease defined by bilirubin > 2 times the upper limit of normal (ULN) or alanine transferase (ALT) or aspartate aminotransferase (AST) > 3 times the ULN on repeat testing -Poorly controlled diabetes mellitus -History of vertigo within 3 months of study entry -History of syncope without an explainable or treated cause -History of untreated intracranial aneurysm or poorly controlled seizure disorder -Amputation of a limb -Cognitive impairment, related to ALS or otherwise, sufficient to impair the patient's ability to understand and/or comply with study procedures and giving informed consent -Cancer with metatstic potential (other than basal cell carcinoma, carcinoma in situ of cervix, or squamous cell carcinoma of the skin excised with clean margins) daignosed and treated within the last 2 years -Any other condition, impairment or social circumstance that, in the opinion of the Investigator, would render the patient not suitable to participate in the study. Has taken any investigational study drug within 30 days or 5 half-lives of the prior agent, whichever is greater, prior to dosing Previously received CK-2017357 in any previous clinical trial",Ii,Both
0,Patients with amyotrophic lateral sclerosis who are receiving riluzole.,"Ages Eligible for Study: 18 Years and older Genders Eligible for Study: Both Inclusion Criteria: Able to comprehend and willing to sign an Informed Consent Form (ICF). Males or females 18 years of age or older. A diagnosis of familial or sporadic ALS (defined as meeting the possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS according to the World Federation of Neurology El Escorial criteria). Maximum voluntary grip strength in at least one hand between 10 & 40 pounds (females) and 10 & 60 pounds (males). Able to swallow tablets with water. Currently taking and tolerating a stable dose of 50 mg BID riluzole. Willing and able to reduce daily dose of riluzole to 50mg QD for 5 weeks. Not currently taking or willing and able to remain off theophylline-containing medications during study participation. Patient has a caregiver who is capable of observing and reporting patient status. Upright Slow Vital Capacity (SVC) >50% of predicted for age, height, and sex. Able to perform pulmonary function tests.",CY 4025 NCT01486849 TrialTroveID-155650,Adults; Older Adults,year(s),,155650,Delay Disease Progression,,18.0,"Exclusion Criteria: Life expectancy <3 months. Receipt of investigational study drug within 30 days or 5 half-lives of the prior agent, whichever is greater, prior to dosing. Any prior treatment with CK-2017357. Any use of non-invasive positive pressure ventilation (NIPPV), such as Continuous Positive Airway Pressure (CPAP) or Bilevel Positive Airway Pressure (BiPAP). Other protocol-defined inclusion/exclusion criteria may apply.",Ii,Both
0,Healthy volunteers.,,CY 4013 TrialTroveID-142278,,,,142278,Healthy subjects,,,,I,
0,"Patients with amyotrophic lateral sclerosis. 24 patients, average age was 55 (range: 28-75) years; 50% were males.","Ages Eligible for Study: 18 Years and older; Genders Eligible for Study: Both Key Inclusion Criteria: Able to comprehend and willing to sign an Informed Consent Form (ICF). Males or females 18 years of age or older. A diagnosis of familial or sporadic ALS (defined as meeting the possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS according to the World Federation of Neurology El Escorial criteria). Maximum voluntary grip strength in at least one hand between 10 & 40 pounds (females) and 10 & 60 pounds (males). Upright Slow Vital Capacity (SVC) >50% of predicted for age, height, and sex. Able to swallow tablets with water. Willing and able to remain off riluzole for 4 weeks (Part A only) Currently taking and tolerating a stable dose of 50 mg BID riluzole (Part B only) Willing and able to reduce daily dose of riluzole to 50 mg for 4 weeks (Part B only) Willing and able to refrain from caffeine-containing products during study participation Willing and able to remain off warfarin and theophylline-containing medications during study participation Has a caregiver who is capable of observing and reporting patient status, and also assisting in the proper use of nocturnal oximetry equipment Able to perform pulmonary function tests.",CY 4024 NCT01378676 TrialTroveID-139315,Adults; Older Adults,year(s),,139315,Delay Disease Progression,,18.0,"Key Exclusion Criteria: Life expectancy <3 months. Participation in any trial in which receipt of investigational study drug occurred within 30 days or 5 half-lives of the prior agent, whichever is greater, prior to dosing. Any prior treatment with CK-2017357. Use of non-invasive positive pressure ventilation (NIPPV) for any part of the day or night.",Ii,Both
0,Healthy subjects,"1. Age > or = 18 years old, both men and women are welcome; 2. The weight of male subjects is > or = 50.0 kg, the weight of female subjects is > or = 45.0 kg, and the body mass index (BMI) is between 19 and 26 kg/m2 (including the boundary value) 3. Subjects voluntarily signed written informed consent;",CTR20233326 DUXACT-2310019 TrialTroveID-496378,Adults; Older Adults,year(s),,496378,(N/A); Healthy subjects; Spinal Cord Injury - motor; Traumatic Brain Injury (TBI) - motor,,18.0,"1 (Consultation) Those who have suffered or are currently suffering from any clinically serious diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry and metabolic abnormalities or any other diseases that can interfere with the test results (Such as: hepatic insufficiency, renal insufficiency, hypotension, orthostatic hypotension, bradycardia, arrhythmia, etc.); 2 (Consultation) Those who have a history of allergies to drugs, food or other substances, or are allergic to any ingredients in this product; 3 (Inquiry) Those who have undergone surgery within 28 days before taking the study drug for the first time, or who plan to have surgery during the trial; 4 (Inquiry) Those who have used any drugs or health products (including Chinese herbal medicine) within 14 days before taking the study drug for the first time; 5 (Inquiry) Have you used any drugs that inhibit or induce hepatic drug metabolism within 30 days before taking the study drug for the first time (such as: inducers—barbiturates, carbamazepine, phenytoin, rifampicin; inhibitors—SSRIs) Antidepressants, cimetidine, cyclosporine, macrolides, verapamil, quinolones, azole antifungals, HIV protease inhibitors, etc.); 6 (Inquiry) Those who have used any clinical trial drug or enrolled in any drug/medical device clinical trial within 3 months before taking the study drug for the first time; 7 (Inquiry) Those who donated blood within 3 months before taking the study drug for the first time, or those who lost more than 400 mL of blood within 3 months before taking the study drug for the first time 8 (Inquiry) Those who cannot tolerate venipuncture and/or have a history of fainting from blood or needles 9 (Inquiry) Those who have used oral contraceptives within 30 days before taking the study drug for the first time, or those who have used long-acting estrogen or progesterone injections or implants within 6 months before taking the study drug for the first time; 10 (Inquiry) Those who have had unprotected sex within 14 days before taking the study drug for the first time (females), or women who are pregnant or breastfeeding; 11 (Inquiry) Those who cannot take one or more non-drug contraceptive measures during the trial; 12 (Consultation) Those who have special dietary requirements, cannot adhere to a uniform diet or have difficulty swallowing; 13 13) (Inquiry) Those who drink excessive amounts of tea, coffee or caffeinated beverages (more than 8 cups, 1 cup = 250 mL) every day within 3 months before taking the study drug for the first time; 14 (Inquiry) Within 48 hours before taking the study drug for the first time, you have consumed or plan to consume any foods or beverages containing caffeine (such as coffee, strong tea, chocolate, etc.) or foods rich in xanthines (such as sardines, animal liver, etc.) or beverages;",I,Both
0,Healthy subjects.,"1 Age ≥ 18 years old, both male and female; 2 The weight of male subjects is ≥50.0 kg, the weight of female subjects is ≥45.0 kg, and the body mass index (BMI) is between 19 and 26 kg/m2 (including boundary values); 3 The subjects voluntarily signed a written informed consent.",CTR20231984 DUXACT-2305053 TrialTroveID-442676,Adults; Older Adults,year(s),,442676,(N/A); Healthy subjects; Spinal Cord Injury - motor; Traumatic Brain Injury (TBI) - motor,,18.0,"1 (Interview) Previously or currently suffering from any clinically serious diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry and metabolic abnormalities, or any other diseases that can interfere with test results (such as: liver insufficiency, renal insufficiency, hypotension, orthostatic hypotension, bradycardia, arrhythmia, etc.); 2 (Inquiry) Those who have a history of allergies to drugs, food or other substances, or are allergic to any ingredients in this product; 3 (Inquiry) Those who have undergone surgery within 28 days before taking the study drug for the first time, or plan to have surgery during the trial period; 4 (Inquiry) Those who have used any medicine or health care product (including Chinese herbal medicine) within 14 days before taking the study medicine for the first time; 5 (Inquiry) Any drug that inhibits or induces liver drug metabolism has been used within 30 days before taking the study drug for the first time (such as: inducers-barbiturates, carbamazepine, phenytoin, rifampin, etc.; inhibitors-SSRIs Antidepressants, cimetidine, cyclosporine, macrolides, verapamil, quinolones, azole antifungals, HIV protease inhibitors, etc.); 6 (Inquiry) Those who used any clinical trial drug or enrolled in any drug/medical device clinical trial within 3 months before taking the study drug for the first time; 7 (Inquiry) Blood donors within 3 months before taking the study drug for the first time, or those who lost more than 400 mL of blood within 3 months before taking the study drug for the first time; 8 (Interrogation) Those who cannot tolerate venipuncture and/or have a history of haemorrhage and needle fainting; 9 (Inquiry) Those who have used oral contraceptives within 30 days before taking the study drug for the first time, or those who have used long-acting estrogen or progesterone injections or implants within 6 months before taking the study drug for the first time; 10 (Inquiry) Those who had unprotected sex (female) within 14 days before taking the study drug for the first time, or pregnant or lactating women; 11 (Inquiry) Those who cannot take one or more non-drug contraceptive measures during the trial period; 12 (Interrogation) Those who have special requirements for diet, cannot follow a unified diet or have difficulty swallowing; 13 (Inquiry) Those who drank excessive tea, coffee or caffeinated beverages (more than 8 cups, 1 cup = 250 mL) within 3 months before taking the study drug for the first time; 14 (Interrogation) Within 48 hours before taking the study drug for the first time, have consumed or planned to consume any food or drink containing caffeine (such as coffee, strong tea, chocolate, etc.) or food rich in xanthine (such as sardines, animal liver, etc.) or beverages; 15 (Inquiry) Those who have consumed or plan to consume grapefruit or grapefruit-related citrus fruits (such as lime, grapefruit), carambola, papaya, pomegranate or the above fruit products within 14 days before taking the study drug for the first time; 16 (Inquiry) Smokers or those who smoked more than 5 cigarettes per day within 3 months before taking the study drug for the first time; 17 (Interview) Alcoholics or regular drinkers within 6 months before taking the study drug for the first time, that is, drinking more than 14 units of alcohol per week (1 unit ≈ 200?mL beer with 5% alcohol content or 25?mL alcohol content with 40 % spirits or 85?mL wine with an alcohol content of 12%); 18 (Inquiry) Those who have irregular bowel movements within 7 days before taking the study drug for the first time; 19 Abnormal vital signs with clinical significance [reference value range: 90 mmHg ≤ systolic blood pressure < 140 mmHg, 60 mmHg ≤ diastolic blood pressure < 90 mmHg, 60 beats/min ≤ pulse (resting) ≤ 100 beats/min; judged by the research doctor Subject to], or abnormalities judged by the research doctor to be clinically significant, such as physical examination, electrocardiogram, laboratory examination, etc.; 20 Failed alcohol test or positive drug of abuse screen (methamphetamine, morphine, ketamine, THC, MDMA); twenty one Those who may not be able to complete the trial due to other reasons or who the researchers think should not be included.",I,Both
0,Patients with Amyotrophic Lateral Sclerosis,"Participants with ALS (El Escorial criteria: possible, laboratory-supported probable, probable or definite) Capable of providing informed consent and complying with trial procedures. High inflammatory profile of PBMC gene expression Upright SVC > or = 40% of predicted value for gender, height and age at Screening and in the opinion of the investigator is able to comply with and complete the trial. Women must not be able to become pregnant for the duration of the study. Negative tuberculosis blood or skin test at Screening Not taking riluzole, or on a stable dosage for at least 30 days prior to Screening. Subjects medically able to undergo lumbar puncture (LP) Subjects must agree not to take live attenuated vaccines 30 days before Screening, throughout the duration of the trial and for 60 days following the subject's last dose of study drug Geographic accessibility to the study site Additional MRI-PET Inclusion Criteria (MGH only): High or mixed affinity to bind TSPO protein (Ala/Ala or Ala/Thr) (see section 7.1) Upper Motor Neuron Burden (UMNB) Scale Score > or = 25 (out of 45) at the Screening Visit. Able to safely undergo PET/MRI scans based on the opinion of the site investigator.",2015TCZALS-001 NCT02469896 TCZALS-001 TrialTroveID-221108,Adults; Older Adults,year(s),year(s),221108,Delay Disease Progression,75.0,18.0,"Prior use of Tocilizumab, cell-depleting therapies, alkylating agents, total lymphoid irradiation Stem cell therapies Dependence on mechanical ventilation as defined as being unable to lay supine without it, unable to sleep without it, or continuous daytime use Presence of tracheostomy at Screening Exposure to any anti-inflammatory agent currently under investigation for the treatment of patients with ALS (off label use or investigational) within 30 days prior to the Screening Visit (examples include NP001 and Lunasin). Medications that do not have an anti-inflammatory mechanism, such as mexiletine or retigabine are allowed if on stable dose for 30 days prior to Screening visit Treatment with a prohibited medication within 30 days of the Screening Visit Treatment with intravenous gamma globulin, plasmapheresis or Prosorba column within 6 months of Screening Presence of diaphragm pacing system at Screening. Primary or secondary immunodeficiency (history of or currently active) unless related to primary disease under investigation History of or active diverticulitis, diverticulosis requiring antibiotic treatment, peptic ulcer disease, or gastrointestinal (GI) tract perforation, or chronic ulcerative lower GI disease such as Crohn's disease, ulcerative colitis or other symptomatic lower GI conditions that might predispose to perforations Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other opportunistic infections. History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies Presence of any of the following clinical conditions: bleeding diathesis, or any other clinical condition that would, in the opinion of the investigator, place the patient at increased risk during LP. Drug abuse or alcoholism within the past 12 months. Unstable cardiac, pulmonary, renal, hepatic, endocrine, hematologic, or active infectious disease, including current or prior malignancy. Rheumatic autoimmune disease, mixed connective tissue disease, scleroderma, polymyositis, or significant systemic involvement secondary to rheumatoid arthritis. Evidence of active malignant disease, malignancies diagnosed within the previous 5 years, or breast cancer diagnosed within the previous 5 years. Human immunodeficiency virus infection or other immunodeficient state.Uncontrolled hypertension defined as systolic blood pressure > 170 or diastolic blood pressure > 110. Unstable psychiatric illness defined as psychosis or untreated major depression within 90 days of the Screening Visit Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening Screening alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin > than 1.5 times the upper limit of normal (ULN), serum creatinine > 1.6 mg/dL in female patients and > 1.9 mg/dL in male patients (patients with serum creatinine values exceeding limits may be eligible for the study if their estimated glomerular filtration rate (GFR) are >30), hemoglobin < 85 g/L, white blood cells < 3.0 x 109/L, absolute neutrophil count of <2000/mm3, absolute lymphocyte count < 0.5 x 109/L, platelet concentration of <100,000/mm3, positive Hepatitis B surface antigen (HBsAg) Pregnant women or women currently breastfeeding No history of chicken pox infection or no history of varicella zoster vaccination Any reason in the opinion of the investigator that the patient may not be able to comply with study procedures, complete the study or is unsuitable for immunosuppressive therapy. Additional MR-PET Exclusion Criteria (MGH only): Any contraindication to undergo MRI studies such as History of a cardiac pacemaker or pacemaker wires Metallic particles in the body Vascular clips in the head Prosthetic heart valves Claustrophobia Radiation exposure that exceeds the site's current guidelines Current use of tobacco products including cigarettes, e-cigarettes, cigars, snuff and chewing tobacco, or nicotine replacement products such as gum, or patch Taking any other anti-inflammatory or immune modulating medications except for over the counter NSAIDs Unwilling or unable to discontinue benzodiazepine usage (other than Lorazepam, Clonazepam, or Zolpidem) for one day prior to scanning",Ii,Both
1,Patients with SOD1-associated Amyotrophic Lateral Sclerosis(ALS),,TrialTroveID-501003,,,,501003,Unspecified,,,,Iv,Both
1,Participants With Superoxide Dismutase 1-Amyotropic Lateral Sclerosis,"Medically able to undergo the program procedures, as determined by the treating healthcare professional (HCP). Weakness attributable to ALS and associated with a mutation in the SOD1 gene (SOD1-ALS).",233AS001 NCT04972487 TrialTroveID-409676,Adults; Older Adults,year(s),,409676,Delay Disease Progression,,18.0,Previous or current participation in a clinical trial of tofersen. Use of an investigational medicinal product (IMP) for amyotrophic lateral sclerosis (ALS) within 5 half-lives of the IMP before the first dose of tofersen. Participant's primary place of residence is outside of the country of treatment.,Iii,Both
1,Clinically Presymptomatic Amyotrophic Lateral Sclerosis With a Confirmed Superoxide Dismutase 1 Mutation,"Key Part A Inclusion Criteria: Participants should have a protocol-defined rapidly progressive SOD1 mutation, confirmed by a central reader, or a SOD1 mutation that is approved for inclusion by an external mutation adjudication committee. Participants with plasma NfL level less than the protocol-defined threshold. Participants who are clinically presymptomatic for ALS (i.e., must not have clinically manifest ALS).",233AS303 ATLAS EudraCT Number: 2020-004590-51 jRCT2071210032 NCT04856982 PMR 4436-1 TrialTroveID-339454,Adults; Older Adults,year(s),,339454,Delay Disease Progression,,18.0,"Key Part A Exclusion Criteria: History or positive test result at screening for human immunodeficiency virus (HIV). The requirement for testing at Screening may be omitted if it is not permitted by local regulations. Current hepatitis C infection (defined as positive Hepatitis C Virus (HCV) antibody and detectable HCV RNA). Participants with positive HCV antibody and undetectable HCV Ribonucleic Acid (RNA) are eligible to participate in the study (United States Centers for Disease Control and Prevention). Current hepatitis B infection (defined as positive for hepatitis B surface antigen (HBsAg) and/or anti-Hepatitis B Core antibody (HBc)). Participants with immunity to hepatitis B from previous natural infection (defined as negative HBsAg, positive anti-HBc, and positive anti-hepatitis B surface antibody (HBs) or vaccination (defined as negative HBsAg, negative anti-HBc, and positive anti- HBs) are eligible to participate in the study. History of systemic hypersensitivity reaction to tofersen, the excipients contained in the formulation, and if appropriate, any diagnostic agents to be administered during the study. History of confounding neuromuscular or neurological disorder that is expected to have a progressive (i.e., worsening) course during the study, and/or is expected to be associated with elevations in NF, in the opinion of the Investigator. Presence of risk for increased or uncontrolled bleeding and/or risk of bleeding that if not managed optimally could place a participant at an increased risk for intraoperative or postoperative bleeding. Significant cognitive impairment, clinical dementia, or unstable psychiatric illness, including psychosis, suicidal ideation, suicide attempt, or untreated major depression ≤ 90 days of screening, which in the opinion of the Investigator would interfere with the study procedures. Treatment with riluzole and/or edaravone. If the participant has been on riluzole and/or edaravone, the medication(s) must be discontinued for at least 5 half-lives prior to screening. Use of off-label treatments for ALS. Treatment with another investigational drug (including investigational drugs for ALS through compassionate use programs), biological agent, or device within 1 month or 5 half-lives of study agent, whichever is longer. Specifically, no prior treatment with small interfering RNA, stem cell therapy, or gene therapy is allowed. Anticipated need, in the opinion of the Investigator, for administration of any antiplatelet or anticoagulant medication (e.g., clopidogrel) that cannot be safely continued or held for an LP procedure, if necessary, according to local or institutional guidelines and/or Investigator determination. Current enrollment or a plan to enroll in any interventional clinical study in which an investigational treatment, biological agent, device, or approved therapy for investigational use. Participation in a noninterventional study focused on ALS natural history may be allowed at the discretion of the Investigator. NOTE: Other protocol defined Inclusion/Exclusion criteria will apply.",Ii/Iii,Both
0,Healthy Volunteers,"Must have a body mass index between 18 and 30 kilogram per square meter (kg/m^2), inclusive. All men must practice highly effective contraception during the study and for 5 months after their last dose of study treatment. All female participants must be of non-childbearing potential and must meet 1 of the following criteria to participate in the study: a. Postmenopausal, b. History of bilateral oophorectomy (performed at least 6 weeks prior to Screening), c. History of hysterectomy (performed at least 6 weeks prior to Screening), or d. History of female surgical sterilization (e.g., bilateral tubal ligation; performed at least 6 weeks prior to Screening).",233HV101 NCT03764488 TrialTroveID-338255,Adults,year(s),year(s),338255,Healthy subjects,65.0,18.0,"History of or ongoing clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease, as determined by the Investigator. Clinically significant abnormal laboratory test values, as determined by the Investigator, at Screening or Check-in. Use of any prescription medication, over-the-counter medication (e.g., aspirin and nonsteroidal anti-inflammatory drugs [excluding acetaminophen]), or dietary and herbal supplements (e.g., St. John's wort) within 28 days of Check-in and an unwillingness to refrain from use through end of study (i.e., through the Day 91 visit), unless specifically permitted elsewhere within the protocol. Current enrollment in any other drug, biologic, device, or clinical study, or treatment with an investigational drug or approved therapy for investigational use within 30 days (6 months for biologics) or 5 half-lives, whichever is longer, prior to Check-in. History or physical examination that could be suggestive of a medical or mechanical condition, disorder, or disease that could represent a relative contraindication to lumbar puncture (LP), including but not limited to: (a) medication use that prolongs coagulation times, including aspirin; (b) known disorders of the coagulation cascade, platelet function, or platelet count; (c) low white blood cell counts; (d) chronic low back pain; (e) prior lumbar spine surgery; (f) anatomical factors at or near the LP site; (g) clinical signs of raised intracranial pressure (e.g., headache, papilledema, or focal neurologic signs). Contraindications to radiation exposure for research purposes. Exposure to ionizing radiation within the last 12 months that would result in approaching the exposure limits for healthy volunteers. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",I,Both
1,Participants with Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation (SOD1-ALS),"Must have diagnosis of superoxide dismutase 1-amyotrophic lateral sclerosis (SOD1-ALS), and must have completed the End of Study Visit for either Parts A, B, or C of Study 233AS101 (NCT02623699) (i.e., were not withdrawn). If taking riluzole, participant must be receiving a stable dose for > or = 30 days prior to Day 1. If taking edaravone, participant must have initiated edaravone > or = 60 days (2 treatment cycles) prior to Day 1. Edaravone may not be administered on dosing days during this study. Medically able to undergo the study procedures, and to adhere to the visit schedule at the time of study entry, as determined by the Investigator. For female participants of childbearing potential must agree to practice effective contraception during the study and be willing and able to continue contraception for 5 months after their last dose of study treatment. Participants from Study 233AS101 Parts A and B must have a washout > or = 16 weeks between the last dose of study treatment received in Study 233AS101 and the first dose of BIIB067 received in the current Study 233AS102.",233AS102 EudraCT Number: 2016-003225-41 JapicCTI-205111 jRCT2080225019 NCT03070119 TrialTroveID-296928 VALOR OLE,Adults; Older Adults,year(s),,296928,Delay Disease Progression,,18.0,"History of allergies to a broad range of anesthetics. Presence of risk for increased or uncontrolled bleeding and/or risk of bleeding that is not managed optimally and could place a participant at an increased risk for bleeding during or after a Lumbar Puncture (LP) procedure. These risks could include, but are not limited to, anatomical factors at or near the LP site (e.g., vascular abnormalities, neoplasms, or other abnormalities) and underlying disorders of the coagulation cascade, platelet function, or platelet count (e.g., hemophilia, Von Willebrand's disease, liver disease). Presence of an implanted shunt for the drainage of CSF or an implanted central nervous system (CNS) catheter. Prior or current treatment with small interfering ribonucleic acid (RNA), stem cell therapy, or gene therapy. Treatment with another investigational drug, biological agent (excluding BIIB067), or device within 1 month or 5 half-lives of study agent, whichever is longer. Current or anticipated need, in the opinion of the Investigator, of a diaphragm pacing system (DPS) during the study period. Current or recent (within 1 month) use, or anticipated need, in the opinion of the Investigator, of copper (II) (diacetyl-bis(N4-methylthiosemicarbazone)) or pyrimethamine. Female participants who are pregnant or currently breastfeeding. Current enrollment in any other interventional study. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply Key Exclusion Criteria: History of allergies to a broad range of anaesthetics. Presence of risk for increased or uncontrolled bleeding and/or risk of bleeding that is not managed optimally and could place a participant at an increased risk for bleeding during or after an LP procedure. These risks could include, but are not limited to, anatomical factors at or near the LP site (e.g., vascular abnormalities, neoplasms, or other abnormalities) and underlying disorders of the coagulation cascade, platelet function, or platelet count (e.g., hemophilia, Von Willebrand’s disease, liver disease).",Iii,Both
1,Adults with Amyotrophic Lateral Sclerosis (ALS) due to superoxide dismutase 1 gene mutations.,"Key Inclusion Criteria: Part A and B Weakness attributable to ALS and documented SOD1 mutation at Screening Visit 2. A forced vital capacity (FVC) > or =50% of predicted value as adjusted for sex, age, and height (from the sitting position). Participants with stable FVC <50% but > or =45%, whose FVC has not declined by more than 5% in the last 6 months may be considered for inclusion, at the discretion of the Investigator. If taking riluzole, participant must be on a stable dose for > or =30 days prior to Day 1 and expected to remain at that dose until the final study visit. Medically able to undergo the study procedures, and to adhere to the visit schedule at the time of study entry, as determined by the Investigator Key Inclusion Criteria: Part C Weakness attributable to ALS and confirmed SOD1 mutation at Screening Visit. If taking riluzole, participant must be on a stable dose for =30 days prior to Day 1 and expected to remain at that dose until the final study visit. If taking edaravone, participant must have initiated edaravone =60 days (2 treatment cycles) prior to Day 1 and expected to remain at that dose until the final study visit, unless the Investigator determines that edaravone should be discontinued for medical reasons, in which case it may not be restarted during the study. Edaravone may not be administered on dosing days of this study. Medically able to undergo the study procedures and to adhere to the visit schedule at the time of study entry, as determined by the Investigator.",233AS101 EudraCT Number: 2015-004098-33 JapicCTI-194777 jRCT2080224702 NCT02623699 Pro00021877 TrialTroveID-269503 VALOR,Adults; Older Adults,year(s),,269503,Delay Disease Progression,,18.0,"Key Exclusion Criteria: Part A and B History of or positive test result for human immunodeficiency virus. History of, or positive test result at Screening, for hepatitis C virus antibody. Current hepatitis B infection (defined as positive for hepatitis B surface antigen [HBsAg] and/or hepatitis B core antibody [HBcAb]). Participants with immunity to hepatitis B from previous natural infection (defined as negative HBsAg, positive hepatitis B surface antibody immunoglobulin G, and positive HBcAb) or vaccination (defined as positive anti-HBs) are eligible to participate in the study. Treatment with another investigational drug, biological agent, or device within 1 month or 5 half-lives of study agent, whichever is longer. Specifically, no prior treatment with small interfering ribonucleic acid, stem cell therapy, or gene therapy is allowed. Current enrollment in any other interventional study. Current or recent (within 1 month) use, or anticipated need, in the opinion of the Investigator, of copper (II) (diacetyl-bis (N4-methylthiosemicarbazone)) or pyrimethamine. Current or anticipated need, in the opinion of the Investigator, of a diaphragm pacing system (DPS) during the study period. Key Exclusion Criteria: Part C History of or positive test result for human immunodeficiency virus. Current hepatitis C infection (defined as positive hepatitis C virus [HCV] antibody and detectable HCV ribonucleic acid [RNA]). Participants with positive HCV antibody and undetectable HCV RNA are eligible to participate in the study (United States Centers for Disease Control and Prevention). Current hepatitis B infection (defined as positive for HBsAg and/or anti-HBc). participants with immunity to hepatitis B from previous natural infection (defined as negative HBsAg, positive anti-HBc, and positive anti-HBs) or vaccination (defined as negative HBsAg, negative anti-HBc, and positive anti-HBs) are eligible to participate in the study. Treatment with another investigational drug (including investigational drugs for ALS through compassionate use programs), biological agent, or device within 1 month or 5 half-lives of study agent, whichever is longer. Specifically, no prior treatment with small interfering RNA, stem cell therapy, or gene therapy is allowed. Current enrollment in any other interventional study. Current or recent (within 1 month) use, or anticipated need, in the opinion of the Investigator, of copper (II) (diacetyl-bis(N4-methylthiosemicarbazone)) or pyrimethamine. Current or anticipated need, in the opinion of the Investigator, of a DPS during the study period. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",Iii,Both
0,Patients with familial Amyotrophic Lateral Sclerosis due to superoxide dismutase 1 gene mutations.,"Ages Eligible for Study: 18 Years and older; Genders Eligible for Study: Both Inclusion criteria: Have clinical signs of weakness associated with ALS. Have familial ALS with a documented SOD1 gene mutation (investigators will discuss genetic testing with prospective participants). Be18 years old or older. Forced Vital capacity (VC) at least 50% predicted value for gender, height and age at screening and not using invasive respiratory support. If taking riluzole, patients must be on stable dosage for at least 30 days prior to starting the study and expect to remain at that dosage until the end of the study. Capable of providing informed consent and willing to comply with trial procedures and time commitments. Medically able to undergo temporary insertion of intrathecal catheter. Documented evidence of MRI examination of the brain within 3 months of screening. Normal test results for coagulation parameters.",ISIS 333611 SOD1 ISIS 333611- CS1 NCT01041222 TrialTroveID-105508,Adults; Older Adults,year(s),,105508,Delay Disease Progression,,18.0,"Exclusion criteria: Treatment with another investigational drug for ALS (e.g. pyrimethamine, ceftriaxone, lithium, tamoxifen, arimoclomol, high dose creatine, biological agent, or device within 1-month of Screening or 5 half-lives of study agent, whichever is longer. No prior treatment with siRNA, cell transplant, or gene therapy is allowed. Dosing in ISIS 333611-CS1 in a previous dose cohort within 60 days of screening. Presence of any of the following clinical conditions: - Drug abuse or alcoholism within one year of the Screening visit. - Unstable cardiac, pulmonary, renal, hepatic, endocrine, hematologic function, or active infectious disease. - Documented history of HIV infection. - Unstable psychiatric illness defined as psychosis or untreated major depression within 90 days of the Screening Visit. Any condition that may impact intrathecal infusion including: - History of structural spinal disease including tumors and hyperplasia. - Presence of an implanted shunt for the drainage of CSF or an implanted CNS catheter. - Clinically significant abnormalities in hematology or clinical chemistry parameters as assessed by the Site Investigator during the Screening visit. - Ongoing medical condition that according to the Site Investigator would interfere with the conduct and assessments of the study. Examples are medical disability (e.g., severe degenerative arthritis, compromised nutritional state, peripheral neuropathy) that would interfere with the assessment of safety and efficacy of study material or device performance, or would compromise the ability of the patient to undergo study procedures. - ALT or AST >or= 3 x ULN, unless discussed with and approved by the Medical Monitor.",I,Both
0,Patients with behavioral variant Frontotemporal Dementia (bvFTD),Diagnosis of frontotemporal dementia (FTD) Age 40 to 85 Assigned durable power of attorney Caregiver willing and able to accept the responsibilities involved in the study Mattis Dementia Rating Scale-2 (MDRS2) score less than 132,AAAF4151 NCT00604591 TrialTroveID-238799,Adults; Older Adults,year(s),year(s),238799,Frontotemporal Dementia,85.0,40.0,"The diagnosis of any other type of dementia besides FTD including Alzheimer's disease, Lewy body dementia, vascular dementia, dementia associated with Parkinson's disease, corticobasal syndrome, and progressive supranuclear palsy. Known allergy or serious adverse reaction to tolcapone Active liver disease Current alcohol abuse Active substance abuse Elevated liver function tests Patient is taking tolcapone or any other catechol-O-methyltransferase (COMT) inhibitor, benserazide, alpha-methyldopa, dobutamine, apomorphine, isoproterenol, an monoamine oxidase inhibitor (MAO-I), or clozapine Symptomatic cardiovascular disease (e.g., angina, transient ischemic attack (TIA) , syncope) Uncontrolled hyper- or hypotension Any other contraindication to tolcapone Any medication that significantly affects the dopamine system, including stimulants and antipsychotic medications Pregnant women",Ii,Both
0,Subjects with amyotrophic lateral sclerosis.,,TrialTroveID-433813,,,,433813,Unspecified,,,,Ii,
0,Healthy volunteers.,,TrialTroveID-411005,,,,411005,Healthy subjects,,,,I,
0,Patients with Amyotrophic Lateral Sclerosis,"Inclusion Criteria: Patients diagnosed as definite, probable or probable-laboratory-supported ALS according to El Escorial Criteria. Patients of less than 2 years after the onset of ALS. Patients with K-ALSFRS-R score > or = 30 and > or = 2 for each item at screening visit (In case of patients with 60%< or = %FVC< or = 70%, each score of items 10 to 12 of K-ALSFRS-R should be > or = 3). 5. Patients with K-ALSFRS-R score decrease of 1 to 4 points during the 12-week observation period before screening. 6. Patients with forced vital capacity (%FVC)> or = 70%, or 60%< or = %FVC< or = 70% with each score of items 10 to 12 of K-ALSFRS-R > or = 3. 7. Patients who are willing and able to comply with scheduled (outpatient) visits by themselves or with the help of caregivers. 8. Patients who are willing to participate in this study and signed informed consent form.",CT1SNR1611ALS1 KCT0004911 NCT04326283 TrialTroveID-370642,Adults; Older Adults,year(s),year(s),370642,Delay Disease Progression,75.0,19.0,"Exclusion Criteria: Patients with primary lateral sclerosis, progressive muscular atrophy or lower motor neuron disease. Patients who have history of ALS treatment of riluzole, edaravone or stem cell therapy within 16 weeks before screening. Patients who have permanently ceased the administration of riluzole due to lack of tolerability and/or efficacy. Patients in Class II to IV according to the New York Heart Association functional classification. Patients with myocardial infarction, unstable arrhythmia, and/or significant cardiovascular disease such as unstable angina within 12 weeks before screening. Patients with the following medical history (past or present) at screening visit. - Neurodegenerative dieases other than ALS (Parkinson's disease, Alzheimer's disease, etc.) - Neurological symptoms due to vitamin B12 deficiency - Clinically significant cognitive impairment, dementia, or mental illness - Renal vein occlusion (RVO), retinopathy, retinal detachments, or neovascular macular degeneration - Interstitial lung disease - Malignant disease within 5 years of the screening visit excluding malignancies with minimal danger/risk of metastasis or death (such as appropriately treated endometrial carcinoma of cervix, basal cell carcinoma, and squamous cell skin carcinoma, localized prostate cancer or mammary duct endothelial carcinoma) 6. Patients with the following disease/procedure history at screening visit. - Clinically significant respiratory disease due to etiological factors other than ALS - Tracheostomy or on a ventilator - Gastrostomy - Liver disease or abnormal liver function (AST or ALT> or = 3 times the normal upper limit) - Absolute Neutrophil Count (ANC)<1,500/µL - Hemoglobin<9 g/dL - Platelet<75,000/µL - Total bilirubin>2 times the normal upper limit - Serious kidney failure (serum creatinine> or = 1.5 mg/dl) - Patients determined to have activity of viral, bacterial infection (Hbs Ag, HCV Ab, HIV Ab, CMV lgM, EBV lgM, HSV lgM, Syphilis) - Patients with hemorrhagic trend (prothrombin time (PT) and activated partial thromboplastin time (aPTT)>1.5 times the upper normal limit) - QTcB (Bazett's formula)> or = 480 msec as measured by 12-lead ECG (electrocardiogram) - LVEF (left ventricular ejection fraction)<normal lower limit - Patients with impaired drug absorption due to disorders such as gastrointestinal obstruction - Uncontrolled diabetes (HbA1c>7.5%) - Uncontrolled hypertension (SBP/DBP> or =150/100 mmHg) 7. Patients who are pregnant or lactating (breastfeeding). 8. Females and males of childbearing potential who do not consent to the use of effective or scientifically approved contraceptives* for the duration of the study and up to 4 months after the last dose of the study drug. *oral contraceptive pill, hormonal contraceptive implant, intrauterine device or intrauterine system implant, double blocking method (both male (condom) and female (contraceptive diaphragm, cervical sponge, cervical cap) must use contraceptives), sterility procedures (vasectomy, tubal ligation, etc.). 9. Patients with history of severe allergic reaction to the components/ingredients of the investigational drug or its similar components or DSMO (dimethyl sulfoxide). 10. Participation in other clinical trials with drug administration (medication) or therapeutic procedures within 4 weeks prior to screening visit. 11. Patients who are determined to be ineligible for study enrollment by the investigators.",Iii,Both
0,Patients with Amyotrophic Lateral Sclerosis ALS.,,TrialTroveID-192426,,,,192426,Delay Disease Progression,,,,Iii,
0,Patients with Amyotrophic Lateral Sclerosis (ALS).,"Subject has the ability to understand the purpose and risks of the study and provide a signed and dated informed consent and authorization to collect and use protected health information (PHI) in accordance with national and local subject privacy regulations. Subject lives within reasonable driving distance of study center (approximately 3 hours). Subject has a caregiver willing/able to assist in the transportation and care required by study participation. Subject is 18 - 80 years of age (inclusive) on the first day of the Screening Period. Subject is diagnosed with sporadic or familial ALS within the past 48 months. Subject meets the laboratory-supported probable, clinically probable, or definite criteria for diagnosing ALS according to the World Federation of Neurology El Escorial criteria. Subject has an upright FVC =65% of predicted value for age, height, and gender at Screening. Subject has not taken riluzole for at least 30 days prior to the first day of the Screening Period, or has been on a stable dose of riluzole for at least 30 days prior to the first day of the Screening Period (Riluzole-naïve subjects are permitted in the study). Subject is medically able to undergo the study procedures and physically able to adhere to the visit schedule at the time of study entry. Women of childbearing capacity must have a negative pregnancy test during the Screening Period and at the Pre-Operative Visit. Subject must agree to practice effective birth control during study participation.",ALTA-BOLT NCT02478450 QALS-101 TrialTroveID-197470,Adults; Older Adults,year(s),,197470,Delay Disease Progression,,18.0,"Subject in whom causes of neuromuscular weakness other than ALS have not been practically excluded. Subject with a diagnosis of significant cognitive impairment, clinical dementia, or major psychiatric illness including psychosis, bipolar disease, major depression, as determined by the DSM-V. Subject with a diagnosis of other neurodegenerative disease (e.g., Parkinson's disease, Alzheimer's disease). Subject with a diagnosis of any medical condition that impairs nerve or muscle function (e.g., notable peripheral neuropathy, metabolic muscle disease). Subject with a clinically significant history of unstable cardiac, pulmonary, renal, hepatic, endocrine, hematologic, or active malignancy or infectious disease or other medically significant illness, which, in the opinion of the Investigator, would preclude study participation. Subject with a history of spine surgery or anatomic variation incompatible with route of administration (as determined by neurosurgeon). Subject with severe cervical or lumbar stenosis, cord compression, or cervical or lumbar myelopathy. Subject with abnormal flow voids on the surface of the spinal cord suggestive of arteriovenous malformation (AVM). Subject demonstrating any evidence of CNS malignancy or CNS lesions as defined by imaging studies of the CNS (MRI of brain and spinal cord). Subject having uncontrolled hypertension (Systolic BP>180mmHg and/or Diastolic BP >110mmHg) or having a history of thrombotic events or poorly controlled medical conditions that, in the opinion of the Investigator and/or surgeon, increase risk of surgery. Subject who cannot undergo MRI examination because of the presence of a pacemaker, an implanted defibrillator or certain other implanted electronic or metallic devices, or who have been or might have been exposed to metal fragments, or any reason the subject cannot undergo an MRI routinely for the duration of the trial. Subject with clinically significant abnormal clinical laboratory values, as determined by the Investigator during the Screening Period. Subject who is immune compromised or who has a condition contraindicated to treatment with immunosuppression agents (e.g., tuberculosis, latent infection). Subject with an aspartate aminotransferase (AST) or alanine aminotransferase (ALT) value >3.0 times the upper limit of normal or creatinine >1.5 times the upper limit of normal and/or eGFR <50cc/min during the Screening Period. Subject with a history of alcohol or drug abuse or dependence within 1 year of the first day of the Screening Period, per DSM-V criteria. Subject unlikely to comply with study requirements, as determined by Investigator. Subject who has been exposed to any other experimental agent (off-label use or investigational) within 30 days of the first day of the Screening Period. Biologic agents may need additional time for washout and will be evaluated by the Sponsor on a case-by-case basis. Subject who has previously been administered stem cells. Subject with pre-existing anti-human leukocyte antigen (HLA) class I or class II antibodies directed against the Q-Cells®, as determined by panel reactive antibody (PRA) assay during the Screening Period. Subject with an allergy to Q-Cells® or any of its constituents (e.g., chicken eggs), or an allergy to any of the co-administered immunosuppressants or any of their excipients. Subject with any medical condition or using concomitant medication that would contraindicate the use of tacrolimus, mycophenolate mofetil, or prednisone as determined by Investigator. Subject with evidence of deep vein thrombosis (DVT) by venous ultrasound or any previous evidence of DVT. Subject who, in the opinion of the Investigator, has taken or is taking concomitant medications, supplements, or other agents that may interfere with the safety evaluation of Q-Cells® or may affect the course of the subject's ALS progression.",Iii,Both
1,Patients With Amyotrophic Lateral Sclerosis,"1. Sporadic or familial ALS. 2. Age 18 years or older. 3. Cohort 1: Patients who do not qualify for any reasonably accessible ongoing clinical trial. 4. Cohort 2: Patients who have completed the open label extension (OLE) period of Regimen E of the HEALEY ALS Platform Trial and are not eligible for enrollment in another treatment regimen of the platform study. 5. Capable of providing informed consent and complying with study procedures, in the Site Investigator's (SI's) opinion. 6. Participants have established care with a physician at the specialized ALS center involved in the study and will maintain this clinical care throughout the duration of the EAP. 7. Participants must have a life expectancy of at least 6 months in SI's opinion.",NCT05597436 SLS-005-EAP TrialTroveID-446326,Adults; Older Adults,year(s),,446326,Unspecified,,18.0,"1. Current diagnosis or healthcare professional-recommended treatment (medication, exercise or diet) of diabetes mellitus. 2. Screening glucose >=140 mg/dl. 3. Known hypersensitivity to trehalose. 4. Current use of oral trehalose. 5. Inability for participant to return to site for weekly drug administration, until approved for home infusions. 6. Screening body weight >144 kilograms. 7. Participant with a history of any clinically significant or unstable medical condition or lab abnormality based on the SI's judgment that may interfere with assessment of the study objectives, with safety or full participation. 8. Females who are pregnant or nursing or who plan to get pregnant during the course of the EAP. 9. Females of child-bearing potential, or males, who are unwilling or unable to use highly effective methods of birth control. 10. Use of investigational treatments for ALS (as part of participation in a clinical trial or another EAP) within 5 half-lives (if known) or 30 days (whichever is longer) prior to the Screening Visit. 11. Permanent assisted ventilation (PAV), defined as more than 22 hours per day of noninvasive or invasive mechanical ventilation for more than seven consecutive days. The date of onset of PAV is the first day of the seven days. 12. Active cancer or history of cancer, except for the following: basal cell carcinoma or successfully treated squamous cell carcinoma of the skin, cervical carcinoma in situ, prostatic carcinoma in situ, or other malignancies curatively treated and with no evidence of disease recurrence for at least 3 years. 13. Presence of unstable psychiatric disease, cognitive impairment, dementia, or substance abuse that would impair ability of the participant to provide informed consent, in the SI's opinion. 14. Patients who chose to take experimental medications and/or supplements, and that is the only reason they are not eligible for trials, won't be eligible for the EAP.",Iv,Both
0,Patients with amyotrophic lateral sclerosis (ALS).,,TrialTroveID-444199,,,,444199,Unspecified,,,,I,
0,"Patients with Huntington's disease. Participants with ALS, spinocerebellar ataxia and Huntington's disease.","1. Men and women, 18 - 75 years (inclusive) of age at screening 2. Signed informed consent 3. Must meet the disease specific criteria for ALS, SCA or HD listed below: a) ALS: -Diagnosis of probable, lab-supported probable, or definitive ALS -Onset of signs and symptoms of disease within the past 2 years -Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score greater than 30 at the screening visit -Slow Vital Capacity (SVC) greater than 50% of predicted for gender, height, and age at the screening visit b)HD: -Clinical diagnosis of HD with documented genetic confirmation -Onset of signs and symptoms of disease within the past 2 years and onset between the ages of 18 and 50 years (inclusive) -Unified Huntington's Disease Rating Scale (UHDRS)-Total Functional Capacity (TFC) score of 7 to 13 (inclusive) at the screening visit -Body Mass Index (BMI) between 20 kg/m2 and 32 kg/m2 (inclusive) c)SCA3: -Clinical diagnosis of SCA3 with documented genetic confirmation -Modified scale for assessment and rating of ataxia (m-SARA) total score greater than 4 at the screening visit. -m-SARA gait component score greater than 1 at the screening visit. 5. Stable doses of all concomitant medications for 30 days prior to study entry and agree to remain on stable doses for the duration of the study. 6. Negative serum beta-human chorionic gonadotropin (ß-hCG) pregnancy result at the screening visit for female participants of childbearing potential 7. Willingness to comply with sexual abstinence or contraception guidelines of this study",ACTRN12621001755820 SLS-005-204 TrialTroveID-426932,Adults; Older Adults,year(s),year(s),426932,(N/A); Delay Disease Progression; Spinocerebellar Ataxia,75.0,18.0,"1. Current participation in another clinical trial or completed participation in an interventional trial less than 30 days prior to the screening visit (90 days for a biological treatment). 2. History of gene therapy, cell transplants, or brain surgery aimed at treating the medical condition of interest within 1 year of the screening visit. 3. Prior treatment with SLS-005, any other intravenous trehalose formulation, or known hypersensitivity to trehalose. 4. Current diagnosis and/or healthcare professional-recommended treatment (medication and/or diet) of diabetes mellitus type 1 or type 2. 5. HbA1c greater than or equal to 6.5% at the screening visit 6. Pregnant or breastfeeding. 7. History of alcohol or drug abuse within the last 2 years. 8. Chronic liver disease including Hepatitis B; Hepatitis C unless successful curative treatment is documented; human immunodeficiency virus (HIV) infection. 9. Prior history of drug-induced liver injury (DILI) and/or laboratory results at screening that indicate inadequate liver function 10. Laboratory results at screening that indicate inadequate renal function 11. Any current cardiovascular disease or abnormality on 12-lead electrocardiogram (ECG) at screening that, in the investigator’s opinion, is clinically significant and could be a potential safety risk to the participant. 12. Any current psychiatric, neurological, or cognitive disorder that, in the investigator’s opinion, may interfere with the participant’s ability to provide informed consent or appropriately complete the study’s safety or efficacy assessments. 13. Significant suicide risk as indicated by a “yes” response to #4 or #5 under Suicidal Ideation or any “yes” response under Suicidal Behavior on the Columbia Suicide Severity Rating Scale (C-SSRS) during the screening visit. 14. Any other medical condition or abnormal finding during screening that, in the investigator’s opinion, could confound collection or interpretation of safety or efficacy data or be a potential safety risk to the participant.",Ii,Both
1,Patients with either familial or sporadic amyotrophic lateral sclerosis.,No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT NCT04297683).,2019P003518E HEALEY ALS - Regimen E NCT05136885 TrialTroveID-381547,Adults; Older Adults,year(s),,381547,Delay Disease Progression,,18.0,"The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683). Current diagnosis or healthcare professional-recommended treatment (medication, exercise or diet) of diabetes mellitus Master Protocol screening glucose >140 mg/dl Prior treatment with IV trehalose or known hypersensitivity to trehalose Current use of oral trehalose (see prohibited medication Section 5.9) Inability for participant to return to site for weekly drug administration, until approved for home infusions",Ii/Iii,Both
0,Patients with Amyotrophic Lateral Sclerosis.,"Ages Eligible for Study: 18 Years to 85 Years, Genders Eligible for Study: Both Inclusion Criteria: El Escorial Classification of laboratory supported probable, probable, or definite ALS. Age 18 - 85 years. Male or female. FVC greater than or equal to 70% predicted. Patients diagnosed with amyotrophic lateral sclerosis who are currently being treated with riluzole, with no history of liver disease, heart disease or diabetes.",20071808 NCT00919555 PNA TrialTroveID-093634,Adults; Older Adults,year(s),year(s),93634,Delay Disease Progression,85.0,18.0,"Exclusion Criteria: Patients with FVC below 1.5 L or below 70% predicted. History of liver disease. Severe renal failure (CrCl<30). History of coronary artery disease requiring placement of stents, bypass surgery or previous myocardial infarction. EKG at baseline with evidence for previous myocardial infarction, cardiomyopathy, or arrhythmia. History of intolerance to Riluzole, Tretinoin, or Pioglitazone HCL. History of diabetes. Any other comorbid condition which would make completion of trial unlikely.",Iii,Both
0,Patients with Amyotrophic Lateral Sclerosis (ALS),"Familial or sporadic ALS diagnosed as probable, laboratory-supported probable or definite according to the World Federation of Neurology El Escorial criteria, Age 18 or older, Capable of providing informed consent and complying with trial procedures, Appel ALS score less than 100, Able to stand on a scale with assistance, Willing to chart food intake during the 12 week study, Patients either not taking Riluzole (Rilutek) or on a stable dose for 30 days or more, Not taking Coenzyme Q10 or on a stable dose and brand for 30 days, Absence of exclusion criteria.",1307014081 NCT02716662 TrialTroveID-275427,Adults; Older Adults,year(s),year(s),275427,Unspecified,99.0,18.0,"Forced vital capacity <40% of predicted, Dependence on mechanical ventilation for more than 12 hours per day, Exposure to any experimental agent within 30 days of entry or at any time during the trial, Women who are breastfeeding, who are pregnant or are planning to become pregnant, Women of childbearing potential not practicing a medically accepted form of contraception, Enrollment in another research study within 30 days of or during this trial, Mini-Mental State Exam (MMSE) score <20, Patients with symptomatic cardiac disease or hypercholesterolemia, Patients with myocardial infarction within 6 months of this trial, Renal dysfunction defined as BUN and creatinine >2xULN, Known mitochondrial disease, BMI<18.5, Prior use of a 4:1 ketogenic diet or Atkins diet within 1 month of this trial, Impaired liver function, defined as AST or ALT of 3xULN, Patients who have a pacemaker or other internal electronic medical device, Known allergy or hypersensitivity to milk or soy products.",Ii,Both
0,Healthy subjects,,BHV4157-108 TrialTroveID-512076,,,,512076,Healthy subjects,,,,I,
0,Healthy subjects,,BHV4157- 103 TrialTroveID-512073,,,,512073,Healthy subjects,,,,I,
0,healthy subjects,,BHV4157-101 TrialTroveID-512071,,,,512071,Healthy subjects,,,,I,
0,"8 Subjects with moderate HI (Child-Pugh score 7-9 points), and 8 healthy subjects (HS) Subjects in the two groups were matched for age (± 10 years, but ≤80 years), body mass index (± 15%), and gender.",,BHV4157-104 TrialTroveID-512045,Children; Adults; Older Adults,,year(s),512045,Healthy subjects,80.0,,,I,
0,Patients with Amyotrophic Lateral Sclerosis,"Lab supported probable or more definite ALS by El Escorial Criteria Age greater than or equal to 18 years Willing and able to provide informed consent On riluzole at a stable dose for at least 30d or not taking this On Radicava at a stable dose for at least 30d or not taking this Life expectancy at least 6 months Currently managed on a reasonably stable diet, avoidance of fasting, carnitine or medium chain triglyceride (MCT) oils Must stop any other experimental ALS treatment for at least 30 days prior to screening If sexually active, must agree to use contraceptive or abstinence for duration of treatment with triheptanoin Females of child bearing age must have negative pregnancy test at screening",NCT03506425 PALS Pro00092250 TrialTroveID-323085,Adults; Older Adults,year(s),,323085,Delay Disease Progression,,18.0,"Unwilling or unable to provide informed consent Previous intolerance or adverse reaction to triheptanoin or MCT Conditions that will prohibit MRI scanning (metal in eye, some surgical implants, claustrophobia, inability to lie supine) Have any other co-morbid conditions that in the opinion of the study investigator, places the participant at increased risk of complications, interferes with study participation or compliance, or confounds study objectives",Iii,Both
0,Familial or sporadic ALS,"1. Signed informed consent prior to the initiation of any study-specific procedures 2. Familial or sporadic ALS/MND, defined as clinically possible, probable, or definite as per the El Escorial criteria 3. Relative TRICALS risk profile between -6.0 to -2.0 (75% of patients with ALS/MND) 4. Metabolic index (defined as measured resting energy expenditure as a % of predicted resting energy expenditure) equal to or greater than 110%. 5. The use of riluzole will be permitted during the study. Participants taking riluzole must be on a stable dose for at least 30 days prior to the baseline visit, or stopped taking riluzole at least 30 days prior to the baseline visit. 6. Ability to swallow tablets 7. Able to lie with torso elevated at a 35 degree angle for 30 minutes without respiratory support 8. Aged over 18 years 9. Able to give informed consent (as judged by the investigator) and able to comply with all study visits and all study procedures Females must not be able to become pregnant (e.g. post-menopausal, surgically sterile or using highly effective birth control methods) for the duration of the study. Highly effective methods of birth control are those with a failure rate of < 1% per year when employed consistently and correctly, e.g. Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral intravaginal transdermal Progestogen-only hormonal contraception associated with inhibition of ovulation: oral injectable implantable intrauterine device (IUD) intrauterine hormone-releasing system ( IUS) vasectomised partner Females of child-bearing potential must have a negative serum pregnancy test at screening and baseline and be non-lactating",ACTRN12620000945921 EudraCT Number: 2020-005018-17 MetFlex MetFlex-003 NCT04788745 NL75615.041.20 TrialTroveID-386811,Adults; Older Adults,year(s),year(s),386811,Delay Disease Progression,75.0,18.0,"1. Unable to provide informed consent 2. History of, or current diagnosis of diabetes or medical condition that impacts whole body energy expenditure (e.g. Hashimoto’s, heart disease) 3. Tracheostomy or non-invasive ventilation (NIV) use > 22 hours per day 4. Inability to swallow tablets 5. Contraindication therapy 6. Evidence of malignant disease 7. Significant neuromuscular disease other than ALS/MND 8. Ongoing disease that may cause neuropathy 9. Pregnancy or breastfeeding 10. Deprivation of freedom by administrative or court order Parkinson's disease or parkinsonism, tremor, restless-leg syndrome Safety Laboratory Criteria at screening related to significant kidney disease: Creatinine clearance < 50 mL / min (Cockcroft-Gault) based on Cystatin C Females actively seeking to become pregnant who are not using an adequate form of contraceptive as detailed in the Inclusion criteria.",Ii,Both
0,,,TrialTroveID-490028,,,,490028,(N/A); Frontotemporal Dementia,,,,I,
1,Amyotrophic Lateral Sclerosis Patients With Fused in Sarcoma Mutations.,"Inclusion Criteria for Part 1: Participants must be ≥10 years of age at the time of informed consent and have signs or symptoms consistent with an ALS disease (in the opinion of the Investigator). Genetic mutation in FUS confirmed by a testing laboratory that is Clinical Laboratory Improvement Amendments (CLIA) certified and European Conformity (CE)-marked, or equivalent. Mutations must be reviewed and approved by a variant classification committee. Upright (sitting position) slow vital capacity (SVC) is ≥ 50% of predicted value (as adjusted for sex, age, and height) OR if SVC is < 50% of predicted value, must be 10 to 30 years of age (inclusive) at the time of informed consent AND had ALS symptom onset within 12 months before the time of informed consent. Participants taking edaravone, riluzole, Relyvrio (sodium phenylbutyrate/taurursodiol combination, called Albrioza in Canada), sodium phenylbutyrate, or tauroursodeoxycholic acid (TUDCA, also known as taurursodiol or urosodiol) must be on a stable dose for ≥ 28 days prior to Day 1, and willing to continue on that dose throughout the duration of the study, unless the Investigator determines that it should be discontinued for medical reasons, in which case it may not be restarted during the study. Stable concomitant medications and nutritional support for at least 1 month prior to Study Day 1. Concomitant medications or nutritional support that have not been stable for at least 1 month prior to Study Day 1 may be allowed in consultation with the Sponsor Medical Monitor or designee. Females must not be pregnant or lactating. Males and females must be willing to following protocol-specified contraception requirements, or be surgically sterile, or be post-menopausal (females). Has an informant/caregiver who, in the Investigator's judgment, has frequent and sufficient contact with the participant as to be able to provide accurate information about the participant's cognitive and functional abilities throughout the study. In addition, a patient who is < 18 years old must have a trial partner (parent, caregiver, or other) who is reliable, competent, at least 18 years of age, and willing to accompany the patient to all trial visits. Inclusion Criteria for Part 2: Completed, or rescued from, Part 1, or Enrolled and received at least 1 dose of ION363 in the Investigator-initiated study program Patient meeting Criteria #1-2 is otherwise suitable for study participation, in the opinion of the Investigator",BASEC2023-01222 EudraCT Number: 2020-005522-28 FUS-ALS ION363-CS1 NCT04768972 NL78827.000.22 SNCTP000005657 TrialTroveID-389024,Children; Adults; Older Adults,year(s),,389024,Delay Disease Progression,,10.0,"Exclusion Criteria for Part 1: Requiring permanent ventilation (> 22 hours of mechanical ventilation [invasive or noninvasive] per day for > 21 consecutive days) and/or tracheostomy. Any known genetic variant (other than those in the FUS gene) that is pathogenic or likely to be pathogenic for the ALS-frontotemporal dementia (FTD) spectrum of disease. Positive test result for: Human immunodeficiency virus (HIV) Hepatitis C (HCV), unless previously treated and has been serum/plasma HCV RNA negative for at least 6 months after the end of treatment Hepatitis B (HBV) by HBV surface antigen test, unless currently on nucleotide/nucleoside analogue treatment Clinically significant abnormalities in medical history (e.g., previous acute coronary syndrome within 3 months before Screening, major surgery within 2 months before Screening) or physical examination. Uncontrolled hypertension (blood pressure [BP] > 160/100 millimeters of mercury [mm Hg]). Malignancy within 1 year before Screening, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated. Participants with a history of other malignancies that have been treated with curative intent and which have not recurred within 6 months may also be eligible per Investigator judgement. Obstructive hydrocephalus Known significant brain or spinal disease that would interfere with the lumbar puncture (LP) process, CSF circulation or safety assessment, including tumors or abnormalities by magnetic resonance imaging (MRI) or computed tomography, subarachnoid hemorrhage, suggestion of raised intracranial pressure on MRI or ophthalmic examination, spinal stenosis or curvature, Chiari malformation, syringomyelia, tethered spinal cord syndrome and connective tissue disorders such as Ehlers-Danlos syndrome and Marfan syndrome. Concurrent participation in any other interventional clinical study. Previous or current treatment with an oligonucleotide (including small interfering RNA [siRNA], tofersen). This exclusion criterion does not apply to COVID-19 vaccinations, which are allowed. Treatment with another investigational drug, biological agent, or device within 1 month before Screening, or 5 half-lives of investigational agent, whichever is longer. History of gene therapy or cell transplantation or any other experimental brain surgery. Anticipated need, in the opinion of the Investigator, for administration of any antiplatelet or anticoagulant medication that cannot be safely paused before and/or after an LP procedure according to local or institutional guidelines and/or Investigator determination after consultation with the appropriate treating physician. Low-dose aspirin (≤ 100 mg/day, administered as monotherapy) is permitted and may be continued through the LP procedure. Have any other conditions, which, in the opinion of the Investigator would make the participant unsuitable for inclusion or could interfere with the individual participating in or completing the study, in the opinion of the Investigator.",Iii,Both
1,Subjects with amyotrophic lateral sclerosis.,"Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both Inclusion Criteria: Participants will be people with ALS, at least 18 years of age. Participants must be medically able to undergo the study procedures and have a caregiver or other individual who will be available to help with daily study medication administration. Have an FVC (forced vital capacity, a respiratory measurement) of at least 60 percent of normal. Participants should live within a reasonable distance of the study site, due to frequent study visits. Patients with familial or sporadic ALS. Patients may be on riluzole, but have to be on a stable dose for at least 30 days prior to screening. Capable of providing informed consent and complying with trial procedures. Vital capacity (VC) at least 60% predicted value for gender, height and age at screening. Women must not be able to become pregnant (e.g. post menopausal, surgically sterile, or using adequate birth control methods) for the duration of the study. Adequate contraception includes: abstinence, hormonal contraception (oral contraception, implanted contraception, injected contraception or other hormonal (patch or contraceptive ring, for example) contraception), intrauterine device (IUD) in place for > or = 3 months, or barrier method in conjunction with spermicide. Women of childbearing potential must have a negative pregnancy test at screening and be non-lactating. First ALS symptoms occurred no more than 3 years prior to screening visit. Subjects medically able to undergo placement of central venous catheter as determined by the investigator (to include absence of systemic infection, a medical disorder which precludes line placement) At screening, eligible participants had a diagnosis of probable lab-supported, probable, or definite ALS by El Escorial Criteria [28], a vital capacity (VC) > or = 60% of the predicted normal value for height, age and gender, symptom duration of less than 3 years, and were not on riluzole or were on a stable dose for > or = 30 days. Trial participants were discouraged from starting or stopping riluzole during the trial but were not prevented from doing so.",CEF-ALS -2006 CEF-ALS-2006 NCT00349622 NINDS NINDS CRC TrialTroveID-079062,Adults; Older Adults,year(s),,79062,Delay Disease Progression,,18.0,"Exclusion Criteria Participants cannot be taking any other experimental medications for ALS. Have a history of sensitivity to cephalosporin antibiotics (such as Ancef, Keflex, Ceclor, Ceftin, Lorabid, Suprax, or Fortaz). Dependence on mechanical ventilation (invasive) for any part of the day or night prior to the screening visit. Exposure to ceftriaxone or any cephalosporin within 30 days prior to the screening visit. History of known sensitivity or intolerability to ceftriaxone or to any other cephalosporin. History of known sensitivity or intolerability to penicillin or any beta lactam (including mild rash). Exposure to any other investigational agent within 30 days prior to screening visit. Known immune compromising illness or therapy. Active gastrointestinal disease within 30 days of the screening visit. History of antibiotic-induced colitis. Biliary disease (including gall stones) presently or in the past. Presence of any of the following clinical conditions a) Drug abuse or alcoholism b) Unstable cardiac, pulmonary, renal, hepatic, endocrine, hematologic, or active infectious disease c) AIDS or AIDS-related complex d) Unstable psychiatric illness defined as psychosis, untreated major depression within 90 days of the baseline visit. Laboratory values: Screening creatinine greater than 1.5, creatinine clearance less than 70 cc/min, alanine aminotransferase (ALT) greater than 3.0 times the upper limit of normal or, total bilirubin greater than 1.5 times the upper limit of normal, absolute neutrophil count of < or 1000/ul, platelet concentration of <100,000/ul, hematocrit level of <33 for female or <35 for male, or coagulation tests > 1.5 times upper limit of normal. Women of childbearing potential not practicing adequate contraception. Exclusion criteria included use of mechanical ventilation, known sensitivity to beta-lactam antibiotics, pregnancy, exposure to investigational agents within 30 days of screening, active gastrointestinal or biliary disease within 30 days of screening, history of antibiotic-induced colitis, or clinically significant abnormal safety laboratory values.",Iii,Both
1,Patients with ALS.,,TrialTroveID-121975,,,,121975,Delay Disease Progression,,,,Iv,
0,Subjects diagnosis of probable or definite ALS.,"Inclusion Criteria Clinical diagnosis of probable or definite ALS. 18 to 80 years of age. Forced vital capacity respiratory test (FVC) greater than 50 percent of normal (""predicted"" value). If a woman of childbearing age, must have a negative pregnancy test, be non-lactating (not nursing a baby), and either surgically sterile or using an effective method of birth control (double-barrier method or oral contraception). Be willing and able to give informed consent. Be able to take oral medications, either by mouth or by PEG feeding tube. Be willing to return for study visits and adhere to the medication regimens. Have a disease duration of less than five years since symptom onset. Have at least five of the 10 testable upper-extremity muscle groups (grip strength and extensors/flexors of shoulders and elbows) measured at MRC grade 4 or better.",TrialTroveID-080604,Adults; Older Adults,year(s),year(s),80604,Delay Disease Progression,80.0,18.0,,Ii,
0,"Patients with definite or probable ALS. Patients with a predicted forced vital capacity (FVC) < 50%, gastrostomy and on wheelchair were excluded.",,TrialTroveID-087393,,,,87393,Delay Disease Progression,,,,Ii,
1,Depressed patients with Amyotrophic Lateral Sclerosis,Documented diagnosis of definite or probable ALS Informed and written consent for enrollment in study Gender: both male and female Age: 25-80 years BDI score 19 or above Depression diagnosis by mental health provider,22974 NCT02851914 TrialTroveID-283695,Adults; Older Adults,year(s),year(s),283695,"Adults, major depression; Comorbidities in depression; Elderly, major depression",80.0,25.0,"History of psychotic disorder, premorbid bipolar depression ALS-FRS score < 26 Cognitive impairment Currently on SSRIs or TCAs. However if for some reason they are off their treatment, then they can be enrolled in the study after a washout period of 30 days. Currently on other antidepressants such as monoamine oxidase inhibitors (MAOIs), selective norepinephrine re-uptake inhibitors (SNRIs) etc.",Iv,Both
1,Patients with Amyotropic Lateral Sclerosis.,"Patients: Man or woman with sporadic ALS and a possible, probable or definite diagnosis regarding the revised Escorial criteria (Forbes et al., 2001). Patients are followed quarterly according to national recommendations. At the end of the follow up period (1 year for each patient), all patients remaining in the "" possible "" group of diagnosis will be excluded. Disease onset (date of onset of muscle weakness) < 18 months at the time of inclusion. Age: 30 to 80 years-old, inclusive. Patient treated by riluzole at a steady dosage since at least 3 months. Patient accepting to give informed consent Controls: Subject accepting to give informed consent",9632 NCT02756104 TrialTroveID-278122 VITALS,Adults; Older Adults,year(s),year(s),278122,Delay Disease Progression,80.0,30.0,"Patients: A previous treatment with VD in the preceding 2 years, whatever the dose used. Patient with an already known autoimmune disorder Patient with severe ALS involvement suggesting that survival over the 1 year follow up is highly unlikely (ex : tetraplegia, use of non-invasive ventilation for more than 10 hrs/day, ALSFRS-R (ALS Functional Rating Scale) score < à 20). Pregnant or breast-feeding woman. Patient without social security insurance Controls: Subject with an already known neurodegenerative disorder Subject with an already known autoimmune disorder Subject who received a treatment with VD in the preceding 2 years, whatever the dose used. Pregnant or breastfeeding woman Subject without social security insurance",Iv,Both
0,Patients with amyotrophic lateral sclerosis.,All had probable or definite ALS by the World Federation of Neurology criteria. Patients were required to have a forced vital capacity of at least 60% of the predicted value at study entry.,TrialTroveID-119185,Adults,year(s),year(s),119185,Unspecified,65.0,37.0,,Ii,Both
1,Patients with probable or definite Amyotrophic Lateral Sclerosis (ALS).,"Patients with definite or probable sporadic ALS, according the revised El Escorial criteria, were enrolled. They had to be at or above 20 yr of age, and have disease duration of less than 60 months. The Appel ALS rating scale (AALSRS) total score had to be between 40 and 120 at baseline.",TrialTroveID-121977,Adults; Older Adults,year(s),,121977,Delay Disease Progression,,20.0,"Patients who had a forced vital capacity of less than 30%, those with signs of major psychiatric disorders and/or dementia, and acute cholecystitis or occlusion of bile duct, or patients who had another concomitant conditions likely to interfere with drug compliance and outcome assessment were excluded. Additional exclusion criteria were pregnancy and participation to other clinical trials.",Iii,Female
0,Subjects with ALS,"1. Male and/or female patients aged between 18 and 80 years (inclusive at screening). 2. Diagnosis of probable or definite ALS, according to the revised version of the El Escorial World Federation of Neurology criteria. Refer Appendix III - El Escorial Criteria. 3. Time since onset of first symptom of ALS ≤9 months 4. Slow Vital Capacity (SVC) ≥ 50% of the predicted value 5. Be able to swallow the study capsules during study 6. Either not currently receiving riluzole or on a stable dose of riluzole for at least 4 weeks before the screening visit. Participants receiving riluzole are expected to remain on the same dose throughout the duration of the study 7. Either not currently receiving edaravone or on edaravone treatment. Participants receiving edaravone must have completed at least 1 cycle of treatment before the screening visit and are expected to continue with stable dose edaravone treatment throughout the duration of the study. 8. Female patients must be non-pregnant, non-lactating and women of child-bearing potential/ sexually active women, unless surgically sterile (at least 6 months prior to study drug administration) or postmenopausal* for at least 12 consecutive months, must agree to use adequate contraception (hormonal contraceptives [combined estrogen and progestogen oral contraceptive, patch, contraceptive vaginal ring, injectable progestogen, and implants] or contraceptive subdermal implant or percutaneous contraceptive patches or intrauterine device [IUD] or intrauterine system [IUS]; vasectomy and tubal ligation or barrier method of birth control; female condom with spermicide, cervical cap, diaphragm with spermicide, contraceptive sponge), absolute sexual abstinence, use of condom with spermicide by sexual partner or sterile [at least 6 months prior to study drug administration], during study and up to 32 days after the last dose of study drug. *Postmenopausal defined as 12 months of spontaneous amenorrhea with an appropriate clinical profile (e.g., age appropriate, >45 years, in the absence of hormone replacement therapy). 9. All male patients should avoid fathering a child by either true abstinence, hormonal or barrier method (e.g., male condom with diaphragm, male condom with cervical cap) or with their sexual partner the use of effective means of contraception throughout and till 92 days of administration of the last dose. They must not donate sperm for at least 92 days after the last dose of study drug. 10. Ability to provide written informed consent and to be compliant with the schedule of protocol assessments. In case of illiterate patients, thumb impression of the patients will be obtained along with the signature of the impartial witness or legally authorized representative (LAR) on the consent form prior to patient's participation in the trial.Date of ALS Symptom Onset. For the purposes of this study, the date of symptom onset will be defined as the date the subject first had symptoms of their disease, i.e., weakness. To be eligible for this study, the date of symptom onset must be no greater than exactly 9 months prior to the Screening Visit date.",CTRI/2023/10/058660 NCT05981040 TrialTroveID-480510 ZYIL1.23.003,Adults; Older Adults,year(s),year(s),480510,Delay Disease Progression,80.0,18.0,"1. With significant cognitive impairment, psychiatric disease, other neurodegenerative disorder (e.g., Parkinson disease or AD), substance abuse other causes of neuromuscular weakness, or any other condition that would make the participants unsuitable for participating in the study or could interfere with assessment or completing the study in the opinion of the Investigator. 2. History of recent serious infection (e.g., pneumonia, septicemia) within 4 weeks of the screening visit; infection requiring hospitalization or treatment with IV antibiotics, antivirals, or antifungals within 4 weeks of screening; or chronic bacterial infection (such as tuberculosis) deemed unacceptable as per the Investigator's judgment 3. With active herpes zoster infection within 2 months prior to the screening visit 4. A documented history of attempted suicide within 6 months prior to the screening visit, or in the Investigator's judgment are at risk for a suicide attempt 5. History of unstable or severe cardiac, pulmonary, oncological, hepatic, or renal disease or another medically significant illness other than ALS precluding their safe participation in this study 6. Participants who are pregnant or are currently breastfeeding 7. A known history of allergy to any ingredients of ZYIL1 8. Patients taking concomitant medicines within 7 days or 5 half-lives of the medication (whichever is longer) prior to first dose of study drug administration till end of the study, which are substrate of CYP1A2 enzymes (e.g., alosetron, caffeine, duloxetine, melatonin, ramelteon, tasimelteon, tizanidine etc.) and CYP2B6 enzymes (e.g., bupropion, efavirenz etc.). 9. Use of any steroids, colchicine or anti-IL-1 inhibitors within 7 days or 5 half-lives of the medication (whichever is longer) prior to first dose of study drug administration. 10. Use of any investigational drugs concurrently or within 4 weeks or 5 half-lives (whichever is longer), prior to first dose of study drug administration. 11. Any clinically significant and/or laboratory significant value or other instability that would prevent the patient from participating in the study as determined by the Investigator. 12. Received a live vaccine within 14 days before the screening visit or planning to receive during the study 13. Participants who have received stem cell or gene therapy for ALS at any time in the past 14. Any of the following laboratory values at screening - Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3.0 × upper limit of normal (ULN) - Bilirubin >1.5 × ULN unless the participant has documented Gilbert syndrome (isolated bilirubin >1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin is <35%) - Estimated glomerular filtration rate <60 mL/min/1.73 m2 (Modification of Diet in Renal Disease [MDRD]) 15. QT interval corrected for heart rate using Fridericia's method (QTcF) > 450 msec at screening. 16. Contraindications to lumbar puncture including but not limited to lumbar scoliosis, coagulopathy, infection at site of puncture, use of anticoagulants at the time of study enrolment. 17. Participant with seizure disorder or history of seizures within 6 months. 18. Surgery within last 3 months or planned major surgery within next 3 months from the date of screening (other than minor cosmetic surgery and minor dental surgery). 19. Use or intended use of any medications/products known to alter drug absorption, metabolism, or elimination processes including St John's Wort within 4 weeks prior to receiving study drug and up to end of study. Use of such medication will be considered on a case-by-case basis as per the opinion of the Investigator and/or independent medical monitor. 20. Use of grapefruit or similar substances (Seville oranges or marmalade, grapefruit juice, grapefruit hybrids, pomelos, exotic citrus fruits or fruit juices) within 7 days prior to first dose of study drug until last dose administration. 21. Donation of blood or blood products within 3 months prior to screening. 22. History of, or positive screening test for, hepatitis C infection (defined as positive for hepatitis C virus antibody), hepatitis B infection (defined as positive for hepatitis B surface antigen), or human immunodeficiency virus I or II. 23. Use or intended use of any over-the-counter (vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations) or prescription medications within 7 days or 5 half-lives (whichever is longer) prior to receiving study drug, with the exception of hormone replacement therapy and therapies for chronic stable diseases that have been stable for at least 30 days prior to screening and until Day 1, unless deemed acceptable by the Investigator. 24. Inability to be venipunctured or tolerate venous puncture.",Ii,Both
0,Adult Subjects With Amyotrophic Lateral Sclerosis,"Key Inclusion Criteria: ALS with preserved function, defined as: Onset of the first symptom leading to the diagnosis of ALS ≤24 months at the time of the initial Screening Visit Revised EL Escorial criteria of either: (i) Clinically definite ALS (ii) Clinically probable ALS A total ALSFRS-R score of at least 34 at the start of the Screening Period No significant respiratory compromise as evidenced by slow vital capacity ≥60% at the start of the Screening Period All chronic concomitant medications (both prescription and over the counter), and non-pharmacologic therapy regimens, excluding standard-of-care therapy riluzole, edaravone, or sodium phenylbutyrate/taurursodiol, should be stable and unchanged from 14 days prior to the start of the Screening Period and intend to remain stable and unchanged throughout the course of the study Female participants must have a negative breast cancer imaging screening status (not considered clinically abnormal and/or requiring further evaluation/treatment) within 6 months prior to the Screening Visit, or during the Screening Period. Standard-of-care therapy for the treatment of ALS (riluzole, edaravone, or sodium phenylbutyrate/taurursodiol) should be stable and unchanged from 30 (-3) days prior to the start of the Screening Period and intend to remain stable and unchanged throughout the course of the study. Following the double-blind period, eligible patients will havethe option to enter a28-week long-term extension periodin which they will receive open-label utreloxastat.",CardinALS EudraCT Number: 2021-006511-29 jRCT2011230040 jRCT2011230043 NCT05349721 NL81540.041.22 PTC857-CNS-001-ALS TrialTroveID-418007,Adults; Older Adults,year(s),year(s),418007,Delay Disease Progression,80.0,18.0,"Females who are pregnant or nursing or plan to become pregnant during the study Participants with clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular/ischemic disease or any other condition that, in the opinion of the investigator would jeopardize the safety of the participant or impact the validity of the study results Any clinically significant medical or psychiatric condition or medical history that, in the opinion of the investigator or the medical monitor, would interfere with the participant's ability to participate in the study or increase the risk of participation for that participant Current participation in any other investigational study with an investigational product or participation within 30 days prior to the start of the Screening Period or 5 half-lives of the previously taken investigational drug, whichever is longer Participant has previously received PTC857 Participant is receiving a combination of edaravone and sodium phenylbutyrate/taurursodiol treatment, where applicable, within 30 days prior to the start of the Screening Period For female participants, any past medical history of breast cancer, regardless of remission status, or any first degree relative with history of breast cancer",Ii,Both
1,Patients with sporadic amyotrophic lateral sclerosis.,,TrialTroveID-252287,,,,252287,Delay Disease Progression,,,,Iv,
1,"Patients with amyotrophic lateral sclerosis, gender (55 men and 50 men),mean age (59.4 + or - 10; 58.6 + or - 10),","Inclusion criteria: Laboratory-supported, probable, or definite ALS according to El Escorial revised criteria, Age between 18 and 75 years, sVC 70% or higher, onset 18 months or less. Inclusion criteria were onset of weakness < or = 18 months and slow vital capacity (sVC) > or = 70% of predicted in seated position at screening visit.",EPO200901 EPOS TRIAL EudraCT Number: 2009-016066-91 TrialTroveID-198292,Adults; Older Adults,year(s),year(s),198292,Delay Disease Progression,75.0,18.0,"Exclusion criteria: any contraindication to the use of rhEPO tracheotomy or >23h of non-invasive ventilation daily for 14 consecutive days first-degree relative with ALS diagnosis of neurodegenerative disease in addition to ALS history of myocardial infarction or thrombotic vascular events (such as stroke, transient ischemic attack, pulmonary emboli, deep vein, arterial, retinal thrombosis), clinically evident cardiac disease (ischemic heart disease or congestive heart failure), uncontrolled hypertension, active malignancy, polycythemia, myeloproliferative disorder, hypercoagulable disorders, porphyria, known hypersensitivity to human albumin history of unstable medical condition in the previous 2 years female subjects pregnant or lactating use of experimental drug or participation in a clinical trial within 3 months prior to screening.",Iii,Both
0,Patients with probable and definite Amyotrophic Lateral Sclerosis.,Patients with probable and definite ALS on the basis of El Escorial criteria were recruited for this study.,TrialTroveID-121485,,,,121485,Delay Disease Progression,,,,Ii,
0,Patients with amyotrophic lateral sclerosis.,,TrialTroveID-109807,,,,109807,Unspecified,,,,Ii,
0,Patients with definite amyotrophic lateral sclerosis were recruited.,Patients with probable and definite ALS on the basis of El Escorial criteria were recruited for this study.,TrialTroveID-080342,,,,80342,Delay Disease Progression,,,,Ii,
0,Patients with sporadic ALS were included in our study.,"Amyotrophic Lateral Sclerosis (ALS) patients with cervical onset of the disease were included in the study. The age of patients in the treatment and placebo group was 41.8 + or -4.1 and 52.0 + or -10.8 years, respectively. The duration of the disease in patients of the treatment and placebo groups was 17.6 + or - 8.9 and 15.0 + or -11.7 months, respectively",TrialTroveID-121506,Adults,year(s),year(s),121506,Delay Disease Progression,63.0,38.0,,Ii,Both
0,Subjects With Semantic Variant Primary Progressive Aphasia,"1. Between 18 and 85 years of age (inclusive) at the initial screening visit; 2. Meets 2011 consensus criteria for svPPA (Gorno-Tempini et al. 2011); 3. MRI at screening is consistent with the underlying svPPA with no large strokes or severe white matter disease (Fazekas Grade < or =2; Fazekas et al. 1987); 4. CDR® plus NACC FTLD (Miyagawa et al. 2020) global score at screening < or = 1; 5. The following medications are allowed, but must be stable for 2 months prior to the initial screening visit: 1. Food and Drug Administration (FDA)-approved Alzheimer's disease (AD) medications; 2. FDA-approved psychotropic medications; 6. Other medications (except those listed under",21-35516 NCT05184569 TrialTroveID-422602 Veri-T-001,Adults; Older Adults,year(s),year(s),422602,Frontotemporal Dementia,85.0,18.0,"exclusion criteria) are allowed as long as the dose is stable for 30 days prior to the initial screening visit; 7. Has a reliable study partner who agrees to accompany the participant to visits, and spends at least 5 hours per week with the participant; 8. Agrees to 2 LPs; 9. Signed and dated written informed consent obtained from the participant and the participant's study partner in accordance with local Institutional Review Board (IRB) regulations; 10. WOCBP must agree to abstain from sex or use highly effective birth control that includes two methods of contraception (one of which must be a barrier method) for the duration of the screening period, the RDBPC treatment period, and for 30 days after the last dose of study drug (active or placebo); 11. Males must agree to abstain from sex with WOCBP or use an adequate method of contraception for the duration of the RDBPC treatment period and for 90 days after the last dose of study drug (active or placebo); 12. Able to swallow pills whole without crushing or chewing. 1. A clinical diagnosis of probable AD (McKhann et al. 2011) or previous biomarker evidence of AD biology using amyloid positron emission tomography (PET) imaging, CSF amyloid beta (Aβ)/total tau (t-tau) ratio, CSF/plasma amyloid beta isoform with 40 amino acid residues (Aβ40)/amyloid beta isoform with 42 amino acid residues (Aβ42) ratio, or plasma phosphorylated tau [phosphorylated tau at residue 181 (p-tau181) and phosphorylated tau at residue 217 (p-tau217)] assessments; 2. A clinical diagnosis of a comorbid FTLD-associated clinical syndrome other than svPPA, including: 1. logopenic primary progressive aphasia (lvPPA; Gorno-Tempini et al. 2011); 2. non-fluent/agrammatic variant primary progressive aphasia (nfvPPA; Gorno-Tempini et al. 2011); - c. behavioral variant for frontotemporal dementia (bvFTD; Rascovsky et al. 2011). Patients who meet diagnostic criteria for svPPA (Gorno-Tempini et al. 2011) may still be included if they have a secondary diagnosis of bvFTD, so long as the PI can reasonably attribute their disinhibition, dietary changes, compulsions, and/or loss of empathy to anterior temporal lobe atrophy (Seeley et al. 2005) and MRI is consistent with right anterior atrophy (or left temporal atrophy in participants with suspected right hemispheric language dominance); d. progressive supranuclear palsy (PSP; Höglinger et al. 2017); e. corticobasal syndrome (CBS; Armstrong et al. 2013); 3. Any other medical condition other than FTLD that is likely to account for cognitive or behavioral deficits (e.g., uncontrolled seizure disorder, stroke, vascular dementia, substance abuse or alcoholism, Lewy body disease); 4. History of uncontrolled thyroid disease or evidence thereof [i.e., abnormal free thyroxine (T4) levels and thyroid stimulating hormone (TSH) > 10 milli-international units (mIU)/liter (L) at screening (confirmed by repeat)]; 5. Serious autoimmune disease, or ongoing immunocompromised state; 6. History of significant cardiovascular, hematologic, renal, or hepatic disease (or laboratory evidence thereof at screening); 7. History or presence of gastrointestinal (GI) or other disease known to interfere with absorption, distribution, metabolism, or excretion of drugs, or a history of surgery known to interfere with absorption or excretion of drugs (i.e., gastric bypass); 8. Within 1 year prior to initial screening visit or between screening and baseline (pre-dose Day 1), any of the following: myocardial infarction; hospitalization for congestive heart failure; hospitalization for, or symptoms of, unstable angina; or syncope; 9. History of major psychiatric illness or untreated depression that in the opinion of the PI would pose a safety risk or interfere with the appropriate interpretation of study data; 10. Neutrophil count <1,500/cubic millimeter (mm3), platelets <100,000/mm3, serum creatinine >1.5 x upper limit of normal (ULN), total bilirubin (TBL) >1.5 x ULN, alanine aminotransferase (ALT) >1.5 x ULN, aspartate aminotransferase (AST) >1.5 x ULN, or international normalized ratio (INR) >1.2 at screening (confirmed by repeat); 11. Evidence of any clinically significant findings on screening or baseline evaluations which, in the opinion of the PI would pose a safety risk or interfere with appropriate interpretation of study data; 12. Corrected QT interval by Fridericia (QTcF) > or = 470 milliseconds (msec) or uncontrolled arrhythmia or frequent premature ventricular contractions (PVCs; >5/minute) or Mobitz Type II second or third degree atrioventricular (AV) block or left bundle branch block or right bundle branch block with a QRS duration > or = 150 msec or intraventricular conduction defect with a QRS duration > or = 150 msec or evidence of acute or sub-acute myocardial infarction or ischemia or other ECG findings at screening or baseline that, in the PI's opinion, would preclude participation in the study; 13. Pathologic renal findings at screening as defined by the presence of either of the following criteria: 1. Estimated glomerular filtration rate (eGFR) [determined by the Modification of Diet in Renal Disease (MDRD) Study equation] < 30 milliliter (mL)/minute/1.73 square meter (m2). The MDRD Study equation is as follows: eGFR (mL/minute/1.73 m2) = 175 x (Scr)-1.154 x (Age)-0.203 x (0.742 if female) x (1.212 if African American), where Scr = serum creatinine in mg/deciliter (dL) as measured by a method calibrated to an isotope dilution mass spectrometry (IDMS) reference method; 2. Serum creatinine > or = 2.5 mg/dL; 14. Hemoglobin A1C >7.5% at screening (confirmed by repeat); 15. Current or recent history (within four weeks prior to initial screening visit) of a clinically significant bacterial, fungal, or mycobacterial infection; 16. Current clinically significant viral infection, including",I,Both
1,Patients with Amyotrophic Lateral Sclerosis,No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT NCT04297683).,2019P003518B HEALEY ALS Platform Trial - Regimen B NCT04436510 TrialTroveID-377434,Adults; Older Adults,year(s),,377434,Delay Disease Progression,,18.0,"The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683). Participants who are taking strong inhibitors of CYP1A2 (i.e., ciprofloxacin, enoxacin, fluvoxamine, zafirlukast) for chronic/long-term use defined as more than two weeks. Participants who are taking strong inhibitors of CYP3A4 (i.e., conivaptan, itraconazole, ketoconazole, posaconazole, troleandomycin, voriconazole, clarithromycin, diltiazem, idelalisib, nefazodone, and certain antiviral agents [cobicistat, danoprevir, ritonavir, elvitegravir, indinavir, lopinavir, paritaprevir, ombitasavir, dasabuvir, saquinavir, tipranavir, nelfinavir]) for chronic/long-term use defined as more than two weeks. Note: Topical antifungal use is not exclusionary. Participants should not consume large quantities of grapefruit juice (more than 8oz per day) on a regular basis.",Ii/Iii,Both
0,Healthy Volunteers,"Inclusion Criteria Part A & B: 1. Healthy men or women aged 18 to 55 years. 2. Body Mass Index between 18 and 32 kg/m2, with a minimum weight of 50 kg. 3. Effective contraception required during the study and for at least 90 days after their last dose. 4. Participants in group 3, where the food effect is being investigated, must be able to eat a high-fat meal within 30 minutes for breakfast.",NCT06226064 Ph1/VES001 SORT-IN-1 TrialTroveID-501625,Adults,year(s),year(s),501625,Healthy subjects,55.0,18.0,"Exclusion Criteria Part A & B: 1. Medical conditions or treatments that could interfere with the study. 2. History of any known neurologic disease, cognitive impairment, or a history of seizure, (significant) head trauma, or loss of consciousness. 3. History of active malignancy (active cancer cells or tumors) within the last 5 years. 4. Abnormal laboratory test results or infectious diseases (Hepatitis B, Hepatitis C, and/or HIV). 5. Recent medication or supplement use, unless allowed by the investigator. 6. Participation in other research studies involving study treatment or devices. 7. Positive tests for illegal drugs or alcohol at screening. 8. Heavy smoking or inability to abstain from smoking during the study. 9. Excessive consumption of caffeine (more than 8 cups per day). 10. History of severe allergic reactions to medication 11. Recent blood donation or significant blood loss. 12. Pregnancy, breastfeeding, or plans to become pregnant (for women).",I,Both
0,Patients with Amyotrophic Lateral Sclerosis.,,TrialTroveID-080132,,,,80132,Delay Disease Progression,,,,Ii,
1,Subjects with Amyotrophic Lateral Sclerosis (ALS),1. ALS patients who meet the diagnostic criteria of GCC; 2. Aged ≥18 years old; 3. The treatment process and treatment medications are clearly recorded.,ChiCTR2300075878 TrialTroveID-487477,Adults; Older Adults,year(s),,487477,Delay Disease Progression,,18.0,"1. Medical records record that patients have spinal cord and brainstem tumors, malignant tumors, severe infections, and severe trauma; 2. Medical records record that patients have severe liver and kidney diseases.",Iv,Both
1,Patients with Amyotrophic Lateral Sclerosis (ALS).,"Ages Eligible for Study:18 Years and above, Inclusion Criteria: Adults (> age 18 years). Probable or definite ALS by El Escorial Revised criteria. At least 2 painful muscle cramps in one or more of the limbs per week. May have tried other medications for cramping in the past. If participants are currently on treatment for cramps and are continuing to have at least 2 cramps per week, they can be included in the trial. In this situation, the individual's previous cramp medication can be continued during the trial. Ideally, patients should not have any medication alterations during the duration of the trial. Willing to discontinue supplementary vitamin E and multivitamins containing > 400 IU of vitamin E during the trial.",ALSClin-001 NCT00372879 R-06-451 TrialTroveID-079052,Adults; Older Adults,year(s),,79052,Symptom relief,,18.0,"Exclusion Criteria: Patients who are unable to safely consume the trial capsules. Individuals with significant dysphagia can be included into the study if they have a functioning PEG tube or GJ tube, through which the medication can be given. Patients who are unable to fill out the daily diary, either personally or via a proxy. Patients who have had medication changes within the last 4 weeks prior to the onset of the trial will be excluded.",Iii,Both
0,Patients with amyotrophic lateral sclerosis,"A clinical diagnosis by a study investigator of laboratory-supported probable, probable, or definite ALS, according to a modified El Escorial criterion (Appendix 2). 21 to 80 years of age inclusive. If patients are taking riluzole for ALS, they must be on a stable dose for at least thirty days prior to the baseline visit. Willing and able to give signed informed consent that has been approved by the Institutional Review Board (IRB).",19-094 MICABO-ALS NCT04244630 TrialTroveID-366405,Adults; Older Adults,year(s),year(s),366405,Delay Disease Progression,80.0,21.0,"Diagnosis of other neurodegenerative diseases (Parkinson disease, Alzheimer disease, etc.). Clinically significant history of unstable medical illness (unstable angina, advanced cancer, etc.) over the last 30 days. Infection with the human immunodeficiency virus (HIV) Limited mental capacity such that the patient cannot provide written informed consent or comply with evaluation procedures. History of recent alcohol or drug abuse or noncompliance with treatment or other experimental protocols. 6 Receipt of any investigational drug within the past 30 days.",Ii,Both
0,Patients with Amyotrophic lateral sclerosis (ALS),"Patients who have a decrease of 1 to 4 points on the ALSFRS-R score during the 12-weeks observation period prior to screening and enrollment Patients of less than 2 years after the diagnosis of ALS. Patients without respiratory symptoms (orthopnea, dyspnea) Capable of giving signed informed consent",2018613-6392 42595 NCT04140136 NMRR-18-1592-42595 T3-ALS-01 TrialTroveID-332308,,,,332308,Delay Disease Progression,,,"Patients who have developed respiratory failure necessitating ventilation Patients who have developed unsafe swallowing necessitating enteral feeding tube insertion Patients with other neurodegenerative disease such as Parkinson's disease and significant mental health illness Patients with certain concomitant diseases which may affect the assessment of safety/efficacy i.e. malignancy within the last 5 years, congestive heart disease, liver disease, kidney failure, bleeding disorders and other autoimmune diseases etc. Pregnant, lactating, and probably pregnant patients. Patients taking vitamin E tocopherol or tocotrienols supplements within 1 month from screening and randomisation. Patients who have participated in other trials within 12 weeks before consent, or who are participating in other clinical trials at present. Women of child bearing potential or nursing mother, unless they are willing to practice effective contraceptive measures.",Ii,Both
0,Patients with a diagnosis of NPC1.,"1. Aged greater than or equal to 18 and less than or equal to 60 years old at time of enrollment, either gender, and any ethnicity. 2. Diagnosis of NPC1 based upon one of the following: - Two NPC1 mutations; - Positive filipin staining and at least one NPC1 mutation; - Vertical supranuclear gaze palsy (VSNGP) in combination with either: - One NPC1 mutation, or - Positive filipin staining and no pathogenic NPC2 mutations. 3. Patients with at least one neurological manifestation of NPC1. For example, but not limited to, hearing loss, vertical supranuclear gaze palsy, ataxia, dementia, dystonia, seizures, dysarthria, or dysphagia. 4. A patient s cultured skin fibroblasts when treated with 10 M Vorinostat must exhibit a reduction in the filipin lysosomal storage organelle ratio equivalent to 75% of the response measured in NPC1 positive control fibroblasts. 5. Ability to travel to the NIH Clinical Center repeatedly for evaluation and follow-up. 6. If taking miglustat, the patient must have been taking a constant dose of the medication for no less than three months prior to baseline evaluation and must be willing to maintain that dose level for the duration of the trial. 7. Willing to discontinue all non-prescription supplements, with the exception of an age-appropriate multivitamin. 8. Women of reproductive age must be willing to use an effective method of contraception for the duration of the trial. 9. Willing to participate in all aspects of trial design including serial blood and CSF collections.",14-CH-0102 140102 NCT02124083 TrialTroveID-232576,Adults,year(s),year(s),232576,Niemann-Pick Type C,60.0,18.0,"1. Aged below 18 or above 60 years of age at enrollment in the trial. 2. Severe manifestations of NPC1 that would interfere with the patient s ability to comply with the requirements of this protocol. 3. Neurologically asymptomatic patients. 4. Patients who have received any form of cyclodextrin or an HDACi in an attempt to treat NPC1. 5. History of hypersensitivity reactions to Vorinostat or components of the formulation. 6. Pregnancy or breastfeeding at any time during the study. 7. Patients with suspected infection of the CNS or any systemic infection. 8. Neutropenia, defined as an absolute neutrophil count (ANC) of less than 1,500 per microliter. 9. Thrombocytopenia defined as a platelet count less than 75,000 per microliter, or a history of greater than or equal to grade 2 thrombocytopenia (50,000-75,000 platelets/microliter). 10. Prior use of anticoagulants or history/presence of a bleeding disorder. 11. Hepatic laboratory parameters (aspartate aminotransferase (AST), alanine aminotransferase, (ALT)) greater than four-times upper limit of normal. 12. Presence of anemia defined as two standard deviations below normal for age and gender. 13. Serum creatinine level greater than 1.5 times the upper limit of normal. 14. Hematuria (greater than15 RBC/mcL or positive hemoglobin). This exclusion criteria will not apply to a female currently menstruating who has no history of renal disease or other evidence of renal impairment (eg hypertension, serum creatinine above upper limit of normal, history of renal disease). Urinalyis will be repeated after menses has ended and drug discontinued if hematuria persists. Efforts will be made to avoid menses in scheduling the initial admission. 15. Proteinuria (1+ protein on urinalysis) Patient will not be excluded if urine protein/creatinine ratio is normal or if classified as benign by either patient's primary medical provider or upon obtaining a nephrology consult. 16. Serum potassium or Magnesium outside of the normal laboratory range prior to initiation of vorinostat therapy. 17. Diabetes or a fasting glucose greater than 106 mg/dl. 18. Active pulmonary disease, oxygen requirement or clinically significant history of decreased blood oxygen saturation, pulmonary therapy, or requiring active suction. 19. Patients with uncontrolled seizures per either of the criteria below. 1. Unstable frequency, type or duration of seizures. Quantified by a seizure log over the two months prior to enrollment. 2. Patients requiring antiepileptic medication changes (other than dose adjustments for weight) in the two months prior to enrollment, or requiring three or more antiepileptic medications to control seizures. 20. Use of another HDAC inhibitor or compounds with established HDAC inhibitory activity, including valproic acid, unless discontinued at least 2 months prior to enrollment. 21. History of a thromboembolic event (such as DVT or Pulmonary embolism). 22. Patients, who in the opinion of the investigators, are unable to comply with the protocol or have specific health concerns that would potentially increase the risk of participation.",Iii,Both
0,Patients with neuro-inflammatory disorders.,,TrialTroveID-048557,,,,48557,(N/A); Unspecified,,,,Ii,
0,Healthy volunteers.,,TrialTroveID-023032,,,,23032,Healthy subjects,,,,I,
0,Patients with Amyotrophic Lateral Sclerosis,- Have a diagnosis of ALS according to the Gold Coast Diagnostic Criteria. - Have either sporadic amyotrophic lateral sclerosis (sALS) or familial amyotrophic lateral sclerosis (fALS). - Treatment Research Initiative to Cure ALS (TRICALS) risk profile > -6 and < -2. - Have slow vital capacity (SVC) ≥ 75% of the predicted value. - Have a score of 3 or 4 on Item #3 (Swallowing) of the Harmonized ALS-FRS-R. Participants with a score of 3 can be enrolled with the Sponsor's approval only if they are able to safely swallow capsules. - Have a body weight ≥ 45 kg and body mass index (BMI) ≥ 18 kg/m^2.,EudraCT Number: 2023-506509-21 NCT06215755 TrialTroveID-501026 VGCS-50635-002,Adults; Older Adults,year(s),year(s),501026,Delay Disease Progression,74.0,18.0,"- Have active psychiatric disease, substance abuse, neuromuscular weakness other than ALS, or any other medical condition that, in the opinion of the Investigator, might confound the results of the study or interfere with the intake or absorption of the study drug or participation for the full duration of the study. - Have a history of unstable or severe cardiac, pulmonary, neurological, oncological, hepatic, or renal disease or another medically significant illness other than ALS precluding their safe participation in this study. - Have a history of substance use disorder or illicit drug use in the last year. - Have a history of serious infection (e.g., pneumonia, septicemia) ≤ 4 weeks of Screening; infection requiring hospitalization or treatment with intravenous (IV) antibiotics, antivirals, or antifungals within 4 weeks of Screening; or chronic bacterial infection (e.g., tuberculosis) deemed unacceptable as per the Investigator's judgment. Additional protocol-defined criteria may apply.",I,Both
0,Healthy volunteers and patients with ALS,"Participant inclusion criteria Inclusion criteria for Parts 1 and 2: 1. Healthy male or female aged between 18 to 65 years old at screening (inclusive) 2. For male and female subjects of childbearing potential: Subjects and their spouse/partners who are of childbearing potential must use highly effective contraception when engaging in sexual activity consisting of 2 forms of birth control (1 of which must be a barrier method such as latex or polyurethane condoms) starting at screening and continue throughout the clinical study period, and for 90 days after the final study drug administration. 3. For males: Subject must not donate sperm starting at screening and throughout the clinical study period, and for 90 days after the final study drug administration. Inclusion criteria for Part 3: 1. Diagnosis of laboratory-supported probable, probable, or definite (sporadic) amyotrophic lateral sclerosis (ALS) according to the El Escorial World Federation of Neurology revised research diagnostic criteria (Ludolph et al. 2015) 2. Aged between 18 and 80 years old 3. 5 years or less since the onset of ALS symptoms 4. Forced vital capacity (FVC) ≥50% predicted value 5. Able to swallow medication for the duration of the study (in the opinion of the investigator)",CHDR2219 EudraCT Number: 2022-002747-22 ISRCTN14792372 TrialTroveID-408472,Adults,year(s),year(s),408472,Healthy subjects; Unspecified,65.0,18.0,"Participant exclusion criteria Exclusion criteria for Parts 1 and 2: 1. History of clinically significant hematological, renal, neurologic, pancreatic, gastrointestinal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, immunological, allergic disease, or other major disorders 2. Current significant medical or psychiatric condition 3. Evidence of clinically significant hepatic or renal impairment in the opinion of the investigator, including alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >1.5 the upper limit of normal (ULN) or bilirubin > 1.5ULN. Patients with Gilbert syndrome without evidence of hepatic impairment may be enrolled. 4. Poor peripheral venous access 5. A lifetime history of suicidal behavior or suicidal ideation as determined by a positive response (‘’Yes’’) to either question 4 or question 5 of the C-SSRS at screening 6. For part 2 only: Subjects not eligible for lumbar puncture (anti-coagulation, anti-aggregation or blood coagulation pathologies, recent spine surgery, acquired or congenital spine malformation, clinical signs of intracranial hypertension, cutaneous infection at the punction site) Exclusion criteria for Part 3: 1. Amyotrophic lateral sclerosis (ALS) patients with a known mutation in the SOD1 or C9orf72 gene 2. Tracheotomy and/or ventilator-dependent (or daily use of non-invasive ventilation ≥ 22 hours for 7 consecutive days) 3. After percutaneous gastrostomy (PEG) operation 4. Subjects not eligible for lumbar puncture (anti-coagulation, anti-aggregation or blood coagulation pathologies, recent spine surgery, acquired or congenital spine malformation, clinical signs of intracranial hypertension, cutaneous infection at the punction site)",I,Both
0,,,TrialTroveID-350224,,,,350224,Unspecified,,,,I,
0,Patients with Amyotrophic Lateral Sclerosis.,"Adult patients (at least 18 years old) The minimum patient's weight is not less than 40 kg Diagnosis of sporadic ALS, definite or probable, as defined by El Escorial World Federation of Neurology criteria History of ALS symptoms less than 2 years duration from the first symptoms of the disease More than 6 months from diagnosis of the disease Disease progression at 6 past months at least 3 points during this period of time assessed in ALSFRS-R scale ALSFRS-R scale of at least 30 at screening appointment Forced vital capacity >70% of predicted value for age, gender and height Treatment with stable dose of riluzole(2x 50mg per 24h) before baseline visit (for at least 1 month) Capable of providing written informed consent Able to comply with study requirements and willing to follow all study procedures and follow-up visits Women of child-bearing age and men with partners of child-bearing potential must agree to use two forms of contraceptive therapy throughout the course of the trial Women of child-bearing age must undergo pregnancy test Polish-language native speakers or patients who are proficient in the Polish language",ALSTEM EudraCT Number: 2018-004171-12 NCT04651855 TrialTroveID-390891,Adults; Older Adults,year(s),,390891,Delay Disease Progression,,18.0,"Pregnancy or breastfeeding Tracheostomy Ventilator dependence Renal disease with creatinine >2mg/dl Liver disease with ALT, AST or GGTP 2-fold higher than upper normal limit Positive test for HBV, HCV, HIV with NAT method Positive tests for syphilis Any other clinically significant abnormalities on laboratory evaluation Any condition that would compromise ability of undergoing lumbar puncture Active systemic disease Autoimmune disease (Hashimoto disease under control is allowed) Uncontrolled diabetes (HbA1c > 8%) Pulmonary disease that could affect interpretation of spirometry Neurological concomitant disease Unstable psychiatric concomitant disease High risk of suicide History of substance abuse within past year History of malignancy, within the previous 5 years, including melanoma with exception of localized skin cancers Any other clinically significant medical condition that can compromise patient's safety in the opinion of the investigator Treatment with immunomodulatory drugs (for example immunoglobulins, corticosteroids or other immunosuppressant) in last 6 months Participation in another clinical trial in last 6 months Previous cellular therapy of any kind Hypersensitivity to any component used in the cell culture Nuchal rigidity and other signs of meningitis Patients on chronic anticoagulation treatment (heparin/ warfarin/acenocoumarol/(N)OAC)",Iii,Both
0,Healthy Japanese adult males,"Min age: 20 years; Max age: 35 years; Gender : Male Inclusion criteria: Healthy Japanese adult males. Between the ages of 20-35 at the time of informed consent. Subjects determined by the investigator to be adequate for this study based on the screening tests. Body mass index (BMI) is greater than or equal to 18.5 and less than 25.0. Subjects who have negative result for hepatitis B virus surface antigen (HBs antigen), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV antigen and antibody), serological test for syphilis and treponema pallidum. Non-smokers. Subjects who are willing to follow study procedures during the study participation period. Subjects signed informed consent form voluntary.",TrialTroveID-216205 UMIN000015054,Adults,year(s),year(s),216205,Healthy subjects,35.0,20.0,"Exclusion criteria: Subject with serious concomitant or pre-existing conditions (e.g., hepatic disorder, renal disorder, cardiovascular disorder, digestive disorder, cancer, allergy) which are inadequate for participating in this study. QTc is over 450 ms of the 12-lead electrocardiogram at screening. Subjects who made blood donation of more than or equal to 400 mL within 12 weeks prior to dosing, or subjects who made component blood donation or blood donation of more than or equal to 200 mL within 4 weeks prior to dosing. Subjects who took any medications or supplements within 4 weeks prior to dosing. Subjects who consumed any foods or drinks containing grapefruits (e.g., juice and/or pulp) within 7 days prior to dosing. Subjects who consumed any foods or drinks containing alcohol or caffeine within 3 days prior to dosing. Subjects who received other investigational agents within 16 weeks prior to dosing. Subjects who engaged in excessive exercise within 3 days prior to dosing. Subjects who do not agree to use appropriate contraception methods for 90 days after dosing. Subjects determined by the investigator to be inadequate for this study for any other reasons.",I,Male
0,Subjects With Amyotrophic Lateral Sclerosis (ALS) or Dementia,"1. Patient has the ability and is willing to provide signed written informed consent prior to any study procedures. 2. Patient successfully completed the Phase 1b/2a study with WVE-004, WVE-004-001. 3. In the opinion of the Investigator, the patient is able to tolerate all study procedures, is willing to comply with all other protocol requirements, and tolerated study drug in the parent study. 4. Patient is willing to practice highly effective contraception for the duration of the study and for 5 months after the last dose of study drug if the patient or their partner are of childbearing potential. Non-childbearing potential and highly effective methods of contraception are defined in the protocol (Section 5.2.1). In addition, willingness to forego sperm or ova (egg) donation for the duration of the study and 5 months after completion of the study. 5. Patient has identified a study partner(s) for the duration of the study.",EudraCT Number: 2022-002267-29 NCT05683860 NL81832.000.22 TrialTroveID-445376 WVE-004-002,Adults,year(s),year(s),445376,Frontotemporal Dementia; Unspecified,65.0,18.0,"1. Patient has a clinically significant medical finding on the physical examination other than C9orf72-associated ALS or FTD that, in the judgment of the Investigator or Sponsor, will make the patient unsuitable for participation in and/or completion of the trial procedures. a. Prior or ongoing medical conditions, including acute illness, within 28 days of Screening visit; b. Clinically significant abnormality on laboratory testing at Screening, including but not limited to renal insufficiency, which is defined as creatinine clearance <40 mL/min. 2. Patient has a positive hepatitis B surface antigen or hepatitis C antibody test. 3. Patients who are pregnant (as determined by a serum pregnancy test) or breast feeding at the Screening visit or plans to become pregnant during the trial. 4. Patients deemed to be at significant risk for suicidal behavior based on Investigator assessment and/or active suicidal ideation. 5. Patient has a bone, spine, bleeding (e.g., hemophilia, Von Willebrand disease, or liver disease), or other disorder that exposes the patient to a risk of injury or unsuccessful LP. 6. Patient received prior treatment with viral or cellular-based gene therapy. 7. Patient received any other investigational drug, biological agent, or device within 1 month or 5 half-lives of study agent, whichever is longer. Patient received an investigational oligonucleotide within the past 6 months or 5 half-lives of the drug, whichever is longer. 8. Patient anticipates using antiplatelet or anticoagulant therapy during the course of the study. Patients who received antiplatelet or anticoagulant therapy must complete one of the following washout periods before the Screening visit: a. A 7-day washout period for antiplatelet therapy, b. A 1-day washout period for anticoagulants (except warfarin), or c. A 5-day washout period for warfarin. 9. Patient was noncompliant in the opinion of the Investigator or Sponsor when participating in study WVE-004-001. 10. Patient is directly or indirectly involved in the conduct and administration of this trial as an Investigator, sub-investigator, trial coordinator, or other trial staff member, or the patient is a first-degree family member, significant other, or relative residing with one of the above persons involved directly or indirectly in the trial.",Iii,Both
0,Patients with documented C9orf72 expansion and confirmed ALS or FTD diagnosis. Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD).,"ALS-Specific Inclusion Criteria: 1. Diagnosis of ALS based on clinical manifestations. 2. ALS: Clinically diagnosed possible, laboratory supported probable, probable, or definite criteria for diagnosing ALS according to the World Federation of Neurology revised El Escorial criteria. 3. Patients receiving riluzole have been on a stable dose for a minimum of 30 days. 4. Patients on edaravone have received a minimum of 1 cycle (28 days). 5. Patients discontinuing riluzole or edaravone had the last dose administered =1 month prior to Screening. FTD-Specific Inclusion Criteria: 6. FTD: Must have Global Clinical Dementia Rating – Frontotemporal Lobar Degeneration (CDR® plus NACC FTLD) score of 0.5 or 1. 7. FTD: Able to undergo periodic magnetic resonance imaging (MRI) of the brain. Patients with mixed phenotype (ALS and FTD) need not undergo MRI if their ALS symptoms prevent it. Mixed Phenotype (ALS and FTD) Inclusion Criteria: 8. Patients who are mixed phenotype (ALS and FTD) must meet both the ALS-specific and FTD-specific criteria. Inclusion Criteria Common to Both Diseases: 9. Patient must have the ability and be willing to provide written informed consent prior to any trial-related procedures. 10. Documented mutation (GGGGCC [G4C2] repeat expansion) in the first intronic region of the C9orf72 gene. 11. Body mass index (BMI) =32 kg/m2. 12. Forced vital capacity (FVC) of >50% predicted. 13. Age of =18 and =80 years at Screening visit. 14. Willing and able to comply with scheduled visits, drug administration plan, laboratory tests, trial restrictions, and all trial procedures. 15. Willingness to practice highly effective contraception for the duration of the trial if patients or their partners are of childbearing potential. Non-childbearing potential and highly effective methods of contraception will be defined in the protocol.",EudraCT Number: 2020-005193-94 FOCUS-C9 NCT04931862 NL76122.000.21 TrialTroveID-319020 WVE-004-001,Adults; Older Adults,year(s),year(s),319020,Frontotemporal Dementia; Unspecified,80.0,18.0,"1. Clinically significant medical finding on the physical examination other than C9orf72-associated ALS or FTD that, in the judgment of the Investigator, will make the patient unsuitable for participation in, and/or completion of the trial procedures, including, but not limited to: a. Prior or ongoing medical conditions, including acute illness, within 28 days of Screening visit; b. Clinically significant abnormality on laboratory testing at Screening. 2. Positive hepatitis B surface antigen or hepatitis C antibody test. 3. Known to be positive for human immunodeficiency virus (HIV). 4. History of substance use disorder (except nicotine) within 6 months prior to the Screening Visit. 5. Significant cognitive impairment; or unstable psychiatric illness, including active psychosis, active suicidal ideation, recent suicide attempt, or untreated major depression, within the last 90 days, as determined by the Investigator. Mental status, psychiatric medical history, and eligibility for the study must be documented in the screening questionnaire. 6. Pregnant (as determined by a serum pregnancy test) or breast feeding at the Screening Visit, or plans to become pregnant during the trial. 7. Clinically significant abnormality on Screening electrocardiogram (ECG), including, but not limited to, a confirmed QT interval using Fridericia’s correction method (QTcF) of =450 msec for males or =470 msec for females. 8. Bone, spine, bleeding, or other disorder that exposes the patient to risk of injury or unsuccessful lumbar puncture. 9. Dementia due to a condition other than C9orf72-associated ALS or FTD, including, but not limited to, Alzheimer disease, Parkinson disease, dementia with Lewy bodies, Huntington's disease, or vascular dementia. Prior or Concomitant Medications 10. Positive for opioids (unprescribed), cocaine, amphetamines, methadone, barbiturates, methamphetamine, and phencyclidine at the Screening Visit. 11. Changes in nutritional or herbal supplements or concomitant medications within 1 month prior to Screening visit or plans to modify dose or regimen during the trial. 12. Received prior treatment with viral or cellular-based gene therapy. 13. Received any other investigational drug, biological agent, or device within 1 month of 5 half-lives of study agent, whichever is longer. Received an investigational oligonucleotide, within the past 6 months or 5 half-lives of the drug, whichever is longer. Trial Compliance 14. Implantable central nervous system (CNS) device that may interfere with ability to administer trial drug via lumbar puncture or undergo MRI scan. 15. Deemed to be at significant risk for suicidal behavior based on Investigator assessment and/or active suicidal ideation. 16. Known hypersensitivity to any oligonucleotide, as demonstrated by a systemic allergic reaction, such as changes in pulse, blood pressure, breathing function, etc. 17. Patient is directly or indirectly involved in the conduct and administration of this trial as an Investigator, sub investigator, trial coordinator, or other trial staff member, or the patient is a first-degree family member, significant other, or relative residing with one of the above persons involved directly or indirectly in the trial.",Iii,Both
1,Patients who have amyotrophic lateral sclerosis and who have completed previous studies with this study medication. Subjects who have completed a full term in previous efficacy and long-term studies of this drug.,,97.039P TrialTroveID-088863,,,,88863,Unspecified,,,,Iii,
0,Patients of amyotrophic lateral sclerosis (ALS).,Ages Eligible for Study: 25 Years to 65 Years Inclusion Criteria: Patients aged between 25 and 65 years. ALS patients who can visit the clinic for six months. Forced Vital Capacity (FVC) > 70%. Patients who can walk by themselves. Change in ALSFRS-R score from -1 to -4 during 12 weeks before the initial administration. Patients who are willing to give informed consent. Did not receive tube feeding · patients without significant bulbar palsy Patients can be Doppo ALSFRS before 12 weeks of study drug administration started ·-variation of the R score is -1 (minus one) to -4 (Minus 4) patients,JapicCTI-090746 jRCT2080220719 NCT00886977 TrialTroveID-107667 YAM80-01,Adults,year(s),year(s),107667,Delay Disease Progression,65.0,25.0,"Exclusion Criteria: The patient underwent a tracheotomy has been already Patients who are already equipped with a ventilator History of severe drug allergy (shock, anaphylactoid reactions), patients with Is considered a significant impact on prognosis than ALS, such as severe heart failure with advanced cancer Patients with complications Ru Serious (for example, which requires hospitalization or surgery), pulmonary disease, heart disease, Kidney disease, ischemic heart disease with severe complications, such as patients with cerebrovascular disease Is scheduled for surgery is considered a significant impact on prognosis during clinical trials Patients Patients who are pregnant or potentially pregnant women (woman who may become pregnant And, the pregnancy test is negative and if it is not done between the time when getting consent from study drug dosing File. However, the doctors decided not obviously pregnant during menstruation and post-menopausal women Except in the case. ) In patients with possible pregnancy, contraception from the end of two years of taking and taking Female patient from making, contraception and carried out six months and quit taking the medication or Male patients have Preparation retinoids (vitamin A, etretinate, tretinoin) was administered to In patients, patients who have taken in the past or etretinate or Patients with hypervitaminosis A Of patients with triglyceride levels greater than 400mg/dL fasting Patients participating in another clinical trial 2 weeks before the start of drug administration Geosphere, other drugs with ALS (or Rirutekku edaravone). Other patients judged as inappropriate investigator",Ii,Both
1,Patients with Amyotrophic Lateral Sclerosis,The following inclusion criterion is in addition to the inclusion criteria specified in the Master Protocol (NCT NCT04297683). Vaccination with a quadrivalent meningococcal vaccine and meningococcal serotype B vaccine at least 14 days prior to the first dose of study drug at the Baseline (Day 0) visit. Meningococcal vaccines (including boosters) should be administered in accordance with the study's vaccination worksheet.,2019P003518A HEALEY ALS Platform Trial - Regimen A NCT04436497 TrialTroveID-377436,Adults; Older Adults,year(s),,377436,Delay Disease Progression,,18.0,The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683). History of meningococcal disease. Prior treatment with a complement inhibitor.,Ii/Iii,Both
0,,,TrialTroveID-157730,,,,157730,Unspecified,,,,I,
1,Patients with amyotrophic lateral sclerosis.,,TrialTroveID-148595,,,,148595,Delay Disease Progression,,,,Ii/Iii,
